<SEC-DOCUMENT>0001819790-22-000023.txt : 20220511
<SEC-HEADER>0001819790-22-000023.hdr.sgml : 20220511
<ACCEPTANCE-DATETIME>20220511170944
ACCESSION NUMBER:		0001819790-22-000023
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220511
DATE AS OF CHANGE:		20220511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tarsus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001819790
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				814717861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39614
		FILM NUMBER:		22914668

	BUSINESS ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		(949) 409-9820

	MAIL ADDRESS:	
		STREET 1:		15440 LAGUNA CANYON ROAD
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tars-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:da1c4284-d55c-45f0-a6eb-8007076173b6,g:baa10d6b-a9ec-46bb-8e50-7a6ef1f55cb8,d:33713c367fc84a8b901b03655de07e3d--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:tars="http://tarsusrx.com/20220331" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>tars-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl8yLTEtMS0xLTI2NjM1_4689b037-b9c7-48ce-883c-9666e3e4fb22">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl8zLTEtMS0xLTI2NjM1_6ece19bd-41a7-4af1-91aa-5a56ca433f06">0001819790</ix:nonNumeric><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl80LTEtMS0xLTI2NjM1_eec0dc65-eab1-4323-a0dc-4d336f77f9eb">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl81LTEtMS0xLTI2NjM1_54730e0b-8ac5-4715-a788-63c7f7fdac77">2022</ix:nonNumeric><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl82LTEtMS0xLTI2NjM1_5e997339-c203-40b9-8385-31283630ef01">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i5cf536a1081447dc9478dce9063ad678_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTM5MTI_01c7ccdd-ab1b-4a6d-8be3-01ce640cfa8d">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_439b7687-e8d3-4543-9c80-be7d57d59b72">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_c0a0454b-2a50-41a4-8b96-b87633545102">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_6efd016f-2e3f-4e4b-96a2-61e9bf7e61bf">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_9a33a609-33f6-4820-89f2-c43f54cb768e">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="tars-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id14bd9926cf44163a2bdbd7e313ace4f_I20220504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7273965429d14abfa8d691f9d822bdae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i849ffd4d92344da1bec87e7d90d1b485_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i080af938313c43d2b539cdefbcdfec98_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54381f41a7eb4b0ea3fbbbaeff54f01f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f4a4782309e4d14a530821ddb8049b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29bc79115d7a4e0ca6736b6a0bd45d7e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8026e35afb834d3cb1f3553098db8877_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc4f887cfb0f4ab5be157a6b1b3689d8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0a5d596de347dfb2ee05dbf213d003_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bea9a87fa149f5b7b6f0c53df117f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71110d20496a42568cfa4272b640c494_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i281e4ce0faee4e93b52b1c855c37b40e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00db3f28f47a45fd81332519739fb47a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7f2066d6ab4d298b57b9551607ddc1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1ad78fb81b430cab2abc5651cadb29_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3d5c72a6a94f73955e1eb952386f30_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec2fec07baf4b5ea65315e3604b264b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc4893dbff5444e2a914be14ba1cb379_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d5cd01a5b74ad69d8cfb82b0ddb6b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2407365462b6484e866e2a0897a6f31f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb871a3740c464480f7fcef3e833411_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514947c5e4b04a378154c04684c04412_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5af16c925384bbda1b2f1b0f73319cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1e1fe52f054a159eaad037bb720a9d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80221d972a4407a82832333ee98fc87_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i015bde96678a4498b78f135f2e37fe8a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7ac172fd5445a9afde9ded686451dd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09758e9a44594ebf8985740d1bf5f229_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2668fef555454ab6c59b2d437e7cca_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64ab1022c5cf4cbf9f780e24d3f48ca8_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>tars:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i45f4cdbf078647fdb5714433c4e54968_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b6b657919b045119943a31c80f1d1c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c2f7bb7a9144feb30baaa206b3c84f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a55c6f2a5cd4609a8fd119dfcd1fcfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7529cd5b41004750957c29f40fae72bc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b632727d0924b539bb949a88a28ac4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2f6cc3612846ed80ef0e9ff22f78ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26735dafdb274401bedfa5360ff79acb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd617ed38c64f83b2e2428b1abde32a_I20201008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic93546034bb142b0a219d72347552482_I20201008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0927937cbbe4b248a2bb3faaf75bded_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cf536a1081447dc9478dce9063ad678_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7789b1b50744a99ead19fcb7d24c12_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03a5a0a91cb4b4586a1f8ee04c3d481_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic881c21880004c5ba362cfa7ce7524e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f6cd5005f34480babb33821fa0f5fb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f101ec5e8914faab8d26c11caedd9bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892bc751c437460d89238d3ba9e8f045_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d25ce27b22641beb0bec11792f01c1f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b53435adf9489a9a2daaff37121c44_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173cbb1387d1404085a5f0d1575e8f62_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861c82a1ea2c4d4ea4ae4e378321bb54_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27aa992f7c3f4d339542898fcd3905bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ceb379731724bc085f3a4a5ce44d64f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3682bcf6d66f4973a7dd133d281d269e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6faf816d5daa4e378b018c9347358012_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3a8147113984483bdbe2570de069cf9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4444dc36754b42916b70015ae04028_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i345bf687446f417ab073133b4f3e6ebf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie13603c0d53747d793240ebb726383c8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8e806d3fc746b4bd86d42fd6cde4af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe41f993362a4d1abb88ecf74110902f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf5353fdcc224f7e8dfbe5f04a6b0e2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if839d9e3a48348b2b756e1a2885fa244_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d31760273a4e2f823c7e5fc3f3807d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d18c2021abb45cd8eca7bf510a0d79c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9facda38ea4ff4885250a21f36b6ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f4e89147429457a865e2def1c688c45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="warrant"><xbrli:measure>tars:warrant</xbrli:measure></xbrli:unit><xbrli:context id="ic100186e6c824064b3a569935e610798_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f49b8447904e059af26b60c492701c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia85a91d80e654470aeccc73aa5fa1fb5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>tars:contract</xbrli:measure></xbrli:unit><xbrli:context id="i2d2fc086b90b461a8bd0825aacc11371_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieadb94479fbf491289eeb4a699120c85_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2984a704b5f7467bb0b60220ced68c69_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd124fd3b0484daab9a49f0bec4f620f_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee22ca2e06b493897071cb5cc9e2fee_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8f8ea4259c4cda90b6fffc07aba79d_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie486f40913eb4e9e91e41e6b75802f58_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8bcfe9ca0640bbb09e4739c1c4c378_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cecf80c420649d6a1e32ab01aa11f92_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide977ec78e02409981089603c186b138_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654c73f76ece4f4e803421b8c7263cb3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7a6b8164094267801b75fac6b39956_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7611af61f5418b9266c2bcd8eb6fe9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea920d7fcd75406d81b03da8bad1093a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="arrangement"><xbrli:measure>tars:arrangement</xbrli:measure></xbrli:unit><xbrli:context id="i3167f524706142c2b2851c8bb31f1c12_D20210326-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia19be9b7fe5245089c2073e846d30204_D20210326-20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92802321216247e484f937d0e0c27e93_D20210326-20210326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576dbd0507c245d1a503f15affe1eed2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e151303adb4b01ba45467aa1597d0a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DrugSupplyAgreementMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35b7053fdb8f495f94c86835ef706e83_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:SalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c7c8089e4c24cf6b318fdbcbb0fcd5f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c16329db554147aa835e3f640a2243_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd505db08864f8599c4b88afd5d91d4_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1d86abba614b28bb93de20e5a65f46_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1bbc0f5a2e4184a13f69cd709213c4_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eb8e35e7edf4dcc8e5184077317c4e2_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica98a2fa29594ad7be66a55c9a1e20db_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33662385a14248f389cd589e0b07949d_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a6e2fcbec9d4f2a814387f5e90b9f5f_D20220317-20220317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-17</xbrli:startDate><xbrli:endDate>2022-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie708af9133d548c5b4bab9d679747cd1_D20220317-20220317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-17</xbrli:startDate><xbrli:endDate>2022-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d088c0af04542eba408c2f8416ec22d_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526c288d95b145d18ad85df06471783c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438915cd287c48788084761ed5ad3ba4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id27ce663af03415ca6600c5007c2ea01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85e9ecd5338406897413769276e54ff_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1808d691f65a4626825a224635438903_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c435dd6d8af4033acf4c6e936b27500_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb812a752d3463a8d2c1bc50512d96b_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819790</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i33713c367fc84a8b901b03655de07e3d_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:110%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:110%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:110%">FORM <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQy_51266b9f-7b4e-41e9-9e72-127cc0e6b31d">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6MTIxYTA3OGJlYWYyNGZkYzgzZTBlYmE5ZjJhODMyZTgvdGFibGVyYW5nZToxMjFhMDc4YmVhZjI0ZmRjODNlMGViYTlmMmE4MzJlOF8wLTAtMS0xLTI2NjM1_c44e9764-bceb-4dce-b8b4-4d58e550ca84">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:15pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the quarterly period ended <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xMjk_1db6f429-6700-4c8e-abd0-3e9e1560f875">March&#160;31, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6NjI3ZGU4OGMzOWU4NGM1ZTk0OTI3Y2E0Yzc4YThkOWMvdGFibGVyYW5nZTo2MjdkZTg4YzM5ZTg0YzVlOTQ5MjdjYTRjNzhhOGQ5Y18wLTAtMS0xLTI2NjM1_5d0b8a6b-8013-4999-a125-d10790499052">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:9pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the transition period from _____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%;text-decoration:underline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">to ____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%;text-decoration:underline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#160;</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:  <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTM5_c93c7474-ba1e-4a6a-940b-4872a2aad996">001-39614</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQz_2cc90191-da45-4bf2-83b1-0361b7e11caa">TARSUS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:48.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6ZGQ4ZjkwZTU4MTlkNGYyYThkODVkZmE1MWY2MGQ0ZTgvdGFibGVyYW5nZTpkZDhmOTBlNTgxOWQ0ZjJhOGQ4NWRmYTUxZjYwZDRlOF8wLTAtMS0xLTI2NjM1_33adc12e-8da3-4da8-848d-d7d7aafc164a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6ZGQ4ZjkwZTU4MTlkNGYyYThkODVkZmE1MWY2MGQ0ZTgvdGFibGVyYW5nZTpkZDhmOTBlNTgxOWQ0ZjJhOGQ4NWRmYTUxZjYwZDRlOF8wLTItMS0xLTI2NjM1_81ede369-2485-4a78-a437-473020ed46f9">81-4717861</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:48.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6Y2Y1NzBkYTQxOTE4NGMyNmE1ZTJjNDVmNzM4OTdiNmIvdGFibGVyYW5nZTpjZjU3MGRhNDE5MTg0YzI2YTVlMmM0NWY3Mzg5N2I2Yl8wLTAtMS0xLTI2NjM1_94c88503-14a1-49db-ad82-ddacb3f4f382">15440 Laguna Canyon Road, Suite 160</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6Y2Y1NzBkYTQxOTE4NGMyNmE1ZTJjNDVmNzM4OTdiNmIvdGFibGVyYW5nZTpjZjU3MGRhNDE5MTg0YzI2YTVlMmM0NWY3Mzg5N2I2Yl8xLTAtMS0xLTI2NjM1L3RleHRyZWdpb246NGEyZTkxYTBkMWFkNDc4NGFlMmFjY2I3YzYwZTJjNzdfNA_0a96ea76-6442-4c3a-878f-730116f9aefb">Irvine</ix:nonNumeric>, <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6Y2Y1NzBkYTQxOTE4NGMyNmE1ZTJjNDVmNzM4OTdiNmIvdGFibGVyYW5nZTpjZjU3MGRhNDE5MTg0YzI2YTVlMmM0NWY3Mzg5N2I2Yl8xLTAtMS0xLTI2NjM1L3RleHRyZWdpb246NGEyZTkxYTBkMWFkNDc4NGFlMmFjY2I3YzYwZTJjNzdfOA_ca42d579-bdcb-4111-8339-675b9cdbac6b">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6Y2Y1NzBkYTQxOTE4NGMyNmE1ZTJjNDVmNzM4OTdiNmIvdGFibGVyYW5nZTpjZjU3MGRhNDE5MTg0YzI2YTVlMmM0NWY3Mzg5N2I2Yl8xLTItMS0xLTI2NjM1_2499b7de-39e1-4cce-8a8d-34e2696c9d5d">92618</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQw_75647abd-f27f-4dd0-b4a8-da55d39cdc0a">(949)</ix:nonNumeric> <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ0_6cf9cdb1-05e1-48fa-a3be-ece395468c23">409-9820</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.216%"><tr><td style="width:1.0%"></td><td style="width:40.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6OTJlZTkxNTY5YjRiNDkzODhjNTBiMTgzMDkzODM2MTAvdGFibGVyYW5nZTo5MmVlOTE1NjliNGI0OTM4OGM1MGIxODMwOTM4MzYxMF8xLTAtMS0xLTI2NjM1_10a91585-c8b1-49fe-875a-1012d5f3958b">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6OTJlZTkxNTY5YjRiNDkzODhjNTBiMTgzMDkzODM2MTAvdGFibGVyYW5nZTo5MmVlOTE1NjliNGI0OTM4OGM1MGIxODMwOTM4MzYxMF8xLTEtMS0xLTI2NjM1_13723a9a-7108-424b-aabf-40f18d009ded">TARS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Nasdaq Global Market LLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6OTJlZTkxNTY5YjRiNDkzODhjNTBiMTgzMDkzODM2MTAvdGFibGVyYW5nZTo5MmVlOTE1NjliNGI0OTM4OGM1MGIxODMwOTM4MzYxMF8xLTItMS0xLTI2NjM1L3RleHRyZWdpb246MzUyZmUzNWY3NTBiNDBiNzg1NTU4M2FjMGVkYjhjNGVfMzQ_be8e3bfd-665d-4d0f-bc0f-2f173becbb97">Nasdaq Global Select Market</ix:nonNumeric>)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ1_a76de9ee-def8-4e7c-90b1-75d78ddf2919">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ2_bcced387-f1f0-42db-99a5-04face97d0eb">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6YmFjMzNjY2QzYjE3NGQ0YjkxODYxYmVlN2ViM2Q1ZTUvdGFibGVyYW5nZTpiYWMzM2NjZDNiMTc0ZDRiOTE4NjFiZWU3ZWIzZDVlNV8xLTAtMS0xLTI2NjM1_b6704a2e-51be-41e9-824e-37eafa4fa059">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6YmFjMzNjY2QzYjE3NGQ0YjkxODYxYmVlN2ViM2Q1ZTUvdGFibGVyYW5nZTpiYWMzM2NjZDNiMTc0ZDRiOTE4NjFiZWU3ZWIzZDVlNV8xLTQtMS0xLTI2NjM1_4b94f8a3-d52b-4148-b7d6-8fcb76249768">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6YmFjMzNjY2QzYjE3NGQ0YjkxODYxYmVlN2ViM2Q1ZTUvdGFibGVyYW5nZTpiYWMzM2NjZDNiMTc0ZDRiOTE4NjFiZWU3ZWIzZDVlNV8yLTQtMS0xLTI2NjM1_fb1ae3f2-972f-4dba-b0da-be1841c8a8e0">&#9746;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ3_e18863ef-bc78-4abe-ac15-b9101be5ca4e">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ4_0d4bc9fb-21df-4db9-856a-c65431d586e6">&#9744;</ix:nonNumeric>  No &#9746;</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id14bd9926cf44163a2bdbd7e313ace4f_I20220504" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xODU4_17747fb2-451c-4bf6-8ba6-282c8e4815a5">20,727,701</ix:nonFraction> shares of common stock, $0.0001 par value, outstanding as of May 4, 2022.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:94.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_10">Part I - Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_13">Item 1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_67">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_67">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_70">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_70">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_73">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_73">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_76">Part II - Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_76">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_79">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_79">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_82">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_82">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_85">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_85">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_88">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_88">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_91">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_91">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_94">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_94">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_97">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_97">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_100">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33713c367fc84a8b901b03655de07e3d_100">40</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i33713c367fc84a8b901b03655de07e3d_13"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item I. Financial Statements (Unaudited)</span></div><div id="i33713c367fc84a8b901b03655de07e3d_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:93.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pages</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_19">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_22">Condensed Statements of Operations and Comprehensive (Loss) Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_25">Condensed Statements of Preferred Stock and Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_28">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_31">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and par value amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfNS0xLTEtMS0yNjYzNQ_bfcb53b3-aeb0-4959-98b2-8dde3c5d6da5">175,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfNS0zLTEtMS0yNjYzNQ_cb0d447f-2235-4976-9173-e0eda1b0f611">171,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfNy0xLTEtMS0yNjYzNQ_308c125d-96c9-4206-8be0-1b91e50ce8d6">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfNy0zLTEtMS0yNjYzNQ_036d861f-ad9b-4f59-b5fd-154f35b09214">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfOC0xLTEtMS0zMDQ3Nw_6f01b8d8-e759-4a56-b1a5-1ed375cb7485">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfOC0zLTEtMS0zMDQ4NA_bf51a5e0-55ae-475b-8760-04121cb7c187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfOS0xLTEtMS0yNjYzNQ_504f1b4f-f4b6-4f11-840b-37e8fd71ee1d">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfOS0zLTEtMS0yNjYzNQ_049a3b7c-bd16-4baf-b1a5-46697460bfad">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTAtMS0xLTEtMjY2MzU_4e075f8b-a522-4243-991d-ace20284e355">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTAtMy0xLTEtMjY2MzU_15078290-045b-4175-8917-7682769f1249">4,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTEtMS0xLTEtMjY2MzU_5edea847-0306-4507-b1f1-1c281b3bc1ed">178,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTEtMy0xLTEtMjY2MzU_120e8698-3239-440e-a5dd-c009025cda57">175,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTItMS0xLTEtMjY2MzU_750dfd27-56e5-4051-ac85-eb19cbe6a299">915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTItMy0xLTEtMjY2MzU_e676de62-601d-41fa-baab-5c439178ed51">755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTMtMS0xLTEtMjY2MzU_ab61c151-fa2c-40b5-8e8f-11b19157657b">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTMtMy0xLTEtMjY2MzU_51a94551-d71d-4b6d-95fb-aff21646a522">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTQtMS0xLTEtMjY2MzU_8437174d-8ab5-409b-94d8-c142ffb76c7e">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTQtMy0xLTEtMjY2MzU_04c60336-bbf3-4459-9a6e-fafe8084da5d">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTUtMS0xLTEtMjY2MzU_6f44dc0a-9f58-4408-a59a-b4c760c2019d">181,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTUtMy0xLTEtMjY2MzU_11299d09-9d9c-4b30-b9ce-de3889ff422a">178,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTgtMS0xLTEtMjY2MzU_123df97d-08b5-4a84-88e3-9f410ceb32b7">10,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTgtMy0xLTEtMjY2MzU_54f7eaf5-5cc0-4b7d-8b97-1b1401bebe33">8,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTktMS0xLTEtMjY2MzU_5d7be76b-a89b-4af1-baaf-d5885fd016f5">1,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTktMy0xLTEtMjY2MzU_ba1e6c4d-b150-42f9-84e3-38887ed0cacb">2,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjAtMS0xLTEtMjY2MzU_32251c76-b21d-49dd-a8ed-fb14aadfd051">12,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjAtMy0xLTEtMjY2MzU_8897ef8e-05e3-42ed-9568-7a771e1f53e7">11,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjEtMS0xLTEtMzA1MjI_54dca8bc-f735-4fc5-9822-7bafeed10d14">19,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjEtMy0xLTEtMzA1Mjk_b0e54397-5853-4265-9739-f7be5244d9f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjEtMS0xLTEtMjY2MzU_3e92aeb4-0eca-4ccb-aa4e-7db559624453">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjEtMy0xLTEtMjY2MzU_6981828c-a064-4c8a-8f93-3718819b9e62">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjItMS0xLTEtMjY2MzU_5de0b7d1-3675-4f25-af40-2309d87dbd0b">32,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjItMy0xLTEtMjY2MzU_25890f66-67e3-4fdf-bea4-b6b27f0f9971">12,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Note 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjMtMS0xLTEtMjY2MzU_751be429-3c14-48e7-af31-85529298d87d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjMtMy0xLTEtMjY2MzU_495f4119-a127-422b-9357-ce3039366cdc"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y18yMQ_71239956-c6d9-45fb-9a53-09f982a7edf8"><ix:nonFraction unitRef="usdPerShare" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y18yMQ_b96fb616-26e4-4a27-b27a-e19665f201d8">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y18zNQ_2ab43e64-ba28-4a6b-8e53-97735fd13ca4"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y18zNQ_625002e2-f600-4a41-b206-a415f6e94a67">10,000,000</ix:nonFraction></ix:nonFraction> authorized; <ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y182Mw_1df92529-5bbc-41fb-8a8a-0ab26e6cadb4"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y182Mw_1e229738-48c3-48cf-a345-97be38fd9573"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y182Mw_8cc8225f-0b01-4069-a3dd-547923cdf577"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y182Mw_f6ce038f-6b2b-4721-8230-642d04b821ae">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMS0xLTEtMjY2MzU_5655de59-c39a-4790-9a16-8bd2f9a658d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMy0xLTEtMjY2MzU_a88ea61b-97ed-4012-8cc7-b071d4cc3308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xOA_41a88a13-2656-44cd-8051-bad9f8644fb1"><ix:nonFraction unitRef="usdPerShare" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xOA_a68a9183-7714-43a1-8f54-daaeda28003a">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18zMg_85cd0be9-634f-4530-a040-7bfbb2d26fe1"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18zMg_873d8f4d-f174-4b32-908d-ba5a2ea9e2e1">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M181NA_e4d53f1f-79f1-4221-a850-30478bcd4356">20,731,062</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M183NQ_abeaa55e-c3b7-4fd7-afa9-a6c4f2261dd8">20,718,528</ix:nonFraction> outstanding, which excludes <ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="tars:CommonStockSharesSubjectToRepurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xMDY_df9015dd-9f0f-420a-afe9-2abd9c805660">12,534</ix:nonFraction> shares subject to repurchase at March&#160;31, 2022 (unaudited);  <ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xNTc_e9f4f36b-dc4d-42da-ba20-43e2c2cbd7e7">20,726,580</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xNzg_aafaf77d-d712-4e93-94c0-cd2deb30b9ca">20,698,737</ix:nonFraction> outstanding, which excludes <ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="tars:CommonStockSharesSubjectToRepurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18yMDk_32831530-e005-4b25-b4ae-7de39468d2da">27,840</ix:nonFraction> shares subject to repurchase at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMS0xLTEtMjY2MzU_5ed1a3d6-a42d-4adb-8310-d1a476e218ab">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMy0xLTEtMjY2MzU_2c853add-eb90-42d7-901c-c44d5aa43f8f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjctMS0xLTEtMjY2MzU_7064a0e4-33aa-4aaa-af4c-e9c9433f7b9a">216,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjctMy0xLTEtMjY2MzU_2940f95b-d79c-47bc-9847-da646c8f7129">213,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjgtMS0xLTEtMjY2MzU_51cfcc8f-4a0c-4269-ac09-0a8d53aba5ee">66,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjgtMy0xLTEtMjY2MzU_f9f459f5-1644-4c83-b027-bcd4760c13fb">46,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjktMS0xLTEtMjY2MzU_5e330de7-f981-4951-8f7c-5e0936f6090a">149,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjktMy0xLTEtMjY2MzU_43e68e71-4f00-46a4-ba95-6386f22c9069">166,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMzAtMS0xLTEtMjY2MzU_ca11ca05-0a3c-4757-a13c-34e3d0013751">181,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMzAtMy0xLTEtMjY2MzU_72d7c26c-fd47-4657-8575-ab17cfb235fb">178,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080af938313c43d2b539cdefbcdfec98_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMy01LTEtMS0yNjYzNQ_f7558a8d-69d8-432a-a848-b51bdbbb34e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54381f41a7eb4b0ea3fbbbaeff54f01f_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMy03LTEtMS0yNjYzNQ_252b4c2b-9f5d-4b81-85f5-6aab9c8e3ea5">33,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f4a4782309e4d14a530821ddb8049b3_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNC01LTEtMS0yNjYzNQ_b52d9a45-4e54-4287-b016-e5aa0eb3c5f2">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29bc79115d7a4e0ca6736b6a0bd45d7e_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNC03LTEtMS0yNjYzNQ_d9adfa0b-e167-48e7-aefd-8b2218d8f03f">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNS01LTEtMS0yNjYzNQ_1000d62d-662a-4cef-a016-c51f95de2920">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNS03LTEtMS0yNjYzNQ_c9de247d-1f28-4cb8-87f5-4a053f6044b9">33,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of license fees and collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8026e35afb834d3cb1f3553098db8877_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNy01LTEtMS0yNjYzNQ_49ccb660-c789-49df-ba66-7db10d4b86b3">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4f887cfb0f4ab5be157a6b1b3689d8_D20210101-20210331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNy03LTEtMS0yNjYzNQ_eb9fccfb-7495-402b-a150-aa752b246064">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfOC01LTEtMS0yNjYzNQ_6bc2e9e6-6ca3-4e48-a80f-9abb8cb15004">12,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfOC03LTEtMS0yNjYzNQ_6d9e570d-5a9a-48bb-927e-8245cd79ca10">16,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfOS01LTEtMS0yNjYzNQ_a1805982-1ab1-4bd0-bcf4-41d85c5d6af8">7,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfOS03LTEtMS0yNjYzNQ_27711d3e-d010-4b31-9c41-a53d6a2d3973">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTAtNS0xLTEtMjY2MzU_fbf6ce6e-d393-4e8e-ada8-7b3ab56b8f64">20,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTAtNy0xLTEtMjY2MzU_e9bfc31e-dd7e-48af-9537-eed1dd783067">22,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income from operations before other (expense) income and income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTEtNS0xLTEtMjY2MzU_0fb496b7-7f05-4a2e-8ad5-6f6f692c2cfc">19,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTEtNy0xLTEtMjY2MzU_79867e26-7af8-4b47-91ec-709b64dacc22">10,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest (expense) income, net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTMtNS0xLTEtMjY2MzU_b30906ef-50c3-4af5-bf8c-f56cb63d892c">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTMtNy0xLTEtMjY2MzU_c268d89c-c9d3-4992-bf28-dd4466ca891f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTQtNS0xLTEtMjY2MzU_0887ff0d-3d73-446d-899d-32a532ba8901">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTQtNy0xLTEtMjY2MzU_b6a05403-c5d6-4057-a3d4-b6e4819967f1">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTUtNS0xLTEtMjcwMTA_235c2e92-43e9-4553-9b66-727c7af268bc">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTUtNy0xLTEtMjcwMTA_fe11ca3a-0b43-4087-b1dc-3072fdf719cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTUtNS0xLTEtMjY2MzU_9b1f12ec-ba8d-4613-8efb-262f3de8b0d2">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTUtNy0xLTEtMjY2MzU_696f34f7-d394-45d1-8bd2-103a91fe7d83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTYtNS0xLTEtMjY2MzU_2a5413d9-47e7-4771-ad14-b17e85e6275f">716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTYtNy0xLTEtMjY2MzU_84299222-775b-4349-9c2b-3ae55eb2afcb">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTctNS0xLTEtMjY2MzU_7fa0c91c-d1a8-4f82-aed1-12f5e176d728">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTctNy0xLTEtMjY2MzU_10e6556a-a111-415b-af4b-d304e2b13374">313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income and comprehensive (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTgtNS0xLTEtMjY2MzU_55b98144-8fa4-4b4b-81f9-8416ae0241ad"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTgtNS0xLTEtMjY2MzU_dd9912bc-83e1-47fd-acd7-852f052d60ea">20,238</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTgtNy0xLTEtMjY2MzU_60bd9f47-3d41-42c4-a8e5-aa8f9dbe60f4"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTgtNy0xLTEtMjY2MzU_94a9eafe-4e13-4d74-a879-5b66a2cd4136">10,376</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) per share, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjAtNS0xLTEtMjY2MzU_e3287c77-308d-4d30-90e3-af5baba3eff1">0.98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjAtNy0xLTEtMjY2MzU_7035b968-290b-4fc7-8e8f-1c69450c05db">0.51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjEtNS0xLTEtMjY2MzU_b3f884c0-7387-43b4-9f17-bcd2adf78cee">0.98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjEtNy0xLTEtMjY2MzU_ac390df3-cf0c-4fa3-924d-44765b0b5433">0.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjMtNS0xLTEtMjY2MzU_3f6dafb1-8d66-4d60-9139-489103d16488">20,710,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjMtNy0xLTEtMjY2MzU_46f3da31-e22d-4e6d-a8b2-7b961e9cf02d">20,336,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjQtNS0xLTEtMjY2MzU_df738d43-b9b0-4c5c-a830-ef3d24fa4e7a">20,710,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjQtNy0xLTEtMjY2MzU_f96b5fe4-8d7d-43f4-8a03-0ecfb2970dc1">21,824,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.291%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi0xLTEtMS0yNjYzNQ_0ed78ba9-ae01-413a-8d48-37863d30fa1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi0zLTEtMS0yNjYzNQ_4b41407d-e53b-4716-b8a0-8eb7cc1225b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a0a5d596de347dfb2ee05dbf213d003_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi01LTEtMS0yNjYzNQ_51905746-fb1a-49d5-9d57-9cadeaa7f79e">20,698,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0a5d596de347dfb2ee05dbf213d003_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi03LTEtMS0yNjYzNQ_be8050a4-5419-4c07-8c27-0cfda0b81464">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bea9a87fa149f5b7b6f0c53df117f8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi05LTEtMS0yNjYzNQ_da798ce7-84ac-4925-93d2-7310642aad5b">213,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71110d20496a42568cfa4272b640c494_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi0xMS0xLTEtMjY2MzU_ede2744d-23cf-4cbf-8891-646b1a6d9e65">46,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi0xMy0xLTEtMjY2MzU_f58bc740-934a-48fb-aa26-839a52aeacfc">166,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i281e4ce0faee4e93b52b1c855c37b40e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMy0xMS0xLTEtMjY2MzU_fe4d4bdf-f0c3-42bb-8f55-2dfa400f8196">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMy0xMy0xLTEtMjY2MzU_f319e1a8-825b-48b7-9338-e7a4fb080ede">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db3f28f47a45fd81332519739fb47a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNC05LTEtMS0yNjYzNQ_b036bc63-50f9-4165-8f5f-66afd55fcc07">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNC0xMy0xLTEtMjY2MzU_13150872-160d-430b-97e0-7f2a2a77a1e3">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida7f2066d6ab4d298b57b9551607ddc1_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNS01LTEtMS0yNjYzNQ_4a950a74-ea3b-403d-9a14-18eb72b9752c">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon the vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida7f2066d6ab4d298b57b9551607ddc1_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNi01LTEtMS0zMDg4NA_db8ce575-cc0b-439c-b23e-9ac8d4762b26">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lapse of repurchase rights related to common stock issued pursuant to stock option exercises prior to vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida7f2066d6ab4d298b57b9551607ddc1_D20220101-20220331" decimals="INF" name="tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNi01LTEtMS0yNjYzNQ_2b990c32-1234-4d39-8f16-ae772b28fd89">15,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00db3f28f47a45fd81332519739fb47a_D20220101-20220331" decimals="-3" name="tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNi05LTEtMS0yNjYzNQ_bac46b92-1e72-4a84-8922-b445fe97de51">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNi0xMy0xLTEtMjY2MzU_afc5a596-5537-4816-8f74-9bde3209f77f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy0xLTEtMS0yNjYzNQ_09981e91-d2b7-489e-9fac-4be7dc412c27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy0zLTEtMS0yNjYzNQ_f11604eb-80e9-44c4-b061-894c1e292b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c1ad78fb81b430cab2abc5651cadb29_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy01LTEtMS0yNjYzNQ_e8302ade-6287-486c-92c3-e84ebd2e7f8e">20,718,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1ad78fb81b430cab2abc5651cadb29_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy03LTEtMS0yNjYzNQ_df054d92-58bc-4160-b14d-0cdc2edf787b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3d5c72a6a94f73955e1eb952386f30_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy05LTEtMS0yNjYzNQ_4cdd6e8c-38d6-42a1-b20b-bcbc0aede330">216,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibec2fec07baf4b5ea65315e3604b264b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy0xMS0xLTEtMjY2MzU_5baff17f-6606-4f8d-b540-732e3a24240a">66,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy0xMy0xLTEtMjY2MzU_8a3c63ad-41ed-41ce-b99c-5ecb90f8aada">149,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.290%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi0xLTEtMS0yNjYzNQ_495f8cac-b621-43a0-8a59-d01abf63f340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi0zLTEtMS0yNjYzNQ_02ede807-b424-4bef-852b-01e85c6540d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3d5cd01a5b74ad69d8cfb82b0ddb6b1_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi01LTEtMS0yNjYzNQ_3f455f00-a961-4edd-b455-036048c343a7">20,323,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d5cd01a5b74ad69d8cfb82b0ddb6b1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi03LTEtMS0yNjYzNQ_10224086-8c68-4b7e-b9df-4af8bfed431f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2407365462b6484e866e2a0897a6f31f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi05LTEtMS0yNjYzNQ_5d15efd2-e558-4db2-bac5-8ac32bcd91da">198,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eb871a3740c464480f7fcef3e833411_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi0xMS0xLTEtMjY2MzU_6f38af0a-8ba5-41ab-a6db-82dcfab8b753">32,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi0xMy0xLTEtMjY2MzU_b1e8833d-43d4-4823-bf6c-9cc584fdf715">165,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514947c5e4b04a378154c04684c04412_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMy0xMS0xLTEtMjY2MzU_2f210f16-dbca-4040-9240-97d214ec488e">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMy0xMy0xLTEtMjY2MzU_bd1d8381-8e12-41e1-9370-2354af6e48d0">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognition of stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5af16c925384bbda1b2f1b0f73319cf_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNC05LTEtMS0yNjYzNQ_42df6676-8406-4bbd-b502-b49431ebdb31">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNC0xMy0xLTEtMjY2MzU_f6098133-352e-4dac-b0d0-b074fe3eeb3f">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f1e1fe52f054a159eaad037bb720a9d_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS01LTEtMS0zMjQ2NA_51903e28-1dbf-4a01-929e-bff58b94f365">13,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5af16c925384bbda1b2f1b0f73319cf_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS05LTEtMS0zMjQ2NA_7916a993-5aa2-41f0-abf2-1cf102baf6ee">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS0xMy0xLTEtMzI0NjQ_a57c7224-0d72-4565-9a9e-360378c137ae">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued as consideration for in-license rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f1e1fe52f054a159eaad037bb720a9d_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS01LTEtMS0yNjYzNQ_96c421fb-6190-4ae0-818c-e86321771120">187,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5af16c925384bbda1b2f1b0f73319cf_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS05LTEtMS0yNjYzNQ_98b64e22-6a7c-4776-be17-acec77a75902">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS0xMy0xLTEtMjY2MzU_a4075634-68d8-4618-b509-4cfcbb60f23a">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id80221d972a4407a82832333ee98fc87_I20210331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi0xLTEtMS0yNjYzNQ_22114822-0fb8-4614-80f0-9df700548bb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80221d972a4407a82832333ee98fc87_I20210331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi0zLTEtMS0yNjYzNQ_3d0345ae-5e74-4714-9d4b-865ae444d4ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i015bde96678a4498b78f135f2e37fe8a_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi01LTEtMS0yNjYzNQ_8af00fc3-5e09-4097-8f7e-bd9e28dffe85">20,524,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015bde96678a4498b78f135f2e37fe8a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi03LTEtMS0yNjYzNQ_64818566-0127-404f-8db9-c255959edec8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7ac172fd5445a9afde9ded686451dd_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi05LTEtMS0yNjYzNQ_441d747d-a6d4-4b4d-b037-06c52899d4c9">205,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09758e9a44594ebf8985740d1bf5f229_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi0xMS0xLTEtMjY2MzU_7fddca71-e631-416a-b503-cc49eae4a0ca">22,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80221d972a4407a82832333ee98fc87_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi0xMy0xLTEtMjY2MzU_cc4107dd-b624-4a00-ad3f-514acc2845fa">183,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMy0xLTEtMS0yNjYzNQ_7f56cbe9-4db1-4ac5-905f-6709e3c7d91b">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMy0zLTEtMS0yNjYzNQ_05fd9123-6663-4b8d-890d-864beed3a19a">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNS0xLTEtMS0yNjYzNQ_28c9f082-35c5-404a-aea8-a99d9a38c83e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNS0zLTEtMS0yNjYzNQ_ac50f8fd-3d6b-4493-bcd3-8d5d9f694e56">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and accretion of long-term debt related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNi0xLTEtMS0zMTI0Mw_2a68854d-1d65-4501-941f-3bc49099948c">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNi0zLTEtMS0zMTI0Mw_b93a9f24-3902-4aa8-a621-c016dea92206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNi0xLTEtMS0yNjYzNQ_752e1062-bbbc-425f-b715-7b67607e82d9">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNi0zLTEtMS0yNjYzNQ_d5c29a8a-edfa-415e-8a86-095170776e42">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="tars:OperatingLeaseNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNy0xLTEtMS0yNjYzNQ_2294620e-1afe-4605-8cb2-8e8f1ba5756d">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="tars:OperatingLeaseNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNy0zLTEtMS0yNjYzNQ_f21af0a9-00f3-4d0d-89f8-d8bda54e32e2">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfOC0xLTEtMS0yNjYzNQ_ffe65ba7-f461-4708-89d1-334a498ca162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfOC0zLTEtMS0yNjYzNQ_35fce4f2-a981-4e52-90f0-134a1cc4dbc0">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfOS0xLTEtMS0yNjYzNQ_2d71b3d2-41f6-437f-b041-aec6afdaf8a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfOS0zLTEtMS0yNjYzNQ_ea573579-e261-4730-b0f4-bf1fe2e51a23">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTAtMS0xLTEtMjczMDU_3ade89e6-7ef6-4310-9a48-a72eb5948e35">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTAtMy0xLTEtMjczMDU_408a402c-e355-44f8-8c59-7c3620615c45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of equity warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTAtMS0xLTEtMjY2MzU_8bc83427-259c-4ed7-a1ae-9c7c6de8ae8a">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTAtMy0xLTEtMjY2MzU_cb67ebab-7520-49de-a801-1f9a7144117a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss (gain) from transactions denominated in a foreign currency</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTItMS0xLTEtMjY2MzU_850e89b3-aa11-49aa-88a2-cf939b2c2c40">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTItMy0xLTEtMjY2MzU_5ac61e2e-0c83-4426-83ae-616aea1fcb57">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to in-license agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTMtMS0xLTEtMjY2MzU_5821672f-d5b7-48ac-8daf-7e483ddef644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTMtMy0xLTEtMjY2MzU_011ca312-0b5e-4798-b6d6-fe91d1381a4d">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTUtMS0xLTEtMjY2MzU_c4ba4a3d-576a-4298-b5a9-58d0ecce8f20">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTUtMy0xLTEtMjY2MzU_77846f77-56fe-4234-8fef-4dcc1664ba31">25,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTYtMS0xLTEtMjY2MzU_a647d4a4-59dc-45a0-a7f1-1c2874524c49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTYtMy0xLTEtMjY2MzU_a81fa5f3-d0a1-4e1e-af67-38a54e08e12f">7,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTctMS0xLTEtMjY2MzU_e8981a99-53e8-4911-b778-29768bd2594f">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTctMy0xLTEtMjY2MzU_ff90f99e-3f07-4bc9-afdf-9234531b4f1e">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTgtMS0xLTEtMjY2MzU_8e9ac87d-251a-4f69-a640-6af8c43d6a4a">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTgtMy0xLTEtMjY2MzU_67091026-4304-4c61-901c-4594aa39409f">321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTktMS0xLTEtMjY2MzU_e52e0593-6562-48ae-91d9-4904a445db2b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTktMy0xLTEtMjY2MzU_bca99c00-08d8-4fa6-846d-0575ee7f6908">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjAtMS0xLTEtMjY2MzU_107d989c-ab8a-48c9-8a4b-015bd0f99660">1,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjAtMy0xLTEtMjY2MzU_33672169-50ec-476b-aa00-a565f55220d7">5,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjEtMS0xLTEtMjY2MzU_aaa4d51f-4e57-4fa9-af4e-d0b7971e63f4">993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjEtMy0xLTEtMjY2MzU_211b14a0-a4dd-4811-8b3e-2f8129115232">355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjItMS0xLTEtMjY2MzU_ba6fda11-25fd-496d-b8e8-745f51035829">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjItMy0xLTEtMjY2MzU_8bac714e-f82a-4410-b5df-6f7dc24c5f21">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjMtMS0xLTEtMjY2MzU_d46373d9-bd32-4a3a-853b-78dc0ea34fa2">15,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjMtMy0xLTEtMjY2MzU_5ccd6d2c-96b0-4b10-bdd2-0dbfcd0a8dc6">11,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjUtMS0xLTEtMjY2MzU_c60d317a-2891-45e1-8aa7-c8133e35caad">161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjUtMy0xLTEtMjY2MzU_00a3a67c-daff-4987-818d-3c6e78cc3142">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjYtMS0xLTEtMjY2MzU_4f5348f5-1486-49aa-aff8-a205540b19ab">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjYtMy0xLTEtMjY2MzU_7131745b-cb6c-4af5-9d51-9279a047dd20">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of vested stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="tars:ProceedsFromEarlyExerciseOfStockOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzAtMS0xLTEtMjczNjk_ebe53628-88aa-45bf-92c5-13d9185c023a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="tars:ProceedsFromEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzAtMy0xLTEtMjczNjk_32d9a014-dc20-4419-be78-652adcc33307">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of deferred offering costs </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="tars:PaymentsOfDeferredStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzEtMS0xLTEtMjczMzQ_54720601-5e87-493f-9297-74dd8d0b0d3b">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="tars:PaymentsOfDeferredStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzEtMy0xLTEtMjczMzQ_7af2f83f-c234-48f8-abbe-3053092dbae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzUtMS0xLTEtMzEyNjg_d7a70522-143f-4b6d-a54f-d93ac6e4e777">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzUtMy0xLTEtMzEyODU_e3c638ba-5bd7-427f-bab1-6241084ff02e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzYtMS0xLTEtMzEyNjg_ea0bb7a9-6fab-4898-84ee-d538fdba4d84">815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzYtMy0xLTEtMzEyODU_5121d61a-de3a-4016-ba13-a3035e26c6f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzItMS0xLTEtMjY2MzU_02b4e168-42a7-4893-8e6e-e6bbeef480b0">19,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzItMy0xLTEtMjY2MzU_2865d152-daf8-4135-aa79-ebf438f23526">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzMtMS0xLTEtMjY2MzU_f994c23c-5273-41a5-9455-2100ff2b2447">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzMtMy0xLTEtMjY2MzU_edb869d5-9ed8-4a32-b042-2b14d8fd27e6">11,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash &#8212; beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzQtMS0xLTEtMjY2MzU_d4064c8c-f7ad-41aa-8bf1-efb180d78b4b">171,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzQtMy0xLTEtMjY2MzU_ef1b83b1-86af-496f-9870-493ae2821268">168,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash &#8212; end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzUtMS0xLTEtMjY2MzU_0a24243a-5631-4f5c-bf35-99642cf2d0ff">175,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80221d972a4407a82832333ee98fc87_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzUtMy0xLTEtMjY2MzU_27e3ac02-e346-4c45-8632-0d89c5805282">156,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzctMS0xLTEtMjY2MzU_671563dd-d479-4e9b-baeb-5431e67453c3">175,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80221d972a4407a82832333ee98fc87_I20210331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzctMy0xLTEtMjY2MzU_ae550f17-7cab-4544-b987-19e83886fe9e">156,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzgtMS0xLTEtMjY2MzU_3345ddd6-f935-4d82-b3ca-bf6904133a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80221d972a4407a82832333ee98fc87_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzgtMy0xLTEtMjY2MzU_c358738a-d4fa-492d-be23-5f60db8af626">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzktMS0xLTEtMjY2MzU_0227e350-c9e1-4f98-bc43-42a7b4887f1b">175,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80221d972a4407a82832333ee98fc87_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzktMy0xLTEtMjY2MzU_b13011e6-a0c6-4308-8b02-8948d1050f44">156,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Disclosures Noncash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">"Interest expense" paid in cash</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDgtMS0xLTEtMzEzMjI_1e488573-469b-4787-8874-c5a09baaef32">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDgtMy0xLTEtMzEzMjI_614420a6-6c88-444f-8018-f06153995b53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions of "property and equipment, net" included within "accounts payable and other accrued liabilities"</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDMtMS0xLTEtMjY2MzU_31d14ae3-af7d-404e-b398-7c1fdebf2e07">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDMtMy0xLTEtMjY2MzU_39d58f92-ef2e-4121-a5c3-79a341e55ee8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expensing of "operating lease right-of-use assets" upon lease termination</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="tars:OperatingLeaseRightOfUseAssetLeaseTerminationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDQtMS0xLTEtMjY2MzU_f7bf1da5-2023-4962-8613-ab162b101725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="tars:OperatingLeaseRightOfUseAssetLeaseTerminationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDQtMy0xLTEtMjY2MzU_a743a9b8-2e9e-4729-9d60-7aedfacd41e7">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock issued for in-license agreements</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDUtMS0xLTEtMjY2MzU_26b626ac-924f-4ba1-a9e6-c72be0c83464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDUtMy0xLTEtMjY2MzU_2a63792f-0b2c-457c-b47e-6981fd099afa">5,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred offering costs included within "accounts payable and accrued liabilities"</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="tars:DeferredOfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDctMS0xLTEtMjY2MzU_f14537e5-9ae3-4e94-b2d2-6888cdf2ba3d">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="tars:DeferredOfferingCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDctMy0xLTEtMjY2MzU_3f8f23a1-b0a4-411f-a309-c28b922acdc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_31"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i33713c367fc84a8b901b03655de07e3d_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjMzNg_77a74df9-0090-4116-ac6a-b6903d9b82e7" continuedAt="i14cab932da974e01be1b87d5a1102c12" escape="true">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="i14cab932da974e01be1b87d5a1102c12" continuedAt="ie5394c9a85f0413a9e98d687d3b6d794"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Description of Business</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(b)  Liquidity</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has no product sales and has accumulated losses and negative cash flows from operations since inception (other than consideration received from an out-licensing agreement, as discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), resulting in an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfMTcxMg_caa1adc5-c200-44a7-b6ca-7b40e0238baa">66.9</ix:nonFraction> million as of March&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfMTcyOA_3f2ed77d-cd1e-4cf2-94f4-b2fea32b83c7">46.7</ix:nonFraction> million as of December&#160;31, 2021. The Company&#8217;s cash and cash equivalents were $<ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfMTc4Ng_c163bd07-3d03-48c2-9b9e-bd7ba5038482">175.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfMTc5Mw_c052d1c0-8792-4aca-856c-5bce8525fc6f">171.3</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The Company expects to continue to incur operating losses and negative cash flows.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 2, 2022, the Company executed a loan and security agreement (the "Credit Facility") with Hercules Capital, Inc. ("Hercules") and Silicon Valley Bank ("SVB"). This $<ix:nonFraction unitRef="usd" contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjU5NzA2OTc4MjE0Mw_f264f34f-65a2-4b1e-bde6-429217df914f">175</ix:nonFraction>&#160;million Credit Facility has tranched availability. Capital draws are at the Company's election and are in $<ix:nonFraction unitRef="usd" contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202" decimals="-6" name="tars:LineOfCreditFacilityDrawDownIncrements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjU5NzA2OTc4MjE0Nw_b0fcf740-304e-46ee-9c9b-c0e8ec8bd78e">5</ix:nonFraction>&#160;million increments. In February 2022, the Company made a $<ix:nonFraction unitRef="usd" contextRef="i64ab1022c5cf4cbf9f780e24d3f48ca8_D20220201-20220228" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjU5NzA2OTc4MjE1MQ_4827a5e7-ac21-4305-95fe-db3ab3c1851b">20</ix:nonFraction>&#160;million draw (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). </span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has funded its inception-to-date operations primarily through equity capital raises, proceeds from its out-license agreement, and draw downs on its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating requirements beyond at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q. Accordingly, the accompanying financial statements in this Form 10-Q have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations currently consist of its corporate organization build-out, intellectual property licensing activities, and preclinical and clinical study progression. The Company faces the clinical, business, and liquidity risks that are typically associated with biopharma companies; it must significantly invest in and conduct research and development activities, achieve research and development outcomes that are inherently uncertain, recruit and retain skilled personnel (including executive management), and expand and defend its intellectual property rights.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Management expects the Company to continue to incur losses in the foreseeable future as a result of research and development activities and other operating expenses. The Company may be required to raise additional capital to fund its future operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, if at all. If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. The Company's Credit Facility imposes additional covenants that restrict operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase common stock, make certain investments, or engage in certain merger or asset sale transactions. Any debt financing or additional equity raise may contain terms that are not favorable to the Company or its stockholders. The Company&#8217;s potential inability to raise capital when needed could have a negative impact on its financial condition and ability to pursue planned business strategies. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own. If the Company is required to enter into collaborations and other arrangements to address its liquidity needs, it may have to give up certain rights that limit its ability to develop and commercialize product candidates or may have other terms that are not favorable to the Company or its stockholders, which could materially and adversely affect its business and financial prospects. These factors may adversely impact the Company's ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Operating Segment  </span></div></ix:continuation><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjMzNw_8b1eeef0-6ee5-47dd-b8d3-c5aae72d6bbb" continuedAt="if40b263d34c24de790817e8b98ef994d" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie5394c9a85f0413a9e98d687d3b6d794"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if40b263d34c24de790817e8b98ef994d">To date, the Company has operated and managed its business and financial information on an aggregate basis based on the Company's organizational structure, for the purposes of evaluating financial performance and the allocation of capital and personnel resources, consistent with the way operations and investments are centrally managed and evaluated. Accordingly, the Company&#8217;s management determined that it operates <ix:nonFraction unitRef="segment" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNTU0Mw_07fcfb4e-4c19-4610-9a22-50c93886d435"><ix:nonFraction unitRef="segment" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNTU0Mw_e8a14729-7b99-4881-b29c-ec247b452041">one</ix:nonFraction></ix:nonFraction> reportable operating segment. This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div></ix:continuation><div id="i33713c367fc84a8b901b03655de07e3d_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1Mzg_3764417a-84fa-416b-8b8f-a21bbd56bf37" continuedAt="i90454a4f8b434484950f9449e3e679ba" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES</ix:nonNumeric></span></div><ix:continuation id="i90454a4f8b434484950f9449e3e679ba" continuedAt="if5ddebd701904702a718e3059632fe44"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1Mjk_4b9b0be0-e6e7-4037-ab00-2475356e2eac" continuedAt="i6236e77fa01540f389fad2308306b108" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i6236e77fa01540f389fad2308306b108"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements have been prepared in conformity with accounting principles generally accepted ("GAAP") in the United States ("U.S.") for interim financial information and pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2022, the interim Condensed Statements of Operations and Comprehensive (Loss) Income, and Stockholders&#8217; Equity for the three months ended March&#160;31, 2022 and 2021, and the interim Condensed Cash Flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2022 or any other interim or annual period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March&#160;14, 2022.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to forecast and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no significant changes in the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2022, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on March 14, 2022.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below:</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(ii) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzU_b6c7a683-eb68-4d84-97b7-0acc3610b530" continuedAt="i37553d26572f4f04b39ebe2bd4deade8" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="if5ddebd701904702a718e3059632fe44" continuedAt="idc768890b25645d3b3a5ed9485149e3b"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i37553d26572f4f04b39ebe2bd4deade8">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iii) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfNTQ5NzU1ODE3NzcxNg_cc30b8b8-4bb2-4538-b747-5ca03c937eb3" continuedAt="iad1404f2b03143e2b22309f13c46f605" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><ix:continuation id="iad1404f2b03143e2b22309f13c46f605" continuedAt="ibdd905c4cd2a4ea9b97da29f896bbaac"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities represent LianBio Ophthalmology Limited ("LianBio") common stock (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibdd905c4cd2a4ea9b97da29f896bbaac">) designated as "available-for-sale securities" with associated gains or losses recorded within "other expense, net" within the Condensed Statements of Operations at each reporting period.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iv) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1Mzc_02d96482-5a88-4b96-960f-49e2e7f732bc" continuedAt="ieb8a874c23464bb994590ee5018ab5e5" escape="true">Concentration of Credit Risk and Other Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="ieb8a874c23464bb994590ee5018ab5e5"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak. The COVID-19 pandemic continues to evolve and its impact on the Company&#8217;s business will depend on several factors that are highly uncertain and unpredictable, including, the efficacy and adoption of vaccines, future resurgences of the virus and its variants, and the speed at which government restrictions are lifted. To date, the Company&#8217;s operations have not been significantly impacted by the COVID-19 pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#8217;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#8217;s potential product candidates, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, it could have a materially adverse impact on the business.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(v) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzE_d6898f9e-b35d-4c61-b870-1d0d3751e2e9" continuedAt="id5dc815e4fd445d0aab6ce390223d2f3" escape="true">Revenue Recognition for Out-License Arrangements</ix:nonNumeric></span></div><ix:continuation id="id5dc815e4fd445d0aab6ce390223d2f3" continuedAt="i2842e2150dba417795c1c26833a3c4be"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has one out-license arrangement that allows the third-party licensee to market the its TP-03 product candidate (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement, as described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="idc768890b25645d3b3a5ed9485149e3b" continuedAt="ia07ec2580aac4046baaa088880e7c7e0"><ix:continuation id="i2842e2150dba417795c1c26833a3c4be" continuedAt="ib9c6e209290048e58e203faf08bb0484"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement includes the following forms of consideration: (i) non-refundable upfront license payments, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales threshold milestones, (v) development milestone payments, and (vi) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determined the milestone and other contingent amounts to be "constrained" until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the &#8220;most likely amount&#8221; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. </span></div></ix:continuation></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia07ec2580aac4046baaa088880e7c7e0" continuedAt="i6c28429002ee4ee59f17433f2a9c5ef6"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib9c6e209290048e58e203faf08bb0484">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. A "performance obligation" is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s "transaction price" is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(vi) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1NDA_2c59d796-51d6-4cb0-8d98-1dd520e3dbf6" continuedAt="i58afec7db60142e0b5ca483ff679a1da" escape="true">Research and Development Costs</ix:nonNumeric></span></div><ix:continuation id="i58afec7db60142e0b5ca483ff679a1da"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, clinical manufacturing costs, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set or a business, as defined under applicable GAAP. The Company&#8217;s executed in-license agreements (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have no alternative future use, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vii) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzI_36b93bcd-bd98-40b4-8eab-bf1c9b9d39c0" continuedAt="ie1af21b7bd4d48af80db2b939da7fe8e" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ie1af21b7bd4d48af80db2b939da7fe8e" continuedAt="i69ca1aa9544749e09236f56b09e6942b"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. The Black-Scholes pricing model is used to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing share price preceding the date of grant.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the same period of occurrence. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a)&#160;the fair value of the Company&#8217;s common stock on the date of the option grant for all awards granted prior to the Initial Public Offering ("IPO"), (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management estimates the expected term of awarded stock options utilizing the &#8220;simplified method&#8221; for awards as the Company does not yet have sufficient exercise history since its November 2016 corporate formation. The Company lacks company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i6c28429002ee4ee59f17433f2a9c5ef6" continuedAt="ibca359fd7faa436cb02745e29bc5f6d7"><ix:continuation id="i69ca1aa9544749e09236f56b09e6942b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the awarded stock option. The Company&#8217;s expected dividend yield is <ix:nonFraction unitRef="number" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMTcxMzI_6ace9531-fdbb-4c29-a3b7-06fd57c60030">zero</ix:nonFraction> because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the Statements of Operations and Comprehensive (Loss) Income within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(viii) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzQ_a26716a5-2638-42d8-b44b-2f58db61a87b" continuedAt="i9f192aaf22b8406aaddb153f4fa8e974" escape="true">Net (Loss) Income per Share</ix:nonNumeric></span></div><ix:continuation id="i9f192aaf22b8406aaddb153f4fa8e974"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common stock equivalents outstanding for the period determined using the "treasury-stock method" and "if-converted method" as applicable. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s "participating securities" include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses, so in periods of net losses, the "two-class method" of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Also, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three months ended March&#160;31, 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in this period.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ix) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1NDE_c839ca97-c1bc-458f-836d-f3b1a0aaabf5" continuedAt="i87a6dfb48967444aae471f4924ade0b9" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i87a6dfb48967444aae471f4924ade0b9" continuedAt="ib2ca9bcd9be8478682f5b34719975115"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. The Company's equity warrant holdings are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ibca359fd7faa436cb02745e29bc5f6d7"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib2ca9bcd9be8478682f5b34719975115">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(x) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1NDI_25a4602e-ff4d-40bc-8a02-77aec022b247" continuedAt="i801fd5795cc24bb9902159abe9eaabb0" escape="true">Comprehensive (Loss) Income </ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i801fd5795cc24bb9902159abe9eaabb0">Comprehensive (loss) income represents all changes in stockholders&#8217; equity (deficit), except those resulting from distributions to stockholders. For all periods presented in the accompanying Condensed Financial Statements, comprehensive (loss) income was the same as reported net (loss) income.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xi) <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzA_f7195154-f410-4b89-8c64-efa446253e75" continuedAt="icbb9be953af24ec5a0072017162484c0" escape="true">Recently Issued or Effective Accounting Standards</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icbb9be953af24ec5a0072017162484c0">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.</ix:continuation></span></div></ix:continuation><div id="i33713c367fc84a8b901b03655de07e3d_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyNw_c9280aee-f45e-4c92-ab0a-b38dbea1b0da" continuedAt="i0248081d1e814d239d26388c760f8d6d" escape="true">BALANCE SHEET ACCOUNT DETAIL</ix:nonNumeric></span></div><ix:continuation id="i0248081d1e814d239d26388c760f8d6d" continuedAt="i4eee68e3afd243cc84f86044ffc170f6"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Property and Equipment, Net </span></div><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyNA_03039f27-8290-44c5-b960-42f54e132957" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Property and equipment, net&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f4cdbf078647fdb5714433c4e54968_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMS0xLTEtMS0yNjYzNQ_c6a9def6-f51d-4fad-a474-c2ae08ca738c">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6b657919b045119943a31c80f1d1c7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMS0zLTEtMS0yNjYzNQ_7736ab50-8a97-403b-a43c-df91443a7c47">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c2f7bb7a9144feb30baaa206b3c84f_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMi0xLTEtMS0yNjYzNQ_da7de2d7-19e0-410a-ba43-2f8ace1ed80c">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a55c6f2a5cd4609a8fd119dfcd1fcfb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMi0zLTEtMS0yNjYzNQ_6dc3a6d2-cb7f-4b54-ad4c-c4e500f8f718">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7529cd5b41004750957c29f40fae72bc_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMy0xLTEtMS0yNjYzNQ_dff62847-8b8d-45f0-9581-a4597d4a3ea6">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b632727d0924b539bb949a88a28ac4c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMy0zLTEtMS0yNjYzNQ_3ca1a41c-b7f9-4fd1-be0e-a397b01fcf7e">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2f6cc3612846ed80ef0e9ff22f78ee_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNC0xLTEtMS0yNjYzNQ_d2a97d2e-865b-4608-a13c-677d65a92b64">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26735dafdb274401bedfa5360ff79acb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNC0zLTEtMS0yNjYzNQ_9b3ff729-b70c-4cfe-8a37-857bbb58faba">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNS0xLTEtMS0yNjYzNQ_1192775b-642d-4d76-b5b7-8569e4bf5674">1,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNS0zLTEtMS0yNjYzNQ_2fc9db17-45e4-4403-a118-1daba72b24b6">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNi0xLTEtMS0yNjYzNQ_855a5b81-e2ff-42c0-858a-813847c3f95a">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNi0zLTEtMS0yNjYzNQ_800f6277-6f3a-43a1-8209-8444a6347027">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNy0xLTEtMS0yNjYzNQ_f5f17921-f2dc-4feb-a555-a2f369015e00">915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNy0zLTEtMS0yNjYzNQ_e34d0817-2fe5-4f12-b631-d0817b452d4c">755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense (included within &#8220;total operating expenses&#8221; in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income) for the three months ended March 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTA5OTUxMTYyOTY5OA_cfd13d25-5ddd-4d8d-a50e-c864dae969d4">41</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTA5OTUxMTYyOTcxMw_741b47b6-4b68-475d-a467-ecae6125eb30">64</ix:nonFraction> thousand, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Other Assets</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i4eee68e3afd243cc84f86044ffc170f6"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyNQ_f73e5edf-aba6-46ce-973a-401497a8ef29" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Other assets" consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:DepositAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMS0xLTEtMS0yNjYzNQ_96ffbcc9-f65a-4db0-ad7d-73192b076e5b">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:DepositAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMS0zLTEtMS0yNjYzNQ_c5ae0cab-3b07-4174-b9a8-90998d6f9491">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="tars:EquityWarrantRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMi0xLTEtMS0yNjYzNQ_851c95f0-cd0b-4307-99f5-c68b43f2dad1">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="tars:EquityWarrantRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMi0zLTEtMS0yNjYzNQ_adeaae96-999b-4a30-a9fb-b72dde780c9b">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMy0xLTEtMS0yNjYzNQ_fd679448-1c3b-4e9f-a29c-83962e1dd6a3">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMy0zLTEtMS0yNjYzNQ_6ef60db7-2b55-491b-a6e1-55aae5349d92">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfNC0xLTEtMS0yNjYzNQ_76f236a0-898b-45cc-b886-9ddbc1dc1456">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfNC0zLTEtMS0yNjYzNQ_6da267bb-8f84-4ee8-96c7-d98a66f2f3a7">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Accounts Payable and Other Accrued Liabilities&#160;</span></div><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyOA_f4754b74-8e67-4bdb-87f7-233c346e4e83" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Accounts payable and other accrued liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfMS0xLTEtMS0yNjYzNQ_f1547683-58ac-4ea2-a85d-28a9bc51e2ed">4,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfMS0zLTEtMS0yNjYzNQ_d407525d-6013-4b91-82d3-4044f7521b80">2,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfMy0xLTEtMS0yNjYzNQ_9ca54971-6d3f-4976-a645-94775084cf04">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfMy0zLTEtMS0yNjYzNQ_23e72b9b-ee6b-47b6-a240-65e709e16442">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="tars:AccruedClinicalStudiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNC0xLTEtMS0yNjYzNQ_99a70c19-203a-49de-9a16-42b6c1ff06b8">5,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="tars:AccruedClinicalStudiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNC0zLTEtMS0yNjYzNQ_34a7c9dd-8e3a-4004-adb7-976b646c00fd">4,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNS0xLTEtMS0yNjYzNQ_d87e27a3-8725-4123-8a8e-f3f0da0ae631">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNS0zLTEtMS0yNjYzNQ_767b8833-07d7-4622-a9e7-a734f81ec9cf">697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNi0xLTEtMS0zMTgwMg_9aacc8b3-8573-4c58-8d3a-55f03d1848d0">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNi0zLTEtMS0zMTgwMg_a54eef6f-dcce-42b2-bf3f-bec3b7621853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNi0xLTEtMS0yNjYzNQ_ad0f7325-644c-48a2-ab14-1d19193d5134">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNi0zLTEtMS0yNjYzNQ_8da23b48-1db4-4663-b3ec-da53841a1eed">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock option pre-vesting exercise liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNy0xLTEtMS0yNjYzNQ_7ad4d522-da71-4c89-ab20-7f56a5866826">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNy0zLTEtMS0yNjYzNQ_88b6ba23-52c6-4b68-9539-fa2af79eb205">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfOC0xLTEtMS0yNjYzNQ_5f74f89d-3f1b-4544-8b3b-eca05a4f47d2">10,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfOC0zLTEtMS0yNjYzNQ_74b9ea9d-82d7-4994-a175-b76c0a1edd6d">8,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Other Long-Term Liabilities</span></div><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:OtherLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyNg_4405a65f-7de9-4ac8-9545-a045b629ef42" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other long-term liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, non-current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfMS0xLTEtMS0yNjYzNQ_61ebe891-82f1-40ec-b0b5-780eb8007161">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfMS0zLTEtMS0yNjYzNQ_0f78043e-a6ae-4111-bf2f-aa3026c58e1e">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfMi0xLTEtMS0yNjYzNQ_210a71aa-8bb4-4e66-a4ec-16d59217fbd3">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfMi0zLTEtMS0yNjYzNQ_644f41c9-5fc6-4746-9517-3ef08589e874">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfNC0xLTEtMS0yNjYzNQ_5df369c0-d88f-4f3a-ac9e-81ed4a43814f">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfNC0zLTEtMS0yNjYzNQ_8e84d7d4-bad1-4e49-a754-7286d5f0ca35">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i33713c367fc84a8b901b03655de07e3d_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfOTQ2_a4db15fa-98f3-45c8-bb0f-6da9436416c9" continuedAt="ief63f1b8ebd848f78ff7fefe9d73e6d4" escape="true">STOCKHOLDERS&#8217; EQUITY AND EQUITY INCENTIVE PLANS</ix:nonNumeric></span></div><ix:continuation id="ief63f1b8ebd848f78ff7fefe9d73e6d4" continuedAt="i446e4d7c6e594c288866409050adc123"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Outstanding and Reserves for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfNzM0_6aab2eeb-73b2-4b51-afca-3398cd8571d0"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfNzM0_8ccb9f38-40e0-45e3-91d2-4b944cf3763e"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfNzM0_aaaec789-795e-43be-879a-c0b8a49468f3"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfNzM0_dbc900ad-179b-4858-b8f5-db0e2e74366c">20.7</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million common shares issued and outstanding.  Each share of common stock is entitled to one vote. </span></div><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfOTQ1_f5b17432-bce4-4b33-8592-c2d8b3864d49" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan (the "ESPP") is summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMS0xLTEtMS0yNjYzNQ_44d6128d-7008-4be8-bcf8-579df5db58c3">8,954,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMS0zLTEtMS0yNjYzNQ_087d50e7-5a6b-45bc-8bdf-554ec3d83bd0">9,266,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMi0xLTEtMS0yNjYzNQ_0bb0de1a-5780-4c4e-b121-0776237c61dc">2,700,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMi0zLTEtMS0yNjYzNQ_417b7f53-ab8c-4453-9fa6-3a0e96f0c789">2,493,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMy0xLTEtMS0yNjYzNQ_e1e20851-4ec1-479e-a7e7-03aa272414fc">3,561,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMy0zLTEtMS0yNjYzNQ_87066706-e28b-40a1-95bd-ba900b575512">2,759,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units outstanding under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfNC0xLTEtMS0yNjYzNQ_ec6adf2a-e86c-443d-ab78-ba444b87336b">351,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfNC0zLTEtMS0yNjYzNQ_6f8db2c7-f9f4-4ac9-961d-d3e11352a796">17,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfNS0xLTEtMS0yNjYzNQ_9e6bac0c-7b3c-4198-bac3-e816d23702d0">15,567,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfNS0zLTEtMS0yNjYzNQ_09bed73f-0d51-4549-8b9e-ce83d288f198">14,536,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i446e4d7c6e594c288866409050adc123" continuedAt="i61ba24960434470f95600885ecc7ee1c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors and stockholders adopted and approved the Company's 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) on October 8, 2020. The 2020 Plan replaced the Company's 2016 Equity Incentive Plan that was adopted in December 2016 (the &#8220;2016 Plan&#8221;).  However, awards outstanding under the 2016 Plan will continue to be governed by its original terms. The number of shares of the Company's common stock that were initially available for issuance under the 2020 Plan equaled the initial sum of <ix:nonFraction unitRef="shares" contextRef="i6dd617ed38c64f83b2e2428b1abde32a_I20201008" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTI1MTI_0f3e5ab4-b824-48b2-a729-bd5e7bc03812">9,000,000</ix:nonFraction> shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="ic93546034bb142b0a219d72347552482_I20201008" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTI1Mjg_63ffba37-5634-44cb-af2c-6ba34acc18e1">2,432,980</ix:nonFraction> shares that were then available for issuance under the 2016 Plan. The 2020 Plan provides for the following types of awards: incentive and non-statutory stock options, stock appreciation rights, restricted shares, and restricted stock units.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock reserved for issuance under the 2020 Plan are increased automatically on the first day of each fiscal year, commencing in 2021 and through 2030, by a number equal to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lesser of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) <ix:nonFraction unitRef="number" contextRef="id0927937cbbe4b248a2bb3faaf75bded_I20220331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTMxOTQxMzk1NDMyNjQ_68e3b039-ef3c-40a1-a19d-a634624fb592">4</ix:nonFraction>% of the shares of common stock outstanding on the last day of the prior fiscal year; or (ii) the number of shares determined by the Company's Board of Directors. In general, to the extent that any awards under the 2020 or 2016 Plans are forfeited, terminate, expire or lapse without the issuance of shares, or if the Company reacquires the shares subject to awards granted under the 2020 or 2016 Plans, those shares will again become available for issuance under the 2020 Plan, as will shares applied to pay the exercise or purchase price of an award or to satisfy tax withholding obligations related to any award.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2022, all awards issued under the 2020 Plan and 2016 Plan were in the form of stock options and restricted stock units. These stock award agreements have service and/or performance conditions for vesting, unless immediately vested on the date of grant. Stock awards granted typically have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTM5MTI_01c7ccdd-ab1b-4a6d-8be3-01ce640cfa8d">one</span> to <ix:nonNumeric contextRef="i1c7789b1b50744a99ead19fcb7d24c12_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYxOA_ccb5c552-1b6f-4505-b42a-3a235ec8b39d">four-year</ix:nonNumeric> service conditions for full vesting. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options must be exercised, if at all, no later than <ix:nonNumeric contextRef="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTMxOTQxMzk1NDMyNjk_feebe1f7-fdee-4a70-9303-f743f02ddfaf">10</ix:nonNumeric> years from the date of grant. Upon termination of employment, vested stock options may be exercised within <ix:nonNumeric contextRef="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYyOQ_0f550e1e-181c-4796-ab44-7083f9cfbda2">12</ix:nonNumeric> months after the date of termination upon death, <ix:nonNumeric contextRef="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYyNQ_0c242b42-9176-4c67-a45e-790b92752e16">six months</ix:nonNumeric> after the date of termination upon disability, and <ix:nonNumeric contextRef="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331" name="tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYzMw_c193c1df-ef28-4d4a-b033-a5586d3d9a0c">three months</ix:nonNumeric> after the date of termination for all other separations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Vesting Exercise Feature of Certain Stock Options </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Plan permitted certain option holders to exercise awarded options prior to vesting. Upon this early exercise, the options became subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These unvested options are subject to repurchase by the Company upon employee termination at the same price exercised. These unvested shares of common stock are reported as issued (but not outstanding) on the accompanying Condensed Balance Sheets while subject to repurchase by the Company. These shares are also excluded from the basic net (loss) income per share until the repurchase right lapses upon vesting, but are included in the diluted net income per share for the three months ended March&#160;31, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially records a liability for these early exercises that is subsequently reclassified into stockholders&#8217; equity on a pro rata basis as vesting occurs. As of March&#160;31, 2022 and December&#160;31, 2021, the Company recorded the unvested portion of the exercise proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTYxOTE_2ef0ab9b-f1b8-4ef4-8597-262e71f80a64">25</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTYxOTk_a9899195-df58-4639-b83a-222781b7b480">56</ix:nonFraction> thousand, respectively, within "accounts payable and other accrued liabilities" in the accompanying Condensed Balance Sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-5" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTA5OTUxMTYzMDI0MA_aa040b10-3e3d-49b8-8d20-423d38f09af9">2.7</ix:nonFraction>&#160;million shares of common stock are authorized and remain available for issuance under the Company's ESPP. Beginning on January 1, 2021, and each January 1st thereafter, pursuant to the terms of the ESPP, the number of common stock available for issuance under the ESPP is automatically increased by an amount equal to the least of (i) <ix:nonFraction unitRef="number" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ0NDU2MQ_b30b601f-31f0-4469-8344-a3b470e1b397">one</ix:nonFraction> percent of the total number of shares of common stock outstanding on the last day of the previous fiscal year, (ii) <ix:nonFraction unitRef="shares" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-5" name="tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ0NDUxOA_a9aa6c93-33cb-45d0-8ef5-273b315724da">2.3</ix:nonFraction>&#160;million shares, or (iii) a number of shares determined by the board of directors.  </span></div></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><ix:continuation id="i61ba24960434470f95600885ecc7ee1c" continuedAt="id3c49c32b4f948a38ca84863c5393e31"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the ESPP, eligible employees can purchase common stock through scheduled payroll deductions. The purchase price is equal to the closing price of the Company's common stock on the first or last day of the offering period (whichever is less), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">minus</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id3c49c32b4f948a38ca84863c5393e31"> a <ix:nonFraction unitRef="number" contextRef="id03a5a0a91cb4b4586a1f8ee04c3d481_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYzNw_256b9fd2-87c0-4336-bb82-65308e63566f">15</ix:nonFraction>% discount.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div id="i33713c367fc84a8b901b03655de07e3d_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RleHRyZWdpb246MDQxYmEyODBjMmUyNDk2Y2JkY2NlMGRhMzNhNmMwZGJfNTY4OQ_73cab9a6-fd4e-42df-8419-e000dad558c6" continuedAt="i8c55a66a70954ee4b153cbdb74db3b8f" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i8c55a66a70954ee4b153cbdb74db3b8f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Summary</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is recorded in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income based on the designated department of the recipient. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RleHRyZWdpb246MDQxYmEyODBjMmUyNDk2Y2JkY2NlMGRhMzNhNmMwZGJfNTY4NQ_df1f366c-f86d-41af-a145-b2c92b690807" continuedAt="if860743ce2e44d248911c2c94c59ed17" escape="true">Stock-based compensation expense for the three months ended March 31, 2022 and 2021 was as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="if860743ce2e44d248911c2c94c59ed17"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic881c21880004c5ba362cfa7ce7524e5_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfMi0xLTEtMS0yNjYzNQ_15b584b8-5624-44d7-906f-e544ae4cd768">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f6cd5005f34480babb33821fa0f5fb_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfMi0zLTEtMS0yNjYzNQ_ed132b54-94ac-44e8-ad45-d32251a3bb2b">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f101ec5e8914faab8d26c11caedd9bb_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfMy0xLTEtMS0yNjYzNQ_cf320617-bae4-4d3f-ab50-e520f851e2f6">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892bc751c437460d89238d3ba9e8f045_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfMy0zLTEtMS0yNjYzNQ_2ddcbc5b-06e4-4dae-b83b-4774401a54a8">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfNC0xLTEtMS0yNjYzNQ_aab49798-6f5b-4618-a529-2e5835ae787f">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfNC0zLTEtMS0yNjYzNQ_5b07a66f-6ba0-4134-8a1c-9ce843ab4969">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_52"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RleHRyZWdpb246YWY2ZmMzZmJkMjg1NGQ5MDg0MDdkNzgxNmQ5OTkyOGZfMTE3MA_eedd9540-d76f-467a-b74c-3919292bef76" continuedAt="ic3039554d58c43738344bdad6e12c06c" escape="true">NET (LOSS) INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ic3039554d58c43738344bdad6e12c06c"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RleHRyZWdpb246YWY2ZmMzZmJkMjg1NGQ5MDg0MDdkNzgxNmQ5OTkyOGZfMTE3MQ_fb3ebbf7-13e2-4c44-8571-0cb2980f6d05" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net (loss) income per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMy01LTEtMS0yNjYzNQ_987407c8-8fe5-4a63-93b6-34d5e7119f50">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMy03LTEtMS0yNjYzNQ_6072de7d-f3e1-4e2c-ad83-c3aa750bba85">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: undistributed income allocated to participating securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNC01LTEtMS0yNjYzNQ_7de00700-39d4-45a0-8891-c66ae602ebfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNC03LTEtMS0yNjYzNQ_9b02298c-c028-4915-b3f9-187f8ee005ce">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income available to common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNS01LTEtMS0yNjYzNQ_8ea37423-1972-4a61-8284-c4f15e6cc966">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNS03LTEtMS0yNjYzNQ_2e498120-0773-489b-bd78-8f74e895af4c">10,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNy01LTEtMS0yNjYzNQ_0561de9c-7c68-4b6f-bf79-6353261cd05e">20,710,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNy03LTEtMS0yNjYzNQ_7604ac92-b2f1-41aa-844c-66c5dac2399a">20,336,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) per share&#8212;basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfOC01LTEtMS0yNjYzNQ_e3287c77-308d-4d30-90e3-af5baba3eff1">0.98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfOC03LTEtMS0yNjYzNQ_7035b968-290b-4fc7-8e8f-1c69450c05db">0.51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTEtNS0xLTEtMjY2MzU_a3ec6fe4-e6d5-41b4-8f8f-e4db3add1f03">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTEtNy0xLTEtMjY2MzU_8bdb1a5a-bd34-4b1f-9557-5b653b555758">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: undistributed income reallocated to participating securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTItNS0xLTEtMjY2MzU_158a328c-39f1-498a-bd16-457f2fffc0ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTItNy0xLTEtMjY2MzU_503d6ace-5787-4d65-b7b5-336179d8e047">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income available to common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTMtNS0xLTEtMjY2MzU_43e57a54-da90-48c5-99f4-2ef5eff850c0">20,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTMtNy0xLTEtMjY2MzU_9da28153-c499-4713-8b2c-f0e417d436dd">10,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTUtNS0xLTEtMjY2MzU_ae4c2ad9-9301-4537-a9be-8a3ed9dcbcd2">20,710,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTUtNy0xLTEtMjY2MzU_63db5d49-df93-445b-bce4-67e28fa4b451">20,336,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTctNS0xLTEtMjY2MzU_cde08da9-1881-402a-adc3-fba9a52ce4cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTctNy0xLTEtMjY2MzU_edabea56-f2fb-4f64-95b9-df0089a9654e">1,488,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTgtNS0xLTEtMjY2MzU_01e601fb-8622-44f4-b527-562af8e75c30">20,710,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTgtNy0xLTEtMjY2MzU_2af01d3f-90c3-445f-8350-257d978382dd">21,824,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share&#8212;diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTktNS0xLTEtMjY2MzU_b3f884c0-7387-43b4-9f17-bcd2adf78cee">0.98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTktNy0xLTEtMjY2MzU_ac390df3-cf0c-4fa3-924d-44765b0b5433">0.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RleHRyZWdpb246YWY2ZmMzZmJkMjg1NGQ5MDg0MDdkNzgxNmQ5OTkyOGZfNTQ5NzU1ODE0MTY0MQ_be109860-b9ca-40fe-9e0b-e36b95e9e5aa" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share because their impact under the &#8220;treasury stock method&#8221; and &#8220;if-converted method&#8221; would have been anti-dilutive for the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:71.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.411%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d25ce27b22641beb0bec11792f01c1f_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfMi0xLTEtMS0yODI5Ng_b1b3f240-c512-4523-8668-5d14fddf3d73">3,561,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67b53435adf9489a9a2daaff37121c44_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfMi0zLTEtMS0yODI5Ng_b3972324-96f6-4498-86c2-8bcb3e289ff6">632,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options early-exercised and unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i173cbb1387d1404085a5f0d1575e8f62_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfMy0xLTEtMS0yODI5Ng_6d8da35b-6793-490c-9800-dd92f0e4a1ca">12,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i861c82a1ea2c4d4ea4ae4e378321bb54_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfMy0zLTEtMS0yODI5Ng_5fd836c9-dd40-4a5b-9ebf-afad61af7423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27aa992f7c3f4d339542898fcd3905bd_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfNC0xLTEtMS0yODI5Ng_91416059-d60f-4a37-aa27-bd419f12bfbd">351,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ceb379731724bc085f3a4a5ce44d64f_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfNC0zLTEtMS0yODI5Ng_23b418d7-2be2-45bc-bf56-d3b493c06e30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfNS0xLTEtMS0yODI5Ng_4f978722-2b0d-4351-b23d-1b3a74decd2b">3,925,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfNS0zLTEtMS0yODI5Ng_c10969ab-6a4a-406e-a5ac-256c363ed846">632,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_55"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMjU0Mw_01fbc4c2-aa88-4e14-a2d4-028b6e823543" continuedAt="icc8c6f0eac884aa2974872cde014d200" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="icc8c6f0eac884aa2974872cde014d200" continuedAt="i602ddbb5d5854d32acdd5887229701f1"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMjU0NA_0b7c92a7-9245-4054-a1a7-b15e567c50a3" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(ix)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3682bcf6d66f4973a7dd133d281d269e_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMy0xLTEtMS0yNjYzNQ_0c297fea-94d2-4c71-8171-a04b7a76acd2">175,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6faf816d5daa4e378b018c9347358012_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMy0zLTEtMS0yNjYzNQ_c524fe54-331e-4d37-812a-103a9701b72a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a8147113984483bdbe2570de069cf9_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMy01LTEtMS0yNjYzNQ_61b7d135-aa0e-493c-8348-4792f8660ce0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4444dc36754b42916b70015ae04028_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMy03LTEtMS0yNjYzNQ_dab14778-1c4a-4e38-aae2-97c3f2098cef">175,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio (included in "marketable securities")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345bf687446f417ab073133b4f3e6ebf_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC0xLTEtMS0zMDYzNQ_844cb114-6b06-4ed3-b5ed-f8ad03cb424a">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13603c0d53747d793240ebb726383c8_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC0zLTEtMS0zMDYzNQ_675b92e6-3741-4f2a-8b74-fb5a92e451f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8e806d3fc746b4bd86d42fd6cde4af_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC01LTEtMS0zMDYzNQ_9c8b0647-30f6-4533-bf7b-02d6b5b478e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC03LTEtMS0zMDk3Mw_9d7143b9-e696-406c-bcea-2b9e74fbeb9b">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants in LianBio (included in "other assets")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345bf687446f417ab073133b4f3e6ebf_I20220331" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC0xLTEtMS0yNjYzNQ_c3efc5c1-6a69-4326-a5d3-11657addf6ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13603c0d53747d793240ebb726383c8_I20220331" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC0zLTEtMS0yNjYzNQ_ea2b8307-062d-452b-97be-e72cd46984a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8e806d3fc746b4bd86d42fd6cde4af_I20220331" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC01LTEtMS0yNjYzNQ_86c0fa19-47df-47de-a391-a3f67c75ea18">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC03LTEtMS0yNjYzNQ_a25a9418-0b5f-4d1b-ba41-bbd79b217225">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345bf687446f417ab073133b4f3e6ebf_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNS0xLTEtMS0yNjYzNQ_40364d05-9595-4a15-a17b-da7f7cbff543">175,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13603c0d53747d793240ebb726383c8_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNS0zLTEtMS0yNjYzNQ_fcb8459c-98d9-4ea7-b410-8db62a2c9696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8e806d3fc746b4bd86d42fd6cde4af_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNS01LTEtMS0yNjYzNQ_7ab4560f-2d11-42b2-8b94-3062cd7725d6">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNS03LTEtMS0yNjYzNQ_aaa1afe0-e0da-4483-83e2-f46b50458f48">175,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe41f993362a4d1abb88ecf74110902f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTAtMS0xLTEtMjY2MzU_372e1ca4-d739-474a-a8d0-dac805459bcf">171,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5353fdcc224f7e8dfbe5f04a6b0e2a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTAtMy0xLTEtMjY2MzU_17e7ac4d-6899-4db8-8116-e144ab761885">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if839d9e3a48348b2b756e1a2885fa244_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTAtNS0xLTEtMjY2MzU_4a3da773-0108-4028-9c99-1e039b5590ed">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d31760273a4e2f823c7e5fc3f3807d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTAtNy0xLTEtMjY2MzU_e0acbc3e-576a-4dd1-8ee2-e7eb07cdaa38">171,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio (included in "marketable securities")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d18c2021abb45cd8eca7bf510a0d79c_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTItMS0xLTEtMzA5ODY_18ff711e-ed38-4528-8192-22158ad32767">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9facda38ea4ff4885250a21f36b6ee_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTItMy0xLTEtMzA5ODY_72615b13-2e66-47a9-9584-316517186e69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4e89147429457a865e2def1c688c45_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTItNS0xLTEtMzA5ODY_bebbd10d-72f0-4594-b734-c273093c5727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTItNy0xLTEtMzA5ODY_ead66481-5917-43e3-99ad-ffbe71439df1">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants in LianBio (included in "other assets")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d18c2021abb45cd8eca7bf510a0d79c_I20211231" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTMtMS0xLTEtMzA5ODY_104954c1-8e08-481f-9eb0-17375dee22e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9facda38ea4ff4885250a21f36b6ee_I20211231" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTMtMy0xLTEtMzA5ODY_f044c274-eeb4-41a5-8475-c480ec1273a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4e89147429457a865e2def1c688c45_I20211231" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTMtNS0xLTEtMzA5ODY_d48fd8d7-a3d8-4445-bc0d-b6e181a1f12b">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="tars:EquityWarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTMtNy0xLTEtMzA5ODY_8c28c70b-05ea-409f-b422-6ec88561e1d8">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d18c2021abb45cd8eca7bf510a0d79c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTEtMS0xLTEtMjY2MzU_2a5817bd-4eb7-4090-a8df-0b96479a2009">171,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9facda38ea4ff4885250a21f36b6ee_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTEtMy0xLTEtMjY2MzU_dc2578d4-78d8-45df-a622-39f38e699cba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4e89147429457a865e2def1c688c45_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTEtNS0xLTEtMjY2MzU_7332fa93-84b4-4804-9cbe-849236cfa89a">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTEtNy0xLTEtMjY2MzU_d4778641-2d61-4280-bd1c-89cb994e8b97">172,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund holdings are included in "cash and cash equivalents" on the accompanying Condensed Balance Sheets and are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the fair value hierarchy because they have readily-available market prices in active markets that are publicly observable at the measurement date. These money market funds are invested in U.S. Treasury bills and notes, and other obligations issued or guaranteed as to principal and interest by the U.S. Government or its agencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, a stated number of common stock in LianBio, a then privately-held pharmaceutical company focused on China. The warrants vest upon the achievement of certain clinical and regulatory events and have an exercise price at common stock par value. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, <ix:nonFraction unitRef="warrant" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="tars:NumberOfVestedWarrants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMTY0OTI2NzQ0Njc2Mw_e3c04d57-acf6-4703-a361-5caa72b772e2">one</ix:nonFraction> of these <ix:nonFraction unitRef="warrant" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="INF" name="tars:NumberOfWarrants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMTY0OTI2NzQ0Njc2Nw_a9cc1c91-0944-46cb-8ad7-6ed73fc7baa0">three</ix:nonFraction> warrants vested and converted to <ix:nonFraction unitRef="shares" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="0" name="tars:EquitySecuritiesFVNINumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMTY0OTI2NzQ0Njc3MQ_4424c9bd-0ee1-42bb-b623-85604edad497">78,373</ix:nonFraction> shares of LianBio common stock ("equity securities") which were recorded within "marketable securities" on the accompanying Balance Sheet as of December 31, 2021. The LianBio common stock is classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the fair value hierarchy because their value is based on the closing common stock price of LianBio.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining two unvested tranches of these warrants are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the fair value measurement hierarchy. The most significant assumptions used in the option pricing valuation model to determine the fair value as of March&#160;31, 2022 included: LianBio common stock volatility (based on the historical volatility of similar companies), the probability of achievement of discrete clinical and regulatory milestones for the remaining two unvested tranches of these warrants, and application of an assumed discount rate for the unvested warrants as of March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These warrants allow for "noncash settlement" and therefore met the criteria to be recognized as a "derivative asset" on the accompanying Condensed Balance Sheets and are presented within "other assets" as of March&#160;31, 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). They will be remeasured with a corresponding amount reported in "other expense, net" on the accompanying statements of operations and comprehensive (loss) income at each reporting date, until exercised or expired. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-indent:49.5pt"><span><br/></span></div><ix:continuation id="i602ddbb5d5854d32acdd5887229701f1"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMjU0Mg_ed871c2d-b6b1-4c24-b5b7-03caa1194dfd" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the equity warrants presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrants represents a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> financial instrument:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrants, presented on the Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOmQ2ZTFmZThmYmM0NzQzNjZhYjI0ZmJkZWU4NThkODNkL3RhYmxlcmFuZ2U6ZDZlMWZlOGZiYzQ3NDM2NmFiMjRmYmRlZTg1OGQ4M2RfMS0xLTEtMS0yNjYzNQ_bad01d38-35a3-4cad-a3f3-0798cc1fdb4b">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrants included in "total revenues" within the Condensed Statement of Operations for the three months ended March 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic100186e6c824064b3a569935e610798_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOmQ2ZTFmZThmYmM0NzQzNjZhYjI0ZmJkZWU4NThkODNkL3RhYmxlcmFuZ2U6ZDZlMWZlOGZiYzQ3NDM2NmFiMjRmYmRlZTg1OGQ4M2RfMi0xLTEtMS0yNjYzNQ_9773d80a-7398-49c3-98b8-38b468a2549c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrants included in "other expense, net" within the Condensed Statement of Operations for the three months ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96f49b8447904e059af26b60c492701c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOmQ2ZTFmZThmYmM0NzQzNjZhYjI0ZmJkZWU4NThkODNkL3RhYmxlcmFuZ2U6ZDZlMWZlOGZiYzQ3NDM2NmFiMjRmYmRlZTg1OGQ4M2RfMy0xLTEtMS0yNjYzNQ_4f97041b-10d1-468b-8457-5c3fc7e6bfa0">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOmQ2ZTFmZThmYmM0NzQzNjZhYjI0ZmJkZWU4NThkODNkL3RhYmxlcmFuZ2U6ZDZlMWZlOGZiYzQ3NDM2NmFiMjRmYmRlZTg1OGQ4M2RfNC0xLTEtMS0yNjYzNQ_bfdedd2f-3c3d-46c0-be05-7f0e4131952d">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrants, presented on the Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjhjZTFhOTI4MzAzZjRlZTI4MGU4OWU5OGQ1MTk0MTJiL3RhYmxlcmFuZ2U6OGNlMWE5MjgzMDNmNGVlMjgwZTg5ZTk4ZDUxOTQxMmJfMS0xLTEtMS0zMjk3NQ_4ad19fee-c998-48c0-8174-b7eb03345130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial fair value estimate of equity warrants (included in "other assets" within the Consolidated Balance Sheet) upon issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjhjZTFhOTI4MzAzZjRlZTI4MGU4OWU5OGQ1MTk0MTJiL3RhYmxlcmFuZ2U6OGNlMWE5MjgzMDNmNGVlMjgwZTg5ZTk4ZDUxOTQxMmJfMi0xLTEtMS0zMjk3NQ_5f93c180-584a-4ee9-83be-05e00f854e9e">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80221d972a4407a82832333ee98fc87_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjhjZTFhOTI4MzAzZjRlZTI4MGU4OWU5OGQ1MTk0MTJiL3RhYmxlcmFuZ2U6OGNlMWE5MjgzMDNmNGVlMjgwZTg5ZTk4ZDUxOTQxMmJfMy0xLTEtMS0zMjk3NQ_8bce495c-26a7-4a3c-ad68-7494dfacca3d">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i33713c367fc84a8b901b03655de07e3d_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfODYyNQ_53752ae0-893c-4c26-9d11-55631d9600d5" continuedAt="i382e75e1631d4ad7ba0aa739757edd59" escape="true">COMMITMENTS&#160;&amp; CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i382e75e1631d4ad7ba0aa739757edd59" continuedAt="i1a0b2d37e2164ae9a9e76751d635ffc4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Facility Leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of business, the Company enters lease agreements with unaffiliated third parties for facilities and office equipment. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had <ix:nonFraction unitRef="contract" contextRef="ia85a91d80e654470aeccc73aa5fa1fb5_I20220331" decimals="INF" name="tars:LesseeOperatingLeaseNumberOfLeaseContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMjUw_7e385fa7-1c75-42e6-953e-83225f5da7d7"><ix:nonFraction unitRef="contract" contextRef="i2d2fc086b90b461a8bd0825aacc11371_I20211231" decimals="INF" name="tars:LesseeOperatingLeaseNumberOfLeaseContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMjUw_b1f70b14-11b2-48b4-adf3-0fd2aec3adf4">four</ix:nonFraction></ix:nonFraction> active leases in Irvine, California for adjacent office and laboratory suites. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, the Company entered into a <ix:nonNumeric contextRef="ieadb94479fbf491289eeb4a699120c85_I20210131" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfODYyMw_b618722e-8e5f-4bfb-967f-9bf1ee6cfa84">six-month</ix:nonNumeric> lease for an additional administrative office suite that was not capitalized due to its under 12-month term. The company does not recognize lease asset and liabilities for leases with a term of 12 months or less. On July 30, 2021, the Company executed an amendment to extend the term of this lease and lease an additional office suite, both expiring January 31, 2024. This amendment was accounted for as a "lease modification" and resulted in the recognition of an "operating lease right-of-use asset" valued at $<ix:nonFraction unitRef="usd" contextRef="i2984a704b5f7467bb0b60220ced68c69_I20210730" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNzg1_6793df8c-fc8b-4f70-b129-4c9b165d18c5">0.7</ix:nonFraction>&#160;million as of the execution date.  The Company's two other capitalized facility leases commenced on June 1, 2020 and also expire on January&#160;31, 2024. One includes a renewal option that was not reasonably certain to be exercised at the time of lease commencement. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating leases have annual rent that is payable monthly and carry fixed annual increases. Under these arrangements, real estate taxes, certain operating expenses, and common area maintenance are paid by the Company.  Since these costs are variable in nature, they are excluded from the measurement of the reported right-of-use asset and liability and are expensed as incurred. During the year ended December 31, 2021 and for the three months ended March 31, 2022, the Company had no sublease arrangements with it as lessor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Captions</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="tars:ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTQ5NzU1ODE1MDA3NQ_cac814e9-5d0f-4f96-aa23-29f478cedbf7" continuedAt="i4598312381cd467692c4c563d74cace3" escape="true">The below table summarizes the lease asset and liability accounts presented on the accompanying Condensed Balance Sheets:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i1a0b2d37e2164ae9a9e76751d635ffc4" continuedAt="i8ddae948403741f4be8b8fc79d79b311"><div><ix:continuation id="i4598312381cd467692c4c563d74cace3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:34.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets - non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMS00LTEtMS0yODcwOA_be30d614-2481-4156-a094-98456dd49937">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMS02LTEtMS0yODcwOA_637d9869-b63e-484b-91d9-c1f03f58b1bf">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_439b7687-e8d3-4543-9c80-be7d57d59b72"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_c0a0454b-2a50-41a4-8b96-b87633545102">Accounts payable and other accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy00LTEtMS0yODcwOA_d779e9aa-49b9-45c4-8813-862fb1596362">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy02LTEtMS0yODcwOA_9626aba1-d672-4e82-a9fd-ce8c901d56be">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability - non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_6efd016f-2e3f-4e4b-96a2-61e9bf7e61bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_9a33a609-33f6-4820-89f2-c43f54cb768e">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC00LTEtMS0yODcwOA_34d08e8a-ee65-4bed-be61-ce1731d3ea30">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC02LTEtMS0yODcwOA_95d181b0-b08f-4440-ab17-2e836d4b1fd4">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNS00LTEtMS0yODcwOA_111d760c-37b9-4ba3-819f-6054c792d818">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNS02LTEtMS0yODcwOA_37d680ed-2ed2-4973-8825-0f629ee4c4bf">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Lease Expense</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The liability associated with each lease is amortized over the respective lease term using the &#8220;effective interest rate method.&#8221; The Company&#8217;s right-of-use asset is amortized over the lease term on a straight-line basis to lease expense, as reported on an allocated basis within &#8220;research and development&#8221; and &#8220;general and administrative&#8221; expenses in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income. The Company combines lease and non-lease components in the recognition of lease expense. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfODYyNA_03149953-63c1-4cb8-b393-510e9a8c22fc" continuedAt="ic8e47b32df324ef5ba1c3f972ce5676b" escape="true">The components of lease cost were as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center;text-indent:49.5pt"><ix:continuation id="ic8e47b32df324ef5ba1c3f972ce5676b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfMi0xLTEtMS0yNjYzNQ_086db222-c354-49ce-8825-9f5f3589d65d">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfMi0zLTEtMS0yNjYzNQ_338fec05-71da-4b23-964b-b56ca1a0c844">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfMy0xLTEtMS0yNjYzNQ_fc1306ff-0162-4866-9caf-249e86e54828">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfMy0zLTEtMS0yNjYzNQ_7adc0551-d6bc-4ab4-8b54-98eb4be1e706">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfNC0xLTEtMS0yNjYzNQ_d7394e2f-839d-4dc1-af06-42b548caa739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfNC0zLTEtMS0yNjYzNQ_253363bf-e0ed-4aea-a029-959ea555dc7c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfNS0xLTEtMS0yNjYzNQ_6550bc4c-5ad7-4137-8984-47507bb55945">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfNS0zLTEtMS0yNjYzNQ_a2372355-15d3-43d8-b2a7-e053649392f5">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Remaining Lease Term and Applied Discount Rate </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company's facility leases had a weighted average remaining lease term of <ix:nonNumeric contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMjgxNg_864e872c-9668-48d2-802e-d38af4c423dc">1 year, 10 months</ix:nonNumeric>. The weighted-average estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMjkwMg_e29de2f3-450a-4edd-92fb-2735b2c295ac">10</ix:nonFraction>% was utilized to present value future minimum lease payments since an implicit interest rate was not readily determinable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Contractual Lease Payments </span></div><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfODYyMg_77e19904-f1bd-4bc4-9ac2-d89ae1f06ea1" escape="true"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases - Future Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfMS0xLTEtMS0yNjYzNQ_c3d2725c-f90a-4684-9ce0-da26384d3804">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfMi0xLTEtMS0yNjYzNQ_6680b7ef-350a-469c-b4f4-f257dc8acce3">761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfMy0xLTEtMS0yNjYzNQ_11ef0abf-1674-424e-a0d4-89685f7a432d">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfNC0xLTEtMS0yNjYzNQ_fd0cf022-9f7f-4577-a95e-b0ba7d17bd34">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfNS0xLTEtMS0yNjYzNQ_843ec69a-60c8-47e6-8f11-80f220986267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfNi0xLTEtMS0yNjYzNQ_0237c4c3-740f-4c0a-a553-2179c5d89b85">1,175</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfNy0xLTEtMS0yNjYzNQ_aaf54858-e128-44ab-9261-0b4f4dfcd479">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfOC0xLTEtMS0yNjYzNQ_91153b8c-00b3-45f5-8812-c5a60f7bba8d">1,060</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) In-License Agreements for Lotilaner</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">January 2019 Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company entered into a license agreement with Elanco Tiergesundheit AG (&#8220;Elanco&#8221;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8ddae948403741f4be8b8fc79d79b311" continuedAt="i0a826dc6d6c44518a0272dc62f1a05a7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment or cure of any eye or skin disease or condition in humans (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid a $<ix:nonFraction unitRef="usd" contextRef="icd124fd3b0484daab9a49f0bec4f620f_D20190101-20190131" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMzgyMw_37e32a40-968b-4481-ad15-380b36886d37">1.0</ix:nonFraction> million upfront payment at execution of the Eye and Derm Elanco Agreement in January 2019. In September 2020, the Company made a required $<ix:nonFraction unitRef="usd" contextRef="iaee22ca2e06b493897071cb5cc9e2fee_D20200901-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMzkzMw_f6c9dfc7-372d-4a08-be0a-00bcaab49bf8">1.0</ix:nonFraction> million clinical milestone payment associated with the first two U.S. pivotal trials for the treatment of Demodex blepharitis. The Company paid an additional $<ix:nonFraction unitRef="usd" contextRef="i3d8f8ea4259c4cda90b6fffc07aba79d_D20210401-20210430" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNDA4OQ_3bda2de2-e33e-42e0-a4ac-11f3249b7699">2.0</ix:nonFraction> million for its second pivotal trial milestone in April 2021, which was recorded in &#8220;research and development&#8221; expense in the accompanying Statements of Operations and Comprehensive Loss for the three months ended March 31, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may make further cash payments to Elanco pursuant to the Eye and Derm Elanco Agreement upon achievement of certain clinical milestones in the treatment of human skin diseases using lotilaner for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="ie486f40913eb4e9e91e41e6b75802f58_I20190131" decimals="INF" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNDUzNg_bba730a4-7ce9-4c7e-bf34-145b5d16d174">3.0</ix:nonFraction> million and various commercial and sales threshold milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="i9e8bcfe9ca0640bbb09e4739c1c4c378_I20190131" decimals="INF" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNDYyMQ_547c8a1d-069b-46c5-80ca-b47004feb7ca">79.0</ix:nonFraction> million. In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the China Out-License discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company made a contractual payment in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1cecf80c420649d6a1e32ab01aa11f92_D20210401-20210630" decimals="-5" name="tars:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTE4Mg_bee2f225-e503-4579-9ccf-644d3860ff5b">2.5</ix:nonFraction> million to Elanco following the receipt of $<ix:nonFraction unitRef="usd" contextRef="ide977ec78e02409981089603c186b138_D20210401-20210630" decimals="-6" name="tars:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTIyMQ_b224419f-ada1-48ee-8d6c-4f12ae7a94e6">25</ix:nonFraction> million of initial proceeds from LianBio during the second quarter of 2021.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">September 2020 Agreement for All Other Diseases or Conditions in Humans</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the Company executed an expanded in-license agreement with Elanco, granting the Company a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of "all other" diseases and conditions in humans (i.e., beyond that of the eye or skin) (the &#8220;All Human Uses Elanco Agreement&#8221;). The Company issued Elanco <ix:nonFraction unitRef="shares" contextRef="iaee22ca2e06b493897071cb5cc9e2fee_D20200901-20200930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTc2Ng_b9f22a0b-b673-43d1-a71a-bf5ceae6a140">222,460</ix:nonFraction> shares of its common stock at the execution of the All Human Uses Elanco Agreement. The fair value of these shares was $<ix:nonFraction unitRef="usd" contextRef="iaee22ca2e06b493897071cb5cc9e2fee_D20200901-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTg3Ng_7ddef45f-d68d-4ccb-9f88-cbb2e64d79d3">3.1</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="i654c73f76ece4f4e803421b8c7263cb3_I20200930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTg4MA_3e7dae13-bd6b-45ba-89f4-0eb1256f1cb8">14.0003</ix:nonFraction> per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is required to make further cash payments to Elanco under the All Human Uses Elanco Agreement upon the achievement of various clinical milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="i9d7a6b8164094267801b75fac6b39956_I20220331" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNjE3MQ_357496e9-9662-4f89-8666-9dc94f5c4d53">4.5</ix:nonFraction> million and various commercial and sales threshold milestones for an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="i0b7611af61f5418b9266c2bcd8eb6fe9_I20220331" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNjI1Ng_4b9af256-f80a-4cb6-950e-15813d666d60">77.0</ix:nonFraction> million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net product sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, the Company entered into the China Out-License agreement with LianBio (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), which obligated it to grant Elanco an additional fixed <ix:nonFraction unitRef="shares" contextRef="iea920d7fcd75406d81b03da8bad1093a_D20210301-20210331" decimals="INF" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNjgyNQ_b235767e-94b3-4b5e-af34-9f4bfac585e1">187,500</ix:nonFraction> shares of the Company's common stock that were otherwise required to be granted no later than the 18-month anniversary of the All Human Uses Elanco Agreement for the Company's continued license exclusivity.  These additional shares were valued at $<ix:nonFraction unitRef="usd" contextRef="iea920d7fcd75406d81b03da8bad1093a_D20210301-20210331" decimals="-5" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNzA2OA_356d1cd5-ef55-448a-a873-7f3485134cd3">5.5</ix:nonFraction> million based on the Company's stock closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea920d7fcd75406d81b03da8bad1093a_D20210301-20210331" decimals="INF" name="tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNzExNw_293686ee-a5ca-41c6-bc35-120b3887800f">29.30</ix:nonFraction> per share (on the date the issuance became contractually required) and were reported within "research and development" expense within the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income for the three months ended March 31, 2021.  </span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with <ix:nonFraction unitRef="arrangement" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="INF" name="tars:NumberOfEmploymentArrangementsWithExecutiveOfficers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNzQ0OQ_f4fc07ce-e5cd-441d-9884-068ebfc9310e">eight</ix:nonFraction> of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Litigation Contingencies</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i0a826dc6d6c44518a0272dc62f1a05a7"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e) Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_61"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMzEzNQ_ee16914f-d97a-4236-9b6b-d34919e3e113" continuedAt="i96d4f9dbd1a5434a99d01d3bbb89a8f8" escape="true">OUT-LICENSE AGREEMENT</ix:nonNumeric></span></div><ix:continuation id="i96d4f9dbd1a5434a99d01d3bbb89a8f8" continuedAt="i3e3e78ac6df04dcf92208cdbdbb8e30e"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in Greater China in March 2021</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 26, 2021, the Company entered into an out-license agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (the &#8220;China Territory&#8221;) for the treatment of Demodex blepharitis and Meibomian Gland Disease (the &#8220;China Out-License&#8221;). LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date the Company received payments from LianBio totaling $<ix:nonFraction unitRef="usd" contextRef="i3167f524706142c2b2851c8bb31f1c12_D20210326-20220331" decimals="-5" name="tars:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMTA5OTUxMTYzMjYzMQ_c95f71f9-119f-4f27-a310-c2bb0bdfd889">55.0</ix:nonFraction>&#160;million related to initial consideration of $<ix:nonFraction unitRef="usd" contextRef="ia19be9b7fe5245089c2073e846d30204_D20210326-20210326" decimals="-5" name="tars:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfNjY2_fd290bc7-741c-480c-8f18-4e36a56a2768">25.0</ix:nonFraction>&#160;million and two clinical development milestone achievements of $<ix:nonFraction unitRef="usd" contextRef="i92802321216247e484f937d0e0c27e93_D20210326-20210326" decimals="-5" name="tars:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfNzMy_aab54015-d005-4840-8fec-a7bf7373eb58">30.0</ix:nonFraction>&#160;million. During the three months ended March 31, 2022 the Company did not receive any cash proceeds in connection with the China Out-License.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is also eligible to receive other payments and consideration from LianBio upon achievement of certain additional milestones, including: (i) TP-03 clinical development and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i576dbd0507c245d1a503f15affe1eed2_I20220331" decimals="-5" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMTA5OTUxMTYzMjc3NA_29d66cb5-6d31-4140-86ff-739c68d544e5">45.0</ix:nonFraction>&#160;million, (ii) an expected drug supply agreement milestone of $<ix:nonFraction unitRef="usd" contextRef="i31e151303adb4b01ba45467aa1597d0a_I20220331" decimals="-6" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMjE5OTAyMzI2MTAyMw_ae3391e0-0676-4d44-bd8f-275fb58cd973">5.0</ix:nonFraction>&#160;million, (iii) TP-03 sales-based milestones for the China Territory of up to $<ix:nonFraction unitRef="usd" contextRef="i35b7053fdb8f495f94c86835ef706e83_I20220331" decimals="-6" name="tars:CollaborativeArrangementMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMTA5OTUxMTYzMjgwOQ_99995d80-fa65-41c0-92aa-eb92de2037d0">100</ix:nonFraction>&#160;million, (iv) tiered mid-to-high-teen royalties for China Territory TP-03 product sales, and (v) LianBio equity warrants, which are subject to three TP-03 clinical/regulatory achievements for complete vesting, of which one tranche vested in June 2021. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="i0c7c8089e4c24cf6b318fdbcbb0fcd5f_D20220101-20220331" decimals="0" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMTY0OTI2NzQ0NzI4Ng_38800047-f0b5-4029-b040-713cf93e7d91">no</ix:nonFraction> "license fees" and $<ix:nonFraction unitRef="usd" contextRef="ic4c16329db554147aa835e3f640a2243_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfNjA0NzMxMzk1ODMzOQ_e54a519e-e44e-499f-b0f3-fa6264533b3a">0.5</ix:nonFraction> million "collaboration revenue" for the three months ended March 31, 2022 in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income, in accordance with the revenue recognition accounting policy described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 2(vii). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These amounts represent an allocation of the transaction price based upon the partial satisfaction of the performance obligations in the China Out-License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These revenue amounts are each recognized upon satisfaction of the following performance obligations (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the actual or partial completion of clinical activities and related data for the Company's pivotal trials of TP-03 in the treatment of Demodex blepharitis. As part of this revenue recognition model, the Company was required to value the LianBio equity warrants, applying a discounted cash flow model with highly subjective inputs for this then private, pre-revenue company, and also considered the probability of achievement of requisite vesting events. Subsequent adjustments to the estimated initial fair value of these warrants are reported within "total revenues" and "other (expense) income" on the accompanying Condensed Statements of Operations for the three months ended March&#160;31, 2022. The first tranche of these warrants vested and were exercised to LianBio common shares and are reported within "marketable securities" on the accompanying Condensed Balance Sheets as of December&#160;31, 2021 and March&#160;31, 2022 (See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e3e78ac6df04dcf92208cdbdbb8e30e">In future periods, the Company may recognize additional revenue from contractual receipts due from LianBio as (1) performance obligations are satisfied related to the completion of the TP-03 pivotal trial and as associated clinical data and reports are delivered, (2) regulatory approval events are achieved, and (3) LianBio records product sales of TP-03 in the China Territory.</ix:continuation> </span></div><div id="i33713c367fc84a8b901b03655de07e3d_872"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 10. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3NTY_49049556-0285-4567-9afe-103af5a7e705" continuedAt="i3ad579cd8d0d4e10863808701da88052" escape="true">CREDIT FACILITY AGREEMENT</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3ad579cd8d0d4e10863808701da88052" continuedAt="i822c3a344a854853aca5c3d119c44dfd"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company executed the Credit Facility with Hercules and SVB with a term to February 2, 2027. The Credit Facility provides an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3NTg_81067c97-e9b2-4009-b23b-985755314133">175.0</ix:nonFraction>&#160;million with tranched availability as follows: $<ix:nonFraction unitRef="usd" contextRef="i0dd505db08864f8599c4b88afd5d91d4_I20220202" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3NzI_ddde374a-fcb4-41bf-8cc4-50701f7a5194">40.0</ix:nonFraction>&#160;million at closing (with $<ix:nonFraction unitRef="usd" contextRef="i1e1d86abba614b28bb93de20e5a65f46_I20220202" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3ODU_d3d40e65-ad5b-4a18-a98b-5ce4745f3516">20.0</ix:nonFraction>&#160;million drawn in February 2022), $<ix:nonFraction unitRef="usd" contextRef="i0e1bbc0f5a2e4184a13f69cd709213c4_I20220202" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3OTg_c735d266-a1a9-4d0f-a3c6-85fbe44ed63b">25.0</ix:nonFraction>&#160;million upon submission of a New Drug Application ("NDA") with the FDA for TP-03, $<ix:nonFraction unitRef="usd" contextRef="i1eb8e35e7edf4dcc8e5184077317c4e2_I20220202" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4MTE_360ffc77-b1c4-432e-8edd-4ce8eb54017c">35.0</ix:nonFraction>&#160;million upon FDA approval of TP-03, and $<ix:nonFraction unitRef="usd" contextRef="ica98a2fa29594ad7be66a55c9a1e20db_I20220202" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0NDM_da81c1a2-146c-4ee9-a7cf-b8383b974119">75.0</ix:nonFraction>&#160;million upon achievement of certain revenue thresholds and other conditions.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the tranches may be drawn down in $<ix:nonFraction unitRef="usd" contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202" decimals="-6" name="tars:LineOfCreditFacilityDrawDownIncrements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4MjQ_0d5d8649-eb59-4850-a33b-326936b72d84">5.0</ix:nonFraction>&#160;million increments at the Company's election. The Credit Facility includes a <ix:nonNumeric contextRef="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202" name="tars:LineOfCreditFacilityInterestOnlyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4NzY_8a7fb860-6bab-46ee-a465-d77f59abbb96">four-year</ix:nonNumeric> interest only period and is extendable to <ix:nonNumeric contextRef="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202" name="tars:LineOfCreditFacilityInterestOnlyPeriodExtended" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4ODg_7a5a658b-a618-45c9-a63a-bfc363dfcc58">five years</ix:nonNumeric> upon meeting certain conditions. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Credit Facility requires interest-only payments from the issuance date through the amortization date of February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to maturity upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on February 2, 2027. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-indent:54pt"><span><br/></span></div><ix:continuation id="i822c3a344a854853aca5c3d119c44dfd"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Principal draws accrue interest on the outstanding principal balance at a floating interest rate per annum equal to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">greater of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> either (i) The Wall Street Journal prime rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonFraction unitRef="number" contextRef="i33662385a14248f389cd589e0b07949d_D20220202-20220202" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0NTg_9a8914b6-cc92-40ad-8028-3b9a720dd992">5.20</ix:nonFraction>% or (ii) <ix:nonFraction unitRef="number" contextRef="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0NjU_c21d8e83-aee8-4e96-9476-bebf8178baea">8.45</ix:nonFraction>%. At execution of the Credit Facility, the interest rate was <ix:nonFraction unitRef="number" contextRef="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0Nzk_cff2837b-187c-46f4-8f2b-6650b6c3a692">8.45</ix:nonFraction>%. On March 17, 2022 this prime rate increased to <ix:nonFraction unitRef="number" contextRef="i3a6e2fcbec9d4f2a814387f5e90b9f5f_D20220317-20220317" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0NzI_ce1b7604-10ee-46d3-990d-96f820ee4aa2">3.50</ix:nonFraction>% and the Credit Facility interest rate increased to <ix:nonFraction unitRef="number" contextRef="ie708af9133d548c5b4bab9d679747cd1_D20220317-20220317" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0ODY_e7827654-fffb-4bc1-9284-423efde246cf">8.70</ix:nonFraction>%.  The Credit Facility interest rate further increased to <ix:nonFraction unitRef="number" contextRef="i2d088c0af04542eba408c2f8416ec22d_D20220505-20220505" decimals="3" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjcwMzU_18ac429d-67fa-4f7c-876f-cd690d006d12">9.20</ix:nonFraction>% on May 5, 2022 based on the updated Wall Street Journal prime rate.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is required to pay a fee upon the earlier of (i) the maturity date or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $<ix:nonFraction unitRef="usd" contextRef="i526c288d95b145d18ad85df06471783c_D20220101-20220331" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzYwNDczMTM5Nzk0MTk_9c091792-cb5e-4281-a30c-d340c8b277c0">1.0</ix:nonFraction> million was derived at the execution of the Credit Facility by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">multiplying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonFraction unitRef="number" contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202" decimals="4" name="tars:LineOfCreditFacilityPeriodicPaymentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzY1OTcwNjk3ODk3Nzc_a6990c03-d0f8-400a-b630-7c0fe785f4b2">4.75</ix:nonFraction>% to the $<ix:nonFraction unitRef="usd" contextRef="i438915cd287c48788084761ed5ad3ba4_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzYwNDczMTM5Nzk0OTg_d82db249-47a1-4569-bca2-b4d18a26f69d">20.0</ix:nonFraction>&#160;million drawn at closing and is accreted to "accrued interest" through the maturity date of the Credit Facility.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March&#160;31, 2022, the carrying value of this debt consisted of $<ix:nonFraction unitRef="usd" contextRef="i438915cd287c48788084761ed5ad3ba4_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4MzY_037af800-5a83-4572-b1e8-b6cf79d45701">20.0</ix:nonFraction>&#160;million principal outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">less </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">issuance costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i438915cd287c48788084761ed5ad3ba4_I20220331" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzYwNDczMTM5NjUxNDY_e0cf9934-cc83-434f-a31e-0c38e496d2b6">0.9</ix:nonFraction> million. These incurred legal and administrative fees were recorded as a "contra-liability" and accreted to interest expense using the "effective interest method" over the loan term.   </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The calculated effective interest rate for this Credit Facility was <ix:nonFraction unitRef="number" contextRef="i438915cd287c48788084761ed5ad3ba4_I20220331" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0OTM_d9a68b7a-3a8d-45fc-a789-2bcebdfaea7e">9.66</ix:nonFraction>% for the three months ended March 31, 2022. As of December&#160;31, 2021 the Company had <ix:nonFraction unitRef="usd" contextRef="id27ce663af03415ca6600c5007c2ea01_I20211231" decimals="0" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzcxNDY4MjU2MDU5MjE_de6314a9-b02a-40b7-afc9-f80fc07f89ef">no</ix:nonFraction> outstanding debt.</span></div><div style="text-indent:54pt"><span><br/></span></div><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0OTk_b77930bc-a60a-406b-9b48-e2e34ccef0cf" escape="true"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2022, the Company recognized "interest expense" on its Condensed Statement of Operations and Comprehensive (Loss) Income in connection with the Credit Facility as follows:  </span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTpkZjk5M2U4Y2EyYWU0NDM4YWYzYTlhYjlmNTllMWJkMC90YWJsZXJhbmdlOmRmOTkzZThjYTJhZTQ0MzhhZjNhOWFiOWY1OWUxYmQwXzEtMS0xLTEtMzE5MTQ_e4bd6aa3-178e-467b-8971-f530f200a36e">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of End of Term Charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTpkZjk5M2U4Y2EyYWU0NDM4YWYzYTlhYjlmNTllMWJkMC90YWJsZXJhbmdlOmRmOTkzZThjYTJhZTQ0MzhhZjNhOWFiOWY1OWUxYmQwXzItMS0xLTEtMzE5MTQ_1448ce8b-ca80-46d5-aa52-5ee640a12f54">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTpkZjk5M2U4Y2EyYWU0NDM4YWYzYTlhYjlmNTllMWJkMC90YWJsZXJhbmdlOmRmOTkzZThjYTJhZTQ0MzhhZjNhOWFiOWY1OWUxYmQwXzMtMS0xLTEtMzE5MTQ_9c43dd59-cb4f-4513-8e58-a750163764dc">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTpkZjk5M2U4Y2EyYWU0NDM4YWYzYTlhYjlmNTllMWJkMC90YWJsZXJhbmdlOmRmOTkzZThjYTJhZTQ0MzhhZjNhOWFiOWY1OWUxYmQwXzQtMS0xLTEtMzE5MTQ_2bab762a-0b36-430e-9ca7-41546493289c">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:54pt"><span><br/></span></div><ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY1MDA_4ed63d18-7bf3-4c1c-bff0-03df2a7ea6c8" escape="true"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The principal balance of this term loan and related accretion and amortization as of March&#160;31, 2022, were as follows:</span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, gross (amount drawn)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzEtMS0xLTEtMzExMzc_428038f3-beae-4660-a9ab-2c2e44e6d28b">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs (legal and other administrative fees)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzItMS0xLTEtMzExMzc_265c8759-3d94-4b11-a194-5a05b7432955">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of End of Term Charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzMtMS0xLTEtMzQ3MjM_408a19c9-94ea-4724-8ddf-7cd4ccf0db50">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzMtMS0xLTEtMzExMzc_56b0f5f4-0979-4a3f-8668-1bfb5b0a1465">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzQtMS0xLTEtMzExMzc_db6c14b3-4330-4f81-92cb-27a1ae035709">19,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_895"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TARSUS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(all tabular amounts presented in thousands, except share, per share, per unit, and number of years)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 11. <ix:nonNumeric contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUyMjI_355de324-42d1-472e-b822-abf632a55f10" continuedAt="idf0ac9d62ee04d8fb9ed722ff3464e44" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="idf0ac9d62ee04d8fb9ed722ff3464e44" continuedAt="i28a4c3196eff4ba8855ec7b939a0121f">May 2022 Follow-on Equity Raise</ix:continuation></span></div><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="i28a4c3196eff4ba8855ec7b939a0121f" continuedAt="i61eba5b1cb3047aa9823eace613ce92d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 5, 2022, the Company completed a follow-on public offering, pursuant to the Company's effective Form S-3 shelf registration statement, through an underwritten sale of <ix:nonFraction unitRef="shares" contextRef="id85e9ecd5338406897413769276e54ff_D20220505-20220505" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUxNzE_5f96f049-5831-482d-a53e-4e29eedbe4b9">5,600,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1808d691f65a4626825a224635438903_I20220505" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUxODI_55b3cf49-4567-445a-a105-d6c63063f67b">13.50</ix:nonFraction> per share.  This resulted in gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8c435dd6d8af4033acf4c6e936b27500_D20220505-20220505" decimals="-5" name="tars:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUxOTA_5d22ea08-1952-44bc-aec1-22cbafc02e81">75.6</ix:nonFraction>&#160;million before underwriting discounts, commissions, and estimated expenses, for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i8c435dd6d8af4033acf4c6e936b27500_D20220505-20220505" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDY1ODU_b89225cd-bce6-4986-82db-33a4a510c4f0">70.6</ix:nonFraction>&#160;million.  </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i61eba5b1cb3047aa9823eace613ce92d">The Company also granted the underwriters a 30-day option to purchase up to <ix:nonFraction unitRef="shares" contextRef="i4eb812a752d3463a8d2c1bc50512d96b_D20220505-20220505" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUyMDk_506fa6c7-d13c-42a7-a8ae-f282faabd143">840,000</ix:nonFraction> additional shares of common stock at the public offering price, less discounts, commissions, and estimated expenses.</ix:continuation>   </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note Regarding Forward-Looking Statements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, future revenue, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms or other similar expressions are intended to identify forward-looking statements. Factors that may cause actual results to differ from expected results, include, among others:</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and progress of our current clinical trials and timing of initiation of our future clinical trials, and the reporting of data from our current and future trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the clinical development of our current and future product candidates, including the size, number and disease areas to be evaluated;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence of Demodex blepharitis and the size of the market opportunity for our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including sales strategy;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of COVID-19 on our business and operations;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients in the United States ("U.S.") or globally, as applicable, who suffer from Demodex blepharitis, Meibomian Gland Disease ("MGD"), rosacea, Lyme disease and malaria and the number of patients that will enroll in our clinical trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approval for our product candidates;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates and our product candidates to meet existing or future regulatory standards;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of our product candidates, including additional indications for which we may pursue;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties (including, for example, the receipt of payments, achievement and timing of milestones under license agreements, and the ability of our third party collaborators to commercialize our product candidates in the territories under license) and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the U.S. and other jurisdictions;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel, in particular sales personnel, and our ability to attract and retain such personnel;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position;</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and</span></div><div style="margin-top:3pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing resources and the proceeds from our Initial Public Offering ("IPO") and Follow-on Public Offering (defined below).</span></div><div style="margin-top:3pt;padding-left:20.25pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and growth prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this report and the documents that we reference in this report and have filed with the SEC as exhibits to this report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of our Business</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Our lead product candidate, TP-03 (lotilaner ophthalmic solution, 0.25%), is a novel investigational eye drop in Phase 3 to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis ("Blephar" is a reference to eyelid and &#8220;itis&#8221; is a reference to inflammation) is an ophthalmic lid margin disease characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. Poorly controlled and progressive blepharitis can lead to corneal damage over time and, in extreme cases, blindness. There are an estimated 25&#160;million people in the U.S. who suffer from Demodex blepharitis.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We designed TP-03 to target and eradicate the root cause of Demodex blepharitis &#8212; Demodex mite infestation. The active pharmaceutical ingredient ("API") of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GABA-Cl") channels.  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have completed four Phase 2 trials, one Phase 2b/3 Saturn-1 trial, and one Phase 3 Saturn-2 trial for TP-03 in Demodex blepharitis. Each of these trials for TP-03 met their primary, secondary and/or exploratory endpoints, with the drug well tolerated.  In May 2022, we announced positive topline results of the Saturn-2 trial and will use the data from the Saturn-1 and Saturn-2 trials to support our submission of a new drug application ("NDA") in the second half of 2022. We believe that TP-03 has the potential to be the first therapeutic approved by the U.S. Food and Drug Administration ("FDA") for the treatment of Demodex blepharitis and become the standard of care. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to further advance our pipeline with the lotilaner API to address several diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. We are developing product candidates to address targeted diseases with high unmet medical needs, which currently include TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Business and Clinical Highlights </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">TP-03 Demodex Blepharitis Pivotal Trials, Saturn-1 &amp; Saturn-2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, we announced positive topline results of the Saturn-2, our second and final pivotal trial. Saturn-2 enrolled 412 adults having more than 10 collarettes per lid and at least mild lid erythema. All pre-specified primary and secondary endpoints were met, TP-03 was well tolerated and complete resolution of Demodex blepharitis was demonstrated in patients treated with TP-03 (lotilaner ophthalmic solution, 0.25%).</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Primary Endpoint:</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">56% of patients on TP-03 achieved the primary endpoint of complete collarette cure, defined as 0-2 collarettes per lid at day 43, compared to 13% on vehicle (p&lt;0.0001).</span></div><div style="padding-left:108pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.46pt">89% of patients on TP-03 achieved a clinically meaningful collarette cure, defined as 0-10 collarettes per lid at day 43 compared to 33% of those on vehicle (p&lt;0.0001). </span></div><div style="padding-left:36pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Secondary Endpoints:</span></div><div style="padding-left:36pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">52% of patients on TP-03 achieved the secondary endpoint of mite eradication defined as 0 mites per lash at day 43, compared to 14% on vehicle (p&lt;0.0001).</span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">31.1% of patients on TP-03 compared to 9.0% of patients on vehicle (p&lt;0.0001) achieved the secondary endpoint of a complete lid erythema cure at day 43.</span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">19.2% of patients on TP-03 achieved the secondary endpoint of a complete composite cure, based on achieving both collarette cure and erythema cure, compared to 4.0% on vehicle (p&lt;0.0001) at day 43.</span></div><div style="padding-left:36pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Safety Profile:</span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">TP-03 was well tolerated with a safety profile similar to the vehicle group. </span></div><div style="padding-left:108pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.46pt">91% of TP-03 patients reported that the drop comfort was neutral to very comfortable. </span></div><div style="padding-left:108pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.46pt">There were no serious treatment-related adverse events nor any treatment-related adverse events leading to treatment discontinuation. </span></div><div style="padding-left:36pt;text-indent:-9pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to use the positive data from the Saturn-1 and Saturn-2 trials to support our submission of an NDA in the second half of 2022.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TP-05 Lyme disease Phase 1 Trial, Callisto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We advanced our Phase 1 Callisto trial, evaluating TP-05, a novel, oral, non-vaccine therapeutic, for the prevention of Lyme disease. In June 2021, we initiated the Callisto trial, a single ascending dose and multiple ascending dose trial to evaluate the safety, tolerability and pharmacokinetics ("PK") of TP-05 in healthy volunteers with data expected in the second half of 2022. There are currently no FDA-approved pharmacological prophylactic options for Lyme disease, which is the most common vector-borne disease in the U.S., transmitted to humans via Borrelia burgdorferi bacterium infection following the bite of a tick vector.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe TP-05 is currently the only non-vaccine, drug-based, preventive therapeutic in development that targets the ticks, and potentially prevents Lyme disease transmission. It is designed to rapidly provide systemic blood levels of lotilaner potentially sufficient to kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">TP-03 China Territory Out-License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: In March 2021, we executed an out-license agreement (the "China Out-License") with LianBio Ophthalmology Limited ("LianBio"), granting exclusive commercial rights to TP-03 for the treatment of Demodex blepharitis and MGD within The People&#8217;s Republic of China, Macau, Hong Kong, and Taiwan (the "China Territory"). LianBio has publicly communicated that they expect to initiate a TP-03 Phase 3 pivotal trial in China for the treatment of Demodex blepharitis in the second half of 2022.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To date, we've received contractual cash proceeds from LianBio of $55&#160;million, representing initial consideration of $25&#160;million, and $30&#160;million for the achievement of two clinical development milestones. We also received equity warrant rights in LianBio as part of this license that are subject to clinical and regulatory vesting provisions.   </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are further eligible to receive (i) Saturn-2 topline data milestone of $15&#160;million and a drug supply agreement execution milestone of $5&#160;million (we expect to receive both in 2022), (ii) China-based clinical and regulatory milestones totaling $30&#160;million ($10 million of which we expect in the second half of 2022 for the initiation of their Phase 3 pivotal trial in China), and (iii) sales threshold milestones in the China Territory totaling $100&#160;million. We are also entitled to receive tiered mid-to-high teen royalties on the net product sales of TP-03 within the China Territory.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Credit Facility with Hercules Capital and Silicon Valley Bank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 2, 2022, we executed a loan and security agreement with Hercules Capital and Silicon Valley Bank (the "Credit Facility). This $175 million Credit Facility has tranched availability as follows: </span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$40 million at closing (with $20 million drawn in February 2022 and $20 million remaining available)</span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$25 million upon NDA submission of TP-03</span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$35 million upon FDA approval of TP-03 </span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$50 million upon achievement of certain quarterly revenue thresholds</span></div><div style="padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$25 million available with lender approval</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Capital draws are at our election and are in $5 million increments. This Credit Facility includes a four-year interest only period and is extendable to five years upon meeting certain conditions that we expect to achieve. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Follow-on Public Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 5, 2022, we completed a follow-on public offering, pursuant to our effective Form S-3 shelf registration statement, through an underwritten sale of 5.6 million shares of our common stock at a price to the public of $13.50 per share.  Gross proceeds were $75.6&#160;million before underwriting discounts, commissions, and estimated expenses.  We granted the underwriters a 30-day option to purchase up to 840,000 additional shares of common stock at the public offering price, less discounts, commissions, and estimated expenses.   </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Financial Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated as a Delaware corporation in November 2016, and our headquarters is located in Irvine, California. Since our inception, we have devoted substantially all of our resources to organizing and staffing our company, acquiring intellectual property, clinical development of our product candidates, building our research and development capabilities, raising capital, and enhancing our corporate infrastructure. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have financed our operations through private placements of preferred stock, convertible promissory notes, the net proceeds from issuance of common stock in our IPO and Follow-on Public Offering, cash proceeds from our out-licensing arrangements, and draw downs on our Credit Facility. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net operating losses in every year since our inception and expect to continue to incur significant operating expenses and, other than the effect of license fee revenue from the China Out-License Agreement, increasing operating losses for the foreseeable future. Our net (loss) income was $(20.2) million and $10.4 million for the three months ended March 31, 2022 and 2021, respectively. Our net losses and any net income we may generate may fluctuate significantly from quarter to quarter and year to year and could be substantial. As of March&#160;31, 2022 and December&#160;31, 2021, we had an accumulated deficit of $66.9 million and $46.7 million, respectively, from our research and development and general and administrative activities since our inception. We anticipate that our operating expenses will increase significantly as we:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct and complete clinical activities for our lead product candidate, TP-03, for the treatment of Demodex blepharitis including our Phase 3 trial, Saturn-2;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance the clinical development of TP-03 for the potential treatment of MGD, TP-04 for the potential treatment of rosacea and TP-05 for potential Lyme prophylaxis and community malaria reduction;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory and marketing approvals for product candidates that successfully complete clinical development, if any;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish our own sales force in the U.S. to commercialize our products for which we obtain regulatory approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage with contract manufacturers to ensure a sufficient supply chain capacity to provide commercial quantities of any products for which we may obtain marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional staff, including clinical, scientific, technical, regulatory, marketing, operations, financial, and other support personnel, to execute our business plan; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add information systems and personnel to support our product development and potential future commercialization efforts, and to enable us to operate as a public company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for sale and we have not yet generated any revenue from product sales. However, we recognized "license fees" and "collaboration revenue" from our China Out-License for the three months ended March 31, 2022 and 2021 for an aggregate $0.5 million and $33.4 million, respectively (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and expect to recognize additional revenue under these captions from this arrangement in future periods.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenues from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate and commercially launch such product. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, or collaborations, strategic alliances, or licensing arrangements with third parties. Adequate funding may not be available to us when needed on acceptable terms, or at all. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital or enter into such agreements as and when needed, we could be forced to significantly delay, scale back, or discontinue our product development and/or commercialization plans, which would negatively and adversely affect our financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug product development, we are unable to accurately forecast the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, our aggregate cash, cash equivalents and marketable securities was $175.3 million &#8211; see the section below titled &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations &#8212; Liquidity and Capital Resources.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic on our Operations</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to contain the spread of COVID-19 in the U.S. (including in California where our corporate headquarters and laboratory facility are located) and other countries have included quarantines, shelter-in-place orders, and various other government restrictions in order to control the spread of this virus.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been monitoring the COVID-19 pandemic as it continues to progress and its potential impact on our business. We have taken important steps to ensure the workplace safety of our employees when working within our laboratory and administrative offices, or when traveling to our clinical trial sites. We have also implemented a vaccination policy and we may take further actions as may be required by federal, state or local authorities.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have been able to continue our key business activities and advance our clinical programs. However, in the future, it is possible that our clinical development timelines and business plans could be adversely affected. We maintain regular communication with our vendors and clinical sites to appropriately plan for, and mitigate, the impact of the COVID-19 pandemic on our operations. The ultimate effect from this pandemic on our development timelines for TP-03 and our other product candidates is inherently uncertain.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the section titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on March&#160;14, 2022 and in this Quarterly Report, for a further discussion of the potential adverse impact of COVID-19 on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2022&#160;and 2021</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33,311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,893)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of license fees and collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,658)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) income from operations before other (expense) income and income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,521)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,235)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) income, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of equity warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expense, net </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(716)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) income and comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,614)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Fees and Collaboration Revenue </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and collaboration revenue was $0.5 million for the three months ended March 31, 2022. This amount was attributable to the contractual milestones under the China Out-License (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that have been fully or partially completed by March&#160;31, 2022. These amounts represent the satisfaction of the transfer of TP-03 license rights to LianBio and the partial completion of clinical-related "performance obligations".</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will recognize additional "license fee and collaboration revenue" to the extent the contractual performance obligations are further satisfied or other events occur, specifically related to (i) milestone payments upon TP-03 pivotal trial completion and the delivery of associated clinical data and reports to our licensee, (ii) achievement of regulatory events that trigger milestone payments, and (iii) our licensee's product sales of TP-03 in the China Territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of License Fees and Collaboration Revenue</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of license fees and collaboration revenue decreased by $1.3 million for the three months ended March&#160;31, 2022, as compared to the prior year period. These amounts relate to our contractual payment obligations to our licensor that are attached to our China Out-License proceeds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $4.2 million for the three months ended March&#160;31, 2022, as compared to the prior year period. The decrease was primarily due to non-recurring costs in the prior year period including (i) a contractual payment in March 2021 in the form of 187,500 shares of our common stock then valued at $5.5 million to extend the period of our September 2020 in-license agreement, and (ii) contractual payment of $2 million under our January 2019 in-license for the commencement of our Saturn-2 trial. These decreases were partially offset by (i) increased clinical and preclinical study costs of $1.3 million, (ii) increased manufacturing and formulation costs of $0.6&#160;million, and (iii)&#160;increased payroll and personnel-related costs, including stock-based compensation, of $1.1&#160;million, for eight employee additions period over period to drive our product development initiatives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $2.8 million for the three months ended March&#160;31, 2022, as compared to the prior year period. The increase was primarily due to (i) a $2.1 million increase in payroll and personnel-related costs, including stock-based compensation, for 14 employee additions period over period to support our business growth, and (ii) increased commercial and market research costs of $0.6 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net increased by $0.7 million which primarily consists of (i) interest expense of $0.3 million related to the Credit Facility executed in February 2022, (ii) mark-to-market decrease of $0.2 million for the LianBio equity warrants we received as part of our China Out-License in March 2021, and (iii) mark-to-market decrease of $0.2 million for revaluation of LianBio common stock held (after our exercise of the first warrant tranche).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit for Income Taxes</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a valuation allowance against our net deferred tax assets as of March&#160;31, 2022 and 2021 due to the uncertainty that such assets will be realized. We evaluate the recoverability of our deferred tax assets on at least an annual basis. For the three months ended March 31, 2022, we recorded a nominal income tax benefit of $1 thousand due to the losses we incurred in that period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to be dependent upon equity, debt financing, and/or other forms of capital raises at least until we are able to generate significant ongoing positive cash flows to support our operations. As of March&#160;31, 2022, we had cash and cash equivalents of $175.0&#160;million and marketable securities of $0.3&#160;million.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since our inception, our operations have been substantially financed by cash proceeds of $61 million from private placements of preferred stock, the proceeds from our IPO, China Out-License consideration, a credit facility capital draw, and proceeds from our Follow-on Public Offering (defined below). In connection with our IPO, we sold 6,325,000 shares of our common stock (inclusive of the full exercise of the underwriters&#8217; option to purchase 825,000 shares of common stock). After deducting underwriting discounts, commissions and other related expenses, our IPO proceeds were $91.7 million. In May 2022, we sold 5,600,000 shares of our common stock at a price to the public of $13.50 per share (exclusive of up to 840,000 additional shares of common stock that the underwriters have an option to purchase at the public offering price) (the &#8220;Follow-on Public Offering). After deducting, discounts, commissions, and other related expenses, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">he net proceeds to us from the Follow-on Public Offering are expected to be approximately $70.6 million.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have received $55 million of total proceeds in connection with our China Out-License (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). We expect to receive an additional $30&#160;million during 2022 for the achievement of certain clinical development milestones (inclusive of our Saturn-2 topline data milestone of $15 million that was achieved in May 2022) for aggregate milestone receipts through December 2022 of $85&#160;million. The remaining $120 million of potential milestones under this out-license will be received upon future clinical, regulatory and sales achievements within the China Territory. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we drew $20 million from our credit facility with Hercules Capital and Silicon Valley Bank.  This $175 million facility has tranched availability as follows: </span></div><div style="padding-left:36pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $40 million at closing  ($20 million drawn and $20 million available)</span></div><div style="padding-left:36pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $25 million upon NDA submission of TP-03</span></div><div style="padding-left:36pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $35 million upon FDA approval of TP-03</span></div><div style="padding-left:36pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $50 million upon achievement of certain quarterly revenue thresholds</span></div><div style="padding-left:36pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1pt"> $25 million with lender approval</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital draws are at our election and are in $5 million increments. This credit facility includes a four-year interest only period and is extendable to five years upon meeting certain conditions that we expect to achieve. We currently have no other financing commitments, such as lines of credit or guarantees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenditures currently consist of research and development expenses (including activities within our preclinical, clinical, regulatory, and drug manufacturing initiatives) and general and administrative expenses. Our use of cash is impacted by the timing and extent of payments for each of these activities and other business requirements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents and marketable securities of $175.3&#160;million as of March&#160;31, 2022 is sufficient to fund our current and planned operations for at least the next twelve months from the date of this filing on Form 10-Q. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that this $175.3 million, in addition to (i) our May 2022 equity raise net proceeds of $70.6 million, (ii) our expected China Out-License milestone cash proceeds of $30&#160;million during 2022 (with a $15 million cash milestone expected by 2024), and (iii) $80 million of expected availability through 2023 from our Credit Facility (excluding the $20 million draw in February 2022) subject to the achievement of certain regulatory milestones should provide sufficient capital resources to fund our planned corporate expenses, research and development expenses, and capital expenditure requirements at least into 2026. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base this current cash runway estimate on our revenue and expense assumptions that may require future adjustments as part of our ongoing business decisions within pipeline development and our other corporate initiatives. Accordingly, we may require additional capital resources earlier than we currently expect.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 1, 2021, we filed a shelf registration statement (the &#8220;Shelf Registration Statement&#8221;) on Form S-3 with the SEC (that was declared effective by the SEC on November 5, 2021), which permits us to offer up to $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time. Our Shelf Registration Statement is intended to provide us with additional flexibility to access capital markets for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies, or businesses.  As part of this Shelf Registration Statement, we also filed a sales agreement prospectus covering the sale of up to $100 million of our common stock pursuant to an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (the &#8220;Sale Agreement&#8221;) with Jefferies LLC. Through the date of this filing, we have not sold any shares of our common stock in at the market transactions pursuant to the Sale Agreement. We conducted the Follow-on Public Offering pursuant to this Shelf Registration Statement.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any product sales. We do not expect to report any product revenue unless and until we (1)&#160;complete development of any of our product candidates; (2)&#160;obtain applicable regulatory approvals; and then (3)&#160;successfully commercialize or enter into other collaborative agreements for our product candidates with third parties. We do not know with certainty when, or if, any of these items will ultimately occur.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant operating losses for the foreseeable future, and expect these losses to further increase, as we ramp up our clinical development programs and begin activities for commercial launch readiness. We may also encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional capital to fully develop our product candidates and to execute our business strategy. Our requirements of a future capital raise will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of clinical programs we decide to pursue;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and costs of development and commercial manufacturing activities;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing associated with commercializing our product candidates, if they receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time and availability under our Credit Facility;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our implementation of various computerized information systems;</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of COVID-19 on our clinical development or operations; and</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially and adversely affect our business and financial prospects. See the section titled &#8220;Risk Factors&#8221; in this report for additional risks associated with our substantial capital requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Statement of Cash Flows</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash, cash equivalents and restricted cash for each of the periods presented below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) :</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,286)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,794)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,950)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by (Used in) Operating Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $15.3 million for the three months ended March 31, 2022. Though we recognized $0.5 million of license fee and collaboration revenue, no corresponding cash was received in the current three-month period in connection with our China Out-License. In the current three-month period, our cash payments to vendors for our operating activities totaled $10.1 million and payroll-related cash payments (inclusive of 2021 bonus payouts) totaled $5.2 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $11.8 million for the three months ended March 31, 2021. Though we recognized $33.4 million of license fee and collaboration revenue from the China Out-License in the prior year period, no corresponding cash was received until the second quarter of 2021. Our cash payments to vendors for our operating activities totaled $9.2 million and payroll-related cash payments (inclusive of 2020 bonus payouts) totaled $2.7 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.2 million for the three months ended March 31, 2022, which consisted of leasehold improvements for our laboratory and administrative offices and various purchases of computer hardware and office equipment.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three months ended March&#160;31, 2021, which consisted of purchases of property and equipment and leasehold improvements for our laboratory and administrative offices.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $19.1 million for the three months ended March 31, 2022, which was attributable to proceeds from the Credit Facility. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $19 thousand for the three months ended March&#160;31, 2021, and was attributable to proceeds from the exercise of stock options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of our Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and notes to the financial statements.  Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates are different assumptions and conditions. A summary of our critical accounting policies is presented in our filed Annual Report on Form 10-K for the year ended December&#160;31, 2021.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no material changes to our previously reported "Critical Accounting Policies" during the three months ended March 31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows are disclosed in the footnote to which each relates within these accompanying Condensed Financial Statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law and in accordance with our bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our officers and directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of March&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012 (the "JOBS Act") permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">earliest of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1)&#160;the last day of our first fiscal year (a)&#160;following the fifth anniversary of the completion of our IPO, (b)&#160;in which we have total annual gross revenues of at least $1.07&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million of the prior June 30th and (2)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period.</span></div><div id="i33713c367fc84a8b901b03655de07e3d_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of March&#160;31, 2022, we had cash and cash equivalents of $175.0 million, consisting of interest-bearing money market accounts, for which the fair market value would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities and the low-risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents. As of March&#160;31, 2022, we had $19.2 million in variable rate debt outstanding. Our Credit Facility bears interest at an annual rate equal to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">greater of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (i) the Wall Street Journal prime rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 5.20% or (ii) 8.45%. A hypothetical change in interest rate of 10% would have resulted in a nominal change in interest expense for the three months ended March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation, interest rate changes, or foreign currency exchange rate fluctuations had a significant impact on our results of operations for any periods presented herein.</span></div><div id="i33713c367fc84a8b901b03655de07e3d_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended ("Exchange Act")) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i33713c367fc84a8b901b03655de07e3d_79"></div><div style="margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="i33713c367fc84a8b901b03655de07e3d_82"></div><div style="margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, there have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March&#160;14, 2022, other than the below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Development and Commercialization of Our Product Candidates</span></div><div style="text-indent:12.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Clinical drug development is a lengthy, expensive and risky process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results. If clinical trials of our product candidates, particularly TP-03 for the treatment of Demodex blepharitis, do not meet safety or efficacy endpoints or are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.</span></div><div style="text-indent:34.5pt"><span><br/></span></div><div style="text-indent:34.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. The research and development of drugs is an extremely risky industry. Only a small percentage of product candidates that enter the development process ever receive marketing approval. Failure or delay can occur at any time during the clinical trial process. To date, we have focused substantially all of our efforts and financial resources on identifying, acquiring, and developing our product candidates, including conducting preclinical studies and clinical trials. Clinical testing is expensive and can take many years to complete, and we cannot be certain that any clinical trials will be conducted as planned or completed on schedule, if at all. Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials. Our inability to successfully complete preclinical and clinical development could result in additional costs to us and negatively impact our ability to generate revenue. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize product candidates. We currently generate no revenues from sales of any products, and we may never be able to develop or commercialize a marketable product.</span></div><div style="text-indent:34.5pt"><span><br/></span></div><div style="text-indent:34.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have not yet completed full data results for any Phase 3 trials for any product candidate. The results of preclinical and early clinical trials of our product candidates and other products with the same mechanism of action may not be predictive of the results of later-stage clinical trials. Clinical trial failure may result from a multitude of factors including flaws in trial design, dose selection, placebo effect, patient enrollment criteria, relatively smaller sample size in earlier trials, and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval. Furthermore, as more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. For example, our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials. The failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates or cause regulatory authorities to require additional testing before approving any of our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently have two product candidates in clinical development and their risk of failure is high. For example, use of TP-03 requires the patient to follow a prescribed technique to administer the eye drops. Failure to properly administer the eye drops by the patient or inappropriate technique demonstration by the eye care practitioners, may adversely affect the outcome of TP-03 in demonstrating efficacy in one or more clinical trials. We are unable to predict if this product candidate or any of our future product candidates that advance into clinical trials will prove safe or effective in humans or will obtain marketing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">approval. If we are unable to complete preclinical or clinical trials of current or future product candidates, due to safety concerns, or if the results of these trials are not satisfactory to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization. Even if we are able to obtain marketing approvals for any of our product candidates, those approvals may be for indications that are not as broad as desired or may contain other limitations that would adversely affect our ability to generate revenue from sales of those products. Moreover, if we are not able to differentiate our product against other approved products within the same class of drugs, or if any of the other circumstances described above occur, our business would be materially harmed and our ability to generate revenue from that class of drugs would be severely impaired.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:34.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each of our product candidates will require additional clinical development, management of clinical, preclinical (for some of our product candidates) and manufacturing activities, regulatory approval in multiple jurisdictions, achieving and maintaining commercial-scale supply, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We may experience delays in our ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. For example, the FDA had initially recommended that for TP-03 we conduct carcinogenicity testing and has subsequently agreed in Type C meeting minutes that we can submit a carcinogenicity waiver, and if not granted, the carcinogenicity testing could be conducted and submitted as a post-marketing requirement. Furthermore, the FDA recommended that we conduct embryofetal development studies in a second species, which have been completed. Any further recommendations by the FDA could cause delay of any regulatory approval by the FDA and cause our expenses to increase. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize TP-03, our other product candidates, or any other product candidates that we may develop, including:</span></div><div style="text-indent:34.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may experience delays in or failure to reach agreement on acceptable terms with prospective CROs, vendors and clinical sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs, vendors and trial sites;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may fail to obtain sufficient enrollment in our clinical trials, our enrollment needs may grow larger than we anticipate, or participants may fail to complete our clinical trials at a higher rate than we anticipate;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may decide, or regulators or institutional review boards or ethics committees may require us, to suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulators or institutional review boards or ethics committees may not authorize us or our investigators to commence a clinical trial at a prospective clinical trial site or at all or may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may need to delay or suspend one or more trials until we complete additional financing transactions or otherwise receive adequate funding;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or may be delayed;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards or ethics committees to suspend or terminate trials;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulatory authorities may determine that the planned design of our clinical trials is flawed or inadequate;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulatory authorities may suspend or withdraw their approval of a product or impose restrictions on its distribution;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may not be able to timely or at all obtain Investigational New Drug ("IND") treatment for a product candidate;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may modify a preclinical study or clinical trial protocol;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may be unable to establish clinical endpoints that applicable regulatory authorities consider clinically meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities consider likely to predict clinical benefit;</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may experience delays due to the ongoing COVID-19 pandemic, including with respect to the conduct of ongoing clinical trials, receipt of product candidates or other materials, submission of NDAs, filing of IND applications, and starting any clinical trials for other indications or programs; and</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may experience manufacturing delays due to the recent COVID-19 pandemic in our supply chain caused by a shortage of raw materials, a lack of employees on site at our suppliers due to illness, or a lack of productivity at our suppliers due to local or national government quarantine restrictions on coming to the workplace.</span></div></td></tr></table></div><div style="text-indent:34.5pt"><span><br/></span></div><div style="text-indent:34.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may:</span></div><div style="text-indent:34.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">incur unplanned costs;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">be delayed in obtaining marketing approval for our product candidates;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">not obtain marketing approval at all;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obtain marketing approval in some countries and not in others;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">be subject to additional post-marketing testing requirements; or</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have the product removed from the market after obtaining marketing approval.</span></div></td></tr></table></div><div style="text-indent:34.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot be certain whether any of our planned clinical trials will begin on schedule or any preclinical studies we plan to initiate will begin on our intended schedule, or whether any such studies or clinical trials will need to be restructured or will be completed on schedule, or at all. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, or are unable to achieve clinical endpoints due to unforeseen events, such as the COVID-19 pandemic, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to commercialize our product candidates and may harm our business and results of operations.</span></div><div id="i33713c367fc84a8b901b03655de07e3d_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Proceeds from Initial Public Offering</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There has been no material change in the planned use of proceeds from our IPO as described in the Registration Statement on Form S-1 (File No. 333-249076), declared effective by the SEC on October 15, 2020, and the related final prospectus, dated October 15, 2020, filed with the SEC on October 16, 2020, pursuant to Rule 424(b) of the Securities Act.</span></div><div id="i33713c367fc84a8b901b03655de07e3d_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i33713c367fc84a8b901b03655de07e3d_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i33713c367fc84a8b901b03655de07e3d_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101-loanandsecurity.htm">Loan and Security Agreement, dated February 2, 2022, by and among </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101-loanandsecurity.htm">Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101-loanandsecurity.htm">, Hercules Capital, Inc. and Silicon Valley Bank.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-consultingagree.htm">Consulting Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-consultingagree.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-consultingagree.htm"> 1, 2020, between the Registrant and Elizabeth Yeu-Lin, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-consultingagree.htm">M.D., as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-33122.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-33122.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-33122.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-33122.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Tarsus Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i33713c367fc84a8b901b03655de07e3d_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i33713c367fc84a8b901b03655de07e3d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.473%"><tr><td style="width:1.0%"></td><td style="width:29.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.368%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TARSUS PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bobak Azamian, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bobak Azamian, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Director)</span></td></tr></table></div><div style="margin-top:12pt;text-align:right;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.473%"><tr><td style="width:1.0%"></td><td style="width:29.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                         </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.368%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leonard M. Greenstein</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard M. Greenstein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-loanandsecurity.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i05c22e63ae214dd5bd25ac47b8587743_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-right:72.2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LOAN AND SECURITY AGREEMENT, DATED FEBRUARY 2, 2022, BY AND AMONG THE REGISTRANT, HERCULES CAPITAL, INC., AND SILICON VALLEY BANK</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5.95pt;padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS LOAN AND SECURITY AGREEMENT is made and dated as of February 2, 2022 and is entered into by and among TARSUS PHARMACEUTICALS, INC., a Delaware corporation, and each of its Subsidiaries joined hereafter from time to time pursuant to Section 7.13 hereof (hereinafter collectively referred to as the &#8220;Borrower&#8221;), HERCULES CAPITAL, INC., a Maryland corporation (&#8220;Hercules&#8221;), SILICON VALLEY BANK, a California corporation (&#8220;SVB&#8221;), and the several banks and other financial institutions or entities from time to time parties to this Agreement (each, a &#8220;Lender&#8221;, and collectively, referred to as the &#8220;Lenders&#8221;) and Hercules, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#8220;Agent&#8221;).</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:72.02pt;padding-right:72.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.31pt">Borrower has requested the Lenders make available to Borrower five tranches of term loans in an aggregate principal amount of up to One Hundred Seventy Five Million Dollars ($175,000,000) (the &#8220;Term Loans&#8221;)&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.92pt">The Lenders are willing to make the Term Loans on the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:72.05pt;padding-right:72.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AGREEMENT</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, Borrower, Agent and the Lenders agree as follows&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">DEFINITIONS AND RULES OF CONSTRUCTION</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Unless otherwise defined herein, the following capitalized terms shall have the following meanings&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Account Control Agreement(s)&#8221; means any agreement entered into by and among Agent, Borrower and a third party bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account (other than an Excluded Account) or an account holding Investment Property and which perfects Agent&#8217;s first priority security interest in the subject account or accounts.</font></div><div><font><br></font></div><div style="padding-left:72pt;padding-right:72.2pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;ACH Authorization&#8221; means the ACH Debit Authorization Agreement in substantially the form of Exhibit H attached to the Disclosure Letter, provided that account numbers shall be redacted for security purposes if and when filed publicly by the Borrower.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Acquisition&#8221; means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition of all or substantially all of the assets of a Person, or of any business, line of business or division or other unit of operation of a Person, (b) the acquisition of fifty percent (50%) or more of the Equity Interests of any Person, whether or not involving a merger, consolidation or similar transaction with such other Person, or otherwise causing any Person to become a Subsidiary of Borrower, or (c) the acquisition (including through inbound license transactions) of any product or product line, or of the right to use, develop, sell, license or distribute any product or product line (including the acquisition of all or substantially all Intellectual Property assets directed to a particular product or product line) of or from any other Person.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Advance(s)&#8221; means a Term Loan Advance.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Advance Date&#8221; means the funding date of any Advance.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:72pt;padding-right:67.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Advance Request&#8221; means a request for an Advance submitted by Borrower to Agent in substantially the form of Exhibit A attached to the Disclosure Letter, provided that account numbers shall be redacted for security purposes if and when filed publicly by the Borrower.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Affiliate&#8221; means (a) any Person that directly or indirectly controls, is controlled by, or is under common control with the Person in question, (b) any Person directly or indirectly owning, controlling or holding with power to vote twenty percent (20%) or more of the outstanding voting securities of another Person or (c) any Person twenty percent (20%) or more of whose outstanding voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities. As used in the definition of &#8220;Affiliate,&#8221; the term &#8220;control&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Agreement&#8221; means this Loan and Security Agreement, as amended, restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Amortization Date&#8221; means, initially February 2, 2026 or, upon satisfaction of either Interest Only Extension Condition, such later date (as applicable) as provided pursuant to Section 2.2(e).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Annual Forecast&#8221; means a twelve-month operating forecast of Borrower (including Borrower&#8217;s profits and losses and balance sheet) provided to Agent by Borrower pursuant to Section 7.1(g)&#59; provided that each such forecast must be approved by Borrower&#8217;s board of directors and must be reasonably acceptable to the Lenders.</font></div><div><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Anti-Corruption Laws&#8221; means all laws, rules, and regulations of any jurisdiction applicable to Borrower or any of its Affiliates from time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Anti-Terrorism Laws&#8221; means any laws, rules, regulations or orders relating to terrorism or money laundering, including without limitation Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Approval Milestone&#8221; means satisfaction of each of the following events&#58; (a) no default or Event of Default shall have occurred and be continuing&#59; and (b) Borrower shall have delivered evidence and documentation reasonably satisfactory to Agent that the FDA has approved the New Drug Application for TP-03 for the treatment of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Demodex </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Blepharitis with a label claim that it is generally consistent in all material respects with what Borrower sought in its New Drug Application (together with any supplement thereto). For the avoidance of doubt, upon approval, the clinical studies section of the label must include Collarette cure (which is the primary end point for the Phase 3 Saturn-2 trial NCT04784091).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Bank Services&#8221; means any products, credit services, and&#47;or financial accommodations previously, now, or hereafter provided to Borrower or any of its Subsidiaries by SVB or any SVB Affiliate, including, without limitation, any letters of credit, cash management services (including, without limitation, merchant services, direct deposit of payroll, business credit cards, and check cashing services), interest rate swap arrangements, and foreign exchange services as any such products or services may be identified in SVB&#8217;s various agreements related thereto (each, a &#8220;Bank Services Agreement&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Bank Services Agreement&#8221; has the meaning specified in the definition of Bank Services.</font></div><div style="margin-top:3.7pt;padding-left:144pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Bank Services Cap&#8221; means Three Million Dollars ($3,000,000.00).</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Bankruptcy Code&#8221; means the federal bankruptcy law of the United States as from time to time in effect, currently as Title 11 of the United States Code. Section references to current sections of the Bankruptcy Code shall refer to comparable sections of any revised version thereof if section numbering is changed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Blocked Person&#8221; means any Person&#58; (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &#8220;terrorism&#8221; as defined in Executive Order No. 13224, or (e) a Person that is named a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221; on the most current list published by OFAC or other similar list.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Borrower Products&#8221; means all products and service offerings currently being designed, marketed, manufactured, licensed or sold by Borrower or which Borrower intends to sell, license or distribute in the future, including any products or service offerings under development, collectively, together with all products and service offerings that have been sold, licensed or distributed by Borrower since its incorporation.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.2pt;text-align:justify;text-indent:74.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Borrower&#8217;s Books&#8221; means Borrower&#8217;s or any of its Subsidiaries&#8217; books and records including ledgers, federal, state, local and foreign tax returns, records regarding Borrower&#8217;s or its Subsidiaries&#8217; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Business Day&#8221; means any day other than Saturday, Sunday and any other day on which banking institutions in the State of California are closed for business.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Cash&#8221; means all cash, cash equivalents and liquid funds.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Change in Control&#8221; means any reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of Borrower, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of Borrower in which the holders of Borrower&#8217;s outstanding shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each case without regard to whether Borrower is the surviving entity.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Closing Date&#8221; means the date of this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Code&#8221; means the Internal Revenue Code of 1986, as amended (including treasury regulations promulgated thereunder).</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Common Stock&#8221; means the Common Stock, $0.0001 par value per share, of the Borrower. </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Contingent Obligation&#8221; means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any Indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co- made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable&#59; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person&#59; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices&#59; provided, however, that the term &#8220;Contingent </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Obligation&#8221; shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed, without duplication of the primary obligation, to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith&#59; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Copyright License&#8221; means any written agreement granting any license or similar right in, to or under any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest, to which agreement Borrower is or hereafter becomes a party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Copyrights&#8221; means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States of America or of any other country.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Deposit Accounts&#8221; means any &#8220;deposit accounts,&#8221; as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Disclosure Letter&#8221; means the disclosure letter, dated as of the date hereof, delivered by the Borrower to the Agent for the benefit of the Lenders.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Dollars,&#8221; &#8220;dollars&#8221; or use of the sign &#8220;$&#8221; means only lawful money of the United States and not any other currency, regardless of whether that currency uses the &#8220;$&#8221; sign to denote its currency or may be readily converted into lawful money of the United States.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Domestic Subsidiary&#8221; means any Subsidiary organized under the laws of the United States of America, any State thereof, the District of Columbia, or any other jurisdiction within the United States of America.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Due Diligence Fee&#8221; means a one-time fee in the amount of Thirty-Five Thousand Dollars ($35,000), which fee has been paid to the Lenders by Borrower prior to the Closing Date, and shall be deemed fully earned on such date regardless of the early termination of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Equity Interests&#8221; means, with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities or equity ownership interests of such Person.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;ERISA&#8221; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Excluded Account&#8221; means any of the following accounts which are designated as such in writing to Agent as of the Closing Date or, with respect to any account opened after the Closing Date, in the next Compliance Certificate delivered after such account is opened&#58; (i) accounts used exclusively to maintain cash collateral subject to a Permitted Lien under clause (xiv) thereof, (ii) any payroll or benefits account, provided that the aggregate balance of all such accounts shall not exceed the amount of all payroll or related benefit payments for the immediately succeeding two (2) payroll and benefit contribution cycles.</font></div><div style="padding-right:71.85pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;FDA&#8221; means the U.S. Food and Drug Administration or any successor thereto.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Forecast&#8221; means the Annual Forecast or Revised Forecast most recently delivered by Borrower to Agent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Foreign Subsidiary&#8221; means any Subsidiary other than a Domestic Subsidiary.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72.2pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;GAAP&#8221; means generally accepted accounting principles in the United States of America, as in effect from time to time.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Indebtedness&#8221; means indebtedness of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within one hundred twenty (120) days), including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, (d) equity securities of any Person subject to repurchase or redemption other than at the sole option of such Person, (e) &#8220;earnouts&#8221;, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature arising out of purchase and sale contracts, (f) &#91;reserved&#93;,</font></div><div style="margin-top:0.1pt;padding-left:72pt;padding-right:72.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">non-contingent obligations to reimburse any bank or Person in respect of amounts paid under a letter of credit, banker&#8217;s acceptance or similar instrument, and (h) all Contingent Obligations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Initial Facility Charge&#8221; means a one-time fee in the amount of Two Hundred Thousand Dollars ($200,000), payable to Lenders in accordance with Section 4.1(f).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Intellectual Property&#8221; means all of Borrower&#8217;s Copyrights&#59; Trademarks&#59; Patents&#59; Licenses&#59; trade secrets and inventions&#59; mask works&#59; Borrower&#8217;s applications therefor and reissues, extensions, or renewals thereof&#59; and Borrower&#8217;s goodwill associated with any of the foregoing, together with Borrower&#8217;s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Interest Only Extension Conditions&#8221; means the satisfaction of either of the following events prior to the Amortization Date&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">(x) no default or Event of Default shall have occurred and be continuing, (y) Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed and (z) receipt by the Agent of evidence in form and substance reasonably satisfactory to Agent that Borrower has achieved at least $35,000,000 in Net Product Revenue&#59; or</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.58pt">(x) no default or Event of Default shall have occurred and be continuing, (y) Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed and (z) receipt by the Agent of evidence in form and substance satisfactory to Lenders that Borrower has raised at least $200,000,000 of unrestricted (including not subject to any clawback, redemption, escrow or similar contractual restrictions) new net cash proceeds (not including proceeds from the conversion or cancellation of Indebtedness) from the issuance of Equity Interests of Borrower or business development proceeds, between the Closing Date and prior to the Amortization Date, which proceeds shall be promptly deposited in a Deposit Account or securities account of Borrower subject to an Account Control Agreement in favor of Agent, and maintains Unrestricted Cash in an amount equal to or greater than 175% of the Required Cash Amount.</font></div><div style="margin-top:3.7pt;padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Investment&#8221; means, with respect to any Person, (a) any beneficial ownership (including stock, partnership, limited liability company interests, or other securities) of or in any other Person, (b) any loan, advance or capital contribution to any other Person or (c) any Acquisition.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;IRS&#8221; means the United States Internal Revenue Service.</font></div><div><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Joinder Agreements&#8221; means for each Subsidiary (other than a Foreign Subsidiary), a completed and executed Joinder Agreement in substantially the form attached to the Disclosure Letter as Exhibit F.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:71.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;License&#8221; means any Copyright License, Patent License, Trademark License or other Intellectual Property license of rights or interests therein.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Lien&#8221; means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest&#59; for clarity, excluding Intellectual Property licenses and similar rights.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Loan&#8221; means the Advances made under this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Loan Documents&#8221; means this Agreement, the promissory notes (if any), the ACH Authorization, the Account Control Agreements, the Disclosure Letter, the Joinder Agreements, all UCC Financing Statements, any Bank Services Agreements, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Market Capitalization&#8221; means, as of any date of determination, the product of (a) the number of outstanding shares of Common Stock publicly disclosed in the most recent filing of Borrower with the SEC as outstanding as of such date of determination and (b) the closing price of Borrower&#8217;s Common Stock (as quoted on Bloomberg L.P.&#8217;s page or any successor page thereto of Bloomberg L.P. or if such page is not available, any other commercially available source).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Material Adverse Effect&#8221; means a material adverse effect upon&#58; (i) the business, operations, properties, assets or financial condition of Borrower and its Subsidiaries taken as a whole&#59; or</font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii) the ability of Borrower to perform or pay the Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Agent or the Lenders to enforce any of its rights or remedies with respect to the Secured Obligations&#59; or (iii) the Collateral or Agent&#8217;s Liens on the Collateral or the priority of such Liens.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:74.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Maximum Term Loan Amount&#8221; means One Hundred Seventy Five Million and No&#47;100 Dollars ($175,000,000).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Net Product Revenue&#8221; means, as of any date of determination for any applicable trailing three-month period, net product revenue (as determined in accordance with GAAP) from the sale of TP-03 (which for the avoidance of doubt shall not include any royalty, profit sharing, or milestone revenue payment) in the United States, which (in the case of any projected or forecasted Net Product Revenue) shall be calculated based on historical standards and provided forecast methodology and shall not be affected by future changes contemplated by GAAP or other applicable regulatory requirements.</font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;New Drug Application&#8221; means a new drug application submitted by Borrower in the United States for authorization to market a product, as defined in the applicable laws and regulations and submitted to the FDA.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Non-Disclosure Agreement&#8221; means that certain Non-Disclosure Agreement&#47;Confidentiality Agreement by and between Borrower and Agent, dated as of October 27, 2021.</font></div><div style="margin-top:0.15pt;padding-left:144pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:258%">&#8220;OFAC&#8221; means the U.S. Department of Treasury Office of Foreign Assets Control. &#8220;OFAC Lists&#8221; means, collectively, the Specially Designated Nationals and Blocked Persons</font></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and&#47;or any other list of terrorists or other restricted Persons maintained </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.2pt;padding-left:72pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Patent License&#8221; means any written agreement granting any license or similar right in, to or under any Patent in existence or a Patent application that is pending, to which agreement Borrower is or hereafter becomes a party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.85pt;text-align:justify;text-indent:74.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Patents&#8221; means all letters patent of, or rights corresponding thereto, in the United States of America or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States of America or any other country.</font></div><div><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Perfection Certificate&#8221; means a completed certificate entitled &#8220;Perfection Certificate&#8221; delivered by Borrower to Agent and the Lenders, signed by Borrower.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Permitted Convertible Debt&#8221; means issuance by Borrower of convertible notes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such convertible notes shall (a) not require any scheduled amortization or other required payments of principal prior to, or have a scheduled maturity date, earlier than, one hundred eighty (180) days after the Term Loan Maturity Date, (b) be unsecured (or, if secured, be subordinated to the Secured Obligations pursuant to subordination terms in form and substance satisfactory to the Lenders in their sole discretion),</font></div><div style="padding-left:72pt;padding-right:71.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">not be guaranteed by any Subsidiary of Borrower that is not a Borrower and (d) shall specifically designate this Agreement and all Secured Obligations as &#8220;designated senior indebtedness&#8221; or similar term so that the subordination terms referred to in clause (d) of this definition specifically refer to such notes as being such subordination terms&#59; provided further, that any cross-default or cross-acceleration event of default (each howsoever defined) provision contained therein that relates to indebtedness or other payment obligations of Borrower (or any of its Subsidiaries) (such indebtedness or other payment obligations, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cross-Default Reference Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) contains a cure period of at least thirty (30) calendar days (after written notice to the issuer of such Indebtedness by the trustee or to such issuer and such trustee by holders of at least 25% in aggregate principal amount of such Indebtedness then outstanding) before a default, event of default, acceleration or other event or condition under such Cross-Default Reference Obligation results in an event of default under such cross-default or cross-acceleration provision.</font></div><div><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Permitted Indebtedness&#8221; means&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:180pt;padding-right:72.1pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">Indebtedness of Borrower in favor of any Lender or Agent arising under this Agreement or any other Loan Document&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.58pt">Indebtedness existing on the Closing Date which is disclosed in Schedule 1A of the Disclosure Letter&#59;</font></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.53pt">Indebtedness of up to $5,000,000 outstanding at any time secured by a Lien described in clause (vii) of the defined term &#8220;Permitted Liens,&#8221; provided such Indebtedness does not exceed the cost incurred to finance the acquisition, construction or improvement of any fixed or capital assets (including Equipment or software or other intellectual property financed with such Indebtedness)&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">Indebtedness to trade creditors incurred in the ordinary course of business (due within one hundred twenty (120) days, including such Indebtedness incurred in the ordinary course of business with corporate credit cards (not constituting Bank Services), in an amount not to exceed an amount equal to $1,500,000&#59;</font></div><div><font><br></font></div><div style="padding-left:189pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.18pt">Indebtedness that also constitutes a Permitted Investment&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:189pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.13pt">Subordinated Indebtedness&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:35.08pt">reimbursement obligations in connection with letters of credit not constituting Bank Services that are secured by Cash and issued on behalf of the Borrower or a Subsidiary thereof, in an amount not to exceed $500,000 at any time outstanding&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.03pt">other unsecured Indebtedness in an amount not to exceed $1,000,000 at any time outstanding&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.2pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">intercompany Indebtedness as long as either each of the Subsidiary obligor and the Subsidiary obligee under such Indebtedness is a Subsidiary that has executed a Joinder Agreement&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">Permitted Convertible Debt in an aggregate principal amount not to exceed Two Hundred Million Dollars ($200,000,000) at any time outstanding&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more burdensome terms upon Borrower or the applicable Subsidiary, as the case may be.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:146.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Permitted Investment&#8221; means&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">Investments existing on the Closing Date which are disclosed in Schedule 1B of the Disclosure Letter&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.8pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.58pt">(a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof currently having a rating of at least A-2 or P-2 from either Standard &#38; Poor&#8217;s Corporation or Moody&#8217;s Investors Services, (b) commercial paper maturing no more than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard &#38; Poor&#8217;s Corporation or Moody&#8217;s Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than one year from the date of investment therein, (d) money market accounts and (e) Investments pursuant to the investment policy that has been provided to the Agent prior to the Closing Date or any investment policy that has been approved by the Agent&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.53pt">repurchases of stock of the Borrower from former employees, directors, or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed $500,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or could exist after giving effect to the repurchases&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:189pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.13pt">Investments accepted in connection with Permitted Transfers&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:71.8pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower&#8217;s business&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:35.08pt">Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by Borrower&#8217;s Board of Directors&#59;</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:189pt;padding-right:72pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.03pt">Investments consisting of travel advances in the ordinary course of business&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">Investments in newly formed domestic Subsidiaries, provided that each such domestic Subsidiary enters into a Joinder Agreement promptly after its formation by Borrower and execute such other documents as shall be reasonably requested by Agent&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">Investments in Foreign Subsidiaries in an aggregate amount not to exceed $1,000,000 in any fiscal year&#59;</font></div><div><font><br></font></div><div style="padding-left:112.55pt;padding-right:71.9pt;text-align:justify;text-indent:49.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.18pt">Investments consisting of co-promotion, co-commercialization or co- development agreements for any territory (including the United States) in an arm&#8217;s length transaction entered into on commercially reasonable terms&#59; provided that, to the extent the subject of such agreement is the TP-03 program, such agreement is entered into with an established pharmaceutical company&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:35.08pt">joint ventures, in-licensing (including through the consummation of related transactions) or strategic alliances in the ordinary course of Borrower&#8217;s business (including, without limitation, through the nonexclusive or exclusive in-licensing of technology, the development of technology or the providing of technical support)&#59; provided that, at any time the outstanding principal amount of the Term Loans exceeds $30,000,000, then the aggregate amount of cash Investments pursuant to this clause (xii) shall not exceed (1) prior to the satisfaction of the Approval Milestone, $1,000,000 during any fiscal year and (2) following the satisfaction of the Approval Milestone, $5,000,000 during any fiscal year&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:144pt;padding-right:115.5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:225%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:225%;padding-left:32.03pt">additional Investments that do not exceed $1,000,000 in the aggregate. &#8220;Permitted Liens&#8221; means&#58;</font></div><div style="margin-top:0.2pt;padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">Liens in favor of Agent or the Lenders arising under this Agreement or any other Loan Document&#59;</font></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:71.85pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.58pt">Liens existing on the Closing Date which are disclosed in Schedule 1C of the Disclosure Letter&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.53pt">Liens for taxes, fees, assessments or other governmental charges or levies, either not yet delinquent or being contested in good faith by appropriate proceedings diligently conducted&#59; provided, that Borrower maintains adequate reserves therefor on Borrower&#8217;s Books in accordance with GAAP&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower&#8217;s business and imposed without action of such parties&#59; provided, that the payment thereof is not yet required&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.85pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">the following deposits, to the extent made in the ordinary course of business&#58; deposits under worker&#8217;s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens arising under ERISA or environmental Liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:71.85pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:35.08pt">Liens on any fixed or capital assets (including Equipment or software or other intellectual property) constituting purchase money Liens and Liens in connection with capital leases securing Indebtedness permitted in clause (iii) of &#8220;Permitted Indebtedness&#8221;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:189pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.03pt">Liens incurred in connection with Subordinated Indebtedness&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not interfering in any material respect with the business of the licensor&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets)&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:35.08pt">statutory and common law rights of set-off and other similar rights (including under contract) as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms or securities intermediaries&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.2pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.03pt">easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:32.63pt">(A) Liens on Cash securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness and (B) security deposits in connection with real property leases, the combination of (A) and (B) in an aggregate amount not to exceed $2,500,000 at any time&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:35.68pt">Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type described in clauses (i) through (xi) above&#59; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Permitted Out-Licenses&#8221; means each of the following Licenses and similar arrangements for the use of Intellectual Property or any Borrower Product (including, without limitation, in connection with business development transactions and other arrangements), to the extent entered into in the ordinary course of business and on an arms&#8217; length basis and would not result in the legal transfer of title of the Intellectual Property or any Borrower Product that is the subject of any such License or similar arrangement&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">Licenses and similar arrangements on a non-exclusive basis that do not interfere in any material respect with the Borrower&#8217;s business&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.58pt">Licenses and similar rights granted in connection with the TP-04 program, the TP-05 program or any other Borrower program (with the exception of the TP-03 program), which may include global or one or more territory-based exclusive licensing arrangement(s)&#59; provided that such Licenses and similar arrangements are on commercially reasonable terms (as determined by Borrower in good faith using its reasonable business judgment)&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.53pt">Licenses and similar rights granted in connection with the TP-03 program&#59; provided that such licenses are on commercially reasonable terms (as </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">determined by Borrower in good faith using its reasonable business judgment), and which may be exclusive in respect to territory but only as to discrete geographical areas outside of the United States of America.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:146.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Permitted Transfers&#8221; means&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:189pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.63pt">sales of Inventory in the ordinary course of business&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:189pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.58pt">Permitted Out-Licenses&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.53pt">abandonment, lapse or cancellation of any immaterial registrations, issuances or applications to register or issue Intellectual Property that Borrower reasonably determines (in good faith using its reasonable business judgement) not to maintain or renew&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:180pt;padding-right:72.05pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">sale of stock or other shares of the Borrower in the ordinary course of business and the sale of stock or other shares granted to Borrower as consideration in connection with Permitted Out-Licenses and other Investments described in clause (xii) of the defined term &#8220;Permitted Investments&#8221;&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:180pt;padding-right:71.95pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.13pt">to the extent constituting transfers, and without duplication, the transfer of cash or other assets to the extent necessary to consummate Permitted Investments of the type described in clause (xii) of the defined term Permitted Investments, which, for the avoidance of doubt, must be made subject to the terms of such clause (xii) of the defined term Permitted Investments&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:180pt;padding-right:72.1pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:35.08pt">other Transfers of assets having a fair market value of not more than $500,000 in the aggregate in any fiscal year.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:74.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Person&#8221; means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Receivables&#8221; means (a) all of Borrower&#8217;s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (b) all customer lists, software, and business records related thereto.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Register&#8221; has the meaning specified in Section 11.7.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Regulatory Milestone&#8221; means the satisfaction of each of the following events&#58; (a) no default or Event of Default shall have occurred and be continuing&#59; and (b) receipt by the Agent of evidence in form and substance reasonably satisfactory to it that Borrower has filed the New Drug Application for TP-03 for the treatment of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Demodex </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Blepharitis with the FDA.</font></div><div><font><br></font></div><div style="padding-left:72pt;padding-right:71.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Required Cash Amount&#8221; means, as of any date of determination, an amount equal to 175% of the (x) principal balance of the aggregate outstanding Term Loan Advances at such time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(y) the End of Term Charge then applicable and calculated pursuant to Section 2.6 hereof assuming that the End of Term Charge is due as of such date.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Required Lenders&#8221; means, at any time, the holders of more than 50% of the sum of the aggregate unpaid principal amount of the Term Loans then outstanding.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Restricted License&#8221; means any material inbound License with respect to which Borrower is the licensee that expressly prohibits Borrower from granting a security interest in Borrower&#8217;s interest in such License.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Revised Forecast&#8221; means a twelve-month operating forecast of Borrower (including Borrower&#8217;s profits and losses and balance sheet) that revises in any material respect the most recent Annual Forecast approved by the Borrower&#8217;s board of directors or the most recent Revised Forecast, and provided to Agent by Borrower&#59; provided that each such forecast must be presented to the Borrower&#8217;s board of directors and must be reasonably acceptable to the Lenders.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Sanctioned Country&#8221; means, at any time, a country or territory which is the subject or target of any Sanctions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Sanctioned Person&#8221; means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union or any EU member state, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person controlled by any such Person.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Sanctions&#8221; means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or the United Nations Security Council, the European Union or Her Majesty&#8217;s Treasury of the United Kingdom.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;SBA Funding Date&#8221; means each date on which a Lender which is an SBIC funds any portion of the Loans.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;SEC&#8221; means the United States Securities Exchange Commission.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Secured Obligations&#8221; means Borrower&#8217;s obligations under this Agreement and any Loan Document, including, without limitation, (a) any obligation to pay any amount now owing or later arising and (b) all obligations relating to Bank Services, if any.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:74.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Subordinated Indebtedness&#8221; means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Agent in its sole discretion and subject to a subordination agreement in form and substance satisfactory to Agent in its sole discretion.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Subsequent Financing&#8221; means the closing of any Borrower financing involving the sale and issuance of Borrower&#8217;s Equity Interests that is broadly marketed to multiple investors and which becomes effective after the Closing Date.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Subsidiary&#8221; means an entity, whether a corporation, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls, either directly or indirectly, 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 of the Disclosure Letter.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Taxes&#8221; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any governmental authority, including any interest, additions to tax or penalties applicable thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Term Commitment&#8221; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading &#8220;Term Commitment&#8221; opposite such Lender&#8217;s name on Schedule 1.1 of the Disclosure Letter.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Term Loan Advance&#8221; means each of the Tranche 1 Advance, Tranche 2 Advance, Tranche 3 Advance, Tranche 4 Advance, Tranche 5 Advance and any other Term Loan advanced under this Agreement.</font></div><div><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Term Loan Interest Rate&#8221; means for any day a per annum rate of interest equal to the greater of either (i) the prime rate as reported in The Wall Street Journal plus 5.20%, and (ii) 8.45%.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Term Loan Maturity Date&#8221; means February 2, 2027&#59; provided that if such day is not a Business Day, the Term Loan Maturity Date shall be the immediately preceding Business Day.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Trademark License&#8221; means any written agreement granting any license or similar right in, to or under any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest, to which agreement Borrower is or hereafter becomes a party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Trademarks&#8221; means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States of America, any State thereof or any other country or any political subdivision thereof.</font></div><div style="margin-top:3.7pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche&#8221; means with respect to the Tranche 1 Commitment, all Tranche 1 Advances&#59; with respect to the Tranche 2 Commitment, all Tranche 2 Advances&#59; with respect to the Tranche 3 Commitment, all Tranche 3 Advances&#59; with respect to the Tranche 4 Commitment, all Tranche 4 Advances&#59; and with respect to the Tranche 5 Commitment, all Tranche 5 Advances.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche 1 Commitment&#8221; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading &#8220;Tranche 1 Commitment&#8221; opposite such Lender&#8217;s name on Schedule 1.1 of the Disclosure Letter.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche 2 Commitment&#8221; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading &#8220;Tranche 2 Commitment&#8221; opposite such Lender&#8217;s name on Schedule 1.1 of the Disclosure Letter.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche 2 Facility Charge&#8221; means one-half of one percent (0.50%) of each Tranche 2 Advance, which is payable to Lenders in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche 3 Commitment&#8221; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading &#8220;Tranche 3 Commitment&#8221; opposite such Lender&#8217;s name on Schedule 1.1 of the Disclosure Letter.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche 3 Facility Charge&#8221; means one-half of one percent (0.50%) of each Tranche 3 Advance, which is payable to Lenders in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche 4 Draw Test&#8221; means, in respect of any requested Tranche 4 Advance, that immediately before and after such Tranche 4 Advance and giving </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">effect thereto, the ratio of the aggregate outstanding senior secured Indebtedness of Borrower to Net Product Revenue for the trailing three-month period most recently ended does not exceed 4.00&#58;1.00.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche 4 Facility Charge&#8221; means one-half of one percent (0.50%) of each Tranche 4 Advance, which is payable to Lenders in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:68.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Tranche 5 Facility Charge&#8221; means one-half of one percent (0.50%) of the Tranche 5 Advance, which is payable to Lenders in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:71.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;UCC&#8221; means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California&#59; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Agent&#8217;s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the State of California, then the term &#8220;UCC&#8221; shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Unrestricted Cash&#8221; means unrestricted Cash of Borrower maintained in Deposit Accounts or other accounts in Borrower&#8217;s name subject to an Account Control Agreement in favor of Agent, subject to any post-closing period provided under this Agreement to deliver Account Control Agreements.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;U.S. Person&#8221; means any Person that is a &#8220;United States person&#8221; as defined in Section 7701(a)(30) of the Code.</font></div><div style="margin-top:3.7pt;padding-left:144pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:72.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">The following terms are defined in the Sections or subsections referenced opposite such terms&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:178.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.500%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Defined Term&#160;&#160;&#160;&#160;Section</font></div></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agent</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:39.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Amortization Cure Payment</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2(e)</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assignee</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.14</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Borrower</font></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.11</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral</font></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Confidential Information</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.13</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">End of Term Charge</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Event of Default</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Financial Statements</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Person</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lenders</font></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Liabilities</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Maximum Rate</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Open Source License</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.10</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Participant Register</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.8</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prepayment Charge</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Publicity Materials</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.19</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Register</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Rights to Payment</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SBA</font></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.15</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SBIC</font></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.15</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SBIC Act</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.15</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Tranche 1 Advance</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2(a)(i)</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Tranche 2 Advance</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2(a)(ii)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Tranche 3 Advance</font></div></td><td colspan="3" style="border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2(a)(iii)</font></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Tranche 4 Advance</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2(a)(iv)</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #666666;border-left:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Tranche 5 Advance</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #666666;border-left:0.5pt solid #666666;border-right:0.5pt solid #666666;border-top:0.5pt solid #666666;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2(a)(v)</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:72.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">Unless otherwise specified, all references in (x) this Agreement or (y) any Annex, Exhibit or Schedule in the Disclosure Letter to a &#8220;Section,&#8221; &#8220;subsection,&#8221; &#8220;Exhibit,&#8221; &#8220;Annex,&#8221; or &#8220;Schedule&#8221; shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in this Agreement or to the Disclosure Letter, as applicable. </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:72.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">If at any time any change in GAAP would affect the computation of any financial requirement set forth in any Loan Document, and either the Borrower or the Required Lenders shall so request, Agent, Lenders and the Borrower shall negotiate in good faith to amend such requirement to preserve the original intent thereof in light of such change in GAAP&#59; provided that, until so amended, such requirement shall continue to be computed in accordance with GAAP prior to such change&#59; provided that any obligations of a Person that are or would have been treated as operating leases for purposes of GAAP prior to the issuance by the Financial Accounting Standards Board on February 25, 2016 of an Accounting Standards Update (the &#8220;ASU&#8221;) shall continue to be accounted for as operating leases for purposes of all financial definitions, calculations and covenants for purpose of this Agreement (whether or not such operating lease obligations were in effect on such date) notwithstanding the fact that such obligations are required in accordance with the ASU (on a prospective or retroactive basis or otherwise) to be treated as capitalized lease obligations in accordance with GAAP.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws)&#58; (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">THE LOAN</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:175.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.3pt">&#91;Reserved&#93;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:175.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.3pt">Term Loan Advances.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Term Commitment.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:25.63pt">Tranche 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement and the proviso hereto, (A) on the Closing Date, Lenders shall severally (and not jointly) make, and Borrower agrees to draw, a Term Loan Advance in an amount not less than</font></div><div style="padding-left:144pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$20,000,000, and (B) at any time after the Closing Date but prior to December 15, 2022, Borrower may request and Lenders shall severally (and not jointly) make additional Term Loan Advances in minimum increments of $5,000,000 (or if less than $5,000,000 the remaining amount of Term Loan Advances available to be drawn pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.2(a)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the aggregate Term Loan Advances made by any Lender pursuant to clause (A) and (B) above shall not exceed its respective Tranche 1 Commitment and the aggregate principal amount of the Term Loan Advances made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.2(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not exceed $40,000,000.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:144pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.58pt">Tranche 2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement and satisfaction of the Regulatory Milestone, on or prior to March 15, 2023, Borrower may request, and Lenders shall severally (and not jointly) make in an amount not to exceed their respective Tranche 2 Commitments, additional Term Loan Advances in minimum increments of $5,000,000 (or if less than $5,000,000 the remaining amount of Term Loan Advances available to be drawn pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), provided that the aggregate principal amount of the Term Loan Advances </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:144pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.2(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not exceed $25,000,000 (such Term Loan Advances, the &#8220;Tranche 2 Advances&#8221;).</font></div><div style="margin-top:3.7pt;padding-left:144pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:19.53pt">Tranche 3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement and satisfaction of the Approval Milestone, on or prior to March 15, 2024, Borrower may request, and Lenders shall severally (and not jointly) make in an amount not to exceed their respective Tranche 3 Commitments, additional Term Loan Advances in minimum increments of $5,000,000 for the first $30,000,000 advanced pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2.2(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and in minimum increments of $1,000,000 for the subsequent $5,000,000 advanced pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, provided that the aggregate principal amount of the Term Loan Advances made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not exceed</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">$35,000,000 (such Term Loan Advances, the &#8220;Tranche 3 Advances&#8221;).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:20.13pt">Tranche 4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement and satisfaction of the Approval Milestone, on and after June 15, 2023 through and until December 15, 2024, Borrower may request, and Lenders shall severally (and not jointly) make in an amount not to exceed their respective Tranche 4 Commitments, additional Term Loan Advances of $50,000,000 in minimum increments of $5,000,000 (or if less than</font></div><div style="padding-left:144pt;padding-right:72.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$5,000,000 the remaining amount of Term Loan Advances available to be drawn pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2(a)(iv) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provided that the aggregate principal amount of the Term Loan Advances made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not exceed $50,000,000) (such Term Loan Advance, the &#8220;Tranche 4 Advance&#8221;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:23.18pt">Tranche 5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement and conditioned on approval by the Lenders&#8217; respective investment committees in their sole and unfettered discretion, on or prior to December 15, 2024, Borrower may request, and Lenders shall severally (and not jointly) make in an amount not to exceed their respective Tranche 5 Commitments, an additional Term Loan Advance of $25,000,000 (such Term Loan Advance, the &#8220;Tranche 5 Advance&#8221;).</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Maximum Term Loan Amount. The aggregate outstanding Term Loan Advances shall not exceed the Maximum Term Loan Amount.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Advance Request. To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at least one (1) Business Day before the Closing Date (in the case of any Term Loan Advance requested to be made on the Closing Date) and at least five (5) Business Days before each Advance Date (other than the Closing Date) to Agent. The Lenders shall fund the Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Term Loan Advance is satisfied as of the requested Advance Date.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Interest. The principal balance of each Term Loan shall bear interest thereon from such Advance Date at the Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Term Loan Interest Rate will float and change on the day the prime rate as reported in the Wall Street Journal changes from time to time.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Payment. Borrower will pay interest on each Term Loan Advance in arrears on the first Business Day of each month, beginning the month after the Advance Date. Unless either of the Interest Only Extension Conditions has been satisfied prior to the Amortization Date, then Borrower shall repay the aggregate Term Loan principal balance that is outstanding on the day immediately preceding the Amortization Date, in equal monthly installments of principal and interest (mortgage style) beginning on the Amortization Date and continuing on the first Business Day of each month thereafter until the Secured </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Obligations (other than any (x) inchoate indemnity obligations, and (y) Bank Services, to the extent the counterparty Lender has agreed such Bank Services may continue to exist, or that are cash collateralized in accordance with Section 3.3 of this Agreement) have been paid in full. If the Interest Only Extension Conditions have been satisfied prior to the Amortization Date, then the aggregate outstanding Term Loan principal balance shall be due and payable in one installment payment on the Term Loan Maturity Date&#59; provided that, in the event that the Interest Only Extension Conditions have been satisfied in reliance on clause (ii) of such defined term&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">if Borrower fails to maintain Unrestricted Cash in an amount equal or greater than Required Cash Amount at any time following the Amortization Date and prior to the last five (5) days of the calendar month during which such failure has occurred, then Borrower shall repay the aggregate Term Loan principal balance in an amount necessary to comply with such requirement (such payment, an &#8220;Amortization Cure Payment&#8221;) within three (3) Business Days following such failure and for the avoidance of doubt such Amortization Cure Payment shall constitute a prepayment subject to Section 2.5 and Section 2.6&#59;</font></div><div><font><br></font></div><div style="padding-left:144pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">if Borrower fails to maintain Unrestricted Cash in an amount equal or greater than Required Cash Amount at any time following the Amortization Date and during the last five (5) days of the calendar month during which such failure has occurred, then Borrower shall make the necessary Amortization Cure Payment on or before the last Business Day of such calendar month and for the avoidance of doubt such Amortization Cure Payment shall constitute a prepayment subject to Section 2.5 and Section 2.6&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">if Borrower fails to make the applicable Amortization Cure Payment pursuant to clause (i) or (ii) above (as applicable), then the Amortization Date shall immediately and automatically be deemed to be the first Business Day of the calendar month immediately succeeding the calendar month during which the applicable failure to maintain Unrestricted Cash occurred, and Borrower shall be required to repay the aggregate Term Loan principal balance in accordance with the second sentence of this Section 2.2(e) (it being understood that Borrower shall be required to make the first payment due on the Amortization Date to Agent, for the ratable benefit of the Lenders, in immediately available funds on the Amortization Date and Agent shall not initiate a debit entry to Borrower&#8217;s account for such payment).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and payable on the Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. If a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day. Agent, for the benefit of Lenders, will initiate debit entries to the Borrower&#8217;s account as authorized on the ACH Authorization (x) on each payment date of all periodic obligations payable to the Lenders under each Term Loan Advance and (y) out-of-pocket legal fees and costs incurred by Agent or the Lenders in connection with Section 11.12 of this Agreement&#59; provided that in the event that Agent informs Borrower that Agent will not initiate a debit entry to Borrower&#8217;s account for a certain amount of the periodic obligations due on a specific payment date, Borrower shall pay to Agent, for the ratable benefit of the Lenders, such amount of periodic obligations in full in immediately available funds on such payment date&#59; provided, further, that, with respect to clause (x) above, if Agent informs Borrower that the Lenders will not initiate a debit entry as described above later than the date that is three (3) Business Days prior to such payment date, Borrower shall pay to Agent, for the ratable benefit of the Lenders, such amount </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of periodic obligations in full in immediately available funds on the date that is three (3) Business Days after the date on which Agent notifies Borrower of such&#59; provided, further, that in the event that Agent informs Borrower that Lenders will not initiate a debit entry to Borrower&#8217;s account for specified out-of-pocket legal fees and costs incurred by Agent or the Lenders, Borrower shall pay to the Agent such amount in full in immediately available funds within three (3) Business Days.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Maximum Interest. Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties&#8217; intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the &#8220;Maximum Rate&#8221;). If a court of competent jurisdiction shall finally determine that Borrower has actually paid to Lenders an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows&#58; first, to the payment of the Secured Obligations consisting of the outstanding principal&#59; second, after all principal is repaid, to the payment of Lenders&#8217; accrued interest, costs, expenses, professional fees payable pursuant to Section 11.12&#59; and third, after all Secured Obligations (other than any (x) inchoate indemnity obligations, and (y) Bank Services, to the extent the counterparty Lender has agreed such Bank Services may continue to exist, or that are cash collateralized in accordance with Section 3.3 of this Agreement) are repaid, the excess (if any) shall be refunded to Borrower.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Default Interest. In the event any payment is not paid on the scheduled payment date, other than due to a failure of any ACH debit due solely to an administrative or operational error of Agent or Lender or Borrower&#8217;s bank, if Borrower makes the payment within three (3) Business Days following Borrower&#8217;s knowledge of such failure to pay, an amount equal to four percent 4%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.2(d) plus four percent (4%) per annum. In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.2(d) or Section 2.4, as applicable.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Prepayment. At its option, Borrower may prepay all or a portion of the outstanding Advances by paying the entire principal balance (or such portion thereof), all accrued and unpaid interest thereon, together with a prepayment charge equal to the following percentage of the Advance amount being prepaid&#58; with respect to each Advance, if such Advance amounts are prepaid in any of the first twelve (12) months following the Closing Date, 2.0%&#59; after twelve (12) months but on or prior to twenty four (24) months, 1.5%&#59; and after twenty four (24) months, but on or prior to thirty six (36) months, 0.5% (each, a &#8220;Prepayment Charge&#8221;). If at any time Borrower elects to make a prepayment, and at such time, there are outstanding Advances under multiple Tranches, the Prepayment Charge shall be determined by applying the amount of such prepayment in the following order&#58; first, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the latest initial funding date&#59; second, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the next latest initial funding date and so on until the entire principal balance of all Advances made hereunder (and all accrued but unpaid interest thereon) is paid in full. Borrower agrees that the Prepayment Charge is a reasonable calculation of the Lenders&#8217; lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances. Borrower shall prepay the outstanding amount of all principal and </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:71.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">accrued interest through the prepayment date and the Prepayment Charge upon the occurrence of a Change in Control or any other prepayment hereunder. Notwithstanding the foregoing, Agent and the Lenders agree to waive the Prepayment Charge if Agent and the Lenders (in their sole and absolute discretion) agree in writing to refinance the Advances prior to the Term Loan Maturity Date. Subject to the second sentence of this paragraph, any amounts paid under this Section shall be applied by Agent to the then unpaid amount of any Secured Obligations (including principal and interest) pro rata to all scheduled amounts owed of a specific Tranche. For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">End of Term Charge. On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays in full or in part the outstanding Secured Obligations (other than any (x) inchoate indemnity obligations, and (y) Bank Services), or (iii) the date that the Secured Obligations become due and payable (including, without limitation, by acceleration of the Secured Obligations during an Event of Default pursuant to Section 9), Borrower shall pay the Lenders a charge of 4.75% of the aggregate original principal amount of the Term Loan Advances made hereunder less the aggregate amount of all charges paid in accordance with the foregoing in connection with all prior partial prepayments (the &#8220;End of Term Charge&#8221;). Notwithstanding the required payment date of such End of Term Charge, the applicable pro rata portion of the End of Term Charge shall be deemed earned by the Lenders on the date the applicable Term Loan Advance is made. For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Pro Rata Treatment. Each payment (including prepayment) on account of any fee and any reduction of the Term Loan Advances shall be made pro rata according to the Term Commitments of the relevant Lender. Except with respect to any payment received by SVB with respect to obligations of Borrower in connection with Bank Services and except as otherwise provided in this Agreement, all of the rights, interests and obligations of each Lender under this Agreement and related Loan Documents, including security interests in the Collateral under this Agreement, shall be shared by the Lenders in the ratio of (a) the aggregate outstanding principal amount of such Lender&#8217;s Term Loan Advances to Borrower under this Agreement to (b) the aggregate outstanding principal amount of all Term Loan Advances to Borrower under this Agreement. Each Lender shall promptly remit to the other Lender such sums as may be necessary to ensure the ratable repayment of each Lender&#8217;s portion of any Term Loan Advance. Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lender also received its scheduled payment on such date&#59; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to the other Lender such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Agent. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation &#8220;ratably,&#8221; &#8220;proportionally&#8221; or in similar terms shall refer to this ratio. The provisions hereof shall apply irrespective of the time or order of attachment or perfection of security interests, or the time or order of filing or recording of financing statements.</font></div><div><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Taxes&#59; Increased Costs. The Borrower, the Agent and the Lenders each hereby agree to the terms and conditions set forth on Addendum 1 attached hereto.</font></div><div style="margin-top:3.7pt;padding-left:103.55pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Treatment of Prepayment Charge and End of Term Charge. Borrower agrees that any Prepayment Charge and any End of Term Charge payable shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, and Borrower agrees that it is reasonable under the circumstances currently existing and existing as of the Closing Date. </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:103.55pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Prepayment Charge and the End of Term Charge shall also be payable in the event the Secured Obligations (and&#47;or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure, or by any other means. Borrower expressly waives (to the fullest extent it may lawfully do so) the provisions of any present or future statute or law that prohibits or may prohibit the collection of the foregoing Prepayment Charge and End of Term Charge in connection with any such acceleration. Borrower agrees (to the fullest extent that each may lawfully do so)&#58; (a) each of the Prepayment Charge and the End of Term Charge is reasonable and is the product of an arm&#8217;s length transaction between sophisticated business people, ably represented by counsel&#59; (b) each of the Prepayment Charge and the End of Term Charge shall be payable notwithstanding the then prevailing market rates at the time payment is made&#59; (c) there has been a course of conduct between the Lenders and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Charge and the End of Term Charge as a charge (and not interest) in the event of prepayment or acceleration&#59; (d) Borrower shall be estopped from claiming differently than as agreed to in this paragraph. Borrower expressly acknowledges that their agreement to pay each of the Prepayment Charge and the End of Term Charge to the Lenders as herein described was on the Closing Date and continues to be a material inducement to the Lenders to provide the Term Loan Advances.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SECURITY INTEREST</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Borrower grants to Agent a security interest in all of Borrower&#8217;s right, title, and interest in, to and under all of Borrower&#8217;s personal property and other assets including without limitation the following (except as set forth herein) whether now existing or hereafter acquired (collectively, the &#8220;Collateral&#8221;)&#58; (a) Receivables&#59; (b) Equipment&#59; (c) Fixtures&#59; (d) General Intangibles (other than Intellectual Property)&#59; (e) Inventory&#59; (f) Investment Property&#59; (g) Deposit Accounts&#59; (h) Cash&#59; (i) Goods&#59; and all other tangible and intangible personal property (other than Intellectual Property) of Borrower whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, and any of Borrower&#8217;s property in the possession or under the control of Agent&#59; and, to the extent not otherwise included, all Proceeds of each of the foregoing, in each instance, expressly excluding Intellectual Property&#59; and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, however, subject to Section 3.2 below, that the Collateral shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Intellectual Property (the &#8220;Rights to Payment&#8221;). Notwithstanding the foregoing, but subject to Section 3.2 below, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Agent&#8217;s security interest in the Rights to Payment. For the avoidance of doubt, Borrower shall not be required to cause any guaranty or pledge of security interests that could, in Borrower&#8217;s reasonable judgment in consultation with Lender, cause material adverse tax consequences to Borrower.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Notwithstanding the broad grant of the security interest set forth in Section 3.1, above, the Collateral shall not include (a) any right, title or interest in, to or under any nonassignable licenses or contracts (including, without limitation, any Licenses), which by their terms require the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections 9406, 9407 and 9408 of the UCC), provided further, that upon the termination of such prohibition or such consent being provided with respect to any license or contract, such license or contract shall automatically be included in the Collateral, (b) more </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">than 65% of the presently existing and hereafter arising issued and outstanding Equity Interests owned by Borrower of any Foreign Subsidiary which Equity Interests entitle the holder thereof to vote for directors or any other matter (c) property for which the granting of a security interest therein is contrary to applicable law, provided that upon the cessation of any such restriction or prohibition, such property shall automatically be included in the Collateral,</font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d) any Excluded Accounts, (e) any cash collateral deposit subject to a Permitted Lien hereunder, if the grant of a security interest with respect to such property pursuant to this Agreement would be prohibited by the agreement creating such Permitted Lien or would otherwise constitute a default thereunder or create a right of termination a party thereto (other than Borrower), provided that upon the termination and release of such cash collateral, such property shall automatically be included in the Collateral and (f) any intent-to-use United States Trademark application for which neither (i) an amendment to allege use to bring the application into conformity with 15 U.S.C. &#167; 1051(a) has been filed with and accepted by the United States Patent and Trademark Office, nor (ii) a verified statement of use under 15 U.S.C. &#167; 1051(d) has been filed with and accepted by the United States Patent and Trademark Office.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">The security interest granted in Section 3.1 of this Agreement shall automatically terminate and be released upon the payment in full of the Secured Obligations (other than (x) contingent indemnification or reimbursement obligations that are not yet due and payable and (y) Bank Services, to the extent the counterparty Lender has agreed such Bank Services may continue to exist, or that are cash collateralized in accordance with last sentence of this Section 3.3) and Lender has no further commitment or obligation hereunder or under the other Loan Documents to make any further Advances. In the event there are Secured Obligations consisting of outstanding Bank Services, unless otherwise agreed by SVB in its sole discretion, Borrower shall provide to SVB cash collateral (and execute, deliver and file any financing statements, security agreements, collateral assignments, notices, control agreements or other documents to perfect or evidence SVB&#8217;s security interest in such cash collateral)&#59; provided that, (x) with respect to any Bank Services consisting of Letters of Credit, the amount of such cash collateral shall not exceed one hundred five percent (105.0%) of the outstanding face amount of any such Letters of Credit, plus all interest, fees, and costs due or to become due in connection therewith (as estimated by SVB in its business judgment), to secure the payment of the Secured Obligations relating to such Letters of Credit and (y) with respect to any other Secured Obligations consisting of Bank Services, an amount equal to the Secured Obligations in respect of such Bank Services then outstanding and any reasonably anticipated amount of the potential monetary exposure to SVB arising therefrom.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">CONDITIONS PRECEDENT TO LOAN</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The obligations of the Lenders to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions, in each case in form and substance reasonably acceptable to Agent&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Initial Advance. On or prior to the Closing Date, Borrower shall have delivered to Agent (or Agent shall have otherwise received) the following&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">executed copies of the Loan Documents, Account Control Agreements, and all other documents and instruments reasonably required by Agent to effectuate the transactions contemplated hereby or to create and perfect the Liens of Agent with respect to all Collateral, in all cases in form and substance reasonably acceptable to Agent&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">a legal opinion of Borrower&#8217;s counsel in form and substance reasonably acceptable to Agent&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">certified copy of resolutions of Borrower&#8217;s board of directors evidencing approval of the Loan and other transactions evidenced by the Loan Documents&#59;</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, certified by the Secretary of State of its state of incorporation, of Borrower&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified could have a Material Adverse Effect&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">payment of the Due Diligence Fee (which has been paid prior to the Closing Date), Initial Facility Charge and reimbursement of Agent&#8217;s and the Lenders&#8217; current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">certified copies, dated as of a recent date, of searches for financing statements filed in the central filing office of the State of Delaware, accompanied by written evidence (including any UCC termination statements reasonably satisfactory to Agent) that the Liens on any Collateral indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Term Loan Advance, will be terminated or released&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Intellectual Property search results&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">all certificates of insurance and copies of each insurance policy and endorsements required pursuant to Section 6.2&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">a duly executed copy of the Perfection Certificate and each exhibit and addendum thereto&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">such other documents as Agent may reasonably request in its good faith business discretion.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:175.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.3pt">All Advances. On each Advance Date&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Agent shall have received (i) an Advance Request for the relevant Advance as required by Section 2.2(c), each duly executed by Borrower&#8217;s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Agent may reasonably request in its good faith business discretion.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The representations and warranties set forth in this Agreement shall be true and correct in all material respects on and as of the applicable Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.</font></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">with respect to any of the Tranche 2 Advance, Tranche 3 Advance, Tranche 4 Advance or the Tranche 5 Advance, the Borrower shall have paid each Tranche 2 Facility Charge, each Tranche 3 Facility Charge, each Tranche 4 Facility Charge, or the Tranche 5 Facility Charge, as applicable&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">with respect to any Tranche 4 Advance, Borrower shall have satisfied the Tranche 4 Draw Test.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in subsections (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">No Default. As of the Closing Date and each Advance Date, (i) no fact or condition exists that constitutes (or, with the passage of time, the giving of notice, or both would constitute) an Event of Default and (ii) no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF BORROWER</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower represents and warrants that&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Corporate Status. Borrower is a corporation duly organized, legally existing and in good standing under the laws its state of incorporation, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect. Borrower&#8217;s present name, former names (if any), locations, place of formation, Tax identification number, organizational identification number and other information are correctly set forth in Exhibit B of the Disclosure Letter, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Agent after the Closing Date.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Collateral. Borrower owns the Collateral and the Intellectual Property, free of all Liens, except for Permitted Liens. Borrower has the power and authority to grant to Agent a Lien in the Collateral as security for the Secured Obligations.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Consents. Borrower&#8217;s execution, delivery and performance of this Agreement and all other Loan Documents, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower&#8217;s Certificate or Articles of Incorporation (as applicable) or bylaws, (iv) do not violate any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject in any material respect and (iv) except as described on Schedule 5.3 of the Disclosure Letter, do not violate any material contract or agreement or require the consent or approval of any other Person which has not already been obtained. The individual or individuals executing the Loan Documents on behalf of Borrower are duly authorized to do so.</font></div><div style="margin-top:3.7pt;padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Material Adverse Effect. No event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse Effect.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Actions Before Governmental Authorities. There are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of Borrower, threatened against or affecting Borrower or its property, that is reasonably expected to result in a Material Adverse Effect.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Laws. Neither Borrower nor any of its Subsidiaries is in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is not in default under (i) any provision of any agreement or instrument evidencing material Indebtedness in any material respect, or (ii) any other material agreement to which it is a party or by which it is bound.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:99pt;padding-right:72.05pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither Borrower nor any of its Subsidiaries is an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:99pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a &#8220;holding company&#8221; or an &#8220;affiliate&#8221; of a &#8220;holding company&#8221; or a &#8220;subsidiary company&#8221; of a &#8220;holding company&#8221; as each term is defined and used in the Public Utility Holding Company Act of 2005. Neither Borrower&#8217;s nor any of its Subsidiaries&#8217; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&#8217;s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws. Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:99pt;padding-right:72.05pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">None of Borrower, any of its Subsidiaries, or, to the knowledge of Borrower, any of Borrower&#8217;s or its Subsidiaries&#8217; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti Terrorism Law, or (iii) is a Blocked Person. None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti Terrorism Law. None of the funds to be provided under this Agreement will be used, directly or indirectly, (a) for any activities in violation of any applicable anti-money laundering, economic sanctions and anti-bribery laws and regulations laws and regulations or (b) for any payment to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended.</font></div><div style="margin-top:3.7pt;padding-left:139.55pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Information Correct and Current. No information, report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant thereto contained, or, when taken as a whole, contains or will contain any material misstatement of fact or, when taken together with all other such information or documents, omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not materially misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Agent, whether prior to or after the Closing Date, shall be (i) provided in good faith and based on the most current data and information available to Borrower, and (ii) the most current of such projections provided to Borrower&#8217;s Board of Directors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">it being understood that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts, that such projections are subject to significant uncertainties and contingencies, many of which are beyond the control of Borrower, that no assurance is given that any particular projections will be realized, and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Tax Matters. Except as described on Schedule 5.8 of the Disclosure Letter, (a) Borrower and its Subsidiaries have filed all federal and state income Tax returns and other material Tax returns that they are required to file (subject to valid extensions), (b) Borrower and its Subsidiaries have duly paid all </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">federal and state income Taxes and other material Taxes or installments thereof that they are required to pay, except Taxes being contested in good faith by appropriate proceedings and for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP, and (c) to the best of Borrower&#8217;s knowledge, no proposed (in writing) or pending Tax assessments, deficiencies, audits or other proceedings with respect to Borrower or any Subsidiary have had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Intellectual Property Claims. Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property material to Borrower&#8217;s business. Except as described on Schedule 5.9 of the Disclosure Letter, (i) each of the material registered Copyrights, registered Trademarks and issued Patents owned by Borrower are subsisting, valid and enforceable, (ii) no material part of the registered Intellectual Property owned by Borrower has been judged invalid or unenforceable in whole or in part, and (iii) no claim has been made to Borrower in writing that any material part of the Intellectual Property owned by Borrower nor Borrower&#8217;s use thereof in the operation of its business violates the rights of any third party. Exhibit C of the Disclosure Letter is a true, correct and complete list of each of Borrower&#8217;s Patents, registered Trademarks, registered Copyrights, and any pending applications to register any of the foregoing, and any material agreements under which Borrower licenses Intellectual Property from third parties (other than shrink wrap software licenses), together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to Borrower&#8217;s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Intellectual Property. Except as described on Schedule 5.10 of the Disclosure Letter, Borrower owns or has a license or other valid and enforceable right to use all material Intellectual Property rights necessary or material to the operation or conduct of Borrower&#8217;s business as currently conducted and proposed to be conducted by Borrower. Without limiting the generality of the foregoing, and in the case of Licenses, except for restrictions that are unenforceable under</font></div><div style="margin-top:3.7pt;padding-left:103.55pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower&#8217;s business, to freely transfer, license or assign the Intellectual Property necessary or material to the operation or conduct of Borrower&#8217;s business as currently conducted and as currently proposed to be conducted by Borrower, without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third party software and other items that are material to Borrower&#8217;s business and used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products except customary covenants in inbound license agreements and equipment leases where Borrower is the licensee or lessee. Borrower is not a party to, nor is it bound by, any Restricted License.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No material software used by Borrower or any of its Subsidiaries (or used in any Borrower Products or any Subsidiaries&#8217; products) are subject to an open-source or similar license (including but not limited to the General Public License, Lesser General Public License, Mozilla Public License, or Affero License) (collectively, &#8220;Open Source Licenses&#8221;) in a manner that would cause any material proprietary software owned by Borrower to have to be (i) distributed to third parties at no charge or a minimal charge (royalty-free basis)&#59; (ii) licensed to third parties to modify, make derivative works based on, decompile, disassemble, or reverse engineer such Borrower proprietary software&#59; or (iii) used in a manner that does could require disclosure or distribution of such Borrower proprietary software in source code form.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Borrower Products. Except as described on Schedule 5.11 of the Disclosure Letter, no material Intellectual Property owned by Borrower or Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any manner Borrower&#8217;s use, transfer or licensing thereof or that may affect the validity, use or enforceability thereof, in each of the foregoing, other than (a) typical restrictions contained in Licenses and (b) office actions and other routine notices or similar documents issued by the United States Patent and Trademark Office or other applicable intellectual property office) in connection with the prosecution or maintenance of registrations, issuances or applications to register or issue Intellectual Property. There is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or to assign any ownership interest in any future Intellectual Property related to the operation or conduct of the business of Borrower or Borrower Products. Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower&#8217;s ownership in any Intellectual Property (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or asserting that any third party has any claim of legal or beneficial ownership with respect thereto nor, to Borrower&#8217;s knowledge, is there a reasonable basis for any such claim. Neither Borrower&#8217;s use of its material Intellectual Property nor the production and sale of Borrower Products infringes the Intellectual Property or other rights of others.</font></div><div><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Financial Accounts. Exhibit D of the Disclosure Letter, as may be updated by the Borrower in a written notice provided to Agent after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Employee Loans. Except for Permitted Investments, Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Capitalization and Subsidiaries. Borrower&#8217;s capitalization as of the Closing Date is set forth on Schedule 5.14 of the Disclosure Letter. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as Schedule 1 of the Disclosure Letter, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">INSURANCE&#59; INDEMNIFICATION</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form, against risks customarily insured against in Borrower&#8217;s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification agreement found in Section 6.3. Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance (inclusive of umbrella coverage) for each occurrence. Borrower has and agrees to maintain a minimum of $2,000,000 of directors&#8217; and officers&#8217; insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the tangible Collateral, provided that such insurance may be subject to standard exceptions and deductibles. If Borrower fails to obtain the insurance called for by this Section 6.1 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Agent may obtain such insurance or make such payment, and all amounts so paid by Agent are immediately due and payable, bearing interest at the then highest rate applicable to the Secured Obligations, and secured by the Collateral. Agent will make reasonable efforts to provide Borrower with notice of Agent obtaining such insurance at the time it is obtained or within a reasonable time thereafter. No payments by Agent are deemed an agreement to make similar payments in the future or Agent&#8217;s waiver of any Event of Default.</font></div><div><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Certificates. Borrower shall deliver to Agent certificates of insurance that evidence Borrower&#8217;s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower&#8217;s insurance certificate shall state Agent (shown as &#8220;Hercules Capital, Inc., as Agent&#8221;) is an additional insured for commercial general liability, a lenders loss payable for all risk property damage insurance, subject to the insurer&#8217;s approval, and a lenders loss payable for property insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and lender&#8217;s loss payable endorsements for all risk property damage insurance. All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Agent of cancellation (other than cancellation for non-payment of premiums, for which ten (10) days&#8217; advance written notice shall be sufficient) or any other change adverse to Agent&#8217;s interests. Any failure of Agent to scrutinize such insurance certificates for compliance is not a waiver of any of Agent&#8217;s rights, all of which are reserved. Borrower shall provide Agent with copies of each insurance policy, and upon entering or amending any insurance policy required hereunder, Borrower shall provide Agent with copies of such policies and shall promptly deliver to Agent updated insurance certificates with respect to such policies.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Indemnity. Borrower agrees to indemnify and hold Agent, the Lenders and their officers, directors, employees, agents, in-house attorneys, representatives and shareholders (each, an &#8220;Indemnified Person&#8221;) harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable attorneys&#8217; fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal) (collectively, &#8220;Liabilities&#8221;), that may be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases Liabilities to the extent resulting solely from any Indemnified Person&#8217;s gross negligence or willful misconduct. This Section 6.3 shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim. In no event shall any Indemnified Person be liable on any theory of liability for any special, indirect, consequential or punitive damages (including any loss of profits, business or anticipated savings). This Section 6.3 shall survive the repayment of indebtedness under, and otherwise shall survive the expiration or other termination of, this Agreement, in each case subject to the applicable statute of limitations.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 7. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">COVENANTS OF BORROWER</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower agrees as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Financial Reports. Borrower shall furnish to Agent the financial statements and reports listed hereinafter (the &#8220;Financial Statements&#8221;)&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">within thirty (30) days) after the end of each month, (i) a report showing agings of accounts receivable and accounts payable&#59; (ii) a statement of all Cash and cash equivalents for such prior month and (iii) a statement of gross revenue all for such prior month&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">within forty-five (45) days after the end of each calendar quarter, unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, certified by Borrower&#8217;s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year end adjustments&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">within ninety (90) days after the end of each fiscal year, unqualified (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other than a &#8220;going concern&#8221; q</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ualification solely as a result of the occurrence of the Term Loan Maturity Date or other &#8220;going concern&#8221; qualification typical for venture-backed companies similar to Borrower) audited financial statements as of the end of such year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Agent, accompanied by any management report from such accountants&#59; it being agreed that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Ernst &#38; Young Global Limited </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">is acceptable to the Agent&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">within 30 days after the end of each month, a Compliance Certificate in the form of Exhibit E attached to the Disclosure Letter&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;reserved&#93;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">promptly after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements, information or reports that Borrower has made available to holders of its preferred stock or Common Stock and copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">(i) no sooner than the date that the Approval Milestone is satisfied, but in any event prior to such time that the aggregate outstanding principal amount of the Term Loans is equal to or greater than $100,000,000, Borrower shall deliver an Annual Forecast to Agent&#59; and (ii) thereafter no later than January 31st of each calendar year, an Annual Forecast covering each month during that calendar year&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">financial and business projections promptly following their approval by Borrower&#8217;s Board of Directors, and in any event, within 30 days after to the end of Borrower&#8217;s fiscal year, as well as budgets, operating plans and other financial information reasonably requested by Agent&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">solely to the extent either of the Interest Only Extension Conditions have been satisfied, immediate notice of any failure to maintain at any time Unrestricted Cash in an amount equal or greater than 175% of the Required Cash Amount&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">immediate notice if Borrower or any Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:99pt;padding-right:72.2pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower shall not (without the consent of Agent, such consent not to be unreasonably withheld or delayed), make any change in its (a) accounting policies or reporting practices, or (b) fiscal years or fiscal quarters. The fiscal year of Borrower shall end on December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:99pt;padding-right:71.9pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The executed Compliance Certificate, and all Financial Statements required to be delivered pursuant to clauses (a), (b), (c) and (d) shall be sent via e-mail to   with a copy to  and      provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be faxed to Agent at&#58; (650) 473-9194, attention Account Manager&#58; Tarsus Pharmaceuticals, Inc.</font></div><div style="margin-top:6pt;padding-left:98.95pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, documents required to be delivered under Sections 7.1(a), (b), (c) or (f) (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower files such documents with the SEC and such documents are publicly available on the SEC&#8217;s EDGAR filing system or any successor thereto.</font></div><div style="margin-top:6pt;padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Management Rights. Borrower shall permit any representative that Agent or the Lenders authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, however, that so long as no Event of Default has occurred and is continuing, such examinations shall be limited to no more often than once per fiscal year. In addition, any such representative shall have the right, at reasonable times and upon reasonable notice, to meet with management and officers of Borrower to discuss such books of account and records. In addition, Agent or the Lenders shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower&#8217;s business operations. The parties intend that the rights granted Agent and the Lenders shall constitute &#8220;management rights&#8221; within the meaning of 29 C.F.R. Section 2510.3- 101(d)(3)(ii), but that any advice, recommendations or participation by Agent or the Lenders with respect to any business issues shall not be deemed to give Agent or the Lenders, nor be deemed an exercise by Agent or the Lenders of, control over Borrower&#8217;s management or policies.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Further Assurances. Borrower shall from time to time execute, deliver and file, alone or with Agent, any financing statements, security agreements, collateral assignments, notices, control agreements, promissory notes or other documents to perfect, give the highest priority to Agent&#8217;s Lien on the Collateral or otherwise evidence Agent&#8217;s rights herein. Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Agent, and take all further action that may be necessary, or that Agent may reasonably request, to perfect and protect the Liens granted hereby and or pursuant to applicable Loan Documents. In addition, and for such purposes only, Borrower hereby authorizes Agent to execute and deliver on behalf of Borrower and to file such financing statements (including an indication that the financing statement covers &#8220;all assets or all personal property&#8221; of Borrower in accordance with Section 9-504 of the UCC), collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower either in Agent&#8217;s name or in the name of Agent as agent and attorney-in-fact for Borrower. Borrower shall protect and defend Borrower&#8217;s title to the Collateral and Agent&#8217;s Lien thereon against all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, nor shall Borrower permit any Subsidiary to do so, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for (a) the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion, (b) in connection with the refinancing of Permitted Indebtedness permitted under clause (xi) of the definition thereof, (c) purchase money Indebtedness pursuant to its then applicable payment schedule, (d) prepayment by any Subsidiary of (i) inter-company Indebtedness owed by such Subsidiary to any Borrower, or (ii) if such Subsidiary is not a Borrower, intercompany Indebtedness owed by such Subsidiary to another Subsidiary that is not a Borrower or (e) as otherwise permitted hereunder or approved in writing by Agent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Collateral. Borrower shall at all times keep the Collateral, the Intellectual Property and all other property and assets used in Borrower&#8217;s business or in which Borrower now or hereafter holds any interest free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process that could reasonably be expected to result in damages, expenses or liabilities in excess of $1,000,000 affecting the Collateral, the Intellectual Property (other than office actions and other routine notices or similar documents issued by the United States Patent and Trademark Office or other applicable intellectual property office) in connection with the prosecution or maintenance of registrations, issuances or applications to register or issue Intellectual Property), such other property and assets, or any Liens thereon, provided however, that the Collateral and such other property and assets may be subject to Permitted Liens except that there shall be no Liens whatsoever on Intellectual Property. Borrower shall not agree with any Person other than Agent or the Lenders not to encumber its property other than in connection with a Permitted Lien. Borrower shall not enter into or suffer to exist or become effective any agreement that prohibits or limits the ability of any Borrower to create, incur, assume or suffer to exist any Lien upon any of its property (including Intellectual Property), whether now owned or hereafter acquired, to secure its obligations under the Loan Documents to which it is a party other than (a) this Agreement and the other Loan Documents, (b) any agreements governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or limitation shall only be effective against the assets financed thereby) and (c) customary restrictions (including restrictions on scope of licenses and restrictions on the assignment) of or contained within leases, Licenses and other agreements. Borrower shall cause its Subsidiaries to protect and defend such Subsidiary&#8217;s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary&#8217;s material property and material assets free and clear from any Liens whatsoever (except for Permitted Liens, provided however, for the avoidance of doubt, that there shall be no Liens whatsoever on Intellectual Property), and shall give Agent prompt written notice of any legal process affecting such Subsidiary&#8217;s assets (other than office actions and other routine notices or similar documents issued by the United States Patent and Trademark Office or other applicable intellectual property office in connection with the prosecution or maintenance of registrations, issuances or applications to register or issue Intellectual Property), that could reasonably be expected to result in damages, expenses or liabilities in excess of $1,000,000.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries to do so, other than Permitted Investments.</font></div><div><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Distributions. Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other Equity Interest other than pursuant to employee, director or consultant repurchase plans or other </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">similar agreements, provided, however, in each case the repurchase or redemption price does not exceed the original consideration paid for such stock or Equity Interest (unless otherwise permitted under clause (c) of &#8220;Permitted Investments&#8221;), or (b) declare or pay any cash dividend or make any other cash distribution on any class of stock or other Equity Interest, except that a Subsidiary may pay dividends or make other distributions to Borrower or any Subsidiary of Borrower, (c) lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party in excess of $500,000 in the aggregate or (d) waive, release or forgive any Indebtedness owed by any employees, officers or directors in excess of $500,000 in the aggregate.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Transfers. Except for Permitted Transfers, Borrower shall not, and shall not allow any Subsidiary to, voluntarily or involuntarily transfer, sell, lease, license (except as otherwise permitted in this Agreement), lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of its assets.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Mergers and Consolidations. Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of (a) a Subsidiary which is not a Borrower into another Subsidiary or into Borrower or (b) a Borrower into another Borrower).</font></div><div style="margin-top:3.7pt;padding-left:139.55pt;padding-right:72.15pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Taxes. Borrower shall, and shall cause each of its Subsidiaries to, pay when due (subject to valid extensions) all material Taxes of any nature whatsoever now or hereafter imposed or assessed against Borrower, its Subsidiaries or the Collateral, or upon Borrower&#8217;s ownership, possession, use, operation or disposition thereof or upon Borrower&#8217;s rents, receipts or earnings arising therefrom. Borrower shall, and shall cause each of its Subsidiaries to, accurately file on or before the due date therefor (taking into account proper extensions) all federal and state income Tax returns and other material Tax returns required to be filed. Notwithstanding the foregoing, Borrower and its Subsidiaries may contest, in good faith and by appropriate proceedings diligently conducted, Taxes for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Corporate Changes. Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without twenty (20) days&#8217; prior written notice to Agent. Neither Borrower nor any Subsidiary shall suffer a Change of Control. Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business unless&#58; (i) it has provided prior written notice to Agent&#59; and (ii) such relocation shall be within the continental United States of America. Neither Borrower nor any Subsidiary shall relocate any tangible item of Collateral (other than (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up to $150,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit B of the Disclosure Letter to another location described on Exhibit B of the Disclosure Letter) unless (i) it has provided prompt written notice to Agent, (ii) such relocation is within the continental United States of America and, (iii) if such relocation is to a third party bailee, it has used commercially reasonable efforts to deliver a bailee agreement in form and substance reasonably acceptable to Agent.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Deposit Accounts. Borrower shall maintain all of Borrower&#8217;s and any of its Subsidiaries&#8217; Deposit Accounts, operating accounts and excess cash with SVB and SVB&#8217;s Affiliates, which accounts are required to be subject to Account Control Agreements in favor of Agent&#59; provided, notwithstanding the foregoing, Borrower shall be permitted to maintain twenty-five percent (25%) of its Cash with other financial institutions solely to the extent such Cash is held in Deposit Accounts subject to an Account Control Agreement in favor of Agent. In addition to the foregoing, except as permitted pursuant to clause (iv) or (vii) of the definition of Permitted Indebtedness, Borrower and any Subsidiary of Borrower, </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall obtain any business credit card and any letter of credit exclusively from SVB. Notwithstanding anything herein to contrary, in no event shall Borrower be obligated to deliver any Account Control Agreement with respect to an Excluded Account.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Joinder. Borrower shall notify Agent of each Subsidiary formed subsequent to the Closing Date and, within 20 days of formation (or such later date as may be agreed to by Agent in its sole discretion), shall cause any such Subsidiary which is a Domestic Subsidiary to execute and deliver to Agent a Joinder Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Notification of Event of Default. Borrower shall notify Agent immediately of the occurrence of any Event of Default.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">SBA Addendum. One or more affiliates of Agent have received a license from the U.S. Small Business Administration (&#8220;SBA&#8221;) to extend loans as a small business investment company (&#8220;SBIC&#8221;) pursuant to the Small Business Investment Act of 1958, as amended, and the associated regulations (collectively, the &#8220;SBIC Act&#8221;). Portions of the Loan to Borrower may be made by a Lender that is an SBIC. Addendum 2 attached hereto outlines various responsibilities of Agent, each Lender and Borrower associated with a loan made by an SBIC, and such Addendum 2 attached hereto is hereby incorporated in this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Use of Proceeds. Borrower agrees that the proceeds of the Loans shall be used solely to pay related fees and expenses in connection with this Agreement and for working capital and general corporate purposes. The proceeds of the Loans will not be used in violation of Anti- Corruption Laws or applicable Sanctions.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:175.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.8pt">Compliance with Laws.</font></div><div><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower shall maintain, and shall cause its Subsidiaries to maintain, compliance in all material respect with all applicable laws, rules or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and shall, or cause its Subsidiaries to, obtain and maintain all required governmental authorizations, approvals, licenses, franchises, permits or registrations reasonably necessary in connection with the conduct of Borrower&#8217;s business.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:99pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries and their respective officers and employees and to the knowledge of Borrower its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:99pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">None of Borrower, any of its Subsidiaries or any of their respective directors, officers or employees, or to the knowledge of Borrower, any agent for Borrower or its Subsidiaries that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person. No Loan, use of proceeds or other transaction contemplated by this Agreement will violate Anti-Corruption Laws or applicable Sanctions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:175.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.8pt">Financial Covenants.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt;text-decoration:underline">Minimum Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Beginning on May 15, 2023 until the satisfaction of the Approval Milestone (but without limiting either of the Interest Only Extension Conditions or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">2.2(e)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">), Borrower shall at all times maintain Unrestricted Cash in an amount not less than $30,000,000.</font></div><div style="margin-top:3.7pt;padding-left:144pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Conditional Performance Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On and after January 1, 2024, to the extent the aggregate outstanding principal amount of the Term Loans is equal to or greater than $100,000,000, then Borrower shall maintain compliance with any one of the following clauses&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:144pt;padding-right:68.6pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">at all times maintain (A) a minimum Market Capitalization of at least $500,000,000 and (B) Unrestricted Cash in an amount not less than 30% of the aggregate outstanding principal amount of the Term Loans&#59; or</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:144pt;padding-right:72.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">at all times maintain Unrestricted Cash in an amount not less than 50% of the aggregate outstanding principal amount of the Term Loans&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">as of the first day of each month (starting on July 1, 2024), maintain Net Product Revenue for the trailing three-month period most recently ended in an amount not less than 60% of projected Net Product Revenue for such three-month period set forth in the Forecast.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Intellectual Property. Each Borrower shall (i) protect, defend and maintain the validity and enforceability of its Intellectual Property that is necessary or material to the operation or the conduct of the business of Borrower&#59; (ii) promptly advise Agent in writing of material infringements of its Intellectual Property known to Borrower&#59; and (iii) except for Permitted Transfers, not allow any Intellectual Property (other than immaterial Intellectual Property) to be abandoned, forfeited or dedicated to the public without Agent&#8217;s written consent.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Transactions with Affiliates. Borrower shall not and shall not permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction of any kind with any Affiliate of Borrower or such Subsidiary on terms that are less favorable to Borrower or such Subsidiary, as the case may be, than those that might be obtained in an arm&#8217;s length transaction from a Person who is not an Affiliate of Borrower or such Subsidiary other than (a) any equity investments in Borrower by investors of Borrower to the extent not constituting a Change in Control, (b) any compensation, director indemnification or similar arrangements in the ordinary course of business of Borrower and as approved by Borrower&#8217;s Board or (c) any intercompany arrangements entered into in the ordinary course of business and not prohibited hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Post-Closing Obligations. To the extent not actually delivered as of the Closing Date or otherwise waived by Agent in its sole discretion, Borrower shall deliver to Agent the items set forth on Schedule 7.21 to the Disclosure Letter no later than the time specified therein</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RIGHT TO INVEST</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower shall give timely prior written notice to Agent of each Subsequent Financing and shall use commercially reasonable efforts to permit </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:108pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hercules Capital, Inc. or its Affiliates (in its discretion) to participate in Subsequent Financings in an aggregate amount of up to $10,000,000 (with respect to all such Subsequent Financings) on substantially the same terms, conditions and pricing afforded to others participating in such Subsequent Financings (subject to compliance with applicable securities laws and regulations). This Section 8, and all rights and obligations granted hereunder, shall automatically terminate upon the earliest to occur of (a) termination of security interest granted in Section 3.1 of this Agreement, pursuant to the requirements of Section 3.3 of this Agreement or (b) such time that Hercules Capital, Inc. or its Affiliates have purchased $10,000,000 of Borrower&#8217;s Equity Interests in the aggregate in Subsequent Financings.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EVENTS OF DEFAULT</font></div><div style="margin-top:3.7pt;padding-left:67.97pt;padding-right:67.97pt;text-align:center"><font><br></font></div><div style="margin-top:4.55pt;padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The occurrence of any one or more of the following events shall be an Event of Default&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Payments. Borrower fails to pay (i) any amount due under this Agreement or any of the other Loan Documents (other than Bank Services Agreements) on the due date, and (ii) solely with respect to amounts due under Bank Services Agreements, any amount due thereunder, but after giving effect to any grace or cure periods in such Bank Services Agreements&#59; provided, however that an Event of Default shall not occur on account of a failure to pay due solely to an administrative or operational error of Agent or the Lenders or Borrower&#8217;s bank if Borrower had the funds to make the payment when due and makes the payment within three (3) Business Days following Borrower&#8217;s knowledge of such failure to pay&#59; or</font></div><div><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Covenants. Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, or any of the other Loan Documents or any other agreement among Borrower, Agent and the Lenders, and (a) with respect to a default under any covenant under this Agreement (other than with respect to the specific Sections referenced in clause</font></div><div style="padding-left:103.55pt;padding-right:72.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) of this Section 9.2), or any other Loan Document (other than a Bank Services Agreement), such default continues for more than fifteen (15) days after the earlier of the date on which (i) Agent has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default,</font></div><div style="padding-left:103.55pt;padding-right:72.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) solely with respect to a default under any covenant under any Bank Services Agreement, such default continues beyond any applicable grace or cure period provided in such Bank Services Agreement, or (c) with respect to a default under any of Sections 6, 7.1, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.10, 7.11, 7.12, 7.13, 7.14, 7.15, 7.16, 7.17, 7.18, 7.19, 7.20 and 7.21 the occurrence of such default&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Material Adverse Effect. A circumstance has occurred that could reasonably be expected to have a Material Adverse Effect&#59; provided that, for purposes of this Section 9.3, the occurrence of any of the following shall not, in and of itself, constitute a Material Adverse Effect&#58;</font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) failure to achieve the Approval Milestone, the Regulatory Milestone or the Interest Only Extension Conditions, (ii) adverse results or delays with respect to, or the failure to achieve, any clinical or non-clinical trial goals or objectives, (iii) the denial, delay or limitation of approval of the FDA or other regulatory agency with respect to any proposed drug or other Borrower Product or (iv) any revisions to or termination of a strategic alliance, joint venture, co-promotion, co- commercialization or co-development agreements or license arrangement maintained by Borrower so long as the same does not affect the ability of Borrower to perform the Secured Obligations (other than those relating to Bank Services)&#59; or</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Representations. Any representation or warranty made by Borrower in any Loan Document shall have been false or misleading in any material respect when made or when deemed made&#59; or</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Insolvency. Borrower (A) (i) shall make an assignment for the benefit of creditors&#59; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent&#59; or (iii) shall file a voluntary petition in bankruptcy&#59; or</font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances&#59; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1&#47;3% or more) of the assets or property of Borrower&#59; or (vi) shall cease operations of its business as its business has normally been conducted, or terminate substantially all of its employees&#59; or (vii) Borrower or its directors or a majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi)&#59; or (B) either (i) thirty (30) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed&#59; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed&#59; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings&#59; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings&#59; or (v) thirty (30) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Attachments&#59; Judgments. Any portion of Borrower&#8217;s assets is attached or seized, or a levy is filed against any such assets, or a judgment or judgments is&#47;are entered for the payment of money (not covered by independent third party insurance as to which liability has not been rejected by such insurance carrier), individually or in the aggregate, in excess of $2,000,000 which remains unsatisfied, unvacated or unstayed for a period of 30 days after entry, or Borrower is enjoined or in any way prevented by court order from conducting any material part of its business&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.7pt">Other Obligations. The occurrence of any default (subject to the lapse of any related grace or cure period) under (a) any agreement or obligation of Borrower involving any Indebtedness in excess of $2,000,000 if such default gives rise to the right by the holder of any such Indebtedness to accelerate the time for repayment thereof, or (b) any other material agreement if a Material Adverse Effect could reasonably be expected to result from such default.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">REMEDIES</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">General. Upon the occurrence and during the continuance of any one or more Events of Default, Agent may, and at the direction of the Required Lenders shall, take any of the following actions&#58; (a) accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.5, all of the Secured Obligations (including, without limitation, the Prepayment Charge and the End of Term Charge) shall automatically be accelerated and made due and payable, in each case without any further notice or act) and (b) demand that Borrower (i) deposit cash with SVB in an amount equal to at least one hundred five percent (105.0%) of the of the aggregate face amount of all Letters of Credit remaining undrawn, to secure all of the Obligations relating to such Letters of Credit, as collateral security for the repayment of any future drawings under such Letters of Credit, and Borrower shall forthwith deposit and pay such amounts, and (ii) pay in advance all letter of credit fees scheduled to be paid or payable over the </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">remaining term of any Letters of Credit. Borrower hereby irrevocably appoints Agent as its lawful attorney-in-fact to&#58; (a) exercisable following the occurrence of an Event of Default, (i) sign Borrower&#8217;s name on any invoice or bill of lading for any account or drafts against account debtors&#59; (ii) demand, collect, sue, and give releases to any account debtor for monies due, settle and adjust disputes and claims about the accounts directly with account debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Agent&#8217;s or Borrower&#8217;s name, as Agent may elect)&#59; (iii) make, settle, and adjust all claims under Borrower&#8217;s insurance policies&#59; (iv) pay, contest or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same&#59; (v) transfer the Collateral into the name of Agent or a third party as the UCC permits&#59; and (vi) receive, open and dispose of mail addressed to Borrower&#59; and (b) regardless of whether an Event of Default has occurred, (i) endorse Borrower&#8217;s name on any checks, payment instruments, or other forms of payment or security&#59; and (ii) notify all account debtors to pay Agent directly. Borrower hereby appoints Agent as its lawful attorney-in-fact to sign Borrower&#8217;s name on any documents necessary to perfect or continue the perfection of Agent&#8217;s security interest in the Collateral regardless of whether an Event of Default has occurred until all Secured Obligations have been satisfied in full (and any obligations under Bank Services Agreements that constitute Secured Obligations have been cash collateralized in accordance with Section 3.3 of this Agreement) and the Loan Documents have been terminated. Agent&#8217;s foregoing appointment as Borrower&#8217;s attorney in fact, and all of Agent&#8217;s rights and powers, coupled with an interest, are irrevocable until all Secured Obligations have been fully repaid and performed (and any obligations under Bank Services Agreements that constitute Secured Obligations are cash collateralized in accordance with Section 3.3 of this Agreement) and the Loan Documents have been terminated. Agent may, and as directed by each Lender in accordance with Addendum 4 attached hereto shall, exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral. All Agent&#8217;s rights and remedies shall be cumulative and not exclusive.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Collection&#59; Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Agent may, and as directed by each Lender in accordance with Addendum 4 attached hereto shall, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Agent may elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days&#8217; prior written notice to Borrower. Agent may require Borrower to assemble the Collateral and make it available to Agent at a place designated by Agent that is reasonably convenient to Agent and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Agent in the following order of priorities&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:144pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">First, to Agent, in an amount up to the sum of all accrued fees owing to Agent hereunder&#59;</font></div><div style="margin-top:5.95pt;padding-left:144pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Second, to Agent and the Lenders in an amount sufficient to pay in full Agent&#8217;s and the Lenders&#8217; reasonable costs and professionals&#8217; and advisors&#8217; fees and expenses as described in Section 11.12, including all amounts expended to preserve the value of the Collateral, of foreclosure or suit, if any, and of such sale and the exercise of any other rights or remedies, and of all proper fees, expenses, liability and advances, including reasonable legal expenses and attorneys&#8217; fees, incurred or made under the Loan Documents by the Agent and the Lenders&#59;</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.05pt;padding-left:144pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third, to the Lenders, ratably, in an amount up to the sum of all accrued interest owing to the Lenders on the Term Loan Advances hereunder&#59;</font></div><div style="margin-top:6pt;padding-left:144pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fourth, to the Lenders, to the Lenders ratably, in an amount up to the sums of the outstanding principal and premium, if any, owing to the Lenders from Borrower on the Term Loan Advances hereunder&#59;</font></div><div style="margin-top:3.7pt;padding-left:144pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fifth, to the Lenders and Agent ratably (in proportion to all remaining Secured Obligations owing to each), in an amount up to the sum of all other outstanding and unpaid Secured Obligations (including indemnification claims not otherwise satisfied pursuant to the preceding clauses)&#59;</font></div><div style="margin-top:6pt;padding-left:144pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finally, after the full and final payment in Cash of all of the Secured Obligations (other than any (x) inchoate indemnity obligations, and (y) Bank Services, to the extent the counterparty Lender has agreed such Bank Services may continue to exist, or that are cash collateralized in accordance with Section 3.3 of this Agreement), to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.</font></div><div style="margin-top:5.95pt;padding-left:103.5pt;padding-right:72.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agent shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">No Waiver. Agent shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Cumulative Remedies. The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Agent.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Notice. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of&#58; (i) the day of transmission by electronic mail or hand delivery or delivery by an overnight express service or overnight mail delivery service&#59; or</font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.03pt">the third calendar day after deposit in the United States of America mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If to Agent&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HERCULES CAPITAL, INC.</font></div><div style="margin-top:0.1pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Legal Department</font></div><div style="padding-left:180pt;padding-right:145.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Chief Legal Officer&#59; Cristy Barnes&#59; Himani Bhalla 400 Hamilton Avenue, Suite 310</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Palo Alto, CA 94301</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;padding-right:145.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">email&#58;  Telephone&#58; </font></div><div style="margin-top:3.7pt;padding-left:180pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If to the Lenders&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HERCULES CAPITAL, INC.</font></div><div style="margin-top:0.05pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Legal Department</font></div><div style="padding-left:180pt;padding-right:145.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Chief Legal Officer&#59; Cristy Barnes&#59; Himani Bhalla 400 Hamilton Avenue, Suite 310</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Palo Alto, CA 94301</font></div><div style="padding-left:180pt;padding-right:145.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">email&#58; Telephone&#58; </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SILICON VALLEY BANK</font></div><div style="margin-top:0.05pt;padding-left:180pt;padding-right:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4370 La Jolla Village Drive, Suite 1050 San Diego, CA 92122</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Attention&#58; Kristine Rohmer&#59; Annie Kadota&#59; Michael White</font></div><div style="margin-top:0.1pt;padding-left:180pt;padding-right:87.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">email&#58; Telephone&#58; </font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If to Borrower&#58;</font></div><div><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Tarsus Pharmaceuticals, Inc.</font></div><div style="padding-left:180pt;padding-right:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Bryan Wahl, General Counsel 15440 Laguna Canyon Rd. Suite 160,</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Irvine, CA 92618</font></div><div style="padding-left:180pt;padding-right:260.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">email&#58;  Telephone&#58; </font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:180pt;padding-right:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With a copy via email to&#58; (i) Leo Greenstein, Chief Financial Officer</font></div><div style="margin-top:0.05pt;padding-left:180pt;padding-right:68.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">email&#58;      (ii) Jason DelMonico, Gunderson Dettmer Stough Villeneuve Franklin &#38; Hachigian, LLP, email&#58; </font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or to such other address as each party may designate for itself by like notice.</font></div><div style="margin-top:6.05pt;padding-left:175.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.8pt">Entire Agreement&#59; Amendments.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure or confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Agent&#8217;s proposal letter dated December 20, 2021 and the Non-Disclosure Agreement).</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Neither this Agreement, any other Loan Document, nor any terms hereof or thereof may be amended, supplemented or modified except in accordance with the provisions of this Section 11.3(b). The Required Lenders and Borrower party to the relevant Loan Document may, or, with the written consent of the Required Lenders, the Agent and the Borrower party to the relevant Loan Document may, from time to time, (i) enter into written amendments, supplements or modifications hereto and to the other Loan Documents for the purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of the Lenders or of the Borrower hereunder or thereunder or (ii) waive, on such terms and conditions as the Required Lenders or the Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any default or Event of Default and its consequences&#59; provided, however, that no such waiver and no such amendment, supplement or </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">modification shall, without the written consent of each Lender, (A) postpone or forgive the principal amount or extend the final scheduled date of maturity of any Loan, extend the scheduled date of any amortization payment in respect of any Term Loan, reduce the stated rate of any interest (or fee payable hereunder) or extend the scheduled date of any payment thereof&#59; (B) eliminate or reduce the voting rights of any Lender under this Section 11.3(b) without the written consent of such Lender&#59; (C) reduce any percentage specified in the definition of Required Lenders, consent to the assignment or transfer by the Borrower of any of its rights and obligations under this Agreement and the other Loan Documents, release all or substantially all of the Collateral or release a Borrower from its obligations under the Loan Documents&#59; (D) amendments of any provisions in which the action of all Lenders shall be required for Agent to take any action under the Loan Documents&#59; (E) release of all or substantially all of any material portion of the Collateral, authorization of Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any guarantor of all or any portion of the Secured Obligations or its guaranty obligations with respect thereto, except, in each case with respect to this clause&#59; (F) subordination of the Liens granted in favor of Agent securing the Secured Obligations&#59; (G) any forbearance or waiver of rights under the Loan Documents&#59; or (H) amend, modify or waive any provision of Sections 2.7 or 11.18 or Addendums 3 attached hereto or Addendum 5 attached hereto. Any such waiver and any such amendment, supplement or modification shall apply equally to each Lender and shall be binding upon Borrower, the Lender, the Agent and all future holders of the Loans.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">No Waiver. The powers conferred upon Agent and the Lenders by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or the Lenders to exercise any such powers. No omission or delay by Agent or the Lenders at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Agent or the Lenders is entitled, nor shall it in any way affect the right of Agent or the Lenders to enforce such provisions thereafter.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Survival. All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Agent and the Lenders and shall survive the execution and delivery of this Agreement. Sections 6.3, 8, 11.14, 11.15 and 11.17 shall survive the termination of this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Successors and Assigns. The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement or any of the other Loan Documents without Agent&#8217;s express prior written consent, and any such attempted assignment shall be void and of no effect. Agent and the Lenders may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower, and all of such rights shall inure to the benefit of Agent&#8217;s and the Lenders&#8217; successors and assigns&#59; provided that as long as no Event of Default has occurred and is continuing, neither Agent nor any Lender may assign, transfer or endorse its rights hereunder or under the Loan Documents to any party that is a direct competitor of Borrower (as reasonably determined by Agent), it being acknowledged that in all cases, any transfer to an Affiliate of any Lender or Agent shall be allowed. Notwithstanding the foregoing, (x) in connection with any </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">assignment by a Lender as a result of a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party and (y) in connection with a Lender&#8217;s own financing or securitization transactions, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction&#59; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such assignee as Agent reasonably shall require. The Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at one of its offices in the United States a register for the recordation of each assignment pursuant to this Section 11.7, the names and addresses of the Lender(s), and the Term Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;Register&#8221;). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Agent and the Lender(s) shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Participations. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant&#8217;s interest in the Loans or other obligations under the Loan Documents (the &#8220;Participant Register&#8221;)&#59; provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant's interest in any commitments, loans, its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Agent (in its capacity as Agent) shall have no responsibility for maintaining a Participant Register. Borrower agrees that each participant shall be entitled to the benefits of the provisions in Addendum 1 attached hereto (subject to the requirements and limitations therein, including the requirements under Section 7 of Addendum 1 attached hereto (it being understood that the documentation required under Section 7 of Addendum 1 attached hereto shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 11.7&#59; provided that such participant shall not be entitled to receive any greater payment under Addendum 1 attached hereto, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a change in law that occurs after the participant acquired the applicable participation.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.2pt">Governing Law. This Agreement and the other Loan Documents have been negotiated and delivered to Agent and the Lenders in the State of California, and shall have been accepted by Agent and the Lenders in the State of California. Payment to Agent and the Lenders by Borrower of the Secured </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Obligations is due in the State of California. This Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of Section 11.11 is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state or federal court located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally&#58; (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California&#59; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California&#59; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts&#59; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement or the other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:175.55pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.3pt">Mutual Waiver of Jury Trial &#47; Judicial Reference.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER, AGENT AND THE LENDERS SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, &#8220;CLAIMS&#8221;) ASSERTED BY BORROWER AGAINST AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower and the Lenders&#59; Claims that arise out of or are in any way connected to the relationship among Borrower, Agent and the Lenders&#59; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If the waiver of jury trial set forth in Section 11.11(a) is ineffective or unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of the Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding.</font></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 11.10, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Professional Fees. Borrower promises to pay Agent&#8217;s and the Lenders&#8217; fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable and documented attorneys&#8217; fees, UCC searches and filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable and documented attorneys&#8217; and other </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">professionals&#8217; fees and expenses incurred by Agent and the Lenders after the Closing Date in connection with or related to&#58; (a) the Loan&#59; (b) the administration, collection, or enforcement of the Loan&#59; (c) the amendment or modification of the Loan Documents&#59; (d) any waiver, consent, release, or termination under the Loan Documents&#59; (e) the protection, preservation, audit, field exam, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral&#59; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof&#59; and</font></div><div style="padding-left:103.55pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.63pt">any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Agent or the Lenders in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower&#8217;s estate, and any appeal or review thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Confidentiality. Agent and the Lenders acknowledge that certain items of Collateral and information provided to Agent and the Lenders by Borrower are confidential and proprietary information of Borrower, if and to the extent such information either (x) is marked as confidential by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Accordingly, Agent and the Lenders agree that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Agent&#8217;s security interest in the Collateral shall not be disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Agent and the Lenders may disclose any such information&#58; (a) to its Affiliates and its partners, investors, lenders, directors, officers, employees, agents, advisors, counsel, accountants, counsel, representative and other professional advisors if Agent or the Lenders in their commercially reasonable discretion determines that any such party should have access to such information in connection with such party&#8217;s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information&#59; (b) if such information is generally available to the public or to the extent such information becomes publicly available other than as a result of a breach of this Section or becomes available to Agent or any Lender, or any of their respective Affiliates on a non-confidential basis from a source other than the Borrower to the extent not known by Agent or any Lender to be subject to confidentiality&#59; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Agent or the Lenders and any rating agency&#59; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Agent&#8217;s or the Lenders&#8217; counsel&#59; (e) to comply with any legal requirement or law applicable to Agent or the Lenders or demanded by any governmental authority&#59; (f) to the extent reasonably necessary in connection with the exercise of, or preparing to exercise, or the enforcement of, or preparing to enforce, any right or remedy under any Loan Document (including Agent&#8217;s sale, lease, or other disposition of Collateral after default), or any action or proceeding relating to any Loan Document&#59; (g) to any participant or assignee of Agent or the Lenders or any prospective participant or assignee, provided, that such participant or assignee or prospective participant or assignee is subject to confidentiality restrictions that protect against the disclosure of Confidential Information on terms at least as protective as those set forth herein&#59; (h) to any investor or potential investor (and each of their respective Affiliates or clients) in the Agent or the Lenders (or each of their respective Affiliates)&#59; provided that such investor, potential investor, Affiliate or client is subject to confidentiality obligations with respect to the Confidential Information&#59; (i) otherwise to the extent consisting of general portfolio information that does not identify Borrower&#59; or (j) otherwise with the prior consent of Borrower&#59; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this Agreement or the other Loan </font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:103.55pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Documents. Agent&#8217;s and the Lenders&#8217; obligations under this Section 11.13 shall supersede all of their respective obligations under the Non-Disclosure Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Assignment of Rights. Borrower acknowledges and understands that Agent or the Lenders may, subject to Section 11.7, sell and assign all or part of its interest hereunder and under the Loan Documents to any Person or entity (an &#8220;Assignee&#8221;). After such assignment the term &#8220;Agent&#8221; or &#8220;Lender&#8221; as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Agent and the Lenders hereunder with respect to the interest so assigned&#59; but with respect to any such interest not so transferred, Agent and the Lenders shall retain all rights, powers and remedies hereby given. No such assignment by Agent or the Lenders shall relieve Borrower of any of its obligations hereunder. the Lenders agrees that in the event of any transfer by it of the promissory note(s) (if any), it will endorse thereon a notation as to the portion of the principal of the promissory note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Termination&#59; Revival of Secured Obligations. Other than as expressly set forth in Section 11.6 above, this Agreement and the other Loan Documents and all obligations and liabilities of Borrower hereunder or thereunder, shall automatically terminate after all commitments to lend have expired or been terminated and upon the indefeasible payment in full in cash of the Secured Obligations (other than any (x) inchoate indemnity obligations, and (y) Bank Services, to the extent the counterparty Lender has agreed such Bank Services may continue to exist, or that are cash collateralized in accordance with Section 3.3 of this Agreement). Notwithstanding the foregoing, this Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower&#8217;s assets, or if any payment or transfer of Collateral is recovered from Agent or the Lenders. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Agent, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, the Lenders or by any obligee of the Secured Obligations, whether as a &#8220;voidable preference,&#8221; &#8220;fraudulent conveyance,&#8221; or otherwise, all as though such payment, performance, or transfer of Collateral had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Agent or the Lenders in Cash.</font></div><div style="margin-top:3.7pt;padding-left:139.55pt;padding-right:72.05pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any Person other than Agent, the Lenders and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely among Agent, the Lenders and the Borrower.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Agency. Agent and each Lender hereby agree to the terms and conditions set forth on Addendum 3 attached hereto. Borrower acknowledges and agrees to the terms and conditions set forth on Addendum 3 attached hereto.</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Publicity. None of the parties hereto nor any of its respective member businesses and Affiliates shall, without the other parties&#8217; prior written consent (which shall not be unreasonably withheld or delayed), publicize or use (a) the other party's name (including a brief description of the relationship among the parties hereto), logo or hyperlink to such other parties&#8217; web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client lists, public relations materials or on its web site (together, the &#34;Publicity Materials&#34;)&#59; (b) the names of officers of such other parties in the Publicity Materials&#59; and (c) such other parties&#8217; name, trademarks, servicemarks in any news or press release concerning such party&#59; provided however, notwithstanding anything to the contrary herein, no such consent shall be required (i) to the extent necessary to comply with the requests of any regulators, legal requirements or laws applicable to such party, pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other party hereto to the extent reasonably practicable) and (ii) to comply with Section 11.13.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Multiple Borrowers. Each Borrower hereby agrees to the terms and conditions set forth on Addendum 4 attached hereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Intercreditor Provisions. Each of the Lenders and Borrower hereby agrees to the terms and conditions set forth on Addendum 5 attached hereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:103.55pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">Electronic Execution of Certain Other Documents. The words &#8220;execution,&#8221; &#8220;execute&#8221;, &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72.1pt;padding-right:72.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(SIGNATURES TO FOLLOW)</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i05c22e63ae214dd5bd25ac47b8587743_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8.15pt;padding-left:83.75pt;padding-right:87.55pt;text-indent:34.45pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Borrower, Agent and the Lenders have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BORROWER</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#58; </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TARSUS PHARMACEUTICALS, INC.</font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td></tr></table></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="margin-top:8.15pt;padding-left:83.75pt;padding-right:87.55pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accepted in Palo Alto, California&#58;</font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AGENT&#58;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HERCULES CAPITAL, INC.</font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:1pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.981%"><div style="margin-top:0.5pt;padding-left:180pt;text-indent:36pt"><font><br></font></div></div><div style="display:inline-block;max-width:2.037%;min-width:1.037%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.982%"><div><font><br></font></div></div></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LENDERS&#58; </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">HERCULES CAPITAL PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hercules Private Global Venture Growth Fund GP I LLC, its general partner</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hercules Adviser LLC, its sole member</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:1pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Authorized Signatory</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">HERCULES CAPITAL, INC.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:1pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SILICON VALLEY BANK</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:1pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Kristine Rohmer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:180.05pt;padding-right:180.05pt;text-align:center;text-indent:-306pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Loan and Security Agreement&#93;</font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8.15pt;padding-left:83.75pt;padding-right:87.55pt;text-indent:34.45pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Borrower, Agent and the Lenders have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BORROWER</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#58; </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TARSUS PHARMACEUTICALS, INC.</font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:1pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td></tr></table></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="margin-top:8.15pt;padding-left:83.75pt;padding-right:87.55pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accepted in Palo Alto, California&#58;</font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AGENT&#58;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HERCULES CAPITAL, INC.</font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Seth Meyer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.981%"><div style="margin-top:0.5pt;padding-left:180pt;text-indent:36pt"><font><br></font></div></div><div style="display:inline-block;max-width:2.037%;min-width:1.037%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.982%"><div><font><br></font></div></div></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LENDERS&#58; </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">HERCULES CAPITAL PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hercules Private Global Venture Growth Fund GP I LLC, its general partner</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hercules Adviser LLC, its sole member</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Seth Meyer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Authorized Signatory</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">HERCULES CAPITAL, INC.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Seth Meyer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SILICON VALLEY BANK</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:1pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Kristine Rohmer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:180.05pt;padding-right:180.05pt;text-align:center;text-indent:-306pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Loan and Security Agreement&#93;</font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8.15pt;padding-left:83.75pt;padding-right:87.55pt;text-indent:34.45pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Borrower, Agent and the Lenders have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BORROWER</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#58; </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TARSUS PHARMACEUTICALS, INC.</font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="text-indent:1pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td></tr></table></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="margin-top:8.15pt;padding-left:83.75pt;padding-right:87.55pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accepted in Palo Alto, California&#58;</font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AGENT&#58;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HERCULES CAPITAL, INC.</font></div><div style="padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt;text-indent:1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.981%"><div style="margin-top:0.5pt;padding-left:180pt;text-indent:36pt"><font><br></font></div></div><div style="display:inline-block;max-width:2.037%;min-width:1.037%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.982%"><div><font><br></font></div></div></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LENDERS&#58; </font></div><div style="padding-left:252pt;padding-right:72.1pt;text-indent:36pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">HERCULES CAPITAL PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hercules Private Global Venture Growth Fund GP I LLC, its general partner</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hercules Adviser LLC, its sole member</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt;text-indent:1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Authorized Signatory</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">HERCULES CAPITAL, INC.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt;text-indent:1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Seth Meyer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.055%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SILICON VALLEY BANK</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Kristine Rohmer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Kristine Rohmer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</font></td></tr></table></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:288pt;padding-right:72.1pt"><font><br></font></div><div style="padding-left:180.05pt;padding-right:180.05pt;text-align:center;text-indent:-306pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Loan and Security Agreement&#93;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i05c22e63ae214dd5bd25ac47b8587743_19"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Table of Addenda</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:355.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Addendum 1&#58; Taxes&#59; Increased Costs </font></div><div style="padding-right:355.45pt"><font><br></font></div><div style="padding-right:355.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Addendum 2&#58; SBA Provisions </font></div><div style="padding-right:355.45pt"><font><br></font></div><div style="padding-right:355.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Addendum 3&#58; Agent and Lender Terms </font></div><div style="padding-right:355.45pt"><font><br></font></div><div style="padding-right:355.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Addendum 4&#58; Multiple Borrower Terms </font></div><div style="padding-right:355.45pt"><font><br></font></div><div style="padding-right:355.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Addendum 5&#58; Intercreditor Provisions</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i05c22e63ae214dd5bd25ac47b8587743_22"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:190.65pt;padding-right:190.65pt;text-align:center;text-indent:-135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:225%">ADDENDUM 1 to LOAN AND SECURITY AGREEMENT TAXES&#59; INCREASED COSTS</font></div><div style="padding-left:94.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.8pt">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For purposes of this Addendum 1&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:130.65pt;padding-right:71.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Connection Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:130.65pt;padding-right:71.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient (including any assignee or successor), (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (A) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (B) that are Other Connection Taxes, (ii) in the case of a Lender (including any assignee or successor), U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Term Commitment pursuant to a law in effect on the date on which (A) such Lender acquires such interest in the Loan or Term Commitment or (B) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2 or Section 4 of this Addendum 1, amounts with respect to such Taxes were payable either to such Lender&#8217;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#8217;s failure to comply with Section 7 of this Addendum 1 and (iv) any withholding Taxes imposed under FATCA.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:130.65pt;padding-right:71.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code, and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among governmental authorities and implementing such Sections of the Code.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:130.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Lender that is not a U.S. Person.</font></div><div><font><br></font></div><div style="padding-left:130.65pt;padding-right:71.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of the Borrower under any Loan Document and (ii) to the extent not otherwise described in clause (i), Other Taxes.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:130.65pt;padding-right:71.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.59pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:130.65pt;padding-right:71.95pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:130.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Agent or any Lender, as applicable.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:130.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Withholding Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Borrower and the Agent.</font></div><div><font><br></font></div><div style="padding-left:94.65pt;padding-right:71.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Payments Free of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any and all payments by or on account of any obligation of the Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant governmental authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the amount payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional amounts payable under this Section 2 or Section 4 of this Addendum 1) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:94.65pt;padding-right:71.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Payment of Other Taxes by Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Borrower shall timely pay to the relevant governmental authority in accordance with applicable law, or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:94.65pt;padding-right:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Indemnification by Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Borrower shall indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under Section 2 of this Addendum 1 or this Section</font></div><div style="padding-left:94.65pt;padding-right:71.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant governmental authority. A certificate as to the amount of such payment or liability shall be delivered to the Borrower by a Lender (with a copy to the Agent), or by the Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error. In addition, the Borrower agrees to pay, and to save the Agent and any Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar Taxes (excluding Taxes imposed on or measured by the net income of the Agent or such Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:94.65pt;padding-right:71.95pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Indemnification by the Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Lender shall severally indemnify the Agent, within 10 days after demand therefor, for (a) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (b) any Taxes attributable to such Lender&#8217;s failure to comply with the provisions of Section 11.8 of the Agreement relating to the maintenance of a Participant Register and (c) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant governmental authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Agent to the Lender from any other source against any amount due to the Agent under this Section 5.</font></div><div style="padding-left:94.65pt;padding-right:71.95pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:94.65pt;padding-right:71.95pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Evidence of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As soon as practicable after any payment of Taxes by the Borrower to a governmental authority pursuant to the provisions of this Addendum 1, the Borrower shall deliver to the Agent the original or a certified copy of a receipt issued by such governmental authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Agent.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:94.65pt;padding-right:71.95pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Status of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:130.65pt;padding-right:71.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Agent, at the time or times reasonably requested by the Borrower or the Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Agent as will enable the Borrower or the Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Sections 7(b)(i), 7(b)(ii) and 7(b)(iv) of this Addendum 1) shall not be required if in the Lender&#8217;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or commercial position of such Lender.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:130.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.8pt">Without limiting the generality of the foregoing&#58;</font></div><div><font><br></font></div><div style="padding-left:166.65pt;padding-right:71.9pt;text-align:justify;text-indent:-14.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.85pt">any Lender that is a U.S. Person (including any assignee or successor) shall deliver to the Borrower and the Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:166.65pt;padding-right:71.95pt;text-align:justify;text-indent:-17.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.8pt">any Foreign Lender (including any assignee or successor) shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), whichever of the following is applicable&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:202.65pt;padding-right:71.95pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt">in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;interest&#8221; article of such tax treaty and</font></div><div style="padding-left:202.65pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;business profits&#8221; or &#8220;other income&#8221; article of such tax treaty&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:202.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.97pt">executed copies of IRS Form W-8ECI&#59;</font></div><div style="margin-top:3.7pt;padding-left:202.65pt;padding-right:71.75pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:202.65pt;padding-right:71.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt">in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit J-1 attached to the Disclosure Letter to the effect that such Foreign Lender is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, a &#8220;10 percent shareholder&#8221; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a &#8220;controlled foreign corporation&#8221; related to the Borrower as described in Section </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:202.65pt;padding-right:71.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">881(c)(3)(C) of the Code (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">U.S. Tax Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:202.65pt;padding-right:71.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt">to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W- 8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-2 of the Disclosure Letter or Exhibit J-3 of the Disclosure Letter, IRS Form W-9, and&#47;or other certification documents from each beneficial owner, as applicable&#59; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-4 of the Disclosure Letter on behalf of each such direct and indirect partner&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:166.65pt;padding-right:71.9pt;text-align:justify;text-indent:-20.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.75pt">any Foreign Lender (including any assignee or successor) shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Agent to determine the withholding or deduction required to be made&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:166.65pt;padding-right:71.95pt;text-align:justify;text-indent:-20.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.9pt">if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Agent as may be necessary for the Borrower and the Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#8217;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (iv), &#8220;FATCA&#8221; shall include any amendments made to FATCA after the date of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:130.65pt;padding-right:71.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Agent in writing of its legal inability to do so.</font></div><div style="margin-top:3.7pt;padding-left:94.65pt;padding-right:71.85pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:94.65pt;padding-right:71.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Treatment of Certain Refunds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to the provisions of this Addendum 1 (including by the payment of additional amounts pursuant to the provisions of this Addendum 1), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under the provisions of this Addendum 1 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:94.65pt;padding-right:71.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">interest paid by the relevant governmental authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this Section 8 (plus any penalties, interest or other charges imposed by the relevant governmental authority) in the event that such indemnified party is required to repay such refund to such governmental authority. Notwithstanding anything to the contrary in this Section 8, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 8 the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This Section 8 shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:94.65pt;padding-right:71.8pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:9.8pt">Increased Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any change in applicable law shall subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto, and the result shall be to increase the cost to such Recipient of making, converting to, continuing or maintaining any Term Loan or of maintaining its obligation to make any such Loan, or to reduce the amount of any sum received or receivable by such Recipient (whether of principal, interest or any other amount), then, upon the request of such Recipient, the Borrower will pay to such Recipient such additional amount or amounts as will compensate such Recipient for such additional costs incurred or reduction suffered.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:94.65pt;padding-right:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:4.25pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each party&#8217;s obligations under the provisions of this Addendum 1 shall survive the resignation or replacement of the Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Term Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i05c22e63ae214dd5bd25ac47b8587743_25"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:71.92pt;padding-right:71.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDENDUM 2 to LOAN AND SECURITY AGREEMENT</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.55pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.7pt">Borrower&#8217;s Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Borrower shall be deemed to include its &#8220;affiliates&#8221; as defined in Title 13 Code of Federal Regulations Section</font></div><div style="padding-left:103.55pt;padding-right:72.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121.103. Borrower represents and warrants to Agent and Lenders as of each SBA Funding Date and covenants to Agent and Lenders for a period of one year after each SBA Funding Date or for such longer period as set forth below with respect to subsections 2, 3, 4, 5, 6 and 7 below, as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Size Status. Borrower&#8217;s primary NAICS code is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">325412 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and has less than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">100 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">employees in the aggregate&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">No Relender. Borrower&#8217;s primary business activity does not involve, directly or indirectly, providing funds to others, purchasing debt obligations, factoring, or long- term leasing of equipment with no provision for maintenance or repair&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">No Passive Business. Borrower is engaged in a regular and continuous business operation (excluding the mere receipt of payments such as dividends, rents, lease payments, or royalties). Borrower&#8217;s employees are carrying on the majority of day to day operations. Borrower will not pass through substantially all of the proceeds of the Loan to another entity&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">No Real Estate Business. Borrower is not classified under North American Industry Classification System (NAICS) codes 531110 (lessors of residential buildings and dwellings), 531120 (lessors of nonresidential buildings except miniwarehouses), 531190 (lessors of other real estate property), 237210 (land subdivision), or 236117 (new housing for-sale builders). Borrower is not classified under NAICS codes 236118 (residential remodelers), 236210 (industrial building construction), or 236220 (commercial and institutional building construction), if Borrower is primarily engaged in construction or renovation of properties on its own account rather than as a hired contractor. Borrower is not classified under NAICS codes 531210 (offices of real estate agents and brokers), 531311 (residential property managers), 531312 (nonresidential property managers), 531320 (offices of real estate appraisers), or 531390 (other activities related to real estate), unless it derives at least 80 percent of its revenue from non-Affiliate sources. The proceeds of the Loan will not be used to acquire or refinance real property unless Borrower (x) is acquiring an existing property and will use at least 51 percent of the usable square footage for its business purposes&#59; (y) is building or renovating a building and will use at least 67 percent of the usable square footage for its business purposes&#59; or (z) occupies the subject property and uses at least 67 percent of the usable square footage for its business purposes.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">No Project Finance. Borrower&#8217;s assets are not intended to be reduced or consumed, generally without replacement, as the life of its business progresses, and the nature of Borrower&#8217;s business does not require that a stream of cash payments be made to the business&#8217;s financing sources, on a basis associated with the continuing sale of assets (e.g., real estate development projects and oil and gas wells). The primary purpose of the Loan is not to fund production of a single item or defined limited number of items, generally over a defined production period, where such production will constitute the majority of the activities of Borrower (e.g., motion pictures and electric generating plants).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">No Farm Land Purchases. Borrower will not use the proceeds of the Loan to acquire farm land which is or is intended to be used for agricultural or forestry purposes, such as the production of food, fiber, or wood, or is so taxed or zoned. No Foreign Investment. The proceeds of the Loan will not be used substantially for a foreign operation. Borrower will not have, on or within one year after each SBA Funding Date and each other Loan provided by a Lender that is an SBIC more than 49 percent of its employees or tangible assets located outside the United States of America.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.25pt">Small Business Administration Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Agent and Lenders acknowledge that Borrower completed, executed and delivered to Agent prior to each SBA Funding Date SBA Forms 480, 652 and 1031 (Parts A and B) together with a business plan showing Borrower&#8217;s financial projections (including balance sheets and income and cash flows statements) for the period described therein and a written statement (whether included in the purchase agreement or pursuant to a separate statement) from Agent regarding its intended use of proceeds from the sale of securities to Lenders (the &#8220;Use of Proceeds Statement&#8221;). Borrower represents and warrants to Agent and Lenders that the information regarding Borrower and its affiliates set forth in the SBA Form 480, Form 652 and Form 1031 and the Use of Proceeds Statement delivered as of each SBA Funding Date is accurate and complete.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.25pt">Inspection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The following covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are intended to supplement and not to restrict the related provisions of the Loan Documents. Subject to the preceding sentence, Borrower will permit, for so long as Lenders hold any debt or equity securities of Borrower, Agent, Lenders or their representative, at Agent&#8217;s or Lenders&#8217; expense, and examiners of the SBA to visit and inspect the properties and assets of Borrower, to examine its books of account and records, and to discuss Borrower&#8217;s affairs, finances and accounts with Borrower&#8217;s officers, senior management and accountants, all at such reasonable times as may be requested by Agent or Lenders or the SBA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.25pt">Annual Assessment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon request of Agent or Lender, promptly after the end of each calendar year (but in any event prior to February 28 of each year) and at such other times as may be reasonably requested by Agent or Lenders, Borrower will deliver to Agent a written assessment of the economic impact of Lenders&#8217; investment in Borrower, specifying the full-time equivalent jobs created or retained in connection with the investment, the impact of the investment on the businesses of Borrower in terms of expanded revenue and taxes, other economic benefits resulting from the investment (such as technology development or commercialization, minority business development, or expansion of exports) and such other information as may be required regarding Borrower in connection with the filing of Lenders&#8217; SBA Form 468. Lenders will assist Borrower with preparing such assessment. In addition to any other rights granted hereunder, Borrower will grant Agent and Lenders and the SBA access to Borrower&#8217;s books and records for the purpose of verifying the use of such proceeds. Borrower also will furnish or cause to be furnished to Agent and Lenders such other information regarding the business, affairs and condition of Borrower as Agent or Lenders may from time to time reasonably request, and such information shall be certified by the President, Chief Executive Officer or Chief Financial Officer of Borrower to the extent requested by Agent or Lender for compliance with the SBIC Act.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.25pt">Use of Proceeds. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower will use the proceeds from the Loan only for purposes set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Borrower will deliver to Agent from time to time promptly following Agent&#8217;s request, a written report, certified as correct by Borrower&#8217;s Chief Financial Officer, verifying the purposes and amounts for which proceeds from the Loan have been disbursed. Borrower will supply to Agent such additional information and documents as Agent reasonably requests with respect to its use of proceeds and will, to the extent required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, permit Agent and Lenders and the SBA to have access to any and all Borrower records and information and personnel as Agent deems necessary to verify how such proceeds have been or are being used, and to assure that the proceeds have been used for the purposes specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.25pt">Activities and Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Borrower nor any of its affiliates (if any) will engage in any activities or use directly or indirectly the proceeds from the Loan for any purpose for which a small business investment company is prohibited from providing funds by the SBIC Act, including 13 C.F.R. &#167;107.720. Borrower shall not, nor shall it cause or permit any of its subsidiaries to, without obtaining the prior written approval of Agent, change Borrower&#8217;s or any such subsidiary&#8217;s business activities from that conducted on the date hereof to a business activity from which a small business investment company is prohibited from providing funds by the SBIC Act. Borrower agrees that any such change in its or any such subsidiary&#8217;s business activities without such prior written consent of Agent shall constitute a material breach of the obligations of Borrower under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.25pt">Redemption Provisions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any provision to the contrary contained in the Certificate of Incorporation of Borrower, as amended from time to time (the &#8220;Charter&#8221;), if, pursuant to the redemption provisions contained in the Charter, Lenders are entitled to a redemption of its Warrant, such redemption (in the case of Lenders) will be at a price equal to the redemption price set forth in the Charter (the &#8220;Existing Redemption Price&#8221;). If, however, Lenders deliver written notice to Borrower that the then current regulations promulgated under the SBIC Act prohibit payment of the Existing Redemption Price in the case of an SBIC (or, if applied, the Existing Redemption Price would cause any series of preferred stock to lose its classification as an &#8220;equity security&#8221; and Lenders have determined that such classification is unadvisable), the amount Lenders will be entitled to receive shall be the greater of (i) fair market value of the securities being redeemed taking into account the rights and preferences of such securities plus any costs and expenses of Lenders incurred in making or maintaining such warrant, and (ii) the Existing Redemption Price where the amount of accrued but unpaid dividends payable to Lenders is limited to Borrower&#8217;s earnings plus any costs and expenses of Lenders incurred in making or maintaining such warrant&#59; provided, however, the amount calculated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">subsections (i) or (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> above shall not exceed the Existing Redemption Price.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.25pt">Compliance and Resolution. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower agrees that a failure to comply with Borrower&#8217;s obligations under this Addendum, or any other set of facts or circumstances where it has been asserted by any governmental regulatory agency (or Agent or Lenders believe that there is a substantial risk of such assertion) that Agent, Lenders and their affiliates are not entitled to hold, or exercise any significant right with respect to, any securities issued to Lenders by Borrower, will constitute a breach of the obligations of Borrower under the financing agreements among Borrower, Agent and Lenders. In the event of (i) a failure to comply with Borrower&#8217;s obligations under this Addendum&#59; or (ii) an assertion by any governmental regulatory agency (or Agent or Lenders believe that there is a substantial risk of such assertion) of a failure to comply with Borrower&#8217;s obligations under this Addendum, then (y) Agent, Lenders and Borrower will meet and resolve any such issue in good faith to the satisfaction of Borrower, Agent, Lenders, and any governmental regulatory agency, and (z) upon request of Lenders or Agent, Borrower will cooperate and assist with any assignment of the financing agreements among any Lender and Hercules Capital, Inc.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i05c22e63ae214dd5bd25ac47b8587743_28"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:71.97pt;padding-right:71.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDENDUM 3 to LOAN AND SECURITY AGREEMENT</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69.72pt;padding-right:69.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agent and Lender Terms</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each Lender hereby irrevocably appoints Hercules Capital, Inc. to act on its behalf as the Agent hereunder and under the other Loan Documents and irrevocably authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. Agent shall have only those duties which are specified in this Agreement and it may perform such duties by or through its agents, representatives or employees. In performing its duties on behalf of Lenders, Agent shall exercise the same care which it would exercise in dealing with loans made for its own account, but it shall not be responsible to any Lender for the execution, effectiveness, genuineness, validity, enforceability, collectability or sufficiency of all or any of the Loan Documents, or for any representations, warranties, recitals or statements made therein or made in any written or oral statement or in any financial or other statements, instruments, reports, certificates or any other documents furnished or delivered in connection herewith or therewith by Agent to any Lender or by or on behalf of Borrower to Agent or any Lender, or be required to ascertain or inquire as to the performance or observance of any of the terms, conditions, provisions, covenants or agreements contained herein or therein, as to the use of the proceeds of the Term Loan Advances, the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or the satisfaction of any condition set forth in Section 4 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent. Agent shall not be responsible for insuring the Collateral or for the payment of any taxes, assessments, charges or any other charges or liens of any nature whatsoever upon the Collateral or otherwise for the maintenance of the Collateral, except in the event Agent enters into possession of a part or all of the Collateral, in which event Agent shall preserve the part in its possession. Unless the officers of Agent acting in their capacity as officer of Agent on Borrower&#8217;s account have actual knowledge thereof or have been notified in writing thereof by Lenders, Agent shall not be required to ascertain or inquire as to the existence or possible existence of any Event of Default.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:23.18pt">Neither Agent nor any of its officers, directors, employees, attorneys, representatives or agents shall be liable to Lenders for any action taken or omitted hereunder or under any of the other Loan Documents or in connection herewith or therewith unless caused by its or their gross negligence or willful misconduct. No provision of this Agreement or of any other Loan Document shall be deemed to impose any duty or obligation on Agent to perform any act or to exercise any power in any jurisdiction in which it shall be illegal, or shall be deemed to impose any duty or obligation on Agent to perform any act or exercise any right or power if such performance or exercise (a) would subject Agent to a tax in a jurisdiction where it is not then subject to a tax or (b) would require Agent to qualify to do business in any jurisdiction where it is not so qualified. Without prejudice to the generality of the foregoing, no Lender shall have any right of action whatsoever against Agent as a result of Agent acting or (where so instructed) refraining from acting under this Agreement or under any of the other Loan Documents in accordance with the instructions of the Lenders. Agent shall be entitled to refrain from exercising any power, discretion or authority vested in it under this Agreement unless and until it has obtained the written instructions of the Lenders. The agency hereby created shall in no way impair or affect any of the rights and powers of, or impose any duties or obligations upon Agent in its individual capacity. With respect to its participation in the Loan Agreement hereunder, Agent shall have the same rights and powers hereunder as any other Lender and may exercise the same rights and powers as though it were not performing the duties and functions delegated to it hereunder and the term </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;Lender&#8221; or &#8220;Lenders&#8221; or any similar term shall unless the context clearly indicates otherwise include Agent in its individual capacity.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Agent may rely, and shall be fully protected in acting, or refraining to act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed or presented by the proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper party or parties. In the absence of its gross negligence or willful misconduct, Agent may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to Agent and conforming to the requirements of this Agreement or any of the other Loan Documents. Agent may consult with counsel, and any opinion or legal advice of such counsel shall be full and complete authorization and protection in respect of any action taken, not taken or suffered by Agent hereunder or under any Loan Documents in accordance therewith. Agent shall have the right at any time to seek instructions concerning the administration of the Collateral from any court of competent jurisdiction. Agent shall not be under any obligation to exercise any of the rights or powers granted to Agent by this Agreement and the other Loan Documents at the request or direction of the Lenders unless Agent shall have been provided by the Lenders with adequate security and indemnity against the costs, expenses and liabilities that may be incurred by it in compliance with such request or direction.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each Lender agrees to indemnify the Agent in its capacity as such (to the extent not reimbursed by Borrower and without limiting the obligation of Borrower to do so), according to its respective Term Commitment percentages (based upon the total outstanding Term Commitments) in effect on the date on which indemnification is sought under this Addendum 3, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time be imposed on, incurred by or asserted against the Agent in any way relating to or arising out of, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by the Agent under or in connection with any of the foregoing. The agreements in this Section shall survive the payment of the Loans and all other amounts payable hereunder.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">To the extent not reimbursed either by Borrower or from the application of Collateral proceeds pursuant to Section 10.2, a Lender (the &#8220;Indemnified Lender&#8221;) shall be indemnified by the other Lender (an &#8220;Indemnifying Lender&#8221;), on a several basis in proportion to each Lender&#8217;s pro rata portion of the Term Commitment, and each Indemnifying Lender agrees to reimburse the Indemnified Lender for the Indemnifying Lender&#8217;s pro rata share of the following items (an &#8220;Indemnified Payment&#8221;)&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">all reasonable out-of-pocket costs and expenses of the Indemnified Lender incurred by the Indemnified Lender in connection with the discharge of its activities under this Agreement or the Loan Agreement, including reasonable legal expenses and attorneys&#8217; fees&#59; provided, that the Indemnified Lender shall consult with the other Lender regarding the incurrence of such costs and expenses at reasonable intervals (but not more often than monthly) and any such reasonable costs and expenses shall be &#8220;Claims&#8221; hereunder notwithstanding any disagreement by the other Lender as to their incurrence&#59; and</font></div><div style="margin-top:3.7pt;padding-left:144pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever, which may be imposed on, incurred by or asserted against the Indemnified Lender in any way relating to or arising out of this Agreement, or any action taken or omitted by the Indemnified Lender hereunder&#59; provided that the Indemnifying Lender shall not be liable for any portion of such </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:144pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements, if the same results from the Indemnified Lender&#8217;s gross negligence or willful misconduct or from undertaking Enforcement Actions in violation of clause (d) of Addendum 5 attached to the Loan Agreement&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">provided, however, that the Indemnified Lender shall not be reimbursed or indemnified for an Indemnified Payment, except to the extent that the Indemnified Lender paid more than its ratable share of such payment. All Indemnified Payments (as set forth in this paragraph c) to an Indemnified Lender are intended to be paid ratably by the other Lender.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">Agent in Its Individual Capacity. The Person serving as the Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Agent and the term &#8220;Lender&#8221; shall, unless otherwise expressly indicated or unless the context otherwise requires, include each such Person serving as Agent hereunder in its individual capacity.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Exculpatory Provisions. The Agent shall have no duties or obligations except those expressly set forth herein and in the other Loan Documents. Without limiting the generality of the foregoing, the Agent shall not&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:144pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">be subject to any fiduciary or other implied duties, regardless of whether any default or any Event of Default has occurred and is continuing&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:144pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent is required to exercise as directed in writing by the Lenders, provided that the Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Agent to liability or that is contrary to any Loan Document or applicable law&#59; and</font></div><div><font><br></font></div><div style="padding-left:144pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and the Agent shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by any Person serving as the Agent or any of its Affiliates in any capacity.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In connection with any exercise of Enforcement Actions hereunder, neither any Agent nor any Lender or any of its partners, or any of their respective directors, officers, employees, attorneys, accountants, or agents shall be liable as such for any action taken or omitted by it or them, except for its or their own gross negligence or willful misconduct with respect to its duties under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Each Lender and Agent may execute any of its powers and perform any duties hereunder either directly or by or through agents or attorneys-in-fact. Each Lender and Agent shall be entitled to advice of counsel concerning all matters pertaining to such powers and duties. No Lender or Agent shall be responsible for the negligence or misconduct of any agents or attorneys- in-fact selected by it, if the selection of such agents or attorneys-in-fact was done without gross negligence or willful misconduct.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Each Lender agrees that it will make its own independent investigation of the financial condition and affairs of Borrower in connection with the making of Term Loan Advances pursuant to the Loan Agreement and has made and shall continue to make its own appraisal of the creditworthiness of Borrower. Neither the Agent nor any Lender shall have any duty or responsibility either initially or on a continuing basis to make any such investigation or any such appraisal on behalf of all Lenders or to provide the other Lenders with any </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:72.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">credit or other information with respect thereto whether coming into its possession before the date hereof or any time or times thereafter and shall further have no responsibility with respect to the accuracy of or the completeness of the information provided to the Lenders by Borrower.</font></div><div><font><br></font></div><div style="padding-left:108pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">As used in this Addendum 3, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Collateral Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all present and future &#8220;claims&#8221; (used in its broadest sense, as contemplated by and defined in Section 101(5) of the Bankruptcy Code, but without regard to whether such claim would be disallowed under the Bankruptcy Code) of a Lender now or hereafter arising or existing under or relating to this Agreement and related Loan Documents, whether joint, several, or joint and several, whether fixed or indeterminate, due or not yet due, contingent or non-contingent, matured or unmatured, liquidated or unliquidated, or disputed or undisputed, whether under a guaranty or a letter of credit, and whether arising under contract, in tort, by law, or otherwise, any interest or fees thereon (including interest or fees that accrue after the filing of a petition by or against Borrower under the Bankruptcy Code, irrespective of whether allowable under the Bankruptcy Code), any costs of Enforcement Actions, including reasonable attorneys&#8217; fees and costs, and any prepayment or termination premiums.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">As used in this Addendum 3, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Lender and with respect to any Collateral Claim of such Lender or any item of Collateral in which such Lender has or claims a security interest lien or right of offset, any action, whether judicial or nonjudicial, to repossess, collect, accelerate, offset, recoup, give notification to third parties with respect to, sell, dispose of, foreclose upon, give notice of sale, disposition, or foreclosure with respect to, or obtain equitable or injunctive relief with respect to, such Collateral Claim or Collateral. The filing, or the joining in the filing, by any Lender of an involuntary bankruptcy or insolvency proceeding against Borrower also is an Enforcement Action.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i05c22e63ae214dd5bd25ac47b8587743_31"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:71.97pt;padding-right:71.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDENDUM 4 to LOAN AND SECURITY AGREEMENT</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69.75pt;padding-right:69.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Multiple Borrower Terms</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Borrower&#8217;s Agent. Each of the Borrowers hereby irrevocably appoints Tarsus Pharmaceuticals, Inc. as its agent, attorney-in-fact and legal representative for all purposes, including requesting disbursement of the Term Loans and receiving account statements and other notices and communications to Borrowers (or any of them) from the Agent or any Lender. The Agent may rely, and shall be fully protected in relying, on any request for the Term Loan, disbursement instruction, report, information or any other notice or communication made or given by Tarsus Pharmaceuticals, Inc., whether in its own name or on behalf of one or more of the other Borrowers, and the Agent shall not have any obligation to make any inquiry or request any confirmation from or on behalf of any other Borrower as to the binding effect on it of any such request, instruction, report, information, other notice or communication, nor shall the joint and several character of the Borrowers&#8217; obligations hereunder be affected thereby.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:23.18pt">Waivers. Each Borrower hereby waives&#58; (i) any right to require the Agent to institute suit against, or to exhaust its rights and remedies against, any other Borrower or any other person, or to proceed against any property of any kind which secures all or any part of the Secured Obligations, or to exercise any right of offset or other right with respect to any reserves, credits or deposit accounts held by or maintained with the Agent or any Indebtedness of the Agent or any Lender to any other Borrower, or to exercise any other right or power, or pursue any other remedy the Agent or any Lender may have&#59; (ii) any defense arising by reason of any disability or other defense of any other Borrower or any guarantor or any endorser, co-maker or other person, or by reason of the cessation from any cause whatsoever of any liability of any other Borrower or any guarantor or any endorser, co-maker or other person, with respect to all or any part of the Secured Obligations, or by reason of any act or omission of the Agent or others which directly or indirectly results in the discharge or release of any other Borrower or any guarantor or any other person or any Secured Obligations or any security therefor, whether by operation of law or otherwise&#59; (iii) any defense arising by reason of any failure of the Agent to obtain, perfect, maintain or keep in force any Lien on, any property of any Borrower or any other person&#59; (iv) any defense based upon or arising out of any bankruptcy, insolvency, reorganization, arrangement, readjustment of debt, liquidation or dissolution proceeding commenced by or against any other Borrower or any guarantor or any endorser, co-maker or other person, including without limitation any discharge of, or bar against collecting, any of the Secured Obligations (including without limitation any interest thereon), in or as a result of any such proceeding. Until all of the Secured Obligations have been paid, performed, and discharged in full, nothing shall discharge or satisfy the liability of any Borrower hereunder except the full performance and payment of all of the Secured Obligations. If any claim is ever made upon the Agent for repayment or recovery of any amount or amounts received by the Agent in payment of or on account of any of the Secured Obligations, because of any claim that any such payment constituted a preferential transfer or fraudulent conveyance, or for any other reason whatsoever, and the Agent repays all or part of said amount by reason of any judgment, decree or order of any court or administrative body having jurisdiction over the Agent or any of its property, or by reason of any settlement or compromise of any such claim effected by the Agent with any such claimant (including without limitation the any other Borrower), then and in any such event, each Borrower agrees that any such judgment, decree, order, settlement and compromise shall be binding upon such Borrower, notwithstanding any revocation or release of this Agreement or the cancellation of any note or other instrument evidencing any of the Secured Obligations, or any release of any of </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Secured Obligations, and each Borrower shall be and remain liable to the Agent and the Lenders under this Agreement for the amount so repaid or recovered, to the same extent as if such amount had never originally been received by the Agent or any Lender, and the provisions of this sentence shall survive, and continue in effect, notwithstanding any revocation or release of this Agreement. Each Borrower hereby expressly and unconditionally waives all rights of subrogation, reimbursement and indemnity of every kind against any other Borrower, and all rights of recourse to any assets or property of any other Borrower, and all rights to any collateral or security held for the payment and performance of any Secured Obligations, including (but not limited to) any of the foregoing rights which Borrower may have under any present or future document or agreement with any other Borrower or other person, and including (but not limited to) any of the foregoing rights which any Borrower may have under any equitable doctrine of subrogation, implied contract, or unjust enrichment, or any other equitable or legal doctrine.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Consents. Each Borrower hereby consents and agrees that, without notice to or by Borrower and without affecting or impairing in any way the obligations or liability of Borrower hereunder, the Agent may, from time to time before or after revocation of this Agreement, do any one or more of the following in its sole and absolute discretion&#58; (i) accept partial payments of, compromise or settle, renew, extend the time for the payment, discharge, or performance of, refuse to enforce, and release all or any parties to, any or all of the Secured Obligations&#59; (ii) grant any other indulgence to any Borrower or any other Person in respect of any or all of the Secured Obligations or any other matter&#59; (iii) accept, release, waive, surrender, enforce, exchange, modify, impair, or extend the time for the performance, discharge, or payment of, any and all property of any kind securing any or all of the Secured Obligations or any guaranty of any or all of the Secured Obligations, or on which the Agent at any time may have a Lien, or refuse to enforce its rights or make any compromise or settlement or agreement therefor in respect of any or all of such property&#59;</font></div><div style="padding-left:108pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv) substitute or add, or take any action or omit to take any action which results in the release of, any one or more other Borrowers or any endorsers or guarantors of all or any part of the Secured Obligations, including, without limitation one or more parties to this Agreement, regardless of any destruction or impairment of any right of contribution or other right of Borrower&#59; (v) apply any sums received from any other Borrower, any guarantor, endorser, or co-signer, or from the disposition of any Collateral or security, to any Indebtedness whatsoever owing from such person or secured by such Collateral or security, in such manner and order as the Agent determines in its sole discretion, and regardless of whether such Indebtedness is part of the Secured Obligations, is secured, or is due and payable. Each Borrower consents and agrees that the Agent shall be under no obligation to marshal any assets in favor of Borrower, or against or in payment of any or all of the Secured Obligations. Each Borrower further consents and agrees that the Agent shall have no duties or responsibilities whatsoever with respect to any property securing any or all of the Secured Obligations. Without limiting the generality of the foregoing, the Agent shall have no obligation to monitor, verify, audit, examine, or obtain or maintain any insurance with respect to, any property securing any or all of the Secured Obligations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Independent Liability. Each Borrower hereby agrees that one or more successive or concurrent actions may be brought hereon against such Borrower, in the same action in which any other Borrower may be sued or in separate actions, as often as deemed advisable by Agent. Each Borrower is fully aware of the financial condition of each other Borrower and is executing and delivering this Agreement based solely upon its own independent investigation of all matters pertinent hereto, and such Borrower is not relying in any manner upon any representation or statement of the Agent or any Lender with respect thereto. Each Borrower represents and warrants that it is in a position to obtain, and each Borrower hereby assumes full responsibility for obtaining, any additional information concerning any other Borrower&#8217;s financial condition and any other matter pertinent hereto as such Borrower may desire, and such Borrower is not </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">relying upon or expecting the Agent to furnish to it any information now or hereafter in the Agent&#8217;s possession concerning the same or any other matter.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subordination. All Indebtedness of a Borrower now or hereafter arising held by another Borrower is subordinated to the Secured Obligations and the Borrower holding the Indebtedness shall take all actions reasonably requested by Agent to effect, to enforce and to give notice of such subordination.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i05c22e63ae214dd5bd25ac47b8587743_34"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:71.97pt;padding-right:71.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDENDUM 5 to LOAN AND SECURITY AGREEMENT</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:69.75pt;padding-right:69.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Intercreditor Provisions Each Lender party to this Agreement hereby agrees as follows&#58;</font></div><div style="margin-top:0.05pt;padding-left:69.75pt;padding-right:69.75pt;text-align:center"><font><br></font></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Limitation of Further Credit Extensions. After the date hereof, except pursuant to this Agreement and as permitted pursuant, no Lender may make loans to or otherwise extend credit to Borrower (excluding the provision by SVB to Borrower of the Bank Services in an aggregate amount outstanding at any time not to exceed the Bank Services Cap) without notice to and the consent of each other Lender, which consent will not be unreasonably withheld.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:180pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Transfer of Interests.</font></div><div><font><br></font></div><div style="padding-left:144pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">No Lender may sell or otherwise transfer any of its interest in this Agreement or the related Loan Documents without the prior written consent of the other Lenders (which consent may, for the avoidance of doubt, be conditioned on such successor or assign entering into an intercreditor agreement satisfactory to such other Lender), except that no such consent shall be required in connection with (a) any sale, assignment or transfer by any Lender of any of its interest in this Agreement and other Loan Documents to any Affiliate of such Lender or (b) a Lender&#8217;s own financing or securitization transactions, in which case, such Lender may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction&#59; provided that no such assignment, transfer or indorsement under this clause (b) shall release such Lender from any of its obligations under this Agreement or under the Loan Documents or substitute any such Person or party for such Lender as a party hereto until Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Person or party as Agent reasonably shall require.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">The transferee shall assume all obligations of the transferring Lender under this Agreement and the other Loan Documents with respect to the portion of the transferor&#8217;s interest in this Agreement and the other Loan Document transferred, provided, that to the extent the transferor shall not transfer the entirety and shall retain any portion of its interest in this Agreement and the other Loan Documents, the transferor shall retain its obligations under this Agreement and the other Loan Documents with respect to that portion of its interest.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">The transferee shall provide to the other Lender evidence reasonably satisfactory to such Lender that the proposed transferee has the financial ability and legal authority to assume and perform all obligations of the transferring Lender under this Agreement and the other applicable Loan Documents.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Any sale or transfer of an interest in this Agreement and other applicable Loan Documents shall be voidable at the option of the other Lender unless the provisions of this paragraph (b) are satisfied.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i05c22e63ae214dd5bd25ac47b8587743_37"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:108pt;padding-right:72.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Possession of Collateral. If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for the other Lenders for purposes of perfecting Agent&#8217;s or such other Lenders&#8217; security interest therein.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Decision to Exercise Remedies. Upon the occurrence of an Event of Default, Agent shall take such actions and only such actions as Lenders mutually agree to take to enforce their rights and remedies under this Agreement&#59; provided, however, that if after consultation, Lenders cannot mutually agree on what action to take, then either Lender shall have the right upon prior written notice to the other to cause the acceleration of this Agreement on behalf of the Lenders. Upon such acceleration, the Lenders shall mutually agree as to what Enforcement Action to take&#59; provided, however, that if after consultation, Lenders cannot mutually agree on what action to take, then the Lender wishing to take the stronger Enforcement Action (the &#8220;Enforcing Lender&#8221;) shall have the right to determine and shall control the timing, order and type of Enforcement Actions which will be taken and all other matters in connection with any such Enforcement Actions. To facilitate these rights to control Enforcement Actions, upon either Lender becoming the Enforcing Lender, if the Enforcing Lender is not already the Agent, then automatically and without the necessity of any further action being taken by any party, (x) the original Agent shall be deemed to have resigned as Agent and (y) the Lenders shall be deemed to have unanimously appointed the Enforcing Lender as successor Agent under this Agreement and the Loan Documents (and the Enforcing Lender shall be deemed to have accepted such appointment), provided that, once the Enforcing Lender shall have been appointed as the Agent under the provisions of this sentence, the Enforcing Lender as such successor Agent shall no longer be bound by the restrictions of the first sentence of this paragraph, but instead shall have the right to determine and control all Enforcement Actions as provided for in the immediately preceding sentence (subject to the provisions of the following sentence). In taking such Enforcement Actions pursuant to the previous sentence, the Enforcing Lender as such successor Agent shall act reasonably and in good faith and shall consult with and keep the other Lender informed thereof at reasonable intervals&#59; provided, however, that notwithstanding any such consultations and provision of information to the other Lender, the Enforcing Lender as such successor Agent shall retain the right to make all determinations in the event of disagreements between the Enforcing Lender and the other Lender. In all cases with respect to Enforcement Actions, the Enforcing Lender shall have the right to act both on its own behalf and as agent for the other Lender with respect thereto. In addition, the other Lender shall take such actions and execute such documents and instruments as the Enforcing Lender may reasonably request in connection with and to facilitate any such Enforcement Actions and take any other action as the successor Agent requests to perfect or continue Agent&#8217;s Lien in the Collateral or to effect the purposes of this Agreement and the Loan Documents.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Insolvency Events. In the event of any distribution, division, or application, partial or complete, voluntary or involuntary, by operation of law or otherwise, of all or any part of the property of Borrower or the proceeds thereof to the creditors of Borrower, or the readjustment of any Collateral Claims, whether by reason of liquidation, bankruptcy, arrangement, receivership, assignment for the benefit of creditors or any other action or proceeding involving the readjustment of all or any part of any of the Collateral Claims, or the application of the property of Borrower to the payment or liquidation thereof, or upon the dissolution or other winding up of Borrower&#8217;s business, or upon the sale of all or any substantial part of Borrower&#8217;s property (any of the foregoing being hereinafter referred to as an &#8220;Insolvency Event&#8221;), then, and in any such event, and subject to any subordination arrangements to which the Lenders may be subject, (a) all payments and distributions of any kind or character, whether in cash or property or securities in respect of the Lenders&#8217; Collateral Claims shall be distributed pursuant to the provisions of Section 10.2 of this Agreement&#59; (b) each Lender shall promptly file a claim or claims, on the form required in such proceeding, for the full outstanding amount of such Lender&#8217;s Claim, and shall use its best efforts to cause said claim or claims to be approved&#59; (c) each of the Lenders hereby irrevocably agrees that, to the extent that it fails timely to do so, any other Lender may in the name of the first Lender, or otherwise, prove up any </font></div><div style="height:37.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and all Collateral Claims of the first Lender relating to the first Lender&#8217;s Claim&#59; and (d) in the event that, notwithstanding the foregoing, any payment or distribution of any kind or character (other than any payment received by SVB in respect of Bank Services) in respect of a Lender&#8217;s Collateral Claims, whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender&#8217;s ratable share shall be received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the payments of amounts due on the other Lender&#8217;s Collateral Claims.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:180pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">Foreclosure</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Only by mutual agreement shall the Lenders make or cause to be made a credit bid at any foreclosure sale or other sale of any of the Collateral on behalf of the Lenders. If Lenders are the successful bidders at the sale, then (a) the amount to be credited against their respective Collateral Claims shall be allocated pro rata between the Lenders according to the balances of such Collateral Claims, and (b) Lenders shall take title to the Collateral so purchased together, each holding a pro rata undivided interest in such Collateral. The parties shall mutually agree as to the most favorable disposition of any Collateral purchased with any such credit bid.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:144pt;padding-right:71.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">No Lender shall make or cause to be made a cash bid at any foreclosure sale or other sale of any of the Collateral without the prior written consent of the other Lender. If a cash bid is made and is successful, then (a) the proceeds of the sale shall be allocated as set forth in Section 10.2 of this Agreement, and (b) the Lender that entered the successful bid shall acquire the Collateral so purchased for its own account, and the other Lender shall have no further interest in that Collateral upon the payment to such other Lender of the shares of the proceeds in accordance with Section 10.2 of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:108pt;padding-right:72.95pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">Relationship of Lenders.&#160;&#160;&#160;&#160;The relationship among the Lenders is, and at all times shall remain solely that of colenders. Lenders shall not under any circumstances be construed to be partners or joint venturers of one another&#59; nor shall the Lenders under any circumstances be deemed to be in a relationship of confidence or trust or a fiduciary relationship with one another, or to owe any fiduciary duty to one another. Lenders do not undertake or assume any responsibility or duty to one another to select, review, inspect, supervise, pass judgment upon or otherwise inform each other of any matter in connection with Borrower&#8217;s property, any Collateral held by any Lender or the operations of Borrower. Each Lender shall rely entirely on its own judgment with respect to such matters, and any review, inspection, supervision, exercise of judgment or supply of information undertaken or assumed by any Lender in connection with such matters is solely for the protection of such Lender.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">Waterfall. Notwithstanding anything in this Agreement to the contrary, the priorities set forth in Section 10.2 shall not apply to any and&#47;or all of SVB&#8217;s present and future rights (whether described as rights of setoff, banker&#8217;s liens, chargeback or otherwise, and whether available to SVB under the law or under any other agreement between SVB and Borrower concerning any account maintained by Borrower with SVB or any of its affiliates (&#8220;Account&#8221;)) with respect to&#58; (i) the face amount of a check, draft, money order, instrument, wire transfer of funds, automated clearing house entry, credit from a merchant card transaction, other electronic transfer of funds or other item (x) deposited in or credited to any Account and returned unpaid or otherwise uncollected or subject to an adjustment entry, whether for insufficient funds or for any other reason and without regard to the timeliness of the return or adjustment or the occurrence or timeliness of any other person&#8217;s notice of nonpayment or adjustment, (y) subject to a claim against SVB for breach of transfer, presentment, encoding, retention or other warranty under Federal Reserve Regulations or Operating Circulars, clearing house rules, the UCC or other applicable law, or (z) for a merchant card transaction, against which a contractual demand for chargeback has been made&#59; (ii) service charges, fees or expenses payable or reimbursable SVB in connection </font></div><div style="height:37.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with any Account or any related services&#59; and (iii) any adjustments or corrections of any posting or encoding errors, for which SVB shall be senior to each other Lender.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:108pt;padding-right:71.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:7.63pt">Priority of Bank Services&#59; Cash Collateral. The parties agree that (x) notwithstanding anything to the contrary contained in this Agreement, SVB&#8217;s lien on the Collateral shall be senior in priority to the liens of Lenders under the Loan Agreement to the extent of Borrower&#8217;s reimbursement obligations in respect of Bank Services up to the Bank Services Cap (collectively, the &#8220;Reimbursement Obligations&#8221;), and (y) SVB may extend credit to Borrower in connection with the provision of Bank Services and take such action as SVB deems necessary to enforce its rights and remedies (including, without limitation, any Enforcement Action (as defined in Addendum 3) against the Collateral and Borrower) to satisfy the Reimbursement Obligations with respect to Bank Services, all without prior notice to or the consent of Hercules. Notwithstanding the terms of this Agreement to the contrary, any Proceeds of Collection received by Agent or a Lender shall be paid over to SVB to be applied to the Reimbursement Obligations, with any remainder, after satisfaction of the Reimbursement Obligations to SVB, to be distributed to SVB and Hercules in the manner and order set forth in Sections 2.7 and 10.2, as applicable. In addition to the provision of Bank Services by SVB, which may be provided on a cash secured or a non-cash secured basis, the parties acknowledge that Borrower may in the future desire to pledge cash and&#47;or securities in connection with the provision by SVB to Borrower of Bank Services. The parties agree that notwithstanding anything to the contrary contained in this Agreement, Borrower may pledge cash and&#47;or securities in an aggregate amount up to (and without duplication of) the Bank Services Cap to SVB as collateral to secure its obligations to SVB relating to Bank Services (such cash and&#47;or securities and the proceeds thereof (but expressly excluding any other Collateral) being hereinafter referred to as the &#8220;Cash Collateral&#8221;). Hercules may not foreclose upon, or force SVB to take any actions with respect to, the Cash Collateral notwithstanding anything in this Agreement to the contrary. SVB consents to Borrower&#8217;s grant to Lenders of liens and security interests against the Cash Collateral, and the parties agree that the Cash Collateral and proceeds thereof shall be distributed to SVB and Hercules, after satisfaction of the Reimbursement Obligations to SVB, in the manner and order set forth in Sections 2.7 and 10.2, as applicable. This clause (i) shall not in any way (a) limit SVB&#8217;s rights under Section</font></div><div style="margin-top:0.05pt;padding-left:108pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 or (b) supersede the limitations on Bank Services as set forth in clause (a) of this Addendum.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">Representations and Warranties</font></div><div><font><br></font></div><div style="padding-left:144pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Hercules represents and warrants that it is a corporation duly existing and in good standing under the laws of Maryland and is qualified and licensed to do business in, and is in good standing in, any state in which the conduct of its business or its ownership of property requires that it be so qualified, except for such states as to which any failure so to qualify would not have a material adverse effect on Hercules. SVB represents and warrants that it is a banking corporation duly existing and in good standing under the laws of California and it is qualified and licensed to do business in, and is in good standing in, any state in which the conduct of its business or its ownership of property requires, that it be so qualified, except for such states as to which any failure so to qualify would not have a material adverse effect on SVB.</font></div><div style="margin-top:3.7pt;padding-left:144pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Each Lender represents and warrants that it has all necessary power and authority to execute, deliver and perform this Agreement in accordance with the terms hereof and that it has all requisite power and authority to own and operate its properties and to carry on its business as now conducted.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:37.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:144pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">Each Lender represents and warrants that (a) the execution and delivery of this Agreement and the consummation of the transactions contemplated herein have each been duly authorized by all necessary action on the part of such Lender and (b) this Agreement has been duly executed and delivered and constitutes a legal, valid and binding obligation of such Lender, enforceable in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application relating to or affecting the enforcement of creditors&#8217; rights or by general principles of equity.</font></div><div style="height:37.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-consultingagree.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic436f44c417a43249410cf4d62ebdb31_1"></div><div style="min-height:66.96pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.239%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt"><font><br></font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:80.3pt;padding-right:80.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTING AGREEMENT, DATED AUGUST 1, 2020, BETWEEN THE REGISTRANT AND ELIZABETH YEU-LIN, M.D., AS AMENDED</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective as of August 1, 2020, Dr. Elizabeth Yeu (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Tarsus Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Services&#59; Payment&#59; No Violation of Rights or Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Consultant agrees to undertake and complete the Services (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in accordance with and on the schedule specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As the only consideration due Consultant regarding the subject matter of this Agreement, Company will pay Consultant as (and only as) expressly stated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Unless otherwise specifically agreed upon by Company in writing (and notwithstanding any other provision of this Agreement), all activity relating to Services will be performed by and only by Consultant. Consultant agrees that it will not (and will not permit others to) violate any agreement with or rights of any third party or, except as expressly authorized by Company in writing hereafter, use or disclose at any time Consultant&#8217;s own or any third party&#8217;s confidential information or intellectual property in connection with the Services or otherwise for or on behalf of Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt;text-decoration:underline">Ownership&#59; Rights&#59; Proprietary Information&#59; Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.73pt">Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, trademark rights, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">sui generis </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">database rights and all other intellectual property rights of any sort throughout the world) relating to any and all inventions (whether or not patentable), works of authorship, mask works, designations, designs, know-how, ideas and information made or conceived or reduced to practice, in whole or in part, by or for or on behalf of Consultant during the term of this Agreement that relate to the subject matter of or arise out of or in connection with the Services or any Proprietary Information (as defined below) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Consultant will promptly disclose and provide all Inventions to Company. Consultant hereby makes all assignments necessary to accomplish the foregoing ownership&#59; provided that no assignment is made that extends beyond what would be allowed under California Labor Code Section 2870 (attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) if Consultant was an employee of Company. Consultant shall assist Company, at Company&#8217;s expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce and defend any rights assigned. Consultant hereby irrevocably designates and appoints Company as its agent and attorney-in-fact, coupled with an interest, to act for and on Consultant&#8217;s behalf to execute and file any document and to do all other lawfully permitted acts to further the foregoing with the same legal force and effect as if executed by Consultant and all other creators or owners of the applicable Invention.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.05pt">Consultant agrees that all Inventions and all other business, technical and financial information (including, without limitation, the identity of and information relating to customers or employees) developed, learned or obtained by or for or on behalf of Consultant during the period that Consultant is to be providing the Services that relate to Company or the business or demonstrably anticipated business of Company or in connection with the Services, or that are received by or for Company in confidence, constitute &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; Consultant shall hold in confidence and not disclose or, except in performing the Services, use any Proprietary Information. However, Consultant shall not be obligated under this paragraph with respect to information Consultant can document is or becomes readily publicly available </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic436f44c417a43249410cf4d62ebdb31_4"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.239%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt"><font><br></font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-right:7.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without restriction through no fault of Consultant. Upon termination or as otherwise requested by Company, Consultant will promptly provide to Company all items and copies containing or embodying Proprietary Information, except that Consultant may keep its personal copies of its compensation records and this Agreement. Consultant also recognizes and agrees that Consultant has no expectation of privacy with respect to Company&#8217;s telecommunications, networking or information processing systems (including, without limitation, stored computer files, email messages and voice messages) and that Consultant&#8217;s activity, and any files or messages, on or using any of those systems may be monitored at any time without notice.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.73pt">As additional protection for Proprietary Information, Consultant agrees that during the period over which it is to be providing the Services (i) and for one year thereafter, Consultant will not directly or indirectly encourage or solicit any employee or consultant of Company to leave Company for any reason and (ii) Consultant will not engage in any activity that is in any way competitive with the business or demonstrably anticipated business of Company, and Consultant will not assist any other person or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Company. Without limiting the foregoing, Consultant may perform services for other persons, provided that such services do not represent a conflict of interest or a breach of Consultant&#8217;s obligation under this Agreement or otherwise.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.05pt">To the extent allowed by law, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and any license granted Company hereunder includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as &#8220;moral rights,&#8221; &#8220;artist&#8217;s rights,&#8221; &#8220;droit moral,&#8221; or the like. Furthermore, Consultant agrees that notwithstanding any rights of publicity, privacy or otherwise (whether or not statutory) anywhere in the world, and without any further compensation, Company may and is hereby authorized to (and to allow others to) use Consultant&#8217;s name in connection with promotion of its business, products or services. To the extent any of the foregoing is ineffective under applicable law, Consultant hereby provides any and all ratifications and consents necessary to accomplish the purposes of the foregoing to the extent possible. Consultant will confirm any such ratifications and consents from time to time as requested by Company. If any other person is in any way involved in any Services, Consultant will obtain the foregoing ratifications, consents and authorizations from such person for Company&#8217;s exclusive benefit.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.73pt">If any part of the Services or Inventions or information provided hereunder is based on, incorporates, or is an improvement or derivative of, or cannot be reasonably and fully made, used, reproduced, distributed and otherwise exploited without using or violating technology or intellectual property rights owned by or licensed to Consultant (or any person involved in the Services) and not assigned hereunder, Consultant hereby grants Company and its successors a perpetual, irrevocable, worldwide royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such technology and intellectual property rights in support of Company&#8217;s exercise or exploitation of the Services, Inventions, other work or information performed or provided hereunder, or any assigned rights (including any modifications, improvements and derivatives of any of them).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.9pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Warranties and Other Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Consultant represents, warrants and covenants that&#58; (i) the Services will be performed in a professional and workmanlike manner</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic436f44c417a43249410cf4d62ebdb31_7"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.239%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt"><font><br></font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:5pt;padding-right:7.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and that none of such Services nor any part of this Agreement is or will be inconsistent with any obligation Consultant may have to others&#59; (ii) all work under this Agreement shall be Consultant&#8217;s original work and none of the Services or Inventions nor any development, use, production, distribution or exploitation thereof will infringe, misappropriate or violate any intellectual property or other right of any person or entity (including, without limitation, Consultant)&#59; (iii) Consultant has the full right to allow it to provide Company with the assignments and rights provided for herein (and has written enforceable agreements with all persons necessary to give it the rights to do the foregoing and otherwise fully perform this Agreement)&#59; (iv) Consultant shall comply with all applicable laws and Company safety rules in the course of performing the Services&#59; and (v) if Consultant&#8217;s work requires a license, Consultant has obtained that license and the license is in full force and effect.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Either party may terminate this Agreement at any time, with or without cause, upon ten (10) days&#8217; notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (subject to the limitations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement and any remedies for breach of this Agreement shall survive any termination or expiration. Company may communicate the obligations contained in this Agreement to any other (or potential) client or employer of Consultant.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Relationship of the Parties&#59; Independent Contractor&#59; No Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any provision hereof, Consultant is an independent contractor and is not an employee, agent, partner or joint venturer of Company and shall not bind nor attempt to bind Company to any contract. Consultant shall accept any directions issued by Company pertaining to the goals to be attained and the results to be achieved by Consultant, but Consultant shall be solely responsible for the manner and hours in which the Services are performed under this Agreement. Consultant shall not be eligible to participate in any of Company&#8217;s employee benefit plans, fringe benefit programs, group insurance arrangements or similar programs. Company shall not provide workers&#8217; compensation, disability insurance, Social Security or unemployment compensation coverage or any other statutory benefit to Consultant. Consultant shall comply at Consultant&#8217;s expense with all applicable provisions of workers&#8217; compensation laws, unemployment compensation laws, federal Social Security law, the Fair Labor Standards Act, federal, state and local income tax laws, and all other applicable federal, state and local laws, regulations and codes relating to terms and conditions of employment required to be fulfilled by employers or independent contractors. Consultant will ensure that its employees, contractors and others involved in the Services, if any, are bound in writing to the foregoing, and to all of Consultant&#8217;s obligations under any provision of this Agreement, for Company&#8217;s benefit and Consultant will be responsible for any noncompliance by them. Consultant agrees to indemnify Company from any and all claims, damages, liability, settlement, attorneys&#8217; fees and expenses, as incurred, on account of the foregoing or any breach of this Agreement or any other action or inaction by or for or on behalf of Consultant.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement and the services contemplated hereunder are personal to Consultant and Consultant shall not have the right or ability to assign, transfer or subcontract any rights or obligations under this Agreement without the written consent of Company. Any attempt to do so shall be void. Company may fully assign and transfer this Agreement in whole or part.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic436f44c417a43249410cf4d62ebdb31_10"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.239%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt"><font><br></font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:5pt;padding-right:8.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices under this Agreement shall be in writing and shall be deemed given when personally delivered, or three days after being sent by prepaid certified or registered</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">U.S. mail to the address of the party to be noticed as set forth herein or to such other address as such party last provided to the other by written notice.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any breach of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will cause irreparable harm to Company for which damages would not be an adequate remedy, and therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other remedies. The failure of either party to enforce its rights under this Agreement at any time for any period shall not be construed as a waiver of such rights. No changes, additions, modifications or waivers to this Agreement will be effective unless in writing and signed by both parties. In the event that any provision of this Agreement shall be determined to be illegal or unenforceable, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. This Agreement shall be governed by and construed in accordance with the laws of the State of California without regard to the conflicts of laws provisions thereof. In any action or proceeding to enforce rights under this Agreement, the prevailing party will be entitled to recover costs and attorneys&#8217; fees. Headings herein are for convenience of reference only and shall in no way affect interpretation of the Agreement. This Agreement represents the entire understanding and agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties with respect to the subject matter hereof.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.05pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any controversy or claim (except those regarding Inventions, Proprietary Information or intellectual property) arising out of or relating to this Agreement, or the breach thereof, shall be settled by arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof, provided however, that each party will have a right to seek injunctive or other equitable relief in a court of law. The prevailing party will be entitled to receive from the non-prevailing party all costs, damages and expenses, including reasonable attorneys&#8217; fees, incurred by the prevailing party in connection with that action or proceeding, whether or not the controversy is reduced to judgment or award. The prevailing party will be that party who may be fairly said by the arbitrator(s) to have prevailed on the major disputed issues. Consultant hereby consents to the arbitration in the State of California in the county of Orange.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:8.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTICE&#58; This agreement does not affect any immunity under 18 USC Sections 1833(b) (1) or (2), which read as follows (note that for purposes of this statute only, individuals performing work as contractors or consultants are considered to be employees)&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:43.5pt;padding-right:46.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.52pt">An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney&#59; and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic436f44c417a43249410cf4d62ebdb31_13"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.239%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt"><font><br></font></div></td></tr></table></div></div><div style="margin-top:4pt;padding-left:43.5pt;padding-right:46.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.52pt">An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal&#59; and (B) does not disclose the trade secret, except pursuant to court order.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:159.12pt;padding-right:159.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic436f44c417a43249410cf4d62ebdb31_16"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:5pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the parties hereunto have executed this Agreement as of the day and year first above written.</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTANT&#58;&#160;&#160;&#160;&#160;COMPANY&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LIZABETH </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Y</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">EU&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ARSUS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">HARMACEUTICALS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">NC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.093%"><tr><td style="width:1.0%"></td><td style="width:27.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Dr. Elizabeth Yeu</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dr. Elizabeth Yeu</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">       </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.340%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Bobak Azamian</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:46.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic436f44c417a43249410cf4d62ebdb31_22"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:190.75pt;padding-right:190.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:7.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SERVICES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Consultant will occasionally provide general advice and consulting services to the Company as requested and agreed upon between the parties from time to time. The Services are expected to average about 10 hours per week, and include&#58;</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:41pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.05pt">Investor relations support</font></div><div style="padding-left:41pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.05pt">Advisory board leadership</font></div><div style="padding-left:41pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.05pt">Eye care provider education and engagement</font></div><div style="padding-left:41pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.05pt">Commercial strategy support</font></div><div style="padding-left:41pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.05pt">Clinical development and regulatory support</font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FEES&#47;EXPENSES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Monthly fee of $12,500.00, payable monthly in arrears.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expense reimbursement limited to required, reasonable expenses authorized in by the Company in advance, payable 30 days after itemized invoice and delivery of receipts.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">STOCK OPTIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the approval of Company&#8217;s Board of Directors and the terms and conditions of Company&#8217;s 2016 Stock Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the applicable stock option agreement, Consultant shall be granted an option to purchase 247,876 shares of Company&#8217;s Common Stock (as currently constituted), which will vest at rate of 1&#47;48 per month over four years, subject to continued service. The exercise purchase price per share shall be equal to the fair market value per share on the date the option is granted.</font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic436f44c417a43249410cf4d62ebdb31_25"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:190.42pt;padding-right:190.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">California Labor Code Section 2870. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Application of provision providing that employee shall assign or offer to assign rights in invention to employer.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.02pt">Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Result from any work  performed by the employee for his</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employer.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.07pt">To the extent a provision in an employment agreement purports to require</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic436f44c417a43249410cf4d62ebdb31_28"></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.956%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt;padding-left:0.32pt;padding-right:0.32pt;text-align:center;text-indent:19.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">AMENDMENT No. 1 to </font></div><div style="padding-left:0.32pt;padding-right:0.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONSULTING AGREEMENT</font></div></td></tr></table></div></div><div style="margin-top:4.9pt;padding-left:5pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">THIS FIRST AMENDMENT TO CONSULTING AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) is entered into effective as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">October 1, 2020 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Dr. Elizabeth Yeu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Tarsus Pharmaceuticals, Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Consultant and the Company entered into that certain Consulting Agreement dated</font></div><div style="margin-top:1.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August 1, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Original Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">WHEREAS, the Consultant and Company desire to amend the Original Agreement to change the Services and Fees in that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, Consultant and Company mutually agree as follows&#58;</font></div><div style="margin-top:4pt;padding-left:41pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:27.8pt;text-decoration:underline">Fees&#58;</font></div><div style="margin-top:6.85pt;padding-left:87.45pt;text-indent:-10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:2.87pt">Monthly fee of $20,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, paid within one week of each month-end.</font></div><div style="margin-top:4pt;padding-left:41pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:27.8pt;text-decoration:underline">Services&#58; Approximately 16 hours per week within&#58;</font></div><div style="margin-top:6.7pt;padding-left:131.05pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.42pt">Investor relations support</font></div><div style="margin-top:1pt;padding-left:131.05pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.8pt">Advisory board leadership</font></div><div style="margin-top:1.05pt;padding-left:131.05pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.42pt">Eye care provider education and engagement</font></div><div style="margin-top:1pt;padding-left:131.05pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.8pt">Commercial strategy support</font></div><div style="margin-top:0.95pt;padding-left:131.05pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.42pt">Clinical development and regulatory support</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:8.45pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.8pt">Effect of Amendment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as amended as set forth above, the Original Agreement shall continue in full force and effect.</font></div><div style="margin-top:6pt;padding-left:5pt;padding-right:24.45pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%;padding-left:22.8pt">Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This Amendment may be signed in counterparts, each of which shall be deemed an original and all of which, taken together, shall be deemed one and the same document.</font></div><div style="margin-top:6.05pt;padding-left:5pt;padding-right:17.7pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%;padding-left:22.8pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">. This Amendment shall be construed in accordance with the laws of the State of California (without regard to their choice&#8211;of&#8211;law provisions).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have entered this Amendment as of the Effective</font></div><div style="margin-top:1pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONSULTANT&#58;&#160;&#160;&#160;&#160;TARSUS PHARMACEUTICALS, INC.&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.093%"><tr><td style="width:1.0%"></td><td style="width:27.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Dr. Elizabeth Yeu</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dr. Elizabeth Yeu</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chief Medical Adviser</font></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">       </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.340%"><tr><td style="width:1.0%"></td><td style="width:26.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Bobak Azamian</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Title&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311-33122.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2ec09cefd3ab4fe0aa93f5c2b9330b72_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I, Bobak Azamian, M.D., Ph.D., certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact &#160;&#160;&#160;&#160;necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred &#160;&#160;&#160;&#160;during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.452%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date&#58; May&#160;11, 2022</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#47;s&#47; Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312-33122.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3031860813dd47ddb2b56d9166009152_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I, Leo M. Greenstein, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">I have reviewed this Quarterly Report on Form 10-Q of Tarsus Pharmaceuticals, Inc&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact &#160;&#160;&#160;&#160;necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred &#160;&#160;&#160;&#160;during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.452%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date&#58; May&#160;11, 2022</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#47;s&#47; Leo M. Greenstein</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leo M. Greenstein</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chief Financial Officer</font></div><div style="text-align:center;text-indent:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Principal Financial Officer and Principal Accounting Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321-33122.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i64b4ac720370476f885327a3a7ba959a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.1 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Bobak Azamian, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.119%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 1934, as amended&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.730%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information contained in the Report fairly presents, in all material respects, the financial condition and</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">result of operations of the Company.</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.371%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;11, 2022</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bobak Azamian, M.D., Ph.D.</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit322-33122.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5909a75d895a437397362840a54a8548_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:32.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Leo M. Greenstein, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.119%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of 1934, as amended&#59; and</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.327%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.730%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information contained in the Report fairly presents, in all material respects, the financial condition and</font></div><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">result of operations of the Company.</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.371%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;11, 2022</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leo M. Greenstein</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leo M. Greenstein</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></div></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>tars-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:da1c4284-d55c-45f0-a6eb-8007076173b6,g:baa10d6b-a9ec-46bb-8e50-7a6ef1f55cb8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tars="http://tarsusrx.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://tarsusrx.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tars-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://tarsusrx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://tarsusrx.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLossIncome" roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome">
        <link:definition>1003004 - Statement - Condensed Statements of Operations and Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofPreferredStockandStockholdersEquity" roleURI="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Statements of Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandPresentationofFinancialStatements" roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements">
        <link:definition>2101101 - Disclosure - Description of Business and Presentation of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandPresentationofFinancialStatementsDetails" roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails">
        <link:definition>2402401 - Disclosure - Description of Business and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimates" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetail" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetail">
        <link:definition>2106103 - Disclosure - Balance Sheet Account Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailTables" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailTables">
        <link:definition>2307301 - Disclosure - Balance Sheet Account Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails">
        <link:definition>2408403 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailOtherAssetsDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails">
        <link:definition>2409404 - Disclosure - Balance Sheet Account Detail - Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>2410405 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails">
        <link:definition>2411406 - Disclosure - Balance Sheet Account Detail - Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandEquityIncentivePlans" roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlans">
        <link:definition>2112104 - Disclosure - Stockholders' Equity and Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandEquityIncentivePlansTables" roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansTables">
        <link:definition>2313302 - Disclosure - Stockholders' Equity and Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails">
        <link:definition>2414407 - Disclosure - Stockholders' Equity and Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails" roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails">
        <link:definition>2415408 - Disclosure - Stockholders' Equity and Equity Incentive Plans - Shares Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://tarsusrx.com/role/StockBasedCompensation">
        <link:definition>2116105 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://tarsusrx.com/role/StockBasedCompensationTables">
        <link:definition>2317303 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetails" roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails">
        <link:definition>2418409 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShare" roleURI="http://tarsusrx.com/role/NetLossIncomePerShare">
        <link:definition>2119106 - Disclosure - Net (Loss) Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareTables" roleURI="http://tarsusrx.com/role/NetLossIncomePerShareTables">
        <link:definition>2320304 - Disclosure - Net (Loss) Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareDetails" roleURI="http://tarsusrx.com/role/NetLossIncomePerShareDetails">
        <link:definition>2421410 - Disclosure - Net (Loss) Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareAntidilutiveSecuritiesDetails" roleURI="http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails">
        <link:definition>2422411 - Disclosure - Net (Loss) Income Per Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://tarsusrx.com/role/FairValueMeasurements">
        <link:definition>2123107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://tarsusrx.com/role/FairValueMeasurementsTables">
        <link:definition>2324305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails">
        <link:definition>2425412 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2426413 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails">
        <link:definition>2427414 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingencies" roleURI="http://tarsusrx.com/role/CommitmentContingencies">
        <link:definition>2128108 - Disclosure - Commitment &amp; Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesTables" roleURI="http://tarsusrx.com/role/CommitmentContingenciesTables">
        <link:definition>2329306 - Disclosure - Commitment &amp; Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesFacilityLeasesDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails">
        <link:definition>2430415 - Disclosure - Commitment &amp; Contingencies - Facility Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails">
        <link:definition>2431416 - Disclosure - Commitment &amp; Contingencies - Lease Asset and Liability Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesLeaseCostDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails">
        <link:definition>2432417 - Disclosure - Commitment &amp; Contingencies - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" roleURI="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails">
        <link:definition>2433418 - Disclosure - Commitment and Contingencies - Summary of Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1" roleURI="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1">
        <link:definition>2433418 - Disclosure - Commitment and Contingencies - Summary of Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesInLicenseAgreementforLotilanerDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails">
        <link:definition>2434419 - Disclosure - Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentContingenciesEmploymentArrangementsDetails" roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails">
        <link:definition>2435420 - Disclosure - Commitment &amp; Contingencies - Employment Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutLicenseAgreement" roleURI="http://tarsusrx.com/role/OutLicenseAgreement">
        <link:definition>2136109 - Disclosure - Out-License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OutLicenseAgreementDetails" roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails">
        <link:definition>2437421 - Disclosure - Out-License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreement" roleURI="http://tarsusrx.com/role/CreditFacilityAgreement">
        <link:definition>2138110 - Disclosure - Credit Facility Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementTables" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementTables">
        <link:definition>2339307 - Disclosure - Credit Facility Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails">
        <link:definition>2440422 - Disclosure - Credit Facility Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementSummaryofInterestExpenseDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails">
        <link:definition>2441423 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails">
        <link:definition>2442424 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://tarsusrx.com/role/SubsequentEvent">
        <link:definition>2143111 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://tarsusrx.com/role/SubsequentEventDetails">
        <link:definition>2444425 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" abstract="false" name="NumberOfEmploymentArrangementsWithExecutiveOfficers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_LineOfCreditFacilityDrawDownIncrements" abstract="false" name="LineOfCreditFacilityDrawDownIncrements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense" abstract="false" name="OperatingLeaseRightOfUseAssetLeaseTerminationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_ProceedsFromEarlyExerciseOfStockOptions" abstract="false" name="ProceedsFromEarlyExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_IrvineOfficeAndFacilitiesLeaseMember" abstract="true" name="IrvineOfficeAndFacilitiesLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_DeferredOfferingCostsIncurredButNotYetPaid" abstract="false" name="DeferredOfferingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_SalesMilestoneMember" abstract="true" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_EquityIncentivePlan2020Member" abstract="true" name="EquityIncentivePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_LineOfCreditFacilityInterestOnlyPeriodExtended" abstract="false" name="LineOfCreditFacilityInterestOnlyPeriodExtended" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember" abstract="true" name="IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CreditFacilityTrancheFourMember" abstract="true" name="CreditFacilityTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_LesseeOperatingLeaseNumberOfLeaseContracts" abstract="false" name="LesseeOperatingLeaseNumberOfLeaseContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_EquityWarrantsFairValueDisclosure" abstract="false" name="EquityWarrantsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_LicenseAndCollaborationMember" abstract="true" name="LicenseAndCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" abstract="false" name="StockIssuedDuringPeriodValueLapseOfRepurchaseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_ElancoMember" abstract="true" name="ElancoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" abstract="false" name="StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_CollaborativeArrangementMilestonePayment" abstract="false" name="CollaborativeArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommonStockSharesSubjectToRepurchase" abstract="false" name="CommonStockSharesSubjectToRepurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_EquitySecuritiesFVNINumberOfShares" abstract="false" name="EquitySecuritiesFVNINumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_CreditFacilityTrancheThreeMember" abstract="true" name="CreditFacilityTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="tars_DrugSupplyAgreementMilestoneMember" abstract="true" name="DrugSupplyAgreementMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_LianBioMember" abstract="true" name="LianBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" abstract="false" name="ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="tars_ClinicalMilestonesMember" abstract="true" name="ClinicalMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_DevelopmentAndRegulatoryMilestoneMember" abstract="true" name="DevelopmentAndRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommercialAndSalesMilestonesMember" abstract="true" name="CommercialAndSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CollaborativeArrangementMaximumMilestonePayment" abstract="false" name="CollaborativeArrangementMaximumMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_AccruedClinicalStudiesCurrent" abstract="false" name="AccruedClinicalStudiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CreditFacilityTrancheFiveMember" abstract="true" name="CreditFacilityTrancheFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ClinicalDevelopmentMilestonesMember" abstract="true" name="ClinicalDevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_PaymentsOfDeferredStockIssuanceCosts" abstract="false" name="PaymentsOfDeferredStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_NumberOfWarrants" abstract="false" name="NumberOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_CreditFacilityTrancheOneMember" abstract="true" name="CreditFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_LineOfCreditFacilityPeriodicPaymentInterestRate" abstract="false" name="LineOfCreditFacilityPeriodicPaymentInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="tars_EquityIncentivePlan2016Member" abstract="true" name="EquityIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" abstract="true" name="ShareBasedPaymentArrangementEarlyExercisedOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_NumberOfVestedWarrants" abstract="false" name="NumberOfVestedWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="tars_LineOfCreditFacilityInterestOnlyPeriod" abstract="false" name="LineOfCreditFacilityInterestOnlyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_EquityWarrantRights" abstract="false" name="EquityWarrantRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CreditFacilityTrancheTwoMember" abstract="true" name="CreditFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" abstract="false" name="AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" abstract="true" name="ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="tars_OperatingLeaseNoncashExpense" abstract="false" name="OperatingLeaseNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>tars-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:da1c4284-d55c-45f0-a6eb-8007076173b6,g:baa10d6b-a9ec-46bb-8e50-7a6ef1f55cb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a5ee83fd-feab-4a4f-88f3-04d274b72f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7a14cf80-728c-4966-b62a-bd28a17d925e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a5ee83fd-feab-4a4f-88f3-04d274b72f0d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7a14cf80-728c-4966-b62a-bd28a17d925e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_17fd22cb-a485-4742-a463-29c680e33313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a5ee83fd-feab-4a4f-88f3-04d274b72f0d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_17fd22cb-a485-4742-a463-29c680e33313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5eae887d-aaac-4f79-b0d5-24047be87c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a5ee83fd-feab-4a4f-88f3-04d274b72f0d" xlink:to="loc_us-gaap_LiabilitiesCurrent_5eae887d-aaac-4f79-b0d5-24047be87c5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2a43f45a-4f35-4b28-bf25-d1179804cb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_276bca11-a066-419d-bddf-53ad59759ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a43f45a-4f35-4b28-bf25-d1179804cb0f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_276bca11-a066-419d-bddf-53ad59759ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d9495427-ba4a-43c3-8d06-6d076c36848a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a43f45a-4f35-4b28-bf25-d1179804cb0f" xlink:to="loc_us-gaap_CommonStockValue_d9495427-ba4a-43c3-8d06-6d076c36848a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3b1a7676-2067-4d75-8528-ac4ee4813afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a43f45a-4f35-4b28-bf25-d1179804cb0f" xlink:to="loc_us-gaap_PreferredStockValue_3b1a7676-2067-4d75-8528-ac4ee4813afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_04fa417c-645c-4108-8d90-7622b2ba3fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a43f45a-4f35-4b28-bf25-d1179804cb0f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_04fa417c-645c-4108-8d90-7622b2ba3fec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ef67f16-52b3-4036-8fbd-a441ba9ab6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d5db42a5-3e10-4a0a-803d-39afb2c67b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ef67f16-52b3-4036-8fbd-a441ba9ab6ec" xlink:to="loc_us-gaap_Liabilities_d5db42a5-3e10-4a0a-803d-39afb2c67b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e52cb3c8-44b9-49e8-8c26-93ae73955d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ef67f16-52b3-4036-8fbd-a441ba9ab6ec" xlink:to="loc_us-gaap_StockholdersEquity_e52cb3c8-44b9-49e8-8c26-93ae73955d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_27dd3dde-a8b0-4271-b46f-bdbeb4e061ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ef67f16-52b3-4036-8fbd-a441ba9ab6ec" xlink:to="loc_us-gaap_CommitmentsAndContingencies_27dd3dde-a8b0-4271-b46f-bdbeb4e061ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1292ec86-5488-465a-b0af-0255718d314c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5b2c6167-e881-480f-a708-c05017c55b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1292ec86-5488-465a-b0af-0255718d314c" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5b2c6167-e881-480f-a708-c05017c55b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_231998f0-bc3b-48a9-889d-ba087a6589ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1292ec86-5488-465a-b0af-0255718d314c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_231998f0-bc3b-48a9-889d-ba087a6589ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73ccadea-ba17-4aba-934a-85ae451b36f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_22d08aad-b9af-4c02-9088-3618e512fa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73ccadea-ba17-4aba-934a-85ae451b36f8" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_22d08aad-b9af-4c02-9088-3618e512fa7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f9e7927c-d1e6-4d88-a3ba-70ec76b421b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73ccadea-ba17-4aba-934a-85ae451b36f8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f9e7927c-d1e6-4d88-a3ba-70ec76b421b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_37e100b2-8e77-4e6b-94ad-01851fef32dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73ccadea-ba17-4aba-934a-85ae451b36f8" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_37e100b2-8e77-4e6b-94ad-01851fef32dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3792ab91-022b-4317-bd56-04431183b048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73ccadea-ba17-4aba-934a-85ae451b36f8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3792ab91-022b-4317-bd56-04431183b048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_47d62be6-fe4b-4297-8dca-38573745389c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73ccadea-ba17-4aba-934a-85ae451b36f8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_47d62be6-fe4b-4297-8dca-38573745389c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9e46825a-d7f7-4339-b51a-2a75aa1f489a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b6d50cda-0338-4bf6-aecd-74ad2a5d567d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9e46825a-d7f7-4339-b51a-2a75aa1f489a" xlink:to="loc_us-gaap_AssetsCurrent_b6d50cda-0338-4bf6-aecd-74ad2a5d567d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9321e151-f3d3-4a0a-9509-b9b870ef73fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9e46825a-d7f7-4339-b51a-2a75aa1f489a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9321e151-f3d3-4a0a-9509-b9b870ef73fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_142998ac-03cb-427f-84b7-340cafbd6778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9e46825a-d7f7-4339-b51a-2a75aa1f489a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_142998ac-03cb-427f-84b7-340cafbd6778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5058a803-5396-48ee-bbed-afe5968c030a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9e46825a-d7f7-4339-b51a-2a75aa1f489a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5058a803-5396-48ee-bbed-afe5968c030a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_28347fb0-e00e-4c4c-b6f5-569e8d2ad185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0ad6a405-bead-471a-8570-6642cfa17361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_28347fb0-e00e-4c4c-b6f5-569e8d2ad185" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0ad6a405-bead-471a-8570-6642cfa17361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_87b012b7-9e9c-4d6d-bd0d-a83db281176d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_28347fb0-e00e-4c4c-b6f5-569e8d2ad185" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_87b012b7-9e9c-4d6d-bd0d-a83db281176d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a56df373-dc49-47c2-a4fa-5b70e3a27959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_28347fb0-e00e-4c4c-b6f5-569e8d2ad185" xlink:to="loc_us-gaap_OperatingIncomeLoss_a56df373-dc49-47c2-a4fa-5b70e3a27959" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5373b151-d588-418c-8f94-4aa8d1117fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c9b3eb96-ae5b-4356-9548-2c70324f8fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5373b151-d588-418c-8f94-4aa8d1117fa1" xlink:to="loc_us-gaap_OperatingExpenses_c9b3eb96-ae5b-4356-9548-2c70324f8fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3ad93d0a-f082-4fd9-9a41-9e893b0b1b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5373b151-d588-418c-8f94-4aa8d1117fa1" xlink:to="loc_us-gaap_Revenues_3ad93d0a-f082-4fd9-9a41-9e893b0b1b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b6e36e91-ef07-4131-ba79-43669c29d67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e3beb174-8c7f-4858-8d06-9b9aeebdaa37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b6e36e91-ef07-4131-ba79-43669c29d67c" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e3beb174-8c7f-4858-8d06-9b9aeebdaa37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5f6c1180-a691-4dee-9341-33265e502772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b6e36e91-ef07-4131-ba79-43669c29d67c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5f6c1180-a691-4dee-9341-33265e502772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_96949d62-785c-4c27-bab8-3b7e02e30504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b6e36e91-ef07-4131-ba79-43669c29d67c" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_96949d62-785c-4c27-bab8-3b7e02e30504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_08448b73-cc29-41c5-81d6-8a741db814a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b6e36e91-ef07-4131-ba79-43669c29d67c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_08448b73-cc29-41c5-81d6-8a741db814a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c6a2f68a-1226-47d8-bb77-d3b2b37ade67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_58536f6c-21b8-4352-ac71-50f16244fa50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c6a2f68a-1226-47d8-bb77-d3b2b37ade67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_58536f6c-21b8-4352-ac71-50f16244fa50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2609add6-730d-487c-a148-d1e5987df406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c6a2f68a-1226-47d8-bb77-d3b2b37ade67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2609add6-730d-487c-a148-d1e5987df406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4567956e-21fc-470e-962a-0083bd5a2e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c6a2f68a-1226-47d8-bb77-d3b2b37ade67" xlink:to="loc_us-gaap_CostOfRevenue_4567956e-21fc-470e-962a-0083bd5a2e34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_803609fc-8ebc-4842-8995-3aaac906139d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_803609fc-8ebc-4842-8995-3aaac906139d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ee1fd3a1-2dd2-4d41-8040-b2d65f327a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ee1fd3a1-2dd2-4d41-8040-b2d65f327a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d50eee2f-4ba1-408b-ba9e-675640ed280b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d50eee2f-4ba1-408b-ba9e-675640ed280b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4cbb3b4-d93b-454a-9487-57c452e06b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_NetIncomeLoss_f4cbb3b4-d93b-454a-9487-57c452e06b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_9395a448-704e-4581-be99-b795d0927d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_9395a448-704e-4581-be99-b795d0927d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_cb7e983b-8758-4b81-b6e6-da73a7b54bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_cb7e983b-8758-4b81-b6e6-da73a7b54bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_d6849f11-9120-484a-af2b-419b52818a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_d6849f11-9120-484a-af2b-419b52818a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1fb3758c-4d67-4c91-9846-296105e1500a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1fb3758c-4d67-4c91-9846-296105e1500a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense_4925a1be-9ce6-4cb5-8833-51cf04454108" xlink:href="tars-20220331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_tars_OperatingLeaseNoncashExpense_4925a1be-9ce6-4cb5-8833-51cf04454108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_159949bb-5b74-4cbe-9f76-37391b169368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_159949bb-5b74-4cbe-9f76-37391b169368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_ac4885c0-81cc-4edc-b96d-56888dadb383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_ac4885c0-81cc-4edc-b96d-56888dadb383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d69e2174-40bd-4897-bf28-b9b9dd062486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_ShareBasedCompensation_d69e2174-40bd-4897-bf28-b9b9dd062486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5834d4fb-51f7-4dcc-88a5-c871aa481f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5834d4fb-51f7-4dcc-88a5-c871aa481f6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_535ffe6a-8952-486f-8088-770b4e79aaed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_535ffe6a-8952-486f-8088-770b4e79aaed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9a23e5e9-a153-4763-8b6f-1135177c2bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9a23e5e9-a153-4763-8b6f-1135177c2bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_413a97e2-c3ac-4db1-a281-d5e7f67b8392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_413a97e2-c3ac-4db1-a281-d5e7f67b8392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_0f686aa0-034b-49b3-9417-f6434129a5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_0f686aa0-034b-49b3-9417-f6434129a5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_95e551b5-6b19-405b-8937-e79465d160b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_95e551b5-6b19-405b-8937-e79465d160b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_03f9c52a-f8ee-4fdc-b135-77e8cd468947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff80fbfc-492c-49fa-a5f6-46e55ed6c36c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_03f9c52a-f8ee-4fdc-b135-77e8cd468947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8245f2fd-a59d-4d01-95f6-4c6cb710ff43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromEarlyExerciseOfStockOptions_ea3495d6-287b-4d78-9d3b-b30ca4096654" xlink:href="tars-20220331.xsd#tars_ProceedsFromEarlyExerciseOfStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8245f2fd-a59d-4d01-95f6-4c6cb710ff43" xlink:to="loc_tars_ProceedsFromEarlyExerciseOfStockOptions_ea3495d6-287b-4d78-9d3b-b30ca4096654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f7e02a7c-d35e-4fbb-ba93-d07e330e7ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8245f2fd-a59d-4d01-95f6-4c6cb710ff43" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f7e02a7c-d35e-4fbb-ba93-d07e330e7ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PaymentsOfDeferredStockIssuanceCosts_6787095b-7402-4f58-a3e9-887ab8584d76" xlink:href="tars-20220331.xsd#tars_PaymentsOfDeferredStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8245f2fd-a59d-4d01-95f6-4c6cb710ff43" xlink:to="loc_tars_PaymentsOfDeferredStockIssuanceCosts_6787095b-7402-4f58-a3e9-887ab8584d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71ed6762-5e39-4abb-811c-bd9a5326d3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8245f2fd-a59d-4d01-95f6-4c6cb710ff43" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71ed6762-5e39-4abb-811c-bd9a5326d3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9640ce0-4658-4a13-b982-d71496501488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_65fd1903-533d-4aa1-af96-eaae163632ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9640ce0-4658-4a13-b982-d71496501488" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_65fd1903-533d-4aa1-af96-eaae163632ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3575b9b6-6a1e-4cb3-9fd7-595207ba050b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a8b90bb-f130-4578-8de9-fc0a9287c315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3575b9b6-6a1e-4cb3-9fd7-595207ba050b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a8b90bb-f130-4578-8de9-fc0a9287c315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ab8ac62-df94-4a39-9d9f-317968b98591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3575b9b6-6a1e-4cb3-9fd7-595207ba050b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ab8ac62-df94-4a39-9d9f-317968b98591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_860a9798-f6f6-423b-9dce-cea25abddbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3575b9b6-6a1e-4cb3-9fd7-595207ba050b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_860a9798-f6f6-423b-9dce-cea25abddbd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0ff85db-a8b9-4118-bd24-023ebc9420a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0e5c3878-7f24-4b3b-82d8-2e1e4a7950fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0ff85db-a8b9-4118-bd24-023ebc9420a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0e5c3878-7f24-4b3b-82d8-2e1e4a7950fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3e6a0851-9ac9-4971-9c49-48c8daab1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0ff85db-a8b9-4118-bd24-023ebc9420a5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3e6a0851-9ac9-4971-9c49-48c8daab1e58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5e684f17-81cb-4729-8a4c-99971eb763b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fc6b5b9-34f4-4563-9c29-471a4379c267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5e684f17-81cb-4729-8a4c-99971eb763b1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fc6b5b9-34f4-4563-9c29-471a4379c267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_82bbf4e8-c8c5-4b8c-be94-01e88bfce260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5e684f17-81cb-4729-8a4c-99971eb763b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_82bbf4e8-c8c5-4b8c-be94-01e88bfce260" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d1f0df63-5938-49ea-b252-583b06f645e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantRights_3548f2d1-fff7-42d0-8a19-7c4c1cd03b64" xlink:href="tars-20220331.xsd#tars_EquityWarrantRights"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_d1f0df63-5938-49ea-b252-583b06f645e6" xlink:to="loc_tars_EquityWarrantRights_3548f2d1-fff7-42d0-8a19-7c4c1cd03b64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_e27d343c-3496-4e97-9e3f-e8898c5c5319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_d1f0df63-5938-49ea-b252-583b06f645e6" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_e27d343c-3496-4e97-9e3f-e8898c5c5319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_cf184115-d519-4107-8789-1640014064ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_d1f0df63-5938-49ea-b252-583b06f645e6" xlink:to="loc_us-gaap_DepositAssets_cf184115-d519-4107-8789-1640014064ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ed7d2dbf-7ea9-44e1-8ecf-a3fb52b5f244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent_8456e102-328c-4ad6-a4a7-0244cf30699a" xlink:href="tars-20220331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ed7d2dbf-7ea9-44e1-8ecf-a3fb52b5f244" xlink:to="loc_tars_AccruedClinicalStudiesCurrent_8456e102-328c-4ad6-a4a7-0244cf30699a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e1e21f32-3204-410c-8adc-0dba56979ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ed7d2dbf-7ea9-44e1-8ecf-a3fb52b5f244" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e1e21f32-3204-410c-8adc-0dba56979ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_cc8a2fbb-e253-4063-947b-0f2ef354f1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ed7d2dbf-7ea9-44e1-8ecf-a3fb52b5f244" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_cc8a2fbb-e253-4063-947b-0f2ef354f1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_70431912-88e1-4c0d-9e22-ba39125e633c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ed7d2dbf-7ea9-44e1-8ecf-a3fb52b5f244" xlink:to="loc_us-gaap_InterestPayableCurrent_70431912-88e1-4c0d-9e22-ba39125e633c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_7ac9a30e-53a6-4ae0-a71c-35b3b846cac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ed7d2dbf-7ea9-44e1-8ecf-a3fb52b5f244" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_7ac9a30e-53a6-4ae0-a71c-35b3b846cac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fdb54e50-40fc-4c35-81a7-778d4d9db7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ed7d2dbf-7ea9-44e1-8ecf-a3fb52b5f244" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fdb54e50-40fc-4c35-81a7-778d4d9db7fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_2c4526d8-9a12-4a18-9dc7-dc787a65afa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ed7d2dbf-7ea9-44e1-8ecf-a3fb52b5f244" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_2c4526d8-9a12-4a18-9dc7-dc787a65afa8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_14008114-a17b-4621-a34e-32787a427ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_300ad820-e449-4a38-b3a2-00f9fdeb581f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_14008114-a17b-4621-a34e-32787a427ec9" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_300ad820-e449-4a38-b3a2-00f9fdeb581f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_95542a66-ba17-4090-a50f-a3f9e0eadd51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_14008114-a17b-4621-a34e-32787a427ec9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_95542a66-ba17-4090-a50f-a3f9e0eadd51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fba048fe-c065-4a36-80ca-ccbdb45b1c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_bd453b49-73ec-4023-b124-19b2e85251a7" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fba048fe-c065-4a36-80ca-ccbdb45b1c73" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_bd453b49-73ec-4023-b124-19b2e85251a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_fc2ac811-4808-424d-8928-2507d3145bba" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fba048fe-c065-4a36-80ca-ccbdb45b1c73" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_fc2ac811-4808-424d-8928-2507d3145bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_67206986-08a1-4fdd-a5a2-2be4ffe5d259" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fba048fe-c065-4a36-80ca-ccbdb45b1c73" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_67206986-08a1-4fdd-a5a2-2be4ffe5d259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_3d5167df-2426-4817-aeb3-4b38064b7f0e" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fba048fe-c065-4a36-80ca-ccbdb45b1c73" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_3d5167df-2426-4817-aeb3-4b38064b7f0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossIncomePerShareDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#NetLossIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/NetLossIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_4e9112b1-b18e-49ba-9111-7b13b7fbb41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_507ee374-91ec-4dcd-b77d-0b08de7c2c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_4e9112b1-b18e-49ba-9111-7b13b7fbb41f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_507ee374-91ec-4dcd-b77d-0b08de7c2c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_259dec7f-c40b-4c09-bdce-02572748fd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_4e9112b1-b18e-49ba-9111-7b13b7fbb41f" xlink:to="loc_us-gaap_NetIncomeLoss_259dec7f-c40b-4c09-bdce-02572748fd80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a76494ba-8208-416f-84e4-e06665546754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db47d03d-6dda-474f-be40-c529f8d376c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a76494ba-8208-416f-84e4-e06665546754" xlink:to="loc_us-gaap_NetIncomeLoss_db47d03d-6dda-474f-be40-c529f8d376c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_5be2e5f0-857a-4f56-b09a-47a4ab5bd2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a76494ba-8208-416f-84e4-e06665546754" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_5be2e5f0-857a-4f56-b09a-47a4ab5bd2c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74877eeb-b564-45fd-b13a-06462056e4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ee237340-96b0-48c8-85e6-218e83845d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74877eeb-b564-45fd-b13a-06462056e4ce" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ee237340-96b0-48c8-85e6-218e83845d4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d89e8f1-8893-4b73-8031-b615c1472a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74877eeb-b564-45fd-b13a-06462056e4ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d89e8f1-8893-4b73-8031-b615c1472a13" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_003a8bb7-c5cd-4a40-a77b-c4a947689187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_36263807-2f51-45fe-b2a4-c26db94fd598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_003a8bb7-c5cd-4a40-a77b-c4a947689187" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_36263807-2f51-45fe-b2a4-c26db94fd598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_f635d1ef-0355-43a9-b5c9-62d8725e954c" xlink:href="tars-20220331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_003a8bb7-c5cd-4a40-a77b-c4a947689187" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_f635d1ef-0355-43a9-b5c9-62d8725e954c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_479fff60-5b5b-4974-b0f4-c8efdc2d079e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_58d096db-6e16-4210-941d-a2bf46b5d63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_479fff60-5b5b-4974-b0f4-c8efdc2d079e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_58d096db-6e16-4210-941d-a2bf46b5d63d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_31a6e966-8a60-4859-a423-81e4724e0357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_479fff60-5b5b-4974-b0f4-c8efdc2d079e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_31a6e966-8a60-4859-a423-81e4724e0357" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8c52738a-721f-4fe1-a079-a87a4ba35696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_1b446b40-1eee-4eb7-8668-023852c00de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_8c52738a-721f-4fe1-a079-a87a4ba35696" xlink:to="loc_us-gaap_ShortTermLeaseCost_1b446b40-1eee-4eb7-8668-023852c00de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b6776c4b-b2f9-4185-8bc3-ecb0f9a604f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_8c52738a-721f-4fe1-a079-a87a4ba35696" xlink:to="loc_us-gaap_VariableLeaseCost_b6776c4b-b2f9-4185-8bc3-ecb0f9a604f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a0eb7db1-da0b-4d0b-a456-d06050604d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_8c52738a-721f-4fe1-a079-a87a4ba35696" xlink:to="loc_us-gaap_OperatingLeaseCost_a0eb7db1-da0b-4d0b-a456-d06050604d95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_885a365d-5cc0-4d75-a709-842df9d7a2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cb0c9812-262d-416f-86eb-9cfac7826643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_885a365d-5cc0-4d75-a709-842df9d7a2f5" xlink:to="loc_us-gaap_OperatingLeaseLiability_cb0c9812-262d-416f-86eb-9cfac7826643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_56d2ea1f-2bec-4b02-8dc2-1e52c93ae65d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_885a365d-5cc0-4d75-a709-842df9d7a2f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_56d2ea1f-2bec-4b02-8dc2-1e52c93ae65d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00b85588-5ff3-4b0d-a19d-025c44614ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ad9b6c88-b192-4c11-a91e-36cef1a3069a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00b85588-5ff3-4b0d-a19d-025c44614ab0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ad9b6c88-b192-4c11-a91e-36cef1a3069a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a11c44c7-dfdd-4b03-a402-b54733c92f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00b85588-5ff3-4b0d-a19d-025c44614ab0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a11c44c7-dfdd-4b03-a402-b54733c92f7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fa70d8de-8344-4fd5-9863-53d94620331a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00b85588-5ff3-4b0d-a19d-025c44614ab0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fa70d8de-8344-4fd5-9863-53d94620331a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52358130-4240-4bbe-99bb-5b9ddb6e5d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00b85588-5ff3-4b0d-a19d-025c44614ab0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52358130-4240-4bbe-99bb-5b9ddb6e5d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_46dbf6db-9601-43b2-b2c3-02a0de5da32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00b85588-5ff3-4b0d-a19d-025c44614ab0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_46dbf6db-9601-43b2-b2c3-02a0de5da32d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CreditFacilityAgreementSummaryofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9a484bf4-07ff-45b4-a411-0c8a0a948f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_e2efd907-f637-407e-b4aa-a72978d8c575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_9a484bf4-07ff-45b4-a411-0c8a0a948f0f" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_e2efd907-f637-407e-b4aa-a72978d8c575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7bb235f6-0d73-41db-86b9-382dc029b202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_9a484bf4-07ff-45b4-a411-0c8a0a948f0f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7bb235f6-0d73-41db-86b9-382dc029b202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_65d24e69-62fd-4dd1-888c-3cfec945741e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_9a484bf4-07ff-45b4-a411-0c8a0a948f0f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_65d24e69-62fd-4dd1-888c-3cfec945741e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"/>
  <link:calculationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_266ba85e-3eee-4985-ab1d-34d66a591dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_2c14ddf1-f68c-4547-93f9-b05d9d002c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_266ba85e-3eee-4985-ab1d-34d66a591dd3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_2c14ddf1-f68c-4547-93f9-b05d9d002c23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_bae7c21c-cc4e-487e-89a5-a549291a515c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_266ba85e-3eee-4985-ab1d-34d66a591dd3" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_bae7c21c-cc4e-487e-89a5-a549291a515c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_668919d1-2ff5-4ef1-aed0-335403719ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_266ba85e-3eee-4985-ab1d-34d66a591dd3" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_668919d1-2ff5-4ef1-aed0-335403719ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e7684e91-6dd2-468a-b802-063c7b66b040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_266ba85e-3eee-4985-ab1d-34d66a591dd3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e7684e91-6dd2-468a-b802-063c7b66b040" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>tars-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:da1c4284-d55c-45f0-a6eb-8007076173b6,g:baa10d6b-a9ec-46bb-8e50-7a6ef1f55cb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended" id="i12f4382bf48545d6a461e8f0e2fe226a_CondensedStatementsofOperationsandComprehensiveLossIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e16baa11-9f45-4067-896f-0b07e4ca66f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_RevenuesAbstract_e16baa11-9f45-4067-896f-0b07e4ca66f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cd3d1e76-7d89-4a65-b485-40941d540dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e16baa11-9f45-4067-896f-0b07e4ca66f2" xlink:to="loc_us-gaap_Revenues_cd3d1e76-7d89-4a65-b485-40941d540dba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4ae8a24d-1a49-4acc-a634-cdbdb5b64378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:to="loc_us-gaap_CostOfRevenue_4ae8a24d-1a49-4acc-a634-cdbdb5b64378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b331d7fa-928a-441b-b442-8dcdcdd39c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b331d7fa-928a-441b-b442-8dcdcdd39c3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_413538f1-a080-41f5-80ac-38725a71f91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_413538f1-a080-41f5-80ac-38725a71f91a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_507f262a-5b59-4416-9e9d-ba4b574f98f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:to="loc_us-gaap_OperatingExpenses_507f262a-5b59-4416-9e9d-ba4b574f98f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_110f00dc-8536-4549-8940-42adce4435ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_OperatingIncomeLoss_110f00dc-8536-4549-8940-42adce4435ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d28d73de-0d2d-4aa8-97cb-6788ae105f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d28d73de-0d2d-4aa8-97cb-6788ae105f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1ed3c5f5-358b-452e-a828-96df923c10a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1ed3c5f5-358b-452e-a828-96df923c10a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_13073547-0cb3-4f6e-8ca1-6470e866dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_13073547-0cb3-4f6e-8ca1-6470e866dc67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_7d36b72c-87e6-4048-8cb9-30a0929a0dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_7d36b72c-87e6-4048-8cb9-30a0929a0dee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6231e05c-2f11-48fe-8668-3260fd7cfe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6231e05c-2f11-48fe-8668-3260fd7cfe8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bc27bca4-8d8f-4dad-bf4d-d4f2327694c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bc27bca4-8d8f-4dad-bf4d-d4f2327694c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce71e38d-085e-48d2-8ef6-46e3489dbb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_NetIncomeLoss_ce71e38d-085e-48d2-8ef6-46e3489dbb11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2aa65dd8-03f6-43eb-b913-eb74e7ce0a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2aa65dd8-03f6-43eb-b913-eb74e7ce0a58" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1bb36858-1bd8-4aaa-91fb-460fb8d47d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1bb36858-1bd8-4aaa-91fb-460fb8d47d89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_90514d80-ceff-4899-a123-9324f9a1e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bb36858-1bd8-4aaa-91fb-460fb8d47d89" xlink:to="loc_us-gaap_EarningsPerShareBasic_90514d80-ceff-4899-a123-9324f9a1e84c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_82ef23bb-9315-497c-bf29-d9f25f823e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bb36858-1bd8-4aaa-91fb-460fb8d47d89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_82ef23bb-9315-497c-bf29-d9f25f823e2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_250910f3-e2a2-4c99-a4f5-522c2e476054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_250910f3-e2a2-4c99-a4f5-522c2e476054" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ce5ddf-ff1b-46a6-b2ea-0c00b61715eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_250910f3-e2a2-4c99-a4f5-522c2e476054" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ce5ddf-ff1b-46a6-b2ea-0c00b61715eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa70bd90-6a01-4425-9a37-56adc8420e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_250910f3-e2a2-4c99-a4f5-522c2e476054" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa70bd90-6a01-4425-9a37-56adc8420e98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6aa0b979-f3e7-4639-a4b8-72455272a214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_StatementTable_6aa0b979-f3e7-4639-a4b8-72455272a214" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_601db6af-a135-4bdb-893a-56ebaa8ba4db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6aa0b979-f3e7-4639-a4b8-72455272a214" xlink:to="loc_srt_ProductOrServiceAxis_601db6af-a135-4bdb-893a-56ebaa8ba4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_601db6af-a135-4bdb-893a-56ebaa8ba4db_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_601db6af-a135-4bdb-893a-56ebaa8ba4db" xlink:to="loc_srt_ProductsAndServicesDomain_601db6af-a135-4bdb-893a-56ebaa8ba4db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55d224d8-6e12-4a44-bd11-22e08324bca8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_601db6af-a135-4bdb-893a-56ebaa8ba4db" xlink:to="loc_srt_ProductsAndServicesDomain_55d224d8-6e12-4a44-bd11-22e08324bca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember_d868233d-7b0d-4760-9a97-ce73f1dfb727" xlink:href="tars-20220331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_55d224d8-6e12-4a44-bd11-22e08324bca8" xlink:to="loc_tars_LicenseAndCollaborationMember_d868233d-7b0d-4760-9a97-ce73f1dfb727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c382458b-7f15-4d83-9726-2c64d4e95d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tars_LicenseAndCollaborationMember_d868233d-7b0d-4760-9a97-ce73f1dfb727" xlink:to="loc_us-gaap_LicenseAndServiceMember_c382458b-7f15-4d83-9726-2c64d4e95d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember_27c03348-f9c7-4031-b082-f7caef7fa420" xlink:href="tars-20220331.xsd#tars_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tars_LicenseAndCollaborationMember_d868233d-7b0d-4760-9a97-ce73f1dfb727" xlink:to="loc_tars_CollaborationMember_27c03348-f9c7-4031-b082-f7caef7fa420" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedStatementsofPreferredStockandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity" xlink:type="extended" id="i10b658859f394314a759a7fce682a324_CondensedStatementsofPreferredStockandStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_07479fd2-48c8-48e8-9313-d64ad6422ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07479fd2-48c8-48e8-9313-d64ad6422ba4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6d291d70-aa93-4c35-b312-6bf127cdb702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6d291d70-aa93-4c35-b312-6bf127cdb702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c8f05e96-e3c0-4713-8c22-c87893363120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c8f05e96-e3c0-4713-8c22-c87893363120" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_15ede5db-8c4b-44b5-b364-087dee715938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_17177a68-b5e7-44e5-8e27-734f6108c324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_07479fd2-48c8-48e8-9313-d64ad6422ba4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7ee22d84-febe-47fd-8503-6f9bbf284a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7ee22d84-febe-47fd-8503-6f9bbf284a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b4616a9-ddb7-4147-a250-17fed6b7763f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockholdersEquity_3b4616a9-ddb7-4147-a250-17fed6b7763f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_abb3d16d-e59f-4e62-a1c7-457015756f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_NetIncomeLoss_abb3d16d-e59f-4e62-a1c7-457015756f19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d43b566-8095-47f4-b2ea-e69ef42f0504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d43b566-8095-47f4-b2ea-e69ef42f0504" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a79d4d4f-31d9-4f17-aed5-4fa8c182aafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a79d4d4f-31d9-4f17-aed5-4fa8c182aafd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a87e68ed-bf7b-4e1b-9328-e793d8a32448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a87e68ed-bf7b-4e1b-9328-e793d8a32448" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3fcb5655-98da-49af-8f4d-0f48b29c3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3fcb5655-98da-49af-8f4d-0f48b29c3aef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_23bf2d30-c8b3-4c9b-8008-337c96e81084" xlink:href="tars-20220331.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_23bf2d30-c8b3-4c9b-8008-337c96e81084" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_5515af79-f330-44d6-90f9-d47d936ca59e" xlink:href="tars-20220331.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_5515af79-f330-44d6-90f9-d47d936ca59e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1b8bef2b-513c-4d08-b075-c53315f2311a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1b8bef2b-513c-4d08-b075-c53315f2311a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f6602790-0973-40e0-8f19-ed6b7cc7ab05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f6602790-0973-40e0-8f19-ed6b7cc7ab05" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cf68b4ea-443a-4da8-8bbd-557c4ea5c2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76188f67-d791-4969-8b3d-3599a03d4962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_07f8c586-a210-4f79-a30b-c3eec922cea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_07479fd2-48c8-48e8-9313-d64ad6422ba4" xlink:to="loc_us-gaap_StatementTable_07f8c586-a210-4f79-a30b-c3eec922cea7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_17d908e5-e62e-438b-ba49-c2ef1287e341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_07f8c586-a210-4f79-a30b-c3eec922cea7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_17d908e5-e62e-438b-ba49-c2ef1287e341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_17d908e5-e62e-438b-ba49-c2ef1287e341_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17d908e5-e62e-438b-ba49-c2ef1287e341" xlink:to="loc_us-gaap_EquityComponentDomain_17d908e5-e62e-438b-ba49-c2ef1287e341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17d908e5-e62e-438b-ba49-c2ef1287e341" xlink:to="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d7ed1f82-739d-47b0-b57e-88881f1eb46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:to="loc_us-gaap_CommonStockMember_d7ed1f82-739d-47b0-b57e-88881f1eb46a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b442e7e7-776a-455e-a3dd-97dcb133ec80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b442e7e7-776a-455e-a3dd-97dcb133ec80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a6e2e043-5771-45a5-af4c-adaeb0e43d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:to="loc_us-gaap_RetainedEarningsMember_a6e2e043-5771-45a5-af4c-adaeb0e43d81" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#DescriptionofBusinessandPresentationofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="extended" id="if4fe84099b304e588acd6c66393377bd_DescriptionofBusinessandPresentationofFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b2bb8d07-8f24-411f-ba97-1bd4219c1c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b2bb8d07-8f24-411f-ba97-1bd4219c1c82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements_3a1bdadc-77b2-4a7c-8730-25c8b84599ad" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:to="loc_tars_LineOfCreditFacilityDrawDownIncrements_3a1bdadc-77b2-4a7c-8730-25c8b84599ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_e9312601-1254-47f3-a182-bfdabd2b4cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_e9312601-1254-47f3-a182-bfdabd2b4cb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cf4c93e5-1bb5-40e6-bc25-80ae0dab5629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:to="loc_us-gaap_DebtInstrumentTable_cf4c93e5-1bb5-40e6-bc25-80ae0dab5629" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3703d646-5c41-4106-b813-0b2ae6fddf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cf4c93e5-1bb5-40e6-bc25-80ae0dab5629" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3703d646-5c41-4106-b813-0b2ae6fddf7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3703d646-5c41-4106-b813-0b2ae6fddf7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3703d646-5c41-4106-b813-0b2ae6fddf7a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3703d646-5c41-4106-b813-0b2ae6fddf7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fdead0c2-6d74-473e-b152-1f2a76601b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3703d646-5c41-4106-b813-0b2ae6fddf7a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fdead0c2-6d74-473e-b152-1f2a76601b7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_668ae7c8-b489-4edc-a022-9219fa348390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fdead0c2-6d74-473e-b152-1f2a76601b7a" xlink:to="loc_us-gaap_LineOfCreditMember_668ae7c8-b489-4edc-a022-9219fa348390" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended" id="i6fe35b2781d047018f6fe00eeaa40279_BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cd468b9f-7843-4e88-ab98-320f1fd96556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cd468b9f-7843-4e88-ab98-320f1fd96556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e9c82274-20f6-4a61-8ed6-e9e0abe84cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e9c82274-20f6-4a61-8ed6-e9e0abe84cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_529b28e9-1d8a-4fc0-9ed0-967ed900d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_529b28e9-1d8a-4fc0-9ed0-967ed900d48a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_14dacb47-7a8e-4fa0-80b2-ad489a7957d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_Depreciation_14dacb47-7a8e-4fa0-80b2-ad489a7957d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_be6f005c-418f-470f-85a7-3e932b469df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_be6f005c-418f-470f-85a7-3e932b469df8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc089b56-447c-49b1-8f2f-59bcba287ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_be6f005c-418f-470f-85a7-3e932b469df8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc089b56-447c-49b1-8f2f-59bcba287ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc089b56-447c-49b1-8f2f-59bcba287ca2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc089b56-447c-49b1-8f2f-59bcba287ca2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc089b56-447c-49b1-8f2f-59bcba287ca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc089b56-447c-49b1-8f2f-59bcba287ca2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ee9ec0ec-dd5a-4df3-bbc1-da03a83145dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ee9ec0ec-dd5a-4df3-bbc1-da03a83145dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_31881701-3663-419b-9ade-a89ab1df0c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:to="loc_us-gaap_OfficeEquipmentMember_31881701-3663-419b-9ade-a89ab1df0c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_e5c06228-72b2-43be-9642-00a74c40c84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_e5c06228-72b2-43be-9642-00a74c40c84a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6ccaf019-2c9f-4585-be87-fc3b21440643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6ccaf019-2c9f-4585-be87-fc3b21440643" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails" xlink:type="extended" id="iccf4204e835d4beab165929867a1195b_StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b8e0752e-5596-4414-83d4-f4b855c4502d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b8e0752e-5596-4414-83d4-f4b855c4502d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b6b48f93-c195-44c9-a20a-51696c397e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_CommonStockSharesIssued_b6b48f93-c195-44c9-a20a-51696c397e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a0dd3fa2-0621-4d42-b914-8f2b5edb6572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a0dd3fa2-0621-4d42-b914-8f2b5edb6572" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_5b9eb94b-cc71-498f-8962-568cc932aca6" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_5b9eb94b-cc71-498f-8962-568cc932aca6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_23e07244-09eb-4b81-93df-5d0830f49c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_23e07244-09eb-4b81-93df-5d0830f49c96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_28c698d7-0f58-4e35-865c-479ec8f96fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_28c698d7-0f58-4e35-865c-479ec8f96fe1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_37c0546c-0b4b-41d8-8dea-caffc8b9ba18" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_37c0546c-0b4b-41d8-8dea-caffc8b9ba18" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_18667367-a4fc-4c34-9e44-8f98734937f2" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_18667367-a4fc-4c34-9e44-8f98734937f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_9bb87452-b7ae-4f7a-9ae7-e07ec452053e" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_9bb87452-b7ae-4f7a-9ae7-e07ec452053e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_9c693608-fec5-416d-9012-269d7b3873e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_9c693608-fec5-416d-9012-269d7b3873e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_8c5f4eb3-11b8-4cdd-8a49-a45c18d110ce" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_8c5f4eb3-11b8-4cdd-8a49-a45c18d110ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_f04ed841-a4a1-477b-b9b4-b80c12803078" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease_e93e1f68-cbdf-42e3-a83c-60fb59b383f6" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease_e93e1f68-cbdf-42e3-a83c-60fb59b383f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8da3cb33-f59d-4357-b8a7-35186ecf307d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8da3cb33-f59d-4357-b8a7-35186ecf307d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e0ac6203-9743-46ec-ba08-11f0d4a192bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:to="loc_us-gaap_PlanNameAxis_e0ac6203-9743-46ec-ba08-11f0d4a192bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e0ac6203-9743-46ec-ba08-11f0d4a192bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e0ac6203-9743-46ec-ba08-11f0d4a192bc" xlink:to="loc_us-gaap_PlanNameDomain_e0ac6203-9743-46ec-ba08-11f0d4a192bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f7fc15fd-6398-4775-ab13-5e301663cba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e0ac6203-9743-46ec-ba08-11f0d4a192bc" xlink:to="loc_us-gaap_PlanNameDomain_f7fc15fd-6398-4775-ab13-5e301663cba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2020Member_c5376a28-e82f-4083-b1f2-fc03b84b8415" xlink:href="tars-20220331.xsd#tars_EquityIncentivePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f7fc15fd-6398-4775-ab13-5e301663cba4" xlink:to="loc_tars_EquityIncentivePlan2020Member_c5376a28-e82f-4083-b1f2-fc03b84b8415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member_e7d1c02c-6b0e-4fbe-94a5-1649e9fb5fcc" xlink:href="tars-20220331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f7fc15fd-6398-4775-ab13-5e301663cba4" xlink:to="loc_tars_EquityIncentivePlan2016Member_e7d1c02c-6b0e-4fbe-94a5-1649e9fb5fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:to="loc_srt_RangeAxis_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f" xlink:to="loc_srt_RangeMember_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ccee613-bbbe-43a4-874f-b79c9c4a4f96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f" xlink:to="loc_srt_RangeMember_3ccee613-bbbe-43a4-874f-b79c9c4a4f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9a072b0c-9007-4b08-88de-cfccd1ad9e06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ccee613-bbbe-43a4-874f-b79c9c4a4f96" xlink:to="loc_srt_MinimumMember_9a072b0c-9007-4b08-88de-cfccd1ad9e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45a6b20b-ebff-4d1c-8c6a-d27fe5be62d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ccee613-bbbe-43a4-874f-b79c9c4a4f96" xlink:to="loc_srt_MaximumMember_45a6b20b-ebff-4d1c-8c6a-d27fe5be62d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_29374d35-8d6f-4a0c-bef6-936595c432c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:to="loc_us-gaap_AwardTypeAxis_29374d35-8d6f-4a0c-bef6-936595c432c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29374d35-8d6f-4a0c-bef6-936595c432c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_29374d35-8d6f-4a0c-bef6-936595c432c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29374d35-8d6f-4a0c-bef6-936595c432c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3516495d-9ac8-44fc-878d-23d42ca97198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_29374d35-8d6f-4a0c-bef6-936595c432c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3516495d-9ac8-44fc-878d-23d42ca97198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fba83040-b6b6-4e19-a8f5-97561e352c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3516495d-9ac8-44fc-878d-23d42ca97198" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fba83040-b6b6-4e19-a8f5-97561e352c51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fae46070-7335-4524-b7a4-da6fffe4dbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3516495d-9ac8-44fc-878d-23d42ca97198" xlink:to="loc_us-gaap_EmployeeStockMember_fae46070-7335-4524-b7a4-da6fffe4dbcf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended" id="i56f5d80bd91c4cb5a0534a59550291d0_StockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b13f8c00-88f2-4221-8dfc-80002929e362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a92237ab-9e2c-4a4c-895b-7c6d7fd70a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b13f8c00-88f2-4221-8dfc-80002929e362" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a92237ab-9e2c-4a4c-895b-7c6d7fd70a13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_540192e4-3158-45b4-9e36-3835032aa291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b13f8c00-88f2-4221-8dfc-80002929e362" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_540192e4-3158-45b4-9e36-3835032aa291" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_540192e4-3158-45b4-9e36-3835032aa291" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_02f017fc-1ecd-4c75-8641-d29564b28fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_02f017fc-1ecd-4c75-8641-d29564b28fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6130ca78-148a-41bd-9441-a5cf50f52ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_02f017fc-1ecd-4c75-8641-d29564b28fb2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6130ca78-148a-41bd-9441-a5cf50f52ebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6c7a6a04-f190-43cf-8374-5891fc1828ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_02f017fc-1ecd-4c75-8641-d29564b28fb2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6c7a6a04-f190-43cf-8374-5891fc1828ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#NetLossIncomePerShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i2b36600a70f3477496faa5ac7e8b1985_NetLossIncomePerShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_90aa5f18-94a9-400a-8dfe-5a276eb92471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b641774a-2cb8-4732-9179-283e27c3f489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_90aa5f18-94a9-400a-8dfe-5a276eb92471" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b641774a-2cb8-4732-9179-283e27c3f489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc0275b6-6093-4bbb-bdb8-d0558757fbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_90aa5f18-94a9-400a-8dfe-5a276eb92471" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc0275b6-6093-4bbb-bdb8-d0558757fbae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95b282f2-cd7d-4b1b-981e-f823190122e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc0275b6-6093-4bbb-bdb8-d0558757fbae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95b282f2-cd7d-4b1b-981e-f823190122e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95b282f2-cd7d-4b1b-981e-f823190122e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95b282f2-cd7d-4b1b-981e-f823190122e6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95b282f2-cd7d-4b1b-981e-f823190122e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95b282f2-cd7d-4b1b-981e-f823190122e6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6c00ab06-11ea-4ece-b92e-e8a188fc84a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6c00ab06-11ea-4ece-b92e-e8a188fc84a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_50d38d33-9c0e-4cba-a0dd-a9aa6f8b2260" xlink:href="tars-20220331.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:to="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_50d38d33-9c0e-4cba-a0dd-a9aa6f8b2260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_82b5c3e3-a4d6-4eca-83f2-9c7dda8d5c7a" xlink:href="tars-20220331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:to="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_82b5c3e3-a4d6-4eca-83f2-9c7dda8d5c7a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended" id="i3b40fc69431746d4b80b101e7e0a1f91_FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7881bf4d-a58a-488c-93a5-31bbb6b7dce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7881bf4d-a58a-488c-93a5-31bbb6b7dce7" xlink:to="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_978064eb-366a-40a4-90b1-506914dd705b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_978064eb-366a-40a4-90b1-506914dd705b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e8e7affc-9733-455a-a66a-4fa6df8fb35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e8e7affc-9733-455a-a66a-4fa6df8fb35a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_645fc4f2-c337-424d-8d47-35dfd6ec6a1a" xlink:href="tars-20220331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_645fc4f2-c337-424d-8d47-35dfd6ec6a1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_67efb69f-92f2-461f-a210-ee355e84af54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_67efb69f-92f2-461f-a210-ee355e84af54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7881bf4d-a58a-488c-93a5-31bbb6b7dce7" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4220bb-c7b1-4a50-9b03-a5827396263a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4220bb-c7b1-4a50-9b03-a5827396263a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d4220bb-c7b1-4a50-9b03-a5827396263a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4220bb-c7b1-4a50-9b03-a5827396263a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d4220bb-c7b1-4a50-9b03-a5827396263a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4220bb-c7b1-4a50-9b03-a5827396263a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_de8bf903-ddfa-4efa-afb3-fb2c636117f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_de8bf903-ddfa-4efa-afb3-fb2c636117f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_31318fc1-9717-4967-92c6-50a67ed3260f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_31318fc1-9717-4967-92c6-50a67ed3260f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fe99ebed-cf55-4f2f-ab51-4bd4f42af708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fe99ebed-cf55-4f2f-ab51-4bd4f42af708" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_faedd38e-887a-41f8-a7ea-8443345dbe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_faedd38e-887a-41f8-a7ea-8443345dbe25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_faedd38e-887a-41f8-a7ea-8443345dbe25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_faedd38e-887a-41f8-a7ea-8443345dbe25" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_faedd38e-887a-41f8-a7ea-8443345dbe25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a39ee6b-b9ba-4a0e-bc96-b3c1972ceca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_faedd38e-887a-41f8-a7ea-8443345dbe25" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a39ee6b-b9ba-4a0e-bc96-b3c1972ceca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5085c35b-bb36-454b-bb0f-d1056482f9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a39ee6b-b9ba-4a0e-bc96-b3c1972ceca3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5085c35b-bb36-454b-bb0f-d1056482f9fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" xlink:type="extended" id="ic8043ccd08ae4a5699b7eeda5ddfd7e2_FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5c5ebd50-6567-4c2c-8320-9bb0c43cc5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5c5ebd50-6567-4c2c-8320-9bb0c43cc5cc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f877647c-ddce-4aa7-af25-373575d04c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f877647c-ddce-4aa7-af25-373575d04c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_5dbc2feb-2e3b-407e-a5a8-ec58fbcadf57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_5dbc2feb-2e3b-407e-a5a8-ec58fbcadf57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_42ea5e3e-eb89-4da1-927e-5789088fa2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_04a5646f-70b4-4133-adb4-1b7d1176e71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5c5ebd50-6567-4c2c-8320-9bb0c43cc5cc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_04a5646f-70b4-4133-adb4-1b7d1176e71d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_09e6f2e8-8114-4678-af3b-0b6f90e03846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_04a5646f-70b4-4133-adb4-1b7d1176e71d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_09e6f2e8-8114-4678-af3b-0b6f90e03846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_09e6f2e8-8114-4678-af3b-0b6f90e03846_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09e6f2e8-8114-4678-af3b-0b6f90e03846" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_09e6f2e8-8114-4678-af3b-0b6f90e03846_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ea34b2e3-575f-4dbf-8725-7ed1f20a6c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09e6f2e8-8114-4678-af3b-0b6f90e03846" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ea34b2e3-575f-4dbf-8725-7ed1f20a6c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_1236b6d1-cb16-4344-b084-95d141fb0d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea34b2e3-575f-4dbf-8725-7ed1f20a6c6a" xlink:to="loc_us-gaap_SalesMember_1236b6d1-cb16-4344-b084-95d141fb0d79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_3943da09-af98-4ae8-ae0e-8468db27559b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea34b2e3-575f-4dbf-8725-7ed1f20a6c6a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_3943da09-af98-4ae8-ae0e-8468db27559b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesFacilityLeasesDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="extended" id="ie3b18448ac304761b7c3816e4f18460f_CommitmentContingenciesFacilityLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_ea926c95-9155-443f-9acd-24c964411304" xlink:href="tars-20220331.xsd#tars_LesseeOperatingLeaseNumberOfLeaseContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_ea926c95-9155-443f-9acd-24c964411304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_988e6d16-5e23-4305-9dc8-5ce094737512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_988e6d16-5e23-4305-9dc8-5ce094737512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d3a3770a-efe1-4e37-a89a-86963d6ea00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d3a3770a-efe1-4e37-a89a-86963d6ea00e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_95b2ca6f-e1ee-404f-9997-dded16ef5c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_95b2ca6f-e1ee-404f-9997-dded16ef5c29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7c2bdb50-acda-4467-9a0c-7c027f22481b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7c2bdb50-acda-4467-9a0c-7c027f22481b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6713c5c8-e11a-4c8f-aede-2e2cb41bdb78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6713c5c8-e11a-4c8f-aede-2e2cb41bdb78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_613838ef-82fb-4053-8b94-ea1553ceceeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6713c5c8-e11a-4c8f-aede-2e2cb41bdb78" xlink:to="loc_us-gaap_LeaseContractualTermAxis_613838ef-82fb-4053-8b94-ea1553ceceeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_613838ef-82fb-4053-8b94-ea1553ceceeb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_613838ef-82fb-4053-8b94-ea1553ceceeb" xlink:to="loc_us-gaap_LeaseContractualTermDomain_613838ef-82fb-4053-8b94-ea1553ceceeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_10a44896-7a81-42a7-84c8-6fff2cdabb37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_613838ef-82fb-4053-8b94-ea1553ceceeb" xlink:to="loc_us-gaap_LeaseContractualTermDomain_10a44896-7a81-42a7-84c8-6fff2cdabb37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesLeaseMember_e64bd277-a5ee-48d5-b52b-c7a1238dc94e" xlink:href="tars-20220331.xsd#tars_IrvineOfficeAndFacilitiesLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_10a44896-7a81-42a7-84c8-6fff2cdabb37" xlink:to="loc_tars_IrvineOfficeAndFacilitiesLeaseMember_e64bd277-a5ee-48d5-b52b-c7a1238dc94e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember_f10a15fd-3bfb-4e2d-9631-0ecb1ee79d6a" xlink:href="tars-20220331.xsd#tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_10a44896-7a81-42a7-84c8-6fff2cdabb37" xlink:to="loc_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember_f10a15fd-3bfb-4e2d-9631-0ecb1ee79d6a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesInLicenseAgreementforLotilanerDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="extended" id="i582bd7a5ef164a168b2260b01ba847b2_CommitmentContingenciesInLicenseAgreementforLotilanerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9611cf9f-3c7f-4389-a40e-024dcb9b77af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9611cf9f-3c7f-4389-a40e-024dcb9b77af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_4caab028-406e-48e1-8dc6-0fcb714ff262" xlink:href="tars-20220331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_4caab028-406e-48e1-8dc6-0fcb714ff262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_c8236e75-6315-470f-bfc8-54656e5b3aaf" xlink:href="tars-20220331.xsd#tars_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_UpfrontPayment_c8236e75-6315-470f-bfc8-54656e5b3aaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_61339dbf-b1df-4c61-b9ff-ea9fe803fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_61339dbf-b1df-4c61-b9ff-ea9fe803fba6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_fee75fcd-dc4f-448c-ae9c-17faf6058957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_fee75fcd-dc4f-448c-ae9c-17faf6058957" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_af0f83bc-9003-48be-8cc8-343466d31fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_SharePrice_af0f83bc-9003-48be-8cc8-343466d31fa9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_31f686cc-64c8-4236-b404-da4acebb2551" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_31f686cc-64c8-4236-b404-da4acebb2551" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_d7eed1d1-60ec-4bc8-8cca-dd39e2a62b3f" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_d7eed1d1-60ec-4bc8-8cca-dd39e2a62b3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_89b0da3c-9c24-4824-9efc-91a1d347a237" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_89b0da3c-9c24-4824-9efc-91a1d347a237" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6095f5ad-0fa1-4132-bbef-b28c796ac6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6095f5ad-0fa1-4132-bbef-b28c796ac6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fbe976e2-3a04-4903-9e89-0ad646e1a327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6095f5ad-0fa1-4132-bbef-b28c796ac6cb" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fbe976e2-3a04-4903-9e89-0ad646e1a327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c6e519d5-bf76-457b-92ea-2354ee6f4277" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:to="loc_srt_ProductOrServiceAxis_c6e519d5-bf76-457b-92ea-2354ee6f4277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c6e519d5-bf76-457b-92ea-2354ee6f4277_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c6e519d5-bf76-457b-92ea-2354ee6f4277" xlink:to="loc_srt_ProductsAndServicesDomain_c6e519d5-bf76-457b-92ea-2354ee6f4277_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f55c9130-3385-4658-ab4a-0495674b65e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c6e519d5-bf76-457b-92ea-2354ee6f4277" xlink:to="loc_srt_ProductsAndServicesDomain_f55c9130-3385-4658-ab4a-0495674b65e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember_d3aecad1-c644-4de7-89c9-d6f8b7fb7db0" xlink:href="tars-20220331.xsd#tars_ClinicalMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f55c9130-3385-4658-ab4a-0495674b65e7" xlink:to="loc_tars_ClinicalMilestonesMember_d3aecad1-c644-4de7-89c9-d6f8b7fb7db0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember_bffebaec-018f-4a5b-8133-7b0c5dc94b36" xlink:href="tars-20220331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f55c9130-3385-4658-ab4a-0495674b65e7" xlink:to="loc_tars_CommercialAndSalesMilestonesMember_bffebaec-018f-4a5b-8133-7b0c5dc94b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e20b5945-356e-4549-9aa4-f7254a98876b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:to="loc_srt_CounterpartyNameAxis_e20b5945-356e-4549-9aa4-f7254a98876b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e20b5945-356e-4549-9aa4-f7254a98876b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e20b5945-356e-4549-9aa4-f7254a98876b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e20b5945-356e-4549-9aa4-f7254a98876b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc58758e-d508-422b-a675-94a24ba41d02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e20b5945-356e-4549-9aa4-f7254a98876b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc58758e-d508-422b-a675-94a24ba41d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_5493d2b6-9f9a-4f34-81d9-f3f34e2d725a" xlink:href="tars-20220331.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc58758e-d508-422b-a675-94a24ba41d02" xlink:to="loc_tars_LianBioMember_5493d2b6-9f9a-4f34-81d9-f3f34e2d725a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_bf9936f8-67f3-408c-8083-caf2b9a01477" xlink:href="tars-20220331.xsd#tars_ElancoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc58758e-d508-422b-a675-94a24ba41d02" xlink:to="loc_tars_ElancoMember_bf9936f8-67f3-408c-8083-caf2b9a01477" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#OutLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="extended" id="if4d99fd9b6b04ee987b4fe51e33e03c8_OutLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_3318f2eb-6e11-4f5b-b33d-77023429573f" xlink:href="tars-20220331.xsd#tars_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_tars_UpfrontPayment_3318f2eb-6e11-4f5b-b33d-77023429573f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMilestonePayment_4a3041a2-8402-4896-8d23-04c5b68e1e70" xlink:href="tars-20220331.xsd#tars_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_tars_CollaborativeArrangementMilestonePayment_4a3041a2-8402-4896-8d23-04c5b68e1e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_701692c5-3649-4ea3-a687-13459b4f415f" xlink:href="tars-20220331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_701692c5-3649-4ea3-a687-13459b4f415f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e302b201-1acd-4585-8040-a2c366030b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_us-gaap_Revenues_e302b201-1acd-4585-8040-a2c366030b20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d7584a77-4849-4179-9817-d593dfe8d116" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:to="loc_srt_CounterpartyNameAxis_d7584a77-4849-4179-9817-d593dfe8d116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d7584a77-4849-4179-9817-d593dfe8d116_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d7584a77-4849-4179-9817-d593dfe8d116" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d7584a77-4849-4179-9817-d593dfe8d116_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19649131-a2fd-4ac1-974e-176dac61e3af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d7584a77-4849-4179-9817-d593dfe8d116" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19649131-a2fd-4ac1-974e-176dac61e3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_ae185db2-f876-437f-83cf-c9c505a20652" xlink:href="tars-20220331.xsd#tars_LianBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19649131-a2fd-4ac1-974e-176dac61e3af" xlink:to="loc_tars_LianBioMember_ae185db2-f876-437f-83cf-c9c505a20652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5167cf95-09c6-4753-858c-4ca49fb3b060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5167cf95-09c6-4753-858c-4ca49fb3b060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5167cf95-09c6-4753-858c-4ca49fb3b060_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5167cf95-09c6-4753-858c-4ca49fb3b060" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5167cf95-09c6-4753-858c-4ca49fb3b060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39c37a0a-b3ed-4293-b977-7722bd587866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5167cf95-09c6-4753-858c-4ca49fb3b060" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39c37a0a-b3ed-4293-b977-7722bd587866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_6519d56d-2cff-4a3b-bcf3-08ee06ee998a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39c37a0a-b3ed-4293-b977-7722bd587866" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_6519d56d-2cff-4a3b-bcf3-08ee06ee998a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_158120f6-38bc-4c61-817f-bd97c406c0e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:to="loc_srt_ProductOrServiceAxis_158120f6-38bc-4c61-817f-bd97c406c0e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_158120f6-38bc-4c61-817f-bd97c406c0e2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_158120f6-38bc-4c61-817f-bd97c406c0e2" xlink:to="loc_srt_ProductsAndServicesDomain_158120f6-38bc-4c61-817f-bd97c406c0e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_158120f6-38bc-4c61-817f-bd97c406c0e2" xlink:to="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalDevelopmentMilestonesMember_84130221-9722-450a-a918-8fcdbb62d59a" xlink:href="tars-20220331.xsd#tars_ClinicalDevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_ClinicalDevelopmentMilestonesMember_84130221-9722-450a-a918-8fcdbb62d59a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember_35515d7b-6c32-4674-9274-e14e4cae808f" xlink:href="tars-20220331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_DevelopmentAndRegulatoryMilestoneMember_35515d7b-6c32-4674-9274-e14e4cae808f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DrugSupplyAgreementMilestoneMember_80d75a45-76b8-440d-87eb-f169ca9fb069" xlink:href="tars-20220331.xsd#tars_DrugSupplyAgreementMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_DrugSupplyAgreementMilestoneMember_80d75a45-76b8-440d-87eb-f169ca9fb069" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SalesMilestoneMember_cf8bfd3a-b256-4615-8698-8c98079c962f" xlink:href="tars-20220331.xsd#tars_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_SalesMilestoneMember_cf8bfd3a-b256-4615-8698-8c98079c962f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_b639da5d-35e0-4d37-b913-bb068dc3c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_us-gaap_LicenseAndServiceMember_b639da5d-35e0-4d37-b913-bb068dc3c4ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember_f6f29fda-6fb0-4522-83f5-54917211f5cd" xlink:href="tars-20220331.xsd#tars_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_CollaborationMember_f6f29fda-6fb0-4522-83f5-54917211f5cd" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CreditFacilityAgreementDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="extended" id="i044d7cec5fc24c35bccb7e90c4011f41_CreditFacilityAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_93258966-e65b-406f-b3a1-d7ac7e97e22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_93258966-e65b-406f-b3a1-d7ac7e97e22e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements_3351da4a-c5e9-4b26-9636-284838c5feac" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_tars_LineOfCreditFacilityDrawDownIncrements_3351da4a-c5e9-4b26-9636-284838c5feac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityInterestOnlyPeriod_c74eb679-659a-4b5c-a451-7167d9063014" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityInterestOnlyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_tars_LineOfCreditFacilityInterestOnlyPeriod_c74eb679-659a-4b5c-a451-7167d9063014" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityInterestOnlyPeriodExtended_28611447-8d84-4043-b1e0-603606ca3101" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityInterestOnlyPeriodExtended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_tars_LineOfCreditFacilityInterestOnlyPeriodExtended_28611447-8d84-4043-b1e0-603606ca3101" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0fcee7b-26d0-4da9-a7dc-ab226757f50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0fcee7b-26d0-4da9-a7dc-ab226757f50b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_164aaf17-fa5f-4f35-b6c5-eaa0c8a30321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_164aaf17-fa5f-4f35-b6c5-eaa0c8a30321" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c20a50ff-2c7d-47e3-951a-7fb112325070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c20a50ff-2c7d-47e3-951a-7fb112325070" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_379e0306-e7a7-4c54-a56a-fd50f7b541aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_379e0306-e7a7-4c54-a56a-fd50f7b541aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_18373fcf-cfc3-412b-854a-ecc1080cba70" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_18373fcf-cfc3-412b-854a-ecc1080cba70" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_2c047a41-8c5b-45d8-a9f6-c5993239a89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_2c047a41-8c5b-45d8-a9f6-c5993239a89d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_3a468bb6-c047-4c0b-b817-0e3887626721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_3a468bb6-c047-4c0b-b817-0e3887626721" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a3b88fbc-3057-4c63-aef5-b9ae79f24910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a3b88fbc-3057-4c63-aef5-b9ae79f24910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a3b88fbc-3057-4c63-aef5-b9ae79f24910_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3b88fbc-3057-4c63-aef5-b9ae79f24910" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a3b88fbc-3057-4c63-aef5-b9ae79f24910_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_20b53ca3-1ff1-4396-af12-bd07876e3c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3b88fbc-3057-4c63-aef5-b9ae79f24910" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_20b53ca3-1ff1-4396-af12-bd07876e3c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e8243cfa-cd1c-4892-b699-0a16914e5ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_20b53ca3-1ff1-4396-af12-bd07876e3c36" xlink:to="loc_us-gaap_LineOfCreditMember_e8243cfa-cd1c-4892-b699-0a16914e5ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_838f7182-6a69-4953-9dd2-45c7f0025bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_DebtInstrumentAxis_838f7182-6a69-4953-9dd2-45c7f0025bf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_838f7182-6a69-4953-9dd2-45c7f0025bf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_838f7182-6a69-4953-9dd2-45c7f0025bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_838f7182-6a69-4953-9dd2-45c7f0025bf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_838f7182-6a69-4953-9dd2-45c7f0025bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember_321302a9-5982-466d-9cb6-7eb458460f18" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheOneMember_321302a9-5982-466d-9cb6-7eb458460f18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember_91b26810-77a1-414a-8255-7ae382ed2c95" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheTwoMember_91b26810-77a1-414a-8255-7ae382ed2c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember_ac732d53-1863-42fd-b379-2cfb5eacb38e" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheThreeMember_ac732d53-1863-42fd-b379-2cfb5eacb38e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember_a2ac29ee-1ea7-4a3c-9c1b-22bee43c2672" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheFourMember_a2ac29ee-1ea7-4a3c-9c1b-22bee43c2672" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFiveMember_785a74cd-1304-4f28-9f5d-bb27fcc99f18" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheFiveMember_785a74cd-1304-4f28-9f5d-bb27fcc99f18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_1c3101a7-2afc-492e-a871-8a5524d89eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_VariableRateAxis_1c3101a7-2afc-492e-a871-8a5524d89eca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1c3101a7-2afc-492e-a871-8a5524d89eca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_1c3101a7-2afc-492e-a871-8a5524d89eca" xlink:to="loc_us-gaap_VariableRateDomain_1c3101a7-2afc-492e-a871-8a5524d89eca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_88bbebb2-6907-4426-b98b-fce278738ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_1c3101a7-2afc-492e-a871-8a5524d89eca" xlink:to="loc_us-gaap_VariableRateDomain_88bbebb2-6907-4426-b98b-fce278738ffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_d5645273-1ecd-4601-ae75-b8f799a454cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_88bbebb2-6907-4426-b98b-fce278738ffc" xlink:to="loc_us-gaap_PrimeRateMember_d5645273-1ecd-4601-ae75-b8f799a454cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8959a23a-ceca-4fcf-929f-027c97d10552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8959a23a-ceca-4fcf-929f-027c97d10552" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8959a23a-ceca-4fcf-929f-027c97d10552_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8959a23a-ceca-4fcf-929f-027c97d10552" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8959a23a-ceca-4fcf-929f-027c97d10552_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f20501d1-e11e-4f01-a2f0-82ba43756793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8959a23a-ceca-4fcf-929f-027c97d10552" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f20501d1-e11e-4f01-a2f0-82ba43756793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5689f46c-142b-46ac-936b-228ac4b8a795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f20501d1-e11e-4f01-a2f0-82ba43756793" xlink:to="loc_us-gaap_SubsequentEventMember_5689f46c-142b-46ac-936b-228ac4b8a795" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="extended" id="i353bb0799623424585408a24aa8bcfae_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b449bddf-c81f-412e-87a8-d2fea593ce5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b449bddf-c81f-412e-87a8-d2fea593ce5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_270e149e-8de7-41f9-82c7-dba13a01a11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_270e149e-8de7-41f9-82c7-dba13a01a11c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross_bf3daca5-54e7-4539-bbe1-dcf3a290b184" xlink:href="tars-20220331.xsd#tars_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross_bf3daca5-54e7-4539-bbe1-dcf3a290b184" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_04921257-e676-47ef-8196-10cd7df45a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_04921257-e676-47ef-8196-10cd7df45a7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_65c13ab0-559f-479c-b9cb-f203d0ac4493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_65c13ab0-559f-479c-b9cb-f203d0ac4493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5a8fb314-e8e9-4241-a780-6034a8d2cbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_65c13ab0-559f-479c-b9cb-f203d0ac4493" xlink:to="loc_us-gaap_SubsequentEventMember_5a8fb314-e8e9-4241-a780-6034a8d2cbe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f67b6ce9-af6f-41b4-8f30-26a19375de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f67b6ce9-af6f-41b4-8f30-26a19375de3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f67b6ce9-af6f-41b4-8f30-26a19375de3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f67b6ce9-af6f-41b4-8f30-26a19375de3c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f67b6ce9-af6f-41b4-8f30-26a19375de3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e416f6c-e20c-48fd-aa52-f0fbae85ef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f67b6ce9-af6f-41b4-8f30-26a19375de3c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e416f6c-e20c-48fd-aa52-f0fbae85ef9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PublicStockOfferingMember_b34a5311-0f73-41c8-a555-d7032e111f44" xlink:href="tars-20220331.xsd#tars_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e416f6c-e20c-48fd-aa52-f0fbae85ef9a" xlink:to="loc_tars_PublicStockOfferingMember_b34a5311-0f73-41c8-a555-d7032e111f44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e502ef8f-1c8c-4e64-aed2-a5e7b5fdee94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e416f6c-e20c-48fd-aa52-f0fbae85ef9a" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e502ef8f-1c8c-4e64-aed2-a5e7b5fdee94" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>tars-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:da1c4284-d55c-45f0-a6eb-8007076173b6,g:baa10d6b-a9ec-46bb-8e50-7a6ef1f55cb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_tars_PaymentsOfDeferredStockIssuanceCosts_75ba53ea-ce39-48db-961c-709cf806b10f_negatedTerseLabel_en-US" xlink:label="lab_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred offering costs</link:label>
    <link:label id="lab_tars_PaymentsOfDeferredStockIssuanceCosts_label_en-US" xlink:label="lab_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Deferred Stock Issuance Costs</link:label>
    <link:label id="lab_tars_PaymentsOfDeferredStockIssuanceCosts_documentation_en-US" xlink:label="lab_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Deferred Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:href="tars-20220331.xsd#tars_PaymentsOfDeferredStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:to="lab_tars_PaymentsOfDeferredStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_a6ef56a7-06f3-4c70-8685-0be42da6c980_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_65e9b1af-3d38-4201-956f-3be8ff18af14_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb63d571-a053-4b85-9de4-e3ada2110b34_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2a7cf58d-291f-4de1-bb6b-926c05b767d4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2c8c0a29-43f1-49c2-bca9-9e227c358281_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a409b083-6414-468e-ba9c-3cd1ae7de1a1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7fc9da13-3d55-4118-9e78-906c02959ed3_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a70c99c1-caf4-476f-9039-bbb697b338bc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f056284d-7c4d-4dec-aaff-9b945f97718d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_edad6f51-f0ce-4a2e-8b4d-7912ad923a69_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_73f8526a-03e5-4ffb-8538-bf2d83cec88a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d85189a5-f646-42f1-8f66-ac43d13fdeda_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6d60eb88-bfec-48a1-a124-1b3bb6d715a2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_7adf05b1-7bdf-42bd-9110-57af76a17b6c_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Three</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Three [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheThreeMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheThreeMember" xlink:to="lab_tars_CreditFacilityTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_56d13e3a-ad70-441a-95ef-4751becdaa82_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6feed62f-193b-4827-b794-8cde4f888e28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_e8f332d5-b7bb-42cc-b47b-219152a3ffe7_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMaximumMilestonePayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:href="tars-20220331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:to="lab_tars_CollaborativeArrangementMaximumMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_964d110c-f20b-4f45-82a3-231d9758fa57_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b50e54bd-b6c1-4f79-beb4-41c914ce99e4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5bd4cfa0-a70e-4585-9746-858d571ba403_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_67c6a457-c54a-445d-8e78-41e4044db928_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP discount percentage from market price, beginning of purchase period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_09f82314-aba6-4742-812e-63bc83466ba3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_2a0c3eee-cc83-4a8a-b2bb-49b6febbb55d_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_44b2d925-3197-4cc2-a5c6-78bf27a48618_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_94e1161f-75de-4bd3-b387-11fef7263be2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_26da5443-58a1-4d0a-98b5-3142c275e78b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e2220e4-7279-4c7f-bbd9-56fefb0d00ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a3fa2e87-2236-4344-a72c-e22ba6295dee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_029e4c84-5da1-42c4-b187-63e915eb218c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b96bba47-4b94-42aa-ba63-ddc3ea61d9e1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_40a1e255-a0ad-47b8-9971-9a15709fbe24_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_eb3f7a2a-1cf6-400e-b8bf-00531d1a33e9_terseLabel_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_label_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2016 [Member]</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2016Member_documentation_en-US" xlink:label="lab_tars_EquityIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member" xlink:href="tars-20220331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityIncentivePlan2016Member" xlink:to="lab_tars_EquityIncentivePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_44642990-e945-4715-a2c9-6cb8c872d6a5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_5b4f0969-21ad-4283-adbb-6d4ea56895c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross_fff68960-f34d-42e3-bfff-7e0e533c8312_terseLabel_en-US" xlink:label="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued, gross proceeds</link:label>
    <link:label id="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:label id="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="tars-20220331.xsd#tars_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_tars_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e25b7ff0-fb86-49b3-a51f-807a9b8fb3a1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bc51459d-41fc-4a58-a566-a27141b03396_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c52c802b-0258-4d30-80e4-58c35ac29bb3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d79b0da7-aaaf-4310-84df-441002e9f86e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ProceedsFromEarlyExerciseOfStockOptions_d276cdc0-8336-4f2a-b475-da6de72512e0_terseLabel_en-US" xlink:label="lab_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of vested stock options</link:label>
    <link:label id="lab_tars_ProceedsFromEarlyExerciseOfStockOptions_label_en-US" xlink:label="lab_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Early Exercise Of Stock Options</link:label>
    <link:label id="lab_tars_ProceedsFromEarlyExerciseOfStockOptions_documentation_en-US" xlink:label="lab_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Early Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:href="tars-20220331.xsd#tars_ProceedsFromEarlyExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:to="lab_tars_ProceedsFromEarlyExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_fe3e3b43-1fde-4e9c-9615-437e14dd6e98_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_NumberOfWarrants_af86ce63-bdae-4594-b797-34bd25662faf_terseLabel_en-US" xlink:label="lab_tars_NumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants</link:label>
    <link:label id="lab_tars_NumberOfWarrants_label_en-US" xlink:label="lab_tars_NumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants</link:label>
    <link:label id="lab_tars_NumberOfWarrants_documentation_en-US" xlink:label="lab_tars_NumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfWarrants" xlink:href="tars-20220331.xsd#tars_NumberOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_NumberOfWarrants" xlink:to="lab_tars_NumberOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_44f3e58b-c16e-4c7d-be7a-6084946b90f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of equity warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_093c73ae-64e1-4a1d-9691-7528ca444e74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d29c9d01-2907-4e81-9c95-a5b421310c8c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_805fa178-1d2c-4dd1-acd3-a64562a336bc_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_53be79d6-ca68-4f31-8dbd-d4f404e54028_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_a4e1bcc5-4147-43ae-8a89-67eb2dae965d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_21fb5f58-12fe-4b07-af60-197250b047bb_terseLabel_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_label_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:label id="lab_tars_OperatingLeaseNoncashExpense_documentation_en-US" xlink:label="lab_tars_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense" xlink:href="tars-20220331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_OperatingLeaseNoncashExpense" xlink:to="lab_tars_OperatingLeaseNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b94c8f1c-a432-4c00-a1ee-f057a8313992_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditFacilityInterestOnlyPeriod_915393ab-5057-449f-909c-2f4fdece0a27_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditFacilityInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest only period</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityInterestOnlyPeriod_label_en-US" xlink:label="lab_tars_LineOfCreditFacilityInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Interest Only Period</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityInterestOnlyPeriod_documentation_en-US" xlink:label="lab_tars_LineOfCreditFacilityInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Interest Only Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityInterestOnlyPeriod" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityInterestOnlyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditFacilityInterestOnlyPeriod" xlink:to="lab_tars_LineOfCreditFacilityInterestOnlyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease_3d828f8a-46ec-4a8b-a4a7-fea4db14070d_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares reserved for future issuance, annual shares increase (in shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Annual Shares Increase</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Annual Shares Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_de8b41a1-bbca-4120-a62a-fa356e456da5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f6c25ba7-91ef-4ce6-9e2f-8fea86bf222f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8b97fdea-ac6b-4ea4-9124-010e8efed2c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_af041606-a290-4708-99ef-0898e3eb5470_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment &amp; Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77be122b-814e-4bac-ad69-6f4da73854a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_293afb3b-4747-43d1-8ebe-33b5aa2152f7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2eeb434a-91e7-4872-b7b2-fe365382a029_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of "property and equipment, net" included within "accounts payable and other accrued liabilities"</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_289c5450-78ec-4233-9d81-9dd493859795_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_53d902ef-6c62-4980-bbc1-f11971a5517f_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_359f6e4d-b1c9-4ba1-84d7-efc08bd2f07b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock in LianBio (included in "marketable securities")</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e7cc15b4-6645-452d-823d-a5a7b60dd2ab_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_70e1daa0-c546-4855-87be-96102e81ad90_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0360d41a-2d61-43aa-90ef-3cb08d295609_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) per share, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_3e649193-a582-4e28-89c0-ff6fcd7a0d17_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4e4c3e1-b2b6-4b7c-a2ed-0008c95f987a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_832673e9-37b5-4146-8afc-507c285f5fd5_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options reserved for future grant (shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_695a5712-5bb2-4803-bb40-8e2a3979bd19_terseLabel_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_label_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Lease Contracts</link:label>
    <link:label id="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts_documentation_en-US" xlink:label="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Lease Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:href="tars-20220331.xsd#tars_LesseeOperatingLeaseNumberOfLeaseContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:to="lab_tars_LesseeOperatingLeaseNumberOfLeaseContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_cbc0aef9-d883-4de7-9065-69095e9ad140_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for early exercise of stock options</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_ee910fe8-5cb8-4980-8274-f08cfcf99116_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense related to term loan</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_ff7d2ae7-c6c9-4f6e-a70c-d55eb745a3aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on lease termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_69e087ac-0bcc-4103-a9d9-8a05e5904701_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_889bc8c7-a23e-43e1-b70c-e5077a0af45c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_067d3f4a-788a-4b33-94cd-36db378f5b00_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_NumberOfVestedWarrants_b2be5891-9db9-4b26-a995-58e2642e91ff_terseLabel_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vested warrants</link:label>
    <link:label id="lab_tars_NumberOfVestedWarrants_label_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Vested Warrants</link:label>
    <link:label id="lab_tars_NumberOfVestedWarrants_documentation_en-US" xlink:label="lab_tars_NumberOfVestedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Vested Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfVestedWarrants" xlink:href="tars-20220331.xsd#tars_NumberOfVestedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_NumberOfVestedWarrants" xlink:to="lab_tars_NumberOfVestedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_29db0616-33f5-4224-b246-f29dbfb204e8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_2ab568bb-46e9-4a59-b73e-5d3ade55b694_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of term charge, interest rate</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_label_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest Rate</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_documentation_en-US" xlink:label="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:to="lab_tars_LineOfCreditFacilityPeriodicPaymentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_aae4a3bc-f11d-4b89-80e7-5f71d2980dc3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_4c5c7033-4c53-4a2a-8fda-882be04cf5d9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, gross (amount drawn)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_d88fc86a-4e86-436a-9d79-7cde46989b00_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_029602ae-be4f-4149-945d-04e6aae0e366_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8cfaa012-dfe8-430a-98aa-a503a21550e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock option pre-vesting exercise liability, current portion</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_f105707d-5021-495e-9174-99939c5ab3ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_label_en-US" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization, Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9965342f-eeac-4903-8ff6-48f31a119618_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_11a3eab0-08fc-4346-a5ec-67d9aef527ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eca6fb67-b205-48a1-a04f-6f14c0a7d4f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_ea924b0d-c9d7-476b-b608-6e8875949ed4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss (gain) from transactions denominated in a foreign currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_59083efd-9585-4a1b-8fa0-48ba3a1fbf5b_terseLabel_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options early-exercised and unvested</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_label_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Early-Exercised Option [Member]</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_documentation_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Early-Exercised Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:href="tars-20220331.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:to="lab_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7e048bfb-851f-4ac4-bc51-f4d8892925ea_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ce725e85-eb31-4db5-aed2-b96d8e364382_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5e4c6e42-1ae9-4e0c-8cf9-9c5d289ad740_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d98b87be-297c-4fb3-ac1f-692b531155e0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_9e1600ff-ca71-4351-875f-b5f97c7e525d_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution (shares)</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_5b53d701-07d9-4aaa-9857-1bf3983a8f0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8b91eaa0-f3df-4bc9-99c9-ffe8a98d6cd6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_d5c61783-dfb3-42dc-8d02-28817cdda36f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Presentation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6117b4d7-40ac-450b-9bb7-3bf375eb43e5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_99ae0a76-30e8-4948-a6e2-226ea4f0e864_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8b0a0b4e-b8f0-4de5-b51f-7959c899295e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3eac863c-f55c-45f5-8891-976637156c91_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_90a097d7-18ef-4b7d-a044-f5e38677bf47_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of vested stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_50b81733-68b8-49b7-8aad-70f02cddde97_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_0e432be1-ef2b-4e11-9f66-12c1420b2e40_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ClinicalDevelopmentMilestonesMember_45adc2b1-aac0-4212-8185-c1e8fa01430f_terseLabel_en-US" xlink:label="lab_tars_ClinicalDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical development milestones</link:label>
    <link:label id="lab_tars_ClinicalDevelopmentMilestonesMember_label_en-US" xlink:label="lab_tars_ClinicalDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Development Milestones [Member]</link:label>
    <link:label id="lab_tars_ClinicalDevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_tars_ClinicalDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalDevelopmentMilestonesMember" xlink:href="tars-20220331.xsd#tars_ClinicalDevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ClinicalDevelopmentMilestonesMember" xlink:to="lab_tars_ClinicalDevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityIncentivePlan2020Member_e6170c99-2ac0-417a-ae30-1cc73a464265_terseLabel_en-US" xlink:label="lab_tars_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2020Member_label_en-US" xlink:label="lab_tars_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2020 [Member]</link:label>
    <link:label id="lab_tars_EquityIncentivePlan2020Member_documentation_en-US" xlink:label="lab_tars_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2020Member" xlink:href="tars-20220331.xsd#tars_EquityIncentivePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityIncentivePlan2020Member" xlink:to="lab_tars_EquityIncentivePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_62384fe2-02e5-4ff4-b59a-00232c742788_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_1a7ee4ff-30b5-4c3f-b717-ad2a96cd91af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a7c9fd70-de76-4354-8e94-8d11b8d9da6c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_79db4545-85e1-4f20-9a43-3be9b22a395c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_3e2ef49a-60f2-4c0b-a871-17b028ef3afd_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise period from termination upon death</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ce1023f4-cd56-47f0-b3d5-9e4d2566ecd6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_58c27946-fff6-435e-8ce8-686a339edaa3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaid_fe310ed8-c895-4f4a-b5a5-07293bd56da5_terseLabel_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included within "accounts payable and accrued liabilities"</link:label>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_tars_DeferredOfferingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_tars_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DeferredOfferingCostsIncurredButNotYetPaid" xlink:href="tars-20220331.xsd#tars_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DeferredOfferingCostsIncurredButNotYetPaid" xlink:to="lab_tars_DeferredOfferingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4fc13057-aea0-4a5e-8fd8-469b6907f91d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_481f1848-10a7-42c2-92c5-b5f43ef993f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockSharesSubjectToRepurchase_7867e789-a6a3-470a-aa45-9bc488c16e0f_terseLabel_en-US" xlink:label="lab_tars_CommonStockSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, subject to repurchase (shares)</link:label>
    <link:label id="lab_tars_CommonStockSharesSubjectToRepurchase_label_en-US" xlink:label="lab_tars_CommonStockSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Subject To Repurchase</link:label>
    <link:label id="lab_tars_CommonStockSharesSubjectToRepurchase_documentation_en-US" xlink:label="lab_tars_CommonStockSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Subject To Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockSharesSubjectToRepurchase" xlink:href="tars-20220331.xsd#tars_CommonStockSharesSubjectToRepurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockSharesSubjectToRepurchase" xlink:to="lab_tars_CommonStockSharesSubjectToRepurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock_ecfe38c3-912d-4fe0-bb1b-f3ce54d602fc_terseLabel_en-US" xlink:label="lab_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease asset and liability accounts</link:label>
    <link:label id="lab_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock_label_en-US" xlink:label="lab_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Asset and Liability Accounts [Table Text Block]</link:label>
    <link:label id="lab_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock_documentation_en-US" xlink:label="lab_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Asset and Liability Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" xlink:href="tars-20220331.xsd#tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" xlink:to="lab_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a7104d60-e67b-4647-ba8a-7b75f5e794c3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_615cd2e2-6714-47d5-825c-08d2494efc77_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Agreement</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_1e66edff-d029-47ea-abb0-4e7d79123a7d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6d21dd2f-b131-49e8-bfe2-18f11e95773f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_b30113b9-8e6c-4940-911e-a826a5b268df_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise period from termination upon disability</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fc2b72ba-b280-4592-92fc-d470004da65b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_8d74e74c-8c90-4d12-8aa9-6fa479920c21_terseLabel_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities (in shares)</link:label>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_label_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Number Of Shares</link:label>
    <link:label id="lab_tars_EquitySecuritiesFVNINumberOfShares_documentation_en-US" xlink:label="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquitySecuritiesFVNINumberOfShares" xlink:href="tars-20220331.xsd#tars_EquitySecuritiesFVNINumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquitySecuritiesFVNINumberOfShares" xlink:to="lab_tars_EquitySecuritiesFVNINumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_775212a3-1787-4945-918d-c850c3687086_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9a26895d-b1c6-49d7-bcfe-f0221aac9f2a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1ad4f625-7020-44cf-b117-c64a99e49ea3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f7397938-2713-4dd1-b0b2-78a9c9526e16_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_91c629a4-6267-45dc-921a-7870a8c8cc85_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e2182e8d-ab23-44f6-9b50-7d74f1807c0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized; 20,731,062 shares issued and 20,718,528 outstanding, which excludes 12,534 shares subject to repurchase at March&#160;31, 2022 (unaudited); 20,726,580 shares issued and 20,698,737 outstanding, which excludes 27,840 shares subject to repurchase at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_963103e5-ccc2-4826-9d1d-b23f7c74fefd_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d9cc5a82-7571-4225-8617-4b46241c85bc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1b63b724-94f8-4d49-a681-52e314faa2a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_8c5d89c5-696f-4e7d-ad18-91c4d406f245_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_9b17a24c-aa2c-4056-a2c0-d9449734ad07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments measured at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3eb9359f-9b7d-4830-883e-96c4e54925c2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositAssets_e42d816b-bbcf-43b7-94a1-64a22820f873_terseLabel_en-US" xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_us-gaap_DepositAssets_label_en-US" xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DrugSupplyAgreementMilestoneMember_137f7a5f-3833-41c8-a2c1-2a1fd46ab127_terseLabel_en-US" xlink:label="lab_tars_DrugSupplyAgreementMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Supply Agreement Milestone</link:label>
    <link:label id="lab_tars_DrugSupplyAgreementMilestoneMember_label_en-US" xlink:label="lab_tars_DrugSupplyAgreementMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Supply Agreement Milestone [Member]</link:label>
    <link:label id="lab_tars_DrugSupplyAgreementMilestoneMember_documentation_en-US" xlink:label="lab_tars_DrugSupplyAgreementMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Supply Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DrugSupplyAgreementMilestoneMember" xlink:href="tars-20220331.xsd#tars_DrugSupplyAgreementMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DrugSupplyAgreementMilestoneMember" xlink:to="lab_tars_DrugSupplyAgreementMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8d6a6f6e-c32f-4201-9eb2-2fce8baf16c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_fb48ab4d-d1df-41ae-baa8-34d3c9a748cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_da67ead4-5d17-4571-9f3a-771cc2f1ea35_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance, increase percentage on first business day of each of next ten fiscal years</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LianBioMember_a7e34cec-72d1-4a5b-83cb-86dadbd927ad_terseLabel_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio</link:label>
    <link:label id="lab_tars_LianBioMember_label_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio [Member]</link:label>
    <link:label id="lab_tars_LianBioMember_documentation_en-US" xlink:label="lab_tars_LianBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember" xlink:href="tars-20220331.xsd#tars_LianBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LianBioMember" xlink:to="lab_tars_LianBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7818df96-dd8d-4002-937e-f62be73534e4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_df7d12a1-511c-4a12-9a1e-d61b52cb5bb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_0caad879-4604-47b6-88c9-7355c2152bfb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_fb6b8294-a357-43e1-8ca1-614cf6c137c4_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units outstanding under 2020 Equity Incentive Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_845bd5bf-3db7-487f-92b4-b4fb0ce67c9c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_73e134ff-6a4e-4271-9330-d72cabfe406e_terseLabel_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of repurchase rights related to common stock issued pursuant to stock option exercises prior to vesting</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_label_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Lapse Of Repurchase Rights</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_documentation_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Lapse Of Repurchase Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:href="tars-20220331.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:to="lab_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6b1f268e-33aa-4566-9f2d-082157ae3d62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Less): Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99d9ba6e-bf95-4fa5-af84-ddaee784f872_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued, net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4e76c959-7a6b-49f6-8e3d-e46fced8404a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a700dd12-e31d-47a7-9864-a680ce10a818_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of equity warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_ab9b30c5-0c41-4adb-9d84-7974c02fcb6f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2df594d8-9829-4054-9fd5-c5a861da90a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_64e9919a-4686-4f0f-be40-75924b6061ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_ff18b71b-fb7e-4d2b-a7e0-6d42efa5312f_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborativeArrangementMilestonePayment_c032676f-3bd7-416d-a71a-c9e9b8396d7d_terseLabel_en-US" xlink:label="lab_tars_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment achieved</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMilestonePayment_label_en-US" xlink:label="lab_tars_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:label id="lab_tars_CollaborativeArrangementMilestonePayment_documentation_en-US" xlink:label="lab_tars_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMilestonePayment" xlink:href="tars-20220331.xsd#tars_CollaborativeArrangementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborativeArrangementMilestonePayment" xlink:to="lab_tars_CollaborativeArrangementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_07766cf6-2071-474b-bb2c-4ff5aff85381_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_87e7df95-dd68-41ea-97f1-3dbf4b6e985f_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unexercised&#8212;vested and unvested</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_21348ffc-b69e-475f-964f-f37605f2e512_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_41a1b2c3-70a8-4f10-a2e5-03bd5e00d0f9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_71e9eb1f-5517-4fe2-97d8-7e6273821968_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as consideration for in-license rights</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f4dae34c-6504-4a85-bdf8-bc0490647886_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for in-license agreements</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_206a30c9-9199-4525-99cb-b987fa041702_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_18e0a375-a675-44b1-9dc7-efde2f014e61_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1eb3e964-fc2d-488c-a5f2-e023ded332b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_eea26ea2-8b5b-4b86-ac88-543690cc5076_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3f3395e2-0e11-479e-9822-e033e2a6b7f3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from operations before other (expense) income and income taxes</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_222e4e6a-689e-4e01-a6f7-6eb8e86a839f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_03613db9-1292-4ca5-83ce-513909616ec2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_0e55b26a-a69f-48bf-bbc0-72ef828adc33_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a248f0bf-3eaf-4584-b6bd-fa74a1f84759_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a4db3fca-a0d4-43f4-b93e-8369c9ae9e65_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseMember_3f9f5bf3-9e32-42d4-a6e6-af6d6706bc34_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9e87006c-d70e-4c99-8ec9-fcc87b51cbbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_e46ca774-c40f-400b-a9bd-e061b525c2f4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4170bd4b-5394-475d-a1c9-4221d47dedcc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b51b139-477d-4935-8986-19158ed3c0e5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_21742478-6f98-4eaf-9b4f-18a1e7bcfbdb_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d1d0c04b-0ed8-4de0-a5a4-55a9b6217e61_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894f0cfd-ae0d-454f-a8ab-4e687ccb58af_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0c61144c-f8b8-4e2b-a318-f07798f5e459_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0a72a15f-e88d-46ac-96c1-6daf4adcb341_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_947406bf-e2c2-47a4-a2f5-0641ceaafc73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_519ed6a4-5555-42b7-8615-7afe70a7a228_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5131dfc9-293c-4ccf-9829-333e72d98634_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d3252494-dc4c-42b3-8f19-5c54f8f056f7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_df062485-b582-419a-aac8-2aa91fce3edb_terseLabel_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_label_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_tars_DevelopmentAndRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:href="tars-20220331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:to="lab_tars_DevelopmentAndRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditFacilityInterestOnlyPeriodExtended_5a3e23f0-10a2-495b-b85e-f50abf68fc40_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditFacilityInterestOnlyPeriodExtended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest only period, extension</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityInterestOnlyPeriodExtended_label_en-US" xlink:label="lab_tars_LineOfCreditFacilityInterestOnlyPeriodExtended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Only Period, Extended</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityInterestOnlyPeriodExtended_documentation_en-US" xlink:label="lab_tars_LineOfCreditFacilityInterestOnlyPeriodExtended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Only Period, Extended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityInterestOnlyPeriodExtended" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityInterestOnlyPeriodExtended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditFacilityInterestOnlyPeriodExtended" xlink:to="lab_tars_LineOfCreditFacilityInterestOnlyPeriodExtended" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cf28673e-6835-4ef1-9c68-ecd3846e2897_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_be47ca11-d0bb-4363-8146-a7fab0480969_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b37a971f-714a-4a05-a6e7-802b24916314_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contractual lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3d3693b8-b916-49f0-903a-0418e80a45eb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b98e8c57-9656-46fe-a3c9-004db97de5c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a6e4664a-7437-4876-9f09-70f37c51d37c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d29cc349-02ef-45fe-9fdc-cdb908d27f5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as consideration for in-license rights (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_60ab360b-2622-4822-98e9-aca810070f44_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_94794cfa-0af7-42e3-a655-76c4636343f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_6c626442-5851-4e35-9746-73b6609db9f7_terseLabel_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and sales milestones</link:label>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_label_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Sales Milestones [Member]</link:label>
    <link:label id="lab_tars_CommercialAndSalesMilestonesMember_documentation_en-US" xlink:label="lab_tars_CommercialAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember" xlink:href="tars-20220331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommercialAndSalesMilestonesMember" xlink:to="lab_tars_CommercialAndSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7b066448-9b34-41bb-9f12-7f8fa8ad8580_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_136607fa-583c-4c2f-b887-4e78c1d5b13c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d88c268a-4a6d-42e0-9aa8-ab6350a4998a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_ec7ab3d8-2bb6-4fc5-9ee4-1dd0d8f92f7b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_6e3be0da-7e5a-4782-a18a-a2bcd06ee65a_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Four</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Four [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheFourMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheFourMember" xlink:to="lab_tars_CreditFacilityTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_64d89d4d-3b8f-4377-a5b1-ca8817deb408_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_fab87591-9de9-4954-b0a8-b45a5cfa202c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of term charge</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7950c63c-7b90-451e-b7de-cc523ca372f3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_1165d35b-669b-4354-a46c-9e1927a2ca14_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_89de1c60-505c-46b3-9d3e-5977329660b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_feac0bf5-4b0f-412c-89fa-0a5cbb807fcb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_50943a95-ecd3-4cee-a216-e4e2783f2d38_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to in-license agreement</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_184986a4-7d48-49e2-af44-ec34c744786c_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for license agreement, share price (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_26c4acf8-3a8d-408d-b831-931ff4f78bd5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9a9a8a62-dafc-4171-89ff-f7da5ff14ae1_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1be2c5b1-1b8b-464e-9bbc-d88a22a172fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_12b302cb-641b-4e9c-928f-fa9b17686077_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding (shares)</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5423d8d7-aa56-4f55-8ea5-0bf6121bb11f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_23d49828-ab36-4b9b-ad27-8722ec5dd825_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_700be43a-db55-4884-aeeb-a9710a6b2ca5_terseLabel_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of repurchase rights related to common stock issued pursuant to early exercises (shares)</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_label_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Lapse Of Repurchase Rights</link:label>
    <link:label id="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_documentation_en-US" xlink:label="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Lapse Of Repurchase Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:href="tars-20220331.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:to="lab_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dc377171-6bb6-4926-a38f-cf8ce9212ca9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_877e3b2b-6e01-4466-8f6f-abc5231e98ac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon the vesting of restricted stock units (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_963cfdfb-3b7e-416d-a83c-c1dea779f31d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ba5a7206-8b45-4b1a-88b3-04cf4a9606ae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8ea430e6-22a6-4f48-a74f-13e1a0f47166_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1fa465b1-d221-4fb0-9e4a-3cf307749088_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_33a865ec-d0a0-43cd-aa9f-af9988175091_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_02a7d956-30f8-4bda-81e0-8f7b156f2781_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_02438eb7-1e4f-4706-a022-404abbb43739_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_63a804c5-401b-4307-8d7d-ee701828ece5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f547e044-de2a-4cde-b131-daafef78696d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_9241f715-e2ab-4faf-a2cb-f7931d8fe727_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf5e97ea-fae2-490d-96a0-b218415b44ca_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments, undiscounted</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense_32ef5c9c-3e4d-482d-a99d-fe54d96876c9_negatedLabel_en-US" xlink:label="lab_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expensing of "operating lease right-of-use assets" upon lease termination</link:label>
    <link:label id="lab_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense_label_en-US" xlink:label="lab_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right Of Use Asset, Lease Termination Expense</link:label>
    <link:label id="lab_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense_documentation_en-US" xlink:label="lab_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right Of Use Asset, Lease Termination Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense" xlink:href="tars-20220331.xsd#tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense" xlink:to="lab_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7dfe23da-0bb2-4c48-9bdc-a64a75d40c3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_f50e8129-d310-4744-aa8c-1680664559b4_terseLabel_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical studies</link:label>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_label_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:label id="lab_tars_AccruedClinicalStudiesCurrent_documentation_en-US" xlink:label="lab_tars_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent" xlink:href="tars-20220331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AccruedClinicalStudiesCurrent" xlink:to="lab_tars_AccruedClinicalStudiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_9fd3d015-b1f1-467c-91cc-6058b276f20f_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: undistributed income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_778a08e7-4951-482b-b6c9-636ee0faf0e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_14f0f45e-330e-4d75-96ac-3ef5d55d0a07_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution, value</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b20777b3-6439-4e9b-989f-e9b3740655ff_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_19fe6727-b3ff-4975-8283-ec25fcb8325c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9dde1455-2043-4148-bb6d-000db3178893_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6f84d3c0-629b-4f7e-a73c-361f09d3682c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6ef96ab7-2789-4944-be39-04e02f2d9a51_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_844a65e0-3776-4ca3-9248-6bea1d39fe8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_8d2f2ae8-fa11-46bb-8380-6642e2a77f13_terseLabel_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_label_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</link:label>
    <link:label id="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_documentation_en-US" xlink:label="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:to="lab_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8ec41f4c-6815-4241-a303-e6b5628abeff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CollaborationMember_bda39d2c-f436-440e-9968-aa013ef797ae_terseLabel_en-US" xlink:label="lab_tars_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_tars_CollaborationMember_label_en-US" xlink:label="lab_tars_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_tars_CollaborationMember_documentation_en-US" xlink:label="lab_tars_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember" xlink:href="tars-20220331.xsd#tars_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CollaborationMember" xlink:to="lab_tars_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_d932fbcc-5e09-4e28-aefb-24dd67f826f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity warrants</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_00f2b7e5-44a9-47fa-8222-43fda8433077_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity warrants</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_3772821f-804f-4642-ae71-5714831d7fb3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of End of Term Charge</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7f7e74e9-a2d6-4749-83a3-393fbd49b617_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_aff45947-2cfb-4ef6-a36a-d663141fa25d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_dc30ef8e-ba53-4277-a548-1fc2c39dccde_terseLabel_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise period from termination upon all other separations</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_label_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations</link:label>
    <link:label id="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_documentation_en-US" xlink:label="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:to="lab_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_70a42dfc-87fb-4ab7-99d0-b982278932b4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_115aaf32-64b6-4bb7-a558-e591dc1b8f4c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1ff8c003-c341-4766-a945-b92ddc45b07a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c358959b-c7f0-4cf8-a6a1-481069f81fae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_227c68ee-b60d-4432-bf93-85c457b04973_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense for term loan</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4b2a412b-9b8d-4d0e-a2e2-6eaf3105055f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, basis and diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9f3e7525-5957-4055-a375-21d5440e471f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_74402105-e2e7-40d8-853d-158c97fdfd9a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3ef33f38-a6f0-47f6-84a8-b24c354ee7e2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4ae6743c-56ff-44aa-bbe0-060a4c191e9c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_410adbca-903a-4e6c-a8c3-fe35d03ea48f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_46b8fc97-a7ab-4a2a-a5a3-913f1e38bd51_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_fcba2c83-86d0-4a01-8e86-d4d9a4f47e29_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">"Interest expense" paid in cash</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0efbcfdf-3b1b-4bd1-be14-f1eb3f225ac4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income available to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_92d93c15-98b0-48b6-9d53-9125a1c627cf_terseLabel_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units&#8212;unvested</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_label_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member]</link:label>
    <link:label id="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_documentation_en-US" xlink:label="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:href="tars-20220331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:to="lab_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_999879f7-0f6d-41c5-b6be-fafae5d248c6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income available to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_dc1659b1-ce99-448a-a9cd-11064578ce54_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d0447060-b102-429b-b17e-cd61b0d366b8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_acb0ce3a-6cea-4fcf-acd5-5ba5ae1e0df8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_03537c97-f913-4159-851d-159ee543cee4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Detail</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_SalesMilestoneMember_b1c98804-a701-4e68-809f-4e3dda3ee210_terseLabel_en-US" xlink:label="lab_tars_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone</link:label>
    <link:label id="lab_tars_SalesMilestoneMember_label_en-US" xlink:label="lab_tars_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_tars_SalesMilestoneMember_documentation_en-US" xlink:label="lab_tars_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SalesMilestoneMember" xlink:href="tars-20220331.xsd#tars_SalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_SalesMilestoneMember" xlink:to="lab_tars_SalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LicenseAndCollaborationMember_d1dba930-ab2b-4976-8cbf-5e6c9a667f51_terseLabel_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees and Collaboration</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationMember_label_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration [Member]</link:label>
    <link:label id="lab_tars_LicenseAndCollaborationMember_documentation_en-US" xlink:label="lab_tars_LicenseAndCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember" xlink:href="tars-20220331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LicenseAndCollaborationMember" xlink:to="lab_tars_LicenseAndCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3aa6b48c-12dc-4e48-ae57-3871a7a57ea7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4c2e5708-292e-430e-9cce-f473f3f42d2a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies and Use of Estimates</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_45ef4c43-791b-49bd-b112-d1c969fdc047_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f8600b21-5816-42b1-b282-96a36ef84e9e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_8db0d0c1-8dc8-46b6-bfa4-7cf95d213c45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances of Debt, Debt Issuance Costs, and Accumulated Accretion</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_3b608d29-333a-4519-be27-737524f1e8e1_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_21a3ff1d-ec32-4f61-bc51-eb2e4f0a045f_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Two</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheTwoMember" xlink:to="lab_tars_CreditFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ClinicalMilestonesMember_7efcb8fa-586d-4b1d-b907-4bb68dfa3e05_terseLabel_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical milestones</link:label>
    <link:label id="lab_tars_ClinicalMilestonesMember_label_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestones [Member]</link:label>
    <link:label id="lab_tars_ClinicalMilestonesMember_documentation_en-US" xlink:label="lab_tars_ClinicalMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember" xlink:href="tars-20220331.xsd#tars_ClinicalMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ClinicalMilestonesMember" xlink:to="lab_tars_ClinicalMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_077fc72c-5739-46a1-ac8e-d09b918be98c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1854f9ff-54ae-449d-a697-a7180f762338_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_d278d492-05a4-4b7a-9a7d-4c52f5aef7d2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_426cb80e-e4c2-4aa3-b288-7edc228f73cb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_e0a26da7-e6c2-4550-9827-afb312fb6a7c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_79fe5734-966e-4d1c-be49-ef2fd91cf72b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_PublicStockOfferingMember_178a920c-4ef2-4f55-8c10-3c372fc0d139_terseLabel_en-US" xlink:label="lab_tars_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_tars_PublicStockOfferingMember_label_en-US" xlink:label="lab_tars_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_tars_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_tars_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PublicStockOfferingMember" xlink:href="tars-20220331.xsd#tars_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_PublicStockOfferingMember" xlink:to="lab_tars_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0b87afd5-9c27-407d-b5da-3de93cbef75c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_387d4ebe-bad4-45c0-b713-2757a0560b3c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d81d1e57-e172-47ad-a0cb-7167b14fc9cf_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3eb8451d-a5d6-4904-8bf0-4c47d2f93fc6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_25e7c93e-b9bf-4914-8c6c-8e922ade618d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_429849c0-f9ed-4086-b685-24070949dce3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and accretion of long-term debt related costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_97f69bea-5ad9-46c2-9b33-0a6d42d5e015_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_69bb4dfe-6094-458e-9106-20c2a5275ba6_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheFiveMember_b701c5b9-89e8-40e6-a1c4-634d3ceed0ae_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Five</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheFiveMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Five [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheFiveMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFiveMember" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheFiveMember" xlink:to="lab_tars_CreditFacilityTrancheFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_7e719c7c-a699-4b29-819c-1497a957397d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_84cde81d-79c8-41d6-b66d-73499f47305f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9922409d-9d02-432b-9f61-39d902cc47c6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_12d53457-5e41-4258-8710-9d1fdb81943e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of license fees and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5371e838-ae92-471d-a340-671fd67abc2d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0c277b55-dc4e-41b4-847d-67647360166f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0a4b6962-8131-4e60-8e45-dada3a76790e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_db9ab33c-627d-45e7-bdf0-81a31c365f7a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_dea76ab1-917c-4b10-b6ba-3022526acd75_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Draw on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ce4f0590-ab47-45c0-86c4-a168fa44f5ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1b30179f-147a-446a-be25-0e8ab20de3bf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_12227983-a10f-4935-8b42-268d164baa18_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_1dcd1051-6a3b-4f1b-81c1-f59ee59603c7_terseLabel_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</link:label>
    <link:label id="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:to="lab_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4d53dac5-4ccc-4b35-abbc-822bd199417a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ed7908b7-1c22-4364-ad6f-bd4617e8d72a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_ElancoMember_2df394d3-3761-4dbd-965a-8bc6956b8121_terseLabel_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco</link:label>
    <link:label id="lab_tars_ElancoMember_label_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco [Member]</link:label>
    <link:label id="lab_tars_ElancoMember_documentation_en-US" xlink:label="lab_tars_ElancoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember" xlink:href="tars-20220331.xsd#tars_ElancoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_ElancoMember" xlink:to="lab_tars_ElancoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6006a535-bdf3-4a39-a0a1-d56d69195d0a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_0a0d3f8a-5ce6-4b87-b287-dbccc326b173_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_244e7f49-e4a1-4921-943b-35b0601f2747_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_98f4642f-28b8-42be-b533-9f6b90e5c6ba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_e346682b-0249-4fc9-a456-a092b19477b2_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4233ecdf-3d5d-4646-ac20-1492bb5a5756_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5cbb4fb8-0a42-4eba-a00b-f80e38025e82_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_1071b450-c808-48a8-a256-d1961413dca2_terseLabel_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche One</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_label_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche One [Member]</link:label>
    <link:label id="lab_tars_CreditFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_tars_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_CreditFacilityTrancheOneMember" xlink:to="lab_tars_CreditFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_412193e7-1dcf-43fd-afef-7be3ceba594d_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: undistributed income reallocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1335a165-971d-4e8a-8061-342b33010522_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_78404c95-fcd0-473a-9e22-f06750d0b0ff_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_456e9d67-8037-4ff5-8432-96304989c1d7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1457be06-5c9e-4178-9a99-e7c427c0bb64_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_44661db0-ca30-463c-b7ed-b31c7f09c502_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_UpfrontPayment_403d1c91-3969-47fc-994a-f608cf41ddc4_terseLabel_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_tars_UpfrontPayment_label_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_tars_UpfrontPayment_documentation_en-US" xlink:label="lab_tars_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment" xlink:href="tars-20220331.xsd#tars_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_UpfrontPayment" xlink:to="lab_tars_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b02c9f1e-f83d-45b7-aa4f-e902b8a7ea80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_4fd221f5-defe-49b3-9cc1-2a5662adcd3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_961709e7-5d56-445f-a85e-2b33e591f6c8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_91de4578-b0d4-4a10-9307-7826f541e768_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2ad7b221-0094-4927-9903-288e2398868f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2d5ac825-9e1e-48da-9520-1381cf28ab86_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3e08dc80-d97e-470b-84e1-ef99986a4eab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_6d875fcd-45dc-44cf-bfed-c1de1acad55d_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ba0f9714-735a-40fc-84fc-50f0a7c5152f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_07a29ff7-960a-4b1b-b32b-acf78483d100_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f888b1a6-ce04-465b-9912-6c634491aa94_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f1d39b7e-5c0c-4ddc-9d01-62da7ffd2a86_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_7a70086f-daf9-4904-b9d4-8d5dcc25834c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_5f952f99-2128-4bef-953a-1184e8fb728c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_52aee6b6-cc6e-464b-8524-51329c8aec88_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0a70822b-3919-4cb0-a215-a1013c482287_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e6559e34-7504-49a1-8b9f-058be2bc96a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea201aa1-7b05-40e5-b338-2e2e3f6cefb4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa5f1616-ff59-4736-9d75-427052d61a18_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d401c867-52ae-4b1d-b9b2-9047952cb114_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e293ece6-33e3-4f33-950b-71669ac5c547_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityWarrantRights_e416f50b-04bf-4e85-b81a-765cf0f11a9c_terseLabel_en-US" xlink:label="lab_tars_EquityWarrantRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity warrant rights</link:label>
    <link:label id="lab_tars_EquityWarrantRights_label_en-US" xlink:label="lab_tars_EquityWarrantRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrant Rights</link:label>
    <link:label id="lab_tars_EquityWarrantRights_documentation_en-US" xlink:label="lab_tars_EquityWarrantRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrant Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantRights" xlink:href="tars-20220331.xsd#tars_EquityWarrantRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityWarrantRights" xlink:to="lab_tars_EquityWarrantRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_48db7b92-5326-415f-b90d-11082b83464c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b95a9358-60e9-46d3-87d5-c2ef2249150d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock reserved (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_43fc93e5-f059-4b47-8cb3-09b743eea5b0_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock reserved (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_b90d26e1-e249-4053-b40a-ae9e1df2737c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19ae6733-1776-4e5c-a163-29d160d78a8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_730852a9-693c-4f2e-9283-45f42d874682_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_3c665767-b6d0-4cad-a0c5-56383d452b13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember_e1a51518-4992-43c9-b383-720a6ae9d9a7_terseLabel_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine office and facilities, office suite and space lease</link:label>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember_label_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine Office And Facilities, Office Suite And Space Lease [Member]</link:label>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember_documentation_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine Office And Facilities, Office Suite And Space Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember" xlink:href="tars-20220331.xsd#tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember" xlink:to="lab_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dda7de9a-f84e-42cf-a10a-c04d358196c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of vested stock options (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4eaf3ef-d1ac-4cfe-9ae8-5297cc26a1d1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_379ed9b5-3d1b-427c-815e-011a28a90872_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_6bf307e9-9138-4a41-82ce-92d893e8e246_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_43e15b98-1379-4bb1-9c35-2f5c17cc4b8c_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_8c09619b-9384-49da-9a84-633be74b5583_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_af4f069e-906a-441a-b1c4-a14ae76f79fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service condition period for full vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_458bb1a7-060b-4b09-8ec7-78a9da010b97_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest, current</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_23f49316-4cfe-486f-9f2e-40a3e2fe88a9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_04da63f8-2f92-4095-99b4-a28d50def7fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bee17bdc-8525-4a5a-8d43-e0a1ee1c687a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity and Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_51251282-e1d9-49fb-833e-3d1fd53710f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding potentially dilutive securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f6797754-2b8a-418f-88d7-ec22fc47a7b7_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesLeaseMember_5ce7bbf7-4a21-4ad2-8134-a2e473eb3ef4_terseLabel_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine office and laboratory facility</link:label>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesLeaseMember_label_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine Office And Facilities Lease [Member]</link:label>
    <link:label id="lab_tars_IrvineOfficeAndFacilitiesLeaseMember_documentation_en-US" xlink:label="lab_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irvine Office And Facilities Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:href="tars-20220331.xsd#tars_IrvineOfficeAndFacilitiesLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:to="lab_tars_IrvineOfficeAndFacilitiesLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c818828a-6467-4f7e-9bea-f32a6e420dd7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2d137cf-d098-49d4-b87b-f8037c3e14af_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11b82102-4d50-4cee-be2a-2a852c910e77_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_67de2a0c-47eb-41a0-8316-ccebfdb5ce6c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Less): Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9979f7c1-55ea-4091-8ab8-d7ad7ec59231_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_bceacfa3-6777-4f94-8fff-a1318069206b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_9a9a42e6-bbce-415e-a303-3326598c8291_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs (legal and other administrative fees)</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5a42d82-ba52-4e9b-b9d6-902eabbe3c06_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c4f97ffb-2986-4d2e-bbfc-64c57f1da922_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9dad0498-3de4-4763-854b-77239b9e8a3f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c185bd59-6b2a-4a22-b03b-57bfa789b5c9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_20726480-161a-4392-88fa-a941539544e5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_20718613-3da8-46d9-8066-96ce9bd571f8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ae50005c-9101-465f-8028-a8e132f60c10_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_0e344805-8f43-463c-a5d2-731bfe221580_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_317cb9ea-0aa0-4168-838a-c5b20bae53e6_terseLabel_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employment arrangements with executive officers</link:label>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_label_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employment Arrangements With Executive Officers</link:label>
    <link:label id="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_documentation_en-US" xlink:label="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employment Arrangements With Executive Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:href="tars-20220331.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:to="lab_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_12b983a7-a3b6-4a88-800e-debcec736052_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_f7c1bd39-e314-4915-a8a2-d936bc365b01_terseLabel_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increments to draw on credit facility at company's election</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_label_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Draw Down Increments</link:label>
    <link:label id="lab_tars_LineOfCreditFacilityDrawDownIncrements_documentation_en-US" xlink:label="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Draw Down Increments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_LineOfCreditFacilityDrawDownIncrements" xlink:to="lab_tars_LineOfCreditFacilityDrawDownIncrements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ab9f72c0-84fd-4e32-bc6d-1660f3c2964a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3c910ded-109f-4b00-82e8-ede96d3f39ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87dc661d-70ed-4d92-8b02-2cdacd2c89b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1472f88f-ee41-4c06-b94d-2f548728a94a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued or Effective Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ec01f71c-9ba8-4351-9d46-ce7d62b83216_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_db2cca44-2ac1-43e0-9e6d-0b9cf08c449c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_4685e1cc-3f45-40d4-99b4-1304f3e1a968_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_fb47248d-d29a-4770-826a-d6c2c798db38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of End of Term Charge</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_903850c5-d4ee-4d1b-902d-87a704144922_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_681838c1-1e4c-4aa8-88c2-4c96b9991079_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6ec35e72-723c-4b94-a0bf-ca2df526a9f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_d466a001-72ab-4b45-9519-32e03763a75c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e5f91b2-aa54-4481-91d5-b726e8dd0ce0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e280dd1a-7cc8-40e9-bcb9-00ced4fc0fdb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_3913c44e-8c39-40cb-9591-46df6da20de4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_4872bba9-cfa5-4490-990b-bd28d5885de5_terseLabel_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity warrants in LianBio (included in "other assets")</link:label>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_label_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Fair Value Disclosure</link:label>
    <link:label id="lab_tars_EquityWarrantsFairValueDisclosure_documentation_en-US" xlink:label="lab_tars_EquityWarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure" xlink:href="tars-20220331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tars_EquityWarrantsFairValueDisclosure" xlink:to="lab_tars_EquityWarrantsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_3e3012b2-6424-45b7-8efd-f3a70df57f8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cf953963-3e13-43bd-8416-6fe0b74099d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9a7fd29d-62ac-4e93-8c29-c3eba7f9e74f_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1ab251ce-c996-4870-a413-602016627880_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e803e4f7-8245-4ac4-bc83-f3d55e9f97f7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>tars-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:da1c4284-d55c-45f0-a6eb-8007076173b6,g:baa10d6b-a9ec-46bb-8e50-7a6ef1f55cb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tarsusrx.com/role/Cover" xlink:type="simple" xlink:href="tars-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ba850e4d-1902-417e-9b33-58df4b8c1e06" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_DocumentType_ba850e4d-1902-417e-9b33-58df4b8c1e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bf48ec73-2f3f-4f13-b389-c835ec895885" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_DocumentQuarterlyReport_bf48ec73-2f3f-4f13-b389-c835ec895885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_57d1fb75-1c75-411a-ac1e-755ae60df232" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_DocumentPeriodEndDate_57d1fb75-1c75-411a-ac1e-755ae60df232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_fe852482-60d3-4331-826c-92b197d052b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_DocumentTransitionReport_fe852482-60d3-4331-826c-92b197d052b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_011e6ef0-6f33-438e-b369-16e41bb52e30" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityFileNumber_011e6ef0-6f33-438e-b369-16e41bb52e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5569f7f1-1465-4c76-9234-aeec8259ea7b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityRegistrantName_5569f7f1-1465-4c76-9234-aeec8259ea7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b8feb562-e459-43ca-9464-f881145b3eca" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b8feb562-e459-43ca-9464-f881145b3eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cbfdd260-37b5-4e8f-af2b-a85132d0d7ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityTaxIdentificationNumber_cbfdd260-37b5-4e8f-af2b-a85132d0d7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4ecb474d-8096-45af-aaac-7a6e3a287be0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityAddressAddressLine1_4ecb474d-8096-45af-aaac-7a6e3a287be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_59e0b84a-3452-4df7-9fd3-1dd02dfc4557" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityAddressCityOrTown_59e0b84a-3452-4df7-9fd3-1dd02dfc4557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4b8ada04-5c13-4215-963c-09c0576a41f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityAddressStateOrProvince_4b8ada04-5c13-4215-963c-09c0576a41f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_16bdf75a-e099-43d4-91d0-ae4e0e4902e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityAddressPostalZipCode_16bdf75a-e099-43d4-91d0-ae4e0e4902e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1f2191b4-3544-4885-9ac9-d6b6cf028318" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_CityAreaCode_1f2191b4-3544-4885-9ac9-d6b6cf028318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2ff41fe0-226e-4487-962a-3b9432d405a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_LocalPhoneNumber_2ff41fe0-226e-4487-962a-3b9432d405a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_906f52ee-0fe8-4e64-a31f-11ffb8c998f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_Security12bTitle_906f52ee-0fe8-4e64-a31f-11ffb8c998f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0fd0feaf-b4ea-4f98-8d68-47f18ab237a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_TradingSymbol_0fd0feaf-b4ea-4f98-8d68-47f18ab237a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9d76201f-a2c3-4772-9242-d2fda31ef1a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_SecurityExchangeName_9d76201f-a2c3-4772-9242-d2fda31ef1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9b76eabe-e479-4d11-a753-92a97f11cfe3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityCurrentReportingStatus_9b76eabe-e479-4d11-a753-92a97f11cfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_07408bcc-8402-4263-9f5b-c04ff05ebb49" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityInteractiveDataCurrent_07408bcc-8402-4263-9f5b-c04ff05ebb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5379c771-5531-4486-8d04-1c6d811210ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityFilerCategory_5379c771-5531-4486-8d04-1c6d811210ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_75778f90-2766-4a93-98a2-8f08958be2e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntitySmallBusiness_75778f90-2766-4a93-98a2-8f08958be2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f3c018e6-69b9-4ec8-9c90-8a668ac97521" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityEmergingGrowthCompany_f3c018e6-69b9-4ec8-9c90-8a668ac97521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_898e4fc9-c554-4a0d-abfc-8274acd374a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityExTransitionPeriod_898e4fc9-c554-4a0d-abfc-8274acd374a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d73d5c1a-be6f-47bc-84dd-c8fadafeeef6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityShellCompany_d73d5c1a-be6f-47bc-84dd-c8fadafeeef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d9153b73-54b0-4fff-9943-c9b96d74ce89" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d9153b73-54b0-4fff-9943-c9b96d74ce89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8a6be822-bf18-482a-87d5-d00b796f038d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_AmendmentFlag_8a6be822-bf18-482a-87d5-d00b796f038d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0695020d-6aa0-4378-8a87-63c671498ada" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_EntityCentralIndexKey_0695020d-6aa0-4378-8a87-63c671498ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bc5516ba-09c3-48c2-9bf5-0aeefb341e72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_CurrentFiscalYearEndDate_bc5516ba-09c3-48c2-9bf5-0aeefb341e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_49509c99-c373-4127-9687-8b9afae1c2df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_DocumentFiscalYearFocus_49509c99-c373-4127-9687-8b9afae1c2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_eb389740-8175-451c-838f-bfe593bf474e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_98910635-fc51-499a-b1a4-5936d5722a06" xlink:to="loc_dei_DocumentFiscalPeriodFocus_eb389740-8175-451c-838f-bfe593bf474e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_acbb881a-cee8-433b-88f8-ff18555fffe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ebb0d975-33ce-4e21-8d8a-de23a7a000b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acbb881a-cee8-433b-88f8-ff18555fffe8" xlink:to="loc_us-gaap_AssetsAbstract_ebb0d975-33ce-4e21-8d8a-de23a7a000b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_218c26f4-add6-49a0-a5e1-8fc7ecdd621b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebb0d975-33ce-4e21-8d8a-de23a7a000b0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_218c26f4-add6-49a0-a5e1-8fc7ecdd621b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef844f9d-d668-4479-802d-2eed0285e3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_218c26f4-add6-49a0-a5e1-8fc7ecdd621b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef844f9d-d668-4479-802d-2eed0285e3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_df4eaabb-fe31-4f46-a9a2-cf7377ca9527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_218c26f4-add6-49a0-a5e1-8fc7ecdd621b" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_df4eaabb-fe31-4f46-a9a2-cf7377ca9527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ac1a5d17-7d10-4bd8-9e39-c9853d3676ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_218c26f4-add6-49a0-a5e1-8fc7ecdd621b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ac1a5d17-7d10-4bd8-9e39-c9853d3676ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_729f2441-b5fa-4470-8cf5-22e5de4489f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_218c26f4-add6-49a0-a5e1-8fc7ecdd621b" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_729f2441-b5fa-4470-8cf5-22e5de4489f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0e29c9b-2553-404a-b83a-3e9c085f3734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_218c26f4-add6-49a0-a5e1-8fc7ecdd621b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0e29c9b-2553-404a-b83a-3e9c085f3734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_74c39c93-5ccf-45dc-8b5d-a389b9a0ba82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_218c26f4-add6-49a0-a5e1-8fc7ecdd621b" xlink:to="loc_us-gaap_AssetsCurrent_74c39c93-5ccf-45dc-8b5d-a389b9a0ba82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_173daed9-0215-4af9-ae82-47912986b017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebb0d975-33ce-4e21-8d8a-de23a7a000b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_173daed9-0215-4af9-ae82-47912986b017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0caa67cb-94eb-4a85-b719-626655b23a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebb0d975-33ce-4e21-8d8a-de23a7a000b0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0caa67cb-94eb-4a85-b719-626655b23a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_89636ccb-2a6b-45ec-9cf1-21734ec8dbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebb0d975-33ce-4e21-8d8a-de23a7a000b0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_89636ccb-2a6b-45ec-9cf1-21734ec8dbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8f7a5aec-d074-420f-8cf9-97ff40c5c260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebb0d975-33ce-4e21-8d8a-de23a7a000b0" xlink:to="loc_us-gaap_Assets_8f7a5aec-d074-420f-8cf9-97ff40c5c260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acbb881a-cee8-433b-88f8-ff18555fffe8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_961cd81d-10e3-4a6c-a774-8ffc7c9b6ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_961cd81d-10e3-4a6c-a774-8ffc7c9b6ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_314d5afe-0a51-4e42-be55-5cec2204f874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_961cd81d-10e3-4a6c-a774-8ffc7c9b6ddb" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_314d5afe-0a51-4e42-be55-5cec2204f874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fbd1271a-b5d5-43f4-b0be-54c3dfefc498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_961cd81d-10e3-4a6c-a774-8ffc7c9b6ddb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fbd1271a-b5d5-43f4-b0be-54c3dfefc498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bfcd221f-3884-426a-a096-79fbe59b1199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_961cd81d-10e3-4a6c-a774-8ffc7c9b6ddb" xlink:to="loc_us-gaap_LiabilitiesCurrent_bfcd221f-3884-426a-a096-79fbe59b1199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_771253dc-30e0-4a8f-9285-5839f6989d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_771253dc-30e0-4a8f-9285-5839f6989d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_30d0d406-5492-4247-9161-801caf5c7d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_30d0d406-5492-4247-9161-801caf5c7d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f7eb003-9c4e-4724-a23d-4213366649d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:to="loc_us-gaap_Liabilities_5f7eb003-9c4e-4724-a23d-4213366649d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f60c2a24-a13b-43b2-9944-24e15165e80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f60c2a24-a13b-43b2-9944-24e15165e80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_11725ad6-cfb3-4dbb-a3fe-0993b38010d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:to="loc_us-gaap_StockholdersEquityAbstract_11725ad6-cfb3-4dbb-a3fe-0993b38010d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9f62cc29-904d-4a01-8c14-a98e0f7bcad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11725ad6-cfb3-4dbb-a3fe-0993b38010d0" xlink:to="loc_us-gaap_PreferredStockValue_9f62cc29-904d-4a01-8c14-a98e0f7bcad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7567801d-8fac-46b7-996d-8f6f73d8e92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11725ad6-cfb3-4dbb-a3fe-0993b38010d0" xlink:to="loc_us-gaap_CommonStockValue_7567801d-8fac-46b7-996d-8f6f73d8e92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a875f40a-68f5-4ab8-8d10-442d5ed1c9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11725ad6-cfb3-4dbb-a3fe-0993b38010d0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a875f40a-68f5-4ab8-8d10-442d5ed1c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_052280e0-d2d2-4e85-a29c-bbfd0a1713e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11725ad6-cfb3-4dbb-a3fe-0993b38010d0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_052280e0-d2d2-4e85-a29c-bbfd0a1713e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eff5a908-f3c6-4bdc-9151-c083066371f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11725ad6-cfb3-4dbb-a3fe-0993b38010d0" xlink:to="loc_us-gaap_StockholdersEquity_eff5a908-f3c6-4bdc-9151-c083066371f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a62d3238-8f6b-40cb-8ca8-415708606d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0cbb1906-8604-4f71-81dc-f2a66cdca3ba" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a62d3238-8f6b-40cb-8ca8-415708606d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_48bd6209-7c5a-430f-86f8-1c9e6de36a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_48bd6209-7c5a-430f-86f8-1c9e6de36a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bf73dc87-09c2-4b74-832a-f83935ed453e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bf73dc87-09c2-4b74-832a-f83935ed453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b883d6e2-15b8-491f-b6f6-7dded6dccdad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b883d6e2-15b8-491f-b6f6-7dded6dccdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_738783d5-1988-48b2-8808-4458640ccc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_738783d5-1988-48b2-8808-4458640ccc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6ed6b8f0-0248-4505-9af3-ae7aeb06e9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6ed6b8f0-0248-4505-9af3-ae7aeb06e9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0698d839-3aaf-48ab-b50e-0e7ca0575244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0698d839-3aaf-48ab-b50e-0e7ca0575244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7f6a4fbe-8d50-4ac1-81c7-2561b2903095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_us-gaap_CommonStockSharesIssued_7f6a4fbe-8d50-4ac1-81c7-2561b2903095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_85cadc87-d5ce-4b2d-aaa7-cb277de4e0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_85cadc87-d5ce-4b2d-aaa7-cb277de4e0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockSharesSubjectToRepurchase_ba9b05ca-0c3a-48d4-b72c-53ca5feb03bb" xlink:href="tars-20220331.xsd#tars_CommonStockSharesSubjectToRepurchase"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1fd5af4-687f-4e3c-960b-525e0451f430" xlink:to="loc_tars_CommonStockSharesSubjectToRepurchase_ba9b05ca-0c3a-48d4-b72c-53ca5feb03bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b2e3177b-594f-4cda-9aa0-b7a45ba7e381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6aa0b979-f3e7-4639-a4b8-72455272a214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b2e3177b-594f-4cda-9aa0-b7a45ba7e381" xlink:to="loc_us-gaap_StatementTable_6aa0b979-f3e7-4639-a4b8-72455272a214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_601db6af-a135-4bdb-893a-56ebaa8ba4db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6aa0b979-f3e7-4639-a4b8-72455272a214" xlink:to="loc_srt_ProductOrServiceAxis_601db6af-a135-4bdb-893a-56ebaa8ba4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55d224d8-6e12-4a44-bd11-22e08324bca8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_601db6af-a135-4bdb-893a-56ebaa8ba4db" xlink:to="loc_srt_ProductsAndServicesDomain_55d224d8-6e12-4a44-bd11-22e08324bca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LicenseAndCollaborationMember_d868233d-7b0d-4760-9a97-ce73f1dfb727" xlink:href="tars-20220331.xsd#tars_LicenseAndCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_55d224d8-6e12-4a44-bd11-22e08324bca8" xlink:to="loc_tars_LicenseAndCollaborationMember_d868233d-7b0d-4760-9a97-ce73f1dfb727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c382458b-7f15-4d83-9726-2c64d4e95d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_LicenseAndCollaborationMember_d868233d-7b0d-4760-9a97-ce73f1dfb727" xlink:to="loc_us-gaap_LicenseAndServiceMember_c382458b-7f15-4d83-9726-2c64d4e95d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember_27c03348-f9c7-4031-b082-f7caef7fa420" xlink:href="tars-20220331.xsd#tars_CollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tars_LicenseAndCollaborationMember_d868233d-7b0d-4760-9a97-ce73f1dfb727" xlink:to="loc_tars_CollaborationMember_27c03348-f9c7-4031-b082-f7caef7fa420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6aa0b979-f3e7-4639-a4b8-72455272a214" xlink:to="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e16baa11-9f45-4067-896f-0b07e4ca66f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_RevenuesAbstract_e16baa11-9f45-4067-896f-0b07e4ca66f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cd3d1e76-7d89-4a65-b485-40941d540dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e16baa11-9f45-4067-896f-0b07e4ca66f2" xlink:to="loc_us-gaap_Revenues_cd3d1e76-7d89-4a65-b485-40941d540dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4ae8a24d-1a49-4acc-a634-cdbdb5b64378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:to="loc_us-gaap_CostOfRevenue_4ae8a24d-1a49-4acc-a634-cdbdb5b64378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b331d7fa-928a-441b-b442-8dcdcdd39c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b331d7fa-928a-441b-b442-8dcdcdd39c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_413538f1-a080-41f5-80ac-38725a71f91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_413538f1-a080-41f5-80ac-38725a71f91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_507f262a-5b59-4416-9e9d-ba4b574f98f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bf5aeeb4-a422-4cdf-97b5-db94214bd32d" xlink:to="loc_us-gaap_OperatingExpenses_507f262a-5b59-4416-9e9d-ba4b574f98f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_110f00dc-8536-4549-8940-42adce4435ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_OperatingIncomeLoss_110f00dc-8536-4549-8940-42adce4435ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d28d73de-0d2d-4aa8-97cb-6788ae105f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d28d73de-0d2d-4aa8-97cb-6788ae105f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1ed3c5f5-358b-452e-a828-96df923c10a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1ed3c5f5-358b-452e-a828-96df923c10a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_13073547-0cb3-4f6e-8ca1-6470e866dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_13073547-0cb3-4f6e-8ca1-6470e866dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_7d36b72c-87e6-4048-8cb9-30a0929a0dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_7d36b72c-87e6-4048-8cb9-30a0929a0dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6231e05c-2f11-48fe-8668-3260fd7cfe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9af21079-a479-44ac-9853-eabcf33d816a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6231e05c-2f11-48fe-8668-3260fd7cfe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bc27bca4-8d8f-4dad-bf4d-d4f2327694c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bc27bca4-8d8f-4dad-bf4d-d4f2327694c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce71e38d-085e-48d2-8ef6-46e3489dbb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_NetIncomeLoss_ce71e38d-085e-48d2-8ef6-46e3489dbb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2aa65dd8-03f6-43eb-b913-eb74e7ce0a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2aa65dd8-03f6-43eb-b913-eb74e7ce0a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1bb36858-1bd8-4aaa-91fb-460fb8d47d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1bb36858-1bd8-4aaa-91fb-460fb8d47d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_90514d80-ceff-4899-a123-9324f9a1e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bb36858-1bd8-4aaa-91fb-460fb8d47d89" xlink:to="loc_us-gaap_EarningsPerShareBasic_90514d80-ceff-4899-a123-9324f9a1e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_82ef23bb-9315-497c-bf29-d9f25f823e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bb36858-1bd8-4aaa-91fb-460fb8d47d89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_82ef23bb-9315-497c-bf29-d9f25f823e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_250910f3-e2a2-4c99-a4f5-522c2e476054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01a191aa-7f2f-4e87-bbb6-b4b670d1348d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_250910f3-e2a2-4c99-a4f5-522c2e476054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ce5ddf-ff1b-46a6-b2ea-0c00b61715eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_250910f3-e2a2-4c99-a4f5-522c2e476054" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ce5ddf-ff1b-46a6-b2ea-0c00b61715eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa70bd90-6a01-4425-9a37-56adc8420e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_250910f3-e2a2-4c99-a4f5-522c2e476054" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa70bd90-6a01-4425-9a37-56adc8420e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedStatementsofPreferredStockandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5f51041e-7acc-4da8-878f-e3c3f82d0108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_07f8c586-a210-4f79-a30b-c3eec922cea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5f51041e-7acc-4da8-878f-e3c3f82d0108" xlink:to="loc_us-gaap_StatementTable_07f8c586-a210-4f79-a30b-c3eec922cea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_17d908e5-e62e-438b-ba49-c2ef1287e341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_07f8c586-a210-4f79-a30b-c3eec922cea7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_17d908e5-e62e-438b-ba49-c2ef1287e341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17d908e5-e62e-438b-ba49-c2ef1287e341" xlink:to="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d7ed1f82-739d-47b0-b57e-88881f1eb46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:to="loc_us-gaap_CommonStockMember_d7ed1f82-739d-47b0-b57e-88881f1eb46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b442e7e7-776a-455e-a3dd-97dcb133ec80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b442e7e7-776a-455e-a3dd-97dcb133ec80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a6e2e043-5771-45a5-af4c-adaeb0e43d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dd3df24b-f7a7-423e-aa3b-b71ec3525635" xlink:to="loc_us-gaap_RetainedEarningsMember_a6e2e043-5771-45a5-af4c-adaeb0e43d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_07479fd2-48c8-48e8-9313-d64ad6422ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_07f8c586-a210-4f79-a30b-c3eec922cea7" xlink:to="loc_us-gaap_StatementLineItems_07479fd2-48c8-48e8-9313-d64ad6422ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07479fd2-48c8-48e8-9313-d64ad6422ba4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6d291d70-aa93-4c35-b312-6bf127cdb702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6d291d70-aa93-4c35-b312-6bf127cdb702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c8f05e96-e3c0-4713-8c22-c87893363120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c8f05e96-e3c0-4713-8c22-c87893363120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_15ede5db-8c4b-44b5-b364-087dee715938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_15ede5db-8c4b-44b5-b364-087dee715938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_17177a68-b5e7-44e5-8e27-734f6108c324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0fbff390-776d-4eb4-8384-bcce4f453b09" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_17177a68-b5e7-44e5-8e27-734f6108c324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_07479fd2-48c8-48e8-9313-d64ad6422ba4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7ee22d84-febe-47fd-8503-6f9bbf284a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7ee22d84-febe-47fd-8503-6f9bbf284a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b4616a9-ddb7-4147-a250-17fed6b7763f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockholdersEquity_3b4616a9-ddb7-4147-a250-17fed6b7763f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_abb3d16d-e59f-4e62-a1c7-457015756f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_NetIncomeLoss_abb3d16d-e59f-4e62-a1c7-457015756f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d43b566-8095-47f4-b2ea-e69ef42f0504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d43b566-8095-47f4-b2ea-e69ef42f0504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a79d4d4f-31d9-4f17-aed5-4fa8c182aafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a79d4d4f-31d9-4f17-aed5-4fa8c182aafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a87e68ed-bf7b-4e1b-9328-e793d8a32448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a87e68ed-bf7b-4e1b-9328-e793d8a32448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3fcb5655-98da-49af-8f4d-0f48b29c3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3fcb5655-98da-49af-8f4d-0f48b29c3aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_23bf2d30-c8b3-4c9b-8008-337c96e81084" xlink:href="tars-20220331.xsd#tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights_23bf2d30-c8b3-4c9b-8008-337c96e81084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_5515af79-f330-44d6-90f9-d47d936ca59e" xlink:href="tars-20220331.xsd#tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights_5515af79-f330-44d6-90f9-d47d936ca59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1b8bef2b-513c-4d08-b075-c53315f2311a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1b8bef2b-513c-4d08-b075-c53315f2311a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f6602790-0973-40e0-8f19-ed6b7cc7ab05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f6602790-0973-40e0-8f19-ed6b7cc7ab05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cf68b4ea-443a-4da8-8bbd-557c4ea5c2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cf68b4ea-443a-4da8-8bbd-557c4ea5c2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76188f67-d791-4969-8b3d-3599a03d4962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc87c55d-c219-445e-bbe3-60e812867137" xlink:to="loc_us-gaap_StockholdersEquity_76188f67-d791-4969-8b3d-3599a03d4962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="tars-20220331.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e36956e7-df86-4e7f-9ecf-d27f37a7b41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e36956e7-df86-4e7f-9ecf-d27f37a7b41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18dc45c0-ce22-4fb1-a372-cb62b5773b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e36956e7-df86-4e7f-9ecf-d27f37a7b41b" xlink:to="loc_us-gaap_NetIncomeLoss_18dc45c0-ce22-4fb1-a372-cb62b5773b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e36956e7-df86-4e7f-9ecf-d27f37a7b41b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_3a7a033e-620e-4f3d-a1f9-add2b6acc58c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_3a7a033e-620e-4f3d-a1f9-add2b6acc58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ab69eb5b-3662-44ce-93cb-476786fcf78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ab69eb5b-3662-44ce-93cb-476786fcf78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_01010f63-84ff-49dc-b102-d74b8d5a992a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_ShareBasedCompensation_01010f63-84ff-49dc-b102-d74b8d5a992a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseNoncashExpense_54863d87-865c-4218-88de-a41ac42cc4f4" xlink:href="tars-20220331.xsd#tars_OperatingLeaseNoncashExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_tars_OperatingLeaseNoncashExpense_54863d87-865c-4218-88de-a41ac42cc4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae22b0f9-68b6-4068-907a-c22ac9c056f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae22b0f9-68b6-4068-907a-c22ac9c056f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_5a343ede-ec1f-4044-8dfb-af0296661254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_5a343ede-ec1f-4044-8dfb-af0296661254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_02e0d0d3-fa3f-4ebf-bc71-aecd316a7064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_02e0d0d3-fa3f-4ebf-bc71-aecd316a7064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_43edf009-fcbd-4afd-bdf7-809e107d9c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_43edf009-fcbd-4afd-bdf7-809e107d9c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_6c87ca87-d72c-4024-8876-9b0f51aff12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_6c87ca87-d72c-4024-8876-9b0f51aff12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_0d748914-6752-4917-ad57-ab5191e19c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_0d748914-6752-4917-ad57-ab5191e19c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_67e1ebc4-4993-4b64-be17-6db880174f4d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc15ad0c-4f92-43b1-8d5d-36322767ea2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc15ad0c-4f92-43b1-8d5d-36322767ea2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_28c7015e-f84c-4c96-8306-5e12466a3314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_28c7015e-f84c-4c96-8306-5e12466a3314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_8b9fb631-dfcf-4597-81bf-8d2ef0243027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_8b9fb631-dfcf-4597-81bf-8d2ef0243027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfd5dd13-2bff-44e3-b8d8-d4e724f3182f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfd5dd13-2bff-44e3-b8d8-d4e724f3182f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f3af867e-2b1f-40ee-8565-ae33e9f265c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f3af867e-2b1f-40ee-8565-ae33e9f265c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_78526196-5557-4bd7-90de-9f1475649cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_78526196-5557-4bd7-90de-9f1475649cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_15425df5-a9b2-4788-8d0d-956160394efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_15425df5-a9b2-4788-8d0d-956160394efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_023c44e3-4297-4868-aa21-08a13ddf5a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_992f0627-9849-4afe-b02a-dd0208237e44" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_023c44e3-4297-4868-aa21-08a13ddf5a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_354990b0-287e-4827-8f0f-d4e3723dcc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e36956e7-df86-4e7f-9ecf-d27f37a7b41b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_354990b0-287e-4827-8f0f-d4e3723dcc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4338f5d7-dab0-4d9f-8468-933d09497396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4338f5d7-dab0-4d9f-8468-933d09497396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8dfd9612-093f-409e-9991-9e7791a22093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4338f5d7-dab0-4d9f-8468-933d09497396" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8dfd9612-093f-409e-9991-9e7791a22093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_734842f2-36aa-48af-b6c7-faaeee47e4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4338f5d7-dab0-4d9f-8468-933d09497396" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_734842f2-36aa-48af-b6c7-faaeee47e4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_079d682d-d263-48cd-aed9-d35406fa0a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_079d682d-d263-48cd-aed9-d35406fa0a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ProceedsFromEarlyExerciseOfStockOptions_558e0365-7532-45ae-8331-2935221f9995" xlink:href="tars-20220331.xsd#tars_ProceedsFromEarlyExerciseOfStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_079d682d-d263-48cd-aed9-d35406fa0a59" xlink:to="loc_tars_ProceedsFromEarlyExerciseOfStockOptions_558e0365-7532-45ae-8331-2935221f9995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PaymentsOfDeferredStockIssuanceCosts_1c115dcc-dbef-4b2a-af06-8a5e2e69cd4d" xlink:href="tars-20220331.xsd#tars_PaymentsOfDeferredStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_079d682d-d263-48cd-aed9-d35406fa0a59" xlink:to="loc_tars_PaymentsOfDeferredStockIssuanceCosts_1c115dcc-dbef-4b2a-af06-8a5e2e69cd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_df2b07fb-9136-41bb-9d3d-edd13bf0e905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_079d682d-d263-48cd-aed9-d35406fa0a59" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_df2b07fb-9136-41bb-9d3d-edd13bf0e905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3b641ed3-dbef-4ebc-948e-3ec5a241cbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_079d682d-d263-48cd-aed9-d35406fa0a59" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3b641ed3-dbef-4ebc-948e-3ec5a241cbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b928be9-4390-42cd-97bc-6a2b7c71b209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_079d682d-d263-48cd-aed9-d35406fa0a59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b928be9-4390-42cd-97bc-6a2b7c71b209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dda46f40-5ac0-44ab-9fc0-2f88cdf86473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dda46f40-5ac0-44ab-9fc0-2f88cdf86473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_850aae1e-28e9-4408-9ee1-d51803dfe42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_850aae1e-28e9-4408-9ee1-d51803dfe42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc51f276-4120-485f-bea8-3739d79c7908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc51f276-4120-485f-bea8-3739d79c7908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_4c583e73-6d55-4994-9bc1-1476cb77cee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_4c583e73-6d55-4994-9bc1-1476cb77cee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dafde461-0855-4790-a58d-f8d27a306540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_4c583e73-6d55-4994-9bc1-1476cb77cee6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dafde461-0855-4790-a58d-f8d27a306540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f1f6f53f-7448-4102-befd-88e1fc2598fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_4c583e73-6d55-4994-9bc1-1476cb77cee6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f1f6f53f-7448-4102-befd-88e1fc2598fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b721ba26-320f-4fec-b449-2e44aa8e546e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_4c583e73-6d55-4994-9bc1-1476cb77cee6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b721ba26-320f-4fec-b449-2e44aa8e546e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b4b26c8-1f48-4ea9-b5e9-eb2254723cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8bbc156f-b103-4389-86e7-24ac8091f9d9" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b4b26c8-1f48-4ea9-b5e9-eb2254723cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4bee6314-4e68-4043-997d-145b7cf1f105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b4b26c8-1f48-4ea9-b5e9-eb2254723cbf" xlink:to="loc_us-gaap_InterestPaidNet_4bee6314-4e68-4043-997d-145b7cf1f105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a062aabc-2f9c-4f3b-aef4-c6a6ee50f799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b4b26c8-1f48-4ea9-b5e9-eb2254723cbf" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a062aabc-2f9c-4f3b-aef4-c6a6ee50f799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense_62aec747-dd88-44a6-b0f7-9b353c28913c" xlink:href="tars-20220331.xsd#tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b4b26c8-1f48-4ea9-b5e9-eb2254723cbf" xlink:to="loc_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense_62aec747-dd88-44a6-b0f7-9b353c28913c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_44cb338f-4261-4425-abd6-681c73fa3c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b4b26c8-1f48-4ea9-b5e9-eb2254723cbf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_44cb338f-4261-4425-abd6-681c73fa3c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DeferredOfferingCostsIncurredButNotYetPaid_1f0cfdb8-3fad-41fb-a7d3-09b374101e52" xlink:href="tars-20220331.xsd#tars_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7b4b26c8-1f48-4ea9-b5e9-eb2254723cbf" xlink:to="loc_tars_DeferredOfferingCostsIncurredButNotYetPaid_1f0cfdb8-3fad-41fb-a7d3-09b374101e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" xlink:type="simple" xlink:href="tars-20220331.xsd#DescriptionofBusinessandPresentationofFinancialStatements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c9e83eb-451e-4fbe-af72-85ce0f65f99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7df5d435-9540-4494-9c2a-f4728a561308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c9e83eb-451e-4fbe-af72-85ce0f65f99a" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7df5d435-9540-4494-9c2a-f4728a561308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#DescriptionofBusinessandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64214a07-7dc2-4ba0-86ad-6e09c27c1753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_57c01faf-ec95-43cd-bb68-c1aa29cde796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64214a07-7dc2-4ba0-86ad-6e09c27c1753" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_57c01faf-ec95-43cd-bb68-c1aa29cde796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18632a80-414e-4327-8f45-fd195eb39d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64214a07-7dc2-4ba0-86ad-6e09c27c1753" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18632a80-414e-4327-8f45-fd195eb39d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_6729c64d-f76c-4547-98f3-abe51b5956d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64214a07-7dc2-4ba0-86ad-6e09c27c1753" xlink:to="loc_us-gaap_NumberOfReportableSegments_6729c64d-f76c-4547-98f3-abe51b5956d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_831fe1d6-68d9-41df-82bc-dbca1180a78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64214a07-7dc2-4ba0-86ad-6e09c27c1753" xlink:to="loc_us-gaap_NumberOfOperatingSegments_831fe1d6-68d9-41df-82bc-dbca1180a78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cf4c93e5-1bb5-40e6-bc25-80ae0dab5629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64214a07-7dc2-4ba0-86ad-6e09c27c1753" xlink:to="loc_us-gaap_DebtInstrumentTable_cf4c93e5-1bb5-40e6-bc25-80ae0dab5629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3703d646-5c41-4106-b813-0b2ae6fddf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cf4c93e5-1bb5-40e6-bc25-80ae0dab5629" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3703d646-5c41-4106-b813-0b2ae6fddf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fdead0c2-6d74-473e-b152-1f2a76601b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3703d646-5c41-4106-b813-0b2ae6fddf7a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fdead0c2-6d74-473e-b152-1f2a76601b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_668ae7c8-b489-4edc-a022-9219fa348390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fdead0c2-6d74-473e-b152-1f2a76601b7a" xlink:to="loc_us-gaap_LineOfCreditMember_668ae7c8-b489-4edc-a022-9219fa348390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cf4c93e5-1bb5-40e6-bc25-80ae0dab5629" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b2bb8d07-8f24-411f-ba97-1bd4219c1c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b2bb8d07-8f24-411f-ba97-1bd4219c1c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements_3a1bdadc-77b2-4a7c-8730-25c8b84599ad" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:to="loc_tars_LineOfCreditFacilityDrawDownIncrements_3a1bdadc-77b2-4a7c-8730-25c8b84599ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_e9312601-1254-47f3-a182-bfdabd2b4cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdd5bbe-f83f-4222-a164-7568b6913bb6" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_e9312601-1254-47f3-a182-bfdabd2b4cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" xlink:type="simple" xlink:href="tars-20220331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimates"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bc2f75fd-bab1-49c6-8387-5d30e9c6ac13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_08616555-c968-433e-a579-c8d8938b03cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bc2f75fd-bab1-49c6-8387-5d30e9c6ac13" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_08616555-c968-433e-a579-c8d8938b03cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" xlink:type="simple" xlink:href="tars-20220331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_568f43ed-d875-44e4-af24-bb467d0622c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_568f43ed-d875-44e4-af24-bb467d0622c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5677cc59-c5a1-412d-a0bc-b466246ac1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5677cc59-c5a1-412d-a0bc-b466246ac1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_21339f40-c231-4157-9e37-a4399ea4b3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_21339f40-c231-4157-9e37-a4399ea4b3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_c34e0536-32cb-49d5-be09-d8e499c28c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_c34e0536-32cb-49d5-be09-d8e499c28c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_53bf188d-9aa8-4968-8632-ba1e33928138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_53bf188d-9aa8-4968-8632-ba1e33928138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2ceb714b-766b-485f-9bb6-d3b635e7467b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_2ceb714b-766b-485f-9bb6-d3b635e7467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7c143499-b44b-4837-a75e-7e5c883bc13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7c143499-b44b-4837-a75e-7e5c883bc13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_13b6959e-d754-47f3-b1a9-425dcdf11b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_13b6959e-d754-47f3-b1a9-425dcdf11b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2b48ed67-0e3d-496e-adfb-f7f72ededc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2b48ed67-0e3d-496e-adfb-f7f72ededc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e7aea356-089d-4d2b-b328-f732eb08e23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e7aea356-089d-4d2b-b328-f732eb08e23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_80365419-0b0d-40cf-b182-69264dd9a01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_80365419-0b0d-40cf-b182-69264dd9a01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_85280994-92a0-499c-96c0-128d838bf5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_043dd383-a0d7-4867-9a57-f86b5520af7c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_85280994-92a0-499c-96c0-128d838bf5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3d445255-d576-47ba-87d2-8dd087a082a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f541571e-682b-4edc-98ce-47d29038be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3d445255-d576-47ba-87d2-8dd087a082a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f541571e-682b-4edc-98ce-47d29038be5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetail" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetail"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1b78a0df-1c33-41f7-b50f-b7e08a07ff23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ed598217-459c-4173-bc63-f5be925d921d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1b78a0df-1c33-41f7-b50f-b7e08a07ff23" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ed598217-459c-4173-bc63-f5be925d921d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailTables" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bccdbae1-430f-4e10-94b7-c0c84f5d9463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_596de0a4-e5f9-44dd-981c-a58a2074106c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bccdbae1-430f-4e10-94b7-c0c84f5d9463" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_596de0a4-e5f9-44dd-981c-a58a2074106c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_b29ba832-4098-46e0-a6e5-2802f58af77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bccdbae1-430f-4e10-94b7-c0c84f5d9463" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_b29ba832-4098-46e0-a6e5-2802f58af77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d449b322-5814-4e3e-bbe2-def71d9585eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bccdbae1-430f-4e10-94b7-c0c84f5d9463" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d449b322-5814-4e3e-bbe2-def71d9585eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock_78e287e2-7c1b-4041-b1e3-252d1b13dce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bccdbae1-430f-4e10-94b7-c0c84f5d9463" xlink:to="loc_us-gaap_OtherLiabilitiesTableTextBlock_78e287e2-7c1b-4041-b1e3-252d1b13dce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a33fe4fd-1178-47b9-a140-45a287db2934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_be6f005c-418f-470f-85a7-3e932b469df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a33fe4fd-1178-47b9-a140-45a287db2934" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_be6f005c-418f-470f-85a7-3e932b469df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc089b56-447c-49b1-8f2f-59bcba287ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_be6f005c-418f-470f-85a7-3e932b469df8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc089b56-447c-49b1-8f2f-59bcba287ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc089b56-447c-49b1-8f2f-59bcba287ca2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ee9ec0ec-dd5a-4df3-bbc1-da03a83145dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ee9ec0ec-dd5a-4df3-bbc1-da03a83145dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_31881701-3663-419b-9ade-a89ab1df0c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:to="loc_us-gaap_OfficeEquipmentMember_31881701-3663-419b-9ade-a89ab1df0c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_e5c06228-72b2-43be-9642-00a74c40c84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_e5c06228-72b2-43be-9642-00a74c40c84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6ccaf019-2c9f-4585-be87-fc3b21440643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ea55e48-e7c0-4816-ba8d-d874c1d4ba1f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6ccaf019-2c9f-4585-be87-fc3b21440643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_be6f005c-418f-470f-85a7-3e932b469df8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cd468b9f-7843-4e88-ab98-320f1fd96556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cd468b9f-7843-4e88-ab98-320f1fd96556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e9c82274-20f6-4a61-8ed6-e9e0abe84cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e9c82274-20f6-4a61-8ed6-e9e0abe84cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_529b28e9-1d8a-4fc0-9ed0-967ed900d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_529b28e9-1d8a-4fc0-9ed0-967ed900d48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_14dacb47-7a8e-4fa0-80b2-ad489a7957d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca050be7-d098-4410-9e3e-c6b5d7356b3e" xlink:to="loc_us-gaap_Depreciation_14dacb47-7a8e-4fa0-80b2-ad489a7957d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ad9e7f7-d385-4254-a2d1-bb9364ab9f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_9c4cc30a-74be-46b8-b1d9-ed8075bc2c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ad9e7f7-d385-4254-a2d1-bb9364ab9f4f" xlink:to="loc_us-gaap_DepositAssets_9c4cc30a-74be-46b8-b1d9-ed8075bc2c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantRights_0f22d2bc-7912-466e-b672-0dff84386b63" xlink:href="tars-20220331.xsd#tars_EquityWarrantRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ad9e7f7-d385-4254-a2d1-bb9364ab9f4f" xlink:to="loc_tars_EquityWarrantRights_0f22d2bc-7912-466e-b672-0dff84386b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_c23af4d6-571d-4ed9-be8c-78e229114079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ad9e7f7-d385-4254-a2d1-bb9364ab9f4f" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_c23af4d6-571d-4ed9-be8c-78e229114079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c75b6d78-62d9-4193-b201-fa638699f103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ad9e7f7-d385-4254-a2d1-bb9364ab9f4f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c75b6d78-62d9-4193-b201-fa638699f103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_75dbe0bb-28f8-4e6f-b78c-96bc5c9d6c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_75dbe0bb-28f8-4e6f-b78c-96bc5c9d6c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_902fd032-45f3-4517-b842-f568d6fc9ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_902fd032-45f3-4517-b842-f568d6fc9ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AccruedClinicalStudiesCurrent_04e0e518-d13d-47be-bf69-bf1504aac08d" xlink:href="tars-20220331.xsd#tars_AccruedClinicalStudiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:to="loc_tars_AccruedClinicalStudiesCurrent_04e0e518-d13d-47be-bf69-bf1504aac08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0eff82ad-581a-4448-ae97-50edef0f9bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0eff82ad-581a-4448-ae97-50edef0f9bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_2ff5e41e-034e-4c3a-ad7b-109e9a2572d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:to="loc_us-gaap_InterestPayableCurrent_2ff5e41e-034e-4c3a-ad7b-109e9a2572d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_6bce815b-f56d-48c2-95e1-618558c2f277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_6bce815b-f56d-48c2-95e1-618558c2f277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_21a46dfb-d763-411b-a354-06535bef9761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_21a46dfb-d763-411b-a354-06535bef9761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_4fbaf218-6f82-473e-91ec-bb999b27304c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d3bbeea-2cb7-416b-901b-1cb1ce3ed14e" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_4fbaf218-6f82-473e-91ec-bb999b27304c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e19ab14d-c207-46d8-9009-610d226b3572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_444ee362-65e7-46b4-9f69-2a1b90008049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e19ab14d-c207-46d8-9009-610d226b3572" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_444ee362-65e7-46b4-9f69-2a1b90008049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e95b2600-e205-440a-aa49-935a6f32e38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e19ab14d-c207-46d8-9009-610d226b3572" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e95b2600-e205-440a-aa49-935a6f32e38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3a7b1d5a-9a9f-4f4a-b320-34afe742dd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e19ab14d-c207-46d8-9009-610d226b3572" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3a7b1d5a-9a9f-4f4a-b320-34afe742dd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlans" xlink:type="simple" xlink:href="tars-20220331.xsd#StockholdersEquityandEquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2c99913a-8886-4c27-b5c0-dca33c7db361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a1febc06-e248-47b8-8c4d-ed08b5b0b132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2c99913a-8886-4c27-b5c0-dca33c7db361" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a1febc06-e248-47b8-8c4d-ed08b5b0b132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansTables" xlink:type="simple" xlink:href="tars-20220331.xsd#StockholdersEquityandEquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fd0b27b5-27ee-46b0-8abb-4becfe54f18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_923bfba3-78e7-480d-88d0-9d14ee764bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fd0b27b5-27ee-46b0-8abb-4becfe54f18c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_923bfba3-78e7-480d-88d0-9d14ee764bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec1d8886-0bb9-4cca-b485-180048501a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec1d8886-0bb9-4cca-b485-180048501a46" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e0ac6203-9743-46ec-ba08-11f0d4a192bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:to="loc_us-gaap_PlanNameAxis_e0ac6203-9743-46ec-ba08-11f0d4a192bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f7fc15fd-6398-4775-ab13-5e301663cba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e0ac6203-9743-46ec-ba08-11f0d4a192bc" xlink:to="loc_us-gaap_PlanNameDomain_f7fc15fd-6398-4775-ab13-5e301663cba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2020Member_c5376a28-e82f-4083-b1f2-fc03b84b8415" xlink:href="tars-20220331.xsd#tars_EquityIncentivePlan2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f7fc15fd-6398-4775-ab13-5e301663cba4" xlink:to="loc_tars_EquityIncentivePlan2020Member_c5376a28-e82f-4083-b1f2-fc03b84b8415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityIncentivePlan2016Member_e7d1c02c-6b0e-4fbe-94a5-1649e9fb5fcc" xlink:href="tars-20220331.xsd#tars_EquityIncentivePlan2016Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f7fc15fd-6398-4775-ab13-5e301663cba4" xlink:to="loc_tars_EquityIncentivePlan2016Member_e7d1c02c-6b0e-4fbe-94a5-1649e9fb5fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:to="loc_srt_RangeAxis_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ccee613-bbbe-43a4-874f-b79c9c4a4f96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9a8ad204-fda9-4744-abe7-8fd4cceaaa9f" xlink:to="loc_srt_RangeMember_3ccee613-bbbe-43a4-874f-b79c9c4a4f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9a072b0c-9007-4b08-88de-cfccd1ad9e06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ccee613-bbbe-43a4-874f-b79c9c4a4f96" xlink:to="loc_srt_MinimumMember_9a072b0c-9007-4b08-88de-cfccd1ad9e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45a6b20b-ebff-4d1c-8c6a-d27fe5be62d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ccee613-bbbe-43a4-874f-b79c9c4a4f96" xlink:to="loc_srt_MaximumMember_45a6b20b-ebff-4d1c-8c6a-d27fe5be62d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_29374d35-8d6f-4a0c-bef6-936595c432c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:to="loc_us-gaap_AwardTypeAxis_29374d35-8d6f-4a0c-bef6-936595c432c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3516495d-9ac8-44fc-878d-23d42ca97198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_29374d35-8d6f-4a0c-bef6-936595c432c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3516495d-9ac8-44fc-878d-23d42ca97198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fba83040-b6b6-4e19-a8f5-97561e352c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3516495d-9ac8-44fc-878d-23d42ca97198" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fba83040-b6b6-4e19-a8f5-97561e352c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fae46070-7335-4524-b7a4-da6fffe4dbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3516495d-9ac8-44fc-878d-23d42ca97198" xlink:to="loc_us-gaap_EmployeeStockMember_fae46070-7335-4524-b7a4-da6fffe4dbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e78a939e-29be-4fe7-b567-3c5d235d0f98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b8e0752e-5596-4414-83d4-f4b855c4502d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b8e0752e-5596-4414-83d4-f4b855c4502d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b6b48f93-c195-44c9-a20a-51696c397e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_CommonStockSharesIssued_b6b48f93-c195-44c9-a20a-51696c397e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a0dd3fa2-0621-4d42-b914-8f2b5edb6572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a0dd3fa2-0621-4d42-b914-8f2b5edb6572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_5b9eb94b-cc71-498f-8962-568cc932aca6" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_5b9eb94b-cc71-498f-8962-568cc932aca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_23e07244-09eb-4b81-93df-5d0830f49c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_23e07244-09eb-4b81-93df-5d0830f49c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_28c698d7-0f58-4e35-865c-479ec8f96fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_28c698d7-0f58-4e35-865c-479ec8f96fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_37c0546c-0b4b-41d8-8dea-caffc8b9ba18" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath_37c0546c-0b4b-41d8-8dea-caffc8b9ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_18667367-a4fc-4c34-9e44-8f98734937f2" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability_18667367-a4fc-4c34-9e44-8f98734937f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_9bb87452-b7ae-4f7a-9ae7-e07ec452053e" xlink:href="tars-20220331.xsd#tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations_9bb87452-b7ae-4f7a-9ae7-e07ec452053e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_9c693608-fec5-416d-9012-269d7b3873e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_9c693608-fec5-416d-9012-269d7b3873e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_8c5f4eb3-11b8-4cdd-8a49-a45c18d110ce" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_8c5f4eb3-11b8-4cdd-8a49-a45c18d110ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease_f04ed841-a4a1-477b-b9b4-b80c12803078" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease_e93e1f68-cbdf-42e3-a83c-60fb59b383f6" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease_e93e1f68-cbdf-42e3-a83c-60fb59b383f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8da3cb33-f59d-4357-b8a7-35186ecf307d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f24f34d8-8b8d-4864-ac6d-6322b901c0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_8da3cb33-f59d-4357-b8a7-35186ecf307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d7d4e8e4-18b6-4cf7-9ee0-5297b6752fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_9121757e-07bd-4795-8f1a-5ae27a8f0cfe" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7d4e8e4-18b6-4cf7-9ee0-5297b6752fb5" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant_9121757e-07bd-4795-8f1a-5ae27a8f0cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_5389bd5e-9958-4af3-966d-9f44925bb275" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7d4e8e4-18b6-4cf7-9ee0-5297b6752fb5" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan_5389bd5e-9958-4af3-966d-9f44925bb275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_74f05fdf-68f0-40cd-a1c0-5240079a0bf1" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7d4e8e4-18b6-4cf7-9ee0-5297b6752fb5" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding_74f05fdf-68f0-40cd-a1c0-5240079a0bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_1c4834a7-3df6-4d4c-92b0-509d936f233c" xlink:href="tars-20220331.xsd#tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7d4e8e4-18b6-4cf7-9ee0-5297b6752fb5" xlink:to="loc_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant_1c4834a7-3df6-4d4c-92b0-509d936f233c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0ebc49ea-6a4e-4041-9bce-7f942b557f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7d4e8e4-18b6-4cf7-9ee0-5297b6752fb5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0ebc49ea-6a4e-4041-9bce-7f942b557f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="tars-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2852c27e-3415-4cb3-afb2-698b492c02c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6700f340-fbc2-4987-8175-081e47c94fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2852c27e-3415-4cb3-afb2-698b492c02c8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6700f340-fbc2-4987-8175-081e47c94fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="tars-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3388db58-a673-42ef-a83a-6e66e4b091cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0b7fd3e6-3776-48fd-8c22-21b082e9bef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3388db58-a673-42ef-a83a-6e66e4b091cb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0b7fd3e6-3776-48fd-8c22-21b082e9bef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ddd71d68-14bf-4d39-80c1-bef83aa49d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_540192e4-3158-45b4-9e36-3835032aa291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ddd71d68-14bf-4d39-80c1-bef83aa49d27" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_540192e4-3158-45b4-9e36-3835032aa291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_540192e4-3158-45b4-9e36-3835032aa291" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_02f017fc-1ecd-4c75-8641-d29564b28fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c4f85790-b1d1-46e5-9602-7b3b5e4cd12d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_02f017fc-1ecd-4c75-8641-d29564b28fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6130ca78-148a-41bd-9441-a5cf50f52ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_02f017fc-1ecd-4c75-8641-d29564b28fb2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6130ca78-148a-41bd-9441-a5cf50f52ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6c7a6a04-f190-43cf-8374-5891fc1828ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_02f017fc-1ecd-4c75-8641-d29564b28fb2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6c7a6a04-f190-43cf-8374-5891fc1828ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b13f8c00-88f2-4221-8dfc-80002929e362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_540192e4-3158-45b4-9e36-3835032aa291" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b13f8c00-88f2-4221-8dfc-80002929e362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a92237ab-9e2c-4a4c-895b-7c6d7fd70a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b13f8c00-88f2-4221-8dfc-80002929e362" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a92237ab-9e2c-4a4c-895b-7c6d7fd70a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="tars-20220331.xsd#NetLossIncomePerShare"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_015e7625-e94e-4258-a096-183e435fe3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_072c2837-407b-4235-86fb-c38a8d0a3307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_015e7625-e94e-4258-a096-183e435fe3b5" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_072c2837-407b-4235-86fb-c38a8d0a3307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossIncomePerShareTables" xlink:type="simple" xlink:href="tars-20220331.xsd#NetLossIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ec8acfc6-0fab-4cfb-b1d5-1309f58da631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_54bd5d6b-65f7-42ae-a29c-460526f37141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ec8acfc6-0fab-4cfb-b1d5-1309f58da631" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_54bd5d6b-65f7-42ae-a29c-460526f37141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d20b7367-9cb4-4a94-85a5-46ec1134539b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ec8acfc6-0fab-4cfb-b1d5-1309f58da631" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d20b7367-9cb4-4a94-85a5-46ec1134539b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossIncomePerShareDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#NetLossIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f76d60c4-e1da-4132-b9ab-07460386fe8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_57357f21-e0e1-46b0-9b58-58ab3eb31726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f76d60c4-e1da-4132-b9ab-07460386fe8b" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_57357f21-e0e1-46b0-9b58-58ab3eb31726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00293443-c1c7-4d69-baf6-f949f66edd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_57357f21-e0e1-46b0-9b58-58ab3eb31726" xlink:to="loc_us-gaap_NetIncomeLoss_00293443-c1c7-4d69-baf6-f949f66edd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_44500e70-145b-45ec-878e-fbb06eff53bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_57357f21-e0e1-46b0-9b58-58ab3eb31726" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_44500e70-145b-45ec-878e-fbb06eff53bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e3cfb85b-0184-46c0-8325-9d6558e23c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_57357f21-e0e1-46b0-9b58-58ab3eb31726" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e3cfb85b-0184-46c0-8325-9d6558e23c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_af4a9517-dc85-4ec6-bafe-7fc507a8db9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_57357f21-e0e1-46b0-9b58-58ab3eb31726" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_af4a9517-dc85-4ec6-bafe-7fc507a8db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a4e97bb1-f71f-444a-960e-9a5ff15642ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_57357f21-e0e1-46b0-9b58-58ab3eb31726" xlink:to="loc_us-gaap_EarningsPerShareBasic_a4e97bb1-f71f-444a-960e-9a5ff15642ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f76d60c4-e1da-4132-b9ab-07460386fe8b" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eab080fd-d21d-41a6-95f1-59823084a14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:to="loc_us-gaap_NetIncomeLoss_eab080fd-d21d-41a6-95f1-59823084a14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_a9e5ca34-4281-4810-9375-8aa048415827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_a9e5ca34-4281-4810-9375-8aa048415827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_66dc5907-8157-43ba-923a-6db45d3a2bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_66dc5907-8157-43ba-923a-6db45d3a2bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c43398d-fdc0-4ac7-a78c-3caa4962c654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c43398d-fdc0-4ac7-a78c-3caa4962c654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_67b8f67f-93e0-4207-b8ff-6a923831c487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_67b8f67f-93e0-4207-b8ff-6a923831c487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fff46ffe-1678-480e-a67f-644066b0003c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_67b8f67f-93e0-4207-b8ff-6a923831c487" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fff46ffe-1678-480e-a67f-644066b0003c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22743ebb-5aeb-4b61-847f-523165c9d69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22743ebb-5aeb-4b61-847f-523165c9d69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7423070d-ab72-415d-8058-e93e9dd74774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d451ec52-2c21-4956-9bd6-83bd0fd13378" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7423070d-ab72-415d-8058-e93e9dd74774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#NetLossIncomePerShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1cc52f48-5862-4c0d-93fd-a0ffbc6b6570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc0275b6-6093-4bbb-bdb8-d0558757fbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1cc52f48-5862-4c0d-93fd-a0ffbc6b6570" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc0275b6-6093-4bbb-bdb8-d0558757fbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95b282f2-cd7d-4b1b-981e-f823190122e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc0275b6-6093-4bbb-bdb8-d0558757fbae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95b282f2-cd7d-4b1b-981e-f823190122e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_95b282f2-cd7d-4b1b-981e-f823190122e6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6c00ab06-11ea-4ece-b92e-e8a188fc84a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6c00ab06-11ea-4ece-b92e-e8a188fc84a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_50d38d33-9c0e-4cba-a0dd-a9aa6f8b2260" xlink:href="tars-20220331.xsd#tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:to="loc_tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember_50d38d33-9c0e-4cba-a0dd-a9aa6f8b2260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_82b5c3e3-a4d6-4eca-83f2-9c7dda8d5c7a" xlink:href="tars-20220331.xsd#tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ef3eed2-69fb-4515-b24d-b8d01e3b4371" xlink:to="loc_tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember_82b5c3e3-a4d6-4eca-83f2-9c7dda8d5c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_90aa5f18-94a9-400a-8dfe-5a276eb92471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc0275b6-6093-4bbb-bdb8-d0558757fbae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_90aa5f18-94a9-400a-8dfe-5a276eb92471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b641774a-2cb8-4732-9179-283e27c3f489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_90aa5f18-94a9-400a-8dfe-5a276eb92471" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b641774a-2cb8-4732-9179-283e27c3f489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="tars-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e6a47db9-881b-4539-aa86-0b51df63f1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6bb29e08-6c08-4c6c-ba7d-7bf8087d2445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e6a47db9-881b-4539-aa86-0b51df63f1b9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6bb29e08-6c08-4c6c-ba7d-7bf8087d2445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="tars-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc803f12-be9a-492c-bf2e-5098d28d7341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_09953faa-6137-4b34-a525-0e2e270ef6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc803f12-be9a-492c-bf2e-5098d28d7341" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_09953faa-6137-4b34-a525-0e2e270ef6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_64e1eaa1-072b-4650-afe1-819ba96a5f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc803f12-be9a-492c-bf2e-5098d28d7341" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_64e1eaa1-072b-4650-afe1-819ba96a5f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_33ae3879-3eb0-4bbf-9c3c-20d7c36c8e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_33ae3879-3eb0-4bbf-9c3c-20d7c36c8e3c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4220bb-c7b1-4a50-9b03-a5827396263a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4220bb-c7b1-4a50-9b03-a5827396263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4220bb-c7b1-4a50-9b03-a5827396263a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_de8bf903-ddfa-4efa-afb3-fb2c636117f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_de8bf903-ddfa-4efa-afb3-fb2c636117f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_31318fc1-9717-4967-92c6-50a67ed3260f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_31318fc1-9717-4967-92c6-50a67ed3260f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fe99ebed-cf55-4f2f-ab51-4bd4f42af708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f132f7ee-4dbd-4de5-b8f1-b5456711253f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fe99ebed-cf55-4f2f-ab51-4bd4f42af708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_faedd38e-887a-41f8-a7ea-8443345dbe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_faedd38e-887a-41f8-a7ea-8443345dbe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a39ee6b-b9ba-4a0e-bc96-b3c1972ceca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_faedd38e-887a-41f8-a7ea-8443345dbe25" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a39ee6b-b9ba-4a0e-bc96-b3c1972ceca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5085c35b-bb36-454b-bb0f-d1056482f9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a39ee6b-b9ba-4a0e-bc96-b3c1972ceca3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5085c35b-bb36-454b-bb0f-d1056482f9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7881bf4d-a58a-488c-93a5-31bbb6b7dce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ee8174b3-c8fd-441a-9798-5a91149e5c0a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7881bf4d-a58a-488c-93a5-31bbb6b7dce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7881bf4d-a58a-488c-93a5-31bbb6b7dce7" xlink:to="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_978064eb-366a-40a4-90b1-506914dd705b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_978064eb-366a-40a4-90b1-506914dd705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e8e7affc-9733-455a-a66a-4fa6df8fb35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e8e7affc-9733-455a-a66a-4fa6df8fb35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquityWarrantsFairValueDisclosure_645fc4f2-c337-424d-8d47-35dfd6ec6a1a" xlink:href="tars-20220331.xsd#tars_EquityWarrantsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:to="loc_tars_EquityWarrantsFairValueDisclosure_645fc4f2-c337-424d-8d47-35dfd6ec6a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_67efb69f-92f2-461f-a210-ee355e84af54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f2a4f905-059d-46f4-a341-5c81758cb57c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_67efb69f-92f2-461f-a210-ee355e84af54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_447d2471-243c-4cdc-be72-b22601272b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfWarrants_50e4a483-9e17-4462-94aa-2119407e5d46" xlink:href="tars-20220331.xsd#tars_NumberOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_447d2471-243c-4cdc-be72-b22601272b2b" xlink:to="loc_tars_NumberOfWarrants_50e4a483-9e17-4462-94aa-2119407e5d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfVestedWarrants_0d321e81-77b1-41f3-bbc2-75ba30381847" xlink:href="tars-20220331.xsd#tars_NumberOfVestedWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_447d2471-243c-4cdc-be72-b22601272b2b" xlink:to="loc_tars_NumberOfVestedWarrants_0d321e81-77b1-41f3-bbc2-75ba30381847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_EquitySecuritiesFVNINumberOfShares_2ceceba4-5230-4eb6-859e-f3db9bf04cdc" xlink:href="tars-20220331.xsd#tars_EquitySecuritiesFVNINumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_447d2471-243c-4cdc-be72-b22601272b2b" xlink:to="loc_tars_EquitySecuritiesFVNINumberOfShares_2ceceba4-5230-4eb6-859e-f3db9bf04cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e7a82c63-050d-40ad-81a8-cce4731ed805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_04a5646f-70b4-4133-adb4-1b7d1176e71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e7a82c63-050d-40ad-81a8-cce4731ed805" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_04a5646f-70b4-4133-adb4-1b7d1176e71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_09e6f2e8-8114-4678-af3b-0b6f90e03846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_04a5646f-70b4-4133-adb4-1b7d1176e71d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_09e6f2e8-8114-4678-af3b-0b6f90e03846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ea34b2e3-575f-4dbf-8725-7ed1f20a6c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09e6f2e8-8114-4678-af3b-0b6f90e03846" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ea34b2e3-575f-4dbf-8725-7ed1f20a6c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_1236b6d1-cb16-4344-b084-95d141fb0d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea34b2e3-575f-4dbf-8725-7ed1f20a6c6a" xlink:to="loc_us-gaap_SalesMember_1236b6d1-cb16-4344-b084-95d141fb0d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_3943da09-af98-4ae8-ae0e-8468db27559b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ea34b2e3-575f-4dbf-8725-7ed1f20a6c6a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_3943da09-af98-4ae8-ae0e-8468db27559b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5c5ebd50-6567-4c2c-8320-9bb0c43cc5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_04a5646f-70b4-4133-adb4-1b7d1176e71d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5c5ebd50-6567-4c2c-8320-9bb0c43cc5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5c5ebd50-6567-4c2c-8320-9bb0c43cc5cc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f877647c-ddce-4aa7-af25-373575d04c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f877647c-ddce-4aa7-af25-373575d04c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_5dbc2feb-2e3b-407e-a5a8-ec58fbcadf57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_5dbc2feb-2e3b-407e-a5a8-ec58fbcadf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_42ea5e3e-eb89-4da1-927e-5789088fa2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_144fde80-6dc3-4188-87f0-3bff3aca4c29" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_42ea5e3e-eb89-4da1-927e-5789088fa2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingencies" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingencies"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9cad1d4-f19e-4476-a70e-df883d637c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fdecc69a-c35b-4624-ae77-b47a846d6a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9cad1d4-f19e-4476-a70e-df883d637c1b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fdecc69a-c35b-4624-ae77-b47a846d6a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesTables" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1f9f6b27-4645-42f8-9bf4-842326fdaaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock_b49b0608-c898-4e19-b0b3-4ddfe70d6a7d" xlink:href="tars-20220331.xsd#tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1f9f6b27-4645-42f8-9bf4-842326fdaaa0" xlink:to="loc_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock_b49b0608-c898-4e19-b0b3-4ddfe70d6a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e2548ec0-6e1c-4d89-990a-753289b0702e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1f9f6b27-4645-42f8-9bf4-842326fdaaa0" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e2548ec0-6e1c-4d89-990a-753289b0702e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_90d7963b-0a83-4cb4-bc31-904e9814176e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1f9f6b27-4645-42f8-9bf4-842326fdaaa0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_90d7963b-0a83-4cb4-bc31-904e9814176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesFacilityLeasesDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_61eb3046-2559-4dde-b466-d4c4ae2ab210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6713c5c8-e11a-4c8f-aede-2e2cb41bdb78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_61eb3046-2559-4dde-b466-d4c4ae2ab210" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6713c5c8-e11a-4c8f-aede-2e2cb41bdb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_613838ef-82fb-4053-8b94-ea1553ceceeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6713c5c8-e11a-4c8f-aede-2e2cb41bdb78" xlink:to="loc_us-gaap_LeaseContractualTermAxis_613838ef-82fb-4053-8b94-ea1553ceceeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_10a44896-7a81-42a7-84c8-6fff2cdabb37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_613838ef-82fb-4053-8b94-ea1553ceceeb" xlink:to="loc_us-gaap_LeaseContractualTermDomain_10a44896-7a81-42a7-84c8-6fff2cdabb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesLeaseMember_e64bd277-a5ee-48d5-b52b-c7a1238dc94e" xlink:href="tars-20220331.xsd#tars_IrvineOfficeAndFacilitiesLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_10a44896-7a81-42a7-84c8-6fff2cdabb37" xlink:to="loc_tars_IrvineOfficeAndFacilitiesLeaseMember_e64bd277-a5ee-48d5-b52b-c7a1238dc94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember_f10a15fd-3bfb-4e2d-9631-0ecb1ee79d6a" xlink:href="tars-20220331.xsd#tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_10a44896-7a81-42a7-84c8-6fff2cdabb37" xlink:to="loc_tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember_f10a15fd-3bfb-4e2d-9631-0ecb1ee79d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6713c5c8-e11a-4c8f-aede-2e2cb41bdb78" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_ea926c95-9155-443f-9acd-24c964411304" xlink:href="tars-20220331.xsd#tars_LesseeOperatingLeaseNumberOfLeaseContracts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_tars_LesseeOperatingLeaseNumberOfLeaseContracts_ea926c95-9155-443f-9acd-24c964411304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_988e6d16-5e23-4305-9dc8-5ce094737512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_988e6d16-5e23-4305-9dc8-5ce094737512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d3a3770a-efe1-4e37-a89a-86963d6ea00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d3a3770a-efe1-4e37-a89a-86963d6ea00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_95b2ca6f-e1ee-404f-9997-dded16ef5c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_95b2ca6f-e1ee-404f-9997-dded16ef5c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7c2bdb50-acda-4467-9a0c-7c027f22481b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9cf4b2aa-0b6a-4f25-8158-d84298d6f06e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7c2bdb50-acda-4467-9a0c-7c027f22481b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_98a86bdf-ada1-44fc-b02b-41f6c7b01799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d89d7851-2b18-4fd1-a4c2-6c0cabf05c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_98a86bdf-ada1-44fc-b02b-41f6c7b01799" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d89d7851-2b18-4fd1-a4c2-6c0cabf05c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef8c69c5-9eb0-4bcf-b010-d6203f0aa9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_98a86bdf-ada1-44fc-b02b-41f6c7b01799" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef8c69c5-9eb0-4bcf-b010-d6203f0aa9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_96137c00-dfd1-4325-a94a-b9dad6783956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef8c69c5-9eb0-4bcf-b010-d6203f0aa9cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_96137c00-dfd1-4325-a94a-b9dad6783956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_61777175-88cf-4d09-ac3e-3ae864e0d63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_98a86bdf-ada1-44fc-b02b-41f6c7b01799" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_61777175-88cf-4d09-ac3e-3ae864e0d63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_317eb8da-bd96-44b6-aa80-e5f2858bc43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_61777175-88cf-4d09-ac3e-3ae864e0d63f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_317eb8da-bd96-44b6-aa80-e5f2858bc43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c98e5ecc-c622-41f8-8f53-31190c9f91ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_98a86bdf-ada1-44fc-b02b-41f6c7b01799" xlink:to="loc_us-gaap_OperatingLeaseLiability_c98e5ecc-c622-41f8-8f53-31190c9f91ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d92dc2c8-bac4-4e12-9246-a8a775b99663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_334406c1-09de-4067-ace1-a383acfa32e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d92dc2c8-bac4-4e12-9246-a8a775b99663" xlink:to="loc_us-gaap_OperatingLeaseCost_334406c1-09de-4067-ace1-a383acfa32e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_95b6eb06-1b4a-40c7-a54d-8350b533f7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d92dc2c8-bac4-4e12-9246-a8a775b99663" xlink:to="loc_us-gaap_VariableLeaseCost_95b6eb06-1b4a-40c7-a54d-8350b533f7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_df409c1c-cffa-424e-8db1-132d34011de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d92dc2c8-bac4-4e12-9246-a8a775b99663" xlink:to="loc_us-gaap_ShortTermLeaseCost_df409c1c-cffa-424e-8db1-132d34011de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_13ef77c8-4bd0-4422-a816-7864ecb42695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d92dc2c8-bac4-4e12-9246-a8a775b99663" xlink:to="loc_us-gaap_LeaseCost_13ef77c8-4bd0-4422-a816-7864ecb42695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f56fa48d-bc54-4721-8bc2-5b5dd568309e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f56fa48d-bc54-4721-8bc2-5b5dd568309e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_daad2b1e-6470-46a1-8f78-3f5163de3f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_daad2b1e-6470-46a1-8f78-3f5163de3f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c3e681e-27e5-4d18-b689-c5c51ff112f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c3e681e-27e5-4d18-b689-c5c51ff112f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ebfabefd-9862-4a70-ac71-c0b5db264956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ebfabefd-9862-4a70-ac71-c0b5db264956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dfb5c4cc-0952-423f-9a3b-ff88640e2ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dfb5c4cc-0952-423f-9a3b-ff88640e2ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7cba933c-7370-4da9-b9e7-459cdf780029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7cba933c-7370-4da9-b9e7-459cdf780029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d3b6196-64b4-45ac-8aef-a48fbb035d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d3b6196-64b4-45ac-8aef-a48fbb035d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ac61de10-9889-44c9-9880-518bdf9a8f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b497f7f-7efd-4a72-8f16-e12900693799" xlink:to="loc_us-gaap_OperatingLeaseLiability_ac61de10-9889-44c9-9880-518bdf9a8f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesInLicenseAgreementforLotilanerDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f4121d81-865b-461a-84b8-75b085fd05ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f4121d81-865b-461a-84b8-75b085fd05ff" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6095f5ad-0fa1-4132-bbef-b28c796ac6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8ce6af7e-f8b6-4421-ba40-c700bd0f7b70" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6095f5ad-0fa1-4132-bbef-b28c796ac6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fbe976e2-3a04-4903-9e89-0ad646e1a327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6095f5ad-0fa1-4132-bbef-b28c796ac6cb" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fbe976e2-3a04-4903-9e89-0ad646e1a327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c6e519d5-bf76-457b-92ea-2354ee6f4277" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:to="loc_srt_ProductOrServiceAxis_c6e519d5-bf76-457b-92ea-2354ee6f4277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f55c9130-3385-4658-ab4a-0495674b65e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c6e519d5-bf76-457b-92ea-2354ee6f4277" xlink:to="loc_srt_ProductsAndServicesDomain_f55c9130-3385-4658-ab4a-0495674b65e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalMilestonesMember_d3aecad1-c644-4de7-89c9-d6f8b7fb7db0" xlink:href="tars-20220331.xsd#tars_ClinicalMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f55c9130-3385-4658-ab4a-0495674b65e7" xlink:to="loc_tars_ClinicalMilestonesMember_d3aecad1-c644-4de7-89c9-d6f8b7fb7db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CommercialAndSalesMilestonesMember_bffebaec-018f-4a5b-8133-7b0c5dc94b36" xlink:href="tars-20220331.xsd#tars_CommercialAndSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f55c9130-3385-4658-ab4a-0495674b65e7" xlink:to="loc_tars_CommercialAndSalesMilestonesMember_bffebaec-018f-4a5b-8133-7b0c5dc94b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e20b5945-356e-4549-9aa4-f7254a98876b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:to="loc_srt_CounterpartyNameAxis_e20b5945-356e-4549-9aa4-f7254a98876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc58758e-d508-422b-a675-94a24ba41d02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e20b5945-356e-4549-9aa4-f7254a98876b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc58758e-d508-422b-a675-94a24ba41d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_5493d2b6-9f9a-4f34-81d9-f3f34e2d725a" xlink:href="tars-20220331.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc58758e-d508-422b-a675-94a24ba41d02" xlink:to="loc_tars_LianBioMember_5493d2b6-9f9a-4f34-81d9-f3f34e2d725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ElancoMember_bf9936f8-67f3-408c-8083-caf2b9a01477" xlink:href="tars-20220331.xsd#tars_ElancoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc58758e-d508-422b-a675-94a24ba41d02" xlink:to="loc_tars_ElancoMember_bf9936f8-67f3-408c-8083-caf2b9a01477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_113319c7-b6c1-447a-bc57-ac820b1a823f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9611cf9f-3c7f-4389-a40e-024dcb9b77af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9611cf9f-3c7f-4389-a40e-024dcb9b77af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_4caab028-406e-48e1-8dc6-0fcb714ff262" xlink:href="tars-20220331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_4caab028-406e-48e1-8dc6-0fcb714ff262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_c8236e75-6315-470f-bfc8-54656e5b3aaf" xlink:href="tars-20220331.xsd#tars_UpfrontPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_UpfrontPayment_c8236e75-6315-470f-bfc8-54656e5b3aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_61339dbf-b1df-4c61-b9ff-ea9fe803fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_61339dbf-b1df-4c61-b9ff-ea9fe803fba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_fee75fcd-dc4f-448c-ae9c-17faf6058957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_fee75fcd-dc4f-448c-ae9c-17faf6058957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_af0f83bc-9003-48be-8cc8-343466d31fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_us-gaap_SharePrice_af0f83bc-9003-48be-8cc8-343466d31fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_31f686cc-64c8-4236-b404-da4acebb2551" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices_31f686cc-64c8-4236-b404-da4acebb2551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_d7eed1d1-60ec-4bc8-8cca-dd39e2a62b3f" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices_d7eed1d1-60ec-4bc8-8cca-dd39e2a62b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_89b0da3c-9c24-4824-9efc-91a1d347a237" xlink:href="tars-20220331.xsd#tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1fe570fd-a8a7-4259-ba07-a68a42423839" xlink:to="loc_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices_89b0da3c-9c24-4824-9efc-91a1d347a237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CommitmentContingenciesEmploymentArrangementsDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5c38b780-2636-4fd3-81f5-27d7e4ad2849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_ad001d38-27bd-4c8a-a593-2f59e2566fc6" xlink:href="tars-20220331.xsd#tars_NumberOfEmploymentArrangementsWithExecutiveOfficers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5c38b780-2636-4fd3-81f5-27d7e4ad2849" xlink:to="loc_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers_ad001d38-27bd-4c8a-a593-2f59e2566fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreement" xlink:type="simple" xlink:href="tars-20220331.xsd#OutLicenseAgreement"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ba44087-9b21-4436-ace1-6c3a842561a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dd52ac38-481c-42c5-8a47-08137187722b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ba44087-9b21-4436-ace1-6c3a842561a9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dd52ac38-481c-42c5-8a47-08137187722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#OutLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/OutLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06158a8f-ab42-4b73-b958-f52894a22cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06158a8f-ab42-4b73-b958-f52894a22cf8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d7584a77-4849-4179-9817-d593dfe8d116" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:to="loc_srt_CounterpartyNameAxis_d7584a77-4849-4179-9817-d593dfe8d116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19649131-a2fd-4ac1-974e-176dac61e3af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d7584a77-4849-4179-9817-d593dfe8d116" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19649131-a2fd-4ac1-974e-176dac61e3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LianBioMember_ae185db2-f876-437f-83cf-c9c505a20652" xlink:href="tars-20220331.xsd#tars_LianBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19649131-a2fd-4ac1-974e-176dac61e3af" xlink:to="loc_tars_LianBioMember_ae185db2-f876-437f-83cf-c9c505a20652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5167cf95-09c6-4753-858c-4ca49fb3b060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5167cf95-09c6-4753-858c-4ca49fb3b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39c37a0a-b3ed-4293-b977-7722bd587866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5167cf95-09c6-4753-858c-4ca49fb3b060" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39c37a0a-b3ed-4293-b977-7722bd587866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_6519d56d-2cff-4a3b-bcf3-08ee06ee998a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39c37a0a-b3ed-4293-b977-7722bd587866" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_6519d56d-2cff-4a3b-bcf3-08ee06ee998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_158120f6-38bc-4c61-817f-bd97c406c0e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:to="loc_srt_ProductOrServiceAxis_158120f6-38bc-4c61-817f-bd97c406c0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_158120f6-38bc-4c61-817f-bd97c406c0e2" xlink:to="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_ClinicalDevelopmentMilestonesMember_84130221-9722-450a-a918-8fcdbb62d59a" xlink:href="tars-20220331.xsd#tars_ClinicalDevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_ClinicalDevelopmentMilestonesMember_84130221-9722-450a-a918-8fcdbb62d59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DevelopmentAndRegulatoryMilestoneMember_35515d7b-6c32-4674-9274-e14e4cae808f" xlink:href="tars-20220331.xsd#tars_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_DevelopmentAndRegulatoryMilestoneMember_35515d7b-6c32-4674-9274-e14e4cae808f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_DrugSupplyAgreementMilestoneMember_80d75a45-76b8-440d-87eb-f169ca9fb069" xlink:href="tars-20220331.xsd#tars_DrugSupplyAgreementMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_DrugSupplyAgreementMilestoneMember_80d75a45-76b8-440d-87eb-f169ca9fb069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SalesMilestoneMember_cf8bfd3a-b256-4615-8698-8c98079c962f" xlink:href="tars-20220331.xsd#tars_SalesMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_SalesMilestoneMember_cf8bfd3a-b256-4615-8698-8c98079c962f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_b639da5d-35e0-4d37-b913-bb068dc3c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_us-gaap_LicenseAndServiceMember_b639da5d-35e0-4d37-b913-bb068dc3c4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborationMember_f6f29fda-6fb0-4522-83f5-54917211f5cd" xlink:href="tars-20220331.xsd#tars_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_64dbaca6-eebf-4880-8da2-e6e9a1adb867" xlink:to="loc_tars_CollaborationMember_f6f29fda-6fb0-4522-83f5-54917211f5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_524892b1-1a52-4521-8f63-755f293928b6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_UpfrontPayment_3318f2eb-6e11-4f5b-b33d-77023429573f" xlink:href="tars-20220331.xsd#tars_UpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_tars_UpfrontPayment_3318f2eb-6e11-4f5b-b33d-77023429573f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMilestonePayment_4a3041a2-8402-4896-8d23-04c5b68e1e70" xlink:href="tars-20220331.xsd#tars_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_tars_CollaborativeArrangementMilestonePayment_4a3041a2-8402-4896-8d23-04c5b68e1e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CollaborativeArrangementMaximumMilestonePayment_701692c5-3649-4ea3-a687-13459b4f415f" xlink:href="tars-20220331.xsd#tars_CollaborativeArrangementMaximumMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_tars_CollaborativeArrangementMaximumMilestonePayment_701692c5-3649-4ea3-a687-13459b4f415f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e302b201-1acd-4585-8040-a2c366030b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_89c6e0c5-4e62-4e70-85bc-73709650a86a" xlink:to="loc_us-gaap_Revenues_e302b201-1acd-4585-8040-a2c366030b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreement" xlink:type="simple" xlink:href="tars-20220331.xsd#CreditFacilityAgreement"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_161b0959-c49e-434d-9f6c-7c3d51e7e895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_25abd93d-ff73-43f7-8bdd-f9444d4c0a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_161b0959-c49e-434d-9f6c-7c3d51e7e895" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_25abd93d-ff73-43f7-8bdd-f9444d4c0a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementTables" xlink:type="simple" xlink:href="tars-20220331.xsd#CreditFacilityAgreementTables"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_035b49a2-838a-4f33-953b-73dca2eefe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_8008ef38-4aa4-4a51-b0fd-1c015ba99f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_035b49a2-838a-4f33-953b-73dca2eefe5c" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_8008ef38-4aa4-4a51-b0fd-1c015ba99f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_826ffb7a-3829-4542-98b5-e4412ceb75a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_035b49a2-838a-4f33-953b-73dca2eefe5c" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_826ffb7a-3829-4542-98b5-e4412ceb75a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CreditFacilityAgreementDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7d76755b-5704-443c-8aea-d7018c8cbfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d76755b-5704-443c-8aea-d7018c8cbfe6" xlink:to="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a3b88fbc-3057-4c63-aef5-b9ae79f24910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a3b88fbc-3057-4c63-aef5-b9ae79f24910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_20b53ca3-1ff1-4396-af12-bd07876e3c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3b88fbc-3057-4c63-aef5-b9ae79f24910" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_20b53ca3-1ff1-4396-af12-bd07876e3c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e8243cfa-cd1c-4892-b699-0a16914e5ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_20b53ca3-1ff1-4396-af12-bd07876e3c36" xlink:to="loc_us-gaap_LineOfCreditMember_e8243cfa-cd1c-4892-b699-0a16914e5ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_838f7182-6a69-4953-9dd2-45c7f0025bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_DebtInstrumentAxis_838f7182-6a69-4953-9dd2-45c7f0025bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_838f7182-6a69-4953-9dd2-45c7f0025bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheOneMember_321302a9-5982-466d-9cb6-7eb458460f18" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheOneMember_321302a9-5982-466d-9cb6-7eb458460f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheTwoMember_91b26810-77a1-414a-8255-7ae382ed2c95" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheTwoMember_91b26810-77a1-414a-8255-7ae382ed2c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheThreeMember_ac732d53-1863-42fd-b379-2cfb5eacb38e" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheThreeMember_ac732d53-1863-42fd-b379-2cfb5eacb38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFourMember_a2ac29ee-1ea7-4a3c-9c1b-22bee43c2672" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheFourMember_a2ac29ee-1ea7-4a3c-9c1b-22bee43c2672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_CreditFacilityTrancheFiveMember_785a74cd-1304-4f28-9f5d-bb27fcc99f18" xlink:href="tars-20220331.xsd#tars_CreditFacilityTrancheFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_33f41cb5-90be-48b4-98d9-b1dfad3214c9" xlink:to="loc_tars_CreditFacilityTrancheFiveMember_785a74cd-1304-4f28-9f5d-bb27fcc99f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_1c3101a7-2afc-492e-a871-8a5524d89eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_VariableRateAxis_1c3101a7-2afc-492e-a871-8a5524d89eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_88bbebb2-6907-4426-b98b-fce278738ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_1c3101a7-2afc-492e-a871-8a5524d89eca" xlink:to="loc_us-gaap_VariableRateDomain_88bbebb2-6907-4426-b98b-fce278738ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_d5645273-1ecd-4601-ae75-b8f799a454cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_88bbebb2-6907-4426-b98b-fce278738ffc" xlink:to="loc_us-gaap_PrimeRateMember_d5645273-1ecd-4601-ae75-b8f799a454cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8959a23a-ceca-4fcf-929f-027c97d10552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8959a23a-ceca-4fcf-929f-027c97d10552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f20501d1-e11e-4f01-a2f0-82ba43756793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8959a23a-ceca-4fcf-929f-027c97d10552" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f20501d1-e11e-4f01-a2f0-82ba43756793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5689f46c-142b-46ac-936b-228ac4b8a795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f20501d1-e11e-4f01-a2f0-82ba43756793" xlink:to="loc_us-gaap_SubsequentEventMember_5689f46c-142b-46ac-936b-228ac4b8a795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3edd65a6-3651-4f97-89df-e2210a43587b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_93258966-e65b-406f-b3a1-d7ac7e97e22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_93258966-e65b-406f-b3a1-d7ac7e97e22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityDrawDownIncrements_3351da4a-c5e9-4b26-9636-284838c5feac" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityDrawDownIncrements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_tars_LineOfCreditFacilityDrawDownIncrements_3351da4a-c5e9-4b26-9636-284838c5feac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityInterestOnlyPeriod_c74eb679-659a-4b5c-a451-7167d9063014" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityInterestOnlyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_tars_LineOfCreditFacilityInterestOnlyPeriod_c74eb679-659a-4b5c-a451-7167d9063014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityInterestOnlyPeriodExtended_28611447-8d84-4043-b1e0-603606ca3101" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityInterestOnlyPeriodExtended"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_tars_LineOfCreditFacilityInterestOnlyPeriodExtended_28611447-8d84-4043-b1e0-603606ca3101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0fcee7b-26d0-4da9-a7dc-ab226757f50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0fcee7b-26d0-4da9-a7dc-ab226757f50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_164aaf17-fa5f-4f35-b6c5-eaa0c8a30321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_164aaf17-fa5f-4f35-b6c5-eaa0c8a30321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c20a50ff-2c7d-47e3-951a-7fb112325070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c20a50ff-2c7d-47e3-951a-7fb112325070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_379e0306-e7a7-4c54-a56a-fd50f7b541aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_379e0306-e7a7-4c54-a56a-fd50f7b541aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_18373fcf-cfc3-412b-854a-ecc1080cba70" xlink:href="tars-20220331.xsd#tars_LineOfCreditFacilityPeriodicPaymentInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_tars_LineOfCreditFacilityPeriodicPaymentInterestRate_18373fcf-cfc3-412b-854a-ecc1080cba70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_2c047a41-8c5b-45d8-a9f6-c5993239a89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_2c047a41-8c5b-45d8-a9f6-c5993239a89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_3a468bb6-c047-4c0b-b817-0e3887626721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c753e2c-4419-4ef3-9c61-4cc6f01dcf68" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_3a468bb6-c047-4c0b-b817-0e3887626721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CreditFacilityAgreementSummaryofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d3339863-42f8-4a6c-91bd-ed42965646c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f64fe69d-3cdd-4361-a7f4-b741e85dd596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d3339863-42f8-4a6c-91bd-ed42965646c9" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_f64fe69d-3cdd-4361-a7f4-b741e85dd596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_ac4cc55a-0c21-401a-908c-59c708d37627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d3339863-42f8-4a6c-91bd-ed42965646c9" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_ac4cc55a-0c21-401a-908c-59c708d37627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_d5f53edb-7c8f-49e9-92a4-b991c44d3787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d3339863-42f8-4a6c-91bd-ed42965646c9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_d5f53edb-7c8f-49e9-92a4-b991c44d3787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_0fa0a358-c607-4945-82ac-15ca24f4a171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d3339863-42f8-4a6c-91bd-ed42965646c9" xlink:to="loc_us-gaap_InterestExpenseDebt_0fa0a358-c607-4945-82ac-15ca24f4a171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_08867a8c-fc36-4a85-aead-9cdc9c8f6eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_848a4f0e-763e-4f95-82a6-bc9cf3277a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_08867a8c-fc36-4a85-aead-9cdc9c8f6eac" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_848a4f0e-763e-4f95-82a6-bc9cf3277a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_47abaa02-83c5-455e-b645-76f8e55fc328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_08867a8c-fc36-4a85-aead-9cdc9c8f6eac" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_47abaa02-83c5-455e-b645-76f8e55fc328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_38242351-7099-4a4a-8429-cb0ffc27127c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_08867a8c-fc36-4a85-aead-9cdc9c8f6eac" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_38242351-7099-4a4a-8429-cb0ffc27127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_11d4b51b-1f26-422d-b833-b4d6a10b500f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_08867a8c-fc36-4a85-aead-9cdc9c8f6eac" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_11d4b51b-1f26-422d-b833-b4d6a10b500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_df5394bd-ce8c-48ae-98c9-fc8683bae0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_08867a8c-fc36-4a85-aead-9cdc9c8f6eac" xlink:to="loc_us-gaap_LongTermDebt_df5394bd-ce8c-48ae-98c9-fc8683bae0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEvent" xlink:type="simple" xlink:href="tars-20220331.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9315b76f-6763-4b12-b049-e068ccf01b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_0144bdc5-3e42-4498-88ce-2b2febfb96ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9315b76f-6763-4b12-b049-e068ccf01b4d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_0144bdc5-3e42-4498-88ce-2b2febfb96ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="tars-20220331.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://tarsusrx.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_aa875da0-dd91-4cfe-9acf-4ee815e3053e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_aa875da0-dd91-4cfe-9acf-4ee815e3053e" xlink:to="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_65c13ab0-559f-479c-b9cb-f203d0ac4493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e60e0978-59f4-4d6b-9ae3-e3fc61cd7461" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_65c13ab0-559f-479c-b9cb-f203d0ac4493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5a8fb314-e8e9-4241-a780-6034a8d2cbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_65c13ab0-559f-479c-b9cb-f203d0ac4493" xlink:to="loc_us-gaap_SubsequentEventMember_5a8fb314-e8e9-4241-a780-6034a8d2cbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f67b6ce9-af6f-41b4-8f30-26a19375de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f67b6ce9-af6f-41b4-8f30-26a19375de3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e416f6c-e20c-48fd-aa52-f0fbae85ef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f67b6ce9-af6f-41b4-8f30-26a19375de3c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e416f6c-e20c-48fd-aa52-f0fbae85ef9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_PublicStockOfferingMember_b34a5311-0f73-41c8-a555-d7032e111f44" xlink:href="tars-20220331.xsd#tars_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e416f6c-e20c-48fd-aa52-f0fbae85ef9a" xlink:to="loc_tars_PublicStockOfferingMember_b34a5311-0f73-41c8-a555-d7032e111f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e502ef8f-1c8c-4e64-aed2-a5e7b5fdee94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e416f6c-e20c-48fd-aa52-f0fbae85ef9a" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e502ef8f-1c8c-4e64-aed2-a5e7b5fdee94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_253a3bd7-8185-44a8-9d69-48fcb3f25a42" xlink:to="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b449bddf-c81f-412e-87a8-d2fea593ce5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b449bddf-c81f-412e-87a8-d2fea593ce5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_270e149e-8de7-41f9-82c7-dba13a01a11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_270e149e-8de7-41f9-82c7-dba13a01a11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross_bf3daca5-54e7-4539-bbe1-dcf3a290b184" xlink:href="tars-20220331.xsd#tars_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_tars_SaleOfStockConsiderationReceivedOnTransactionGross_bf3daca5-54e7-4539-bbe1-dcf3a290b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_04921257-e676-47ef-8196-10cd7df45a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dd3359af-226c-4f0c-bf93-0cb9ecc90f9e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_04921257-e676-47ef-8196-10cd7df45a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536315021800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TARSUS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-4717861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15440 Laguna Canyon Road, Suite 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">409-9820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TARS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,727,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536314824968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 175,010<span></span>
</td>
<td class="nump">$ 171,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,131<span></span>
</td>
<td class="nump">4,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">178,755<span></span>
</td>
<td class="nump">175,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">181,483<span></span>
</td>
<td class="nump">178,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">10,805<span></span>
</td>
<td class="nump">8,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">2,798<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,610<span></span>
</td>
<td class="nump">11,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan, net</a></td>
<td class="nump">19,180<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">32,286<span></span>
</td>
<td class="nump">12,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 20,731,062 shares issued and 20,718,528 outstanding, which excludes 12,534 shares subject to repurchase at March&#160;31, 2022 (unaudited); 20,726,580 shares issued and 20,698,737 outstanding, which excludes 27,840 shares subject to repurchase at December&#160;31, 2021</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">216,103<span></span>
</td>
<td class="nump">213,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(66,910)<span></span>
</td>
<td class="num">(46,672)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">149,197<span></span>
</td>
<td class="nump">166,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 181,483<span></span>
</td>
<td class="nump">$ 178,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536314992696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">20,731,062<span></span>
</td>
<td class="nump">20,726,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">20,718,528<span></span>
</td>
<td class="nump">20,698,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockSharesSubjectToRepurchase', window );">Common stock, subject to repurchase (shares)</a></td>
<td class="nump">12,534<span></span>
</td>
<td class="nump">27,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockSharesSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Subject To Repurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockSharesSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536315377256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive (Loss) Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">$ 33,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,081<span></span>
</td>
<td class="nump">16,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,946<span></span>
</td>
<td class="nump">5,160<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,060<span></span>
</td>
<td class="nump">22,718<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations before other (expense) income and income taxes</a></td>
<td class="num">(19,521)<span></span>
</td>
<td class="nump">10,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income, net</a></td>
<td class="num">(316)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity securities</a></td>
<td class="num">(192)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of equity warrants</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(716)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(20,238)<span></span>
</td>
<td class="nump">10,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (20,238)<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) per share, basic (usd per share)</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted (usd per share)</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted Average Number of Shares Outstanding, Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (shares)</a></td>
<td class="nump">20,710,224<span></span>
</td>
<td class="nump">20,336,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (shares)</a></td>
<td class="nump">20,710,224<span></span>
</td>
<td class="nump">21,824,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember', window );">License fees and Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of license fees and collaboration revenue</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 1,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_LicenseAndCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536316844856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,323,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">165,980<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 198,821<span></span>
</td>
<td class="num">$ (32,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">10,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of vested stock options</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued as consideration for in-license rights (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as consideration for in-license rights</a></td>
<td class="nump">5,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,524,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 183,232<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">205,697<span></span>
</td>
<td class="num">(22,469)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2021</a></td>
<td class="nump">20,698,737<span></span>
</td>
<td class="nump">20,698,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 166,730<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">213,398<span></span>
</td>
<td class="num">(46,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(20,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation expense</a></td>
<td class="nump">2,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon the vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights', window );">Lapse of repurchase rights related to common stock issued pursuant to stock option exercises prior to vesting</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as consideration for in-license rights</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2022</a></td>
<td class="nump">20,718,528<span></span>
</td>
<td class="nump">20,718,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 149,197<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 216,103<span></span>
</td>
<td class="num">$ (66,910)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Lapse Of Repurchase Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Lapse Of Repurchase Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536315211656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (20,238)<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and accretion of long-term debt related costs</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,674<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_OperatingLeaseNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Loss on lease termination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity securities</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of equity warrants</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized loss (gain) from transactions denominated in a foreign currency</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock pursuant to in-license agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Contract asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">926<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">1,969<span></span>
</td>
<td class="nump">5,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and benefits</a></td>
<td class="num">(993)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,286)<span></span>
</td>
<td class="num">(11,794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ProceedsFromEarlyExerciseOfStockOptions', window );">Proceeds from exercise of vested stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_PaymentsOfDeferredStockIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from term loan</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(815)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">19,125<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="nump">3,678<span></span>
</td>
<td class="num">(11,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8212; beginning of period</a></td>
<td class="nump">171,332<span></span>
</td>
<td class="nump">168,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8212; end of period</a></td>
<td class="nump">175,010<span></span>
</td>
<td class="nump">156,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">175,010<span></span>
</td>
<td class="nump">156,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">175,010<span></span>
</td>
<td class="nump">156,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">"Interest expense" paid in cash</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Additions of "property and equipment, net" included within "accounts payable and other accrued liabilities"</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense', window );">Expensing of "operating lease right-of-use assets" upon lease termination</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for in-license agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_DeferredOfferingCostsIncurredButNotYetPaid', window );">Deferred offering costs included within "accounts payable and accrued liabilities"</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_DeferredOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_DeferredOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_OperatingLeaseNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_OperatingLeaseNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right Of Use Asset, Lease Termination Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_PaymentsOfDeferredStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Deferred Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_PaymentsOfDeferredStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ProceedsFromEarlyExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Early Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ProceedsFromEarlyExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320556888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Presentation of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Presentation of Financial Statements</a></td>
<td class="text">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Description of Business</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(b)  Liquidity</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has no product sales and has accumulated losses and negative cash flows from operations since inception (other than consideration received from an out-licensing agreement, as discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), resulting in an accumulated deficit of $66.9 million as of March&#160;31, 2022 and $46.7 million as of December&#160;31, 2021. The Company&#8217;s cash and cash equivalents were $175.0 million and $171.3 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The Company expects to continue to incur operating losses and negative cash flows.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 2, 2022, the Company executed a loan and security agreement (the "Credit Facility") with Hercules Capital, Inc. ("Hercules") and Silicon Valley Bank ("SVB"). This $175&#160;million Credit Facility has tranched availability. Capital draws are at the Company's election and are in $5&#160;million increments. In February 2022, the Company made a $20&#160;million draw (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). </span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has funded its inception-to-date operations primarily through equity capital raises, proceeds from its out-license agreement, and draw downs on its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating requirements beyond at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q. Accordingly, the accompanying financial statements in this Form 10-Q have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations currently consist of its corporate organization build-out, intellectual property licensing activities, and preclinical and clinical study progression. The Company faces the clinical, business, and liquidity risks that are typically associated with biopharma companies; it must significantly invest in and conduct research and development activities, achieve research and development outcomes that are inherently uncertain, recruit and retain skilled personnel (including executive management), and expand and defend its intellectual property rights.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Management expects the Company to continue to incur losses in the foreseeable future as a result of research and development activities and other operating expenses. The Company may be required to raise additional capital to fund its future operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, if at all. If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. The Company's Credit Facility imposes additional covenants that restrict operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase common stock, make certain investments, or engage in certain merger or asset sale transactions. Any debt financing or additional equity raise may contain terms that are not favorable to the Company or its stockholders. The Company&#8217;s potential inability to raise capital when needed could have a negative impact on its financial condition and ability to pursue planned business strategies. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own. If the Company is required to enter into collaborations and other arrangements to address its liquidity needs, it may have to give up certain rights that limit its ability to develop and commercialize product candidates or may have other terms that are not favorable to the Company or its stockholders, which could materially and adversely affect its business and financial prospects. These factors may adversely impact the Company's ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Operating Segment  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has operated and managed its business and financial information on an aggregate basis based on the Company's organizational structure, for the purposes of evaluating financial performance and the allocation of capital and personnel resources, consistent with the way operations and investments are centrally managed and evaluated. Accordingly, the Company&#8217;s management determined that it operates one reportable operating segment. This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320557448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Use of Estimates</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements have been prepared in conformity with accounting principles generally accepted ("GAAP") in the United States ("U.S.") for interim financial information and pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2022, the interim Condensed Statements of Operations and Comprehensive (Loss) Income, and Stockholders&#8217; Equity for the three months ended March&#160;31, 2022 and 2021, and the interim Condensed Cash Flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2022 or any other interim or annual period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March&#160;14, 2022.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to forecast and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no significant changes in the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2022, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on March 14, 2022.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(ii) Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iii) Marketable Securities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities represent LianBio Ophthalmology Limited ("LianBio") common stock (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) designated as "available-for-sale securities" with associated gains or losses recorded within "other expense, net" within the Condensed Statements of Operations at each reporting period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(iv) Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak. The COVID-19 pandemic continues to evolve and its impact on the Company&#8217;s business will depend on several factors that are highly uncertain and unpredictable, including, the efficacy and adoption of vaccines, future resurgences of the virus and its variants, and the speed at which government restrictions are lifted. To date, the Company&#8217;s operations have not been significantly impacted by the COVID-19 pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#8217;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#8217;s potential product candidates, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, it could have a materially adverse impact on the business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(v) Revenue Recognition for Out-License Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has one out-license arrangement that allows the third-party licensee to market the its TP-03 product candidate (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement, as described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement includes the following forms of consideration: (i) non-refundable upfront license payments, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales threshold milestones, (v) development milestone payments, and (vi) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determined the milestone and other contingent amounts to be "constrained" until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the &#8220;most likely amount&#8221; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. A "performance obligation" is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s "transaction price" is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(vi) Research and Development Costs</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, clinical manufacturing costs, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set or a business, as defined under applicable GAAP. The Company&#8217;s executed in-license agreements (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have no alternative future use, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(vii) Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. The Black-Scholes pricing model is used to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing share price preceding the date of grant.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the same period of occurrence. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a)&#160;the fair value of the Company&#8217;s common stock on the date of the option grant for all awards granted prior to the Initial Public Offering ("IPO"), (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management estimates the expected term of awarded stock options utilizing the &#8220;simplified method&#8221; for awards as the Company does not yet have sufficient exercise history since its November 2016 corporate formation. The Company lacks company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the awarded stock option. The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the Statements of Operations and Comprehensive (Loss) Income within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(viii) Net (Loss) Income per Share</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common stock equivalents outstanding for the period determined using the "treasury-stock method" and "if-converted method" as applicable. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s "participating securities" include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses, so in periods of net losses, the "two-class method" of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Also, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three months ended March&#160;31, 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in this period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ix) Fair Value Measurements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. The Company's equity warrant holdings are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(x) Comprehensive (Loss) Income </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income represents all changes in stockholders&#8217; equity (deficit), except those resulting from distributions to stockholders. For all periods presented in the accompanying Condensed Financial Statements, comprehensive (loss) income was the same as reported net (loss) income.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(xi) Recently Issued or Effective Accounting Standards</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320445672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Detail</a></td>
<td class="text">BALANCE SHEET ACCOUNT DETAIL<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Property and Equipment, Net </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Property and equipment, net&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense (included within &#8220;total operating expenses&#8221; in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income) for the three months ended March 31, 2022 and 2021 was $41 thousand and $64 thousand, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Other Assets</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Other assets" consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Accounts Payable and Other Accrued Liabilities&#160;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Accounts payable and other accrued liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock option pre-vesting exercise liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,805&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,680&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Other Long-Term Liabilities</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other long-term liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, non-current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320604760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity and Equity Incentive Plans</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY AND EQUITY INCENTIVE PLANS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Outstanding and Reserves for Future Issuance</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, the Company had 20.7 million common shares issued and outstanding.  Each share of common stock is entitled to one vote. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan (the "ESPP") is summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,954,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,266,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,700,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,493,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,561,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,759,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units outstanding under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,567,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,536,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors and stockholders adopted and approved the Company's 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) on October 8, 2020. The 2020 Plan replaced the Company's 2016 Equity Incentive Plan that was adopted in December 2016 (the &#8220;2016 Plan&#8221;).  However, awards outstanding under the 2016 Plan will continue to be governed by its original terms. The number of shares of the Company's common stock that were initially available for issuance under the 2020 Plan equaled the initial sum of 9,000,000 shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2,432,980 shares that were then available for issuance under the 2016 Plan. The 2020 Plan provides for the following types of awards: incentive and non-statutory stock options, stock appreciation rights, restricted shares, and restricted stock units.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock reserved for issuance under the 2020 Plan are increased automatically on the first day of each fiscal year, commencing in 2021 and through 2030, by a number equal to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lesser of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) 4% of the shares of common stock outstanding on the last day of the prior fiscal year; or (ii) the number of shares determined by the Company's Board of Directors. In general, to the extent that any awards under the 2020 or 2016 Plans are forfeited, terminate, expire or lapse without the issuance of shares, or if the Company reacquires the shares subject to awards granted under the 2020 or 2016 Plans, those shares will again become available for issuance under the 2020 Plan, as will shares applied to pay the exercise or purchase price of an award or to satisfy tax withholding obligations related to any award.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2022, all awards issued under the 2020 Plan and 2016 Plan were in the form of stock options and restricted stock units. These stock award agreements have service and/or performance conditions for vesting, unless immediately vested on the date of grant. Stock awards granted typically have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTM5MTI_01c7ccdd-ab1b-4a6d-8be3-01ce640cfa8d">one</span> to four-year service conditions for full vesting. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 12 months after the date of termination upon death, six months after the date of termination upon disability, and three months after the date of termination for all other separations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Vesting Exercise Feature of Certain Stock Options </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Plan permitted certain option holders to exercise awarded options prior to vesting. Upon this early exercise, the options became subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These unvested options are subject to repurchase by the Company upon employee termination at the same price exercised. These unvested shares of common stock are reported as issued (but not outstanding) on the accompanying Condensed Balance Sheets while subject to repurchase by the Company. These shares are also excluded from the basic net (loss) income per share until the repurchase right lapses upon vesting, but are included in the diluted net income per share for the three months ended March&#160;31, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially records a liability for these early exercises that is subsequently reclassified into stockholders&#8217; equity on a pro rata basis as vesting occurs. As of March&#160;31, 2022 and December&#160;31, 2021, the Company recorded the unvested portion of the exercise proceeds of $25 thousand and $56 thousand, respectively, within "accounts payable and other accrued liabilities" in the accompanying Condensed Balance Sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, a total of 2.7&#160;million shares of common stock are authorized and remain available for issuance under the Company's ESPP. Beginning on January 1, 2021, and each January 1st thereafter, pursuant to the terms of the ESPP, the number of common stock available for issuance under the ESPP is automatically increased by an amount equal to the least of (i) one percent of the total number of shares of common stock outstanding on the last day of the previous fiscal year, (ii) 2.3&#160;million shares, or (iii) a number of shares determined by the board of directors.  </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the ESPP, eligible employees can purchase common stock through scheduled payroll deductions. The purchase price is equal to the closing price of the Company's common stock on the first or last day of the offering period (whichever is less), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">minus</span> a 15% discount.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320655384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Summary</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is recorded in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income based on the designated department of the recipient. Stock-based compensation expense for the three months ended March 31, 2022 and 2021 was as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320650136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text">NET (LOSS) INCOME PER SHARE<div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net (loss) income per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: undistributed income allocated to participating securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income available to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,336,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) per share&#8212;basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: undistributed income reallocated to participating securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income available to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,336,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,488,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,824,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share&#8212;diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share because their impact under the &#8220;treasury stock method&#8221; and &#8220;if-converted method&#8221; would have been anti-dilutive for the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.411%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,561,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options early-exercised and unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,925,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320649576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(ix)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio (included in "marketable securities")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants in LianBio (included in "other assets")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio (included in "marketable securities")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants in LianBio (included in "other assets")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market fund holdings are included in "cash and cash equivalents" on the accompanying Condensed Balance Sheets and are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the fair value hierarchy because they have readily-available market prices in active markets that are publicly observable at the measurement date. These money market funds are invested in U.S. Treasury bills and notes, and other obligations issued or guaranteed as to principal and interest by the U.S. Government or its agencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, contemporaneous with the China Out-License transaction (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, a stated number of common stock in LianBio, a then privately-held pharmaceutical company focused on China. The warrants vest upon the achievement of certain clinical and regulatory events and have an exercise price at common stock par value. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, one of these three warrants vested and converted to 78,373 shares of LianBio common stock ("equity securities") which were recorded within "marketable securities" on the accompanying Balance Sheet as of December 31, 2021. The LianBio common stock is classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the fair value hierarchy because their value is based on the closing common stock price of LianBio.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining two unvested tranches of these warrants are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the fair value measurement hierarchy. The most significant assumptions used in the option pricing valuation model to determine the fair value as of March&#160;31, 2022 included: LianBio common stock volatility (based on the historical volatility of similar companies), the probability of achievement of discrete clinical and regulatory milestones for the remaining two unvested tranches of these warrants, and application of an assumed discount rate for the unvested warrants as of March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These warrants allow for "noncash settlement" and therefore met the criteria to be recognized as a "derivative asset" on the accompanying Condensed Balance Sheets and are presented within "other assets" as of March&#160;31, 2022 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). They will be remeasured with a corresponding amount reported in "other expense, net" on the accompanying statements of operations and comprehensive (loss) income at each reporting date, until exercised or expired. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the equity warrants presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrants represents a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> financial instrument:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrants, presented on the Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrants included in "total revenues" within the Condensed Statement of Operations for the three months ended March 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrants included in "other expense, net" within the Condensed Statement of Operations for the three months ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrants, presented on the Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial fair value estimate of equity warrants (included in "other assets" within the Consolidated Balance Sheet) upon issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320623720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment &amp; Contingencies</a></td>
<td class="text">COMMITMENTS&#160;&amp; CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Facility Leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of business, the Company enters lease agreements with unaffiliated third parties for facilities and office equipment. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had four active leases in Irvine, California for adjacent office and laboratory suites. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, the Company entered into a six-month lease for an additional administrative office suite that was not capitalized due to its under 12-month term. The company does not recognize lease asset and liabilities for leases with a term of 12 months or less. On July 30, 2021, the Company executed an amendment to extend the term of this lease and lease an additional office suite, both expiring January 31, 2024. This amendment was accounted for as a "lease modification" and resulted in the recognition of an "operating lease right-of-use asset" valued at $0.7&#160;million as of the execution date.  The Company's two other capitalized facility leases commenced on June 1, 2020 and also expire on January&#160;31, 2024. One includes a renewal option that was not reasonably certain to be exercised at the time of lease commencement. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating leases have annual rent that is payable monthly and carry fixed annual increases. Under these arrangements, real estate taxes, certain operating expenses, and common area maintenance are paid by the Company.  Since these costs are variable in nature, they are excluded from the measurement of the reported right-of-use asset and liability and are expensed as incurred. During the year ended December 31, 2021 and for the three months ended March 31, 2022, the Company had no sublease arrangements with it as lessor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Captions</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the lease asset and liability accounts presented on the accompanying Condensed Balance Sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:34.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets - non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_439b7687-e8d3-4543-9c80-be7d57d59b72"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_c0a0454b-2a50-41a4-8b96-b87633545102">Accounts payable and other accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability - non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_6efd016f-2e3f-4e4b-96a2-61e9bf7e61bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_9a33a609-33f6-4820-89f2-c43f54cb768e">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Lease Expense</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The liability associated with each lease is amortized over the respective lease term using the &#8220;effective interest rate method.&#8221; The Company&#8217;s right-of-use asset is amortized over the lease term on a straight-line basis to lease expense, as reported on an allocated basis within &#8220;research and development&#8221; and &#8220;general and administrative&#8221; expenses in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income. The Company combines lease and non-lease components in the recognition of lease expense. The components of lease cost were as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:49.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Remaining Lease Term and Applied Discount Rate </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company's facility leases had a weighted average remaining lease term of 1 year, 10 months. The weighted-average estimated incremental borrowing rate of 10% was utilized to present value future minimum lease payments since an implicit interest rate was not readily determinable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Contractual Lease Payments </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases - Future Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) In-License Agreements for Lotilaner</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">January 2019 Agreement for Skin and Eye Disease or Conditions in Humans</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Company entered into a license agreement with Elanco Tiergesundheit AG (&#8220;Elanco&#8221;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment or cure of any eye or skin disease or condition in humans (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid a $1.0 million upfront payment at execution of the Eye and Derm Elanco Agreement in January 2019. In September 2020, the Company made a required $1.0 million clinical milestone payment associated with the first two U.S. pivotal trials for the treatment of Demodex blepharitis. The Company paid an additional $2.0 million for its second pivotal trial milestone in April 2021, which was recorded in &#8220;research and development&#8221; expense in the accompanying Statements of Operations and Comprehensive Loss for the three months ended March 31, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may make further cash payments to Elanco pursuant to the Eye and Derm Elanco Agreement upon achievement of certain clinical milestones in the treatment of human skin diseases using lotilaner for an aggregate maximum of $3.0 million and various commercial and sales threshold milestones for an aggregate maximum of $79.0 million. In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the China Out-License discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company made a contractual payment in the amount of $2.5 million to Elanco following the receipt of $25 million of initial proceeds from LianBio during the second quarter of 2021.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">September 2020 Agreement for All Other Diseases or Conditions in Humans</span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, the Company executed an expanded in-license agreement with Elanco, granting the Company a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of "all other" diseases and conditions in humans (i.e., beyond that of the eye or skin) (the &#8220;All Human Uses Elanco Agreement&#8221;). The Company issued Elanco 222,460 shares of its common stock at the execution of the All Human Uses Elanco Agreement. The fair value of these shares was $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is required to make further cash payments to Elanco under the All Human Uses Elanco Agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.5 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net product sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, the Company entered into the China Out-License agreement with LianBio (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), which obligated it to grant Elanco an additional fixed 187,500 shares of the Company's common stock that were otherwise required to be granted no later than the 18-month anniversary of the All Human Uses Elanco Agreement for the Company's continued license exclusivity.  These additional shares were valued at $5.5 million based on the Company's stock closing price of $29.30 per share (on the date the issuance became contractually required) and were reported within "research and development" expense within the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income for the three months ended March 31, 2021.  </span></div><div style="text-indent:56.55pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) Employment Agreements</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements with eight of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Litigation Contingencies</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e) Indemnities and Guarantees</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320619768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Out-License Agreement</a></td>
<td class="text">OUT-LICENSE AGREEMENT<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License of TP-03 Commercial Rights in Greater China in March 2021</span></div><div><span><br/></span></div><div style="text-indent:56.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 26, 2021, the Company entered into an out-license agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (the &#8220;China Territory&#8221;) for the treatment of Demodex blepharitis and Meibomian Gland Disease (the &#8220;China Out-License&#8221;). LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.</span></div><div><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date the Company received payments from LianBio totaling $55.0&#160;million related to initial consideration of $25.0&#160;million and two clinical development milestone achievements of $30.0&#160;million. During the three months ended March 31, 2022 the Company did not receive any cash proceeds in connection with the China Out-License.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is also eligible to receive other payments and consideration from LianBio upon achievement of certain additional milestones, including: (i) TP-03 clinical development and regulatory milestones of up to $45.0&#160;million, (ii) an expected drug supply agreement milestone of $5.0&#160;million, (iii) TP-03 sales-based milestones for the China Territory of up to $100&#160;million, (iv) tiered mid-to-high-teen royalties for China Territory TP-03 product sales, and (v) LianBio equity warrants, which are subject to three TP-03 clinical/regulatory achievements for complete vesting, of which one tranche vested in June 2021. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized no "license fees" and $0.5 million "collaboration revenue" for the three months ended March 31, 2022 in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income, in accordance with the revenue recognition accounting policy described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 2(vii). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These amounts represent an allocation of the transaction price based upon the partial satisfaction of the performance obligations in the China Out-License</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These revenue amounts are each recognized upon satisfaction of the following performance obligations (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the actual or partial completion of clinical activities and related data for the Company's pivotal trials of TP-03 in the treatment of Demodex blepharitis. As part of this revenue recognition model, the Company was required to value the LianBio equity warrants, applying a discounted cash flow model with highly subjective inputs for this then private, pre-revenue company, and also considered the probability of achievement of requisite vesting events. Subsequent adjustments to the estimated initial fair value of these warrants are reported within "total revenues" and "other (expense) income" on the accompanying Condensed Statements of Operations for the three months ended March&#160;31, 2022. The first tranche of these warrants vested and were exercised to LianBio common shares and are reported within "marketable securities" on the accompanying Condensed Balance Sheets as of December&#160;31, 2021 and March&#160;31, 2022 (See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</span></div>In future periods, the Company may recognize additional revenue from contractual receipts due from LianBio as (1) performance obligations are satisfied related to the completion of the TP-03 pivotal trial and as associated clinical data and reports are delivered, (2) regulatory approval events are achieved, and (3) LianBio records product sales of TP-03 in the China Territory.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320591672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility Agreement</a></td>
<td class="text">CREDIT FACILITY AGREEMENT<div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company executed the Credit Facility with Hercules and SVB with a term to February 2, 2027. The Credit Facility provides an aggregate principal amount of up to $175.0&#160;million with tranched availability as follows: $40.0&#160;million at closing (with $20.0&#160;million drawn in February 2022), $25.0&#160;million upon submission of a New Drug Application ("NDA") with the FDA for TP-03, $35.0&#160;million upon FDA approval of TP-03, and $75.0&#160;million upon achievement of certain revenue thresholds and other conditions.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the tranches may be drawn down in $5.0&#160;million increments at the Company's election. The Credit Facility includes a four-year interest only period and is extendable to five years upon meeting certain conditions. </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Credit Facility requires interest-only payments from the issuance date through the amortization date of February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to maturity upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on February 2, 2027. </span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Principal draws accrue interest on the outstanding principal balance at a floating interest rate per annum equal to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">greater of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> either (i) The Wall Street Journal prime rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">plus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 5.20% or (ii) 8.45%. At execution of the Credit Facility, the interest rate was 8.45%. On March 17, 2022 this prime rate increased to 3.50% and the Credit Facility interest rate increased to 8.70%.  The Credit Facility interest rate further increased to 9.20% on May 5, 2022 based on the updated Wall Street Journal prime rate.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is required to pay a fee upon the earlier of (i) the maturity date or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.0 million was derived at the execution of the Credit Facility by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">multiplying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.75% to the $20.0&#160;million drawn at closing and is accreted to "accrued interest" through the maturity date of the Credit Facility.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March&#160;31, 2022, the carrying value of this debt consisted of $20.0&#160;million principal outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">less </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">issuance costs of approximately $0.9 million. These incurred legal and administrative fees were recorded as a "contra-liability" and accreted to interest expense using the "effective interest method" over the loan term.   </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The calculated effective interest rate for this Credit Facility was 9.66% for the three months ended March 31, 2022. As of December&#160;31, 2021 the Company had no outstanding debt.</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2022, the Company recognized "interest expense" on its Condensed Statement of Operations and Comprehensive (Loss) Income in connection with the Credit Facility as follows:  </span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of End of Term Charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The principal balance of this term loan and related accretion and amortization as of March&#160;31, 2022, were as follows:</span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, gross (amount drawn)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs (legal and other administrative fees)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of End of Term Charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320650136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">SUBSEQUENT EVENTMay 2022 Follow-on Equity Raise<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 5, 2022, the Company completed a follow-on public offering, pursuant to the Company's effective Form S-3 shelf registration statement, through an underwritten sale of 5,600,000 shares of its common stock at a price of $13.50 per share.  This resulted in gross proceeds of $75.6&#160;million before underwriting discounts, commissions, and estimated expenses, for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">net proceeds of approximately $70.6&#160;million.  </span>The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of common stock at the public offering price, less discounts, commissions, and estimated expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536315005288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segment</a></td>
<td class="text">To date, the Company has operated and managed its business and financial information on an aggregate basis based on the Company's organizational structure, for the purposes of evaluating financial performance and the allocation of capital and personnel resources, consistent with the way operations and investments are centrally managed and evaluated. Accordingly, the Company&#8217;s management determined that it operates one reportable operating segment. This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Condensed Financial Statements have been prepared in conformity with accounting principles generally accepted ("GAAP") in the United States ("U.S.") for interim financial information and pursuant to Form 10-Q and with the rules and regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Balance Sheet as of March&#160;31, 2022, the interim Condensed Statements of Operations and Comprehensive (Loss) Income, and Stockholders&#8217; Equity for the three months ended March&#160;31, 2022 and 2021, and the interim Condensed Cash Flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2022 or any other interim or annual period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March&#160;14, 2022.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to forecast and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no significant changes in the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2022, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on March 14, 2022.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below:</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities represent LianBio Ophthalmology Limited ("LianBio") common stock (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span>) designated as "available-for-sale securities" with associated gains or losses recorded within "other expense, net" within the Condensed Statements of Operations at each reporting period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">Concentration of Credit Risk and Other Risks and Uncertainties<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) outbreak. The COVID-19 pandemic continues to evolve and its impact on the Company&#8217;s business will depend on several factors that are highly uncertain and unpredictable, including, the efficacy and adoption of vaccines, future resurgences of the virus and its variants, and the speed at which government restrictions are lifted. To date, the Company&#8217;s operations have not been significantly impacted by the COVID-19 pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#8217;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#8217;s potential product candidates, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, it could have a materially adverse impact on the business.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text">Revenue Recognition for Out-License Arrangements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has one out-license arrangement that allows the third-party licensee to market the its TP-03 product candidate (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#8217;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement, as described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's out-license arrangement includes the following forms of consideration: (i) non-refundable upfront license payments, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales threshold milestones, (v) development milestone payments, and (vi) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Terms for Receipt of Payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual terms that establish the Company&#8217;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Upfront License Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Development Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determined the milestone and other contingent amounts to be "constrained" until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company utilizes the &#8220;most likely amount&#8221; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#8217;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Threshold Milestones:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. </span></div>The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. A "performance obligation" is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#8217;s "transaction price" is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development Costs<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, clinical manufacturing costs, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set or a business, as defined under applicable GAAP. The Company&#8217;s executed in-license agreements (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have no alternative future use, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. The Black-Scholes pricing model is used to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing share price preceding the date of grant.  </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#8217;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the same period of occurrence. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#8217;s judgment, including (a)&#160;the fair value of the Company&#8217;s common stock on the date of the option grant for all awards granted prior to the Initial Public Offering ("IPO"), (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management estimates the expected term of awarded stock options utilizing the &#8220;simplified method&#8221; for awards as the Company does not yet have sufficient exercise history since its November 2016 corporate formation. The Company lacks company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the awarded stock option. The Company&#8217;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based compensation expense is reported in the Statements of Operations and Comprehensive (Loss) Income within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income per Share</a></td>
<td class="text">Net (Loss) Income per Share<div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common stock equivalents outstanding for the period determined using the "treasury-stock method" and "if-converted method" as applicable. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s "participating securities" include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses, so in periods of net losses, the "two-class method" of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Also, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. </span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to a net loss for the three months ended March&#160;31, 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in this period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.</span></div><div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. The Company's equity warrant holdings are carried at fair value based on unobservable market inputs (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div>Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive (Loss) Income</a></td>
<td class="text">Comprehensive (Loss) Income Comprehensive (loss) income represents all changes in stockholders&#8217; equity (deficit), except those resulting from distributions to stockholders. For all periods presented in the accompanying Condensed Financial Statements, comprehensive (loss) income was the same as reported net (loss) income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued or Effective Accounting Standards</a></td>
<td class="text">Recently Issued or Effective Accounting StandardsRecently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#8217;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#8217;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320789016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Property and equipment, net&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Other assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Other assets" consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Accounts payable and other accrued liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical studies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock option pre-vesting exercise liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,805&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,680&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Other long-term liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other long-term liabilities&#8221; consists of the following:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, non-current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320487832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Stock details</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan (the "ESPP") is summarized below:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,954,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,266,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,700,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,493,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options issued and outstanding under 2020 and 2016 Equity Incentive Plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,561,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,759,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units outstanding under 2020 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of common stock reserved</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,567,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,536,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320479624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based compensation</a></td>
<td class="text">Stock-based compensation expense for the three months ended March 31, 2022 and 2021 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536319477144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Net (loss) income per share, basis and diluted</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table sets forth the computation of basic and diluted net (loss) income per share:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: undistributed income allocated to participating securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income available to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,336,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) per share&#8212;basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: undistributed income reallocated to participating securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income available to common shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,238)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,336,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,488,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,710,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,824,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share&#8212;diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.98)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding potentially dilutive securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share because their impact under the &#8220;treasury stock method&#8221; and &#8220;if-converted method&#8221; would have been anti-dilutive for the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.411%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options, unexercised&#8212;vested and unvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,561,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options early-exercised and unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units&#8212;unvested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,925,214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320622760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial instruments measured at fair value</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2(ix)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio (included in "marketable securities")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants in LianBio (included in "other assets")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock in LianBio (included in "marketable securities")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity warrants in LianBio (included in "other assets")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in fair value of equity warrants</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in fair value of the equity warrants presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrants represents a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> financial instrument:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrants, presented on the Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrants included in "total revenues" within the Condensed Statement of Operations for the three months ended March 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revaluation of equity warrants included in "other expense, net" within the Condensed Statement of Operations for the three months ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Warrants, presented on the Balance Sheets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial fair value estimate of equity warrants (included in "other assets" within the Consolidated Balance Sheet) upon issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536314939896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock', window );">Lease asset and liability accounts</a></td>
<td class="text">The below table summarizes the lease asset and liability accounts presented on the accompanying Condensed Balance Sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:34.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets - non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_439b7687-e8d3-4543-9c80-be7d57d59b72"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_c0a0454b-2a50-41a4-8b96-b87633545102">Accounts payable and other accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability - non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_6efd016f-2e3f-4e4b-96a2-61e9bf7e61bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_9a33a609-33f6-4820-89f2-c43f54cb768e">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease cost</a></td>
<td class="text">The components of lease cost were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future contractual lease payments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases - Future Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments, undiscounted</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Less): Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Lease Asset and Liability Accounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320469640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Summary of Interest Expense</a></td>
<td class="text"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2022, the Company recognized "interest expense" on its Condensed Statement of Operations and Comprehensive (Loss) Income in connection with the Credit Facility as follows:  </span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense for term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of End of Term Charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense related to term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Balances of Debt, Debt Issuance Costs, and Accumulated Accretion</a></td>
<td class="text"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The principal balance of this term loan and related accretion and amortization as of March&#160;31, 2022, were as follows:</span></div><div style="text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, gross (amount drawn)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs (legal and other administrative fees)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of End of Term Charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536316882152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Presentation of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Feb. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,332<span></span>
</td>
<td class="nump">$ 156,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_LineOfCreditFacilityDrawDownIncrements', window );">Increments to draw on credit facility at company's election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Draw on line of credit</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityDrawDownIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Draw Down Increments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityDrawDownIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536319489048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Use of Estimates (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536316981432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 1,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">(Less): Accumulated depreciation and amortization</a></td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536315024200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantRights', window );">Equity warrant rights</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other long term assets</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquityWarrantRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Warrant Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquityWarrantRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536315339912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable and other</a></td>
<td class="nump">$ 4,028<span></span>
</td>
<td class="nump">$ 2,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_AccruedClinicalStudiesCurrent', window );">Accrued clinical studies</a></td>
<td class="nump">5,740<span></span>
</td>
<td class="nump">4,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liability</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest, current</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Employee stock option pre-vesting exercise liability, current portion</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">$ 10,805<span></span>
</td>
<td class="nump">$ 8,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AccruedClinicalStudiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Studies, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AccruedClinicalStudiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536319097080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Detail - Other Long-Term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536312112424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Equity Incentive Plans - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 08, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">20,718,528<span></span>
</td>
<td class="nump">20,698,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">20,731,062<span></span>
</td>
<td class="nump">20,726,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (in shares)</a></td>
<td class="nump">15,567,224<span></span>
</td>
<td class="nump">14,536,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease', window );">Common stock reserved for issuance, increase percentage on first business day of each of next ten fiscal years</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Liability for early exercise of stock options</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan', window );">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</a></td>
<td class="nump">2,700,475<span></span>
</td>
<td class="nump">2,493,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease', window );">Common stock, shares reserved for future issuance, annual shares increase (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath', window );">Exercise period from termination upon death</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability', window );">Exercise period from termination upon disability</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations', window );">Exercise period from termination upon all other separations</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">ESPP discount percentage from market price, beginning of purchase period</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service condition period for full vesting</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service condition period for full vesting</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2020Member', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease', window );">Common stock reserved for issuance, increase percentage on first business day of each of next ten fiscal years</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Annual Shares Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tars_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tars_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536312102056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity and Equity Incentive Plans - Shares Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant', window );">Stock options reserved for future grant (shares)</a></td>
<td class="nump">8,954,066<span></span>
</td>
<td class="nump">9,266,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan', window );">Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan</a></td>
<td class="nump">2,700,475<span></span>
</td>
<td class="nump">2,493,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding', window );">Stock options issued and outstanding (shares)</a></td>
<td class="nump">3,561,261<span></span>
</td>
<td class="nump">2,759,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant', window );">Restricted stock units outstanding under 2020 Equity Incentive Plan</a></td>
<td class="nump">351,422<span></span>
</td>
<td class="nump">17,251<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved (shares)</a></td>
<td class="nump">15,567,224<span></span>
</td>
<td class="nump">14,536,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536314815720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,674<span></span>
</td>
<td class="nump">$ 1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,996<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536316806088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (20,238)<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: undistributed income allocated to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income available to common shareholders</a></td>
<td class="num">$ (20,238)<span></span>
</td>
<td class="nump">$ 10,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (shares)</a></td>
<td class="nump">20,710,224<span></span>
</td>
<td class="nump">20,336,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) per share, basic (usd per share)</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (20,238)<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Less: undistributed income reallocated to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income available to common shareholders</a></td>
<td class="num">$ (20,238)<span></span>
</td>
<td class="nump">$ 10,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (shares)</a></td>
<td class="nump">20,710,224<span></span>
</td>
<td class="nump">20,336,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Common stock options (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,488,552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (shares)</a></td>
<td class="nump">20,710,224<span></span>
</td>
<td class="nump">21,824,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted (usd per share)</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2740-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536314893864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">3,925,214<span></span>
</td>
<td class="nump">632,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options, unexercised&#8212;vested and unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">3,561,261<span></span>
</td>
<td class="nump">632,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember', window );">Stock options early-exercised and unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">12,531<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember', window );">Restricted stock units&#8212;unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net income (loss) per share</a></td>
<td class="nump">351,422<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536319427656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio (included in "marketable securities")</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants in LianBio (included in "other assets")</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">175,719<span></span>
</td>
<td class="nump">172,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">175,010<span></span>
</td>
<td class="nump">171,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio (included in "marketable securities")</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants in LianBio (included in "other assets")</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">175,301<span></span>
</td>
<td class="nump">171,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">175,010<span></span>
</td>
<td class="nump">171,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio (included in "marketable securities")</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants in LianBio (included in "other assets")</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Common stock in LianBio (included in "marketable securities")</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquityWarrantsFairValueDisclosure', window );">Equity warrants in LianBio (included in "other assets")</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquityWarrantsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Warrants, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquityWarrantsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536316748792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>warrant </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_NumberOfWarrants', window );">Number of warrants</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_NumberOfVestedWarrants', window );">Number of vested warrants</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_EquitySecuritiesFVNINumberOfShares', window );">Equity securities (in shares) | shares</a></td>
<td class="nump">78,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_EquitySecuritiesFVNINumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_EquitySecuritiesFVNINumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_NumberOfVestedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Vested Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_NumberOfVestedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_NumberOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_NumberOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536312304504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Revaluation of equity warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Fair value, end of period</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Revaluation of equity warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Revaluation of equity warrants</a></td>
<td class="num">$ (245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536316589960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Facility Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimated incremental borrowing rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesLeaseMember', window );">Irvine office and laboratory facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_LesseeOperatingLeaseNumberOfLeaseContracts', window );">Number of leases | contract</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember', window );">Irvine office and facilities, office suite and space lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LesseeOperatingLeaseNumberOfLeaseContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Lease Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LesseeOperatingLeaseNumberOfLeaseContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536316854360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Lease Asset and Liability Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accounts payable and other accrued liabilities<span></span>
</td>
<td class="text">Accounts payable and other accrued liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease payments</a></td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 1,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536319659688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536315374792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Summary of Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining nine months)</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments, undiscounted</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">(Less): Imputed interest</a></td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease payments</a></td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 1,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536312007320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for license agreement, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for license agreement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for license agreement, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock issued for license agreement, share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices', window );">Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | LianBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Clinical milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">License agreement | Commercial and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
<td class="nump">$ 77,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_ElancoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_ElancoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_ClinicalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_CommercialAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320779144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment &amp; Contingencies - Employment Arrangements (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>arrangement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers', window );">Number of employment arrangements with executive officers</a></td>
<td class="nump">8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_NumberOfEmploymentArrangementsWithExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employment Arrangements With Executive Officers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_NumberOfEmploymentArrangementsWithExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536312172520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tars_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_UpfrontPayment', window );">Upfront payment received</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Clinical development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMilestonePayment', window );">Milestone payment achieved</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Drug Supply Agreement Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Sales-Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_CollaborativeArrangementMaximumMilestonePayment', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tars_LianBioMember', window );">LianBio | License agreement | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tars_LianBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tars_LianBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_DrugSupplyAgreementMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_DrugSupplyAgreementMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tars_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tars_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536316389448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Mar. 17, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_LineOfCreditFacilityDrawDownIncrements', window );">Increments to draw on credit facility at company's election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_LineOfCreditFacilityInterestOnlyPeriod', window );">Interest only period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_LineOfCreditFacilityInterestOnlyPeriodExtended', window );">Interest only period, extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest', window );">End of term charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_LineOfCreditFacilityPeriodicPaymentInterestRate', window );">End of term charge, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility, Tranche Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityDrawDownIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Draw Down Increments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityDrawDownIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Interest Only Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityInterestOnlyPeriodExtended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Interest Only Period, Extended</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityInterestOnlyPeriodExtended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_LineOfCreditFacilityPeriodicPaymentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Periodic Payment, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_LineOfCreditFacilityPeriodicPaymentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tars_CreditFacilityTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320668840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility Agreement - Summary of Interest Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense for term loan</a></td>
<td class="nump">$ 274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of End of Term Charge</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense related to term loan</a></td>
<td class="nump">$ 329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536319636920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan, gross (amount drawn)</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Debt issuance costs (legal and other administrative fees)</a></td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Accretion of End of Term Charge</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Accumulated amortization of debt issuance costs</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan, net</a></td>
<td class="nump">$ 19,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140536320728056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details) - Subsequent Event<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>May 05, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share) | $ / shares</a></td>
<td class="nump">$ 13.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tars_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Stock issued, gross proceeds | $</a></td>
<td class="nump">$ 75.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Stock issued, net proceeds | $</a></td>
<td class="nump">$ 70.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares) | shares</a></td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Underwriters' option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued (shares) | shares</a></td>
<td class="nump">840,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tars_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tars_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tars_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tars_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tars_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>tars-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:tars="http://tarsusrx.com/20220331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tars-20220331.xsd" xlink:type="simple"/>
    <context id="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id14bd9926cf44163a2bdbd7e313ace4f_I20220504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="i7273965429d14abfa8d691f9d822bdae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i849ffd4d92344da1bec87e7d90d1b485_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i080af938313c43d2b539cdefbcdfec98_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i54381f41a7eb4b0ea3fbbbaeff54f01f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f4a4782309e4d14a530821ddb8049b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i29bc79115d7a4e0ca6736b6a0bd45d7e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8026e35afb834d3cb1f3553098db8877_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc4f887cfb0f4ab5be157a6b1b3689d8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:LicenseAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a0a5d596de347dfb2ee05dbf213d003_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77bea9a87fa149f5b7b6f0c53df117f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71110d20496a42568cfa4272b640c494_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i281e4ce0faee4e93b52b1c855c37b40e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i00db3f28f47a45fd81332519739fb47a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ida7f2066d6ab4d298b57b9551607ddc1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6c1ad78fb81b430cab2abc5651cadb29_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a3d5c72a6a94f73955e1eb952386f30_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibec2fec07baf4b5ea65315e3604b264b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibc4893dbff5444e2a914be14ba1cb379_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3d5cd01a5b74ad69d8cfb82b0ddb6b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2407365462b6484e866e2a0897a6f31f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3eb871a3740c464480f7fcef3e833411_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i514947c5e4b04a378154c04684c04412_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia5af16c925384bbda1b2f1b0f73319cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6f1e1fe52f054a159eaad037bb720a9d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id80221d972a4407a82832333ee98fc87_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i015bde96678a4498b78f135f2e37fe8a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1c7ac172fd5445a9afde9ded686451dd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i09758e9a44594ebf8985740d1bf5f229_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifd2668fef555454ab6c59b2d437e7cca_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="i64ab1022c5cf4cbf9f780e24d3f48ca8_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i45f4cdbf078647fdb5714433c4e54968_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8b6b657919b045119943a31c80f1d1c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84c2f7bb7a9144feb30baaa206b3c84f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3a55c6f2a5cd4609a8fd119dfcd1fcfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7529cd5b41004750957c29f40fae72bc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7b632727d0924b539bb949a88a28ac4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f2f6cc3612846ed80ef0e9ff22f78ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i26735dafdb274401bedfa5360ff79acb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6dd617ed38c64f83b2e2428b1abde32a_I20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-08</instant>
        </period>
    </context>
    <context id="ic93546034bb142b0a219d72347552482_I20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-08</instant>
        </period>
    </context>
    <context id="id0927937cbbe4b248a2bb3faaf75bded_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tars:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5cf536a1081447dc9478dce9063ad678_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c7789b1b50744a99ead19fcb7d24c12_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id03a5a0a91cb4b4586a1f8ee04c3d481_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic881c21880004c5ba362cfa7ce7524e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if4f6cd5005f34480babb33821fa0f5fb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f101ec5e8914faab8d26c11caedd9bb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i892bc751c437460d89238d3ba9e8f045_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9d25ce27b22641beb0bec11792f01c1f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67b53435adf9489a9a2daaff37121c44_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i173cbb1387d1404085a5f0d1575e8f62_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i861c82a1ea2c4d4ea4ae4e378321bb54_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEarlyExercisedOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i27aa992f7c3f4d339542898fcd3905bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1ceb379731724bc085f3a4a5ce44d64f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tars:ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3682bcf6d66f4973a7dd133d281d269e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6faf816d5daa4e378b018c9347358012_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic3a8147113984483bdbe2570de069cf9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c4444dc36754b42916b70015ae04028_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i345bf687446f417ab073133b4f3e6ebf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie13603c0d53747d793240ebb726383c8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2d8e806d3fc746b4bd86d42fd6cde4af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibe41f993362a4d1abb88ecf74110902f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf5353fdcc224f7e8dfbe5f04a6b0e2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if839d9e3a48348b2b756e1a2885fa244_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48d31760273a4e2f823c7e5fc3f3807d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d18c2021abb45cd8eca7bf510a0d79c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc9facda38ea4ff4885250a21f36b6ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f4e89147429457a865e2def1c688c45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic100186e6c824064b3a569935e610798_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96f49b8447904e059af26b60c492701c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia85a91d80e654470aeccc73aa5fa1fb5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2d2fc086b90b461a8bd0825aacc11371_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieadb94479fbf491289eeb4a699120c85_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i2984a704b5f7467bb0b60220ced68c69_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tars:IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="icd124fd3b0484daab9a49f0bec4f620f_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="iaee22ca2e06b493897071cb5cc9e2fee_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d8f8ea4259c4cda90b6fffc07aba79d_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ie486f40913eb4e9e91e41e6b75802f58_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i9e8bcfe9ca0640bbb09e4739c1c4c378_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i1cecf80c420649d6a1e32ab01aa11f92_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ide977ec78e02409981089603c186b138_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:ElancoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i654c73f76ece4f4e803421b8c7263cb3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9d7a6b8164094267801b75fac6b39956_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0b7611af61f5418b9266c2bcd8eb6fe9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea920d7fcd75406d81b03da8bad1093a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3167f524706142c2b2851c8bb31f1c12_D20210326-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia19be9b7fe5245089c2073e846d30204_D20210326-20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="i92802321216247e484f937d0e0c27e93_D20210326-20210326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="i576dbd0507c245d1a503f15affe1eed2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i31e151303adb4b01ba45467aa1597d0a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:DrugSupplyAgreementMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35b7053fdb8f495f94c86835ef706e83_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0c7c8089e4c24cf6b318fdbcbb0fcd5f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic4c16329db554147aa835e3f640a2243_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tars:LianBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tars:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0dd505db08864f8599c4b88afd5d91d4_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="i1e1d86abba614b28bb93de20e5a65f46_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="i0e1bbc0f5a2e4184a13f69cd709213c4_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="i1eb8e35e7edf4dcc8e5184077317c4e2_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="ica98a2fa29594ad7be66a55c9a1e20db_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tars:CreditFacilityTrancheFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i33662385a14248f389cd589e0b07949d_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i3a6e2fcbec9d4f2a814387f5e90b9f5f_D20220317-20220317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <context id="ie708af9133d548c5b4bab9d679747cd1_D20220317-20220317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <context id="i2d088c0af04542eba408c2f8416ec22d_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i526c288d95b145d18ad85df06471783c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i438915cd287c48788084761ed5ad3ba4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id27ce663af03415ca6600c5007c2ea01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id85e9ecd5338406897413769276e54ff_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tars:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i1808d691f65a4626825a224635438903_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i8c435dd6d8af4033acf4c6e936b27500_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i4eb812a752d3463a8d2c1bc50512d96b_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819790</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>tars:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="warrant">
        <measure>tars:warrant</measure>
    </unit>
    <unit id="contract">
        <measure>tars:contract</measure>
    </unit>
    <unit id="arrangement">
        <measure>tars:arrangement</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl8yLTEtMS0xLTI2NjM1_4689b037-b9c7-48ce-883c-9666e3e4fb22">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl8zLTEtMS0xLTI2NjM1_6ece19bd-41a7-4af1-91aa-5a56ca433f06">0001819790</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl80LTEtMS0xLTI2NjM1_eec0dc65-eab1-4323-a0dc-4d336f77f9eb">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl81LTEtMS0xLTI2NjM1_54730e0b-8ac5-4715-a788-63c7f7fdac77">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80L2ZyYWc6MmQxM2MyNzU1NmZmNDI0NDlkMzU1OGRlZGY3Mzg4MDUvdGFibGU6NzZkMDM2Y2Q1Njc1NDk2MDkyZmFhMjkzMjU0NzJhNTYvdGFibGVyYW5nZTo3NmQwMzZjZDU2NzU0OTYwOTJmYWEyOTMyNTQ3MmE1Nl82LTEtMS0xLTI2NjM1_5e997339-c203-40b9-8385-31283630ef01">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i5cf536a1081447dc9478dce9063ad678_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTM5MTI_01c7ccdd-ab1b-4a6d-8be3-01ce640cfa8d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_439b7687-e8d3-4543-9c80-be7d57d59b72">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_c0a0454b-2a50-41a4-8b96-b87633545102">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_6efd016f-2e3f-4e4b-96a2-61e9bf7e61bf">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_9a33a609-33f6-4820-89f2-c43f54cb768e">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQy_51266b9f-7b4e-41e9-9e72-127cc0e6b31d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6MTIxYTA3OGJlYWYyNGZkYzgzZTBlYmE5ZjJhODMyZTgvdGFibGVyYW5nZToxMjFhMDc4YmVhZjI0ZmRjODNlMGViYTlmMmE4MzJlOF8wLTAtMS0xLTI2NjM1_c44e9764-bceb-4dce-b8b4-4d58e550ca84">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xMjk_1db6f429-6700-4c8e-abd0-3e9e1560f875">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6NjI3ZGU4OGMzOWU4NGM1ZTk0OTI3Y2E0Yzc4YThkOWMvdGFibGVyYW5nZTo2MjdkZTg4YzM5ZTg0YzVlOTQ5MjdjYTRjNzhhOGQ5Y18wLTAtMS0xLTI2NjM1_5d0b8a6b-8013-4999-a125-d10790499052">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTM5_c93c7474-ba1e-4a6a-940b-4872a2aad996">001-39614</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQz_2cc90191-da45-4bf2-83b1-0361b7e11caa">TARSUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6ZGQ4ZjkwZTU4MTlkNGYyYThkODVkZmE1MWY2MGQ0ZTgvdGFibGVyYW5nZTpkZDhmOTBlNTgxOWQ0ZjJhOGQ4NWRmYTUxZjYwZDRlOF8wLTAtMS0xLTI2NjM1_33adc12e-8da3-4da8-848d-d7d7aafc164a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6ZGQ4ZjkwZTU4MTlkNGYyYThkODVkZmE1MWY2MGQ0ZTgvdGFibGVyYW5nZTpkZDhmOTBlNTgxOWQ0ZjJhOGQ4NWRmYTUxZjYwZDRlOF8wLTItMS0xLTI2NjM1_81ede369-2485-4a78-a437-473020ed46f9">81-4717861</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6Y2Y1NzBkYTQxOTE4NGMyNmE1ZTJjNDVmNzM4OTdiNmIvdGFibGVyYW5nZTpjZjU3MGRhNDE5MTg0YzI2YTVlMmM0NWY3Mzg5N2I2Yl8wLTAtMS0xLTI2NjM1_94c88503-14a1-49db-ad82-ddacb3f4f382">15440 Laguna Canyon Road, Suite 160</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6Y2Y1NzBkYTQxOTE4NGMyNmE1ZTJjNDVmNzM4OTdiNmIvdGFibGVyYW5nZTpjZjU3MGRhNDE5MTg0YzI2YTVlMmM0NWY3Mzg5N2I2Yl8xLTAtMS0xLTI2NjM1L3RleHRyZWdpb246NGEyZTkxYTBkMWFkNDc4NGFlMmFjY2I3YzYwZTJjNzdfNA_0a96ea76-6442-4c3a-878f-730116f9aefb">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6Y2Y1NzBkYTQxOTE4NGMyNmE1ZTJjNDVmNzM4OTdiNmIvdGFibGVyYW5nZTpjZjU3MGRhNDE5MTg0YzI2YTVlMmM0NWY3Mzg5N2I2Yl8xLTAtMS0xLTI2NjM1L3RleHRyZWdpb246NGEyZTkxYTBkMWFkNDc4NGFlMmFjY2I3YzYwZTJjNzdfOA_ca42d579-bdcb-4111-8339-675b9cdbac6b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6Y2Y1NzBkYTQxOTE4NGMyNmE1ZTJjNDVmNzM4OTdiNmIvdGFibGVyYW5nZTpjZjU3MGRhNDE5MTg0YzI2YTVlMmM0NWY3Mzg5N2I2Yl8xLTItMS0xLTI2NjM1_2499b7de-39e1-4cce-8a8d-34e2696c9d5d">92618</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQw_75647abd-f27f-4dd0-b4a8-da55d39cdc0a">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ0_6cf9cdb1-05e1-48fa-a3be-ece395468c23">409-9820</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6OTJlZTkxNTY5YjRiNDkzODhjNTBiMTgzMDkzODM2MTAvdGFibGVyYW5nZTo5MmVlOTE1NjliNGI0OTM4OGM1MGIxODMwOTM4MzYxMF8xLTAtMS0xLTI2NjM1_10a91585-c8b1-49fe-875a-1012d5f3958b">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6OTJlZTkxNTY5YjRiNDkzODhjNTBiMTgzMDkzODM2MTAvdGFibGVyYW5nZTo5MmVlOTE1NjliNGI0OTM4OGM1MGIxODMwOTM4MzYxMF8xLTEtMS0xLTI2NjM1_13723a9a-7108-424b-aabf-40f18d009ded">TARS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6OTJlZTkxNTY5YjRiNDkzODhjNTBiMTgzMDkzODM2MTAvdGFibGVyYW5nZTo5MmVlOTE1NjliNGI0OTM4OGM1MGIxODMwOTM4MzYxMF8xLTItMS0xLTI2NjM1L3RleHRyZWdpb246MzUyZmUzNWY3NTBiNDBiNzg1NTU4M2FjMGVkYjhjNGVfMzQ_be8e3bfd-665d-4d0f-bc0f-2f173becbb97">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ1_a76de9ee-def8-4e7c-90b1-75d78ddf2919">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ2_bcced387-f1f0-42db-99a5-04face97d0eb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6YmFjMzNjY2QzYjE3NGQ0YjkxODYxYmVlN2ViM2Q1ZTUvdGFibGVyYW5nZTpiYWMzM2NjZDNiMTc0ZDRiOTE4NjFiZWU3ZWIzZDVlNV8xLTAtMS0xLTI2NjM1_b6704a2e-51be-41e9-824e-37eafa4fa059">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6YmFjMzNjY2QzYjE3NGQ0YjkxODYxYmVlN2ViM2Q1ZTUvdGFibGVyYW5nZTpiYWMzM2NjZDNiMTc0ZDRiOTE4NjFiZWU3ZWIzZDVlNV8xLTQtMS0xLTI2NjM1_4b94f8a3-d52b-4148-b7d6-8fcb76249768">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGFibGU6YmFjMzNjY2QzYjE3NGQ0YjkxODYxYmVlN2ViM2Q1ZTUvdGFibGVyYW5nZTpiYWMzM2NjZDNiMTc0ZDRiOTE4NjFiZWU3ZWIzZDVlNV8yLTQtMS0xLTI2NjM1_fb1ae3f2-972f-4dba-b0da-be1841c8a8e0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ3_e18863ef-bc78-4abe-ac15-b9101be5ca4e">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xOTQ4_0d4bc9fb-21df-4db9-856a-c65431d586e6">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id14bd9926cf44163a2bdbd7e313ace4f_I20220504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xL2ZyYWc6ODgyZWMxMjU2NzM3NDBkMGI2MmE3YjQwMjU5OGFhNTIvdGV4dHJlZ2lvbjo4ODJlYzEyNTY3Mzc0MGQwYjYyYTdiNDAyNTk4YWE1Ml8xODU4_17747fb2-451c-4bf6-8ba6-282c8e4815a5"
      unitRef="shares">20727701</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfNS0xLTEtMS0yNjYzNQ_bfcb53b3-aeb0-4959-98b2-8dde3c5d6da5"
      unitRef="usd">175010000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfNS0zLTEtMS0yNjYzNQ_cb0d447f-2235-4976-9173-e0eda1b0f611"
      unitRef="usd">171332000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfNy0xLTEtMS0yNjYzNQ_308c125d-96c9-4206-8be0-1b91e50ce8d6"
      unitRef="usd">291000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfNy0zLTEtMS0yNjYzNQ_036d861f-ad9b-4f59-b5fd-154f35b09214"
      unitRef="usd">483000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfOC0xLTEtMS0zMDQ3Nw_6f01b8d8-e759-4a56-b1a5-1ed375cb7485"
      unitRef="usd">17000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfOC0zLTEtMS0zMDQ4NA_bf51a5e0-55ae-475b-8760-04121cb7c187"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfOS0xLTEtMS0yNjYzNQ_504f1b4f-f4b6-4f11-840b-37e8fd71ee1d"
      unitRef="usd">306000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfOS0zLTEtMS0yNjYzNQ_049a3b7c-bd16-4baf-b1a5-46697460bfad"
      unitRef="usd">92000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTAtMS0xLTEtMjY2MzU_4e075f8b-a522-4243-991d-ace20284e355"
      unitRef="usd">3131000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTAtMy0xLTEtMjY2MzU_15078290-045b-4175-8917-7682769f1249"
      unitRef="usd">4045000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTEtMS0xLTEtMjY2MzU_5edea847-0306-4507-b1f1-1c281b3bc1ed"
      unitRef="usd">178755000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTEtMy0xLTEtMjY2MzU_120e8698-3239-440e-a5dd-c009025cda57"
      unitRef="usd">175952000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTItMS0xLTEtMjY2MzU_750dfd27-56e5-4051-ac85-eb19cbe6a299"
      unitRef="usd">915000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTItMy0xLTEtMjY2MzU_e676de62-601d-41fa-baab-5c439178ed51"
      unitRef="usd">755000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTMtMS0xLTEtMjY2MzU_ab61c151-fa2c-40b5-8e8f-11b19157657b"
      unitRef="usd">926000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTMtMy0xLTEtMjY2MzU_51a94551-d71d-4b6d-95fb-aff21646a522"
      unitRef="usd">1074000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTQtMS0xLTEtMjY2MzU_8437174d-8ab5-409b-94d8-c142ffb76c7e"
      unitRef="usd">887000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTQtMy0xLTEtMjY2MzU_04c60336-bbf3-4459-9a6e-fafe8084da5d"
      unitRef="usd">1126000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTUtMS0xLTEtMjY2MzU_6f44dc0a-9f58-4408-a59a-b4c760c2019d"
      unitRef="usd">181483000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTUtMy0xLTEtMjY2MzU_11299d09-9d9c-4b30-b9ce-de3889ff422a"
      unitRef="usd">178907000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTgtMS0xLTEtMjY2MzU_123df97d-08b5-4a84-88e3-9f410ceb32b7"
      unitRef="usd">10805000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTgtMy0xLTEtMjY2MzU_54f7eaf5-5cc0-4b7d-8b97-1b1401bebe33"
      unitRef="usd">8680000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTktMS0xLTEtMjY2MzU_5d7be76b-a89b-4af1-baaf-d5885fd016f5"
      unitRef="usd">1805000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMTktMy0xLTEtMjY2MzU_ba1e6c4d-b150-42f9-84e3-38887ed0cacb"
      unitRef="usd">2798000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjAtMS0xLTEtMjY2MzU_32251c76-b21d-49dd-a8ed-fb14aadfd051"
      unitRef="usd">12610000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjAtMy0xLTEtMjY2MzU_8897ef8e-05e3-42ed-9568-7a771e1f53e7"
      unitRef="usd">11478000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjEtMS0xLTEtMzA1MjI_54dca8bc-f735-4fc5-9822-7bafeed10d14"
      unitRef="usd">19180000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjEtMy0xLTEtMzA1Mjk_b0e54397-5853-4265-9739-f7be5244d9f1"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjEtMS0xLTEtMjY2MzU_3e92aeb4-0eca-4ccb-aa4e-7db559624453"
      unitRef="usd">496000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjEtMy0xLTEtMjY2MzU_6981828c-a064-4c8a-8f93-3718819b9e62"
      unitRef="usd">699000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjItMS0xLTEtMjY2MzU_5de0b7d1-3675-4f25-af40-2309d87dbd0b"
      unitRef="usd">32286000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjItMy0xLTEtMjY2MzU_25890f66-67e3-4fdf-bea4-b6b27f0f9971"
      unitRef="usd">12177000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjMtMS0xLTEtMjY2MzU_751be429-3c14-48e7-af31-85529298d87d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjMtMy0xLTEtMjY2MzU_495f4119-a127-422b-9357-ce3039366cdc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y18yMQ_71239956-c6d9-45fb-9a53-09f982a7edf8"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y18yMQ_b96fb616-26e4-4a27-b27a-e19665f201d8"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y18zNQ_2ab43e64-ba28-4a6b-8e53-97735fd13ca4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y18zNQ_625002e2-f600-4a41-b206-a415f6e94a67"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y182Mw_1df92529-5bbc-41fb-8a8a-0ab26e6cadb4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y182Mw_1e229738-48c3-48cf-a345-97be38fd9573"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y182Mw_8cc8225f-0b01-4069-a3dd-547923cdf577"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo0YjBlMTQ1N2RjMTc0OGY1ODYzMWVjYTBjMDJhZWE2Y182Mw_f6ce038f-6b2b-4721-8230-642d04b821ae"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMS0xLTEtMjY2MzU_5655de59-c39a-4790-9a16-8bd2f9a658d3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjUtMy0xLTEtMjY2MzU_a88ea61b-97ed-4012-8cc7-b071d4cc3308"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xOA_41a88a13-2656-44cd-8051-bad9f8644fb1"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xOA_a68a9183-7714-43a1-8f54-daaeda28003a"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18zMg_85cd0be9-634f-4530-a040-7bfbb2d26fe1"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18zMg_873d8f4d-f174-4b32-908d-ba5a2ea9e2e1"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M181NA_e4d53f1f-79f1-4221-a850-30478bcd4356"
      unitRef="shares">20731062</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M183NQ_abeaa55e-c3b7-4fd7-afa9-a6c4f2261dd8"
      unitRef="shares">20718528</us-gaap:CommonStockSharesOutstanding>
    <tars:CommonStockSharesSubjectToRepurchase
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xMDY_df9015dd-9f0f-420a-afe9-2abd9c805660"
      unitRef="shares">12534</tars:CommonStockSharesSubjectToRepurchase>
    <us-gaap:CommonStockSharesIssued
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xNTc_e9f4f36b-dc4d-42da-ba20-43e2c2cbd7e7"
      unitRef="shares">20726580</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18xNzg_aafaf77d-d712-4e93-94c0-cd2deb30b9ca"
      unitRef="shares">20698737</us-gaap:CommonStockSharesOutstanding>
    <tars:CommonStockSharesSubjectToRepurchase
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMC0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpjMTIzNGI2MDUxZGU0MWY3YWVmMDQzZDhmNmY1ZTI0M18yMDk_32831530-e005-4b25-b4ae-7de39468d2da"
      unitRef="shares">27840</tars:CommonStockSharesSubjectToRepurchase>
    <us-gaap:CommonStockValue
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMS0xLTEtMjY2MzU_5ed1a3d6-a42d-4adb-8310-d1a476e218ab"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjYtMy0xLTEtMjY2MzU_2c853add-eb90-42d7-901c-c44d5aa43f8f"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjctMS0xLTEtMjY2MzU_7064a0e4-33aa-4aaa-af4c-e9c9433f7b9a"
      unitRef="usd">216103000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjctMy0xLTEtMjY2MzU_2940f95b-d79c-47bc-9847-da646c8f7129"
      unitRef="usd">213398000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjgtMS0xLTEtMjY2MzU_51cfcc8f-4a0c-4269-ac09-0a8d53aba5ee"
      unitRef="usd">-66910000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjgtMy0xLTEtMjY2MzU_f9f459f5-1644-4c83-b027-bcd4760c13fb"
      unitRef="usd">-46672000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjktMS0xLTEtMjY2MzU_5e330de7-f981-4951-8f7c-5e0936f6090a"
      unitRef="usd">149197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMjktMy0xLTEtMjY2MzU_43e68e71-4f00-46a4-ba95-6386f22c9069"
      unitRef="usd">166730000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMzAtMS0xLTEtMjY2MzU_ca11ca05-0a3c-4757-a13c-34e3d0013751"
      unitRef="usd">181483000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8xOS9mcmFnOmYxNzQwYTVjYTViYzQyNDZhMGU1NDdlYjZhNjg0MjhjL3RhYmxlOjE5MmFlOTg5YWMyYzRlNjJiMzgyYmZhY2VhOWI0OGEyL3RhYmxlcmFuZ2U6MTkyYWU5ODlhYzJjNGU2MmIzODJiZmFjZWE5YjQ4YTJfMzAtMy0xLTEtMjY2MzU_72d7c26c-fd47-4657-8575-ab17cfb235fb"
      unitRef="usd">178907000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i080af938313c43d2b539cdefbcdfec98_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMy01LTEtMS0yNjYzNQ_f7558a8d-69d8-432a-a848-b51bdbbb34e0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54381f41a7eb4b0ea3fbbbaeff54f01f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMy03LTEtMS0yNjYzNQ_252b4c2b-9f5d-4b81-85f5-6aab9c8e3ea5"
      unitRef="usd">33311000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f4a4782309e4d14a530821ddb8049b3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNC01LTEtMS0yNjYzNQ_b52d9a45-4e54-4287-b016-e5aa0eb3c5f2"
      unitRef="usd">539000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29bc79115d7a4e0ca6736b6a0bd45d7e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNC03LTEtMS0yNjYzNQ_d9adfa0b-e167-48e7-aefd-8b2218d8f03f"
      unitRef="usd">121000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNS01LTEtMS0yNjYzNQ_1000d62d-662a-4cef-a016-c51f95de2920"
      unitRef="usd">539000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNS03LTEtMS0yNjYzNQ_c9de247d-1f28-4cb8-87f5-4a053f6044b9"
      unitRef="usd">33432000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="i8026e35afb834d3cb1f3553098db8877_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNy01LTEtMS0yNjYzNQ_49ccb660-c789-49df-ba66-7db10d4b86b3"
      unitRef="usd">33000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="idc4f887cfb0f4ab5be157a6b1b3689d8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfNy03LTEtMS0yNjYzNQ_eb9fccfb-7495-402b-a150-aa752b246064"
      unitRef="usd">1297000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfOC01LTEtMS0yNjYzNQ_6bc2e9e6-6ca3-4e48-a80f-9abb8cb15004"
      unitRef="usd">12081000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfOC03LTEtMS0yNjYzNQ_6d9e570d-5a9a-48bb-927e-8245cd79ca10"
      unitRef="usd">16261000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfOS01LTEtMS0yNjYzNQ_a1805982-1ab1-4bd0-bcf4-41d85c5d6af8"
      unitRef="usd">7946000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfOS03LTEtMS0yNjYzNQ_27711d3e-d010-4b31-9c41-a53d6a2d3973"
      unitRef="usd">5160000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTAtNS0xLTEtMjY2MzU_fbf6ce6e-d393-4e8e-ada8-7b3ab56b8f64"
      unitRef="usd">20060000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTAtNy0xLTEtMjY2MzU_e9bfc31e-dd7e-48af-9537-eed1dd783067"
      unitRef="usd">22718000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTEtNS0xLTEtMjY2MzU_0fb496b7-7f05-4a2e-8ad5-6f6f692c2cfc"
      unitRef="usd">-19521000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTEtNy0xLTEtMjY2MzU_79867e26-7af8-4b47-91ec-709b64dacc22"
      unitRef="usd">10714000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTMtNS0xLTEtMjY2MzU_b30906ef-50c3-4af5-bf8c-f56cb63d892c"
      unitRef="usd">-316000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTMtNy0xLTEtMjY2MzU_c268d89c-c9d3-4992-bf28-dd4466ca891f"
      unitRef="usd">9000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTQtNS0xLTEtMjY2MzU_0887ff0d-3d73-446d-899d-32a532ba8901"
      unitRef="usd">37000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTQtNy0xLTEtMjY2MzU_b6a05403-c5d6-4057-a3d4-b6e4819967f1"
      unitRef="usd">-34000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTUtNS0xLTEtMjcwMTA_235c2e92-43e9-4553-9b66-727c7af268bc"
      unitRef="usd">-192000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTUtNy0xLTEtMjcwMTA_fe11ca3a-0b43-4087-b1dc-3072fdf719cf"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTUtNS0xLTEtMjY2MzU_9b1f12ec-ba8d-4613-8efb-262f3de8b0d2"
      unitRef="usd">-245000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTUtNy0xLTEtMjY2MzU_696f34f7-d394-45d1-8bd2-103a91fe7d83"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTYtNS0xLTEtMjY2MzU_2a5413d9-47e7-4771-ad14-b17e85e6275f"
      unitRef="usd">-716000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTYtNy0xLTEtMjY2MzU_84299222-775b-4349-9c2b-3ae55eb2afcb"
      unitRef="usd">-25000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTctNS0xLTEtMjY2MzU_7fa0c91c-d1a8-4f82-aed1-12f5e176d728"
      unitRef="usd">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTctNy0xLTEtMjY2MzU_10e6556a-a111-415b-af4b-d304e2b13374"
      unitRef="usd">313000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTgtNS0xLTEtMjY2MzU_55b98144-8fa4-4b4b-81f9-8416ae0241ad"
      unitRef="usd">-20238000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTgtNS0xLTEtMjY2MzU_dd9912bc-83e1-47fd-acd7-852f052d60ea"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTgtNy0xLTEtMjY2MzU_60bd9f47-3d41-42c4-a8e5-aa8f9dbe60f4"
      unitRef="usd">10376000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMTgtNy0xLTEtMjY2MzU_94a9eafe-4e13-4d74-a879-5b66a2cd4136"
      unitRef="usd">10376000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjAtNS0xLTEtMjY2MzU_e3287c77-308d-4d30-90e3-af5baba3eff1"
      unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjAtNy0xLTEtMjY2MzU_7035b968-290b-4fc7-8e8f-1c69450c05db"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjEtNS0xLTEtMjY2MzU_b3f884c0-7387-43b4-9f17-bcd2adf78cee"
      unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjEtNy0xLTEtMjY2MzU_ac390df3-cf0c-4fa3-924d-44765b0b5433"
      unitRef="usdPerShare">0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjMtNS0xLTEtMjY2MzU_3f6dafb1-8d66-4d60-9139-489103d16488"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjMtNy0xLTEtMjY2MzU_46f3da31-e22d-4e6d-a8b2-7b961e9cf02d"
      unitRef="shares">20336022</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjQtNS0xLTEtMjY2MzU_df738d43-b9b0-4c5c-a830-ef3d24fa4e7a"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yMi9mcmFnOmI0OTE5MDRlZWU4YTQ2MjBhZmE4NzlhNmI3ZDcyMDhlL3RhYmxlOjJkOWI2ZGNlODkxNjQwYzM5YzFkMzIzNWI1ZmViMjYyL3RhYmxlcmFuZ2U6MmQ5YjZkY2U4OTE2NDBjMzljMWQzMjM1YjVmZWIyNjJfMjQtNy0xLTEtMjY2MzU_f96b5fe4-8d7d-43f4-8a03-0ecfb2970dc1"
      unitRef="shares">21824574</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi0xLTEtMS0yNjYzNQ_0ed78ba9-ae01-413a-8d48-37863d30fa1a"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi0zLTEtMS0yNjYzNQ_4b41407d-e53b-4716-b8a0-8eb7cc1225b7"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3a0a5d596de347dfb2ee05dbf213d003_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi01LTEtMS0yNjYzNQ_51905746-fb1a-49d5-9d57-9cadeaa7f79e"
      unitRef="shares">20698737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3a0a5d596de347dfb2ee05dbf213d003_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi03LTEtMS0yNjYzNQ_be8050a4-5419-4c07-8c27-0cfda0b81464"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77bea9a87fa149f5b7b6f0c53df117f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi05LTEtMS0yNjYzNQ_da798ce7-84ac-4925-93d2-7310642aad5b"
      unitRef="usd">213398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71110d20496a42568cfa4272b640c494_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi0xMS0xLTEtMjY2MzU_ede2744d-23cf-4cbf-8891-646b1a6d9e65"
      unitRef="usd">-46672000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMi0xMy0xLTEtMjY2MzU_f58bc740-934a-48fb-aa26-839a52aeacfc"
      unitRef="usd">166730000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i281e4ce0faee4e93b52b1c855c37b40e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMy0xMS0xLTEtMjY2MzU_fe4d4bdf-f0c3-42bb-8f55-2dfa400f8196"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfMy0xMy0xLTEtMjY2MzU_f319e1a8-825b-48b7-9338-e7a4fb080ede"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i00db3f28f47a45fd81332519739fb47a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNC05LTEtMS0yNjYzNQ_b036bc63-50f9-4165-8f5f-66afd55fcc07"
      unitRef="usd">2674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNC0xMy0xLTEtMjY2MzU_13150872-160d-430b-97e0-7f2a2a77a1e3"
      unitRef="usd">2674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ida7f2066d6ab4d298b57b9551607ddc1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNS01LTEtMS0yNjYzNQ_4a950a74-ea3b-403d-9a14-18eb72b9752c"
      unitRef="shares">225</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ida7f2066d6ab4d298b57b9551607ddc1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNi01LTEtMS0zMDg4NA_db8ce575-cc0b-439c-b23e-9ac8d4762b26"
      unitRef="shares">4257</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights
      contextRef="ida7f2066d6ab4d298b57b9551607ddc1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNi01LTEtMS0yNjYzNQ_2b990c32-1234-4d39-8f16-ae772b28fd89"
      unitRef="shares">15309</tars:StockIssuedDuringPeriodSharesLapseOfRepurchaseRights>
    <tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights
      contextRef="i00db3f28f47a45fd81332519739fb47a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNi05LTEtMS0yNjYzNQ_bac46b92-1e72-4a84-8922-b445fe97de51"
      unitRef="usd">31000</tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights>
    <tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNi0xMy0xLTEtMjY2MzU_afc5a596-5537-4816-8f74-9bde3209f77f"
      unitRef="usd">31000</tars:StockIssuedDuringPeriodValueLapseOfRepurchaseRights>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy0xLTEtMS0yNjYzNQ_09981e91-d2b7-489e-9fac-4be7dc412c27"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy0zLTEtMS0yNjYzNQ_f11604eb-80e9-44c4-b061-894c1e292b1f"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6c1ad78fb81b430cab2abc5651cadb29_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy01LTEtMS0yNjYzNQ_e8302ade-6287-486c-92c3-e84ebd2e7f8e"
      unitRef="shares">20718528</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6c1ad78fb81b430cab2abc5651cadb29_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy03LTEtMS0yNjYzNQ_df054d92-58bc-4160-b14d-0cdc2edf787b"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a3d5c72a6a94f73955e1eb952386f30_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy05LTEtMS0yNjYzNQ_4cdd6e8c-38d6-42a1-b20b-bcbc0aede330"
      unitRef="usd">216103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibec2fec07baf4b5ea65315e3604b264b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy0xMS0xLTEtMjY2MzU_5baff17f-6606-4f8d-b540-732e3a24240a"
      unitRef="usd">-66910000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOmVmOWU4MmRkZjNlMzQ5ZThiZTNlNDg2YWIwOWEyZmQzL3RhYmxlcmFuZ2U6ZWY5ZTgyZGRmM2UzNDllOGJlM2U0ODZhYjA5YTJmZDNfNy0xMy0xLTEtMjY2MzU_8a3c63ad-41ed-41ce-b99c-5ecb90f8aada"
      unitRef="usd">149197000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi0xLTEtMS0yNjYzNQ_495f8cac-b621-43a0-8a59-d01abf63f340"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi0zLTEtMS0yNjYzNQ_02ede807-b424-4bef-852b-01e85c6540d2"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if3d5cd01a5b74ad69d8cfb82b0ddb6b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi01LTEtMS0yNjYzNQ_3f455f00-a961-4edd-b455-036048c343a7"
      unitRef="shares">20323201</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if3d5cd01a5b74ad69d8cfb82b0ddb6b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi03LTEtMS0yNjYzNQ_10224086-8c68-4b7e-b9df-4af8bfed431f"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2407365462b6484e866e2a0897a6f31f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi05LTEtMS0yNjYzNQ_5d15efd2-e558-4db2-bac5-8ac32bcd91da"
      unitRef="usd">198821000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3eb871a3740c464480f7fcef3e833411_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi0xMS0xLTEtMjY2MzU_6f38af0a-8ba5-41ab-a6db-82dcfab8b753"
      unitRef="usd">-32845000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMi0xMy0xLTEtMjY2MzU_b1e8833d-43d4-4823-bf6c-9cc584fdf715"
      unitRef="usd">165980000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i514947c5e4b04a378154c04684c04412_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMy0xMS0xLTEtMjY2MzU_2f210f16-dbca-4040-9240-97d214ec488e"
      unitRef="usd">10376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfMy0xMy0xLTEtMjY2MzU_bd1d8381-8e12-41e1-9370-2354af6e48d0"
      unitRef="usd">10376000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia5af16c925384bbda1b2f1b0f73319cf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNC05LTEtMS0yNjYzNQ_42df6676-8406-4bbd-b502-b49431ebdb31"
      unitRef="usd">1363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNC0xMy0xLTEtMjY2MzU_f6098133-352e-4dac-b0d0-b074fe3eeb3f"
      unitRef="usd">1363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6f1e1fe52f054a159eaad037bb720a9d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS01LTEtMS0zMjQ2NA_51903e28-1dbf-4a01-929e-bff58b94f365"
      unitRef="shares">13773</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia5af16c925384bbda1b2f1b0f73319cf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS05LTEtMS0zMjQ2NA_7916a993-5aa2-41f0-abf2-1cf102baf6ee"
      unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS0xMy0xLTEtMzI0NjQ_a57c7224-0d72-4565-9a9e-360378c137ae"
      unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i6f1e1fe52f054a159eaad037bb720a9d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS01LTEtMS0yNjYzNQ_96c421fb-6190-4ae0-818c-e86321771120"
      unitRef="shares">187500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ia5af16c925384bbda1b2f1b0f73319cf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS05LTEtMS0yNjYzNQ_98b64e22-6a7c-4776-be17-acec77a75902"
      unitRef="usd">5494000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNS0xMy0xLTEtMjY2MzU_a4075634-68d8-4618-b509-4cfcbb60f23a"
      unitRef="usd">5494000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id80221d972a4407a82832333ee98fc87_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi0xLTEtMS0yNjYzNQ_22114822-0fb8-4614-80f0-9df700548bb3"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id80221d972a4407a82832333ee98fc87_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi0zLTEtMS0yNjYzNQ_3d0345ae-5e74-4714-9d4b-865ae444d4ab"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i015bde96678a4498b78f135f2e37fe8a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi01LTEtMS0yNjYzNQ_8af00fc3-5e09-4097-8f7e-bd9e28dffe85"
      unitRef="shares">20524474</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i015bde96678a4498b78f135f2e37fe8a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi03LTEtMS0yNjYzNQ_64818566-0127-404f-8db9-c255959edec8"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c7ac172fd5445a9afde9ded686451dd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi05LTEtMS0yNjYzNQ_441d747d-a6d4-4b4d-b037-06c52899d4c9"
      unitRef="usd">205697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09758e9a44594ebf8985740d1bf5f229_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi0xMS0xLTEtMjY2MzU_7fddca71-e631-416a-b503-cc49eae4a0ca"
      unitRef="usd">-22469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id80221d972a4407a82832333ee98fc87_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yNS9mcmFnOmNjYjU2YzU2NzdjYTRhYjZiZDgxMzRjNTEyZGU3NmEzL3RhYmxlOjgxYWFiNGE1MjRmMDQ2MjFiN2VkMGYwYjIwYjY1MzY3L3RhYmxlcmFuZ2U6ODFhYWI0YTUyNGYwNDYyMWI3ZWQwZjBiMjBiNjUzNjdfNi0xMy0xLTEtMjY2MzU_cc4107dd-b624-4a00-ad3f-514acc2845fa"
      unitRef="usd">183232000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMy0xLTEtMS0yNjYzNQ_7f56cbe9-4db1-4ac5-905f-6709e3c7d91b"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMy0zLTEtMS0yNjYzNQ_05fd9123-6663-4b8d-890d-864beed3a19a"
      unitRef="usd">10376000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNS0xLTEtMS0yNjYzNQ_28c9f082-35c5-404a-aea8-a99d9a38c83e"
      unitRef="usd">41000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNS0zLTEtMS0yNjYzNQ_ac50f8fd-3d6b-4493-bcd3-8d5d9f694e56"
      unitRef="usd">64000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNi0xLTEtMS0zMTI0Mw_2a68854d-1d65-4501-941f-3bc49099948c"
      unitRef="usd">55000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNi0zLTEtMS0zMTI0Mw_b93a9f24-3902-4aa8-a621-c016dea92206"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNi0xLTEtMS0yNjYzNQ_752e1062-bbbc-425f-b715-7b67607e82d9"
      unitRef="usd">2674000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNi0zLTEtMS0yNjYzNQ_d5c29a8a-edfa-415e-8a86-095170776e42"
      unitRef="usd">1363000</us-gaap:ShareBasedCompensation>
    <tars:OperatingLeaseNoncashExpense
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNy0xLTEtMS0yNjYzNQ_2294620e-1afe-4605-8cb2-8e8f1ba5756d"
      unitRef="usd">113000</tars:OperatingLeaseNoncashExpense>
    <tars:OperatingLeaseNoncashExpense
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNy0zLTEtMS0yNjYzNQ_f21af0a9-00f3-4d0d-89f8-d8bda54e32e2"
      unitRef="usd">43000</tars:OperatingLeaseNoncashExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfOC0xLTEtMS0yNjYzNQ_ffe65ba7-f461-4708-89d1-334a498ca162"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfOC0zLTEtMS0yNjYzNQ_35fce4f2-a981-4e52-90f0-134a1cc4dbc0"
      unitRef="usd">-70000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfOS0xLTEtMS0yNjYzNQ_2d71b3d2-41f6-437f-b041-aec6afdaf8a2"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfOS0zLTEtMS0yNjYzNQ_ea573579-e261-4730-b0f4-bf1fe2e51a23"
      unitRef="usd">-2000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTAtMS0xLTEtMjczMDU_3ade89e6-7ef6-4310-9a48-a72eb5948e35"
      unitRef="usd">-192000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTAtMy0xLTEtMjczMDU_408a402c-e355-44f8-8c59-7c3620615c45"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTAtMS0xLTEtMjY2MzU_8bc83427-259c-4ed7-a1ae-9c7c6de8ae8a"
      unitRef="usd">-245000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTAtMy0xLTEtMjY2MzU_cb67ebab-7520-49de-a801-1f9a7144117a"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTItMS0xLTEtMjY2MzU_850e89b3-aa11-49aa-88a2-cf939b2c2c40"
      unitRef="usd">-1000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTItMy0xLTEtMjY2MzU_5ac61e2e-0c83-4426-83ae-616aea1fcb57"
      unitRef="usd">35000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTMtMS0xLTEtMjY2MzU_5821672f-d5b7-48ac-8daf-7e483ddef644"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTMtMy0xLTEtMjY2MzU_011ca312-0b5e-4798-b6d6-fe91d1381a4d"
      unitRef="usd">5494000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTUtMS0xLTEtMjY2MzU_c4ba4a3d-576a-4298-b5a9-58d0ecce8f20"
      unitRef="usd">17000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTUtMy0xLTEtMjY2MzU_77846f77-56fe-4234-8fef-4dcc1664ba31"
      unitRef="usd">25000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTYtMS0xLTEtMjY2MzU_a647d4a4-59dc-45a0-a7f1-1c2874524c49"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTYtMy0xLTEtMjY2MzU_a81fa5f3-d0a1-4e1e-af67-38a54e08e12f"
      unitRef="usd">7199000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTctMS0xLTEtMjY2MzU_e8981a99-53e8-4911-b778-29768bd2594f"
      unitRef="usd">225000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTctMy0xLTEtMjY2MzU_ff90f99e-3f07-4bc9-afdf-9234531b4f1e"
      unitRef="usd">227000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTgtMS0xLTEtMjY2MzU_8e9ac87d-251a-4f69-a640-6af8c43d6a4a"
      unitRef="usd">-926000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTgtMy0xLTEtMjY2MzU_67091026-4304-4c61-901c-4594aa39409f"
      unitRef="usd">321000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTktMS0xLTEtMjY2MzU_e52e0593-6562-48ae-91d9-4904a445db2b"
      unitRef="usd">-14000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMTktMy0xLTEtMjY2MzU_bca99c00-08d8-4fa6-846d-0575ee7f6908"
      unitRef="usd">1255000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjAtMS0xLTEtMjY2MzU_107d989c-ab8a-48c9-8a4b-015bd0f99660"
      unitRef="usd">1969000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjAtMy0xLTEtMjY2MzU_33672169-50ec-476b-aa00-a565f55220d7"
      unitRef="usd">5063000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjEtMS0xLTEtMjY2MzU_aaa4d51f-4e57-4fa9-af4e-d0b7971e63f4"
      unitRef="usd">-993000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjEtMy0xLTEtMjY2MzU_211b14a0-a4dd-4811-8b3e-2f8129115232"
      unitRef="usd">-355000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjItMS0xLTEtMjY2MzU_ba6fda11-25fd-496d-b8e8-745f51035829"
      unitRef="usd">-43000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjItMy0xLTEtMjY2MzU_8bac714e-f82a-4410-b5df-6f7dc24c5f21"
      unitRef="usd">123000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjMtMS0xLTEtMjY2MzU_d46373d9-bd32-4a3a-853b-78dc0ea34fa2"
      unitRef="usd">-15286000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjMtMy0xLTEtMjY2MzU_5ccd6d2c-96b0-4b10-bdd2-0dbfcd0a8dc6"
      unitRef="usd">-11794000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjUtMS0xLTEtMjY2MzU_c60d317a-2891-45e1-8aa7-c8133e35caad"
      unitRef="usd">161000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjUtMy0xLTEtMjY2MzU_00a3a67c-daff-4987-818d-3c6e78cc3142"
      unitRef="usd">175000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjYtMS0xLTEtMjY2MzU_4f5348f5-1486-49aa-aff8-a205540b19ab"
      unitRef="usd">-161000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMjYtMy0xLTEtMjY2MzU_7131745b-cb6c-4af5-9d51-9279a047dd20"
      unitRef="usd">-175000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <tars:ProceedsFromEarlyExerciseOfStockOptions
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzAtMS0xLTEtMjczNjk_ebe53628-88aa-45bf-92c5-13d9185c023a"
      unitRef="usd">0</tars:ProceedsFromEarlyExerciseOfStockOptions>
    <tars:ProceedsFromEarlyExerciseOfStockOptions
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzAtMy0xLTEtMjczNjk_32d9a014-dc20-4419-be78-652adcc33307"
      unitRef="usd">19000</tars:ProceedsFromEarlyExerciseOfStockOptions>
    <tars:PaymentsOfDeferredStockIssuanceCosts
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzEtMS0xLTEtMjczMzQ_54720601-5e87-493f-9297-74dd8d0b0d3b"
      unitRef="usd">60000</tars:PaymentsOfDeferredStockIssuanceCosts>
    <tars:PaymentsOfDeferredStockIssuanceCosts
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzEtMy0xLTEtMjczMzQ_7af2f83f-c234-48f8-abbe-3053092dbae2"
      unitRef="usd">0</tars:PaymentsOfDeferredStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzUtMS0xLTEtMzEyNjg_d7a70522-143f-4b6d-a54f-d93ac6e4e777"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzUtMy0xLTEtMzEyODU_e3c638ba-5bd7-427f-bab1-6241084ff02e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzYtMS0xLTEtMzEyNjg_ea0bb7a9-6fab-4898-84ee-d538fdba4d84"
      unitRef="usd">815000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzYtMy0xLTEtMzEyODU_5121d61a-de3a-4016-ba13-a3035e26c6f8"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzItMS0xLTEtMjY2MzU_02b4e168-42a7-4893-8e6e-e6bbeef480b0"
      unitRef="usd">19125000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzItMy0xLTEtMjY2MzU_2865d152-daf8-4135-aa79-ebf438f23526"
      unitRef="usd">19000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzMtMS0xLTEtMjY2MzU_f994c23c-5273-41a5-9455-2100ff2b2447"
      unitRef="usd">3678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzMtMy0xLTEtMjY2MzU_edb869d5-9ed8-4a32-b042-2b14d8fd27e6"
      unitRef="usd">-11950000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzQtMS0xLTEtMjY2MzU_d4064c8c-f7ad-41aa-8bf1-efb180d78b4b"
      unitRef="usd">171332000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzQtMy0xLTEtMjY2MzU_ef1b83b1-86af-496f-9870-493ae2821268"
      unitRef="usd">168149000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzUtMS0xLTEtMjY2MzU_0a24243a-5631-4f5c-bf35-99642cf2d0ff"
      unitRef="usd">175010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id80221d972a4407a82832333ee98fc87_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzUtMy0xLTEtMjY2MzU_27e3ac02-e346-4c45-8632-0d89c5805282"
      unitRef="usd">156199000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzctMS0xLTEtMjY2MzU_671563dd-d479-4e9b-baeb-5431e67453c3"
      unitRef="usd">175010000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id80221d972a4407a82832333ee98fc87_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzctMy0xLTEtMjY2MzU_ae550f17-7cab-4544-b987-19e83886fe9e"
      unitRef="usd">156179000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzgtMS0xLTEtMjY2MzU_3345ddd6-f935-4d82-b3ca-bf6904133a48"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id80221d972a4407a82832333ee98fc87_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzgtMy0xLTEtMjY2MzU_c358738a-d4fa-492d-be23-5f60db8af626"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzktMS0xLTEtMjY2MzU_0227e350-c9e1-4f98-bc43-42a7b4887f1b"
      unitRef="usd">175010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id80221d972a4407a82832333ee98fc87_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfMzktMy0xLTEtMjY2MzU_b13011e6-a0c6-4308-8b02-8948d1050f44"
      unitRef="usd">156199000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDgtMS0xLTEtMzEzMjI_1e488573-469b-4787-8874-c5a09baaef32"
      unitRef="usd">127000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDgtMy0xLTEtMzEzMjI_614420a6-6c88-444f-8018-f06153995b53"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDMtMS0xLTEtMjY2MzU_31d14ae3-af7d-404e-b398-7c1fdebf2e07"
      unitRef="usd">41000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDMtMy0xLTEtMjY2MzU_39d58f92-ef2e-4121-a5c3-79a341e55ee8"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <tars:OperatingLeaseRightOfUseAssetLeaseTerminationExpense
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDQtMS0xLTEtMjY2MzU_f7bf1da5-2023-4962-8613-ab162b101725"
      unitRef="usd">0</tars:OperatingLeaseRightOfUseAssetLeaseTerminationExpense>
    <tars:OperatingLeaseRightOfUseAssetLeaseTerminationExpense
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDQtMy0xLTEtMjY2MzU_a743a9b8-2e9e-4729-9d60-7aedfacd41e7"
      unitRef="usd">38000</tars:OperatingLeaseRightOfUseAssetLeaseTerminationExpense>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDUtMS0xLTEtMjY2MzU_26b626ac-924f-4ba1-a9e6-c72be0c83464"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDUtMy0xLTEtMjY2MzU_2a63792f-0b2c-457c-b47e-6981fd099afa"
      unitRef="usd">5494000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <tars:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDctMS0xLTEtMjY2MzU_f14537e5-9ae3-4e94-b2d2-6888cdf2ba3d"
      unitRef="usd">55000</tars:DeferredOfferingCostsIncurredButNotYetPaid>
    <tars:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8yOC9mcmFnOjNjMjU5NjIwMGY0ZTRlZDk4Nzk2ZWJhNjZlNmY2MTM3L3RhYmxlOjVkMTdkODU4NWQyODQ5Y2Q4NTkxNzdjY2FjY2Q1YjM2L3RhYmxlcmFuZ2U6NWQxN2Q4NTg1ZDI4NDljZDg1OTE3N2NjYWNjZDViMzZfNDctMy0xLTEtMjY2MzU_3f8f23a1-b0a4-411f-a309-c28b922acdc0"
      unitRef="usd">0</tars:DeferredOfferingCostsIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjMzNg_77a74df9-0090-4116-ac6a-b6903d9b82e7">DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a) Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tarsus Pharmaceuticals, Inc. (&#x201c;Tarsus&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;(b)  Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has no product sales and has accumulated losses and negative cash flows from operations since inception (other than consideration received from an out-licensing agreement, as discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;), resulting in an accumulated deficit of $66.9 million as of March&#160;31, 2022 and $46.7 million as of December&#160;31, 2021. The Company&#x2019;s cash and cash equivalents were $175.0 million and $171.3 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The Company expects to continue to incur operating losses and negative cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 2, 2022, the Company executed a loan and security agreement (the "Credit Facility") with Hercules Capital, Inc. ("Hercules") and Silicon Valley Bank ("SVB"). This $175&#160;million Credit Facility has tranched availability. Capital draws are at the Company's election and are in $5&#160;million increments. In February 2022, the Company made a $20&#160;million draw (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Note 10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has funded its inception-to-date operations primarily through equity capital raises, proceeds from its out-license agreement, and draw downs on its credit facility. The Company estimates that its existing capital resources will be sufficient to meet projected operating requirements beyond at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q. Accordingly, the accompanying financial statements in this Form 10-Q have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operations currently consist of its corporate organization build-out, intellectual property licensing activities, and preclinical and clinical study progression. The Company faces the clinical, business, and liquidity risks that are typically associated with biopharma companies; it must significantly invest in and conduct research and development activities, achieve research and development outcomes that are inherently uncertain, recruit and retain skilled personnel (including executive management), and expand and defend its intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Management expects the Company to continue to incur losses in the foreseeable future as a result of research and development activities and other operating expenses. The Company may be required to raise additional capital to fund its future operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, if at all. If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. The Company's Credit Facility imposes additional covenants that restrict operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase common stock, make certain investments, or engage in certain merger or asset sale transactions. Any debt financing or additional equity raise may contain terms that are not favorable to the Company or its stockholders. The Company&#x2019;s potential inability to raise capital when needed could have a negative impact on its financial condition and ability to pursue planned business strategies. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own. If the Company is required to enter into collaborations and other arrangements to address its liquidity needs, it may have to give up certain rights that limit its ability to develop and commercialize product candidates or may have other terms that are not favorable to the Company or its stockholders, which could materially and adversely affect its business and financial prospects. These factors may adversely impact the Company's ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c) Operating Segment  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has operated and managed its business and financial information on an aggregate basis based on the Company's organizational structure, for the purposes of evaluating financial performance and the allocation of capital and personnel resources, consistent with the way operations and investments are centrally managed and evaluated. Accordingly, the Company&#x2019;s management determined that it operates one reportable operating segment. This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d) Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfMTcxMg_caa1adc5-c200-44a7-b6ca-7b40e0238baa"
      unitRef="usd">-66900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfMTcyOA_3f2ed77d-cd1e-4cf2-94f4-b2fea32b83c7"
      unitRef="usd">-46700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfMTc4Ng_c163bd07-3d03-48c2-9b9e-bd7ba5038482"
      unitRef="usd">175000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfMTc5Mw_c052d1c0-8792-4aca-856c-5bce8525fc6f"
      unitRef="usd">171300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjU5NzA2OTc4MjE0Mw_f264f34f-65a2-4b1e-bde6-429217df914f"
      unitRef="usd">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tars:LineOfCreditFacilityDrawDownIncrements
      contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjU5NzA2OTc4MjE0Nw_b0fcf740-304e-46ee-9c9b-c0e8ec8bd78e"
      unitRef="usd">5000000</tars:LineOfCreditFacilityDrawDownIncrements>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i64ab1022c5cf4cbf9f780e24d3f48ca8_D20220201-20220228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjU5NzA2OTc4MjE1MQ_4827a5e7-ac21-4305-95fe-db3ab3c1851b"
      unitRef="usd">20000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNjMzNw_8b1eeef0-6ee5-47dd-b8d3-c5aae72d6bbb">To date, the Company has operated and managed its business and financial information on an aggregate basis based on the Company's organizational structure, for the purposes of evaluating financial performance and the allocation of capital and personnel resources, consistent with the way operations and investments are centrally managed and evaluated. Accordingly, the Company&#x2019;s management determined that it operates one reportable operating segment. This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNTU0Mw_07fcfb4e-4c19-4610-9a22-50c93886d435"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF8zNC9mcmFnOmIzZmQwYWNmYWRiYTQyMDNhNTYyYTI4OGMyNWE4YzdhL3RleHRyZWdpb246YjNmZDBhY2ZhZGJhNDIwM2E1NjJhMjg4YzI1YThjN2FfNTU0Mw_e8a14729-7b99-4881-b29c-ec247b452041"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1Mzg_3764417a-84fa-416b-8b8f-a21bbd56bf37">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Condensed Financial Statements have been prepared in conformity with accounting principles generally accepted ("GAAP") in the United States ("U.S.") for interim financial information and pursuant to Form 10-Q and with the rules and regulations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Balance Sheet as of March&#160;31, 2022, the interim Condensed Statements of Operations and Comprehensive (Loss) Income, and Stockholders&#x2019; Equity for the three months ended March&#160;31, 2022 and 2021, and the interim Condensed Cash Flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2022 or any other interim or annual period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March&#160;14, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to forecast and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There have been no significant changes in the Company&#x2019;s significant accounting policies during the three months ended March&#160;31, 2022, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on March 14, 2022.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;(ii) Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(iii) Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities represent LianBio Ophthalmology Limited ("LianBio") common stock (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) designated as "available-for-sale securities" with associated gains or losses recorded within "other expense, net" within the Condensed Statements of Operations at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(iv) Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) outbreak. The COVID-19 pandemic continues to evolve and its impact on the Company&#x2019;s business will depend on several factors that are highly uncertain and unpredictable, including, the efficacy and adoption of vaccines, future resurgences of the virus and its variants, and the speed at which government restrictions are lifted. To date, the Company&#x2019;s operations have not been significantly impacted by the COVID-19 pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#x2019;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#x2019;s potential product candidates, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) dependence on key individuals and sole source suppliers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product candidates require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, it could have a materially adverse impact on the business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(v) Revenue Recognition for Out-License Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has one out-license arrangement that allows the third-party licensee to market the its TP-03 product candidate (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#x2019;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's out-license arrangement, as described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's out-license arrangement includes the following forms of consideration: (i) non-refundable upfront license payments, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales threshold milestones, (v) development milestone payments, and (vi) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Terms for Receipt of Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual terms that establish the Company&#x2019;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Upfront License Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Development Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determined the milestone and other contingent amounts to be "constrained" until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#x2019;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Threshold Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. A "performance obligation" is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#x2019;s "transaction price" is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;(vi) Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, clinical manufacturing costs, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;set or a business, as defined under applicable GAAP. The Company&#x2019;s executed in-license agreements (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and have no alternative future use, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(vii) Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. The Black-Scholes pricing model is used to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing share price preceding the date of grant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#x2019;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the same period of occurrence. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including (a)&#160;the fair value of the Company&#x2019;s common stock on the date of the option grant for all awards granted prior to the Initial Public Offering ("IPO"), (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management estimates the expected term of awarded stock options utilizing the &#x201c;simplified method&#x201d; for awards as the Company does not yet have sufficient exercise history since its November 2016 corporate formation. The Company lacks company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the awarded stock option. The Company&#x2019;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based compensation expense is reported in the Statements of Operations and Comprehensive (Loss) Income within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(viii) Net (Loss) Income per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common stock equivalents outstanding for the period determined using the "treasury-stock method" and "if-converted method" as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s "participating securities" include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses, so in periods of net losses, the "two-class method" of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Also, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to a net loss for the three months ended March&#160;31, 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in this period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(ix) Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. The Company's equity warrant holdings are carried at fair value based on unobservable market inputs (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(x) Comprehensive (Loss) Income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive (loss) income represents all changes in stockholders&#x2019; equity (deficit), except those resulting from distributions to stockholders. For all periods presented in the accompanying Condensed Financial Statements, comprehensive (loss) income was the same as reported net (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(xi) Recently Issued or Effective Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#x2019;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#x2019;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1Mjk_4b9b0be0-e6e7-4037-ab00-2475356e2eac">Basis of Presentation&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Condensed Financial Statements have been prepared in conformity with accounting principles generally accepted ("GAAP") in the United States ("U.S.") for interim financial information and pursuant to Form 10-Q and with the rules and regulations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Balance Sheet as of March&#160;31, 2022, the interim Condensed Statements of Operations and Comprehensive (Loss) Income, and Stockholders&#x2019; Equity for the three months ended March&#160;31, 2022 and 2021, and the interim Condensed Cash Flows for the three months ended March&#160;31, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes related to the three-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2022 or any other interim or annual period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the related notes thereto in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on March&#160;14, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to forecast and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There have been no significant changes in the Company&#x2019;s significant accounting policies during the three months ended March&#160;31, 2022, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on March 14, 2022.  The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below:&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzU_b6c7a683-eb68-4d84-97b7-0acc3610b530">Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfNTQ5NzU1ODE3NzcxNg_cc30b8b8-4bb2-4538-b747-5ca03c937eb3">Marketable Securities&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities represent LianBio Ophthalmology Limited ("LianBio") common stock (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&lt;/span&gt;) designated as "available-for-sale securities" with associated gains or losses recorded within "other expense, net" within the Condensed Statements of Operations at each reporting period.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1Mzc_02d96482-5a88-4b96-960f-49e2e7f732bc">Concentration of Credit Risk and Other Risks and Uncertainties&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) outbreak. The COVID-19 pandemic continues to evolve and its impact on the Company&#x2019;s business will depend on several factors that are highly uncertain and unpredictable, including, the efficacy and adoption of vaccines, future resurgences of the virus and its variants, and the speed at which government restrictions are lifted. To date, the Company&#x2019;s operations have not been significantly impacted by the COVID-19 pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company&#x2019;s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company&#x2019;s potential product candidates, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) dependence on key individuals and sole source suppliers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product candidates require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, it could have a materially adverse impact on the business.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzE_d6898f9e-b35d-4c61-b870-1d0d3751e2e9">Revenue Recognition for Out-License Arrangements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has one out-license arrangement that allows the third-party licensee to market the its TP-03 product candidate (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract&#x2019;s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's out-license arrangement, as described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any license product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's out-license arrangement includes the following forms of consideration: (i) non-refundable upfront license payments, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales threshold milestones, (v) development milestone payments, and (vi) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Terms for Receipt of Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual terms that establish the Company&#x2019;s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Upfront License Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license.  The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Development Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determined the milestone and other contingent amounts to be "constrained" until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise constrained. Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are constrained for revenue recognition until achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee&#x2019;s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Threshold Milestones:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. &lt;/span&gt;&lt;/div&gt;The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. A "performance obligation" is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract&#x2019;s "transaction price" is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1NDA_2c59d796-51d6-4cb0-8d98-1dd520e3dbf6">Research and Development Costs&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, clinical manufacturing costs, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations ("CROs") and clinical trial or pre-clinical study sites.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an as&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;set or a business, as defined under applicable GAAP. The Company&#x2019;s executed in-license agreements (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and have no alternative future use, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzI_36b93bcd-bd98-40b4-8eab-bf1c9b9d39c0">Stock-Based Compensation&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. The Black-Scholes pricing model is used to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing share price preceding the date of grant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award&#x2019;s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. As applicable, the Company reverses previously recognized expense for forfeitures of unvested awards in the same period of occurrence. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management&#x2019;s judgment, including (a)&#160;the fair value of the Company&#x2019;s common stock on the date of the option grant for all awards granted prior to the Initial Public Offering ("IPO"), (b)&#160;the expected term of the stock option until its exercise by the recipient, (c)&#160;stock price volatility over the expected term, (d)&#160;the prevailing risk-free interest rate over the expected term, and (e)&#160;expected dividend payments over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management estimates the expected term of awarded stock options utilizing the &#x201c;simplified method&#x201d; for awards as the Company does not yet have sufficient exercise history since its November 2016 corporate formation. The Company lacks company-specific historical and implied volatility information of its stock.&#160;Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the awarded stock option. The Company&#x2019;s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based compensation expense is reported in the Statements of Operations and Comprehensive (Loss) Income within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMTcxMzI_6ace9531-fdbb-4c29-a3b7-06fd57c60030"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzQ_a26716a5-2638-42d8-b44b-2f58db61a87b">Net (Loss) Income per Share&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common stock equivalents outstanding for the period determined using the "treasury-stock method" and "if-converted method" as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s "participating securities" include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses, so in periods of net losses, the "two-class method" of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Also, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to a net loss for the three months ended March&#160;31, 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in this period.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1NDE_c839ca97-c1bc-458f-836d-f3b1a0aaabf5">Fair Value Measurements&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:56.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. The Company's equity warrant holdings are carried at fair value based on unobservable market inputs (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). &lt;/span&gt;&lt;/div&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1NDI_25a4602e-ff4d-40bc-8a02-77aec022b247">Comprehensive (Loss) Income Comprehensive (loss) income represents all changes in stockholders&#x2019; equity (deficit), except those resulting from distributions to stockholders. For all periods presented in the accompanying Condensed Financial Statements, comprehensive (loss) income was the same as reported net (loss) income.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80MC9mcmFnOjBmM2IwOWU5YjIyZjRjMDI4YWJkZmVhODg0ZGE1N2U1L3RleHRyZWdpb246MGYzYjA5ZTliMjJmNGMwMjhhYmRmZWE4ODRkYTU3ZTVfMjU1MzA_f7195154-f410-4b89-8c64-efa446253e75">Recently Issued or Effective Accounting StandardsRecently issued or effective accounting pronouncements that impact, or may have an impact, on the Company&#x2019;s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company&#x2019;s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyNw_c9280aee-f45e-4c92-ab0a-b38dbea1b0da">BALANCE SHEET ACCOUNT DETAIL&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a) Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Property and equipment, net&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense (included within &#x201c;total operating expenses&#x201d; in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income) for the three months ended March 31, 2022 and 2021 was $41 thousand and $64 thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b) Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"Other assets" consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c) Accounts Payable and Other Accrued Liabilities&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Accounts payable and other accrued liabilities&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee stock option pre-vesting exercise liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d) Other Long-Term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other long-term liabilities&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyNA_03039f27-8290-44c5-b960-42f54e132957">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Property and equipment, net&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i45f4cdbf078647fdb5714433c4e54968_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMS0xLTEtMS0yNjYzNQ_c6a9def6-f51d-4fad-a474-c2ae08ca738c"
      unitRef="usd">596000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b6b657919b045119943a31c80f1d1c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMS0zLTEtMS0yNjYzNQ_7736ab50-8a97-403b-a43c-df91443a7c47"
      unitRef="usd">596000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i84c2f7bb7a9144feb30baaa206b3c84f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMi0xLTEtMS0yNjYzNQ_da7de2d7-19e0-410a-ba43-2f8ace1ed80c"
      unitRef="usd">84000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3a55c6f2a5cd4609a8fd119dfcd1fcfb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMi0zLTEtMS0yNjYzNQ_6dc3a6d2-cb7f-4b54-ad4c-c4e500f8f718"
      unitRef="usd">84000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7529cd5b41004750957c29f40fae72bc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMy0xLTEtMS0yNjYzNQ_dff62847-8b8d-45f0-9581-a4597d4a3ea6"
      unitRef="usd">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7b632727d0924b539bb949a88a28ac4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfMy0zLTEtMS0yNjYzNQ_3ca1a41c-b7f9-4fd1-be0e-a397b01fcf7e"
      unitRef="usd">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2f2f6cc3612846ed80ef0e9ff22f78ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNC0xLTEtMS0yNjYzNQ_d2a97d2e-865b-4608-a13c-677d65a92b64"
      unitRef="usd">330000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i26735dafdb274401bedfa5360ff79acb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNC0zLTEtMS0yNjYzNQ_9b3ff729-b70c-4cfe-8a37-857bbb58faba"
      unitRef="usd">129000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNS0xLTEtMS0yNjYzNQ_1192775b-642d-4d76-b5b7-8569e4bf5674"
      unitRef="usd">1177000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNS0zLTEtMS0yNjYzNQ_2fc9db17-45e4-4403-a118-1daba72b24b6"
      unitRef="usd">976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNi0xLTEtMS0yNjYzNQ_855a5b81-e2ff-42c0-858a-813847c3f95a"
      unitRef="usd">262000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNi0zLTEtMS0yNjYzNQ_800f6277-6f3a-43a1-8209-8444a6347027"
      unitRef="usd">221000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNy0xLTEtMS0yNjYzNQ_f5f17921-f2dc-4feb-a555-a2f369015e00"
      unitRef="usd">915000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjVkYzdhMGY3OGVkYTRiYTNiNDU4M2FjYzdhYzhmYzhhL3RhYmxlcmFuZ2U6NWRjN2EwZjc4ZWRhNGJhM2I0NTgzYWNjN2FjOGZjOGFfNy0zLTEtMS0yNjYzNQ_e34d0817-2fe5-4f12-b631-d0817b452d4c"
      unitRef="usd">755000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTA5OTUxMTYyOTY5OA_cfd13d25-5ddd-4d8d-a50e-c864dae969d4"
      unitRef="usd">41000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTA5OTUxMTYyOTcxMw_741b47b6-4b68-475d-a467-ecae6125eb30"
      unitRef="usd">64000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyNQ_f73e5edf-aba6-46ce-973a-401497a8ef29">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"Other assets" consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:DepositAssets
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMS0xLTEtMS0yNjYzNQ_96ffbcc9-f65a-4db0-ad7d-73192b076e5b"
      unitRef="usd">71000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMS0zLTEtMS0yNjYzNQ_c5ae0cab-3b07-4174-b9a8-90998d6f9491"
      unitRef="usd">71000</us-gaap:DepositAssets>
    <tars:EquityWarrantRights
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMi0xLTEtMS0yNjYzNQ_851c95f0-cd0b-4307-99f5-c68b43f2dad1"
      unitRef="usd">418000</tars:EquityWarrantRights>
    <tars:EquityWarrantRights
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMi0zLTEtMS0yNjYzNQ_adeaae96-999b-4a30-a9fb-b72dde780c9b"
      unitRef="usd">663000</tars:EquityWarrantRights>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMy0xLTEtMS0yNjYzNQ_fd679448-1c3b-4e9f-a29c-83962e1dd6a3"
      unitRef="usd">398000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfMy0zLTEtMS0yNjYzNQ_6ef60db7-2b55-491b-a6e1-55aae5349d92"
      unitRef="usd">392000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfNC0xLTEtMS0yNjYzNQ_76f236a0-898b-45cc-b886-9ddbc1dc1456"
      unitRef="usd">887000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjQ2ZWI4NjcxY2IyNjQwMDM5YjU4ZjAwODMyZTc3ZGU4L3RhYmxlcmFuZ2U6NDZlYjg2NzFjYjI2NDAwMzliNThmMDA4MzJlNzdkZThfNC0zLTEtMS0yNjYzNQ_6da267bb-8f84-4ee8-96c7-d98a66f2f3a7"
      unitRef="usd">1126000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyOA_f4754b74-8e67-4bdb-87f7-233c346e4e83">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Accounts payable and other accrued liabilities&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee stock option pre-vesting exercise liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfMS0xLTEtMS0yNjYzNQ_f1547683-58ac-4ea2-a85d-28a9bc51e2ed"
      unitRef="usd">4028000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfMS0zLTEtMS0yNjYzNQ_d407525d-6013-4b91-82d3-4044f7521b80"
      unitRef="usd">2856000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfMy0xLTEtMS0yNjYzNQ_9ca54971-6d3f-4976-a645-94775084cf04"
      unitRef="usd">635000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfMy0zLTEtMS0yNjYzNQ_23e72b9b-ee6b-47b6-a240-65e709e16442"
      unitRef="usd">609000</us-gaap:OperatingLeaseLiabilityCurrent>
    <tars:AccruedClinicalStudiesCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNC0xLTEtMS0yNjYzNQ_99a70c19-203a-49de-9a16-42b6c1ff06b8"
      unitRef="usd">5740000</tars:AccruedClinicalStudiesCurrent>
    <tars:AccruedClinicalStudiesCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNC0zLTEtMS0yNjYzNQ_34a7c9dd-8e3a-4004-adb7-976b646c00fd"
      unitRef="usd">4407000</tars:AccruedClinicalStudiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNS0xLTEtMS0yNjYzNQ_d87e27a3-8725-4123-8a8e-f3f0da0ae631"
      unitRef="usd">174000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNS0zLTEtMS0yNjYzNQ_767b8833-07d7-4622-a9e7-a734f81ec9cf"
      unitRef="usd">697000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNi0xLTEtMS0zMTgwMg_9aacc8b3-8573-4c58-8d3a-55f03d1848d0"
      unitRef="usd">148000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNi0zLTEtMS0zMTgwMg_a54eef6f-dcce-42b2-bf3f-bec3b7621853"
      unitRef="usd">0</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNi0xLTEtMS0yNjYzNQ_ad0f7325-644c-48a2-ab14-1d19193d5134"
      unitRef="usd">55000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNi0zLTEtMS0yNjYzNQ_8da23b48-1db4-4663-b3ec-da53841a1eed"
      unitRef="usd">55000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNy0xLTEtMS0yNjYzNQ_7ad4d522-da71-4c89-ab20-7f56a5866826"
      unitRef="usd">25000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfNy0zLTEtMS0yNjYzNQ_88b6ba23-52c6-4b68-9539-fa2af79eb205"
      unitRef="usd">56000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfOC0xLTEtMS0yNjYzNQ_5f74f89d-3f1b-4544-8b3b-eca05a4f47d2"
      unitRef="usd">10805000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjJkOWI0ZGE2MjNhYTQyZGFhNGU2NTIyNGMyNGI3YzIwL3RhYmxlcmFuZ2U6MmQ5YjRkYTYyM2FhNDJkYWE0ZTY1MjI0YzI0YjdjMjBfOC0zLTEtMS0yNjYzNQ_74b9ea9d-82d7-4994-a175-b76c0a1edd6d"
      unitRef="usd">8680000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RleHRyZWdpb246NGM2YmE1YTY3ZjE1NDg0M2I5MjA1YWVlN2M5MGJlMDNfMTYyNg_4405a65f-7de9-4ac8-9545-a045b629ef42">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other long-term liabilities&#x201d; consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfMS0xLTEtMS0yNjYzNQ_61ebe891-82f1-40ec-b0b5-780eb8007161"
      unitRef="usd">425000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfMS0zLTEtMS0yNjYzNQ_0f78043e-a6ae-4111-bf2f-aa3026c58e1e"
      unitRef="usd">585000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfMi0xLTEtMS0yNjYzNQ_210a71aa-8bb4-4e66-a4ec-16d59217fbd3"
      unitRef="usd">71000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfMi0zLTEtMS0yNjYzNQ_644f41c9-5fc6-4746-9517-3ef08589e874"
      unitRef="usd">114000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfNC0xLTEtMS0yNjYzNQ_5df369c0-d88f-4f3a-ac9e-81ed4a43814f"
      unitRef="usd">496000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80My9mcmFnOjRjNmJhNWE2N2YxNTQ4NDNiOTIwNWFlZTdjOTBiZTAzL3RhYmxlOjllMjZkOTc5OWMwNzQxZTI4MmRlNmZjZjEwNTExYTkyL3RhYmxlcmFuZ2U6OWUyNmQ5Nzk5YzA3NDFlMjgyZGU2ZmNmMTA1MTFhOTJfNC0zLTEtMS0yNjYzNQ_8e84d7d4-bad1-4e49-a754-7286d5f0ca35"
      unitRef="usd">699000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfOTQ2_a4db15fa-98f3-45c8-bb0f-6da9436416c9">STOCKHOLDERS&#x2019; EQUITY AND EQUITY INCENTIVE PLANS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Outstanding and Reserves for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, the Company had 20.7 million common shares issued and outstanding.  Each share of common stock is entitled to one vote. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan (the "ESPP") is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,954,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,266,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,700,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,493,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,561,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,759,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units outstanding under 2020 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,567,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,536,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Board of Directors and stockholders adopted and approved the Company's 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) on October 8, 2020. The 2020 Plan replaced the Company's 2016 Equity Incentive Plan that was adopted in December 2016 (the &#x201c;2016 Plan&#x201d;).  However, awards outstanding under the 2016 Plan will continue to be governed by its original terms. The number of shares of the Company's common stock that were initially available for issuance under the 2020 Plan equaled the initial sum of 9,000,000 shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;plus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2,432,980 shares that were then available for issuance under the 2016 Plan. The 2020 Plan provides for the following types of awards: incentive and non-statutory stock options, stock appreciation rights, restricted shares, and restricted stock units.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares of common stock reserved for issuance under the 2020 Plan are increased automatically on the first day of each fiscal year, commencing in 2021 and through 2030, by a number equal to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;lesser of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: (i) 4% of the shares of common stock outstanding on the last day of the prior fiscal year; or (ii) the number of shares determined by the Company's Board of Directors. In general, to the extent that any awards under the 2020 or 2016 Plans are forfeited, terminate, expire or lapse without the issuance of shares, or if the Company reacquires the shares subject to awards granted under the 2020 or 2016 Plans, those shares will again become available for issuance under the 2020 Plan, as will shares applied to pay the exercise or purchase price of an award or to satisfy tax withholding obligations related to any award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through March&#160;31, 2022, all awards issued under the 2020 Plan and 2016 Plan were in the form of stock options and restricted stock units. These stock award agreements have service and/or performance conditions for vesting, unless immediately vested on the date of grant. Stock awards granted typically have &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTM5MTI_01c7ccdd-ab1b-4a6d-8be3-01ce640cfa8d"&gt;one&lt;/span&gt; to four-year service conditions for full vesting. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 12 months after the date of termination upon death, six months after the date of termination upon disability, and three months after the date of termination for all other separations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-Vesting Exercise Feature of Certain Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Plan permitted certain option holders to exercise awarded options prior to vesting. Upon this early exercise, the options became subject to a restricted stock agreement and remain subject to the same vesting provisions in the corresponding stock option award. These unvested options are subject to repurchase by the Company upon employee termination at the same price exercised. These unvested shares of common stock are reported as issued (but not outstanding) on the accompanying Condensed Balance Sheets while subject to repurchase by the Company. These shares are also excluded from the basic net (loss) income per share until the repurchase right lapses upon vesting, but are included in the diluted net income per share for the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially records a liability for these early exercises that is subsequently reclassified into stockholders&#x2019; equity on a pro rata basis as vesting occurs. As of March&#160;31, 2022 and December&#160;31, 2021, the Company recorded the unvested portion of the exercise proceeds of $25 thousand and $56 thousand, respectively, within "accounts payable and other accrued liabilities" in the accompanying Condensed Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, a total of 2.7&#160;million shares of common stock are authorized and remain available for issuance under the Company's ESPP. Beginning on January 1, 2021, and each January 1st thereafter, pursuant to the terms of the ESPP, the number of common stock available for issuance under the ESPP is automatically increased by an amount equal to the least of (i) one percent of the total number of shares of common stock outstanding on the last day of the previous fiscal year, (ii) 2.3&#160;million shares, or (iii) a number of shares determined by the board of directors.  &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the ESPP, eligible employees can purchase common stock through scheduled payroll deductions. The purchase price is equal to the closing price of the Company's common stock on the first or last day of the offering period (whichever is less), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;minus&lt;/span&gt; a 15% discount.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfNzM0_6aab2eeb-73b2-4b51-afca-3398cd8571d0"
      unitRef="shares">20700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfNzM0_8ccb9f38-40e0-45e3-91d2-4b944cf3763e"
      unitRef="shares">20700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfNzM0_aaaec789-795e-43be-879a-c0b8a49468f3"
      unitRef="shares">20700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfNzM0_dbc900ad-179b-4858-b8f5-db0e2e74366c"
      unitRef="shares">20700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfOTQ1_f5b17432-bce4-4b33-8592-c2d8b3864d49">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan (the "ESPP") is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,954,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,266,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,700,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,493,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options issued and outstanding under 2020 and 2016 Equity Incentive Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,561,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,759,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units outstanding under 2020 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,567,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,536,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMS0xLTEtMS0yNjYzNQ_44d6128d-7008-4be8-bcf8-579df5db58c3"
      unitRef="shares">8954066</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMS0zLTEtMS0yNjYzNQ_087d50e7-5a6b-45bc-8bdf-554ec3d83bd0"
      unitRef="shares">9266200</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMi0xLTEtMS0yNjYzNQ_0bb0de1a-5780-4c4e-b121-0776237c61dc"
      unitRef="shares">2700475</tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMi0zLTEtMS0yNjYzNQ_417b7f53-ab8c-4453-9fa6-3a0e96f0c789"
      unitRef="shares">2493488</tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMy0xLTEtMS0yNjYzNQ_e1e20851-4ec1-479e-a7e7-03aa272414fc"
      unitRef="shares">3561261</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfMy0zLTEtMS0yNjYzNQ_87066706-e28b-40a1-95bd-ba900b575512"
      unitRef="shares">2759830</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfNC0xLTEtMS0yNjYzNQ_ec6adf2a-e86c-443d-ab78-ba444b87336b"
      unitRef="shares">351422</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfNC0zLTEtMS0yNjYzNQ_6f8db2c7-f9f4-4ac9-961d-d3e11352a796"
      unitRef="shares">17251</tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfNS0xLTEtMS0yNjYzNQ_9e6bac0c-7b3c-4198-bac3-e816d23702d0"
      unitRef="shares">15567224</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RhYmxlOjFmNDUzZDEzMDFhYzQxMTM5Njg0NjEyZDNkMGQ1YmY5L3RhYmxlcmFuZ2U6MWY0NTNkMTMwMWFjNDExMzk2ODQ2MTJkM2QwZDViZjlfNS0zLTEtMS0yNjYzNQ_09bed73f-0d51-4549-8b9e-ce83d288f198"
      unitRef="shares">14536769</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6dd617ed38c64f83b2e2428b1abde32a_I20201008"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTI1MTI_0f3e5ab4-b824-48b2-a729-bd5e7bc03812"
      unitRef="shares">9000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic93546034bb142b0a219d72347552482_I20201008"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTI1Mjg_63ffba37-5634-44cb-af2c-6ba34acc18e1"
      unitRef="shares">2432980</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease
      contextRef="id0927937cbbe4b248a2bb3faaf75bded_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTMxOTQxMzk1NDMyNjQ_68e3b039-ef3c-40a1-a19d-a634624fb592"
      unitRef="number">0.04</tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i1c7789b1b50744a99ead19fcb7d24c12_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYxOA_ccb5c552-1b6f-4505-b42a-3a235ec8b39d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTMxOTQxMzk1NDMyNjk_feebe1f7-fdee-4a70-9303-f743f02ddfaf">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath
      contextRef="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYyOQ_0f550e1e-181c-4796-ab44-7083f9cfbda2">P12M</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability
      contextRef="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYyNQ_0c242b42-9176-4c67-a45e-790b92752e16">P6M</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability>
    <tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations
      contextRef="i07211f3326f448aa8184400ddc47d2e1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYzMw_c193c1df-ef28-4d4a-b033-a5586d3d9a0c">P3M</tars:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTYxOTE_2ef0ab9b-f1b8-4ef4-8597-262e71f80a64"
      unitRef="usd">25000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTM3NDM4OTUzNTYxOTk_a9899195-df58-4639-b83a-222781b7b480"
      unitRef="usd">56000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTA5OTUxMTYzMDI0MA_aa040b10-3e3d-49b8-8d20-423d38f09af9"
      unitRef="shares">2700000</tars:CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ0NDU2MQ_b30b601f-31f0-4469-8344-a3b470e1b397"
      unitRef="number">0.01</tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease>
    <tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ0NDUxOA_a9aa6c93-33cb-45d0-8ef5-273b315724da"
      unitRef="shares">2300000</tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="id03a5a0a91cb4b4586a1f8ee04c3d481_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80Ni9mcmFnOjMzMjg5ODM0YzkzYzQyOTA5ZjVlZTMyZTdkNDlhOTYxL3RleHRyZWdpb246MzMyODk4MzRjOTNjNDI5MDlmNWVlMzJlN2Q0OWE5NjFfMTY0OTI2NzQ1MTYzNw_256b9fd2-87c0-4336-bb82-65308e63566f"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RleHRyZWdpb246MDQxYmEyODBjMmUyNDk2Y2JkY2NlMGRhMzNhNmMwZGJfNTY4OQ_73cab9a6-fd4e-42df-8419-e000dad558c6">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is recorded in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income based on the designated department of the recipient. Stock-based compensation expense for the three months ended March 31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RleHRyZWdpb246MDQxYmEyODBjMmUyNDk2Y2JkY2NlMGRhMzNhNmMwZGJfNTY4NQ_df1f366c-f86d-41af-a145-b2c92b690807">Stock-based compensation expense for the three months ended March 31, 2022 and 2021 was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic881c21880004c5ba362cfa7ce7524e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfMi0xLTEtMS0yNjYzNQ_15b584b8-5624-44d7-906f-e544ae4cd768"
      unitRef="usd">678000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4f6cd5005f34480babb33821fa0f5fb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfMi0zLTEtMS0yNjYzNQ_ed132b54-94ac-44e8-ad45-d32251a3bb2b"
      unitRef="usd">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f101ec5e8914faab8d26c11caedd9bb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfMy0xLTEtMS0yNjYzNQ_cf320617-bae4-4d3f-ab50-e520f851e2f6"
      unitRef="usd">1996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i892bc751c437460d89238d3ba9e8f045_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfMy0zLTEtMS0yNjYzNQ_2ddcbc5b-06e4-4dae-b83b-4774401a54a8"
      unitRef="usd">1019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfNC0xLTEtMS0yNjYzNQ_aab49798-6f5b-4618-a529-2e5835ae787f"
      unitRef="usd">2674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF80OS9mcmFnOjA0MWJhMjgwYzJlMjQ5NmNiZGNjZTBkYTMzYTZjMGRiL3RhYmxlOjRlYWRlYmM1Y2EyYTRkMmJhNTAyMzM0MTRhMzRlNzNhL3RhYmxlcmFuZ2U6NGVhZGViYzVjYTJhNGQyYmE1MDIzMzQxNGEzNGU3M2FfNC0zLTEtMS0yNjYzNQ_5b07a66f-6ba0-4134-8a1c-9ce843ab4969"
      unitRef="usd">1363000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RleHRyZWdpb246YWY2ZmMzZmJkMjg1NGQ5MDg0MDdkNzgxNmQ5OTkyOGZfMTE3MA_eedd9540-d76f-467a-b74c-3919292bef76">NET (LOSS) INCOME PER SHARE&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; table sets forth the computation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: undistributed income allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,710,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,336,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) per share&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: undistributed income reallocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,710,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,336,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,488,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,710,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,824,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;share because their impact under the &#x201c;treasury stock method&#x201d; and &#x201c;if-converted method&#x201d; would have been anti-dilutive for the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.146%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options, unexercised&#x2014;vested and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,561,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options early-exercised and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&#x2014;unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,925,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RleHRyZWdpb246YWY2ZmMzZmJkMjg1NGQ5MDg0MDdkNzgxNmQ5OTkyOGZfMTE3MQ_fb3ebbf7-13e2-4c44-8571-0cb2980f6d05">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; table sets forth the computation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: undistributed income allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,710,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,336,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) per share&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: undistributed income reallocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,710,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,336,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,488,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,710,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,824,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMy01LTEtMS0yNjYzNQ_987407c8-8fe5-4a63-93b6-34d5e7119f50"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMy03LTEtMS0yNjYzNQ_6072de7d-f3e1-4e2c-ad83-c3aa750bba85"
      unitRef="usd">10376000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNC01LTEtMS0yNjYzNQ_7de00700-39d4-45a0-8891-c66ae602ebfb"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNC03LTEtMS0yNjYzNQ_9b02298c-c028-4915-b3f9-187f8ee005ce"
      unitRef="usd">90000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNS01LTEtMS0yNjYzNQ_8ea37423-1972-4a61-8284-c4f15e6cc966"
      unitRef="usd">-20238000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNS03LTEtMS0yNjYzNQ_2e498120-0773-489b-bd78-8f74e895af4c"
      unitRef="usd">10286000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNy01LTEtMS0yNjYzNQ_0561de9c-7c68-4b6f-bf79-6353261cd05e"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfNy03LTEtMS0yNjYzNQ_7604ac92-b2f1-41aa-844c-66c5dac2399a"
      unitRef="shares">20336022</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfOC01LTEtMS0yNjYzNQ_e3287c77-308d-4d30-90e3-af5baba3eff1"
      unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfOC03LTEtMS0yNjYzNQ_7035b968-290b-4fc7-8e8f-1c69450c05db"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTEtNS0xLTEtMjY2MzU_a3ec6fe4-e6d5-41b4-8f8f-e4db3add1f03"
      unitRef="usd">-20238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTEtNy0xLTEtMjY2MzU_8bdb1a5a-bd34-4b1f-9557-5b653b555758"
      unitRef="usd">10376000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTItNS0xLTEtMjY2MzU_158a328c-39f1-498a-bd16-457f2fffc0ee"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTItNy0xLTEtMjY2MzU_503d6ace-5787-4d65-b7b5-336179d8e047"
      unitRef="usd">84000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTMtNS0xLTEtMjY2MzU_43e57a54-da90-48c5-99f4-2ef5eff850c0"
      unitRef="usd">-20238000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTMtNy0xLTEtMjY2MzU_9da28153-c499-4713-8b2c-f0e417d436dd"
      unitRef="usd">10292000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTUtNS0xLTEtMjY2MzU_ae4c2ad9-9301-4537-a9be-8a3ed9dcbcd2"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTUtNy0xLTEtMjY2MzU_63db5d49-df93-445b-bce4-67e28fa4b451"
      unitRef="shares">20336022</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTctNS0xLTEtMjY2MzU_cde08da9-1881-402a-adc3-fba9a52ce4cb"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTctNy0xLTEtMjY2MzU_edabea56-f2fb-4f64-95b9-df0089a9654e"
      unitRef="shares">1488552</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTgtNS0xLTEtMjY2MzU_01e601fb-8622-44f4-b527-562af8e75c30"
      unitRef="shares">20710224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTgtNy0xLTEtMjY2MzU_2af01d3f-90c3-445f-8350-257d978382dd"
      unitRef="shares">21824574</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTktNS0xLTEtMjY2MzU_b3f884c0-7387-43b4-9f17-bcd2adf78cee"
      unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOjIwMTZhNDAyOTcyMzQxYWM4NjkyODZiOTM0OWQzZWFhL3RhYmxlcmFuZ2U6MjAxNmE0MDI5NzIzNDFhYzg2OTI4NmI5MzQ5ZDNlYWFfMTktNy0xLTEtMjY2MzU_ac390df3-cf0c-4fa3-924d-44765b0b5433"
      unitRef="usdPerShare">0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RleHRyZWdpb246YWY2ZmMzZmJkMjg1NGQ5MDg0MDdkNzgxNmQ5OTkyOGZfNTQ5NzU1ODE0MTY0MQ_be109860-b9ca-40fe-9e0b-e36b95e9e5aa">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;share because their impact under the &#x201c;treasury stock method&#x201d; and &#x201c;if-converted method&#x201d; would have been anti-dilutive for the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.146%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options, unexercised&#x2014;vested and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,561,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options early-exercised and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&#x2014;unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,925,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9d25ce27b22641beb0bec11792f01c1f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfMi0xLTEtMS0yODI5Ng_b1b3f240-c512-4523-8668-5d14fddf3d73"
      unitRef="shares">3561261</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67b53435adf9489a9a2daaff37121c44_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfMi0zLTEtMS0yODI5Ng_b3972324-96f6-4498-86c2-8bcb3e289ff6"
      unitRef="shares">632781</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i173cbb1387d1404085a5f0d1575e8f62_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfMy0xLTEtMS0yODI5Ng_6d8da35b-6793-490c-9800-dd92f0e4a1ca"
      unitRef="shares">12531</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i861c82a1ea2c4d4ea4ae4e378321bb54_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfMy0zLTEtMS0yODI5Ng_5fd836c9-dd40-4a5b-9ebf-afad61af7423"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i27aa992f7c3f4d339542898fcd3905bd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfNC0xLTEtMS0yODI5Ng_91416059-d60f-4a37-aa27-bd419f12bfbd"
      unitRef="shares">351422</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1ceb379731724bc085f3a4a5ce44d64f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfNC0zLTEtMS0yODI5Ng_23b418d7-2be2-45bc-bf56-d3b493c06e30"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfNS0xLTEtMS0yODI5Ng_4f978722-2b0d-4351-b23d-1b3a74decd2b"
      unitRef="shares">3925214</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81Mi9mcmFnOmFmNmZjM2ZiZDI4NTRkOTA4NDA3ZDc4MTZkOTk5MjhmL3RhYmxlOmZmNzM0OGYxZDc3NjRlZGRhMTE0MTQ0YmNlODBhZGMwL3RhYmxlcmFuZ2U6ZmY3MzQ4ZjFkNzc2NGVkZGExMTQxNDRiY2U4MGFkYzBfNS0zLTEtMS0yODI5Ng_c10969ab-6a4a-406e-a5ac-256c363ed846"
      unitRef="shares">632781</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMjU0Mw_01fbc4c2-aa88-4e14-a2d4-028b6e823543">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2(ix)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio (included in "marketable securities")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants in LianBio (included in "other assets")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio (included in "marketable securities")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants in LianBio (included in "other assets")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Money Market Funds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market fund holdings are included in "cash and cash equivalents" on the accompanying Condensed Balance Sheets and are classified within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the fair value hierarchy because they have readily-available market prices in active markets that are publicly observable at the measurement date. These money market funds are invested in U.S. Treasury bills and notes, and other obligations issued or guaranteed as to principal and interest by the U.S. Government or its agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, contemporaneous with the China Out-License transaction (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, a stated number of common stock in LianBio, a then privately-held pharmaceutical company focused on China. The warrants vest upon the achievement of certain clinical and regulatory events and have an exercise price at common stock par value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, one of these three warrants vested and converted to 78,373 shares of LianBio common stock ("equity securities") which were recorded within "marketable securities" on the accompanying Balance Sheet as of December 31, 2021. The LianBio common stock is classified within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the fair value hierarchy because their value is based on the closing common stock price of LianBio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining two unvested tranches of these warrants are classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the fair value measurement hierarchy. The most significant assumptions used in the option pricing valuation model to determine the fair value as of March&#160;31, 2022 included: LianBio common stock volatility (based on the historical volatility of similar companies), the probability of achievement of discrete clinical and regulatory milestones for the remaining two unvested tranches of these warrants, and application of an assumed discount rate for the unvested warrants as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These warrants allow for "noncash settlement" and therefore met the criteria to be recognized as a "derivative asset" on the accompanying Condensed Balance Sheets and are presented within "other assets" as of March&#160;31, 2022 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). They will be remeasured with a corresponding amount reported in "other expense, net" on the accompanying statements of operations and comprehensive (loss) income at each reporting date, until exercised or expired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in fair value of the equity warrants presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrants represents a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; financial instrument:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Warrants, presented on the Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revaluation of equity warrants included in "total revenues" within the Condensed Statement of Operations for the three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revaluation of equity warrants included in "other expense, net" within the Condensed Statement of Operations for the three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Warrants, presented on the Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Initial fair value estimate of equity warrants (included in "other assets" within the Consolidated Balance Sheet) upon issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMjU0NA_0b7c92a7-9245-4054-a1a7-b15e567c50a3">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2(ix)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio (included in "marketable securities")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants in LianBio (included in "other assets")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock in LianBio (included in "marketable securities")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity warrants in LianBio (included in "other assets")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3682bcf6d66f4973a7dd133d281d269e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMy0xLTEtMS0yNjYzNQ_0c297fea-94d2-4c71-8171-a04b7a76acd2"
      unitRef="usd">175010000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6faf816d5daa4e378b018c9347358012_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMy0zLTEtMS0yNjYzNQ_c524fe54-331e-4d37-812a-103a9701b72a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3a8147113984483bdbe2570de069cf9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMy01LTEtMS0yNjYzNQ_61b7d135-aa0e-493c-8348-4792f8660ce0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4c4444dc36754b42916b70015ae04028_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMy03LTEtMS0yNjYzNQ_dab14778-1c4a-4e38-aae2-97c3f2098cef"
      unitRef="usd">175010000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i345bf687446f417ab073133b4f3e6ebf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC0xLTEtMS0zMDYzNQ_844cb114-6b06-4ed3-b5ed-f8ad03cb424a"
      unitRef="usd">291000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ie13603c0d53747d793240ebb726383c8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC0zLTEtMS0zMDYzNQ_675b92e6-3741-4f2a-8b74-fb5a92e451f4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i2d8e806d3fc746b4bd86d42fd6cde4af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC01LTEtMS0zMDYzNQ_9c8b0647-30f6-4533-bf7b-02d6b5b478e7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC03LTEtMS0zMDk3Mw_9d7143b9-e696-406c-bcea-2b9e74fbeb9b"
      unitRef="usd">291000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i345bf687446f417ab073133b4f3e6ebf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC0xLTEtMS0yNjYzNQ_c3efc5c1-6a69-4326-a5d3-11657addf6ea"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="ie13603c0d53747d793240ebb726383c8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC0zLTEtMS0yNjYzNQ_ea2b8307-062d-452b-97be-e72cd46984a6"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i2d8e806d3fc746b4bd86d42fd6cde4af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC01LTEtMS0yNjYzNQ_86c0fa19-47df-47de-a391-a3f67c75ea18"
      unitRef="usd">418000</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNC03LTEtMS0yNjYzNQ_a25a9418-0b5f-4d1b-ba41-bbd79b217225"
      unitRef="usd">418000</tars:EquityWarrantsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i345bf687446f417ab073133b4f3e6ebf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNS0xLTEtMS0yNjYzNQ_40364d05-9595-4a15-a17b-da7f7cbff543"
      unitRef="usd">175301000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie13603c0d53747d793240ebb726383c8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNS0zLTEtMS0yNjYzNQ_fcb8459c-98d9-4ea7-b410-8db62a2c9696"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2d8e806d3fc746b4bd86d42fd6cde4af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNS01LTEtMS0yNjYzNQ_7ab4560f-2d11-42b2-8b94-3062cd7725d6"
      unitRef="usd">418000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfNS03LTEtMS0yNjYzNQ_aaa1afe0-e0da-4483-83e2-f46b50458f48"
      unitRef="usd">175719000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibe41f993362a4d1abb88ecf74110902f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTAtMS0xLTEtMjY2MzU_372e1ca4-d739-474a-a8d0-dac805459bcf"
      unitRef="usd">171332000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icf5353fdcc224f7e8dfbe5f04a6b0e2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTAtMy0xLTEtMjY2MzU_17e7ac4d-6899-4db8-8116-e144ab761885"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if839d9e3a48348b2b756e1a2885fa244_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTAtNS0xLTEtMjY2MzU_4a3da773-0108-4028-9c99-1e039b5590ed"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i48d31760273a4e2f823c7e5fc3f3807d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTAtNy0xLTEtMjY2MzU_e0acbc3e-576a-4dd1-8ee2-e7eb07cdaa38"
      unitRef="usd">171332000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i0d18c2021abb45cd8eca7bf510a0d79c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTItMS0xLTEtMzA5ODY_18ff711e-ed38-4528-8192-22158ad32767"
      unitRef="usd">483000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="idc9facda38ea4ff4885250a21f36b6ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTItMy0xLTEtMzA5ODY_72615b13-2e66-47a9-9584-316517186e69"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i6f4e89147429457a865e2def1c688c45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTItNS0xLTEtMzA5ODY_bebbd10d-72f0-4594-b734-c273093c5727"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTItNy0xLTEtMzA5ODY_ead66481-5917-43e3-99ad-ffbe71439df1"
      unitRef="usd">483000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i0d18c2021abb45cd8eca7bf510a0d79c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTMtMS0xLTEtMzA5ODY_104954c1-8e08-481f-9eb0-17375dee22e0"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="idc9facda38ea4ff4885250a21f36b6ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTMtMy0xLTEtMzA5ODY_f044c274-eeb4-41a5-8475-c480ec1273a7"
      unitRef="usd">0</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i6f4e89147429457a865e2def1c688c45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTMtNS0xLTEtMzA5ODY_d48fd8d7-a3d8-4445-bc0d-b6e181a1f12b"
      unitRef="usd">663000</tars:EquityWarrantsFairValueDisclosure>
    <tars:EquityWarrantsFairValueDisclosure
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTMtNy0xLTEtMzA5ODY_8c28c70b-05ea-409f-b422-6ec88561e1d8"
      unitRef="usd">663000</tars:EquityWarrantsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d18c2021abb45cd8eca7bf510a0d79c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTEtMS0xLTEtMjY2MzU_2a5817bd-4eb7-4090-a8df-0b96479a2009"
      unitRef="usd">171815000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idc9facda38ea4ff4885250a21f36b6ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTEtMy0xLTEtMjY2MzU_dc2578d4-78d8-45df-a622-39f38e699cba"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f4e89147429457a865e2def1c688c45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTEtNS0xLTEtMjY2MzU_7332fa93-84b4-4804-9cbe-849236cfa89a"
      unitRef="usd">663000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjUzNTFjNjc0ZDkwZTQ2YWE4ODJiNDRhNjAwNjYxZWViL3RhYmxlcmFuZ2U6NTM1MWM2NzRkOTBlNDZhYTg4MmI0NGE2MDA2NjFlZWJfMTEtNy0xLTEtMjY2MzU_d4778641-2d61-4280-bd1c-89cb994e8b97"
      unitRef="usd">172478000</us-gaap:AssetsFairValueDisclosure>
    <tars:NumberOfVestedWarrants
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMTY0OTI2NzQ0Njc2Mw_e3c04d57-acf6-4703-a361-5caa72b772e2"
      unitRef="warrant">1</tars:NumberOfVestedWarrants>
    <tars:NumberOfWarrants
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMTY0OTI2NzQ0Njc2Nw_a9cc1c91-0944-46cb-8ad7-6ed73fc7baa0"
      unitRef="warrant">3</tars:NumberOfWarrants>
    <tars:EquitySecuritiesFVNINumberOfShares
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMTY0OTI2NzQ0Njc3MQ_4424c9bd-0ee1-42bb-b623-85604edad497"
      unitRef="shares">78373</tars:EquitySecuritiesFVNINumberOfShares>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RleHRyZWdpb246Mjg2MTEzMzIyMDM0NDMwMzlhM2Q1ZWM1ZDQ4YTY2ZWZfMjU0Mg_ed871c2d-b6b1-4c24-b5b7-03caa1194dfd">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in fair value of the equity warrants presented in "other assets" on the accompanying Condensed Balance Sheets. The measurement of the equity warrants represents a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; financial instrument:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Warrants, presented on the Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revaluation of equity warrants included in "total revenues" within the Condensed Statement of Operations for the three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revaluation of equity warrants included in "other expense, net" within the Condensed Statement of Operations for the three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity Warrants, presented on the Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Initial fair value estimate of equity warrants (included in "other assets" within the Consolidated Balance Sheet) upon issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair value as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOmQ2ZTFmZThmYmM0NzQzNjZhYjI0ZmJkZWU4NThkODNkL3RhYmxlcmFuZ2U6ZDZlMWZlOGZiYzQ3NDM2NmFiMjRmYmRlZTg1OGQ4M2RfMS0xLTEtMS0yNjYzNQ_bad01d38-35a3-4cad-a3f3-0798cc1fdb4b"
      unitRef="usd">663000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ic100186e6c824064b3a569935e610798_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOmQ2ZTFmZThmYmM0NzQzNjZhYjI0ZmJkZWU4NThkODNkL3RhYmxlcmFuZ2U6ZDZlMWZlOGZiYzQ3NDM2NmFiMjRmYmRlZTg1OGQ4M2RfMi0xLTEtMS0yNjYzNQ_9773d80a-7398-49c3-98b8-38b468a2549c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i96f49b8447904e059af26b60c492701c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOmQ2ZTFmZThmYmM0NzQzNjZhYjI0ZmJkZWU4NThkODNkL3RhYmxlcmFuZ2U6ZDZlMWZlOGZiYzQ3NDM2NmFiMjRmYmRlZTg1OGQ4M2RfMy0xLTEtMS0yNjYzNQ_4f97041b-10d1-468b-8457-5c3fc7e6bfa0"
      unitRef="usd">-245000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOmQ2ZTFmZThmYmM0NzQzNjZhYjI0ZmJkZWU4NThkODNkL3RhYmxlcmFuZ2U6ZDZlMWZlOGZiYzQ3NDM2NmFiMjRmYmRlZTg1OGQ4M2RfNC0xLTEtMS0yNjYzNQ_bfdedd2f-3c3d-46c0-be05-7f0e4131952d"
      unitRef="usd">418000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ibc4893dbff5444e2a914be14ba1cb379_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjhjZTFhOTI4MzAzZjRlZTI4MGU4OWU5OGQ1MTk0MTJiL3RhYmxlcmFuZ2U6OGNlMWE5MjgzMDNmNGVlMjgwZTg5ZTk4ZDUxOTQxMmJfMS0xLTEtMS0zMjk3NQ_4ad19fee-c998-48c0-8174-b7eb03345130"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjhjZTFhOTI4MzAzZjRlZTI4MGU4OWU5OGQ1MTk0MTJiL3RhYmxlcmFuZ2U6OGNlMWE5MjgzMDNmNGVlMjgwZTg5ZTk4ZDUxOTQxMmJfMi0xLTEtMS0zMjk3NQ_5f93c180-584a-4ee9-83be-05e00f854e9e"
      unitRef="usd">1233000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="id80221d972a4407a82832333ee98fc87_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81NS9mcmFnOjI4NjExMzMyMjAzNDQzMDM5YTNkNWVjNWQ0OGE2NmVmL3RhYmxlOjhjZTFhOTI4MzAzZjRlZTI4MGU4OWU5OGQ1MTk0MTJiL3RhYmxlcmFuZ2U6OGNlMWE5MjgzMDNmNGVlMjgwZTg5ZTk4ZDUxOTQxMmJfMy0xLTEtMS0zMjk3NQ_8bce495c-26a7-4a3c-ad68-7494dfacca3d"
      unitRef="usd">1233000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfODYyNQ_53752ae0-893c-4c26-9d11-55631d9600d5">COMMITMENTS&#160;&amp;amp; CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a) Facility Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the ordinary course of business, the Company enters lease agreements with unaffiliated third parties for facilities and office equipment. As of March&#160;31, 2022 and December&#160;31, 2021, the Company had four active leases in Irvine, California for adjacent office and laboratory suites. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2021, the Company entered into a six-month lease for an additional administrative office suite that was not capitalized due to its under 12-month term. The company does not recognize lease asset and liabilities for leases with a term of 12 months or less. On July 30, 2021, the Company executed an amendment to extend the term of this lease and lease an additional office suite, both expiring January 31, 2024. This amendment was accounted for as a "lease modification" and resulted in the recognition of an "operating lease right-of-use asset" valued at $0.7&#160;million as of the execution date.  The Company's two other capitalized facility leases commenced on June 1, 2020 and also expire on January&#160;31, 2024. One includes a renewal option that was not reasonably certain to be exercised at the time of lease commencement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operating leases have annual rent that is payable monthly and carry fixed annual increases. Under these arrangements, real estate taxes, certain operating expenses, and common area maintenance are paid by the Company.  Since these costs are variable in nature, they are excluded from the measurement of the reported right-of-use asset and liability and are expensed as incurred. During the year ended December 31, 2021 and for the three months ended March 31, 2022, the Company had no sublease arrangements with it as lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Reporting Captions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The below table summarizes the lease asset and liability accounts presented on the accompanying Condensed Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_439b7687-e8d3-4543-9c80-be7d57d59b72"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_c0a0454b-2a50-41a4-8b96-b87633545102"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_6efd016f-2e3f-4e4b-96a2-61e9bf7e61bf"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_9a33a609-33f6-4820-89f2-c43f54cb768e"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Components of Lease Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The liability associated with each lease is amortized over the respective lease term using the &#x201c;effective interest rate method.&#x201d; The Company&#x2019;s right-of-use asset is amortized over the lease term on a straight-line basis to lease expense, as reported on an allocated basis within &#x201c;research and development&#x201d; and &#x201c;general and administrative&#x201d; expenses in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income. The Company combines lease and non-lease components in the recognition of lease expense. The components of lease cost were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:49.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted-Average Remaining Lease Term and Applied Discount Rate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company's facility leases had a weighted average remaining lease term of 1 year, 10 months. The weighted-average estimated incremental borrowing rate of 10% was utilized to present value future minimum lease payments since an implicit interest rate was not readily determinable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Future Contractual Lease Payments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases - Future Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b) In-License Agreements for Lotilaner&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;January 2019 Agreement for Skin and Eye Disease or Conditions in Humans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2019, the Company entered into a license agreement with Elanco Tiergesundheit AG (&#x201c;Elanco&#x201d;) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treatment or cure of any eye or skin disease or condition in humans (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid a $1.0 million upfront payment at execution of the Eye and Derm Elanco Agreement in January 2019. In September 2020, the Company made a required $1.0 million clinical milestone payment associated with the first two U.S. pivotal trials for the treatment of Demodex blepharitis. The Company paid an additional $2.0 million for its second pivotal trial milestone in April 2021, which was recorded in &#x201c;research and development&#x201d; expense in the accompanying Statements of Operations and Comprehensive Loss for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may make further cash payments to Elanco pursuant to the Eye and Derm Elanco Agreement upon achievement of certain clinical milestones in the treatment of human skin diseases using lotilaner for an aggregate maximum of $3.0 million and various commercial and sales threshold milestones for an aggregate maximum of $79.0 million. In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the China Out-License discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company made a contractual payment in the amount of $2.5 million to Elanco following the receipt of $25 million of initial proceeds from LianBio during the second quarter of 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;September 2020 Agreement for All Other Diseases or Conditions in Humans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2020, the Company executed an expanded in-license agreement with Elanco, granting the Company a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of "all other" diseases and conditions in humans (i.e., beyond that of the eye or skin) (the &#x201c;All Human Uses Elanco Agreement&#x201d;). The Company issued Elanco 222,460 shares of its common stock at the execution of the All Human Uses Elanco Agreement. The fair value of these shares was $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is required to make further cash payments to Elanco under the All Human Uses Elanco Agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.5 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net product sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which the Company achieved applicable regulatory approval prior to sublicense execution.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2021, the Company entered into the China Out-License agreement with LianBio (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;), which obligated it to grant Elanco an additional fixed 187,500 shares of the Company's common stock that were otherwise required to be granted no later than the 18-month anniversary of the All Human Uses Elanco Agreement for the Company's continued license exclusivity.  These additional shares were valued at $5.5 million based on the Company's stock closing price of $29.30 per share (on the date the issuance became contractually required) and were reported within "research and development" expense within the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income for the three months ended March 31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(c) Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements with eight of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(d) Litigation Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(e) Indemnities and Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tars:LesseeOperatingLeaseNumberOfLeaseContracts
      contextRef="ia85a91d80e654470aeccc73aa5fa1fb5_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMjUw_7e385fa7-1c75-42e6-953e-83225f5da7d7"
      unitRef="contract">4</tars:LesseeOperatingLeaseNumberOfLeaseContracts>
    <tars:LesseeOperatingLeaseNumberOfLeaseContracts
      contextRef="i2d2fc086b90b461a8bd0825aacc11371_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMjUw_b1f70b14-11b2-48b4-adf3-0fd2aec3adf4"
      unitRef="contract">4</tars:LesseeOperatingLeaseNumberOfLeaseContracts>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ieadb94479fbf491289eeb4a699120c85_I20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfODYyMw_b618722e-8e5f-4bfb-967f-9bf1ee6cfa84">P6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2984a704b5f7467bb0b60220ced68c69_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNzg1_6793df8c-fc8b-4f70-b129-4c9b165d18c5"
      unitRef="usd">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <tars:ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTQ5NzU1ODE1MDA3NQ_cac814e9-5d0f-4f96-aa23-29f478cedbf7">The below table summarizes the lease asset and liability accounts presented on the accompanying Condensed Balance Sheets:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_439b7687-e8d3-4543-9c80-be7d57d59b72"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy0yLTEtMS0yODcwOA_c0a0454b-2a50-41a4-8b96-b87633545102"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_6efd016f-2e3f-4e4b-96a2-61e9bf7e61bf"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC0yLTEtMS0yODcwOA_9a33a609-33f6-4820-89f2-c43f54cb768e"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</tars:ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMS00LTEtMS0yODcwOA_be30d614-2481-4156-a094-98456dd49937"
      unitRef="usd">926000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMS02LTEtMS0yODcwOA_637d9869-b63e-484b-91d9-c1f03f58b1bf"
      unitRef="usd">1074000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy00LTEtMS0yODcwOA_d779e9aa-49b9-45c4-8813-862fb1596362"
      unitRef="usd">635000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfMy02LTEtMS0yODcwOA_9626aba1-d672-4e82-a9fd-ce8c901d56be"
      unitRef="usd">609000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC00LTEtMS0yODcwOA_34d08e8a-ee65-4bed-be61-ce1731d3ea30"
      unitRef="usd">425000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNC02LTEtMS0yODcwOA_95d181b0-b08f-4440-ab17-2e836d4b1fd4"
      unitRef="usd">585000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNS00LTEtMS0yODcwOA_111d760c-37b9-4ba3-819f-6054c792d818"
      unitRef="usd">1060000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i849ffd4d92344da1bec87e7d90d1b485_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjI0NjU5OWNkYThjZjRhNDliM2FjMTdmNzY1NWQxMWU1L3RhYmxlcmFuZ2U6MjQ2NTk5Y2RhOGNmNGE0OWIzYWMxN2Y3NjU1ZDExZTVfNS02LTEtMS0yODcwOA_37d680ed-2ed2-4973-8825-0f629ee4c4bf"
      unitRef="usd">1194000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfODYyNA_03149953-63c1-4cb8-b393-510e9a8c22fc">The components of lease cost were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfMi0xLTEtMS0yNjYzNQ_086db222-c354-49ce-8825-9f5f3589d65d"
      unitRef="usd">143000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfMi0zLTEtMS0yNjYzNQ_338fec05-71da-4b23-964b-b56ca1a0c844"
      unitRef="usd">60000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfMy0xLTEtMS0yNjYzNQ_fc1306ff-0162-4866-9caf-249e86e54828"
      unitRef="usd">39000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfMy0zLTEtMS0yNjYzNQ_7adc0551-d6bc-4ab4-8b54-98eb4be1e706"
      unitRef="usd">60000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfNC0xLTEtMS0yNjYzNQ_d7394e2f-839d-4dc1-af06-42b548caa739"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfNC0zLTEtMS0yNjYzNQ_253363bf-e0ed-4aea-a029-959ea555dc7c"
      unitRef="usd">32000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfNS0xLTEtMS0yNjYzNQ_6550bc4c-5ad7-4137-8984-47507bb55945"
      unitRef="usd">182000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i29f7c6ff4ea54f9c966c3b975341a9f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjk4ZDY0YTc5ZGZkNTQ1ZTc5Yzc0MWNhZGRkMzdjMDIxL3RhYmxlcmFuZ2U6OThkNjRhNzlkZmQ1NDVlNzljNzQxY2FkZGQzN2MwMjFfNS0zLTEtMS0yNjYzNQ_a2372355-15d3-43d8-b2a7-e053649392f5"
      unitRef="usd">152000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMjgxNg_864e872c-9668-48d2-802e-d38af4c423dc">P1Y10M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMjkwMg_e29de2f3-450a-4edd-92fb-2735b2c295ac"
      unitRef="number">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfODYyMg_77e19904-f1bd-4bc4-9ac2-d89ae1f06ea1">&lt;div style="margin-top:12pt;text-indent:49.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The below table summarizes the (i)&#160;minimum lease payments over the next five years and thereafter, (ii)&#160;lease arrangement imputed interest, and (iii)&#160;present value of future lease payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases - Future Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Less): Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfMS0xLTEtMS0yNjYzNQ_c3d2725c-f90a-4684-9ce0-da26384d3804"
      unitRef="usd">349000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfMi0xLTEtMS0yNjYzNQ_6680b7ef-350a-469c-b4f4-f257dc8acce3"
      unitRef="usd">761000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfMy0xLTEtMS0yNjYzNQ_11ef0abf-1674-424e-a0d4-89685f7a432d"
      unitRef="usd">65000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfNC0xLTEtMS0yNjYzNQ_fd0cf022-9f7f-4577-a95e-b0ba7d17bd34"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfNS0xLTEtMS0yNjYzNQ_843ec69a-60c8-47e6-8f11-80f220986267"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfNi0xLTEtMS0yNjYzNQ_0237c4c3-740f-4c0a-a553-2179c5d89b85"
      unitRef="usd">1175000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfNy0xLTEtMS0yNjYzNQ_aaf54858-e128-44ab-9261-0b4f4dfcd479"
      unitRef="usd">115000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RhYmxlOjEwN2JjYjllN2UxYjQyZDA5NzRmN2Q0MjFmNTE2MTkxL3RhYmxlcmFuZ2U6MTA3YmNiOWU3ZTFiNDJkMDk3NGY3ZDQyMWY1MTYxOTFfOC0xLTEtMS0yNjYzNQ_91153b8c-00b3-45f5-8812-c5a60f7bba8d"
      unitRef="usd">1060000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icd124fd3b0484daab9a49f0bec4f620f_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMzgyMw_37e32a40-968b-4481-ad15-380b36886d37"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaee22ca2e06b493897071cb5cc9e2fee_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfMzkzMw_f6c9dfc7-372d-4a08-be0a-00bcaab49bf8"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3d8f8ea4259c4cda90b6fffc07aba79d_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNDA4OQ_3bda2de2-e33e-42e0-a4ac-11f3249b7699"
      unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentExpense>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="ie486f40913eb4e9e91e41e6b75802f58_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNDUzNg_bba730a4-7ce9-4c7e-bf34-145b5d16d174"
      unitRef="usd">3000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i9e8bcfe9ca0640bbb09e4739c1c4c378_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNDYyMQ_547c8a1d-069b-46c5-80ca-b47004feb7ca"
      unitRef="usd">79000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:UpfrontPayment
      contextRef="i1cecf80c420649d6a1e32ab01aa11f92_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTE4Mg_bee2f225-e503-4579-9ccf-644d3860ff5b"
      unitRef="usd">2500000</tars:UpfrontPayment>
    <tars:UpfrontPayment
      contextRef="ide977ec78e02409981089603c186b138_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTIyMQ_b224419f-ada1-48ee-8d6c-4f12ae7a94e6"
      unitRef="usd">25000000</tars:UpfrontPayment>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="iaee22ca2e06b493897071cb5cc9e2fee_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTc2Ng_b9f22a0b-b673-43d1-a71a-bf5ceae6a140"
      unitRef="shares">222460</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="iaee22ca2e06b493897071cb5cc9e2fee_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTg3Ng_7ddef45f-d68d-4ccb-9f88-cbb2e64d79d3"
      unitRef="usd">3100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharePrice
      contextRef="i654c73f76ece4f4e803421b8c7263cb3_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNTg4MA_3e7dae13-bd6b-45ba-89f4-0eb1256f1cb8"
      unitRef="usdPerShare">14.0003</us-gaap:SharePrice>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i9d7a6b8164094267801b75fac6b39956_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNjE3MQ_357496e9-9662-4f89-8666-9dc94f5c4d53"
      unitRef="usd">4500000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i0b7611af61f5418b9266c2bcd8eb6fe9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNjI1Ng_4b9af256-f80a-4cb6-950e-15813d666d60"
      unitRef="usd">77000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices
      contextRef="iea920d7fcd75406d81b03da8bad1093a_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNjgyNQ_b235767e-94b3-4b5e-af34-9f4bfac585e1"
      unitRef="shares">187500</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices
      contextRef="iea920d7fcd75406d81b03da8bad1093a_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNzA2OA_356d1cd5-ef55-448a-a873-7f3485134cd3"
      unitRef="usd">5500000</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices>
    <tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices
      contextRef="iea920d7fcd75406d81b03da8bad1093a_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNzExNw_293686ee-a5ca-41c6-bc35-120b3887800f"
      unitRef="usdPerShare">29.30</tars:AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices>
    <tars:NumberOfEmploymentArrangementsWithExecutiveOfficers
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF81OC9mcmFnOmVjNGZlNjUzY2NjZDQyOTQ5ZGFhYzA0MjdkMjE2MzU5L3RleHRyZWdpb246ZWM0ZmU2NTNjY2NkNDI5NDlkYWFjMDQyN2QyMTYzNTlfNzQ0OQ_f4fc07ce-e5cd-441d-9884-068ebfc9310e"
      unitRef="arrangement">8</tars:NumberOfEmploymentArrangementsWithExecutiveOfficers>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMzEzNQ_ee16914f-d97a-4236-9b6b-d34919e3e113">OUT-LICENSE AGREEMENT&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License of TP-03 Commercial Rights in Greater China in March 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:56.55pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 26, 2021, the Company entered into an out-license agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the People&#x2019;s Republic of China, Hong Kong, Macau, and Taiwan (the &#x201c;China Territory&#x201d;) for the treatment of Demodex blepharitis and Meibomian Gland Disease (the &#x201c;China Out-License&#x201d;). LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To date the Company received payments from LianBio totaling $55.0&#160;million related to initial consideration of $25.0&#160;million and two clinical development milestone achievements of $30.0&#160;million. During the three months ended March 31, 2022 the Company did not receive any cash proceeds in connection with the China Out-License.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is also eligible to receive other payments and consideration from LianBio upon achievement of certain additional milestones, including: (i) TP-03 clinical development and regulatory milestones of up to $45.0&#160;million, (ii) an expected drug supply agreement milestone of $5.0&#160;million, (iii) TP-03 sales-based milestones for the China Territory of up to $100&#160;million, (iv) tiered mid-to-high-teen royalties for China Territory TP-03 product sales, and (v) LianBio equity warrants, which are subject to three TP-03 clinical/regulatory achievements for complete vesting, of which one tranche vested in June 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognized no "license fees" and $0.5 million "collaboration revenue" for the three months ended March 31, 2022 in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income, in accordance with the revenue recognition accounting policy described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Note 2(vii). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These amounts represent an allocation of the transaction price based upon the partial satisfaction of the performance obligations in the China Out-License&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These revenue amounts are each recognized upon satisfaction of the following performance obligations (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the actual or partial completion of clinical activities and related data for the Company's pivotal trials of TP-03 in the treatment of Demodex blepharitis. As part of this revenue recognition model, the Company was required to value the LianBio equity warrants, applying a discounted cash flow model with highly subjective inputs for this then private, pre-revenue company, and also considered the probability of achievement of requisite vesting events. Subsequent adjustments to the estimated initial fair value of these warrants are reported within "total revenues" and "other (expense) income" on the accompanying Condensed Statements of Operations for the three months ended March&#160;31, 2022. The first tranche of these warrants vested and were exercised to LianBio common shares and are reported within "marketable securities" on the accompanying Condensed Balance Sheets as of December&#160;31, 2021 and March&#160;31, 2022 (See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;).&lt;/span&gt;&lt;/div&gt;In future periods, the Company may recognize additional revenue from contractual receipts due from LianBio as (1) performance obligations are satisfied related to the completion of the TP-03 pivotal trial and as associated clinical data and reports are delivered, (2) regulatory approval events are achieved, and (3) LianBio records product sales of TP-03 in the China Territory.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <tars:UpfrontPayment
      contextRef="i3167f524706142c2b2851c8bb31f1c12_D20210326-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMTA5OTUxMTYzMjYzMQ_c95f71f9-119f-4f27-a310-c2bb0bdfd889"
      unitRef="usd">55000000</tars:UpfrontPayment>
    <tars:UpfrontPayment
      contextRef="ia19be9b7fe5245089c2073e846d30204_D20210326-20210326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfNjY2_fd290bc7-741c-480c-8f18-4e36a56a2768"
      unitRef="usd">25000000</tars:UpfrontPayment>
    <tars:CollaborativeArrangementMilestonePayment
      contextRef="i92802321216247e484f937d0e0c27e93_D20210326-20210326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfNzMy_aab54015-d005-4840-8fec-a7bf7373eb58"
      unitRef="usd">30000000</tars:CollaborativeArrangementMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i576dbd0507c245d1a503f15affe1eed2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMTA5OTUxMTYzMjc3NA_29d66cb5-6d31-4140-86ff-739c68d544e5"
      unitRef="usd">45000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i31e151303adb4b01ba45467aa1597d0a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMjE5OTAyMzI2MTAyMw_ae3391e0-0676-4d44-bd8f-275fb58cd973"
      unitRef="usd">5000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <tars:CollaborativeArrangementMaximumMilestonePayment
      contextRef="i35b7053fdb8f495f94c86835ef706e83_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMTA5OTUxMTYzMjgwOQ_99995d80-fa65-41c0-92aa-eb92de2037d0"
      unitRef="usd">100000000</tars:CollaborativeArrangementMaximumMilestonePayment>
    <us-gaap:Revenues
      contextRef="i0c7c8089e4c24cf6b318fdbcbb0fcd5f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfMTY0OTI2NzQ0NzI4Ng_38800047-f0b5-4029-b040-713cf93e7d91"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4c16329db554147aa835e3f640a2243_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF82MS9mcmFnOjI2ODg4YTZiMzg0NTRjZDRiNDgwNDNkNTAxMDdjNzlkL3RleHRyZWdpb246MjY4ODhhNmIzODQ1NGNkNGI0ODA0M2Q1MDEwN2M3OWRfNjA0NzMxMzk1ODMzOQ_e54a519e-e44e-499f-b0f3-fa6264533b3a"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3NTY_49049556-0285-4567-9afe-103af5a7e705">CREDIT FACILITY AGREEMENT&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2022, the Company executed the Credit Facility with Hercules and SVB with a term to February 2, 2027. The Credit Facility provides an aggregate principal amount of up to $175.0&#160;million with tranched availability as follows: $40.0&#160;million at closing (with $20.0&#160;million drawn in February 2022), $25.0&#160;million upon submission of a New Drug Application ("NDA") with the FDA for TP-03, $35.0&#160;million upon FDA approval of TP-03, and $75.0&#160;million upon achievement of certain revenue thresholds and other conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the tranches may be drawn down in $5.0&#160;million increments at the Company's election. The Credit Facility includes a four-year interest only period and is extendable to five years upon meeting certain conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Credit Facility requires interest-only payments from the issuance date through the amortization date of February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to maturity upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on February 2, 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Principal draws accrue interest on the outstanding principal balance at a floating interest rate per annum equal to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;greater of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; either (i) The Wall Street Journal prime rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;plus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 5.20% or (ii) 8.45%. At execution of the Credit Facility, the interest rate was 8.45%. On March 17, 2022 this prime rate increased to 3.50% and the Credit Facility interest rate increased to 8.70%.  The Credit Facility interest rate further increased to 9.20% on May 5, 2022 based on the updated Wall Street Journal prime rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company is required to pay a fee upon the earlier of (i) the maturity date or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.0 million was derived at the execution of the Credit Facility by &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;multiplying &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;4.75% to the $20.0&#160;million drawn at closing and is accreted to "accrued interest" through the maturity date of the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of March&#160;31, 2022, the carrying value of this debt consisted of $20.0&#160;million principal outstanding &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;less &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;issuance costs of approximately $0.9 million. These incurred legal and administrative fees were recorded as a "contra-liability" and accreted to interest expense using the "effective interest method" over the loan term.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The calculated effective interest rate for this Credit Facility was 9.66% for the three months ended March 31, 2022. As of December&#160;31, 2021 the Company had no outstanding debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three months ended March&#160;31, 2022, the Company recognized "interest expense" on its Condensed Statement of Operations and Comprehensive (Loss) Income in connection with the Credit Facility as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense for term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of End of Term Charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense related to term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The principal balance of this term loan and related accretion and amortization as of March&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan, gross (amount drawn)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs (legal and other administrative fees)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of End of Term Charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3NTg_81067c97-e9b2-4009-b23b-985755314133"
      unitRef="usd">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0dd505db08864f8599c4b88afd5d91d4_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3NzI_ddde374a-fcb4-41bf-8cc4-50701f7a5194"
      unitRef="usd">40000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1e1d86abba614b28bb93de20e5a65f46_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3ODU_d3d40e65-ad5b-4a18-a98b-5ce4745f3516"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0e1bbc0f5a2e4184a13f69cd709213c4_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg3OTg_c735d266-a1a9-4d0f-a3c6-85fbe44ed63b"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1eb8e35e7edf4dcc8e5184077317c4e2_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4MTE_360ffc77-b1c4-432e-8edd-4ce8eb54017c"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ica98a2fa29594ad7be66a55c9a1e20db_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0NDM_da81c1a2-146c-4ee9-a7cf-b8383b974119"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tars:LineOfCreditFacilityDrawDownIncrements
      contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4MjQ_0d5d8649-eb59-4850-a33b-326936b72d84"
      unitRef="usd">5000000</tars:LineOfCreditFacilityDrawDownIncrements>
    <tars:LineOfCreditFacilityInterestOnlyPeriod
      contextRef="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4NzY_8a7fb860-6bab-46ee-a465-d77f59abbb96">P4Y</tars:LineOfCreditFacilityInterestOnlyPeriod>
    <tars:LineOfCreditFacilityInterestOnlyPeriodExtended
      contextRef="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4ODg_7a5a658b-a618-45c9-a63a-bfc363dfcc58">P5Y</tars:LineOfCreditFacilityInterestOnlyPeriodExtended>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i33662385a14248f389cd589e0b07949d_D20220202-20220202"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0NTg_9a8914b6-cc92-40ad-8028-3b9a720dd992"
      unitRef="number">0.0520</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0NjU_c21d8e83-aee8-4e96-9476-bebf8178baea"
      unitRef="number">0.0845</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0Nzk_cff2837b-187c-46f4-8f2b-6650b6c3a692"
      unitRef="number">0.0845</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3a6e2fcbec9d4f2a814387f5e90b9f5f_D20220317-20220317"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0NzI_ce1b7604-10ee-46d3-990d-96f820ee4aa2"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="ie708af9133d548c5b4bab9d679747cd1_D20220317-20220317"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0ODY_e7827654-fffb-4bc1-9284-423efde246cf"
      unitRef="number">0.0870</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="i2d088c0af04542eba408c2f8416ec22d_D20220505-20220505"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjcwMzU_18ac429d-67fa-4f7c-876f-cd690d006d12"
      unitRef="number">0.0920</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentInterest
      contextRef="i526c288d95b145d18ad85df06471783c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzYwNDczMTM5Nzk0MTk_9c091792-cb5e-4281-a30c-d340c8b277c0"
      unitRef="usd">1000000</us-gaap:LineOfCreditFacilityPeriodicPaymentInterest>
    <tars:LineOfCreditFacilityPeriodicPaymentInterestRate
      contextRef="ifd2668fef555454ab6c59b2d437e7cca_I20220202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzY1OTcwNjk3ODk3Nzc_a6990c03-d0f8-400a-b630-7c0fe785f4b2"
      unitRef="number">0.0475</tars:LineOfCreditFacilityPeriodicPaymentInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i438915cd287c48788084761ed5ad3ba4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzYwNDczMTM5Nzk0OTg_d82db249-47a1-4569-bca2-b4d18a26f69d"
      unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i438915cd287c48788084761ed5ad3ba4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzU0OTc1NTgxNTg4MzY_037af800-5a83-4572-b1e8-b6cf79d45701"
      unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i438915cd287c48788084761ed5ad3ba4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzYwNDczMTM5NjUxNDY_e0cf9934-cc83-434f-a31e-0c38e496d2b6"
      unitRef="usd">900000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i438915cd287c48788084761ed5ad3ba4_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0OTM_d9a68b7a-3a8d-45fc-a789-2bcebdfaea7e"
      unitRef="number">0.0966</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id27ce663af03415ca6600c5007c2ea01_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzcxNDY4MjU2MDU5MjE_de6314a9-b02a-40b7-afc9-f80fc07f89ef"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY0OTk_b77930bc-a60a-406b-9b48-e2e34ccef0cf">&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three months ended March&#160;31, 2022, the Company recognized "interest expense" on its Condensed Statement of Operations and Comprehensive (Loss) Income in connection with the Credit Facility as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense for term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of End of Term Charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense related to term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTpkZjk5M2U4Y2EyYWU0NDM4YWYzYTlhYjlmNTllMWJkMC90YWJsZXJhbmdlOmRmOTkzZThjYTJhZTQ0MzhhZjNhOWFiOWY1OWUxYmQwXzEtMS0xLTEtMzE5MTQ_e4bd6aa3-178e-467b-8971-f530f200a36e"
      unitRef="usd">274000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTpkZjk5M2U4Y2EyYWU0NDM4YWYzYTlhYjlmNTllMWJkMC90YWJsZXJhbmdlOmRmOTkzZThjYTJhZTQ0MzhhZjNhOWFiOWY1OWUxYmQwXzItMS0xLTEtMzE5MTQ_1448ce8b-ca80-46d5-aa52-5ee640a12f54"
      unitRef="usd">32000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTpkZjk5M2U4Y2EyYWU0NDM4YWYzYTlhYjlmNTllMWJkMC90YWJsZXJhbmdlOmRmOTkzZThjYTJhZTQ0MzhhZjNhOWFiOWY1OWUxYmQwXzMtMS0xLTEtMzE5MTQ_9c43dd59-cb4f-4513-8e58-a750163764dc"
      unitRef="usd">23000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTpkZjk5M2U4Y2EyYWU0NDM4YWYzYTlhYjlmNTllMWJkMC90YWJsZXJhbmdlOmRmOTkzZThjYTJhZTQ0MzhhZjNhOWFiOWY1OWUxYmQwXzQtMS0xLTEtMzE5MTQ_2bab762a-0b36-430e-9ca7-41546493289c"
      unitRef="usd">329000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90ZXh0cmVnaW9uOjMwOWFlYzUyNGI1YTQzMzg4NjBkZjVlMWI2YThhNDQwXzE2NDkyNjc0NjY1MDA_4ed63d18-7bf3-4c1c-bff0-03df2a7ea6c8">&lt;div style="text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The principal balance of this term loan and related accretion and amortization as of March&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan, gross (amount drawn)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs (legal and other administrative fees)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of End of Term Charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzEtMS0xLTEtMzExMzc_428038f3-beae-4660-a9ab-2c2e44e6d28b"
      unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzItMS0xLTEtMzExMzc_265c8759-3d94-4b11-a194-5a05b7432955"
      unitRef="usd">875000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzMtMS0xLTEtMzQ3MjM_408a19c9-94ea-4724-8ddf-7cd4ccf0db50"
      unitRef="usd">-32000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzMtMS0xLTEtMzExMzc_56b0f5f4-0979-4a3f-8668-1bfb5b0a1465"
      unitRef="usd">23000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
    <us-gaap:LongTermDebt
      contextRef="i7273965429d14abfa8d691f9d822bdae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84NzIvZnJhZzozMDlhZWM1MjRiNWE0MzM4ODYwZGY1ZTFiNmE4YTQ0MC90YWJsZTo2NDU0N2U5NTU4NjE0ZGVhOGJhN2Y5MzU4YjA3ODM3YS90YWJsZXJhbmdlOjY0NTQ3ZTk1NTg2MTRkZWE4YmE3ZjkzNThiMDc4MzdhXzQtMS0xLTEtMzExMzc_db6c14b3-4330-4f81-92cb-27a1ae035709"
      unitRef="usd">19180000</us-gaap:LongTermDebt>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="icf7f8741b931466c871602b1ed804bb8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUyMjI_355de324-42d1-472e-b822-abf632a55f10">SUBSEQUENT EVENTMay 2022 Follow-on Equity Raise&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 5, 2022, the Company completed a follow-on public offering, pursuant to the Company's effective Form S-3 shelf registration statement, through an underwritten sale of 5,600,000 shares of its common stock at a price of $13.50 per share.  This resulted in gross proceeds of $75.6&#160;million before underwriting discounts, commissions, and estimated expenses, for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;net proceeds of approximately $70.6&#160;million.  &lt;/span&gt;The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of common stock at the public offering price, less discounts, commissions, and estimated expenses.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id85e9ecd5338406897413769276e54ff_D20220505-20220505"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUxNzE_5f96f049-5831-482d-a53e-4e29eedbe4b9"
      unitRef="shares">5600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1808d691f65a4626825a224635438903_I20220505"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUxODI_55b3cf49-4567-445a-a105-d6c63063f67b"
      unitRef="usdPerShare">13.50</us-gaap:SaleOfStockPricePerShare>
    <tars:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i8c435dd6d8af4033acf4c6e936b27500_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUxOTA_5d22ea08-1952-44bc-aec1-22cbafc02e81"
      unitRef="usd">75600000</tars:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8c435dd6d8af4033acf4c6e936b27500_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDY1ODU_b89225cd-bce6-4986-82db-33a4a510c4f0"
      unitRef="usd">70600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4eb812a752d3463a8d2c1bc50512d96b_D20220505-20220505"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzNzEzYzM2N2ZjODRhOGI5MDFiMDM2NTVkZTA3ZTNkL3NlYzozMzcxM2MzNjdmYzg0YThiOTAxYjAzNjU1ZGUwN2UzZF84OTUvZnJhZzpmNDIyZjk3MDFlYjY0MTMyYTI5MGVmN2FkMmMwN2YzNC90ZXh0cmVnaW9uOmY0MjJmOTcwMWViNjQxMzJhMjkwZWY3YWQyYzA3ZjM0XzE2NDkyNjc0NDUyMDk_506fa6c7-d13c-42a7-a8ae-f282faabd143"
      unitRef="shares">840000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX(%0Y@;X?2&EWI^8/RAW@L?_ 5!+ P04    "  SB:M42[&1W*P%  "=%0
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U8;6_;-A#^*X0;%"W@Q"(E
MZR4O!MH4P_9A6]"TVV=:HB,NDNB25)SLU^\H.Y(L4G(*[$-BO=P=G[LC[[G3
M]4[(1Y4SIM%S653J9I9KO;U<+%2:LY*J"[%E%;S9"%E2#;?R8:&VDM&L42J+
M!?&\<%%27LU6U\VS.[FZ%K4N>,7N)%)U65+Y\ID58G<SP[/7!U_Y0Z[-@\7J
M>DL?V#W3W[=W$NX6K96,EZQ27%1(LLW-[!.^O"6146@D_N)LIWK7R+BR%N+1
MW/R6W<P\@X@5+-7&!(6?)W;+BL)8 AP_#D9G[9I&L7_]:OV7QGEP9DT5NQ7%
MWSS3^<TLGJ&,;6A=Z*]B]RL[.+0T]E)1J.8_VAUDO1E*:Z5%>5 &!"6O]K_T
M^1"(G@(.1A3(08&\5<$_*/B-HWMDC5M?J*:K:REV2!IIL&8NFM@TVN -KTP:
M[[6$MQST].I65!DDA67H,RUHE3)T;VPI=(Z^WW]!'\X^HC/$*_0M%[6B5::N
M%QJ6-<J+]+#$Y_T29&2)WZF\0#Z>(^(1XE"_G5;_PM)6'1^K+\#9UF/2>DP:
M>_Z8Q[64K-*(*@5^7DY8]%N+?F,Q&+-(58X@-B@U%^Q'S9]H 4LX8[4W%3:F
MS!E[6N%HZ6'O>O'4CXE+#/L^:<6.D 8MTF 2*:3BD6FZ+AA2+*TEUYPY4>[-
M+'O+DP0/(-HR0>R[\2U;?,M)?)_25-00."@0*8,H E 7NJ6U,HX&X&P1SPTM
M;*&%D]#^U#F3/5S.L(76JKX7#I#9,LE(5J,66C0)[4ZR+>498L];<Y15LQ=%
M@S<]VNPNR)$-&?O#5-M"@1<LW:CC%G4\B?J;T+1X \#8D>PX6BX'$%UBRV0Y
M$MJD!9F<""T0IM0O34C-R=X"A>DYJIAV84WLW.(A4%NF[\P12NQU5=R;WIV
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M6J3%9<19R*4Q@/=;(?3IQGR@/NE=_@=02P,$%     @ ,XFK5!]O^I6#!0
MF1D  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R]F6UOVS80Q[\*8118
M"\RU2.K)16*@=3(L0#<$2;N]&/:"E>A8J"2Z)!VGWWY'294LB9+LIMV;1 ]W
MI_\='WXG^>(@Y&>UY5RCIRS-U>5LJ_7NS6*AHBW/F'HM=CR'.QLA,Z;A5#XL
MU$YR%A=.6;H@CN,O,I;DL]5%<>U6KB[$7J=)SF\E4OLL8_+K.YZ*P^4,S[Y=
MN$L>MMI<6*PN=NR!WW/]<7<KX6Q11XF3C.<J$3F2?',Y>XO?7%-B' J+OQ)^
M4$?'R*3R28C/YN0FOIPY1A%/>:1-" ;_'OF:IZF)!#J^5$%G]3.-X_'QM^B_
M%<E#,I^8XFN1_IW$>GLY"V<HYANV3_6=./S.JX0\$R\2J2K^HD-EZ\Q0M%=:
M9)4S*,B2O/S/GJI"'#E@.N! *@=RJ@.M'&C'@00##F[EX'8=AG+P*H<B]469
M>U&X*Z;9ZD** Y+&&J*9@Z+ZA3?4*\G-1+G7$NXFX*=7:Y'',.P\1O>::0Y3
M0"LD-N@6QHM+65P7T6?$\NIH*]*82_4+NOZR3_17-$<?[Z_0RQ>OT N4Y.C#
M5NP5&*N+A09YYB&+J)+RKI1"!J1\$)JE%K?UN-M:9!G,N$*<Q?MJW/MM'"=F
MQK(4W;(DGM_D:,UVB5W)]42L*-IG^Q3*&*,KODFB1+>#+&!PZA$B]0B1(JH[
M$/4=?TCR/,D?8$&D+(\X>JFV3'+U"C$-SXE>(XI_1<0ACJWF97"O"&YVC<<5
MF#U:]-!:#SU3SRDRRIC^M RWEN&.RKC.XZ&:_,%D+0;;Q+BGUL2KQ7CGB#E%
M@W=J0?Q:@_\3Y\G:[]6$.)10XF"[K*"6%?R$Z1+TU&#?6X9-B4K10:^(;MOB
MJF^!EV%(<-OLNF\VIR1T/7ON89U[6/C1@=QO\@C@K6 D(.'BZ)79(ZW[Z#]W
M(DT1P._ 9/SOR+ZQK!^^'"W\G]!EO$R%4N:9D<BXK<[+?IT=&OB=ZDQ9M?1A
MIT&/,ZKPCD?B(2^V7X,<9<HR-]2/$>B%5DBQXAY_,L=6_=436M*H3SN38,JJ
MK?\(G7A\U3]Q&24PO"#^D2NS[1<Y(+$SNE6] *U0PQ9-03 DJJ$%'L?%E"AK
M%?N0P,MN#4=MVF(;E.!QEMP7]4&)4GO0R12,.[2@L"[*@8<^&.;N/$TB,_Y(
MFJ9OHJJTKS(,/&=@;\4-;? X;KY'J;74??9X[K*[:TU9M9-H*(7/PM0YS%Q7
MH=N \(CK!D.R&G#A<7)]!SVKB*U]/32XZ@#"8M>KM8U\GK\,.IN@Q6Y.B.L/
M+8(&D/A<0@Z!VUZ*/BN'9GO#+1P^#]IV)>&I/0UN((;'*7;BE"56/7UN#>@A
M#;/(.+/&YZI51A7QA+*0!CUD'#W/G#.D#Q_B^,LPH)U9OS[%LIW#T7O-N2\V
M)TDG_97O^P'MMH86N^[*)WVD$4SI,NRL?(O=W(5GDH$*-/@C]/_O#TG#-#+.
MM),Z1-)'T1S&AO:*-&G75ME BXQ#ZP=TB<3"+C_H38<)J[;^AFYD@F[/Z1*)
M!4YDX*V$-,0AX\2Y@2ZF6' @*2H_GY22]CLXU%M>"#4K$PQ FI9)U.C>PV!,
MJ.XCR27>T(;14(F,4^D]VY5EE'RWE]&6-3VAY.5G%RW:"57]&IB;C+6YSYE,
MO\)L*4=E(I&PWTYZU!E /FFH1L:I]F,R.9Y&1PGM9 +=*-RO!M&Z(OIHI+B[
M'D9MVM^.&G[2<7[^J#Z:G@Q5VD"53KS//:/7H#9.!CCT2&>C7)]BV4Z@(2J=
M>/<[OSFA%IRZ2]SM?M<6N^[^:3$AV,=.YVW\VF(W]_TE[H[?XNBKMOG1 G*!
MAD&AE&_ T7D=0 EE^3M >:+%KOC0_4EH+;+B<,L9S"UC /<W0NAO)^;;>?UK
MS.H_4$L#!!0    ( #.)JU2*BY_V"P@  (<B   8    >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&ULG5IM;]LX$OXKA&]Q:(&Z-BGYK9<$2)TMKL"U&S37W<^T
M1-N\RJ*7I))F?_T-*<6TQ1<[^R6QI"'YS,/A/$-*5T]"_E!;QC3ZN:MJ=3W8
M:KW_,!JI8LMV5+T7>U;#D[60.ZKA4FY&:B\9+6VC734BX_%TM*.\'MQ<V7OW
M\N9*-+KB-;N72#6['97/'UDEGJX'>/!RXQO?;+6Y,;JYVM,->V#Z^_Y>PM7H
MT$O)=ZQ67-1(LO7UX!9_6.8ST\!:_,[9DSKZC8PK*R%^F(O/Y?5@;!"QBA7:
M=$'AWR-;LJHR/0&./[M.!X<Q3</CWR^]?[+.@S,KJMA25'_P4F^O!_,!*MF:
M-I7^)I[^S3J')J:_0E3*_D5/G>UX@(I&:;'K&@."':_;__1G1\11 ^@GW(!T
M#4B_01YID'4-,NMHB\RZ=4<UO;F2X@E)8PV]F1^6&]L:O.&UF<8'+>$IAW;Z
M9BGJ$B:%E>A!4\U@@K1"8HV65&W1)YADA8;H^\,=>O/+6_0+XC7Z[U8TBM:E
MNAII &"Z&17=8!_;P4ADL Q]$;7>*O0K#%J>MA\!\ -Z\H+^(TEV^(7*]RC#
M[Q 9$Q+ L[R\.4[ R0YD9K:_+$:F(^V3%#OTVYY)JGF]0;<F6KGF3'U(C),?
MQLGM.'EDG*^PO-]40JFW,"&%V+'05+1=3&T79C$_W@S!S6Q^-7H\9L@WP^-L
M-CU8G0"<' !.DD3<EO^#T&V#20M8[H6H"UXQ5/>1F\?F9F&H:TP<0HB) V_T
M(MZF!UC3)&]W#%)=P6F;0.H2T9V0FO]E;X0X;+N;')&3XQY_OLDT#Y,W.Z"<
M)5'>'H%J41:%9/8*%F8EZLU0,[F#9+720&T%R[9$A5 ZN")G'K[)I.>";S(.
M>S _>#!/>O"@1?%C:+*K ;8#R5%1BN?>X&0ZRWL(?2.<3;,PR,4!Y"*]B$0]
MM%%7,0"*V$\#,[B2%O[H..LA]&WR"#X\=JEYG$3X'U@G"&:]Y&HO%*W,].^E
M61SZV08&^[/A>[/*@JEXG)C6%G3 9!:9>GPD*/@BU"VM)E)Y'9W]KJ\D2-^$
M1# 2AY$D,7ZOH>2I^%\0GU4'UW )M"I6--(FG"!<XH?"@O0!^T8Q4IVPX"P)
M>+FE]8:9W+BF7*)'6C7,A$.'^HE*2>MP NAZ/N$O[Z> @%$,LQ,IG%:I/LEO
M-E!5OD5KHXP:X"IJ*SD%B:P6-DC:[$\15*=0?M50_TC)ZN(YZ%;N3T7?*=]D
MF$TB;CEIPY.D6Y^5:FA=6/HAN>T@=I3)=VC?2/-$&TGC];#BA4DHB&XD8]%%
M.CD?_[[))%]$- 8[*<33=*UB(TKUY%8I!I)M<DO%Z8I79Z47.U7#9V2M*$1C
M"@*08,8?Z:H*)EOLJ]$0S_J<!(S(9#R.Q:P3+IQ6+BB'(30+W3(1Q.=KD3=C
MOLEPAA>+"#@G6#BM6+_I+9-'](67NZ]$0T*\]1ZTFH41$J=8)*U8]Y+M*2]?
MQ+2-)&%AMVNY(S:(G/AJM"#3'O" T3 C. +<B19)BU9+;6U*@O,X?4'"_8(E
M8#/$9!))/L0)%TD+UV$1[>FS"8$C@DV5V+"3A1M$'Y*PZ:*/W[>:C&,5%W$R
M1M(R=MMA!/125)5%OV(U6_,(U;XL#1>+?NT5LLJB7#O](FG]:F/"U=OGB VH
M3>Y!#:@6B='J)(FD)>GK)1NH(&9?6X9X0N;>J@O9X5E,A8A3(7)&A7H[YL_U
M(U.OV#$3)S\D+3_WC2RVU.2D5U71)"1'TWZE$;2:Q2+0J1$YHT;'<\H/U)R9
MTX#Z!!"'K**(G421Q:OF\Q.4=;#SOW@^,R<UV3FI$05CI6KK2?:3R8(K6Y09
MFH"RMB@3>UMCAHC*SF^0 B8X(N.9TYHLK37W]-E$FX%:LC4#N8$4OH8?AJ;H
M/CX+*,K4PYO:3IW"=9*3I27GE.@V$PH:W,UEOFJ0\7%5UJ&\>(.4'9V\I97E
MA-251ORE2H\3&E"-.>X72@&K&%8G+-GYXSN;KB$-/?(2IG_UC-:'E9)>WEE
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M<VAE970W+GAM;+U9VW(;N1']%13C2J0JFI0H7W;7LJHD68JUM984TW8>4GD
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M G4URY1FL*2TK5#AS,6#8-MC2A1\EHLC;L=PQ4XO<X>&6HP.2)<K>$[&"QH
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M8=SP42(0/\>2:@=L"\TY5.V^PFE?^6>)"<I5=LNPC%& +JHQ+DOX?Q-'_<0
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MTM!H<F)._P)45H'NUU*:P\8::/XNH]]02P,$%     @ ,XFK5--68H@;!
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MR<0'<$@8L4;@]RI* B0P1;;U'+4R5R;7P7SH0&2K=.2Q1J,(^$R8:Y%WQDF
M]'?AUJ^=4XOCIPJI8<NW Y!TEFGP49\2N8SR;X_BB(8W:+L 8*75OM36'N.L
MO_KI7!GR&P1,J)[R>$S0,6M0,&V>N*CJ7@(/=KWC==1ZK2ZG02N]/$AGH(?T
M;]C5O];O)Y[YU_*:Y?[E1@#J0A=TGS7'UN'@9-KSL]?XI30K?DEO9LK2Y/QQ
MJ=#/6EJ YW.#0B!\H0/JMS;?_ =02P,$%     @ ,XFK5.$[ZGOR!@  RA
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MI.G22 G2W>G0 9X7#=,&ZB) ):] C>FC+MW*TE69R6S;?@BW6M^2C6\7R9N
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M#*UC7OL(0:+C7ZJ=6IDZRUIH:4O1CF6!QHZUKN.1;#"B]IYE^Q$0)!><6&_
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M"N#XGPW@#YW=T57]$+UVMJ$_MUJ!LN,#\#OR-GS ">(_WO#]_P%02P,$%
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M:F= WW=*V>/&.9@>Q_4_4$L#!!0    ( #.)JU237'LT>0(  '\%   9
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MRPK'3M#N IZ7"BNS_W .AD%V_1]02P,$%     @ ,XFK5/-8;=);!   R@P
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M<_JQ@<H*T/E*TD#0O%@#[<^7^;]02P,$%     @ ,XFK5.BJ]@$:!   <PH
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ML%20D;S\1P^5$2V Y!D'6!7 Z@.<)P!V!;!?"G J@*.=*5/1/FR10*L%HT?
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MM2DO"@U->6^19[0]R3E(<2PI9Y>^W FLO J4'4$/^G!\1X4\:NMF(J]/F*D
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M;5U_B_?^W@79WZ[AU> 3Y7;,X.KJ$V6X<6#=94EMGW-IZ)LN2-4YOR 375]
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MJ W@^Y)SM7W0#;0GVM-_ 5!+ P04    "  SB:M4QPB,7/,"  #J!P  &0
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MTAC@_[40>K\Q\[Z[WF=_ 5!+ P04    "  SB:M4CVRG9=8"  "%"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S-5DUOXC 0_2M6U$,KM<T7!*@
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M&6\E5V>IRI/S*TPY^('3@H!K@D7!B;I&4H!_P!7-<1Y3G(+/N9"\J([700G
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MI$POH^G?S:![A]>] W=,;WAEB(#"UHTNIA9 =W>K"U#5_CRO%=K;X8>E?8Y
MNP2[7BB%N\!=D>&!2W\#4$L#!!0    ( #.)JU3X%6.M&P,  -D)   9
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MN$G4ZF)?38Q,W=TXE@9O6C><X[<0*!N [Z=2FO7$7K?%UU7O#U!+ P04
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MGA$B5@T'[]:$XS@IWH,S\+!=@W>_O%_87$PG0790N;X^ND8#KF\Q.P=H]BM
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M )@L'C#W%T+HEY/BPV'][7K\'U!+ P04    "  SB:M4_YK)PI("   B!@
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M; ?RP\*V?-3.P'[/E*+]Q+6AYB<R_0502P,$%     @ ,XFK5'69:\>B @
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ,XFK5-5F0><>!   WR$
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MXI-KW;CRG)?Y2C/_T3W^R*9^9W+;E.7<E=W(:\6+P_L)AW<KWO\+4$L#!!0
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M058^R"'(RP?5$%27#YI T*1\T",$/98/>H*@I_)!4PB:E@^2,<HX)DBZP9I
M:T&NA<!K0;"%0&Q!LH7 ;$&TA4!M0;:%P&U!N(5 ;D&ZA<!N0;R%0&]%O95
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MB_J8S]H?O]-/4$L! A0#%     @ ,XFK5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  SB:M4EL_)
M6^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  SB:M4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #.)JU3@/H1O604  !46
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  SB:M42[&1W*P%  "=%0  &               @(&<#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ,XFK5#<R&8W[
M @  ,PH  !@              ("!?A,  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( #.)JU1N31TD?P4  /45   8              "
M@:\6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  SB:M4
M'V_ZE8,%  "9&0  &               @(%D'   >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ ,XFK5(J+G_8+"   AR(  !@
M     ("!'2(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M #.)JU0/6@N'#0L  "P;   8              " @5XJ  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  SB:M4AHH!:;8>  ""7@  &
M            @(&A-0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ ,XFK5,@0EZWO!   E0L  !@              ("!C50  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #.)JU1U(4Z_70D  +09
M   9              " @;)9  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ ,XFK5'D364[H @  :08  !D              ("!1F,
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  SB:M4TU9B
MB!L$   ?"@  &0              @(%E9@  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( #.)JU13F*WRL <  '(5   9
M  " @;=J  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M,XFK5)100;?,#@  P2D  !D              ("!GG(  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  SB:M4X3OJ>_(&  #*$   &0
M            @(&A@0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( #.)JU1SCMX; @<  &01   9              " @<J(  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ,XFK5!+M=OKK @
M&P8  !D              ("! Y   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  SB:M4]?%/T:X>  #(80  &0              @($E
MDP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #.)JU3J
M#*^*4P0  ) +   9              " @0JR  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ ,XFK5)VH/) 1 P  * <  !D
M     ("!E+8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #.)JU2M2'N2>0,  !<(   9              "
M@<S)  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ,XFK
M5&>:<'"< P  60L  !D              ("!?,T  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  SB:M44:T%"!("  "$!   &0
M        @(%/T0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( #.)JU30>[R:DP,  )P-   9              " @9C3  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ,XFK5+AC8P6) @  =P8
M !D              ("!8M<  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  SB:M4,V[$ 4P#  "3"0  &0              @($BV@
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #.)JU0_ .$3
MCP(  !$&   9              " @:7=  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ ,XFK5%SDDXA:!0  W18  !D
M ("!:^   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  S
MB:M4QPB,7/,"  #J!P  &0              @('\Y0  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #.)JU2/;*=EU@(  (4(   9
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M970S."YX;6Q02P$"% ,4    "  SB:M4^!5CK1L#  #9"0  &0
M    @($R^@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M #.)JU2MS0LR1 ,  %(*   9              " @83]  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ ,XFK5'X.^J47 P  :0D  !D
M             ("!_P ! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    "  SB:M4]M)>(Y@"   '!P  &0              @(%-! $ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #.)JU34V3<_U@(
M /P'   9              " @1P' 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ ,XFK5&!9_&JK!   GQ4  !D              ("!
M*0H! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  SB:M4
M/C/ (P4"   >!   &0              @($+#P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( #.)JU1?X;LU#00  *,4   9
M      " @4<1 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ ,XFK5"7QC9.?!   QQ8  !D              ("!BQ4! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  SB:M4_YK)PI("   B!@
M&0              @(%A&@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( #.)JU1CX[32I (  % &   9              " @2H= 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ,XFK5'69:\>B
M @  Q0<  !D              ("!!2 ! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    "  SB:M43]&:IQ@#  ",$0  #0
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:+GAM;%!+!08     .@ Z ,T/  !"+P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>114</ContextCount>
  <ElementCount>256</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Statements of Operations and Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Statements of Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity</Role>
      <ShortName>Condensed Statements of Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Presentation of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements</Role>
      <ShortName>Description of Business and Presentation of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Balance Sheet Account Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetail</Role>
      <ShortName>Balance Sheet Account Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Stockholders' Equity and Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlans</Role>
      <ShortName>Stockholders' Equity and Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossIncomePerShare</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Commitment &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingencies</Role>
      <ShortName>Commitment &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Out-License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/OutLicenseAgreement</Role>
      <ShortName>Out-License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Credit Facility Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreement</Role>
      <ShortName>Credit Facility Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Balance Sheet Account Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailTables</Role>
      <ShortName>Balance Sheet Account Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/BalanceSheetAccountDetail</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Stockholders' Equity and Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansTables</Role>
      <ShortName>Stockholders' Equity and Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlans</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/StockBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Net (Loss) Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossIncomePerShareTables</Role>
      <ShortName>Net (Loss) Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetLossIncomePerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Commitment &amp; Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesTables</Role>
      <ShortName>Commitment &amp; Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CommitmentContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2339307 - Disclosure - Credit Facility Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementTables</Role>
      <ShortName>Credit Facility Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CreditFacilityAgreement</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Use of Estimates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails</Role>
      <ShortName>Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Balance Sheet Account Detail - Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails</Role>
      <ShortName>Balance Sheet Account Detail - Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Balance Sheet Account Detail - Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Detail - Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Stockholders' Equity and Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity and Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Stockholders' Equity and Equity Incentive Plans - Shares Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails</Role>
      <ShortName>Stockholders' Equity and Equity Incentive Plans - Shares Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/StockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Net (Loss) Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossIncomePerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Net (Loss) Income Per Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Commitment &amp; Contingencies - Facility Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Facility Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Commitment &amp; Contingencies - Lease Asset and Liability Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Lease Asset and Liability Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Commitment &amp; Contingencies - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Commitment and Contingencies - Summary of Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitment and Contingencies - Summary of Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails</Role>
      <ShortName>Commitment &amp; Contingencies - In-License Agreement for Lotilaner (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Commitment &amp; Contingencies - Employment Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails</Role>
      <ShortName>Commitment &amp; Contingencies - Employment Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Out-License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/OutLicenseAgreementDetails</Role>
      <ShortName>Out-License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/OutLicenseAgreement</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Credit Facility Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementDetails</Role>
      <ShortName>Credit Facility Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/CreditFacilityAgreementTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails</Role>
      <ShortName>Credit Facility Agreement - Summary of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails</Role>
      <ShortName>Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tars-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tarsusrx.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tarsusrx.com/role/SubsequentEvent</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="tars-20220331.htm">tars-20220331.htm</File>
    <File>exhibit101-loanandsecurity.htm</File>
    <File>exhibit102-consultingagree.htm</File>
    <File>exhibit311-33122.htm</File>
    <File>exhibit312-33122.htm</File>
    <File>exhibit321-33122.htm</File>
    <File>exhibit322-33122.htm</File>
    <File>tars-20220331.xsd</File>
    <File>tars-20220331_cal.xml</File>
    <File>tars-20220331_def.xml</File>
    <File>tars-20220331_lab.xml</File>
    <File>tars-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="454">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tars-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 114,
   "dts": {
    "calculationLink": {
     "local": [
      "tars-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tars-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tars-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tars-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tars-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tars-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 397,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 5,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 10
   },
   "keyCustom": 37,
   "keyStandard": 219,
   "memberCustom": 22,
   "memberStandard": 25,
   "nsprefix": "tars",
   "nsuri": "http://tarsusrx.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://tarsusrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Stockholders' Equity and Equity Incentive Plans",
     "role": "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlans",
     "shortName": "Stockholders' Equity and Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Stock-Based Compensation",
     "role": "http://tarsusrx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Net (Loss) Income Per Share",
     "role": "http://tarsusrx.com/role/NetLossIncomePerShare",
     "shortName": "Net (Loss) Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Fair Value Measurements",
     "role": "http://tarsusrx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Commitment & Contingencies",
     "role": "http://tarsusrx.com/role/CommitmentContingencies",
     "shortName": "Commitment & Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Out-License Agreement",
     "role": "http://tarsusrx.com/role/OutLicenseAgreement",
     "shortName": "Out-License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Credit Facility Agreement",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreement",
     "shortName": "Credit Facility Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Subsequent Event",
     "role": "http://tarsusrx.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Policies)",
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Balance Sheet Account Detail (Tables)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailTables",
     "shortName": "Balance Sheet Account Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://tarsusrx.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Stockholders' Equity and Equity Incentive Plans (Tables)",
     "role": "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansTables",
     "shortName": "Stockholders' Equity and Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://tarsusrx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Net (Loss) Income Per Share (Tables)",
     "role": "http://tarsusrx.com/role/NetLossIncomePerShareTables",
     "shortName": "Net (Loss) Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tars:ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Commitment & Contingencies (Tables)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesTables",
     "shortName": "Commitment & Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tars:ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339307 - Disclosure - Credit Facility Agreement (Tables)",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementTables",
     "shortName": "Credit Facility Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business and Presentation of Financial Statements (Details)",
     "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails",
     "shortName": "Description of Business and Presentation of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates (Details)",
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
     "shortName": "Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepositAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Balance Sheet Account Detail - Other Assets (Details)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails",
     "shortName": "Balance Sheet Account Detail - Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepositAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Balance Sheet Account Detail - Other Long-Term Liabilities (Details)",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails",
     "shortName": "Balance Sheet Account Detail - Other Long-Term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Stockholders' Equity and Equity Incentive Plans - Additional Information (Details)",
     "role": "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails",
     "shortName": "Stockholders' Equity and Equity Incentive Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Stockholders' Equity and Equity Incentive Plans - Shares Reserved for Issuance (Details)",
     "role": "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails",
     "shortName": "Stockholders' Equity and Equity Incentive Plans - Shares Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "role": "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNetOfTax",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Net (Loss) Income Per Share (Details)",
     "role": "http://tarsusrx.com/role/NetLossIncomePerShareDetails",
     "shortName": "Net (Loss) Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Net (Loss) Income Per Share - Antidilutive Securities (Details)",
     "role": "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails",
     "shortName": "Net (Loss) Income Per Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Instruments Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i849ffd4d92344da1bec87e7d90d1b485_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:NumberOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "warrant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i849ffd4d92344da1bec87e7d90d1b485_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:NumberOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "warrant",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i849ffd4d92344da1bec87e7d90d1b485_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)",
     "role": "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails",
     "shortName": "Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i849ffd4d92344da1bec87e7d90d1b485_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Statements of Operations and Comprehensive (Loss) Income",
     "role": "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
     "shortName": "Condensed Statements of Operations and Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Commitment & Contingencies - Facility Leases (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails",
     "shortName": "Commitment & Contingencies - Facility Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Commitment & Contingencies - Lease Asset and Liability Accounts (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails",
     "shortName": "Commitment & Contingencies - Lease Asset and Liability Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Commitment & Contingencies - Lease Cost (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails",
     "shortName": "Commitment & Contingencies - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Commitment and Contingencies - Summary of Minimum Lease Payments (Details)",
     "role": "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails",
     "shortName": "Commitment and Contingencies - Summary of Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Commitment & Contingencies - In-License Agreement for Lotilaner (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
     "shortName": "Commitment & Contingencies - In-License Agreement for Lotilaner (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i3d8f8ea4259c4cda90b6fffc07aba79d_D20210401-20210430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "arrangement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Commitment & Contingencies - Employment Arrangements (Details)",
     "role": "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails",
     "shortName": "Commitment & Contingencies - Employment Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "tars:NumberOfEmploymentArrangementsWithExecutiveOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "arrangement",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Out-License Agreement (Details)",
     "role": "http://tarsusrx.com/role/OutLicenseAgreementDetails",
     "shortName": "Out-License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i92802321216247e484f937d0e0c27e93_D20210326-20210326",
      "decimals": "-5",
      "lang": "en-US",
      "name": "tars:CollaborativeArrangementMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Credit Facility Agreement (Details)",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
     "shortName": "Credit Facility Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icfd9f5a1ea4d4f129f6e78b3185fd367_D20220202-20220202",
      "decimals": null,
      "lang": "en-US",
      "name": "tars:LineOfCreditFacilityInterestOnlyPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Credit Facility Agreement - Summary of Interest Expense (Details)",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails",
     "shortName": "Credit Facility Agreement - Summary of Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)",
     "role": "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails",
     "shortName": "Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i7273965429d14abfa8d691f9d822bdae_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "ibc4893dbff5444e2a914be14ba1cb379_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Statements of Preferred Stock and Stockholders' Equity",
     "role": "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity",
     "shortName": "Condensed Statements of Preferred Stock and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "ibc4893dbff5444e2a914be14ba1cb379_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i1808d691f65a4626825a224635438903_I20220505",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Subsequent Event (Details)",
     "role": "http://tarsusrx.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "i1808d691f65a4626825a224635438903_I20220505",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNetOfTax",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Statements of Cash Flows",
     "role": "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Presentation of Financial Statements",
     "role": "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements",
     "shortName": "Description of Business and Presentation of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates",
     "role": "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates",
     "shortName": "Summary of Significant Accounting Policies and Use of Estimates",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Balance Sheet Account Detail",
     "role": "http://tarsusrx.com/role/BalanceSheetAccountDetail",
     "shortName": "Balance Sheet Account Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tars-20220331.htm",
      "contextRef": "icf7f8741b931466c871602b1ed804bb8_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 48,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tarsusrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r96",
      "r97",
      "r199",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r198",
      "r236",
      "r272",
      "r273",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r404",
      "r406",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r198",
      "r236",
      "r272",
      "r273",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r404",
      "r406",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r163",
      "r260",
      "r262",
      "r373",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r163",
      "r260",
      "r262",
      "r373",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r198",
      "r236",
      "r263",
      "r272",
      "r273",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r404",
      "r406",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r198",
      "r236",
      "r263",
      "r272",
      "r273",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r404",
      "r406",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r96",
      "r97",
      "r199",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_AccruedClinicalStudiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Studies, Current",
        "label": "Accrued Clinical Studies, Current",
        "terseLabel": "Accrued clinical studies"
       }
      }
     },
     "localname": "AccruedClinicalStudiesCurrent",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Share Price, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharePriceIssuedForServices",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Shares, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution (shares)"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversarySharesIssuedForServices",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services",
        "label": "Additional Stock To Be Issued On Eighteen Month Agreement Anniversary, Value, Issued for Services",
        "terseLabel": "Additional shares to be issued upon 18-month anniversary of contract execution, value"
       }
      }
     },
     "localname": "AdditionalStockToBeIssuedOnEighteenMonthAgreementAnniversaryValueIssuedForServices",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_ClinicalDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Development Milestones",
        "label": "Clinical Development Milestones [Member]",
        "terseLabel": "Clinical development milestones"
       }
      }
     },
     "localname": "ClinicalDevelopmentMilestonesMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ClinicalMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Milestones",
        "label": "Clinical Milestones [Member]",
        "terseLabel": "Clinical milestones"
       }
      }
     },
     "localname": "ClinicalMilestonesMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration",
        "label": "Collaboration [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CollaborativeArrangementMaximumMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment",
        "label": "Collaborative Arrangement, Maximum Milestone Payment",
        "terseLabel": "Maximum milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePayment",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CollaborativeArrangementMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment",
        "label": "Collaborative Arrangement, Milestone Payment",
        "terseLabel": "Milestone payment achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayment",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_CommercialAndSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Sales Milestones",
        "label": "Commercial And Sales Milestones [Member]",
        "terseLabel": "Commercial and sales milestones"
       }
      }
     },
     "localname": "CommercialAndSalesMilestonesMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase",
        "label": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Percentage Increase",
        "terseLabel": "Common stock reserved for issuance, increase percentage on first business day of each of next ten fiscal years"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualPercentageIncrease",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Annual Shares Increase",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Annual Shares Increase",
        "terseLabel": "Common stock, shares reserved for future issuance, annual shares increase (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualSharesIncrease",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant",
        "terseLabel": "Restricted stock units outstanding under 2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfRestrictedStockUnitsAvailableForFutureGrant",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant",
        "terseLabel": "Stock options reserved for future grant (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding",
        "terseLabel": "Stock options issued and outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockOptionsIssuedAndOutstanding",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan",
        "terseLabel": "Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CommonStockSharesSubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Subject To Repurchase",
        "label": "Common Stock, Shares Subject To Repurchase",
        "terseLabel": "Common stock, subject to repurchase (shares)"
       }
      }
     },
     "localname": "CommonStockSharesSubjectToRepurchase",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_CreditFacilityTrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche Five",
        "label": "Credit Facility, Tranche Five [Member]",
        "terseLabel": "Credit Facility, Tranche Five"
       }
      }
     },
     "localname": "CreditFacilityTrancheFiveMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CreditFacilityTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche Four",
        "label": "Credit Facility, Tranche Four [Member]",
        "terseLabel": "Credit Facility, Tranche Four"
       }
      }
     },
     "localname": "CreditFacilityTrancheFourMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CreditFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche One",
        "label": "Credit Facility, Tranche One [Member]",
        "terseLabel": "Credit Facility, Tranche One"
       }
      }
     },
     "localname": "CreditFacilityTrancheOneMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CreditFacilityTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche Three",
        "label": "Credit Facility, Tranche Three [Member]",
        "terseLabel": "Credit Facility, Tranche Three"
       }
      }
     },
     "localname": "CreditFacilityTrancheThreeMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_CreditFacilityTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche Two",
        "label": "Credit Facility, Tranche Two [Member]",
        "terseLabel": "Credit Facility, Tranche Two"
       }
      }
     },
     "localname": "CreditFacilityTrancheTwoMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_DeferredOfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Incurred But Not Yet Paid",
        "label": "Deferred Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Deferred offering costs included within \"accounts payable and accrued liabilities\""
       }
      }
     },
     "localname": "DeferredOfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_DevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone",
        "label": "Development And Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_DrugSupplyAgreementMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug Supply Agreement Milestone",
        "label": "Drug Supply Agreement Milestone [Member]",
        "terseLabel": "Drug Supply Agreement Milestone"
       }
      }
     },
     "localname": "DrugSupplyAgreementMilestoneMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ElancoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elanco",
        "label": "Elanco [Member]",
        "terseLabel": "Elanco"
       }
      }
     },
     "localname": "ElancoMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_EquityIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2016",
        "label": "Equity Incentive Plan 2016 [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2016Member",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2020",
        "label": "Equity Incentive Plan 2020 [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_EquitySecuritiesFVNINumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Number Of Shares",
        "label": "Equity Securities, FV-NI, Number Of Shares",
        "terseLabel": "Equity securities (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINumberOfShares",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_EquityWarrantRights": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Warrant Rights",
        "label": "Equity Warrant Rights",
        "terseLabel": "Equity warrant rights"
       }
      }
     },
     "localname": "EquityWarrantRights",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_EquityWarrantsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Warrants, Fair Value Disclosure",
        "label": "Equity Warrants, Fair Value Disclosure",
        "terseLabel": "Equity warrants in LianBio (included in \"other assets\")"
       }
      }
     },
     "localname": "EquityWarrantsFairValueDisclosure",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_IrvineOfficeAndFacilitiesLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Irvine Office And Facilities Lease",
        "label": "Irvine Office And Facilities Lease [Member]",
        "terseLabel": "Irvine office and laboratory facility"
       }
      }
     },
     "localname": "IrvineOfficeAndFacilitiesLeaseMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Irvine Office And Facilities, Office Suite And Space Lease",
        "label": "Irvine Office And Facilities, Office Suite And Space Lease [Member]",
        "terseLabel": "Irvine office and facilities, office suite and space lease"
       }
      }
     },
     "localname": "IrvineOfficeAndFacilitiesOfficeSuiteAndSpaceLeaseMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_LesseeOperatingLeaseNumberOfLeaseContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Lease Contracts",
        "label": "Lessee, Operating Lease, Number Of Lease Contracts",
        "terseLabel": "Number of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfLeaseContracts",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_LianBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LianBio",
        "label": "LianBio [Member]",
        "terseLabel": "LianBio"
       }
      }
     },
     "localname": "LianBioMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_LicenseAndCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaboration",
        "label": "License And Collaboration [Member]",
        "terseLabel": "License fees and Collaboration"
       }
      }
     },
     "localname": "LicenseAndCollaborationMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_LineOfCreditFacilityDrawDownIncrements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Draw Down Increments",
        "label": "Line of Credit Facility, Draw Down Increments",
        "terseLabel": "Increments to draw on credit facility at company's election"
       }
      }
     },
     "localname": "LineOfCreditFacilityDrawDownIncrements",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_LineOfCreditFacilityInterestOnlyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Interest Only Period",
        "label": "Line Of Credit Facility, Interest Only Period",
        "terseLabel": "Interest only period"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestOnlyPeriod",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_LineOfCreditFacilityInterestOnlyPeriodExtended": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Interest Only Period, Extended",
        "label": "Line of Credit Facility, Interest Only Period, Extended",
        "terseLabel": "Interest only period, extension"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestOnlyPeriodExtended",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_LineOfCreditFacilityPeriodicPaymentInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Periodic Payment, Interest Rate",
        "label": "Line of Credit Facility, Periodic Payment, Interest Rate",
        "terseLabel": "End of term charge, interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentInterestRate",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tars_NumberOfEmploymentArrangementsWithExecutiveOfficers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employment Arrangements With Executive Officers",
        "label": "Number Of Employment Arrangements With Executive Officers",
        "terseLabel": "Number of employment arrangements with executive officers"
       }
      }
     },
     "localname": "NumberOfEmploymentArrangementsWithExecutiveOfficers",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesEmploymentArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_NumberOfVestedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Vested Warrants",
        "label": "Number Of Vested Warrants",
        "terseLabel": "Number of vested warrants"
       }
      }
     },
     "localname": "NumberOfVestedWarrants",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_NumberOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants",
        "label": "Number Of Warrants",
        "terseLabel": "Number of warrants"
       }
      }
     },
     "localname": "NumberOfWarrants",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tars_OperatingLeaseNoncashExpense": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Noncash Expense",
        "label": "Operating Lease, Noncash Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseNoncashExpense",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_OperatingLeaseRightOfUseAssetLeaseTerminationExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right Of Use Asset, Lease Termination Expense",
        "label": "Operating Lease, Right Of Use Asset, Lease Termination Expense",
        "negatedLabel": "Expensing of \"operating lease right-of-use assets\" upon lease termination"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetLeaseTerminationExpense",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_PaymentsOfDeferredStockIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of Deferred Stock Issuance Costs",
        "label": "Payments of Deferred Stock Issuance Costs",
        "negatedTerseLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfDeferredStockIssuanceCosts",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_ProceedsFromEarlyExerciseOfStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Early Exercise Of Stock Options",
        "label": "Proceeds From Early Exercise Of Stock Options",
        "terseLabel": "Proceeds from exercise of vested stock options"
       }
      }
     },
     "localname": "ProceedsFromEarlyExerciseOfStockOptions",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Received on Transaction, Gross",
        "label": "Sale of Stock, Consideration Received on Transaction, Gross",
        "terseLabel": "Stock issued, gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales-Based Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Lease Asset and Liability Accounts",
        "label": "Schedule of Lease Asset and Liability Accounts [Table Text Block]",
        "terseLabel": "Lease asset and liability accounts"
       }
      }
     },
     "localname": "ScheduleOfLeaseAssetAndLiabilityAccountsTableTextBlock",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon All Other Separations",
        "terseLabel": "Exercise period from termination upon all other separations"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponAllOtherSeparations",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Death",
        "terseLabel": "Exercise period from termination upon death"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDeath",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period After Date Of Termination Upon Disability",
        "terseLabel": "Exercise period from termination upon disability"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterDateOfTerminationUponDisability",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tars_ShareBasedPaymentArrangementEarlyExercisedOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Early-Exercised Option",
        "label": "Share-based Payment Arrangement, Early-Exercised Option [Member]",
        "terseLabel": "Stock options early-exercised and unvested"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEarlyExercisedOptionMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested",
        "label": "Share-Based Payment Arrangement, Equity Instruments Other Than Options, Restricted Stock Units, Unvested [Member]",
        "terseLabel": "Restricted stock units\u2014unvested"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tars_StockIssuedDuringPeriodSharesLapseOfRepurchaseRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Lapse Of Repurchase Rights",
        "label": "Stock Issued During Period, Shares, Lapse Of Repurchase Rights",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLapseOfRepurchaseRights",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tars_StockIssuedDuringPeriodValueLapseOfRepurchaseRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Lapse Of Repurchase Rights",
        "label": "Stock Issued During Period, Value, Lapse Of Repurchase Rights",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to stock option exercises prior to vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLapseOfRepurchaseRights",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tars_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://tarsusrx.com/20220331",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and other accrued liabilities",
        "totalLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r8",
      "r32"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade accounts payable and other"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r166",
      "r167"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r14",
      "r377",
      "r391"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": {
     "auth_ref": [
      "r31",
      "r337"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of debt issuance costs.",
        "label": "Accumulated Amortization, Debt Issuance Costs",
        "terseLabel": "Accumulated amortization of debt issuance costs"
       }
      }
     },
     "localname": "AccumulatedAmortizationDeferredFinanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r174"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "(Less): Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r291",
      "r358"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r288",
      "r289",
      "r290",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r274",
      "r276",
      "r293",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Recognition of stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r276",
      "r286",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r68",
      "r79",
      "r218",
      "r335"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of End of Term Charge"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r63",
      "r79",
      "r218",
      "r337"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r79",
      "r218",
      "r228",
      "r229",
      "r337"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and accretion of long-term debt related costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of net income (loss) per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r146",
      "r155",
      "r161",
      "r170",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r306",
      "r308",
      "r324",
      "r356",
      "r358",
      "r375",
      "r390"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets:",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r44",
      "r94",
      "r170",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r306",
      "r308",
      "r324",
      "r356",
      "r358"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r277",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r99",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Presentation of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Additions of \"property and equipment, net\" included within \"accounts payable and other accrued liabilities\""
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r28",
      "r81"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r75",
      "r81",
      "r87"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash \u2014 end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash \u2014 beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r75",
      "r327"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r302",
      "r303",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Out-License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/OutLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "License agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r181",
      "r380",
      "r397"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r182",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment &amp; Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total shares of common stock reserved (in shares)",
        "totalLabel": "Total shares of common stock reserved (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails",
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansSharesReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity",
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r358"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 20,731,062 shares issued and 20,718,528 outstanding, which excludes 12,534 shares subject to repurchase at March\u00a031, 2022 (unaudited); 20,726,580 shares issued and 20,698,737 outstanding, which excludes 27,840 shares subject to repurchase at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r53",
      "r54",
      "r60",
      "r382",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r140",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r258",
      "r259",
      "r261"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r64",
      "r94",
      "r170",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r324"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of license fees and collaboration revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r212",
      "r219",
      "r220",
      "r222",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility Agreement"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r93",
      "r98",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r226",
      "r227",
      "r228",
      "r229",
      "r339",
      "r376",
      "r378",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r223",
      "r378",
      "r389"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal outstanding",
        "verboseLabel": "Term loan, gross (amount drawn)"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails",
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38",
      "r93",
      "r98",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r226",
      "r227",
      "r228",
      "r229",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r38",
      "r93",
      "r98",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221",
      "r226",
      "r227",
      "r228",
      "r229",
      "r250",
      "r253",
      "r254",
      "r255",
      "r335",
      "r336",
      "r339",
      "r340",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r208",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedTerseLabel": "Accretion of End of Term Charge"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "negatedTerseLabel": "Debt issuance costs (legal and other administrative fees)",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails",
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Employee stock option pre-vesting exercise liability, current portion"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Liability for early exercise of stock options"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Deposit Assets",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r79",
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r113",
      "r116",
      "r128",
      "r131",
      "r132",
      "r136",
      "r137",
      "r313",
      "r314",
      "r383",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) per share, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic EPS"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r116",
      "r128",
      "r131",
      "r132",
      "r136",
      "r137",
      "r313",
      "r314",
      "r383",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net (loss) income per share, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted EPS"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net (Loss) Income per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net (Loss) Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "negatedTerseLabel": "Change in fair value of equity warrants",
        "terseLabel": "Change in fair value of equity warrants"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options, unexercised\u2014vested and unvested"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails",
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r139",
      "r171",
      "r249",
      "r256",
      "r288",
      "r289",
      "r290",
      "r298",
      "r299",
      "r312",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r407",
      "r408",
      "r409",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Common stock in LianBio (included in \"marketable securities\")"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r169",
      "r401"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized loss on equity securities",
        "terseLabel": "Unrealized loss on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r317",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r317",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in fair value of equity warrants"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r315",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r315",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Financial instruments measured at fair value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r210",
      "r226",
      "r227",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r316",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r210",
      "r264",
      "r265",
      "r270",
      "r271",
      "r316",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r210",
      "r226",
      "r227",
      "r264",
      "r265",
      "r270",
      "r271",
      "r316",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r210",
      "r226",
      "r227",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r316",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Revaluation of equity warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r210",
      "r226",
      "r227",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r80",
      "r325",
      "r326"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Unrealized loss (gain) from transactions denominated in a foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedTerseLabel": "Loss on lease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails",
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails",
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r111",
      "r112",
      "r145",
      "r297",
      "r300",
      "r301",
      "r402"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Contract asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r132"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Common stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r68",
      "r216",
      "r225",
      "r228",
      "r229"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest expense related to term loan"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r70",
      "r217",
      "r228",
      "r229"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Interest expense for term loan"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementSummaryofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Summary of Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest (expense) income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r74",
      "r76",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "\"Interest expense\" paid in cash"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r36"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest, current"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of common stock pursuant to in-license agreement"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r353",
      "r355"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future contractual lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments, undiscounted"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remaining nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "(Less): Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r94",
      "r156",
      "r170",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r307",
      "r308",
      "r309",
      "r324",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r94",
      "r170",
      "r324",
      "r358",
      "r379",
      "r395"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r94",
      "r170",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r307",
      "r308",
      "r309",
      "r324",
      "r356",
      "r357",
      "r358"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "License fees"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, aggregate principal amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payment applied to interest.",
        "label": "Line of Credit Facility, Periodic Payment, Interest",
        "terseLabel": "End of term charge"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r209",
      "r224",
      "r226",
      "r227",
      "r378",
      "r392"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Term loan, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementBalancesofDebtDebtIssuanceCostsandAccumulatedAccretionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r35"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r50",
      "r52",
      "r57",
      "r59",
      "r80",
      "r94",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r111",
      "r112",
      "r125",
      "r146",
      "r154",
      "r157",
      "r160",
      "r162",
      "r170",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r314",
      "r324",
      "r381",
      "r398"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net (loss) income",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity",
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r113",
      "r114",
      "r127",
      "r132",
      "r146",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net (loss) income available to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r115",
      "r120",
      "r121",
      "r122",
      "r123",
      "r127",
      "r132"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net (loss) income available to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued or Effective Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing nonoperating income (expense).",
        "label": "Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r146",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "(Loss) income from operations before other (expense) income and income taxes"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r348",
      "r355"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease payments",
        "totalLabel": "Present value of operating lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails",
      "http://tarsusrx.com/role/CommitmentandContingenciesSummaryofMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailAccountsPayableandAccruedLiabilitiesDetails",
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails",
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails",
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseAssetandLiabilityAccountsDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r352",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Estimated incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r351",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesFacilityLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other long term assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherAssetsDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r65",
      "r79",
      "r172"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailOtherLongTermLiabilitiesDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other liabilities.",
        "label": "Other Liabilities [Table Text Block]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r277",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r358"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Draw on line of credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r173"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r175",
      "r358",
      "r386",
      "r396"
     ],
     "calculation": {
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails",
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment, net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r296",
      "r372",
      "r415"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r10",
      "r81",
      "r87",
      "r374",
      "r393"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r256",
      "r291",
      "r358",
      "r394",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/DescriptionofBusinessandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r171",
      "r288",
      "r289",
      "r290",
      "r298",
      "r299",
      "r312",
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r58",
      "r94",
      "r143",
      "r144",
      "r153",
      "r158",
      "r159",
      "r163",
      "r164",
      "r165",
      "r170",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r324",
      "r384"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Stock issued, net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Stock issued (shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Price per share (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/FairValueMeasurementsChangesinFairValueofEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Outstanding potentially dilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Balances of Debt, Debt Issuance Costs, and Accumulated Accretion"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Net (loss) income per share, basis and diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r276",
      "r285",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r276",
      "r285",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetailPropertyandEquipmentNetofAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r277",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r231",
      "r232",
      "r233",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Stock details"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating Segment"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service condition period for full vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "ESPP discount percentage from market price, beginning of purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r275",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r277",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock issued for license agreement, share price (usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Maximum contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r349",
      "r355"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies and Use of Estimates"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SummaryofSignificantAccountingPoliciesandUseofEstimates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r55",
      "r56",
      "r57",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r139",
      "r171",
      "r249",
      "r256",
      "r288",
      "r289",
      "r290",
      "r298",
      "r299",
      "r312",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r407",
      "r408",
      "r409",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r139",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares issued as consideration for in-license rights (shares)",
        "verboseLabel": "Common stock issued for license agreement (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r249",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon the vesting of restricted stock units (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r249",
      "r256",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of vested stock options (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "netLabel": "Stock issued for in-license agreements",
        "terseLabel": "Shares issued as consideration for in-license rights",
        "verboseLabel": "Common stock issued for license agreement, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/CondensedStatementsofCashFlows",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r249",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of vested stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r94",
      "r168",
      "r170",
      "r324",
      "r358"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets",
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity and Equity Incentive Plans"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/StockholdersEquityandEquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r334",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r334",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r334",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r334",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails",
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r359",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Account Detail"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/BalanceSheetAccountDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r184",
      "r188",
      "r189",
      "r190",
      "r193",
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofPreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesInLicenseAgreementforLotilanerDetails",
      "http://tarsusrx.com/role/OutLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r126",
      "r129",
      "r130"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "terseLabel": "Less: undistributed income allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "auth_ref": [
      "r124",
      "r126",
      "r129",
      "r130"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "terseLabel": "Less: undistributed income reallocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r350",
      "r355"
     ],
     "calculation": {
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CommitmentContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CreditFacilityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r132"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted (shares)",
        "totalLabel": "Diluted weighted average shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r113",
      "r132"
     ],
     "calculation": {
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "netLabel": "Basic weighted average shares outstanding (shares)",
        "terseLabel": "Weighted-average shares outstanding, basic (shares)",
        "verboseLabel": "Basic weighted average shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://tarsusrx.com/role/CondensedStatementsofOperationsandComprehensiveLossIncome",
      "http://tarsusrx.com/role/NetLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r416": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r417": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r418": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r419": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r421": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r422": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001819790-22-000023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001819790-22-000023-xbrl.zip
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M__J7O3>_XCE>C@@?>!I?'A&^[1,1OJ&S?^Y0&\KV:]QW4 : -HCX<)_M!@=
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M25P;%Y(*X*N"E"Y&I&,F.X,=0&40B <N]753,]-Q'A4QOA>+B;S@F>I[P>P
M<0"$=X/*III7.F?"B3L^F4NX&6SN*TE5R>8AK&L]ISWZ/;HN&W0%2GD*WP*_
MYJPN7.%"7=1I)&EH;)W^";R^C!/>:GODO105LCMN=&*@42^ZTM= 'D]4D8EV
MQQ8L9R&,BP3L!=(F)F;BR-<T0:/Z WI6D"9@UC ?Q W_!(P/DUHJ>B(>(MB6
M0-X]^(C"/YG +P<3.BJC-_O[OKRB0?XG>"O/Q^NVMT9;3J*>=LBEZB(I>7TX
M]49[>=Q%ZB"];NWB$;G<RZ')<P4T XLUZR))6$^/)#UR1#*CC *7:"HS'*GD
MF<(1R$0A8^)6XCG^ HH,I2M^P(&#]_DP&.UL;^\&&VHZY31)8'+S2J$A&VSO
MHCC=&@V$8LX.@H\'YZ<G'\Z19/A+G#W:1G.8DI!X,A,52'LGWV(D#W@G<+8;
MOE.G3-#=.I.2(H7 '#^\.SA<ZT0+*(J$"(C./Q*@EPJVWR>HEKXCZ<M^R)NR
MX3C@3:9REJ/9%-4I&0W'^"O>="3?.:'S? *:,.X3R5%B;K#--0QJ$N/(^C6,
MTKDW5BG0%]ZL4&*B!*;,;BD 81)U))UYEQQXE)'-)&;Q==X='5!ZH9&K^"6N
M]E%17P0'S+=I3/2^G'_<W-HQ49T*:U9F\II/G.I (_Y"V0B3)3;Z2(&EH+X\
M4_+,@F2^5,TO([0I2S;!(SBI8Y4&DS1*9KP%286^$=@2S'1F/TJ)AYC];+CI
M,U2>,=<;-.TYA<%IK&N\V]('FK653K#NW+Z-*K]@*YCG CS3FEFXG86J\L$0
M!2$'0Z[R)"8%#_6IO!Y78@Q$<GB8<TW@O>$1*2PN,$R%27Z>?<YO3!H8,U4%
M(A8S1M$'&$S0';C!8?Y$/ 5%,D,C1)$UGTCF-_F(@$Y5L!.<155=9)O;0'^X
M+N\/S[=V]U_O;KT9K<!0>!GVN<B.X@HUFK;PE'@42$Z0+F"Z85B7+B49\]>_
M[.[_FKME!^BJG<$!$Q$[+X 5Y76)3IPLOP[9%:4K.ES#8('FYY6$@.PZ^]^W
M^@K\T_J=K& ..R1SR)H >9=)#^6W@;>*RDO74Z1?SS%[NL>;J6)R&67N@HA7
M*I;,%WC*/+I!%UQH0\FRBA.P1D1!GERJR6>:!_N:>+1!:+-5"C2/R^MH'D1%
M$64\4[E[*LJI^H*SN5#V!:)23C+FR<@N2ER>+YA%-RAA4%)4[#D!)B'5)F0S
M7<&JP][9=*/2AO*9*;0*1#QJ"IJ^GV4/X>-YR9HY?ST[;ZT5(H%+SDM.F@N0
ML9O-:;M?O=&66MT=3/?[]8'1K^7'Z<7J'D9SGZ.=7V+F<+L^84=7)PRWMFXA
MTG74]$'FYAW)U"_8S8;DACX!,+L.0:GL",ZKV-3IR85@DFD-R/<S1%W.#3CU
M;#F& 1D&&49'X,ISK.4.1J/NH7 R0^--HZ(\- >HQ$^&T=I8J4=HO(L8%G0O
MW08F:%20G\:]$T4,RG@,$('M48H+A<HODZE1^3ARBPP-@X DJ>(5N&Y?AD:6
MYI//L)P<HFJK9/I[;5RF"=5^B7R(L@R,FRK7P54;(-'9KN+5).6KE'T,%[LN
M)-IJPID8762/6C.4BU8Q>Y')M9*!=@$T-*7AF\%BF-G3SWOBS%M,(S0G<"[L
MT\4'P7B4F* C1[&*=*38SD%E%]$%D6_6RG6DJ.I-@+ZHP/-%P0QB9P;TWJ@=
M)ZB\59<$Z\!N*+3MYJ ]EG+29DG%^67S>5Z VB6485Q3FBB $>@T_>06[Q/G
MXZGF7.#ELVB&O@;] -(VR-J,50DGA'2]+&(\"_U0&$LN'PNESCU*%2?J+ ?5
M53,;W&M.OB@OK1/*)E,:=RA<]^RNJ9<B;+2%]%&T^;;WW>CY:!J(H@^G9$JL
MMW0DR%A1RAAM,CJL864_JXK_RFKT"8'Y'9O$23KPH+#X>3_P7:,  $V6+"8J
MOBWQ4H[\M,:GN"Y5U^)T;!7G%3A71-([.5#L5Z W?!EW+PH=!?*?C97*Z"W]
M][83]U\?+#H8"(U4^,,6[C^W6%NNI&!WN+_7%P(V!N;;//_<H.+6-8O= 7))
M,,91)-8$^Q"7#D&!=+H YA1J12P,*)$ -CA'SY1K05?1%Q@ _4<4)N"1L BZ
MZ(Y],NA YXQTHCGRLVB<I)([@C1_:, +'*> 22&G>ZPS96*CY52^DZ:DAM7B
M.[DHHAD?DPIH[T+IM5+_KI,Y0P?E5(]#AB3Z 9(,L_&>@DR_81U?[])1=--6
MQN)(!^RHLHD<D/!="'21X6^T;R:H1U?KLBFT"5BE<) ZA#62'H]$[X"#$'Q*
MFI>2[JBIYREC@SVPZ ^C\K(MZ-!=)LX[I/:K*"7W%.4A)/!%3&G1RZ[-8T:Y
M7D8P_Y"=A4FF*P[;E TF7'$199(?1"Q1UWS*-ZTJ$RX_"386%)S<610T\(M(
M2MA5@J[1ODTLAW"R(L%"197Y<1YGRQGQ_&&.J'B*VXR_/85D1E61E2+5"B4*
M+4X]FYG*(.*_]RN1BG,L\ F]T366T=<.CON)HD&_0:'F\(_$E"D1E?A99[D2
M^PLD.9)S,N6[L@;MBFJ1"&[HYH$OOJ%KPZ)"0HB<E-H</5GX0XE)M*E.AD6U
MC?W@-"#YUCER.\&XD7;OL[!'Y55GA5KB*#O?[[']V7?!#O2 '8, PO?OKD71
M-2@/0O!X4G?BRPC&=3L1*9D2#/#@%/,*:L7^.4H\>OW*33SRJM8PT%\7-U[&
M"RB-LSJ]L"$<,J>6#<L\T5H_5HBGWQM+Q0UG53[YW-Y@]]<P^!&C$%LC9%8!
M*#:PWW/.\T!;63MK==U*\%P+]WWL$LD_E#D?QC#/=ND[GS;,G9 R3J<NE\P!
M4YB@RQ>,"7@32C(/C>]Z%V57H\KS54I2!SYE(^'ZD1-8J#&<72E3A@..I:X)
M)?N@TX+"VS:Z;=UKN7D;IT"EZ7CA4F![Y8+RDHLZ EE=*70/P6/SHN1JDTW&
MDF2'"=5K.6XC>2/X&B[GXBOSNNSQS<P+4P4,*V)V23R/\(*9X4JGBO.D-A)9
M,_M"96M=$;PLNLXZ\P+$H:.\B+THN7[@'^96UF*4<:WP1 .E.6_@I&\E-#<L
M(7;F%DE^'SNX<.9>_%^'?R:2S8HY%H1M06D!MFK"3QJ8W/HCA3_=WPV]6( 1
M="G8I /7+0SK!^*D(OP,O4O1!:)_5,$TK;$$6F>U>L\MG5<QFCW]X+_9O.",
M%#<'/ 3%_!JA+T.;IN86&3D'>!W$7:[T=7EFO2+>W.;$')ED[ /.&Q,^Q#DJ
MT]R"O;*YH3-RQ+F2HT</$\F$'3E0#\, 0>TLTB&>PTZI8&M08SPIL4T2BFN;
M6:?KUB1QS9[WD%$4"/&&'Z;^C04;$N/B:B>>.M(W17CLK+K'[.2AQ-2[WT"C
M_V(M#UA2N)[MYR)'#:6<[DLRJV=>J00,B]B0>(\1<^XT="28XE3F1;0U9BL[
M+_(<^&<$*WC[>:?;9!U<*F"W)Z75 DM1DJNJ9^POG,MTF=GBMT:J.3$ICKZY
M_._9??LO0VO2$/2_<]2D[4NZ+K!J/'/DR@6NMM8\G"B1=N3P@ D?E+QPQ*)]
M''QM/Q182%%I9.DLO[:1:IMP2# >A6J%L=I05C@ .H'*S@%*3T"'[#*@T+)Y
M0==UX W!V"FE(( LZT+X[A+QS<YVA#DGYC=;P,O[3]GO1"[V<\C%SVZ=F2F-
MZ,R>@2\/0,L#)N[  S%/(,VN6-KO\UWQ@0;B6T<RL5RHQ;'&6C,UXR FV%N(
M*EWBY3;0+AT><B!,Q#X/2OFSQ$EX./0;7U%DUWR!"H$J,,EU(@XJF<+SQVI?
M1GB@A<C1X>JSEZ0"VN&V$##>0-8 0J<XI0&]H<_C@<%RQT]CE<'F&Z&]L 3S
MN8.6+^,D<F*K.5?ZW/'73AY/71I8"[3K](4_^MN=8PTWL,MIG4I!7'?^(IQ,
M5,<<;BEV7BBN=488G3J@"U%EC<$:RX<KBPUN9D%30]0'E2% !34*<(QAR6,'
M^1HG7"<#=%9I4,P[Y[VZG/1^D] ,P58F#L);FY^[Z&\<*\0V14:G7D;"LMN,
MP]V5YA4""E3!!<0!#L'*GHV3*#39(*T263*_DJ[R7?NL9X[6O&0\VJ,:=P F
M2%6$[U13IP>>H#8I07FJ3#Z7M;/.+Q-0;3>I&\ Y6,4E\@8GW9ZZ 0Q"49IQ
M"*Q[H/RK>93$C<)['RX 45WU!6XTBE6#AED>P-D'GJ"B@FP!:09"@LEG23@:
M7(6856SW6OO]]E#6=P53W(2F;/C&F_Y5USM.%8&<0(#Y2ACH0/O'H.T47%WE
M>1(HY]PSM(QQKG@F+O*2^=)B^"0NAJ;C<WAV_?UEV%S'IR=G!VU5[W@V3_,;
MA6!Q%1B_9-Z>9(0 :H%[#!3"K@^%H"O1[PY#KEZY>REAXB9X=ELRMRK2M:VE
M_10('V9]^=KP0C\('B=&0I#N"X8_NMR6O(9=Y]U$/^:*G);D\VCS:A$9&:PK
MAC_G<.A1TAPZ9IJU&'@0=O[)\$DI3Y Z"(RHZ%<DM#*%:U1RMR]J2,+0Y)PS
MYK20<JH+*(PA^(:_)R"+!)@N)8RQC2_)U<#J*"; )#6>R'_$:'$L3Q^\AH2D
MZ:RC47($3]9]O=+Q;CH.3<<OC7G-]L$ZBT9;3?"3]87CG6X*$3P(1Z1-OLZ#
MC>V!&8I!!W@,JN_ M&<4A).;27J;JKSL0?K>3^Z[HP[^^FEXAL7U.8,^<'F^
MT_R,8Q@2H9V OL)[BO6WZ\R:I1>^$PF+_ X^5!:N]:D4M)GOJ)8%_N;B"<^5
MT4)!78NQ^^P)FO;+FI@VS3H*.NS3A^GFZW#PM]*TXA\'!Q]] K+@*0SJAJH$
M"UC*7.7.=JDR6?>W."E*6XG[8(#)1X3G>OT2-L1-5_(W)G%^T0&6SPGF,-F4
M)((83E/_6BI\8(X;:Y]>H7$1N//HO,;\G%)Q @FA<&@<?A?]8H,41$F5Q#"X
MY/EX'77N3A@(XEIIWQ-,)[B4AHB"\;LQVMX:8-D' WKH)P+?FXUKR5AP4.%N
M2U9"5SMV[<FQP(X*'=I92U2IVT@LTEA0)*W0@8HHMC@(^N1!V<,:O-(-O6(&
M3U$+Q@C5T%+!!9ONE'3FCL]%KAWFN-NTPM6R"V5VB#376,T84-#E[ZPK SN%
MB^9>EKOIKZ$&VE&,WAU,RC=]:1LD$,5X/N2%&+*2TBG)+O(05=I$Q#3&BK=4
M$,HRB8[MK;6413-@E_\++T>&]4'*)'MAO@@2J'X:C8]5#QIC&)=WBB_Z9O0K
MYN<75VCQO-GY-5RZW]TR3LGM6[7UYV8?&Q>#WG1'VQF.J-5?EF>;;OJFL[5$
MTW*>N9.,--:R^2U.6HXF)?)S2E9#*W,SI#&<FA,!)25SL>NDLI]EXY(/:V>^
MSV,'S[X9O(43ACD.WD43=CL> F^XN*_'&RQIW0RWP^.]+<UOT>EYH\%.M7L[
MX;9G!6.J$=_7T!V[PQ&<_S7\YZ*=Z^BVTTX7Z2KB<M-+,./L''4 K(*7SQ\1
MFT'_*'E-\HG5A1+A-D4D)!FFGN$9XRMF4?DYN,[-8*VG1Q9]KV1;GAMM8 DS
M91,#WU<:-+L,65!FZCI*2^V!LOG$K=$QFPY[\6(=<CY)R#-DD/V,9[!0%SFA
MF_D5\ZW1>)58 Z'[@(1+<FU1O1C74%,E/Y87HU!5&OAQ03<D\0AW39->#N>Q
MSK1;0.^WHJJ7;??& H#V!9"E?GBM R!^^1:>#^NVM/7ZH>QH;W6U<1M);Q26
M_>$KZO^\\>5Q4&=!_[QIH<V.20!.K-O>8&WHA'SFBPY4CVWPS?UDA6\*?BZ1
M)'6#.!*P6HS5)J0F%97D2N=CUG^I39HJ$,E 9KSQGP%YYY)YI;.+.':!]*ZA
M<).,6Q&1CLU=BB8>\/LM<+CF_0D/=W*9*)P'_(#F4!5(0!O_P\>\5Y7&:-$E
M>\RM\^*9ZT47G*:>'Z;^G*;=X=[K]6E:_C0UCY#6<-N'J(C(PVZ/D&C(=(;@
M09C RPE ?EDK52DX(3M, $VCZW&$"076F0#J4SDI, G<6DO:IJX9,9D&9Q@
MT*S@OXIC@[#,&!X#K=U6F+"[4+YG]]^EDDPSW15T@BN0IB9QQ/5^#>Q-J-[I
ML%]7IT\W+=TZF2S>D9D'V(BJNL:4F59LEJGE-D&N4V_,2QE2Q-C\G*,<Y-CF
M]-MV/V?;<(W:4=F:-TO=[C8%"SM<$RE%5YQI+5VKJ36':2;]R:4%Q /ABH]6
MY0P,<4&@:N)%&NWO_:05'>QS1YG_=/\!W?E0O-27''.Q_;3OD;NCN[UQ:)B@
MB6R.C7,XVWD]X1)9/:63UF-)2C<_]9IBN,UUJ7 $F!Q0BW0GI$/(;DHO>"UO
MLZ@KF]/4^%OO)'IR>M81?O:B'BVP 4'3_<Z[W_QWGI"OSK"MAJF%=C%)7R=@
MZ;6\#]K1S@$"9Y/<5Y7(7D40CO"A];Q;FFO>V4\3PU>Z_>:[QZ;Q=0#U6T$Z
M6UB^UZKP"\4_9C\;_YG^RO+T;B^0J?F;:@]37CCYFA4KMBO  GT9<ASST]H;
MA6K>!1 _1K(4M3NKBIJ<=02$& :7-W/<E(ENBE!B"N!,%][H#KJA[:5K4V]!
M[:]GXP(E+4)-7-V@;%>L^I+#W _DZAJ/*SC1H,<56)H!F@(;1H0JP"$PL# ,
M_"&.0/#8'CB&!A40<% B'RX;,/B(F,<G8&'"<PD>NU 5^V5=D .-R,>13)V'
MR'$Y:@W:>G<VWJFL/(UX?6SP^%;J]B.&3.=/Z=GL@8J!=F='DA6K:%)QKDM$
M'@(2]=V%ISQ#ON7@=9<PU/C8LP23!"7:#PHZG4MI,G9P^%MP4%>7>6%P_.CK
M1>99&7;K%/QU6RT*R7/QZ? P>,<XIG!&2+4T34MN@@4],$I[. 4N4[^UU8O(
M4Y)ERA;],%XFGEGX^8,?C"<'BHLLAW:! H6+@@TH8A"Z/-*>\IFB8K(V"C\B
M->B$=MUGMMV+5G>I7;<:ZJ;D/PAD&KMR.#"2;7@E$2.Q*=5U*G(,B9-S%7Y%
MTY08.#486( 0225D%F++=H&7(E9;8NPD>F+'>,K1<%P:EMZ.#VFJSK,B6V32
M.773NHU<1^*N,3E*'0%*9\+8&_??=5YQ#=/;-,_Q;2^"WX<?A[89JP,!;#.%
MZ5M)%Z8'>3>3TC75X(B("%IR#>=5!"*+L#_<XO<9@A^Q]6&NP YCQ60EG7A?
M"-5+ES:0@0I31(XIB["97F":N45RF20;8F,U6^- I='B%0P=W.A0:T8$-&WQ
MISNPI#V")K]QL\U6%7U&K Z<%:)HWAV\>+B5O\(8 R=PB$_*71,$MF*'./G&
MHYN%$J8C<<.Z['7ENB>^0RV5G <?:$ XM^01)J$0K'NB7/AS:REA&18UU6OZ
M[1;,5>^AH(]5'A0Y?D^S,+P$S8M2=W+P+Q3PH;QP\5WI^E4T;EB&!?0!^_X/
MP2(Z1V@+H@GV0?MLX$.F3!;1&47D;P(JHM4MJ_"\OL^I[1X,[R08C?9-"'*=
M+K1@#SKCLO?1/H*IB%>W:741L9Z #5UT2W7@'TD.&B(&E;2R4H@_=<,'P^K@
M(9C([D2,V+*=2H=5:8EIP 9;O3@[X-$(SCN_B5(T7?T$6&)(,]WKUDQ2DEL'
MG9GQ.GBT(3\2B+*L&XR.01]6B'6+=OC4L?8#&W2:1.FDEA*VJ&0M!TR;*B^D
M@2C0/>$OFCAHS("+4IZCP)Z)@9@N;IPB<%P!5-Q)CG+ZL^0I,>A@PQJ GW'A
M'1!$N\E2O)H3G"X%DHB;WUT/]WAGYFL:\[W8A*>N=K5-Q0F#MS%>XR35H:=<
M"CG=$JW.,@\ZTZY!S.6B9*I$^O2&C59+=/0L?7";[4:W>PF-RSQ$-+\[.EB%
MI^-%;':>;3INAE9K3.WR0,P8T'2QF'?Q+2 @#_-LRLU-(U*U;"AE?".I&1P_
M][1AB4"[6$8?)E5.[=KWL5W[]FC)#1QUX[<OS0F>?3>V]U[;W<#^7 M*58\4
M1GAUDN>Y!AK_,)V*,:M#70=LAXA/:1@X0X/&V,:/:'1R0DW6-"0[LM7J[Z4A
M&1\QOUU>N=S>;"_#(ONS,WQ.<,E,6H331<U%MKNE!]RK5\$[%0]!_%X,@]TW
M6_MO@HTS-:^&P?8>$O;6"./AIJ>SM?NI>1N:,])^CBV07&#W3&:&;( [PW70
M<&'0\.63HTMV3F9Y4:>J+0R1C4K'O]9]36VK0<-KA*Y.<>E'8)\6<U6>A1F&
M7Q!54[)M(OV#JWKIUI)S17[19P%'?69/>A\<"J9 I5GMHLM"Y[PUB%62Z]@C
MPMJCKRAGE[6XA<-NQ=B'0?7RL 0&E6,]+O*NVX<OX>Z*@I>B&]AYI2^H>S_1
M?)? ;/VNG!\@G:<2-7- =IK&E,U&<@%3J=D1-OI=:JS;X3%,^8]X.L. >Y"Z
M%S^_ ^O52]E#L28/&>0R07%YI,8-&\GD&'LPUU,-C4EW46R8O<)/G&U/(_Y"
M(;_),FJ%!YFTNDJ '_Y.GNW6FHEW"0./Z&$2?Q!'W3 +KTX9J]\F7#O*LB0A
M&WPF0B<@&(HH-2G;Q "IDB!RAIQAB@K:L3'E;R-882+9A:$'/4"O@- #KP5Z
MP 'ALN[G/_1PG Z.@<DQ9F:4$CO8D+8 \AFSS=&;P5 (CD.C*R[B:GCV'E(.
M*#2R7/& &PYAAI\4# F 85L0!##@8'$=_!*G?K]7^O3&I#=U+]L[0ZEZ)Q>J
M;?FCFYV[L#QNZ$RW%<<0LN]7090(/CG49!Q%AM=GO)'+8O2%+OJ*2@LE;KP"
MI<H2[@?4 AUQ&T3B 2ASB\?619^%AH%@"! - !</#" HN0(YG.J]#MW)9 ^\
M@_D%(9LFN@5OQ_/\GA?!M"ZJ2]/R@O+<BKPL-YWJ(_X"00%2G3JG=$&2OFR#
MTI$O\^LRQPX:VGLYL'5$NCVPKKM-1'EG-+F2W]X%:M%\K!/ZPB&#C7QAT^9!
ML"%(@TL.'-KN]"L\'<0D8E1K:5:_D&F$5_WP]T/:"UT&=HH$0/:1)=A5RC Y
M @.]UZ3DH:^40U04MM$U6!6A]@8;.R W)MA1-XX*%B ;+$&T20ETC9X^X=%4
ML%Z84+!;]Z3KQR@+E7NKZ+,A=[$(H ZA? G<X31?-7/;WON)3!"#GFC%I@5A
M:#\?'IZY63H#W9XUTN<D;)V<,/ .EH6<O9(XO4VE8 N9>^S<20;H*X/?2JE>
M:AU89[!E#KPYQH]@V+!CNC>2L*7N+D22ND=!^@.+=EYO=:6S+ 'GN\G ,>N"
M="Y(]XYEH^^R*?]#H<$JGTE):33&:V@)GJ'OI=J04'W*5.L7BE30'\K0Q=4>
M99!_D=(N.^I:V8V(ZI>;MWDF)E(P.M ^Z([^)4M20T?T_,7N='^V>C3<ZV0"
M]1SU@1\M>H*74,O*+R5@:ZL4S0_&9HZQP#L92TJX:.A7F-NFN\](M-[M#^GC
M.]L&*4;W;FL0<:[*)@[S!+.$33$+O &G62I."[#EI-3Q%2&Z3"?"9(:/,@ Y
M^'[3Y MGR^C:5<G>=.IJL4Y\KOE=F4^K:\3O-HI)XI:@&+!#F9- _[1>;' /
M!OE T=EU;I8(K:STT%SUYLR DM$^,ZAR.VB5.;E&A Z7 *O<6!:MT@6K;)^)
M^SR2J&]!-UU"6* CDE0U<7VO,H0@,YU"?[P:\V+Y('8  /PX"O>8D703]P.T
MOR4R9S:W]U='L/VAU]&N0"4V##!DXVF9VWVF\)ZKVUM$@J?F2/W?SA[)[)$P
MH#/7Z^M;8H^_7^O$D&]!][SJD>ZYLS?<(K[D@R[G?AU'LZBP!:X<W"ZKA-$5
MGJI*6#-48L,=XF'PL;J,TJG645VPG\AUJINP^2T"\$>1=9ZB["C0CR4#.]6X
M93P@*Z; 'I'@]G"+6"GKZS;(UM"J%F_UR%A(]]KLIT9F7*HSP$KU^2^](0*M
MSQ.J@,9 \@@@*H,TYTI20>ED/#?F%6[(#7F7 ,9V_:24ZTSVB:QL,AH@* 1D
M,Q764;NH>VTJ=I!6?RAK3Q3OQ>DAFK<LCI[X_,9%L]:E9RTP:ZHUNY4?(8&N
M BVVYX33'\&D>9*+-5VHJ09NT-E\@CPM#JND4ES>VAV?Z6IZUB(WR1& ;[%Z
M@/U?MG160RQ0!'H&"KTRY=$I@=Q@$70!&UEB#T*^!^ND/7VJ4:)C>9X!?*"Z
M->X>_,3 ;Z_ZD##::7$_:RSM!7+Y_IQ5&TC3N[=4M(0Z/7:'2]Y^?;CDD3GW
M$FV-UL$S'YDX&DBQ(G&Y."FHSXAKW(KMB7:' Y@%C-1/ZUHFH3JZT$W76UV[
M)3\1B,_Q+]^HJ+"%S+JFVHF0F+NYH3OBSEY&5Q3]"3#/@?%73!;(P>8V-5:!
M?VA449//I#XX^.M?=E[_&GS,<Q='A5W/$H#Y(\_C&_,CGR7THFL[GC,A+=))
M,(_FJK OE^4L?PC4<?$KHECSW@\%:4_>D9LZ.?G=)6>A,+ZOD(OD^5$K&\:C
M%DP19Z;: 4%VZ7U7*#%L3">?<2<I;KBDZV]U.U3*(%2#P&5^;I8IY2'9$><Y
MB'W'N.'.XD8MR1U0ZX7]Q#65WS4LZ!@8THL]K.RGL)B^4;#W_O!4':6V'<H8
MTHD@F)H>.R)H0DT',UT:9&,',6+ ><%(+^@OK%.$;/5S7G0NBX,5XZ$-V(9@
M!AM-]T3+86<3!#PT2?X&0XKS2RTH=]/HN]V+* 4^4] %8'0\M$U-'DYV"_8>
MCX'&NP]1K7?[GU'M31JSFB)9Z!<)L3Y!-Y)SYZSX.@C4IR"T"0*YC-<TT^SP
MFULKXQQQ]Z:J6+"CWXG*V)^MW#/A6;N33HX)&O"NWB@](*X68RZB;E#4\XH5
M0M!RBHLH,S4OJ-(!YYQ1$*5@K,0$/TBK"M FJM0DPF#-6/;ONIU4'CK=,<&,
MF5/X&*<0+AQ?\@47YR:TL/9TLL)]>,\C^M"704!?;2RE-T2\W<&.4,AJ,W@J
M-1=,NR1-I:!T#C(&6RXR#E(B)>I2(2JM7QTO& @F2U^<I*X)[/HR)ZL:Y>C!
M%%$B&13I[F28MFL,!&99C^=@AUT4T?P2,]@&#GP1*@54"^6^;R-YUB_'64G:
M:\]].+V,1B^F8&QJH=VC5WEZ)97/!"96B5!%AT_4Z <@:%9@"&8JKTM$TDHX
M@.VUM4'5S^JK.8&V, \UNBM7 -%S63^S'7NG)DW1J,6&&%V#3#]"+K,=>=,H
M<PI^=%F6J^<Z]E2+4[_-T01&_5//]7:"7Z>3/(:SCC3F^Y_Y%6=2]>C4[TG\
M?_&AAX-]I5+=RJ9<0I@\:7I'OQEZ#Z/Z[L["WF7J&CBR-%6+$=*D2B9>(613
M%Z!0/Z-'MRZ_X:[T)3>E[PC0VZY=;&1CU24^G'5Q%P7 :3+#3VLBK4=.+S"G
M.2*6KJM2 /6>S,7UXBFS/X399>X!8;:Z$"WO*!JY/2X;KJ+'8D:C;9)1#W)C
M[KX9KJ/ZPI/N4#$G^29RC%P7J6S:@(<#6@'?>YT''25- ^$B)%Q"@ V.*Z$5
M21IH"BMF1I-+57:!C@3;G8&9'/D;$'\J\_'F#2]2G47SR$-#K:Z2(6?*^ZD)
MH7:/6@RJA), &%47Q@$#;!9V7.3-2MIH!]CI89PF)7;=FE_">T4355<$5BNI
M7:NJ/^PY?^R14F9,L3]!G%8!>K;K@@WY349'0V+VZ+K(ZXM+*0'+RGHV,\XN
MQDR(O6XC W),(3*6N@!Q#F2<W*7<+71-.?/@7HUY77%O1=,7PTXNRS-J4%0B
MAAXVIC,?O%<C2,?)94; R:$4S=GC[OULD=_QP+EW,T)S/0?#LQITGDHW18S>
MVRGRZRKC]X!J2I$_9?#CCHDVAES83RD^3:FE#=[%H4*,4DC!(-*CXV\14;<Q
M&OAQP683=8KSD9T*$_]#HV>'KHR,.1K:D),<R-P>.(W7[S7^WAWCWS/M[M%B
MCQW MJ/1WG )Q^9*JN2WM_>$&ZV*'>$,%B2)XY?2U,RE8;(2XMRE4U\E\T[#
M<$')ZT,SOEH(I2^S+* _TD>G<W&GC58/Y&8_D*=&05B^[GT9A,QUDI:7I,5[
M_'7)>H>/DJSW_6B:?7+_Z<02I@-JW1%]04USJG2[IK*4X([VC%_D5ZJ@UIQH
M4U"#3?HU55?D/9*T,)0&-ZKR JB%X(U10*"40/U%GL? 8]!^&=^PDQU4'*X%
MH,@ Y7O'"9:/4(X:Y@K6".SMZW0"2V8<2K9->Q1C(7:%;B-8LRLEX*_XNDYJ
MMN/*SS]WME#"+APKB<3VOZZR1YDAVO')-,U91TAS:93,.)JDX'DQ!:!T\CY0
M,U![ ;HNP?W/%#9B22:(_!\514)HL AM <8-56F&00I#P+O%;K0V33XK S;_
M%=%^SD2@\H+8F%16!Y>>>-12K?,(D#DD@'4ZS5/J&O!$:K#/IRW#['WN0&\(
M5CM$F6 UW5 :WY]U?"'MV6(U :V*")C;JAO/Z20I0*=BK-)2Y+6HXQ;: 'U#
M[1PYH W2VU8DJ?NNL?4POP3/MC71)3>Z;#H8J9GQ4I&ZU[^:042%O\Z+SPY3
M0J\AT*4X<^J,X^?L@\Q V>.VVV5..>FF0[5EBCJ0CIV(0HVS2%7&S*>XH:%N
M%#9.8GP9L2TX4;4J@/>5P88TT,;L;=UD#%-G;K1/:,S\-.9,[8'_+*2F648M
MLKU'-N/]XQQ%@Q[_N6:'[7EK\E:[26;NF#YSX)TZ/CTY.R W6G:5%+G6R>A2
M=O'!V!571<SG"GZBMPN_8F6>HOYFG0KQ;?#*_C!+XT WW4*?$,]LX(-OF(0B
MKA>1<YN)EZLK955/!VM7E*.Q>N7Q<^,M<U#E$D&56P:6=)V^WL_,&TT6%KBL
M21_/"G/T+:CV/<S"H;.-\-'$0[ W&;$".?(DJL?R 7F%]$ JN3/2<GAV>!_G
M9E;8!:40XQ,YGVGAK=LQVU1Y?;?X\/C!^<KJ;/ONY^@/9?E6H^NFY_1P#9'
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MB!3=/U![++7ZD>E$3 2A2I&B1_M[/^FSN?%EX*1LCJ-4VS2^JNDBDQH$TN!
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M:Q-Q6ISK[MI*9I>\=>Q3QKO.U*0NG+J&=:;>T_*V%;&R#PZ(C*LOHN**>(=
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MV,$#V8IM%X"X_%JBG56B21X"#<(+94G4A4 _5O9.%E]H\N?>E/$=&&7>R8;
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M<K1E'_PJK7S)K,,$)#L&)H"E0O@=,!LL6N(Z!G&ED\;K)+VB623SFPPDP<5
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MN 00%/D+\G]F1K>GJ-!(GNXJ@!GWTET?C@7<OUJMO;[6:IT>?SP]/CM^?W[
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MP2$M?)7C\X+A'?])(^?6:X!1WH?,M8N$(=7$Y1@:CTOI^J/_8_ Q0\X"QWM
M:4JC0O]22*4YGPX.MET 4^4S)$#,U,00/R\R=1S8<+=IF07SIB9&<A"Q#D,'
MW105=@FH0GJC>VJK9=6.1ZK=>YEZB(A=:]<M.&KA$B;AHA:=8@%VG=P#S<9L
MVYAI>Z>C"\X'F.BFL&.P.Z<)?1(]=A+-HPF#<W=6^"\&*VQ[C).2].TN,^0
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M!!V/LY/:]_P:P?/%*M@?.5FVQNO&ED3+:R@M#(=I%1-;E0Q=4&X+&SH\?7<
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M97 #QER^+ .N>5<F!L%K"6SI'I-W>!!X9["2%X-K83O&_0AM!M$='4I*S9K
MJ($X1%O"_YM(XNQ],5$0$_T!#(N8^,".R/<<4'%]#Z2BE#;73&(NWH9W.,7(
M\65MX@61NG#IQUD<JV]!8.BMD/I&@A!%;_*"0EN:V8.?PWXGIZ7UR"MEBU!Z
MM?;T-K%$5II%>I/DJ;D]C[(J>0)&05$L&?[W)KIU\?KH;[N(,LY6>%05Z=DA
M;_#[J\-MDOP7MG-O(,NCIUPASN$@IEV%2_B(H/+URB \V^L+#[HZP9HAZ5;D
MC/GUQ$ZKN"%-7%BM9;Y:,/_;GI8TPJ*NQ3)5VG/GJG49CI#,_I9_Z/^N89 S
MY^!'(<<?%_E'8<J?B8*1N_XZ*KLZSP6@XZ8YA9PMV#'RT'HUIK[WU7@VVRJK
M_5NS?;3N3VGP<UBE#IG/0,CA?[-WKE$!KG2]_(8OJRL!2:+=K1YA5:XV$J;N
M_:GH# .V83)DO[30P-SQD -+LT4Y<&.U)^"$5.@#IA"^<#*2\?&I38MUN-I"
M-S=64CR9";>>8-U5^>..8.B7FH7PX=. L3_=UYY+$1$WV57$Y14H)HMX5:&9
M0SA/'!'QM!G^RS2G*MF:IF3D36@B\C:K-ZP)%K:$1+ 0$![GUX#C9\%LF4UA
M?(A2X?3$N+BA5$7.(]=L30:T&G!YO4\4M<2>!PDG4CE4?YV#93\YQC]RDZLL
M^8J%0<N2BF6^&,M[70OJQ 3UWQ5H,ISEPV"TO[=W8$B[)9O"B?X70M_"<1'2
MERYCV 9%4L[QJE5"&AB5[;\ )1<)UX?J'AAIFO$-F"6L=6&F*Y,B7$M54%'S
MR&L'OY/%HA_2PN(?5879&[00K-U)1K?H@DYB-];SKFR9\3LGI&O$7]C.^80J
M$6OY1OJ@@> B)J!&D- 2;F>]6SF;@7*(;:$4(7V<Q%.J[0[;@BOIT"8BX("C
MED@:\!TH0K']DT+U"5SJJ:V]IUD6H4V]D*1T2Y1/&Z!N(="/6DP$/Q-]W1Z9
M9 \RF+R>B/YC:T)YO(U5Z22'V(Z'4JG G:R'CZ5+[?OB@/MM='"-$[\.R&*3
MZA6Q\[K!X"ZMPNH.ZYQ,4@*<M*CBSA,1"H4(>A-<4D]%K_DZ/]X]Y"% #E"Y
MG";1(IHD5:L"3I!<OMR-CU0"FS-XB&A?X!Z&4Y24ZC\;KT(.T^BQ,JH QCW)
M34%(91R%]6'HY>->E824A9F(*F5 \)PG-!"Y_=K/^>=Y-3[-6OAFO!J]20]3
MKX8M.'0,9F<6M6;*?U'#[ANK'DS%@7:B395\A-<WJ@<_U[EJK\SQ-LF2^7).
M6*'-]?IO_ST,7L:P7;@201:\C5;!Z# ,]G;W]@.L7)<R^S*5@(T,NKEJKQB^
M@_4)/.L*FWUPZ=F\V%0Y%5S(.Q9-B+ WN5X]G9F]X=Y./-A<-62:FT$#!.@1
M/!E'WCW5B#%&D H38Q;\8W_W0;0X;?EN!P</K*OV>=EU;<*[KY*;B_6.^U.L
ME^N^W[77C:2*B*6,(#]4]%#NYHV6K02QRD8<)=S]&F5+]""/2*(?A#6T:HVO
M8%D9V)U-[9!#(=+[,B[F$D\#C9/K=K/+RRO=_8_1KCDU(7,F=V&:ZV8IV0-L
M/S"X%;/9*0+(12 II>0KH]U;SN_3Y\.G:^FRV]+T3@7L=GF\<X0)SG/1B-Y&
MQ<>X KE, 5]-P48/:D6D!)4ANV :6\QM>3EXF%#?WS65Y3]U_S,Z/2\>,P[<
M>F\,]WJKALN^Z]'&VQL>/N_>> _:,X=?>\]\(H:N;=.L%Y';[*;ISZX9O1@>
MLK@R$))94H#@F48K@QB>0Y/7P0ZL/E?R!AGUZS(U5RW5!9=M=@;B['V14U#K
M'-'JR]A$B*HBXHJIU741QT^XU06,(4=FH[*B4!0E-Q.$[:X-^I0W*%AE?S(7
M9-=[">35\CXO'(*=>YW#VT'B;@;TV>L-^VPXZ@^GBF"Y.KBX3R(W_YW5+XRS
M"FMOJ)2]'M@!EY_8'Q(ANHTSV!J3V*&T1B=J.TV\*1!A( RYPR0@.JC'QE##
M,U#LU(1^77P#"E *FW)&:+K2:I0&1*_U). Q\\HDFR%,1./E=_4=?<D>D--+
M1L;(YCT$33X%T_T\^LG<=+.=]E6RZ*(Q] %]QD0&/(LI@Y4BWU0=+#;Q(2[7
M;/PP?LTIS:#%D.PCY(U^07S(9NLU]X_GQ;K_-1AI<-SM?/L>*5A7R:)N*(;/
MC"_/>[3T'@2#$0X?H05KQUG,AQNIU!O(S1R$$P<OD#@,!BSI6J/D1\USON-Y
M GF3""%.> )>AWRZX R44K%ZCC/,B6%"ARZ7:3$WQR.-LRN$5SDCD]1X@=/<
M7N>&SBE[P !]-GS#>[9RT.^E6]<D&.M7>;,JL&/"4^TKK3]+:#JE?T@R37"S
MA/IH;,=9*9@7PY>*)VZ>.:DDEF\[*HK(",[[B0P:M0X1?:_%?L:K)E#M98Y)
M@@@;F7 7O2)%WMMI0]*J4<7P>[N"KZ>M+Y /MPC1U\5M?*LJSE[OR%S>@TK\
M1!/QWMGZ#L/@LG$L(KI'0;!)REM,NU&T"R^9ST->$5_G]+Z\O(:KN9%7AV]!
MOA 79@1GZT(*A04XO7J8FX0:62Z)@R+%N#IW@.%Q.*=:4R+)UMN2HT^. C[Z
MWGO6NO<N3HXO3]^=!<^'7RG@T=:-NYS YZ<__W(97+X+3L]^.[FX?#3"_ -?
M<'R;X=DV*#J71H87I*N[R8"\'%W)R'UM"@):+0>!$VL0KX@BLP4@K4-/\/F[
M;T.;[1?8!91V(&[D$&RKR5"A/U9SIN(_#)TS&=><OE3 )DP6S(_7NO5*51^-
M,]"Z_923R;JI=QK4 L38U;&MRP'5_&'RGXJW,\?AL8PW:LI465D#YHR43/A
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M BO<S%>BR.(.BX568+QJ"SJNGR8ZU$*-7C6)S $P6,(#)XM(]SPB1SA%VW7
M=*'+;00(3"&N:]61H>W9@S,+3+'13[\^]UY[R0B_#HV-3)7=#1'JX1H'XL57
M&ZA12E["6M\Z:3)!/,F2E&P!3,CU H:&P:223>R#4 6C8LL %%(:QL@N+:!(
MF^BS;[$O1:?[S=#/C'I3E@F3,'$FWBZK)0C%WPWP^5?TO5U24ML__W[P["?X
M0.ZP<[V?'AE5^2U27_2/DN9ES!HH9C,N*=YJE82ZL.80]5\**XA2#P)""0SS
MO*P"D(B3CW(#Q]!(/D<JPI1 _'EZ$\M5@0A%& AN%5&_\>]*':HF(B'![UMT
M/CL.#=8Q*/(F2@:IS'@-$KQDIX@J6UZX&">5%,O"FH08WG4;1Z _P@-%R4H*
M.R&4L.KTFRXX5M=7-J3N50O#L-#1\2_!N]?!RW?GY^]^/SD/@Z.?3\XN@Z.S
M5\'E+R?!FY.S5R?G%\'%^Y/CT]>GQT=OWOP1_'YT^MO)!?SFC^#\].=?+H/3
MR^#MT1_!+T>_G027[X++\].C-\'+/X)?/YS_@:WC+X^//ER<T!]4HB\,CM\<
MG;Z%?YV_N[AXHG^\^W!V>7(N?UW^<GK^*GA_='[Y!_\Z>'=.;;V#KIW+1SO'
M[]Z\P;)_OYV\^2/46 Q]=Z'1E^#HXN+D_/+D%79*APHC/3H]N[CD$8?><.$]
M\.?I>7!^@B/'QK&-TY_/3D[P2VCFH4_IV_3U8AI*C@:GL9=:OY(6ZYA*?;N>
M7?Y$\8DWN-BR#3780KM(@!!>=-A#BQ+_MM,6YY!9W0./B)/A(0?,>FE9-X&W
M8O)8-$<@J0WYM;I'K(9&55OYW:B'3*-Y=(4(2_0Y3*@<-\<!)NCK!X4BU'SX
MB9L^$ZK2CWI-11L:/DB)9AQZAW2$<IU_3#"EMJ9?K4F@\X4O_C5NAG[?"SVD
M1#IEH\^F.OV)-WY%-WZ73CH:H6U%\3VG=B&:FN)9B:B$HRMXR8Z0PP+G4S:P
M0Q5@):\U?#ET6B0W> .P."Y!>\5]J"CQB/H;>J&(XWS*AE1RDZ3!>]17IQCK
MU!$\W7\.QR5&&PB>GY/*@]<8^3?I*' 78B)*2GRZM0DHTKG Q$**RO-/2ZK,
M9F%=[V%(##;\E3JNWJ06R\\UBR\DL4M4;"^".5U.Q*J^NQ4)@M@/^"HDE1XC
M,MF$[U,, ^=D<CO7FF(*;1_6.L1MY4B^33K!'E)8NUG6<G(B3G*H'1WC8#)G
M*/2M.&)ZBN./)NI$_AJ&-BACBGO0=T-);(Z-N8_Q;N0/*]RPOUP9'#R\,?F)
MZSUEW+%R.R)0DB+S[!%KV*SU2'A=JN#<6/X.)QA,4[54 %ASLC;A;?T6$K)'
MO:EMJ@Y7$.JSF+*/8?U>QU@!W9+1%9B9S$ZK1;1:+_-G%@M0%(V3#)_V8#'$
M]01]YN@ JCA>'-_5,;& ,-X0Y%#1L+'!!I+<E4?1'*I 1<OBE=>/,/AP? S'
M-"HFU](KS)2A8$-9E>Q9$K<.B/ X3:,LSI>EZ3L1,VA)][![9LA_)LE4#^BC
M??TV,/=Y@;G.P[^AL[YPCM4=1P,V.V>V=4:"+6;A.,W)<'B%.ER+L\$+3%C'
MO4(%K9^=_-936*"DK+3P,,Q+RHU)ZB%=)!HHJ;4QD3:4BJ=!O^,\TJ"AF@[$
MFDN(>]"D5TK: Q,5.+G'][!:Q0.%-%7:_P53'\C((A FT#S<R2E.?#0/)45#
M7I<F8+=-(S-T9JDR'&<^XQ2'EX3* 2F5T!?-OI8F9:Y]5/HZXZ&3;8@OKB1\
M&WK+@:@8Q_M"G1)CD94,1ZF];QLX0("BUB>;T HZ:ZR$6C=)?,OA!R6H@U\]
M4MKVIO32J_[HI2#5R5N,RS".LH_%<E%APASEA8&10K1?^&=>7$699"*%+G*L
MA4F D:0Y\O'=YL5'V#LAY78*4C6T:J.$?%KV2]C8+<T3Z-[5AFG!\#\W&#PD
MRC2%8T_*@+.-F>"Z@D%#+X1A&K&R[.F4;Y-LR8(R)^#V. :#;N8FVMI$;O)T
MWK_!MUIJAY;:'S9_"PMPZ<^[4NF=W&FV92:8@$C@W'A>UL0Y)9,[.'.+LEP'
M6(6FD4O*+NE-^:)(X@JWM]NTLTG)#>)0++N(1_<1,38I$1M! \5'CFYZ[ZRQ
M\% 6$.;1($;9(-/IO'-Z(0%HG-0U,'I=9&TN[A'[ C>I8(-[@H[&%!'B-#G_
MHD[CK_R= <JZF<#-]?9O_VWSRHXH  [;.5UUN*,]?QXZI#O&@_AB]#GD8][0
M-EXLC)J$8J7;0I6)F/_,*5A-SL4&-[^DN#H<MTW6*P]>K"D@4T4$\T5B\SHE
MM<-G\+Z%T94YDTT3[VG.7O(D(V^*3S3<2K_A'R$%#>.D=2=$VW05S81U#IBC
M(.<$838D"I8*#/N6$:]MDF'6.UVIJ7+=,ND#?<;YF/A?\7R1YBLR/2D/"?\]
MO4G*G-EQJ?962+B(98;,I^ZG+EN1X!IX=EUCPC2'<J3KHN6 '-V@Q2212**Q
M2G%>BI@VE>&B*.T.-/CRE4H,3@<B0@_CU71E58L6:ALQ>\W+?9!\DR:Z192,
MO$'K$F'PI 4)#XN0+!+9(ARMZCI"*E.300<:1W(_O$H;+20Y,"YX/EI<&U;Y
MI&SWD]4;\_+]:0R.-%8&N^@J0LYX3G)PJH#,.D=F;;MDUK(\I0OR,HF<FN>P
M'*?)1.CA[KJ1QB!_44CR UY33L2OP1MAHVE>:C&R2$J#7I?,EG:32#U875*H
MH86GQ#FV& *G7$#_CHS*Q.0&E" O)UY_*S=YU9\!%'FH3V0>'9_#K\*[IWNY
MK;F<S&R""K:Q8$U!+'E.D%UPB!%55P/M0JJ->4Z'<BRN6Y&[#,PEOUFJ1,P(
MZ8IN5*%&%ZZ@MN@ ^SBV&\.94Z<8%*6Y8,P74WA8V_WND<@9C[67Y7(^%XIE
M&,$BC[-(Y'X;M8QK$?M+83W71)%("# 2A+1MQG77I#\D=;^(H'4<!SDC-%9.
M%R1NZ^!$"W*5^X&=UIFCKL&--XT-M*]]E:P[P!^E(PNLS[1#2CI>"+[B"ZS7
M+>NM7X;&9^'Y<UH>X.\Y1E%G9NQ(E>RN^./Y5XRQV>U881^7T'4,S'&/C*1P
M3$4O&[3>)9G8*Y/%64\M51Z'+F)(36HM<B-@.IJP=U'8D9;EO:]8ITV4U ^Z
M/#[]QD!A*;5/*EHI2F-3+QH1>4!KJ#S566EDCJ_-'*MN1(/,*WF7^92RH>T5
M<(?X1IF%%WDY4"VT=8VP"L,:[;4F.LNEQET+6[H;NF1:VJ%[UJ6;+U[]@'?>
MVJ ^6-W!%PBH_%+=:.*,EDN<4JYG>9KDWO5,XYOF@FV60.3*K=<K[.Y_NN]S
M"B<E[&>I:]OUJC%&3W0VVCR:DOB_2?*T@S'2)3.R@%MWZES*-'OAUU1S^<*R
M_7=1 -90T=OXRO<57W%0[FM%)3M8(]T(_;XA035E_$R)$%_(M/,Q=-6MVY"7
ML?=.QMYP_ZN3\<BI5C,+SHDNS<V]M\[%,O"+29:N*Z)V75&U-N?V\+F5J$J*
M9<A49@U4$%3Z&==,%W/;?9QMXI*!BUA=>4>B<#B.*E+!'+(KK53$A2GU.3UJ
M\!"V+!];&CS\'#2'96ESEEHS"^=QE(D#%E5(@;D<&=W*<$CH1PZW*D<)6&/'
M<#NM4ZA<\IP-(E&Y3EIE.Y5M%[:9\3)7W6S*UR!"$MKRXD6OD,?PDH-'E0.N
MP&NSO1_*'<;$-/>,1I*"*+N&>./KR]7%&F]XY9+XIK/L4BNEW+#IJC2@7P=*
M)2VY!9X2$SAFK$2)S&XP,3$R7RG7+]&>WB;0.65DY<@,&_):V*(TK@J?:\8R
M[W2^*11^GWH&]@(SMFH><ZX'J$/@,ZEOIC)>AJ'>[H]:LRGJT=2VC&,K^]ME
M?V\*4ZCLO[2( S[IYS%QRDN::+WBTC!XY[F\A#H:V0 [D+Y/@VB<W\2-^BQW
MIF$;?F;G;#+M2F2\J*[:W%'\4MD$HR5HK- ,YY8HR"(6^YLXAAW./MCNZ.OF
M[0T#5)</[73S,">B&%9.W%XS,"<39M PM?<0B4BNC*A4PZVU%M>.ZTH$D<)$
MQ)/KG!U,TWB>U4PNOBPPOO4RRCYJSF-9]R!)M(1JYI!O6\GQ(I%K<N%XC5 8
M06//[%@!<TR\*A%7(*$138PS _9A6S:\V0K[P_VF<32XEY"Y8]>T7JYP84B(
MB&9=2X1HSJ2F\9M!U=,WN0A@E:CS&(PO$WA73X,MC8?^,0NA8;>1CU9(G!VJ
M/E]H!+&V@AV*/L;,A;DNK@%[J4F?O-D+$'+L08D6"RQI)-7R'*HR;)LP2NA0
M% 6K@1W C&"\@-%+Z9=MS)T*AK[_2NBKF"6$/,UMUS"3;;6<\*ZS@-^Y<3B-
MU?$J=ZU@:#-1"=-\0WFQM"RX<ER:I:UV+0[7J>2BPZ:XME\MIJO#,L\=LZ1N
M4^/?HS40* ;/83G!(X[]0[HM\3 3\Q:E07"12CY>Q+5'3<V7R#UM/!H,Y(9M
MHJ.NEH;  A>UOE:A]JKF!Q0/+DF:^*YAVT+J%/L0G5A[C7Y619"KABP_F171
M$JN$LJ/G)EY%[H_4;WI+?EP2W^226UZ9Z-J*4X;JR4@=\X]<5!S%!?F-'IM:
MU3'CV#$-MZQ36%LH61*S8J&_7KP.H5F%D)=$YK\-5'3GB:@E@=NX,=4]7!8N
MJ F]\3ZR6 ,A- %Z,%C#UI/13D<E:X_2-&0 <RC&2\MEUQ4=@$U[#%?%)^>
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M%]^\?0<LC.O)KX^^8R_ZEDY /E!D9(31Z")NHX1:V^:_([/G9T1K[#D^!\G
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MG2?A<_$A99Z2B<1&/A%JEX(K[94*7AOUQ];O;X"^*=!0N\F:,J(JO-51D3P
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M=&L=2'R\"7\+#U@4*%A;Z+T2IOO:&L1YKC;PQ?--B0HJHA$2>AX1=MQ^2M-
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M%%EY%^Z?$&N<[685],'17$,0^*=7;R[>A6T)XN%+R=BT_?'D_-G3L_,CBGD
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ML)$@CV$Q7K)3*"@0K_H&F6FJ8F6K3CPWQC<+007<LI.K^B8V8MP^K*GSP*R
MC0U940T2!..M$^1') 3M9DW[1B>"G(&2+/NQ[Y<C"\&/JGQQMLS3N!!RMZ%R
M>C;V /;SK\!6>64P&\18\)$XKA[]J2C1B5#!40G-R[*?SCDA;MTIJ1K" 4NT
MPD.(&M0-Z0J>?1;1DM\L+I4IQ'S28I96/5[G1%.CFEL"*=?8>*1@(NE^L1 [
M'V+O9Q-+,4*%\>F/IV]/)W_Y][/G+_YZ]OC%Z8OSQTZ_*C=9AE/$S-);]MGJ
M1J2WFSN B(3W!Y\6\W:90O#JF;#\T'1 C$<C*QL8=K[2:%(F/%##V&EC=$#Z
MKMLA(,\M#L]XOD4O$(G@) 2"_,7@0$.0I/;I6ZW3PKL_YY)X!]F1.NM7&B-6
MN?VH[Y<58(WF)QY <AS/8N,)E]AAY_+@$&\+@MTW!,6A>)+G.O'.J>OQ,4Y5
M-@[6@(]39-\@0A^CRD>NQS^W0?40>OQML9".-S]K*O*XD8<$UZHK7NT3KO8R
MU7%G+V@'5[F>G7'"$$IUUI2T';K8'H]R<94W6^TUB@5%V8 DN[&9=$G=X?#H
M6990!:>C< V@<O\D5KZ_$JHEDVRA_OVDUW:6'\IFS0P+/W+0#?/"2+<'HX6_
M#O M/-!H(EY+K4NT;<+M!LQY$Z8FN%E CFK?*"$-44_0,F!>^.BT>5? P3=!
M6CO"&"DS"@0]NM4E9DV,CTRTK6IG3WD+%^P<\Z0W=P(Q/:D;ZNVQP9XAV1U/
M(:);LIQ0@Q<-Y] W3;$LD)ZOW=;S#_"Y*[ %847G<8EAC@A7GN4X(7^K9#+.
MB4;/4_GH%X[\N/?@$@C+\D78CMP!Q_$J1EF,6;P+F6C1L4>&^RXQ9X4Q:V@>
M U'X8$4TP(@>C+Q.JP<<E(#<:=AM1)R#S)( EJ@U+X_;D5(?Z-#CK!455YR1
M060/5$9I8D D) &SL=L!,&;$L,A$9]GGK,0'W\C!0I)/H@?=N]A8E]#CIIS/
MD=D7\IU=A;S86AH-FY'2^H9T@\9O7".12L\4>5-A\>=G^=*XM:,[JNZ;YOEJ
MWA$\9;1Q"T^Q@XV,&ER^X\* 9K6>&,#\0/4N831W[ZC/6&&28G[[2B%]+[\"
M2\HU%X6C^K9 ,QSK)D:1QXE\4.S0UE&S-M]L:^B6)TA '>5G%A/IMM0P PA*
MB*BX;.;=&BPYD.8D/'U+$TB+-YSAA*=$]/NL^^M@Y$'%\_P6B<\'>=U9L"V*
M:PO/-H26]34M0"3_094)O10JP^F>'L"-X]-EX\-%4J7H520 Z1BB0$U?2/V'
M X3J%ZP76(=^PB%C*T$U6MFV3 ROGW3KK-1^T5M^3W^]<#6'"O8&R[=V>(AL
M&*A'H,)6VRNPSG^PG6-UQ*!U\\J6Y5B; 8L:'^Q<H!D+Q=J)[17GN=9%(>#$
M%@B#+ Z$.R/N)"3V>TQ9NQNO29;-W=/)%M ?4V*_=B@P!S7D1\?#G]=4(58(
M,!/ ,%0T,>#SO6,W(JDNMT$+S_K/<*RZ53@A%\1WGH$S]Z_%L_MR;#R[*9K=
M%TF;X<47H=D]C-5-:7:?C(EF]_EWIPE[2W[[Y><N;2#T!3\R9K>'??-#\BR,
MV@0=(16E;QH)BBYHS3+X@=?U'/$.^693ER!:TU*4:INWPF;#W>NY&)FVA.(/
MB<A#S0E7LON#02X@->]?3[V3_BC\$T%W0=\'TKSLO?5&0"EW-:DHMP':!F$=
M8(<!@]"E$,K8PSG[0A!73OU00A[^F>S%+4/ L$/T#@<<@=X1"]*:6VJQ<1KE
M5# 40VWKL$_QHJ/D#&66@,7 HP!Z/=*IT RQB4&)8J]-ZOM+#YG=TB<0G1FF
M,"^)6BVNOD#MK.7/:+GQXZ0\CQ\(UA5-M&GV+/H<G7FR,M;(RU98.T(*=^E5
M)31ARA$TB_.*35"( D-(7!Q34H9!$FT7R"7H8!N'92@Y3N*L $%44-TG(H:+
MY1+\_F"3(A8TC+P+QX5^N X#6930SJP E,B\X/:BT+ID!2P/TFX4F7T!SE2B
M*2DL_YHL'M;A9,((3!U3;?*1D9&#*]C>K FK'38++HG5<#(K")=K8H!FH0EG
M"8M"XQ2@"[#Z3<PWXS566*H]9.SI&1)A-3)4@GJUF6O:6K2QIV9@*</F(HF'
M5"/& &D8-ZZOG"C\07&I\:I!YUF<XVBW>91KU/)!J@NP86W4 RUOY]P,%.>!
MNV:U6@I%6UPX+.L9-,VAGY9^)5$D9 85;C,7H<]<U5O=>)O40O>V:KR F1M%
M9ZPI?;(%:XGS:H$#:S--7A3<[1P#?+9,LGBVRK)2;FU,,LN0]*<#EHW&L/NL
M1"<,[G1G;-A*.G.;*NXN'[?8L>MMJ^*.<Y>G'!L*@ K(.\I2"';I*4J_55M0
M@$&6R+6+0F^N6I;-VC-:(B\-Q%2!&(@A@K+UD.O=U9>KGHF%?T*"H=BKVJX1
M2,1%D#T0-E<>$-HKK@-K^$2NO; Z@3;3MHC11+I?!E>WTCW$9$8WP?%M:VQ-
MIVV,X@%8=SP92L0%N^S=D@D)8=1LD>8 S=:6HOG!=X*A*SL0])+!D1OKIG\H
MM(1&E>*?QTUDN?L53U.S%8B$O>)T\DO%?-*%5MT9V %V#V89.) SSS?Y'.1^
MKC5ZKKZI&GKWDII@<.(6$F>>GD"M"T, 8A=L5O+2[%HNG-VF=:WNGH-%'I+-
M%2SP8#YPR[G?TF9X+2&;'XIEWJT>NAK@HVB,Q@N[.SL_*@5U>/TN9E/&L]&>
MZ8'9K-B4\&@U_%-M0*C'#;^JBMNTL<@<DIK>@PYS<9I*C!T6Q6"XDX6R!F.E
MIX2L*9)$)5-.PF'Z25@7,:6*H6'&1]%AOFS"MI]4Q67817(2(!"U[%:3==DR
M% Q)D0PU,%!;W*1NE^Y*-?S 7J)4.=V1#>E:VH7_4U-(+'F>/>YK%T6)-U*$
M!C_\%G1%NRAI2E0PEFX4X?."R[-"&^FAAQ:-BR+6*%MP@%+S%5M:>DMPB]DA
M$/)'LP=!I1$%=?1]F@00=CF(D[IVL'0?Q(5G\FRAWM-G Y !X-Q0P%U[U-YP
M.ONO:^7N$@H.?F4$73@>OW4+AB1@IINXZARO'-!A7=9(NE[)(?$>H)N]I9P9
MIXSSRQSL'E%0+<(\L#]C7VO!IS/]7<VV$B ;IT!2VG!&%^$J?+V//OO=?=B1
M+,DW:Q9Q&5EI9+A&3"!Y :_"!K !'",-D+>)8G@H/@TE]\&+9II=:W)]3;5N
MJ.O3'\5R@:(1VW(EJ21"H'*F57RIO5_P_JJ0- *'3J0<EZ&PV++Y)GCE4&M;
MHHC+T2SV$^I!"Q0]@#@#"+GH/#*..,H8;/10LFT#J.+K<@&&AE@KM#W[I2I@
M$)70S5*DA?JJ-E&N<G00J5"W?CAZ%_!IO62TB#S$*88!@N&3,([$,8O)3<')
M,Q>20(QNI_#Q95?Q2D7!G;(?A!)O;C+^), XXOF?:)P=R19C'!1M/($_A2,4
M_;YU?Z#$:QA)WM#^H W?F9. +O?OP+M=Y U&]182%E%_2%IZW7DPOWA/@+'W
MY1MAEPQ:1!!8X>AS>E-5%M R(*AT6\Q9Z9 VS9@-7!0M1<FI)7#&L3_!=606
M@,OB$(Y%.,+S-N%)<+'47Q+V,;,23<;JPZM19,_JRMK8!WF_(1-; R72SAU4
M7U5SJ)IB%IS\QO"%"W]P $>"Z^:T0FZ6 G_L(%A5.Q'N6"]XU#NHR;(^<!)[
M>4-H"YATZXT(=?@1@QKQ*UVL?L<[%'D0)+!XM242(QQB^8O.@Z4/OPI'&EJE
MK'0?J"\=EFBK* H7J15%P[6Q%O8J9#$U:&0,?-PUNA?-(\4O-^U@08#(E*A%
M >>BP;N6&.'0N+O#K#N-YP#M3+3M(*S1%BM#!?#@,)P$+L8$L*)S8WO@&^*C
M,_$4=)KJ<369=+#80!$#AMTM[T]FY *(:RF-JRVPO,/)W&O$JB.9R-.HV3;A
M2AS!?+=%\2&V&6'O%(T6-N4QE^8@I,4V.48KNP:_%CMZ8]VP=TF2 41GK$=M
MTB/G+#8[Q4DSPA#=57B\!GFFW;F[K>XZ;HU.$07WG1(48(TZF%<\VI[ U]]$
M8) %X,^W"@Z^Y6K>1;&N\"=VD.CDM1#_5+0K7 D!"@A0EX)A8Y(7A;]BG(#B
M"S$M!F/FAQ_W^:)BZ::[7U_6>X3=?GS:6R"-M>RCY:U+"+,!YX._N!5.XII^
M(O<OUT1"X+%W3 - (0*$;(LP\-&5.+.U"**DGF8LCUBF,WO2AM(J_9;D0F.=
M0UC_9);#*#1VOZTA\0RDU5(.TV]H/H4/I9Q-5/U8:R")Y\:5!+3@FVU3P#5H
M5LJ2;*%GTA?ENW.8Q6WI5C6U5UCD:_@4H "HJ/=7)IGV+$C"Q26G-]JNQ"Q'
M[[#C"25*"%6 ,( /)9*O:T1%A8"7Y+."G6^H!,TBX0!:4^"F7MCH9L%,+-F+
MU 0 ^O$!*0"%,+#6%7 $J?37_J G!@+T%^B*!!&5;W5@6B@"IE(_V2B9L:!Z
MJC8W[60/X1B&W,(?NR=V._/G9$?N4"%\_0"8A$\T42JP!LG'D5YHN^:ZU"Q.
M5)+S-P0)R([B!"$SATC!A&K^0Q'R7[8M[C&E\O@:OKS?)U$YB>$%*^1!I5P>
MRZSF*DR=1:7I=%]J)YOL[/'I>69] GR5VAL1>(5@VJ0\S474W35\&J)HUXF5
M8\GCD/$F?AXW;VE!($$A-39Q*=$2 F=/C#A36:Y_: UMP_*)7.<A R;=F2H5
M'I 8AE. .M_XE.$,:+)WQ]?$@PK3U!1V\(5CB!+FB:F!]_Q,9URFYO.WM'[Z
M]"NL93DY9HW2H%O*\R<P$7 D' -M4'2/ZN6C33V'PKYT\=F.3>;U[<Y+DL2+
MD!5 9(-R=1C/P:X,QS#R[5DPW!>19QNY$YH=%8+'92&]S:PX3FM2$]]AA KJ
M7 ^$2$Q@R)-31=[U8'+SK1\Y #.::T"3(9TJ2%;L@%(O(<>!P9UU6/2KU>U4
M7?H^HW#B)2H&I<!YE9=K#:B:TUTE2K'#2EG/@)3HU A+V;AOIKD-S_E85$'J
MN(\_,'K4FL1!I=HSU-8CMN_#'P= IHS]&''X[VG?IV700<;^P-8_S*Q.O%&/
M5"QBAA+&:_<H0L0 #>45,K,!S_NWA-C')L3N)5>.)$:^^*%$ @1+\")2P5%<
MI2ULM"$/"]*K!X"'@ED!7A,0%17+*_9SPU&]+NN5N@?S%1(MG"RP7D^C%L]
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MXDFU? 7^VF?&]DS6Y 9,S[HJ%.5Y8''Q9\TD?)V'\[>1'T['?@J1221>!/]
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MZXS88JLG2Q&OIU:(DB"2]_C.P^F_X"I2H!73?!%?C.2J] .S^/L=99!1?/E
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M4^SV!R^%50=_Q)#7*ZK%0CBH[9-45E*USOTTS4-P?<G@>[-?!]\3SM U2%#
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M-WV]%)\_1?(%Z )BL:)H5@?U5 RTDE_T48AIQAT]]"2&RG QL*%#7,L=^NV
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M6@NDT1J9X(#X.DM&E:VF.MJPU[<W!6NZX2#BD"1SUH:=@9.?MT.2^K2HO^O
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MH7R2!2:SW'.(Z-F9N,A'[(&[!48WQ$? 0S?HJUL:!;X..#3F()(!303_P8*
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M?C09+/,'#[4AOMDR3W.!<5TXB\I"H6B1:CX9Z@"QF@O(K;(?DKQ,YG(_)D+
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M'O!DNWZCP[A7-Z*8:&]SDF;O+B;ZYB:X_0+EV[L@/MO$8B%C20-WSGC0&H7
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MQIH>274\_]UJ.Z^;S4:SB0VDYQ2RFJA+J,\ V)5)NB&GD=1$LI[J+9S(8#+
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M40U(@#U/9N0JE5/!HDM6=M!0#A"1A-%2"2H'>J,\)32=D3PU*F=@+.@>*X$
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MB/OWQ9.2*U VX&'YQPN)\C_=:/B'YQ.^]G.&1;AP43Q8=*%]B!FI7>_RA5]
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M^'WLQ)YM@7R70AM8;7^0ZV1\BS.,86VH\TH0SYD"!S[ =Z8#<]9$G3!_B0)
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MA;-X'Y $=/:ATIF)TAF&B+IWP.'BU,>L]U-8VV3R!AJ":R\<=]:9()517/E
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M&;SD;3<:E T:7>*Z/7@KY'.:TF$_OCW[\$=H]@];]@1&L[)CRHO^N/J K#6
MO4%>N3-Z2/F\X>&10E&VP S).C4 Y1V$LP>/U&VA5+<W@W#SF-$+!M]]&"^0
M\V-ORGOWSDX821$Z8*Z\#EXJ]]B_Y]C<M?<>O0DY'!3];JL9BE*K0!L.;0C
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M+="2)2 AF\7'OY<V:DO+JUN-M>6E#YOSQ5I]>6%RM.I^2O7;ZK'U@U(5<J;
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MZXFQ/L4B]?VC_J"93IY:-V]/9-P$WM!K#IIPPUZII;$70W%XU.L?Y3R;0;>
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M)^NC40%'-U9;<R^:,046!4!LBY;MP:AOH0];H$_9+&20]?)(?.NO!70@NN5
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M(S!/,! DE+B3X(80@C3'#C$5=0J*Q$C"W"+#<H+<D"I:,)D<H4+IN%!Z(UC
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MG=W<Y2O1#:K$[Z>P3)=*4)TND=K^VE?!@[?:>914WGPP>8$,B TI9U.,@<#
MPL$RF7GR^*AL%0"96 B/C5C< \+5KAJ_CMZ3R^@]^.IP%)P9A806F5=(0"_8
M8@"SBX*")$TB8]M6HPIY/'Q-9POP@ 8EC1A/T&.FK=!8EWA>\G&J=9Z/YPMG
M(8QHJ(V.(QR]1=Q[AZSE$:G@A# 2;(Y@<XO<3-(RL6J=YV22A0JFXR<&9\N,
MC":::H\LEAQ@JBW2R3#$%-&:&&>BI'.+TI@)@NFL9UD/)T$>RP,>6M%SYJS/
M$TQ^5"&&\=FBF_4E18C8J4 0DRJ'&*A -G&,*,,@-" . ;NY14;GJ1Y7 :F)
MF?488_SA]2+^"68]*L2/%?'7V <5VN D)9(J3W>DD)"+EB,G'54))V/4<)Z3
MJ"=?$SB5RP)#\]O++ 3KMMO-0:[7.MP$+,,0&A\['C!3_'8FE*=I67G#MTT@
M24U_C[;6NX-8Z*=MT@\;\/NYCI;B&H>K^30LZ+C??-MIMOX]-^@=Q>M&\9+(
MESIA^;+ *SOX(#MXLVZF$C!6@8@0\P2\,!T5,!]&D!:"&FIT9C_9OERS@"^V
M+O;7U?$A0W2ECL^ECM>&96Y$XH089 E5B(.A0(8)A7QDF!DFI0_^3G6<=>]\
M<]#U!WO=%K"(?CEAHOXH=WD8G%1+H:>$T]RYNVF*O5[,'!)$/%_\UX_LVL?8
MV]RSO3@6%V2M_NZ6+0&'K2GU[:/MK?<V!SE7_+-M'<6+IX],':Y,W3U,W=:@
MMGS%U'T+[S_S\/<_K1W:^N;VNWA[_Z]6K?&)U.G&?JWAX9G;9'T%>NU+?I^_
M]FLK_^S!/>DVT2>U3U\52-(8(9&7P2">B^0:*QC")AE-K8HAZ1^/CW?HT:\%
MKRH]FE(]<D8F)XE$5$8@@!:&7?" +8K$2"D2Q22 'N$%,( W]Y.]\4-Q:'O%
MMRS?/XH[=:^?Y=Y_'K4K=:R_=#38Z_; ((?[154J77QV7<P;KU/K.(N2(V>I
M!EV4#ND(-LTHQ40*A'G+?V#3;M6K)QH6*[V:(KV25&!,(T5)8@QZQ0G8."P1
M?!!)1@.:-JQ  48N_W\/.V?/)3]1AFZMWS^ZKHRW)+-5>OCL>DAKW[^2D P5
MU"#AG,^[(X%]L]HB;!V,OM+;X";+OJT?#?H#V\F>5*53$ZI3D5*C& R7VK/\
M1T*6\9QDZ2+3*1BAV$-UZDE-5*53$Z]3VGN0M$@(.TP0Q]* 3H6 !%=@9GQ(
M0JF)LE/5L#?)ZI2DCQAL$9*..L05)4A3AI'D-&#N-"4VSBUVNC^G7?<@9D/E
M*YJE1@RK"EX8G,(.BIKM^;WA#"XC\T6V9.5I*]''MHN]*X?(3R;07GN>Y?AV
MS[T,ZC) 5*W(&!>:KR<[22%"% 9Y9BS T6!D+)%(NT"3L5+HP,:V(J/*D9Y8
M[(YO0]T*NT^&W6OSHU;K:"5Q0.^A2SDF% %94\AA10+WGC&L)Q&[SSHU^U+3
M>#DQH-MYS!S>V!RO85.JB9?Q87'[)ZSX$)CPVFG]_1JMK6P=P_OAVI=MMOWE
M<[NV\NET9V6O76]ODYW&&JX1>.>EKYP F"UAB$HA$><^()TWMG<VF*0EY\F1
M7YK &YNG52G1Q"N1E=H:HAE2*J=O,0NN51(<!6MCL%1CS.QSS-X]A<Y54RQ3
MHHBGM=VO6OB 731(,IX0%^#>6\PQ4BXY1P.5*?[(FCUM&+)2JBE5*L6"3CR@
M1!3/._=09+ .,$0*2Z,UD6:EHO@A$W>C^- $S-_=T,K;HIB51DZ,1I+ZTM?(
M@V"))*1,(CD_E2"K!48,<Z6=#YP)F35R7C$RCR6]3WQR4M3OSHF92@<G1@=9
M_=-7ZZ*U0D3DF5-YZ5).V;<&6>EYHE22D#.VL@X2/2_HS6IMER/B\\7WO:;?
M*^*Q;QT%4,QGUL:![?5OJN+FD=N/?M#H;L3#HY[?L_U8J>2$JN1Q;67[:T@&
M$Q$",@D#_:/8@DX"&Z36!>/!KY42E\OI!.-WVL3^4.K%H%OTSN5^UY3-;T<=
M>Q2:X)#^_D<Q,=Y*-81/MJ[6&_YK-(DG)AT*N0XWI\'F?$,,WG.DGGH75*YT
MF>TGE?/BEIIRCQ[#GT[_JC%\&I3P=/>KA2$[*1504(0B'@U#AGN,?* A.H:=
M\;940FDTD,F;:Y#'.(@_6AVK07S:=?*DMG+PE5'-2([<1(P%N-M4(,=M+IP5
MF>%2@VIFG53SFM]M%.\<Q,>>7_$:BEZ.*[_B$CA'$[351.S#L'8]B2(&8EG(
M.>042(0-#@%X,()?N9*1$FW=W.)-KEO5HYT5:(XK?:*"YF.A>;VTB]>"@>:A
MZ$S>8B<H!,ZI1Q[$)*SE+.DT6=!\!;5FEZ"EN9=MJSBTS8":G<+;PUQ)I2HU
M^]2[(9]W_4?H^;7.\K#?J_I2XS-"_F9=%2RYQ9$CQJP%?F!S0(Q[%(TWG+&D
MG,E<FLAY@MD$)6I529:3R1(J$#\'B*\S"<-Q,L*AH(Q'7#F/C.8*!2NY]#HI
M0DT&,9MGC]^N;UJS+5]F-^"C]E&Y?R6 )C5]\Y7M?//;L]"(/KPF?+INBC;B
MP$*+PJKM=:#;^I>DL3(41F65QF>5=F^&'HA/'JP/L KL\XX:!EF/#<(@67!\
MG!4QSBU*.6]NV:+O]RKT, .8_G5646%Z,C!]C6DDD[@P22 B>5D,GR&'<RD>
M'[B2V!.6<CA1SDMU,Z?H13#]K(797JP4?O_.DGM/LBWP%)JM%PAH7*Z#N%H*
MHS).XS-.![?,=3"&0U0H&4T0-R(O,E >B8@-DTEB@^W<(N%FGIA'%\M^$$2F
M*,KQ2C$_KOA'A?DGQOSU0KPL2AT5P#WEDEDRE\:W1B#)M$R4>H.E <R#EZ'8
MDV\$7@5%?F7OGC(Q[?X$YI[;%PP[]2T#*83ND6O%H80NR>[ZH9_:MTF;J_JO
ME^F:63'Y3[#[T5(G5 / $PX ITLW2)^WA'B+!<*6Y=BW4,@2^,1X9 %CPI3(
M&Z1H,L_UHR>PQHFC%PY256:T,J,3Q9PK,_JL9O0:CU8T*$^E1R!*!3P:S*@6
M2B#KB/+)429R8(\H/6_PF#>:>ADS6M+L-P,+-SW+ZH4_SMK<MKW=9F=(\?%5
M\^4C*']OW+ LG_)#7-)R:XT8"^M]MPW//LF%XCK= =Q]T"T&>[$?B_/%1AFC
M(7;Z\"DU.[;CFV64T YBN2',PM5\YDMO/GH<IPM*0),.N_UR/O]M+[;LH/DM
M_O&]&09[9V;BTH4C,>*+2ZP#U^AH</<ED]*K[Q"]EM]]Z<_<WM*D,*: 6#"I
MDM?<:F<P<9B51<JP K+QE=*YLXOV>F?O<&AW(W*]: ^03?"*;VWKNSWIS[VY
MJF^@;-=Z_GJGW=DU*3U9UPSU'FQLMV=+D0*(8R^?!6VR$].68J^7AZ)__5Q$
M"OS/#/FBFXJ\(U+&PI]O[.)MXG]11;WA.Y>*VEC:V-S:+#[^O;116UI>W6JL
M+2]]V)POUNK+=R/ZLBVC+V++;G^9Y?7ZRFI]<W6EV&PL-59KJ_7&9K'^KEC_
MN+JQU%A;KV\62_658GF]]G%C]6\X<^WS:O';A_7-S=_S"Z_75HL[WWE2WO&W
MK?/5GY/?UK4.C"+=([A'Z,_G15HQ1[?R<IDR1',8>V??VC":#_H/?Z7%/UWO
MS>)]-%7<H:CE@'TQY)04 3JH90_[\>W9AS]"LW_8LB=OFYWR-<N+_AC=?31.
MY0=<#XGEYPT/7UC?7)(H6^!11&[TY-'AA?+0-;XS/*;X@E+JSL-X@?SO'WMT
M9^\ /"M.S)GW?GV"%X01]WW]!QP3[.Z'_NC*GS96W^NV/XG.3D2FN[Z7BW<[
M9W]2]3+WZ:<AU%^FI^Z(6 .]B$4-SMOK%ZO .D)IQLK5_@4C\U?ZL%*0B3WS
MWO,VDZV..2I]GWT4?_JV]]D$<6:ZC#P$I5.?%;01O\7.4>S?9\/-J8'O@^=C
M'ZKL3[DA\,,;.::)X&$(WDR$LMX^T'QH^ARI*E*,_6G5UT?G^4[]K,A,3FY@
MC6TR3#/"/&>!.L&,#S$Y'U+T1G]=*>>("2;H?I/%9X9YTBO/G]2:9Q,9:WB]
ML0KWW6CM?-GBVXU/M+;_U]Y.>Y773UM[]?8:VUGQ)[65O=;%1,8_!^M?UNC.
M^WIK?>7@N+[_Z3NT4VR?OCNHG:Z=UK^LD9WVYV9M?_OF1$;[D]C>WSG8IEL<
MGDOK*W_!F[;V:U\^G=;V:V1[_W-[Y\O:27W_GU0[P:2<Q-C$\'T[;Z&7E!#:
MZH"D"1IQ1BVRFFOD!''!.<=XQ&,K/#]Y2P\J,S239DAPIDGBQ*KHN,/1L@2Z
M;(%7")XP2:49(F=FB/RJ&9K02=5IL47LFBVB@CKNJ4,FB8"XTP1ID022UCKC
M=631BKE%QN89N5GT?.JK/$P^[US.X6(WFDXJ>D-(3"L!K5:RCVPE3=QRE3=N
M,Y'GS#[!,(SV(3B-N7'L$92M,H?W-H?UY1O4S D:C.4"\2@XXE3G[8"(1%%8
MBZ-C7B0ZMP@$>X)6J%=E)L8,3N.\,H2(H"PP<6^E8M))BUW@\%M\!)&IP/D0
M<%[G*H#,D$ ,*!*I$-=1(:"7 6E'*=%!)\Q2+HS\:*(R>>4CRF>SR8CFW@ZP
MX9*)$4&9VA#90Y;%O])5:#ZII!4GSC#"I?1: ;:H(S$ =W'N,>&FRCS>WSQN
MWN N($D<) U(2FH1]S$AF[F+%R09$2(U%(^%NSQ(_Z>HSL4K!30U27F9$@=7
MGR?C#8":.:,$X\2:)*K S22@_3H9\@80S55 )%$-:'<::95$+F0C6)*8<V?*
MP UG-ZM<3"+@9WVZ>_TPYBA.9[>(QX=Y+O&53WQ/_JSW*Y_R7N[V!SD'O75I
MZKM,LO6O+B8YM86P'K)&#E,9F;#):<8#\XXD)@3#1@>GM5(/YO59?];3B Q4
MP_U#AON;<\;<>.^DQ,@K;1 W(2%GI40J.((#=UHZEH?["9JCJ2K5C1>@P?,$
M0/3)X<2M$RX2H:QTQ#&I3= /YNG7 %J1];&A]SI9C\XD#X)#BAN@Z)@Z9(G
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MNR$9G4$R97F<Q)*AA&&!F(XSQ#7)4*R=D;'BF*5L8VM9F:(M@+4 MCKO?0<
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MS1Q2,<-(6IU*9Z3C<GGLHC5@K*PP/P6[6"35K?3>17IG.04L5D:33"!+@FY
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MX$UEM7=* (A>/Q@SJWHNTHLX/*@7@692V)Z^; T[3\ZOWE5+L%.OP,EXO1J
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MI?.QNR!#*_QW$_[98I\\30Q.B,\.! 3 -$%29@)9Y1@H4X0F)%UB8% ;;?_
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M"N/_LCGL'5^^Y;!76N,N\H'L[GEM"K:XMQWL]_30]Q+[?3@X[ \^V7 VM ?
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M!:S-%$L(G"<;6_V>G?/\SP<M%J.9G[!VU\M?![9YSQ!<KG_IK4!-6A0<YUT
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M<N,"IHW43"8=>*M!L\]N)Z*U^MZ#62G+*B>CB3C[;NO(VO#000ARJP)X:[N
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M>XXQ >42A/R_OQYJ0>);9>0?ED(JL]U#]A$6\79C[#$%'5]"B"'S+2(]\\R
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MVO?7X.CXV$:QQF4P\^3+C1=,Z0[K'(Y-5)Z?9%'-=6K'IJIHS];K5;5SAQF
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M((%$!2R Q"KR2FH9,(K'GW!@U"."%1.3T+$4DEF6F+JT__QH_T5]K2HV57J
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M(=UT7)'R/$H#M$ 8$KD/4HGV6!*I$.(.$P%Q"@Q ;)7QB';XSN6CYBMH2V1
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M[F2TL@9?J;L8IF\E$<M19*Z&M&<$:7?DS#6DW2ND3?%@2)A14=7%"AI @Q5
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M<)X&U&4JQ%+#PP(976MX>!!XF*!G$00@<B0 !6TVNP8@"8, ,^&4D$3B%..
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M[E/YDV7IA_@$J-:26;9VNP/=N8O1ZMY2;Y<<A>===*JF8(L%Q3M3%(P&):3
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MC:(UBCYX>%!=A?/> 70B"-E9S(1T%,1_4G!?Q$[-(SDF*L3%Y$I9,[_62#6
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M.8)?Y_H&L."TUS,T,,A&JMC6?YH"RPR>?LY0K,$JBV(,EV>Y=3YFF -4F/^
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M9POKUL7Q]1EH] @V/22."'U"706BVO<4>,BNZR>^9*$,[["O;SE?5[J)L*,
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MJ$/ 2_(.CQ;LE2$+>.0$X/U1-P@CV^&AGS 1<"^._>"6U@9_$^M]=-:_V/?
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M!1.*;5M_38 V:LM4QPY[<!=66T-+%J\I#$,OEAKD60_AOY<YRAM">V)!P-5
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M"G2]-R<2,&ICTS_H4MJ.IE$:;F+'-BMK=GU,QD#6)&^0'%BG6+-6EW!3QRA
MJT=$V)!;Z%NS&,Q'7FK]N&)L-U@F($CPYBO]\8[W)PV(?L:]CW+IP&BGYN::
M%NL'"MP8_6!72/*<MZ4Y,7C$MH?4]%&WVV&A+=KD,I?VJ(YFH79B.,9+['H!
M4DX-YNASS5E(W9(ARD*J"XQ0KYV$\$H<P[AD5@;=>A2[.AH\'1&5@)NK$FIR
MH-G#,-G!OU?9A%\=4,?8CG<V)DT91'E%>O M=OX//A]?.^&DY4F$X5#!FN97
M'O%+X&!M.?%"M]"W3?]XRW.,X>(43;J(FFS!C[SFR!_\E+ W.M_(96.X3!P4
M=)9Y'%S#$IAEUFL7$/Y'_WQN)04Y0*T\T0[$B:1\EDU11,[=VD-WYP1C)9DY
MBGF165S-.X5@RF+3FA'>G-AKB?;!DO:H95;Y+]S)MV:'HW=ENF/<<'M6O+KX
M1JHVKG4Z4C?TH=Y ]?F;,JV\")90PN(@RQ*W:V;E6.DKG.?I*+($9E0UVK#<
M_OQ)X::H!?7_3>$*"[A!#FHXRC6!C$X0BH5CT5E'"[WR*)P%IP6;!-,Y-#U>
MS?,)FHD?T#$7IE4KI!"FXWT H9%O$QY5OEF_+QH5J0@PRP;EI_7#D?>+16,,
M>HF; -4^0+.KK$9>YO,C).VE@05$?QCD$2-&$CV H?N4RJEW.Y\7=*R1FX.9
M-S;P:"[,QS,'O[4P$?8BX!>\ID"?*MWCE ,RM%I2FH6'F" .O</]SL 8ID2\
MT'OGY4KILN&"\8YQ>E/KI/Z'Z4?^G[GWGEME:^/V!%3@#/8,AV[!=Z=:0]!G
MOMK6 N=VRW37O$\1S"'4O$(:1/U5P\DZTFQRS6&(9Z;Y.L%7SO]Y]GZW=^Q]
M@3D1*XP C>S\-^]\?N#XC1;#0!><3ZES,+JR>M9NZF;;AA:QJ-S@#5&Y9:H&
ML*L@%O$XB%6"IN98P^%1KPB4<<>)+Q*LE1I4:1P4@N9#0L80J0DJ-40BP\-A
M/7<)T@9Z"CL.L\-Q'3#C'C_O$EMQ)G25(LX^TRW)$9Z6A8RZD7Z?M74@O^,Z
MRLI-U$(:1S;$6GOL>@J+KWFJS 9/];$&Q1(51BOGDK6AIJ=<C #GQ88&(Q&2
MI!+N)8@.VXG!=[RO)AAM1),M+]3431OA&&[2[#MOG3")"B!4@?.2SI02ZQ@_
MIOO["J#0.4L-,*(4\U%BYM(3X!?7*A:^1#JFVBUBB@1JLFG'3CP&$7I0>&0(
M-,_<56)TI6!_SG3L ^\U:G=N.K?)X0I,8VJW1?M8(<5)[#-JG@SQE# Q97&5
MLHY_F6PR5)HPUW*2CF:C1?!=S6P6P4$,B5%K7$"SE=IY<.)*HKS8[_#Q>$=X
MAN'*HS=J_%BCDXS.*TY 6A.Z^8S<VOIU\QK[2?ZEK!''_G7FL!;A"2+S$]\,
M)EN8BGXTHY"6KRE[Y.#/LN&);T;KDQ7<)*(NU(HAN5'SE36M75G6RN(^ML@?
MB%4"&LII0RWU;S:OC&W.J7'JTKAVWG<C;-:5$EXX8YAOH%:]J)E98F"M5^3O
M*_A B($&%9D_9_Q/(\!/DJ0D4Y"S3PD7%/6ZN_]M K4$<>4 [2+ *M),A[8+
MYL6'4WR48V;W]IR8+DD_G+M_F*)1?KTO$2ZML$-K!HL V6M.T^Y: 3/"5;OZ
M?+?MENO.2*.M^_K;SV0$-QKZSS_FA6*PJ*((J?6CW&[M-TH'_,'I@ \V'5!U
MT_A?.C&P>3KJ&\'F#2\I.Y'E!,8;8=]QP6@WG%8#M.2@.L@0-R</%^.EV\SM
MUJ_]XS9SNQYC>9[,;>T(BL#I8XXNYB[%Y:>Y>JO_\@[N';#I9F^CA.9'7WHG
MCQ?9P,VG:BRP"^4E]#[^M9R+X^/.T?X CT:1P?]"_6(Y-1TZ-;\4X?SO]H\[
M_7Y_X:^[G=["WRU[;*_7.1@<WNNQRW^W/V@'>["W^-?N8W^APY#5M+3<S@5F
M\F(\Y_^U-=BJ$66\[4]_>+WJT4:T4?TD\B%\:(U[=)O\=QF'A1>T$559##.G
MXU7FQ.+Z/+.:,U>Z?&TW&R>(55@XU_G]Z^),MYH_FJ4W_/?^5DU!B<J!KV)3
MTRCT<+KO-FK]3J\PD5E9J5<M!H/Z'M.MM<$;C+;Y@\QVF8BL(!;XJ)>SI+W[
MZA81KI<O2+W]V\_6QNW\-@5(TA(>$>8[35ISH6@$H^_8UBL)=V6LHY%28/#?
M<<=A$9]GN[\*N.KM*LKDMLFNHDM>[3/N?)+&])^-.4F?'*QJ_3#=98Y=;P.T
MY)N?FJ$[,\*+K=/4!,+0? _<\;!Z=YSNG82M]LJZP+9G;G/.W&#@#WJ]]LBU
M1^[)IK;-9V[G.8[;2S<J3YMJ5!8:F/V[3;Q1<-;N>.T/CN^HSIKW^%'5V:HF
M[XO<H5[_KA=.NT-/NT-[O:/GVZ$'<M?HW8/#-5;6WZA#DBZRNI>6EJFO%@?<
MC+-W=_U]IT5X9D/UM>XJV'Q[@WZ[L2]N8[<'??_H>'!G:_YQ-_6EV_GG<W23
M/Q5&?IADU6,&=E_<"!_2RND=K_%1/<5FZ%6"7DU^^%"^ZJI!GK53GH/!QD?>
M7O8&]?S^\6&[1VN]1]NP20=[FQQ.7'\E_G4!F_;K"BWV^G[WJ(U=K?DF'8 Z
M:#=IO3=I>\_O'757U]EK&EY<:YW]MX5-#EZ7D7WH'^\=M#;<6N_1O@_;T^[1
M6N]1WS\\>D8Y>DA;>P/20O,-97[&UEX9,;PA1['K=^^L+^ZZ%!MD +ZT[055
M<]\,=+N]:[^]VWW_8/_HSL;_H^_L2\>);W]R&]4Q;[$MNY?6M,R>LBV7CODT
MDUG07XO@QR.A%3;T./>._?W^W?&,:Z.IGB*SO9E;V^O"1;3WP*B%=GO797NW
M!UV_/]A?/\E]\?"%QDOF<2 ,[IZL+49@LP?Y:D*J9U@_J_)B[NCZU'CW=<55
MMP>]@V?)NK;1NA5VYYX@VG9_GDQZ^G<W/-;(MEA_9<U&ACBM1F&3IGY=L(7!
M71%,;3;\J77!'>!+[>8\<?KX&;$DK\:P_C/)5!!3Z[4XS:FICK1,LGTG7IEU
MW3ONM];UNN[.2Z'J>-F[]&PR]&IL;&8[I$Z(0911+S8BLQ7E?4-]W8J?@BYL
MX+'K[]W!M6OMN4U0W>TNO1(9>F7L YSNE^#(ST>Q7UJ"\/ >(>XV\;O^^WJ/
MV&N[K>N_K0?':PC#>37.P&\J4>.HH 8N/XT5>Z'0QSN<SQ;0NC&[.NC=@0"E
MW==-V==![ZZ,12U4^6%6_C/X(=NQ"U=FQI#)-%-7X*I@B]7*[^]YZTMGA0%L
M0YB6V#'IUM8**QWEC:>3?<#U66L1W^XC!/0.Q0@/OC[/["ZT@M(*RHI0^,'A
M/<L_6V%IA>55"0L6%AST[LY)]/R"0H;E+]0'\M?-Z;&K.Z!\U-QRIQ5N.6FU
M8R/;&]-$]]-*I'G>39![;[J=?0^&$.,O= _=@KKY35+JYJ>JW?RHRS V88_@
MT1,XC04])RB*+!J6W#^T2.DQ(WA %HP*[)\-KU!YD6+O]1);GG*[]ZLH";SS
MLMC5(][.E5JSAN2?TT)YQX\\IJ4CV('%"@KO*@#W9:@4[%,9QS,/-FL:9-CL
M&_Z!3DZL"MBIX:RI+S3NF((%YBW+X0R 3Y3#2>6.\' P\G' ;>&EWS1L79*/
M8:?@W]^^['8'AHN1%$*.N_PI"I+?HI3.&#5?YO'HT<C31C E4AW46!F&N#55
M&9PU6)B1\M(A*!2N)MU:N;?X^LC:7R!'(#ZPH*/T,H$O>JA/<3JP#EL.?>5B
M0=S2 @-STCOBRLZ"U?*"3)E6\+R#$2PN' M)SUUC8V O'8W*S/?RJ1I%8]P&
M."UZ(^"]V]&.%4[8P-F$OE5.87R\[=/HFI)^(.#5K=6['JH8/.MLAGL=Y'DZ
MBNCA>MN],"@"^G!&7>SIY& C;UD<Y<,@8!3!Z"J",>/[\4F9NBQAE"D\5V9"
M4@"CN+R$V<V/V:=WP*/@6>[C_S/WIED:EB.X^8)8Y?9 4QLYK8:^J2R+\'6=
ME37^VMQDFBUUM1MMHX2LU[\S&RP<R%&F@IR5X9M>9[#R#5=5FG"B<CKP(&FA
M%M)I%L%#9BK(I-?\O&I%X=*'O"+(?%(K0ER1!1H=''*4;+A102+XO?B)^<L2
M3O5(J3!?66NNS7FM$$.^M\20WH<Z:\TF'-'Y*3E<EX:(IW8J]SK]QS^5YIUD
MH\%G8/E@ZEY8TOE,T@3N9+@>,F0,&H&0Y5HGSCT/(Z9QB9X"71E!X\&&+[.A
MB+U9]:/P[D+A[1T=^OO=KI=?P<!)"[-\3&#"L%OIZ#M^/&$X8 CGWWNS[QBG
M,%ZZ'\72X$')0R[4M%"3(5P+\.(NO'A7:XK@$I84QV9NAYUFD1Q[;^R&L(F*
M3_Y[D)0!7$'];N_8?:[>,AR^@HM9/X1&$Q1EENSV^<;4ZD%O1>[=J$PYIELZ
M'N>JP$.!"PO++*?$W)\X<+#6S+_SH@QGLETX;D?!R55J'P+GND3#KJ0MQB?A
M=N#%BO.TS^AV)$IC'F0N4_ZY?20L609JEX>ELCQ-$F5M.WJD[YP6VMG=(4\)
M3BTL'[W<E['W:N_%E27!\A18&NE,68LJ-]L.YH;^.YR+,,/(/BZ]ONA= 815
M@Y5&!L,-U)0N'>-)A8YQ@W7E8HY)JRWM>4-MV>\</8&VU.]LUI:L]F H/3,4
M\P50=0\F%CB_WM[JIS\OIVA6T_D?ECFL=IY[EUEZ4UPY2L_1*ZBRLE$D&P"3
M_ [J)]/W5T4GZ)DN%AS9V+U^YQ .U+MIFM-@W]+$84??W41A<241+O>+$J[J
MVJ\$PSR-RV+Q5]P#W:T&.;E)]3.=YT&WNCSN_U]E>C33X%+M#F$3ON\&8QCL
MVR"^"6;YUB_5.<($:VM:7XZ%DQR/'VV2O-9PAXFM_9:N2/P4C"E8F[%XH!/&
M_[7U_T2#P6%O,!H<'(Y'1WO!T?"XVQMV!P?[^Z'J'JI!^/\?;OWZC8)5<-)/
MX86*"@Z"7YMV<@/N"2Y;_J 1N9^=:N6-N1;.YU'%U5N@VSDTJO?F*@)E994T
M&'5Y))J+[2@AW9#GB4:SKJ 3 Z$@ %P/4>%]#$91C$4HZ@<8QOA[4.T?U3 3
M*Q O%-*GJ#9A#7=%?1I#FU\S;]OK4%FMQ@6,00P=*="4(=Y4:!9J.W+>XZO8
MUVZ\XRZC 2\9+.Q 1^?TP"J&^)6*X=&DIF@HL!IP8_ #R::/LKS0DZ!0(;BJ
M.YMG7KG@PS.&C'RK@ \W1GC^ E,H@$,/_P,KQ>XPN!CI#84.@TOX7<YV0D*'
M9*PR,HJ"'QBW4W : Y*?!C.*SAIY=6(-X2DHX;$9OA$.-,4M\A(=8'X4146'
M>+JY1+?CP1#EZ"GZ.H9,P90)ABQQ<NJ;AH7S*+P8CG0! X'_)NB[@?$4Y1WO
MXZI9"U^$#;-A(&S@_L)E"\^QJ%,8+Y\'<DW@B6F9DS]OYXSP(?+A\&LE#93\
M7!B?-B6?7PIN27N!"@IQQ2E"&$Q16KRO*H?5'ZU^]-=&AB]XW*S+9&H;*;\D
M,1B<B!(^;T.,&DP5C8XC\GQ[^/#C(2@M.+W)")P)N@E^,8%_]/!I.4:RMUD0
MX9DU(E3"*V(\PA1GE(S=)3EE()HYV-.4*<"(1G*9HK?"-CKX9Z,@O_+&H%+R
MNNMA24$[WLDB-4(B>!6$_!R*X.)?<%J@&3A?@:)WN-_I5N("CJM" [8%_OIB
MKWQ\LQ))%..^B"B_4Q(*7DTE1%)96"<%F)?#O( =XA 2GP2VDFA!=6B8%N?
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ML%'M>@8B(N0O4) ]*>(9>VI)JJ.<.OK);GHA&&!)07BX4AQDX'F!97X)$A;
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M&!4M:DRW.>J,F N^Y1'X ?T - /@_]%2A[E>2[LW(C 9!:#/R-'YBROTB5T
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ME(/,ULL!YZI^5JCW#XV.% 78?)B 8L06MA<GE%21,U(\]"Y3&*?N$HZ*Q03
MY=T6I.VS3D(KS=D81)+"SN*"@[+2[72<O78L@LJS,A%Z!"GIDKPXLH R _9.
M,]?^Q_?AF<9T%7786E4N28YWK>=05X]P AV,O02RS?DD^:*7\V$6##ZY$%K"
M6M3(,M3(_F+4R!T"20=;+=3D14)-GOZ<-IN\7TZ^?O/.SLC;[K\[__;[AZ_>
MV>>/YU__./EV=O[YWA'0X]LBH(?/&P'M=;Q/X&[''"M4: !O(%!=T+ZHF85U
M!ETS"_S%Z]&D V.:[]3.%PQ2JF+"4 R:?W332?LM<\==I['PY,Q]W^2+=4]+
M#%X@&&9$7<-T"%%WN>J WX\!CMB$%ZD%IN^A_77)MB)>])S&3$P"VH;R2W-1
M@>M,&12\EW)5%-QTEVU7'SL3PC?%_'&L'&TRHXFJF\\Q9#,J9MS%L-!])*^"
M;.*T,!MSEZU[IP2.^NLN$"<=S^TGMGG"<&+\KU#R<Q3T0&Q2<NF+)6D]A05E
M8^03X#K(CFMGP: J'J+DCJ*"7,%GPOL7'T[Q:4[BK[>GD^W2E@Z!3^S<Q>G-
M&@=3>GTL/J-6<U^%(056]KW3(I'B"4YS/N,I8GCBB_3H.S4]^A9.U3U\O;YS
M^'ZEKD9SWUL#.@!:G%/3=3HK+RO-(]&5 E6;7!97H)(X4ZSQ6G@N9SK2SB<'
M"]VD 22&DU'1<MLW\W-1L^)/.9E0AF2B65F&!JM"32K=MJ!3Q&J,A'Q!>TGR
M%.H)66MPN;@/L2\9K#*&%\^\;U]VNP.; D<8A6[2]UY-TE#]\,"LFH(>ANLA
M-U$F:OB;!V,%-QSVJ<,@5(#9X20DH PW*457%[R=-,$J+:RAP3:>3GO/H=L6
M-!UR9TD==)>2+**@P,C]-4RK5B=<?<!J;2;1*9.8/P-[;#?5E<[W8._V\WWK
M]YZR3A</^F^\7+S$W'$6$4A$82!KRW S=]'+XBK-*I4_W/=WR='"?<7H%OK<
M^#NJ\B#!J9]/LAXF'#,KI+LF'R?B*M'GR>!5FYJN7I43ZA/]C0)(N:*J8"J<
MJK;)1NGFZ C5G6 K38PNDAC#[L" LUG'.T_(:LLG%)& @Z1,O4K#ZSF+25U7
MZXVYM69 <)IFR&I8<+#[@BA&.=:2X82M)*A"1J&34:BNHGX3K$!*MZVMXQJG
M(^+B<?J)XNSB6.\>K##E&JL]3XUIAG*";:6+:#RC>SL8H5CR7^T*ZX!UTUFP
M(6TY#5P6K,P<7(TWUY_7J.9"B(2BO*:&<;&HM&B"*S4C\)HN'5*%;64.GQ,E
M:G2TCEG5#R4%KS@RBP/&"'5.S<@3UE_ZV2$N3SZZ4F&)L>EH;/HQ5SJO-QP;
M5(E"@<"#Y0[K875A6!!D?0P\G!6F'1O&T8V[82H(1[6%8_'0UX]M<5]]B42X
M\! R)!]N+NH\2MW!D65M(IA7':&K+1VG<4OF$])5W4X_8+>7O-8.U>'*QI]3
M8L+Y)@43\WQ<X@G6.U!9K\H!<B61!\37)(7CW%;M.5/0E4)M(9Y(M2S=&0:#
M4PNE"P-XI+(:,D8\I*&:*M+X#?W<*U.1@?KVXIN[[U#OFBLOF5L)Y[:;/VI4
M]&;/AQD^&-RFM(%4/NKT7$>5Y3FYD1[NPHV:#+&[<M/JYLXL$LXP M%S]$%Y
MU@N^5O]RJF9GR!1D] /N$:KDP)AZ&N;V!=FYO(&6&X-^JV^@N=:TH5@_\8KL
MMY7M/L>+UIMLO9X\F&!R#!VP**>D0L!$NPM-T*(Z.'0O,C"_\<)<HLOIUAK+
MM8?/%MEDJ#O8#G$1%24G0*J>'P'BL=";PAST',XXH$F*ZDQ)?:Z/"GNDAJG@
M==#>!1LF*5P]ACPOZ'/Z)O,&2TDW/UKB 66)\"#@R[2!SK-AP=!3J%DQMCUY
M@VF,R4%!<R,FQC</P1Q%;1?G#(%<FR)&JY]X28DNK<YB4*6KC@$-HQ1-]@DL
M1,GX66WG\('-2Z+'H:@-4NZ9+U*9[LCTZ:Z/2^(^L,#?R7<Q9EIFXD0R<T'8
M4QJRP'.FL>?XFPD'K/3Y6;#(B^]N78/++>&1[B$"Z09O7T^G C@S0::4F"12
M0PLJ[S?N""8:0^5S*:\HXUR.*3DE<%GX[@7FWB=U.<R:;!UBI];?\EE!L/I'
MG8%",'>OTNV2$_^%:-_K()MQO _.,+Q$\DW:LZP,'%?(?([Q /A.C'O(69WA
M/VX0(>P:&F.V8]@D\#FM)7,B"$"C.>O:/HAK2;-&RUWP9X'CB,*T PY'LJTN
MX4V$9!/W;>/M7J3NG8G%UXJ)(O20?(?EBF_1V515CC4MAN&F&2KK?0YGBWPA
M_*1INH(W($6M*F9675UK&W:QVEZJ9[5UH?5L_=N^P!45;A.%?E,!=T035TD'
M=?]!G/E$X>/!PX]G^NWD$\0VPO 1-=D/4HS^H@N&SDT0485(CF@/C:\@1=/@
MW+F*S]U8^,XT0AN/\H]64"FEW>! I,BH2CGFBH4DNLR>(O@:)9GG+JAO7)C#
MSMA8R&063;.F\Q=,;-Z]$&MTWM 4J)A0W.@W5Z[J2@0#:X4P][S@?))8L+IR
M]),^@D..!+"(\)E<,MEYV^WN!MJSD,IH\\P:P%SG>Y,NB"4T'D2QO*.,8]%D
ME,B=G7M7\*::8 @B@&-JAJ./4>-L@\#F< TSJK^,2+2&>$+!]$JB?_/MJLE6
M);2@9B!%63K-;<" @;=P9NB4-W]: U7TFTDE.!!8YYWV../YD^_A@T8<P4-;
M$'\%][M/4BYWO0$@<M[)ZCY> (+NF"?#47/E YYFX#!S\B@)-1O:TUHIL@0=
MU3WTQ(S6)>3LEBV*VXAF0!V9-@<!B!*79%ML.,%OF*@3<0#A)\5[LQ=B"\A8
M!L@X:&D\UF,LCX:M>!Y=;\W0L[&F7ZBD!N;#1NF<(46VH?2-29=H$5-R+)<_
M(5HS 9A%<\XQ!]P<@QZ-KAPV)&<?5P?(KHGP;L&USL^)L@;7TJ\X1$Z<9DXW
MN8&E2NB&3D?'^P#&/4Y %O#6Y]CXQ9*D /.SVJ^(J3VF&RD4"C&MF65UP'T8
M9FD0,FD?FY!X702TV)Q1(P/)!=RQ;TA6UMP-=4LTKQ8*XR'K.$G'^P.NJ91J
MS>WB,")9 F*:;I9N5G<A@LL (;,R6EX$"O<Z(1CQO2D(4W6$](&2%:9KEA[$
MD%0-Q0V-(1$,\=ZBT(%?@7W8 GRG? !#!!J&O<KZT +77#7SW!RCA-JLQ0U;
M,?!WL'%AOP^!Q,:;'03A")HSP9M,3+\"_[6>J5_15-LH*[D85\UOY6(5>%B)
M.H4S1I:=W&^,+J-(8\0-HUW_@J_DY'=R*,' =OFQ4:(SAU9K[")!#WJGTRFB
MIH=E%(?"&A$X'X,C?!DDHF)\-R/E\"XPA,BI'+:Z1F>JQ'.Y4?9PHEA4@]EZ
M84B2C2&)HFKI):F$A@@8&.0[2>51B[?4OEOG\QJC]9J@_>/[$YTN"C@>J,NH
MFY5[0[1=OX?*YQ:D!F[QW7#V^$!,FV414EMR.,?42:7)94I;VA1.N#%%X]\3
MK-RX4NR02C9L0>KLDDQ[ ;$ERE0\@CJ@:"TF_SD.JQV37'^>X/!JE1R;ZW+I
MY<;:<_'OJ7*$SE^BBT-IM=@KN3$I-'1O1E&2PG$BZ%DE3(.%67A408P%SX>0
M<8(??<,HTBE!("B5'B6E\2PX9JDK-H.Y5]P$$5TC5$HQIN6]S(*$ZE\HP;M@
M2".M99W49!+*>R11&6# I-BUDB,ZB)K*5*-S>M7FULE9'3499K,4;(V:4ZRC
M+A3"DVY/5#IJ4Y46WF5VL^.=)#:L:-XK-[?XG#@DGBE'.#@A*1&9)B%POL<I
M8?+ ,;W-W XY\ZYRL*Y)()(2M!0VZBFQ0A7,-&5(83GM3C>P0P )H_'GP0QT
M+S)'/0_91DIK%^MB/,!\-HT.K+\T&N0;QW=1N$AO*P>X)>5H<BIO'RPY]^O_
MYJR?\5FI/REU(9OFZJW^R[LPRD&'S-Y&"5VL]*5WXJZ*HXN>7+W'-HZ&?VV=
MO$Z7'3UI\2UOEE]WZ%>U?JO\NW[G^+B_\+?=3F_A[Y8]]7BO<]0]6NFQMS0F
MOU?_\6?SO(CT]>!=S1N\O:W]9LSN9MD=FKF)P(Q(Y@W],2'-1AC492=!8=4\
MUQAE*>I+BB>=?CT'&=9M\"I ACP2[TE_&?2@-'RJM-*@BB&#LTK498I>B.Z1
MAX/'A)%K7.%M-H'+W^F2,3\.CEG3()KVMKD]<*L$6B7P<I6 3FY). 23Z%@L
M6(46B&T]9U.356(_EA!!)SX5J6.9&E2PY1A?2(1CAK/1AG,&[1)W)":NU?!*
MLI<I2X$&%X,LZT]O);N5[%<MV:O#IZAY#?U8K8 H<?SY!T:5!$-X=IJ8(=:0
MQ^!-3MH+NQ7KURW62T6/A#9'H*%(F4"'ABDU:L#H4@%V=D[>.$975*.XYF4^
M):*QC.SS*"'J1"VPIAX!(T^Z&S 3FE2P\0DHCQH'00749"(X+/R(RPFY&D!X
M3RJV04 U,10U_3$E@C%$.">.'W*E@AC?@65AK9IHU<2K5A,/H!0H"\B1_/]!
MU6"YE:@#]B4_75>GH8S/H?#(3G># K7?HP]NJ]1T&M1J(P+(J P9]ES; 3X'
MDF],_?F0O?5DW!"D+<USX@O.8VLQ9AV@KF@JRK!PRJ@I;-OJG5;OM'K']0.P
M;Y2@1APQHA2? 6HN@E<002@E"9VO.GABAG>W/G\K?:WTT>R862UO+'!9[O^#
M-.E& TV1NDH2GVUODPXTWH*#>Y5W<K.H&YOZ=J];VVN>&N5Q619;&9CQNXER
MBTDP1&CCDIR$5M);27_UDL[P)!28?U.?I64P'RU5!B.7F]J8F1NAN[/6 -?"
M)@L8B:]E5<SYH=+L&*W4ME+[JJ5VB2@1L @Q['DD=;;(ELKE&8[XE@FS(*/3
M>Q5@_0J,!/S44>X31@BOTP6NNO^SD<)%D4%6%:UPM\+]JH5[25$M$>R"M#BD
MWAIM:JF/FQ+=2"\7!S=<(F"OUE;66EEK9:U9UIPK"G-.81;<2'F1C06/.2S-
M5#T9EG6DY&SF(';:#4V(UAOD GXVI%NRE;I6ZEZUU.D(4+443R@'G30.IU[.
MC/')%B8.XCVR46YOG7U^O[7C4#)2.'C>,FX%KA6X5N!FWB0-H_&,>14J%"&S
M^4I?E*(BA0&VPM,*SZL6GN(JRL)=IJJGYB3"NC:',I[="DXB3F#=O8B?A!3=
MZ3"6ZTWS+48.!^\$';S,MQ=C*Y&M1+YJB6SBQ@83$?X:Y0X3FF7:9N*$Z32&
MGU/+]V:W3[<;,X] Z5,!%G6/RQ@E4+,;Y$I]I]JEF%NS.81JPR@E[$\CY?==
M!V);&FI^'S,[:9RVNC+0N]22[&S].CAL27;68RR/2++3WGWMW?=2[[[Y:EOA
M6R("'&&M.#W_Y]G[W=ZQ!^,,U20:N;!ZL57SJ0!8I9LBQS+'BYDO"$HS+1:0
M_L_C WRF8,AUFZ//[T_@9]SL!O]]]OF]OA$=DE:XS;-"DR_6LQEC\Q:7'8FI
M2KBZ!Y_16LFMIF@UA:LIJMQ'\WH#11LKW>MJ0U?L"E!H=(5A66(2(1;@ +EL
M,TV_C7D21_@#2X4-+G(Z4]PY@Q#[TG^9'ANIS(PEBF,DY&*7UWQ?M WR-<T6
M?C5.A;<NT>'B2V0E2R@\_.\R0"89S)_6<S3@P!."D!?B)LV^$T=ZY\[6]<8S
M]EMR0,/TO'+EI;3_DH*'9611LY2(8]-<658=0T2+L1$\+009C1K("IL;7JR.
M.:L/U;^-DC#ECUIN0D.\+$V<J!LW-H/*<0+ZM_JYT@F[QH4HS'4WJBFOGPYA
M_ZXM+;3+DR_,\4(LI^G?81E4$6D.5GP&UZ#00=8,[BV;37MKMK?FDME%V#$(
M5(UA<<,N.&W$M96*5RT5%GM-MN#2)GF"&9V_=ELI:J7H54L16FJ+":?;Y%XK
M)*V0_+I80)!0#!F>1]BM*--],;E_$_MS[1732D\K/2Y=1;V% %'E<;N;:3K%
MW//RS@+8(XNXCZD#+W49:&6LE;%6QAP9HTQ:' Q5;&BG.,T&KW0)^TONAN>6
M M3BT*9UR4V0H7_5WF>MK+UN6?L9DJ5W(%"M_+3R\YKEAWLZ7MD672 ;U%[)
M=&*11B\$<%L:V7O 7.A3K\)?37V2=;\6MT7,2JU;=,L5W5BBJ>'J#5?F<G.-
MB)M>59_"=?5B7=LN+EANZ R,>*N<+JZ-(ZMTD0%[HL04OPI- \;%/6,,IEPW
MA6MD\6=H$#V 03R^6[BO?]30SW5)RS/)F]J<+O=34DWP7<GMSS4@\7EY FX@
MVH!VDH'K-DN:07!9:E@O&#?^\I=V_K(RY398LIW(\@7-G?D-$E"O-;S&;]N5
MUZLNY&:-NV\[+>,G,%T%ZX+]4\/T)FF>YEP+5V/+4EOIG",K_U+I-,A"9&VL
MK8!A:JPTDZ(OU=NBY1WOPK&!Z^V5>:;<& 9FE.)9A*'S5#BA+>R0PTQ:HW-7
M.-NBRG:>"E,RH1&,HKB_,![F--2=:J0YQ(WRC%I4/PPQ->H+,SG386;!,:'N
M1-3%K7%M5ODZLW5DDVH3.NY0;E (V,*6??2&7G%1^%];M^-FC_:W&G2SB\SN
M/X%B/FS$89\5:N+U.]Z?209Z$5OT@H:ZT#T&/X M!XMZH4:E .-Q=?[D%L)?
MN %ZOA#0\.PSI*NG-EI6$6?29OM+.8RCD7>./4;@?-ZME71U/L-@]/TR2\LD
MW)6IC>D_[Y[JCOU&,!=L"D9MK9+4H,"D_[N^2?0E*ZV@IY6505DX^W(N32VE
M9:-\\2L=$>G!?%' TW47F8](['JQV_.V/R(NYG/:\0:#P6Y_[[A[>+#C(\MU
M'.#1LFV*I2_6Q8=3?,#YJ$B'<.7V]GVOW^UW?=W8VJ.J"+27J-N[OD&0X#JD
MG\]_$Z$Y(0<%FMYPH#\W+;.\#+CC]5<T)_;Z>]O#'=W%TCGU)Z/B_M)_M.;2
M/^AX[]4X((7WYQ1W5B41J'$[_\5=,I]Z&LW%))_3I X47'U_CGMKOC]['>\/
M1*9=<&3J?92/XC0'^_*%[\O>FN_+?L<[)S?A#,WB";<GWLP=D5&TA6E;OPZ.
M%A>FW>'P'IK#^PC5;/JC,,?1+JP;EC&_S<L)K.EL\;(]>ZE;9;CJQU4TC(IW
MSS[ 1ZM_6[9+[]SC?_B\>NR@XWW@S<B]5=77.S>RM'>\.LJ^\3DUL=^8./!!
M9^_P^%YQX.6_.SX^>/#H,FQ2_WBUZ/)='KO?.=X[?/"G'L)3'S[ _CA//>@<
M[NT_QE/W5SL^#YL+8-%X:'5T=)LV(OD3+40*Y',Y 6?-J)';LP%=G-W62A]M
M6 K6/>NT&._)^9[B976'5=B(J6&PX,7-B<(>=SVT&S&ULP2LIFG*-!O#F?=5
M44/>D=)FPTN;\'N8Z4N;TT>*B?T.&X=QL<KLY *I.8$]-NF:IRY&&5EQT\(#
M5R\*/3V'>VCD%3[Z4*]<^)SV(:L^Y#'0!X\J$G,>(8E$#ZRH)S,P[H=,N)]'
M?.OT>_UG]=A_<GSBL,MP>MW>;IP&29"$.0>L9YVK K3L)_@A)1$DCCWS3G3?
M>YTZ^*B&68E],_J4$H#_QV)ZS,92ZWGR[5_$6NC$35*\G#GY>)N-2LQ4G@;3
MJ$#J+S!5.KSG41R-TL3[9Q#':N;]%B3?.PVAF@>5^F?_Z,J&R"0*PU@]C];]
M/TVVQPNX2OJO\RKI/F_P]R?'5U<U_5TD_BMCQ/L$>%NPJCDU/YR_0]9"H3[(
M+$_*RS)?CPOB0>;C]72B?ZB*&X1$N!@&P5U]B*/_">#W5][_I\K=3U'BOZ =
M_:/SON,CDB.8$,JQO0';&_"1)C7HO59GZB7=@(->;W<PZ/7[<N_A$H^E=)%!
M=%&"G41C[\,/,,8)QW6.I$@J\[[4T%2YUQL$N[V][6"'-&UO/Y1_T=OK$*L/
M/P2D=L+TA[WCP1[IKI,PG>)%ZS[_0E'!EC?H]@U:*\B&0:+RW?,?:/'+4_K=
M;K\U_%NU]XAJKS7\7X#:ZZ^H]CYRJV/X6ZOVGOVCK=I[-K77[_3^5ZOW-E[O
M]1_&W.L=>7]V+CJG':.A>H/][JUJ[+A[T*JQ5HT]JQKKMVKL!:BQAS'?6C76
MJK%-5&.];J]S]OEB#139,TS^C.#?WO_Y[>LG[RS)BP"!:>_344FEB;O>MRNL
M>Y2?A_KG80H#(*JMZ50%F2YP1#H 5'1HZ(1!$5 IH3=41+5/;83I/45PR43D
M:C)482C%AN89=D#Z?9W'V9MG_V@K\\\I\Q>GO[<R_RWXD2;I9 8N2J$2ZG%S
M,;I2D\ H@5;X6N%[>.$[/?G4"E^#\)T&\4A8+;U/4?)]B,0HK2BVHOAXHOC^
MP\=6%!M$\;T:$_55*XFM)#Z-)'XZ^:V5Q 9)_(3<M*T0MD+X%$+XY>N'5@@;
MA/ +4A<F16N:MK+X1+*X]SKE\!0;?GI?L!WIF1-0?8\!5:J3WF:^)$RH!+GG
MBBTB9K#Y9! E3#LG)<8>*+:=5D372T27TPX_*ZG+\7'G:']P'TZ7O<[A_L.S
MKQP/.MV]O>?D]EZV-T][G'K(EO*_[IP+77>MAXFFD9MZSCU0<0$R/:.6TXH,
MH5.DYA!\(&U?1LBTBVRYQ564>_\H@PSV)4:FA6F:67[-7G?W'Z9'3(AE2.$<
MUV65J=6@"T_3B>X 3_6M\A"FK(YJ! ^9(7B($N2%AH'9;O'?@BPO<^\+$N<&
M(U72VN=2>MD(<;3(QH%;C,(4UBNB(<UW-#7W) B5)AY&)FLB3\>G$;LRI>-O
M6TK?BS(P":?"1PK?P9DR?7+L+ HN6@RC*O%"JUQ.1'[-2].Y@WI\*"ZMIZ3K
MNY7$;*TX_(X?@L,/%F'KU\<C\5M?GKYG'\NC4_(]_4%MYM^[./O;YY-O?W[]
M<+%0R.^K'!9^SRB!9^2KILF[6"HF>K:=8QHXF&^_&VKEG<B$'9;8GQ[1&R'?
M"!G? WSQ86\H;LB T(ZAN@KBL>:EIM/('_"Y@WR)ER$],"B+JS2#J8:+N50?
M@2"1"/*?W)0>''?V#N]E2O>/.P=[BW]];VJ\HT[O8+7'KGTDX791,8Q4;W^.
MDFJ])O1',/-Z7)_=;XK]U$R<I614/^N<+WAE[P6^4INDSV&4>8O^H_?_:=7:
MWF%G<'!T'[5V?-0Y[KY4_=/,'O?MY.O%GQ?>E]]/OOYQ<OKASV]GIR>?+L#I
M^WS:X/@\@/ANWL(UZ[E?\E^\W])A\-T[^1]X?I#X'I,R?+F"/^X2]5Z)_V[M
MU^-AUF)CIHLIIRC4/9Y.KR(UGB^E>I$SWVZJ'7L/YOVH2+.=GPV6./;P8S"1
MMX9V:VBWAO:+L7I;0_NU&-KU?=Z[I]W9VJ^._?I)I4F0A6"L>7_+E$KR0D7)
MZS-=?WH9-F:F;*?.U<J^R+EN+RL.1J/=_OYD-$K+A%@@Y0,_8<>N7X9O79-Y
M>]W%R;Q?AFDX@S^NBDG\Z_\%4$L#!!0    ( #.)JU2^7\S!90\   &A   1
M    =&%R<RTR,#(R,#,S,2YX<V3M75MSHSH2?I]?P?IA=T[5. &;7'<RIW(]
ME:K,)!4G9\X^3<D@;.U@X9%$+O]^6P(,#B# =A+VV#69Q 9UM]1?J]626O#Y
M]Z>);SQ@QDE CSK6EMDQ,'4"E]#14>?^[J*[W_G]RX</G__1[?YU<GMEG 5.
M.,%4&*<,(X%=XY&(L?'=Q?RGX;%@8GP/V$_R@+K=+XKH-)@^,S(:"Z-G]GHO
M[[)#%UF.W=NWN^[.CM.U=SRSBW;QL+MOFGOFWJZUUQ_N?AH=#A&R3'=WV$4'
M&(KM#J$$WC&[>U#8LSR@'>XKID_\D#MC/$$&-(SRPR=^U!D+,3W<WGY\?-QZ
M[&\%;+3=,TUK^Z^O5P-5M!.7]0G].5?Z:<C\I'Q_6]X>(HZ3X@*QE+G\$G+V
MM.4$DVW95+/?MY*2D@_1<":4"T2=&6=7L*YXGF)>3 .WM^5M*<?LFE:W!Y*0
M$(P,0X$O C8YPQX*?7'4">FO$/G$(]@%8'TLH9LKD+D-31AA\0U-,)\B!U<T
M[<L'PY#:)I-IP(1!<V0>XD-57<Z$)+-D3:5.(GRN @<)972R/ <"U;X<U3;V
M!9??NBF/K2?N=K;KUR#DW1%"TP5JD:6,:A)?:5Z;C/E9!P<'VT_2GHKK46@D
MJGQ7?NQ:O69BRZRMOFSXUDWH5E&'M"\UJT-"MV0="GM0F4544:KOO&8U%"..
MG:U1\+#M8J(LZY==88]Y OFQ&WV<EXPH#83B(:_$UZ930KT@N@"7I!8/$U7>
M8B]Q4SD'6&"OZL\A8@X+_ KCWIZR8(J9()AGG:=B,&;8.^I(U])-7,H/'PVW
MH"9)D9R >7N0M[>!!/M7:4L26@G)48<###Z.=-/FAD\9;MIP(.'@RQ70__?M
M=Y#?M/U XH3^WZ/Y+O::-A](""4+M%Y2W\%]@[A'G=, (K^.(:_=WUX6#_A*
M7%0PX93P2BOQQ82 "GZ,;AH@=@U%]7G[9=D77$*.W6OZ17U^:=4Q<5Q$0_C"
M'&K3S>NQD"R^F"A.JT[J8@K$)\B7 ^5@C+'@]?1;2*E1N*44W@,M#T!=>*;Q
MF(\1,S(B3FL/P@UBT*0Q%@0JN3@B\VST\,C.6A,>X^,<X]_6$:Z9GGC@78/W
M5/7BB+JGP02:.(9"Y %?!9Q?POQT@AN!V)BY'MJ^:=JET*:RC, S4FD&B#/F
MY!D?I<3?C$CFNH-^ R,C9DQ>#)R?H"SU=QSX+F;\_%=(Q//"F-?AK8?<-LV=
MFI#/A!E*BL(]*^]?1B1QW0$_17Q\X0>/S4;(8@YZ\'9,<[<F>)*EH7BN$3QG
MF#N,3"6WP#L).:&82^]XDVE5X%T0"F,607ZJL3K(+<Y< VK/,BTKBC<)=_R
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M!Z.E8Q$TC50EQ7SFEME,D4E2UFL/7>AQ&<DAF<#&9-AITIN)_@U)#TD3YW-
M5!3@K+,D).N8SLXP;VAHD#2B]D)!B5VD?PV80[*"C0FPZ]0WX\#3G,=U^#!Y
M ^/\V_09?!PO8#+BNH 6+C&K:X9"<$^$#.2I6RFCC* *IBX\N '0)ES0WR<7
M6HB@AU_\=)JO&2G'8ET1EAD9%=-<6>9+)!=.:Q$A0+2=B'$7LH8C'V63HY9@
MF$+!R<_EP#Q7F:E [Z!,UD6]Y\S'P>0"=F?%+8'!5A/?,R) 0P&I2IYI'0/3
M >G=2]*RH "="L9DV8?E=_'Z8#(![7FPHQB:>L3C14WWUT$^FTT7Y*_C-%5^
M2I>SRAD9^$C\E$ZPJ&TA/SUBU,BMZ*3];@%U2&Y25X*T$DS/))*006+R-#[M
MB;:67(+(H3 NC7'"9R5T=_-X;1+I'JYA2K,3FNLW\!7B!&G*EZE<^G@XP7Q=
M.J=J:$&^*WHOF/:\,'#DM21N./DQQD1G^_B,6R(]4--Z'PY=<29["JW9B_/B
M^.-D]A7Q+2X3(-? DDJ$X MG,:E(L" P[VM"!+AW8(T/J4\6XDYH!VJ/6Y"G
MK5C:Q:CS.2[.(#B5$F2D88&@,!DBD#N@R4\T@-J(J&SQ?;3,>1B[CNEW&/[&
M17U%WV$Z&2Y.LLS< ]"LDM?+=.*2!4["5%9X-$(6<'UR,+> .B25>7\^7"9\
M*RFT\SUA?E1]&_JG.DR?8++T=A;/8!B^DK>SRA25@"Y(EU@6:)G.A H4C=MQ
M3,Y2 "6B[N.%;@+OD!1D.ZJTETPSTBPM_%M,2*B(RO,_<'$Z8N4HCN91,H^.
M1HPVLJ")TUQX(PH6)7.?1,;-F XI7&E'CT8R:)G;_PCC_.++QUHX=.8&7ABO
M(JI"#"0^*<F8*QITS,8RKNG_PJO(=1]+N@&X0\KWMF-):ZFT<['68<,W!I\C
ML';9RDCZK* F1#(XYG,"IKQQRFFCR.OK&M==AVH3@ICOCB#-Y-#8^1X%U-9+
M"B:R*S0HI0*+1@"3X R *-J'/O'8ZOEM0XAHL^$I ^-*48P4BV6 *3-':EF"
MH;?-];&*6ZNX_;K46TGY"G7O/<5M':$5CG/U94%)@<((5E16JS6%8#B-+$1/
M?EEQJO117]?".3SO>">I[S[E#5V>V4<<%E_?3&"Z(-M:W?2/-5M,*G0D2%T&
M#XGXF*KN=(5Y'1U3FB<H,5OG>ODZ-Z,Z/%=X)RXT$T [A4!XH*X2O$*8X]LZ
MC:_+G^1YU<&.##<>/%?,J$#!FD=D,6)F4- $ZQ-7O(]-NQ76X7F^NRF(9B*X
MQ(I_/KD\0:_HYYWV?[Q; $U'C>MG98U[-IU#76LZ_CC@$5TT_H2O9O/Y;U/Z
M]J7:]"VWB&S]L&:[2'8;9J.-)J035G>OSQE)K[0KD3/D')E..K%HBV'&!O3D
M,&2*E;N\BA=@[*IN5G=Z#U_6 =ZO.,4R7HPX9 N:&Q:1XG[M1 T&'&?6:ID*
M10G*]JFXO0'0EIXGZZIC[D^$RZJFQ?0W,SWD#<U.5=\*V!K5R+O(A233%S D
MIK.M9;Z<=)Y7.4HOA+-]HH\;(1V23]J.#FTDT-X7.3<\,#87Y13+20=B9JI;
M7PHP$\E+5B!=,*&O!W*3\GM89[0="7:=]:[B-P0BUC IF[I6*WQBO@1- 1/X
M+(B&I=-.C#O%O\/XUB_9?)1"5!A##?Q-360:2T&@]DPFQY74Q1?HLZ/N"I2#
MLG>[$N%&AM]KXIOQ^RU^PND)/5U!#BI3Q%^XETR7'%@ +4C7^J BCR):WD7L
MIP@.R9JU%O:]9GD//DVTJ"P&P;!PBA"%$BR"(^6JK U)!@KO^^38-O1I[N/+
M+W# ^>+"3<\_K28U4$6,PFGFDRL4OAJ_VK838@#$F &4Z^38WXWND/++;9AS
MU>%O+*.VF>B;!VV*34+XVO6#1JXS8ETB(BDK:0T:+IV3_5+2WT<<T(4Q#>72
ML!@R8LYU&^@P_D2@/N&_83RMIN+U].KO*J6##9J&*9GS=6=06NX;C)ZIZ)!+
M5-SP/O4_6T,]J*"B"Z/Z2J\=R9;E]]^JW%Y^^F/\YW1 F(S_%_,IY!'W6OM(
MH5&B8=-,),.\R)9Y<%KDZ(6&/GFXS? =4FZ\$YW:RZE]"/LMTK @B_7 A)26
M(NGL68S.L:RBC,I!1MO'_[DCQ+M/^#)'FJ):XO><?.S);+EP=687O%&6; .3
M@EY4BJ@D@^0$,[P(*[4N8'K%-+? .B0';S=N7 US6DFC&?G_C5,:X800/<W'
MX^EXOAB6&OT4E+0\0*97T"F>R<UTB8&@H#L+-,&[7#3OL_GE#F"'Y-.U)4E+
MB33</#A?O"[K,'VDC77!6"2F%C+UCI,_61M<<>Y5S ;(VG<JU#X/XY"<L+84
MN/]L[W<QN5:-OYS,/N_65/#Z.W99%KX!<+NUW_J -\/LTYCN]NO7/^GQOTW/
MN/$TT7N\VA!>BN<E5G$&6?\JP("B-*8M&H.Y]D;IE%C:&./.EN4L7G@'$WQ=
M+I31G-70C#Q7I-!H)CQ&F@FO)?,A&*9J\ZS K5"AS[+A9O@.*L?>B6!7+%![
MR34S1!22#+7BYCFN_J71KW,?ZR*]\VT7$$7)"@23.4NFLQ;,<\U9E-F:HJ0#
MWL>_W0;E(7DR>R)8-R'N.Z^0#4=$69B.!%!S'RDD#LBL,U9SS-+S/EL:V^45
MU ^FO#I(KMU"TX7U_Z)3C"IJED/==&PTL$#N/#,N:2.1VZC[9!EN*0Y[X-S3
M?BAR?S$\9')<!0.:XCS'-1),+UC$$%BDV"#S("G Z%-4T24Y;GXTK=-5GKV]
MIZO=-:XVUABEZ#!0Q,F\,W7K2P5LT;(,3H&+1L?8QU'? ?0F5+0_EG+;EXA[
M<_+<IN-1MIXF00@6A.0UTJ#Y*'47J0C12"\\B#Z-C._&M@G#W ^F[!I+K!V3
MYO.3>H[$Z[+LT$4<_PN&@6+6^<O9\ Z'3^.$\]?#LPF,C^<C4:(BFB\+91W3
M*1!8KRV3P0IN4!C>:9O,5C WX9?_P318-S'NS+2:9KRT]:<&K;5YQCH[3^,U
M("*RD&JGC!0-\UXI9D0J7)-W*?BE#7E7,Z-W/F434H0?@Q1M9[RCT5KW0'B^
M;H!\;2^$D3 AZ!!CK<G6%2NA+LXRY5004=B@;)_MFO?#NU'RD__PUJVY:-O6
MXSW'CP.F\4HPY-<=SX;%^'^7/XX@:>]-XLR+1!.!.;$8;&;&>N\SY*A\IV+U
M.Y!M1*V]E7'NAUE-I=6N3? 1#/@K$7VY3Y*8O<*2;4!9ZTLUCW69.;C:^MO7
MO>XA9VZE]GT6_J_'LQ%??K T>0/)M.N7<HZGK\O+\90\-!II7:FN76N?C^>K
M^')DO-)9%]*#HFZJSD1D[\&PY)T T%X4V^?XL4T1;L2D/>X(VP>3NDBOHS-U
M<\?.D5&F%+3 ?#"2V&\+\[5_H7,\:G0! />5AKH9Y48<^\&RZMVDN+^UX].^
M$" 5&@P,A%%,.ZN8CX10"&6$<TG&TJ>\:4. &['K1\NP]Q!>NRK*LV1_/0B0
MU.M*T2[#U9$6"H)#R9*JQ\'E*!A(7_?)H2O61:]"GUTQMZ':B$/V!^-0,S$U
M(\[+V4 3/%VU%TM?WP] 7EZJL$ZQ?EN['O%BO07@C*O:*"]$Q8(6CA6KE18R
MT#ST28-O@W(C8OUH&?%N8NQH^Z[V9!P%0T,5T3 ;1:#PPD2RS\HQ,LC:FBPL
MC]T:NMR);B-B^1^,6,W%UI%0]>22@5C_UWAQ].QDOI@=KY-C(ZY*2$8"*[43
MEBXUKT'FF+P]]"EKZT.G2I<M0&Y$K_##TZN-$%M63%TW#V<1[+EY\%*;(DNF
MT8=,]IO8$);SD&R*3O!2=)]4Y^88=UIVHOLGQ#Q_261Y </DZXLO.*3Q_'2=
M[/7'9;^S$8+2P63+I'>QGK?H6<@JLJAX LV#M>92]'+#"M2&#SRD[5J=Z')A
M,:J''-HU"X6ORZT.KTL]C?QT)769YQF5N@\7:A-_9>H+')<ECXIE[E IC@YS
M'^M^"Z@MBY\?1.FV8D]K&;59S3Z/YMS9K1=A6><=#^17.,UK6Q93SW_ >DB.
M@^B-)W;;S73*!D_['JJ6VVJ4UB)HV7OX3-=]*\MX-9M^J %TI>_("?(QG)7,
MH JU+3PYGT*0;Y ID%'29I7Z!*5W8_L.2IN;ZY:V NOMQ_TV_83SR_YLL)HG
MY/60+T_XA&(Q>,FR$SI8PX7V?6HD-L?8RDJ_GSU-_W,R'O#&%M,C:TH68=E)
M6.7:2TLPH!EB"(#"*JLD=#JX?&.,W\,6N5V)=I,-;RS!I@=N73K3Z2U-P#!.
M"\SK,Y\N?G#NRC<XC&?Y:FR8)B=YN<4Y'<'T [Z%!;XH!=-BI(PS,43++(C:
MRK*FM$IVS 0CN8O 3:=]4/L=YQZUH (? R?=7(0BAAI7VWN1N2^)0Z"((BG1
MK7/TO;3@PP9^!\SW:W8?]2#!0Z1<#'F>D,B5R*M&C^1/A!P*4<H%2]"]"7TB
MRONF7!YV=^WW3])=2=";I-?E1[VEE\4%SXJM3K14D? E9 E!$O:<8]ZK/WEG
MJX6'[63R_9-T5Q(<AA,V*A3H>9-C/?J]]D(3GD(TJ1F7"F,*6O)./>MV@KV?
MDV(YFJ0\F4-7:$9TK%O69/9,HD -+AA>^NS=:792['?A&&W%P?N=++N-)!LV
M];XT Y?'K= "]T:P (G&'1S];]E4WR>? :) T\=FW(7LAW%G=J)64_EU:YGU
M*TQJ^NW=$>)BO6K_'!<PGISF"N#B66*S0E>=')\LBR7/;Q-8?>M>3;::8]BU
M+5??26G4R.O6$]\,6J^+<'631F3:R< \Z,1"()IA=%9U*I+9_,B]>Y3WWS3)
MQ+%K=JK<G.T2)=E('AU3NI ^-Y;\N64O5R= *T?_[]0ZM=4(#BJ;V8R(UQS(
MNW]Y]S\2\]]#[>CB98Q%HV?))U/;&*3:6H-,BT#O8TDH.QW5<3NN0[+=W8C5
M4#3[-\SG]G/VL+G7W+Z;.;UK*(TLY?7GY&91>"ZD"DRHIR2'>FBX-)*9>LP[
M!>":&-;E!=S@:.(MRR-6[<36#0B6QWR2=VFT+S(+5DK=)"4SI_=#!.:23B)E
MKJ+=K,+JFIL?4NRXNW OE#GL.I4]SM/^?3Q/.*%W"&<GYP>)TF6E52*S5@]P
MQ5 /U5.%D98*I+F24:+3"79W8CLD,]*.(9UDTXPSY!G-YN/334:I"$\AJV'9
MU(IKP<E6.A^8L)ISH;G5J<\FUPLP#BEMW)X)]Y_Q_3L.E[IKP77=M7IX%-L\
MMYNK<>_!-_)!KK8V.^UX=@G$LU,%DEV6.1;F$(A+&@7SF H#5:*1T12I^^SO
MW!;I3I[+^J[/Z)=C$OB[Q4D^-P>>0C447#(E:^\DR):!!L<XC3T5Q6T(L)$/
M<^MC#LF;Z4J3"XY.NYEO>'[#U6T=IT/^>C9@@5(459%Q775L(F<L)\9S!&.#
M(_7=)V[>!-TAN3U[H5(WT;7K"7)Q&MX/D/$44$H>9"U?1UFW8?.:%](N,EXD
M%O+ZBTA]#CBX!=0A^4M[I5 K037</+@ZX7(-Z!2+XYI\=R&9]S0\G7@FSUY*
M%D'1I^0K*M6'--?C.:3Z\;WRI8%X&@9>JRT1YUL@?6N,]+0F$SZLCG>YHA0=
MI "*(S,**% $Y R<H+C11!6]M@E2G[6(^V/>LG?VCT.Y/8FY_:&!R^815S"5
M'(U&PTFAUIVY2=6##,G)<\YGG4..KO0IB+X=UR'UP]XKO1J*JZ7[5$>Z.HK@
M/7SY-E)93QZPV;, I&TUB+IU-#E&?[P#:Z! G_*3&R%MV>;ZQR%.&R$]T%+6
MZ;ZOSEFHNY[5=Y%KTT&V7/$Z]ZQSV4ZA.?=": :B[OBV](J!TD@Q666$E@Y3
MQT6#:S'M[GV=GEEQ_9 5YY"]Y QU+:\"Y5E4(!GG)92,T?A.G?GO '9(B:=&
MC+GJ,;4336^WZ!RL8(R68"U%#<*1O0WDK1F^5,8!.4+.ID_YU)W0#BG#U(DS
M;<73S:HMM[\?S28TY?/5JO&Z*G#QE0PQP232UP*3^3)"J%6G.'S"7&;#Z9[G
M'<Q<NX?O:O<Z34,C0TB1VC'%:!7C,_@X7L#D(HR7L^'ER>)DP%,PHQ*!:U^0
M)6Y-U4B6>9Z I11SU":*Y/ITZ-D:ZDX++UL_[;1/ZO(K;TZ&=$0O9Q7L*&9M
M5"3U[1127,*E8E%(S42($KV1AH*4C59IVF$Z),O:EX(7UG0>2*AM>KQL#WZY
M.>MB0Z/Z.\PUVCI9S!>DB<B,C$J2D,@:,>VY9UKJS'R0GDG#75:"9C1NMHS8
M#>(A6?6#YFL/D3\P?;_M$UE^^<_I>#%_^HDL8LT;G'WKW[4>;62=Y#9XR[BO
M!X*67/NOD+LL(VJZG<G2A+Y,W@+M(:UD?0^D[D6$0U#/3S_#D&\<C2)_W;I<
MF-32TBM+3CU@5'6GG>=61U?XG1YQ;Y"'M,[V/;"YL=B[A7%_X**V/E[E3M_@
ML!S>#I'9K??;-=C:'&RC^.G"*<1G<GP_.T>+=>SW?#PY(=4UTAB$D%&0N^BQ
M-HX&1A\(YJ)0=84BZD[)MJVA[II&^I-<C:JQ8[W9"QBFY'C,EP^?++^,^?WL
M#0R+<1I_7.8SOIWW?3I9Y(T@*J=IBJJ7G5-FT;G,>.0^HTLRJ3YYIMVQ']06
MM+XTO9R@VK/@.YWL3AY"QN0*2YK'6B@16*S=)K@T3CHR%MGW*:3;^F3W/9Z8
MM4<6W5\:?0AQZX!_A?DXC<!9'30-TLL:58EZ((Y&S9!;:XW1UEWNVKQWW;X$
MVO9%(0?)9:XRLSD#TTX71EXV9\G(4'Q6SJ9N/;NW>U'VV,&Z&V]N?TVVD46S
MUV0'?;\:OXDHT13.O'%0V^):%GFH^$%#-#'+U*=48E?DA];Y>F^LVZO(FQ'U
MKZ4<,#_]A -\P#].CB,.K\O:6JT"M_-9,K(KCOR0R**Q=5]\R?6T!& 4?%G)
MC<5>.\2V!-KD&)!:EP>3-5F63WBZ6$EX1:-OA7SKOJGGZ_E&B%(Y19HFV,B7
M+5I(LFB9),/OE=<FZSY3M3OV0[(</1EZ[;DA^Y-Z[[?XRN2L%$W(/J O@GD?
M:NK$*>:Y(H_4"I.$=A)$'^]D*YB'Y.;ODX/]9-DM(?82QL.R[=GO"/.3U1LT
M7_?4A,EO4S*+)\O/UK_/L#C[R@YYLQ:/W36]UGSHK3:/+K<7?WO4>)XFLPI@
M1/P''Z,C!SC5OMVZEI6[2%$D!.VL#\)WZF1T$Z0^O16O&[NRTBK/'9/%B/I>
M(HL2-$O2YAATR2;T\:HWAGA(EK<-AS;KG[BKM-JL6%UHY7$MIF*5R0(+X\H8
MIA4$TO$I,"NS=])@,#K=I;<V>]0AV;^V3.@PU=U,6W4#QXNJP>M^53*[2(H=
MY\LZP^6LD#$^JS<\K>#?P:;M]+Q=C5F[P;8J2K^^KG.D72BE6,X,Q<6U#Z:F
M4+F09O!8<I*9N] GM+H!4.==5\9G'DCG,8NB=GD6O)ZLFAG40Y]M--FJ/F?#
M[[[K:F_%Z V8LN7FJFVDLL="="7 8K"6>; U #6!@984%@BD<$ C:=,^_MWW
M58B^/[[<4S8/8M+JF6R=K-?Y6_<T5#<.H9%-.GO(R"<CG?+ G!2%Z8*" ?&#
M0=VO$$$9&_JT SR#L*LV>7<T&Q;+369G@Q)1D_(B-TY@/0X7R;7SUOK:O]H;
MF3C/V"<Y=!7+(=F7^TG]LH;8<;Z;69'_@F%<DYG?8$3KG$TZ4H15:A\R;YB/
M23%,I/X":2M=^NSQNP+ED*Q$&ZGO-MN=7(<E#N#$MQP%RU!+"#+]!=I8EKGE
MAO[H'/J<Q7$5RR&5_K81^X[SO0?[3^'<!?OYKL[/\'56?A]/Q\<G*RUU>B1@
M$[?@7D]LYRWL/N!F3@2%TWB#PW@&X 1'WAM0UF1F4N+UM&W#P/' O):YA.Q
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M ?-X\1+2JC+H VGE"ODL+#QMO/WB2VV"O$O-[SV?M'/HVV" C0+>*X^*BU$
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MEON\/T JW%&N=B@F;"/K%@RX8N(LTES0"253"9 R3[6#&X$QOEXZQ(WG"G7
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M1>:00NV+5>%JZ8$<>@XY%1F$9Y&[S7I\;/_N!\Z$0TB\05K95HA[3'G!A;:
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M3S_Q>;7,V,M";RZBF"30BV4($4L\F,9I!#TJ4,!)S'#J+:K+3.Y&')LY5$W
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M9!(3/Z$Q,YFJ1KW-;0(W\H).X!O0B@QJF2V"=B["W#^IG8,W\E3OQ^VRU\(
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MO;$=F:1?8UCM(Y%'0=]M#+);$:>-/AX%WJ.XXW%Z<77J<,OJ(BME4TRRIH8
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M&= B6G!$/Y8&+.L,H;&OXQJ_ZHV@-5"@AFP M?;#9D&JSN";B$[/P^B(28T
MZ>70_A:F8T\C3?9XT^R-:Z+E-LX2=3S-)HE'FY>P?+L6_Q2D^/;[:A$'88JD
M"* 7B @B*1&D$2;0\X(P8 D*DC2UCZ S[G^&W(J&Q,V9 VZV-1X1QI$)N(NO
MVSI/M9%V.QF FA0#.H_$#= : *6"ZZ@[:^Q&B,0SE^$5HO.L 3H=L6??S,"[
M1/8@^'HI/LGZB/[-R]V2E.76*]DGB1"*OV#H445D+)20)GX""0\(CAG'/K$*
MA+G0W]R(J[FBXJ(BV=+V4O "LH97@.[P&OO"KY547ZDVL-$74$O;1@"#47S
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MHA"!-"(1])( AU09FIR8>Y::]SLWFN\D!ZM6=,"T[$ MW,LU5S_7%;ZR'/Q
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M><@A8"/3SD"L!E2#[D7BRF+0I]N>N!9TKX+'I:#['Q^:O_1I56954V)T(5#
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M1ZG@(?.$T<&D5:]S8Q8M;>W]59O)8BNWY96R$>)F!.,<QY&)9@-A_9<=D6\
MJ;8I\O_>&Q]M?X-L@Y+;NV.CGJ>]-;8!X^B^V.KE88ST5CP5@C6UH!:!GZ
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M\U6USN[MP?6WZC#U]?/N(TV,>=7=[>'GT[2.D*HCT"<YAD@260+&;#,(G>>
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MM<OXLV&NG0_UO<#]RGZ^EV:TJ9Z**LS@UTW5@RV%K)0T+P!*-0&82P9(IE)
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M2 5XAC(@&=-*EZ2@A9RL%VLV<_3O]D?W6N1;&?&^OE^MC*3I,).P2E5//^P
M/$?/J2\DL7V=2J\8\1.G# [KCAQ(&-:!.&7<T2O_Y(=Z7HNP65MCW\;)?]1?
MEVR^,KM&XRV\73RRZ7Q"(<YTF>7 K&'SQM9, V;K&>J2HDP2K4KH5,#07>38
M7M]6XUVGB=]K)7VO1RX#[7A'$A2^R"S@B9S_-8DS&&'O2BZ+'?;"Q!F&HUL3
M]R?#56_>=F1K*O:LWF[41.A<T5(QH)F" --4 EJP%'"8$9SE'&/!?'P%5\'C
M="-T71>Q[MKXU&A[EVSFTCAL-B!.G:^-==T\N+%0#'0C<]'9HL][O1S7BX2K
MY!.;!JP\Y@M5]/K/)X7?O IT%R0NM: [G^]18^)P]"H/^*/^;:4J[VM;?7HZ
MKPY6FF#W"8)*YX(*@!26 !,H :-4 JUR+&E!RD)0M]X7O75P6G&#ML*H%6L2
M^OZT>-&2MJHX 18:;&S7H<JU_5.="CC;UK1O+/0H:=!K]KJI+^Z,W*B/;66!
MK5=@;$@J(^[J7R5[=K3Y-+'Q]R@I$7L>!BHI$6D^_$I*7(-E9TF)7@,/5U+B
M&KL/2DI<-= 5E89?ORR,65<VOI_+]U7/]>D/]<E\W5:?%K.I>)Z44BN() ,I
MY\;#%I@ RJ4 K,"LS"5.!6+>-87]=!C=SMYN?,#KHYJU/:H'>TZ&XV8_+L2Q
M=_^G*OWN%0/^O=;84-O/=?+:K,N_ASP:Z ]=^-*^GGH,7\2W'U GR_7V'.KJ
MPKSO#,'.Q93-/BU6TTIB[[J\9X<:T^+:+\N[53AI-8Y=E/<B1+%J\IX7?*N2
MO!>AZ*C(>_G9'EO7>R&6&[,&S>^G@LV^K#=RJO8NY5)%,DB!1%D*<(DQ8(P(
MD!4D+0J<YY1CYSJ(G:+&]K9OE$U$HVVRJM7UV-=T0^NP@0P&6.S[NP:K5M&D
MT?3RC9XO:!Z[OF#@#;2]ZP^BWP[."9?.K5KW",/MR9PL.=A\N3W1S[OXS1ZW
MKY=3OEGO&ES:N@"V8("HRK\L/K'E>BJF3]4&<!= 9;R@J9A0+9%,LQSP3&<
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M94998>T<9'TKKIT=K\=.[,UB9GY>+"N7XQ=5M8/BDB$JH0 :HP)@G"I :4$
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MVOO/V<(6!O?L,W?ZX1$MG>U5?*UAE$YRW2 $70%G1 WZ/>\V]^6W^<*GK[R
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M+X4XH'>\-B()]'NQ2#6=/,S7T_7SP\^O9BFLIKN(K$EIB!\:9QLH:/N!IY(
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M7Z_6L/OV8# >[>;#C=R3T*??YE,]%;96=7WV-IU_^[283<5T_[@,"V@X.B4
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MJ8FUU2=!)=S$=U/@#:=S4+9L[&IO;3[O3VEMV[;\P=T()]$G(>DFDSE4[M+
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M<:MMM1]('9MLSX'ZYA$98E>K]?NY6<JJ25?\=3'?]A2US8*MGPH+6V+/O)4
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MVY?4!B:'%MJR+HV-267D75*960\9[L4;:P:"OIF#*SGHJSL6Q"_?[='D]&Q
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MPA/AD^Q.8Q EK>Z%J)LDTITV]USJW)E/]V]@OF[:('\U0U1=4"#2F**LJ*]
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MOFEPSO/A>!05 ^78QTNG +9J[R7Z)[_'267SA2M\U*J3].&#57U .1FCZC7
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MB%"7(W01CG_=BAO#5-8(5D9C9#4S>A?(N+X:QE'UO>:O#T9@-A$D(P0:]Z_
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M-7@C$S"?F+8F*%Z.3VW<1\%^".DX SJ8>'N"R;OY<A5._M_IY[4KQ4TD@.L
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M[.._AY,SG&!Q2A6?(9M:I%2K#QP3&01B9L)IE"DU0=!>Y/6 J*-@,&^MDPZ
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M349IPF7[PH;9@%WTC9T@&!A%]Z<*!E%2!S[6=:XV'26?G:T^S1?3_\(\B36
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M.7D[N_VS:KAMEF9=A^TLFCI>U1&#T8-D@7GA \O8IK#CT:2.Z\,U1F-3O74
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M2TC>V#"N\L:$3&NW10GRN94S#D*H&'*!RTQ,!_FD-O1.*GOK+S3./G^HVCJ
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MD:HYTII13R;J;*4VL=&=F8=I&W>''#>$/$Q!/4/N;XOYDKC)RKA(:\<Z11X
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M=KYK&_T87#>WT8\&1P?9KE<SLFUX,=3U]9;%=1O$I(K3UC.(//,Z54*#-TR
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M-A6ZKR]JP&PMMR@JUP"?1.A< B^#)NC$&$VT.6&;IC_'4MZ)9]@^K?<$BNT
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M4=4)L(U$/%YH;\R7,-Q:RRWYX2[6_C>U6TV4&21F9U1FR32:3?XB:>>4?=E
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M?BY8,2!=B#?9SN00%PC)VU@G(+/]IDVW[5-U3FT>#@U5CQ;/..#U1)L5HU+
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M<V5C=7)I='DN:'1M4$L! A0#%     @ ,XFK5- #F^);)0  P/T  !X
M         ( !F#@! &5X:&EB:70Q,#(M8V]N<W5L=&EN9V%G<F5E+FAT;5!+
M 0(4 Q0    ( #.)JU3$RQY7V @  '$Q   4              "  2]> 0!E
M>&AI8FET,S$Q+3,S,3(R+FAT;5!+ 0(4 Q0    ( #.)JU0+XG0IXP@  '$R
M   4              "  3EG 0!E>&AI8FET,S$R+3,S,3(R+FAT;5!+ 0(4
M Q0    ( #.)JU1Y0P)AQ@4  '@F   4              "  4YP 0!E>&AI
M8FET,S(Q+3,S,3(R+FAT;5!+ 0(4 Q0    ( #.)JU3T>W+"R04  #XF   4
M              "  49V 0!E>&AI8FET,S(R+3,S,3(R+FAT;5!+ 0(4 Q0
M   ( #.)JU2N"+MC0*8! %=M$  1              "  4%\ 0!T87)S+3(P
M,C(P,S,Q+FAT;5!+ 0(4 Q0    ( #.)JU2^7\S!90\   &A   1
M      "  ; B P!T87)S+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( #.)JU1#
MZ2D/91X   @H 0 5              "  40R P!T87)S+3(P,C(P,S,Q7V-A
M;"YX;6Q02P$"% ,4    "  SB:M4/M=:U$4W  #O4@( %0
M@ '<4 , =&%R<RTR,#(R,#,S,5]D968N>&UL4$L! A0#%     @ ,XFK5)F[
M>F/GMP   I8' !4              ( !5(@# '1A<G,M,C R,C S,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( #.)JU3O][\UJFL  #C<!  5              "
M 6Y ! !T87)S+3(P,C(P,S,Q7W!R92YX;6Q02P4&      P #  J P  2ZP$
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
